Mobile phones
Club der roten Bänder

Download PDF document - IdiPAZ

Loading...
Start

INDEX 1

2

INTRODUCTION BY MANAGING DIRECTOR OF HULP AND SCIENTIFIC DIRECTOR OF IDIPAZ EXECUTIVE SUMMARY

4

2.1 Global Analysis 2.2 Research Structure 2.3 Training Report and Teaching 2.4 Innovation and Transfer Activities 2.5 Quality Committe 2.6 Clinical Trials 2.7 Platforms 2.8 Scientific Production 2.9 CIBERs and RETICs 2.10 Institutional Projects 2.11 Internationalization

3

INFORMATION GROUPS BY AREA 3.1 3.2 3.3 3.4 3.5 3.6

4

2

6 10 18 22 34 36 54 74 84 86 88

90

Neuroscience Area Cardiovascular Area Infectious Diseases and Immunity Area Large System Pathologies Area Cancer and Human Molecular Genetics Area Surgery, Transplant and Health Technologies Area

ASSOCIATED CLINICIANS

92 116 140 178 226 268

286

INTERACTIVITY • All menus are interactive • In the bottom right of the pages there are hyperlinks to return to menus and sub-menus or to move to the next page Return to INDEX

Continue

1

1 INTRODUCTION BY MANAGING DIRECTOR OF HULP AND SCIENTIFIC DIRECTOR OF IdiPAZ

Dr. Rafael Pérez-Santamarina Feijóo Managing Director of HULP Chairman of the Board of FIBHULP

Dr. Eduardo López-Collazo Scientific Director of IdiPAZ

Once again, the presentation of the Scientific Report of IdiPAZ provides an opportunity to recognize the achievements and improvements of our researchers. This report reflects the effort of the fifty-two research groups that constitute IdiPAZ, as well as the associated clinical groups. We congratulate all our members for the magnificent performed work and the achieved results. The Hospital La Paz Institute for Health Research (Instituto de Investigación Sanitaria del Hospital Universitario La Paz, IdiPAZ) was created in 2009, as a result of the relationship that has been forged over the years between La Paz University Hospital (HULP), the Autonomous University of Madrid (UAM), and the Foundation for Biomedical Research of La Paz University Hospital (FIBHULP). Since its establishment, IdiPAZ has promoted the configuration of multidisciplinary teams capable of addressing several facets of translational research, bearing in mind the need to generate innovation and transfer the results to the healthcare system. Over the years, we have maintained a progressive growth of our scientific activity, which is structured into six research areas: neurosciences, cardiovascular, infectious diseases and immunity, large system pathology, human cancer and molecular genetics and surgery, and transplants and health technology. The increasing scientific contributions performed by our research groups over the previous years have placed IdiPAZ among the top three health research institutes with the best scientific evaluation of Spain. An evidence of our excellent position in clinical research is the fact that in 2016, IdiPAZ researchers have been improving in terms of scientific production; in particular, we published 1,097 articles, 848 of which were original. In addition, the overall impact factor reached 4,776.4 points, exceeding the 4,000 point threshold for the fourth consecutive year. There has also been a consolidation in the quality of the source journals, with a mean impact factor of 4.35 and with

more than 412 of the manuscripts published in journals in the first quartile of their subject area. The 2016 Scientific Report also shows data reflecting the commitment of IdiPAZ to biomedical research training. The university involvement in most of the research groups has resulted in a high participation in graduate programmes, generating 41 Doctoral Theses this year; it is worth mentioning four of them with European mention. In parallel, our institution is making a great effort to open its activities, therefore we have organized several activities and workshops with the collaboration of our researchers and other institutions to increase our visibility and current potential while improving our plans for the future taking into account the internationalization aspects. In addition, during the period 2012-2016, we are particularly proud for IdiPAZ innovative activity in terms of transferring of biomedical research. IdiPAZ filed 23 priority patents and 17 PCT; 5 national or regional phase entry applications were filed and 26 patents were granted, two of them European patents, which have placed us in a position of national leadership. Finally, we have done an effort to continue and improve our translational research with a direct application to the care of our patients, and in this strategic process 305 new contracts for clinical trials were signed in 2016 The excellence of our research institute is based on our human capital, our people, therefore we wish to express our admiration for them, who enable IdiPAZ to continue advancing to a promising future. There have been many achievements and we are confident that we will achieve many more. Our human potential and desire to continue progressing represent the best guarantee of continued success. Return to INDEX

2

3

EXECUTIVE SUMMARY 2 2.1 Global Analysis

2.2 Research Structure 2.3 Training Report and Teaching 2.3.1 Training Committee 2.3.2 Training Courses 2.3.3 Doctoral Theses

2.4 Innovation and Transfer Activities 2.4.1 Innovation and Transfer Activities 2.4.2 Patents and Trademarks

2.5 Quality Committe 2.6 Clinical Trials 2.7 Platforms 2.7.1 Biobank 2.7.2 UCICEC 2.7.3 Experimental Surgery 2.7.4 Simulation Platform 2.7.5 Cell Culture Unit 2.7.6 Automatic Sequencing Laboratory 2.7.7 Image Laboratory 2.7.8 Flow Cytometry Laboratory 2.7.9 Radioisotope Laboratory 2.7.10 Biostatistics Section 2.7.11 Documentalist 2.7.12 PAIN Platform 2.7.13 Internationalization Platform

2.8 Scientific Production 2.9 CIBERs and RETICs 2.10 Institutional Projects 2.11 Internationalization

4

Return to INDEX

5

2 EXECUTIVE SUMMARY

The quality of the journals in which the articles were published has also experienced a significantly improvement. In 2008, 11.8% of the articles were published in high relevant journals (first decile) of their subject area, and increase until 15.68% in 2016, with a 37.56% of the articles published in journals in the first quartile. Likewise, since 2009, there was an increase in the quality of journals in which IdiPAZ originals, and currently 114 documents were published in first-quartile journals.

2.1 Global Analysis

Distribution by decile and quartile

Publications Originals

1st Decile

1st Quartile

2nd Quartile

3rd Quartile

4th Quartile

Not Indexed

172

412

258

177

107

143

141

335

182

131

82

118

100 90 80 70

In 2016, IdiPAZ research groups completed 1,097 publications, 848 of which were original articles. 51.7% are documents belong to IdiPAZ, the author was the first, the last or the corresponding author of the publication. Total

Impact factor

Mean impact factor

1,097

4,776.43

4.35

Owned Publications

567

1,626.57

2.87

Un-owned Publications

530

3,149.86

5.94

Publications

Originals

848

3,810.68

4.49

Owned Originals

391

962.45

2.46

Un-owned Originals

457

2,848.23

6.23

Distribution by quartile between 2008-2016

Quartile 3 (%)

40

Quartile 4 (%)

30

Not Indexed (%)

10 0

2008

3000 4000

3000 4500

2500 3500

2000 3500 1500 3000 1000 2500 500 2000 0 1500 1000

2008

2009

2010

2011

2012

2013

2014

2015

2016

Total impact factor for original papers between 2008-2016

2008

2009

2010

2011

2012

2013

2014

2015

2012

2013

2014

2015

2016

1500 2500 1000 2000 500 1500 0 1000 500

2008

2009

2010

2011

2012

2013

2014

2015

2016

2008

2009

2010

2011

2012

2013

2014

2015

2016

2008

2009

2010

2011

2012

2013

2014

2015

2016

2008

2009

2010

2011

2012

2013

2014

2015

2016

2016 5

5 4

Mean impact factor for original papers between 2008-2016

5 3 4 2 3 1 2 0

2011

2000 3000

0

500 0

2010

3500

3500

2500 4000

2009

Considering originals published by IdiPAZ researchers, we keep the trend of the last years. For the fifthly consecutive year, the IF of the originals exceeded the 3,000-point threshold, reaching 3,810.68 which represent the highest value for this entire series. Moreover, about 17% of the originals published in 2016 were in first-decile journals of their subject area, and almost 40% were in first quartile journals. 4000

4500

Mean impact factor between 2008-2016

Quartile 2 (%)

50

20

The total Impact Factor (IF) of the scientific production of IdiPAZ reached 4,776.43, 4000 therefore, for first year we exceeded the 4,500-point threshold.

Total impact factor between 2008-2016

Quartile 1 (%)

60

2008

2009

2010

2011

2012

2013

2014

2015

2016

4 5 3 4 2 3 1 2 0 1

1

0 0

6

2008

2009

2010

2011

2012

2013

2014

2015

2016

Continue

7

The degree of integration of IdiPAZ researchers in national and international scientific networks is evidenced by the high number of articles published in collaboration, which accounts near of 82% of the total documents published, and 86.7% of the originals. In addition, collaboration among IdiPAZ research groups is also reflected by the percentage of intramural collaboration, which reached 11% in 2016 for all manuscripts and 9.9% for originals.

450 60

1.000 350

Owned originals between 2008-2016

30 %

20 10

300

800

250 600 200 150

400

Impact factor

40

Papers with international collaboration between 2008-2016

1.200

400

50

100 200

0 2008

2009

2010

2011

2012

Total Original papers

8

The upward trend in scientific activity conducted by our groups is also reinforced by the analysis of IdiPAZ originals. In 2016, 391 original IdiPAZ articles were published, with a mean impact factor of 2.46. The growth rates achieved in previous years have been increased in both indexes.

Number of articles

2.1 Global Analysis

2 EXECUTIVE SUMMARY

2013

2014

2015

2016

50 0

0 2008

2009

2010

2011

2012

2013

2014

2015

2016

Return to EXECUTIVE SUMMARY INDEX

9

2 EXECUTIVE SUMMARY External Scientific Committee Juan Tamargo Menéndez

Professor. Institute of Pharmacology and Toxicology, Spanish National Research Council (CSIC)- Complutense University of Madrid. Madrid Reiner Albert Veitia

Professor. Génomique fonctionnelle. Université Denis Diderot, Paris VII. Group leader of the Molecular Oncology and Ovarian Pathologies, l’Institut Jacques Monod. Paris

2.2 Research Structure

Joaquín Arribas López

Principal investigator. Vall d´Hebron Hospital. Barcelona Chairman of the Technical Committee on Cancer Screening Health Research Fund (FIS). Institute of Health Carlos III Jacinta Cecilia Bustamante

Associate Professor. Paris Descartes University, Laboratory of Human Genetics of Infectious diseases (INSERM U980), Imagine Institut. Center for the Study of Primary Immunodeficiencies, Necker Enfants-Malades Hospital. Paris Carlos Belmonte Martínez

Professor. Miguel Hernández University. Institute of Neuroscienciences. Alicante President of the International Brain Research Organization (IBRO)

Scientific Director Eduardo López-Collazo

Scientific Assistant Director Ignacio Zapardiel Gutiérrez

Juan Pedro Bolaños Hernández

Governing Council Chairman Manuel Molina Muñoz. Health Care Vice Councillor

Isabel Fabregat Romero.

CAM

Centre d´Oncologia Molecular. L ´Hospitalet, Barcelona IDIBELLBellvitge Biomedical Research Institute. Barcelona

Deputy Chairman Rafael Garesse Alarcón. Chancelor of UAM

Executive Committee Chairman Rafael Pérez-Santamarina Feijóo. Chairman of the Board of FIBHULP; permanent delegation to Rodolfo Álvarez-Walther Sala.

Members Juan Antonio Vargas Núñez. Dean of UAM Medical

School Eduardo López-Collazo. Scientific Director of

Members

Carmen Maroto Vela

Rafael Pérez-Santamarina Feijóo. Chairman of

the Board of FIBHULP Rodolfo Álvarez-Sala Walther. FIBHULP Patron Miriam Rabaneda Gudiel. FIBHULP Patron José María Muñoz y Ramón. FIBHULP Patron Juan Antonio Vargas Núñez. FIBHULP Patron Eduardo López-Collazo. Scientific Director of

IdiPAZ Exuperio Díez Tejedor. FIBHULP Patron

Francisco García Río. HULP Representative

Francisco Arnalich Fernández. FIBHULP Patron

Francisco Arnalich Fernández. UAM Representative

Fernando Rodríguez Artalejo. UAM Representative Amparo Cano García. UAM Representative Pablo Lapunzina Badía. FIBHULP Patron Juan José Pérez Blanco. FIBHULP Patron Javier

García-Samaniego

FIBHULP Patron

Secretary Ana Coloma Zapatero. Director of FIBHULP

10

Chief of Infectious diseases Service. Ramón y Cajal Hospital. Madrid Professor. Alcalá University. Madrid

Research Ethics Committee Chairwoman Almudena Castro Conde

Deputy Chairman Jesús Frías Iniesta

Technical Secretary Emma Fernández de Uzquiano

Members María Concepción Prados Sánchez José Ignacio Bernardino de la Serna Antonio Buño Soto Elena García Higuera Jaime Fernández Bujarrabal Nuria Rodríguez Salas Filiberto Chulia Fernández Ángel Robles Marhuenda Fernando Cabañas Gómez Elena Villamañán Bueno Filomena Trocoli González Carlos Lahoz Rallo Miriam Romero Portales Pedro Herranz Pinto Nora Butta Coll

Ana Coloma Zapatero. Director of FIBHULP

Francisco

Santiago Rodríguez de Córdoba

Santiago Moreno Guillén

Almudena Castro Conde. FIBHULP Patron

Ana Coloma Zapatero. Director of FIBHULP

Professor. Chief of Microbiology. Clinical Hospital University of Granada Professor. Cellular and Molecular Medicine Department. Centro de Investigaciones Biológicas

IdiPAZ

Secretary

Professor. Department of Biochemistry and Molecular Biology. University of Salamanca Institute of Functional Biology and Genomics

Nuria Vilaboa Díaz Inmaculada Ibáñez de Cáceres Eduardo López Granados Blanca Fuentes Gimeno Javier de Castro Carpeño Amparo Cano García Francisco Arnalich Fernández Guillermo Reglero Rada Fernando Rodríguez Artalejo Mercedes Salaices Sánchez Nora Butta Coll Rosario Perona Abellón Antonio Pérez Martínez Ignacio Zapardiel Gutiérrez Alfonso Gil Martínez

Rey.

Research Committee Members Eduardo López-Collazo José Luis López-Sendón Enrique Gómez Barrena Francisco García Río Jesús Frías Iniesta Jaime Feliú Batlle Jesús Mingorance Cruz Rafael Selgas Gutiérrez

Rosa Villanueva Peña Ramón Usandizaga Elio

Member from outside the institution Mario Arancón Monge Evangelina Garrido García

Technical Secretary Emma Fernández de Uzquiano Paz Lavilla Uriol Sol de Gracia García Maribel Arribas Álvarez

Continue

11

2 EXECUTIVE SUMMARY

2.2 Research Structure

Animal Welfare Ethics Committee Carmen Fernández Criado Fernando Carceller Benito Nuria Vilaboa Díaz Carlota Largo Aramburu

Training Committee Coordinator Bárbara Martínez de Miguel

Members

Quality Assurance Committee Coordinator José Jonay Ojeda Feo

Members Blanca Fuentes Gimeno Alberto Martín Vega María Luisa Díaz Martínez Margarita Rodrigo Angulo

Technical Secretary Mercedes Ruiz Balibrea Tamara Moruno García

Documentation Service Raúl Román Cañizares

Coordinator of the Scientific Direction Paloma Gómez Campelo

FIBHULP Director Ana Coloma Zapatero

Human Resources Manager Head: Ana Gloria Herrera Puerta

María Quintanar Jaime

Private Projects Manager Francisco Gil Gadea

Clinical Trial Manager

Ana Isabel de Cos Blanco

Head: Sara Moral Álamo

Jesús Solera García



Julián Nevado Blanco

Desirée Hernández López

Public Projects Manager Head: Silvia Arce Santamaría

Raquel Carmona del Mazo

Institutional Project Manager José Luis Narro Villanueva Marisa Tejedor Botello

Contracting Manager and Head of Legal Department Sara Fernández Morata

Accountants Head: Laura López Revuelta

Mónica García López

Researcher Reception and Attention Carmen García Artiaga

12

Continue

13

2 EXECUTIVE SUMMARY

2.2 Research Structure

Research Areas GROUP

Internal Medicine and Systemic Diseases Organic Dysfunction and Failure in the Aggression Respiratory Diseases GROUP

Psychiatry and Mental Health

Neuroscience Area Coordinator: Exuperio Díez Tejedor

Neurology and Cerebrovascular Diseases Neuroprotective Strategies in Neurodegenerative Diseases Structure, Neurochemistry and Plasticity of Neural Circuits of the Cerebral Cortex and Thalamus Involvement of Glycinergic and Glutamatergic Systems in Central Nervous System Pathologies

Nephrology

Consuelo de Dios Perrino Exuperio Díez Tejedor Antonio Cuadrado Pastor Francisco Clascá Cabré Cecilio Giménez Martín

Large System Pathology Area

Neonatology

Coordinator: Francisco García Río

Gynecologic Oncology

GROUP

Cardiovascular Area Coordinator: José Luis López-Sendón Hentschel

Molecular Hepatology

Cardiovascular Epidemiology and Nutrition Coagulopathies and Alterations of Haemostasis Vascular Physiology and Pharmacology Vascular Pharmacology and Metabolism (FARMAVSM)

Víctor Jiménez Yuste Mercedes Salaices Sánchez Carlos F. Sánchez Ferrer

Cancer and Human Molecular Genetics Area

GROUP

AIDS and Infectious Diseases

Lucrecia Herranz de la Morena

Urology

Luis Martínez-Piñeiro Lorenzo

Infectious Diseases and Immunity Area Coordinator: Eduardo López-Collazo

Jesús Mingorance Cruz

Immuno-Rheumatology

María Eugenia Miranda Carús Margarita López Trascasa Pilar Sánchez-Corral Gómez

Lymphocyte Pathophysiology in Immunodeficiencies

Eduardo López Granados

Drug Hypersensibility and Innate Immune Response

Teresa Bellón Heredia

Pediatric Systemic Infections; HIV, tuberculosis, Imported and Emergent Diseases Translational Research in Pediatric Oncology, Hematopoietic Transplantation and Cell Therapy

Maternal and Fetal Medicine

José Luis Bartha Rasero

Emergency and Critical Pathology

Cesar Carballo Carmona

Translational Oncology

DIRECTOR

Pablo Lapunzina Badía Jaime Feliú Battle

Experimental Therapies and Biomarkers in Cancer Oto-Neurosurgery Research Cancer Molecular Pathology and Therapeutic Targets Mechanisms of Tumour Progression Animal and Cell Models for Detection and Characterization of Leukemic Stem Cells Research and Diagnosis of Inherited Metabolic Diseases

Inmaculada Ibáñez de Cáceres Javier de Castro Carpeño Luis Lassaletta Atienza David Hardisson Hernáez Amparo Cano García Carmela Calés Bourguet María Belén Pérez González Francesc García Gonzalo

Eduardo López-Collazo

Diagnosis and Treatment of Diseases associated with Abnormalities of the Complement System

Pediatric Respiratory, Systemic and Neurological Infections & Host Immune Response

Jesús Castro Toro

José Ramón Arribas López

Molecular Microbiology Innate Immune Response

Manuel Quintana Díaz

Endocrine Diseases

Regulation of Ciliary Structure and Function by Phosphoinositides

DIRECTOR

Santiago Quirce Gancedo Ignacio Zapardiel Gutiérrez

Patient Blood Management

GROUP

Fernando Rodríguez Artalejo

Juan Ignacio González Montalvo Paloma Jara Vega

Diagnosis and Treatment of Allergic Diseases

INGEMM- Institute of Medical and Molecular Genetics

Coordinator: Amparo Cano García

14

Adelina Pellicer Martínez

Aging and Fragility in the Elderly

DIRECTOR

José Luis López-Sendón Hentschel

Luis del Peso Ovalle Rafael Selgas Gutiérrez

Health Care Nurses Research

Research on Invasive Clinical Cardiology – ICCI-Paz

Abelardo García de Lorenzo y Mateos Francisco García Río

Regulation of Gene Expression and by Hypoxia

DIRECTOR

DIRECTOR

Francisco Arnalich Férnandez

Cristina Calvo Rey María José Mellado Peña Antonio Pérez Martínez

GROUP

Surgery, Transplant and Health Technologies Area Coordinator: Leopoldo Martínez Martínez

Congenital Malformation Surgery Bone Pathophysiology and Biomaterials Cellular Engineering Clinical Pharmacology Osteoarticular Surgery Research – GICOA Reconstructive and Regenerative Research Transplant

DIRECTOR

Leopoldo Martínez Martínez Nuria Vilaboa Díaz María Paz de Miguel González Jesús Frías Iniesta Enrique Gómez Barrena Luis Landín Jarillo Francisco Hernández Oliveros

Continue

15

2 EXECUTIVE SUMMARY

2.2 Research Structure

Human Resources Public Research Contracts Ramón y Cajal Stabilisation Contracts (I3) - CAM

• Karen Elise Heath. INGEMM - Institute of Medical and

Molecular Genetics Group • Jesús Mingorance Cruz. Molecular Microbiology Group

Miguel Servet Stabilisation Contracts (I2) - ISCIII/ CAM

• Teresa Bellón Heredia. Drug Hypersensibility and Innate

Immune Response Group • Juan Ángel Fresno Vara. Translational Oncology Group • Ángel Campos Barros. INGEMM - Institute of Medical and

Molecular Genetics Group • María Paz de Miguel González. Cellular Engineering

Group • Eduardo López-Collazo. Innate Immune Response Group • Juan Antonio Rey Herranz. Oto-Neurosurgery research

Group • Berta Rodés Soldevila. AIDS and Infectious Diseases

Group • Pilar Sánchez-Corral Gómez. Diagnosis and Treatment

of Diseases Associated with Abnormalities of the Complement System Group • María Rosa Torres Jiménez. Metabolic-Vascular Unit Group • David Vicent López. Molecular Hepatology Group • Nuria Vilaboa Díaz. Bone Pathophysiology and Biomaterials Group

Miguel Servet Contracts Type I - ISCIII

• María Fernández Velasco (MS11/00197). Innate Im-

mune Response Group • Laura Saldaña Quero (MS11/00022). Bone Pathophy-

siology and Biomaterials Group

Miguel Servet Contracts Type II - ISCIII

• Nora Viviana Butta Coll (MSII14/00024). Coagulo-

pathies and Alterations of Haemostasis Group • María Inmaculada Ibáñez de Cáceres (MSII14/00008). Experimental Therapies and Biomarkers

in Cancer Group • Rosa María Rodríguez Pérez (MSII13/000022).

Diagnosis and Treatment of Allergic Diseases Group

Intensification Contracts - ISCIII

• José Ramón Arribas López (INT15/00083). AIDS

and Infectious Diseases Group • Francisco José García Río (INT15/00076). Respira-

tory Diseases Group

Ramón y Cajal Contracts - MINECO

• Rebeca Pérez de Diego (RyC2011-07597). Innate

Immune Response Group

Río Hortega Contracts - ISCIII

• Rocío Montejano Sánchez (CM14/00034). AIDS and

Infectious Diseases Group

16

Juan Rodés Contracts - ISCIII

Programme

Organisation

Total

• Emilio Cendejas Bueno (JR14/00027). Molecular Mi-

crobiology Group • Ignacio Pérez Valero (JR13/00016). AIDS and Infectious

Diseases Group

Sara Borrell Postdoctoral Contracts - ISCIII

• Raquel Rodrigues Díez (CD15/00003). Vascular Phy-

siology and Pharmacology

Predoctoral Fellowship - ISCIII

• Clara Escudero Duch (FI14/00447). Bone Pathophy-

siology and Biomaterials Group • Natalia Stella Ascariz (FI14/00391). Molecular Micro-

biology Group

Predoctoral Contract - MECD

• Irene Francisco Recuero (FPU13/00945). Associated

Clinician • Daniel Ruiz Pérez (FPU13/01638). Respiratory Disea-

ses Group

Technical Support Stabilisation Contracts - CAM

• Francisco Gayá Moreno. AIDS and Infectious Diseases

Group

Ramón y Cajal Stabilisation Contracts (I3)

CAM

2

Miguel Servet Stabilisation Contracts (I2)

ISCIII/ CAM

11

Technical Support Stabilisation Contracts

CAM

3

Miguel Servet Contracts CP Type 1

ISCIII

2

Miguel Servet Contracts CP Type 1I

ISCIII

3

Intensification Contracts

ISCIII

2

Ramón y Cajal Contracts

MINECO

1

Río Hortega Contracts

ISCIII

1

Juan Rodés Contracts

ISCIII

2

Sara Borrell Postdoctoral Contracts

ISCIII

1

Predoctoral Fellowship

ISCIII

2

TOTAL ESTABLISHED

Predoctoral Contract PTA Contracts

ISCIII

1

CAM

6

Youth Guarantee Contracts

MINECO

2

TOTAL PROGRAMMES

TOTAL ESTABLISHED + PROGRAMMES

• Beatriz Sanz Minguela. Cell Culture Unit

Therapies and Biomarkers in Cancer Group • Víctor Manuel Toledano Real (Pta2013-8265-I).

Innate Immune Response Group

Technical Support in Management Contracts - ISCIII

• María Luisa Tejedor Botello (GIS14/00015). Associa-

ted Clinician

Youth Guarantee Contracts - CAM

• Verónica Aparicio Herranz (PEJ15/BIO/AI-045).

Cellular Engineering • Irene Dapia García (PEJ15/BIO/AI-0222). Institute of

Medical and Molecular Genetics • María Fernández Elvira (PEJ15/BIO/TL-0158). Insti-

CAIBER

of Medical and Molecular Genetics

6 14

EU

2

Research Network

ISCIII

14

Research Network

CAM

3

SAF/MAT

MINECO

3

Biobank

ISCIII

3

European Projects

Commercial clinical trials

EECC Promoters

29

Pharmaceutical Industry

71

In-house Projects

FIBHULP

7

ITEMAS Network

ISCIII

4

MINECO

4

Private projects

RETOS

TOTAL EMPLOYEES DEPENDET ON P.I. Private projects

Youth Guarantee Contracts. MINECO

• Gonzalo Polo Paredes (PEJ-2014-A-18995). Experi-

mental Surgery

Pharmaceutical Industry

TOTAL FELLOWS DEPENDET ON P.I.

Technical Unit Staff

160 25

TOTAL STAFF DEPENDENT ON P.I.

Bone Pathophysiology and Biomaterials cular Hepatology

43

ISCIII

• Silvia Sánchez Casanova (PEJ15/BIO/AI-0250). • Cristina Vicente Capa (PEJ15/BIO/TL-0238). Mole-

27

CAIBER

FIS Projects

tute of Medical and Molecular Genetics • Nerea Lobato Vidal (PEJ15/BIO/AI-0286). Institute

2 2

Technical Support in Management Contracts

tion Surgery Group

• Olga Pernía Arias (PTA2012-7141-I). Experimental

MECD MINECO

Youth Guarantee Contracts

• María Teresa Vallejo Cremades. Congenital Malforma-

PTA Contracts - MINECO

16

FIBHULP

25

185 13

TOTAL TECHNICAL UNIT

13

TOTAL

241

• Alexander Otero García (PEJ-2014-A-23662). Cell

Culture Laboratory

Return to EXECUTIVE SUMMARY INDEX

17

2 EXECUTIVE SUMMARY IdiPAZ Demand • Researh Areas Area Coordinators • Research Groups Groups Director

Research Training

2.3 Training Report and Teaching

IdiPAZ TRAINING PLAN

Adapting to the Institute’s strategic objectives

Research Area Training Aimed at basic and clinical researches

IdiPAZ Opportunities • HULP Continuing Education • UAM Training Opportunities • Institute Opportunities

2.3.2. Training courses conducted by IdiPAZ in 2016 TITLE

HEAD

DATES

CREDITS

ASSISTANTS

HOURS

ASSESSMENT

Rosario Madero Jarabo

October 17th-20th

2

21

12

8.9

Lectura crítica de estudios de investigación. Recursos para la elaboración de una revisión sistemática

María Luisa Maquedano Martínez

April 5th-7th, 12nd-13rd

2.1

3

15

9

Normas de buena práctica clínica para investigadores y aspectos éticos de la investigación

Emma Fernández de Uzquiano

April 26th -28th

1

25

6

8.4

Valentini Konstantinidou

27th-29th

2.5

15

12

8.4

Análisis de datos biomédicos con SPSS

2.3.1. Training Committee IdiPAZ’s Training Committee is in charge of defining, elaborating and implementing the organization’s training program. It must also ensure the proper development of the programs’ objectives. This committee is designed in such a way that all members of the IdiPAZ are represented. It is composed of a coordinator and a representative from La Paz University Hospital (HULP) and a representative of the Autonomous University of Madrid (UAM). IdiPAZ’s training plan encompasses all studies la ongoing training (HULP) to postgraduate courses (UAM) which also includes IdiPAZ’s own specialist courses. In order to design its own courses’ the committee annually consults via an online

needs analysis survey IdiPAZ members on their area of interests regarding the training needs observed by group leaders. IdiPAZ’s own courses are meant to complement HULP and UAM courses. These courses are coordinated by an IdiPAZ member who is not only the manager of these courses but also the person in charge of all the administrative documentation required by Spain’s National Health System /Board,Thus IdiPAZ courses have the necessary state accreditation. The committee also is in charge of our professionals’ satisfaction follow up surveys. Our specialist courses are taught by researchers and professionals of related disciplines.

COMPOSITION Coordinator Bárbara Martínez de Miguel

Members Ana Isabel de Cos Blanco Jesús Solera García Julián Nevado Blanco

Técnicas ómicas en investigación biomédica

2.3.3. IdiPAZ Doctoral Theses Áncer Arellano AG. Estudio de la asociación de genotipos del virus del papiloma humano con Chlamydia trachomatis y otros gérmenes en pacientes con fallo reproductivo[dissertation]. Madrid: UAM: 2016(7/10/2016). Directors: Hardisson Hernáez D, Gallegos Ávila G. Arroyo Villa I. Estudio de las poblaciones celulares Th17 y Thf en la patogenia de la artritis reumatoide[dissertation]. Madrid: UAM: 2016(13/01/2016). Directors: Miranda Carús ME, Martín Mola E. Bautista Caro MB. Estudio sobre la biología de las células Th17 y Thf en espondiloartritis[dissertation]. Madrid: UAM: 2016(04/02/2016). Directors: Miranda Carús ME, Martín Mola E. Bernabéu Herrero ME. Defects in complement factor H-related proteins (FHRs) in renal pathology[dissertation]. Madrid: UAM: 2016(09/09/2016). Director: Sánchez-Corral Gómez P. Brogly N. Estudio comparativo de dos técnicas de localización del espacio epidural para la analgesia durante el trabajo de parto: pérdida de resistencia con aire o suero [dissertation]. Madrid: UAM: 2016(30/06/2016). Directors: Gilsanz Rodríguez F, Guasch Arévalo E

18

Continue

19

2.3 Training Report and Teaching

2 EXECUTIVE SUMMARY Brose Piotrowicz IB. Avaliação das propriedades antioxidantes e anti-hipertensivas de peptídeos obtidos do concentrado proteico de farelo de arroz[dissertation]. Rio Grande: Universidade Federal do Rio Grande: 2016(27/05/2016). Directors: Salas Mellado M, Miguel Castro M.

Nozal Aranda P. Autoantibodies against proteins of the alternative complement pathway in renal diseases[dissertation]. Madrid: UAM: 2016(13/09/2016). Director: López Trascasa M.

Cancelliere Fernández N. Evaluación de los modelos educativos, teórico y práctico, en residentes de primer año de especialidades médico-quirúrgicas[dissertation]. Madrid: UAM: 2016(19/9/2016). Directors: Quintana Díaz M, Peña Sánchez JM.

Ossorio González M. CCL18 y su implicación en esclerosis peritoneal: validación clínica de un nuevo marcador diagnóstico y pronóstico de alteración de la función peritoneal[dissertation]. Madrid: UAM: 2016(13/12/2016). Directors: Selgas Gutiérrez R, Bajo Rubio MA.

Carrasco Ramírez P. Podoplanina es un componente de vesículas extracelulares que reprograma el contenido proteico de exosomas y modula la formación de vasos linfáticos [dissertation]. Madrid: UAM: 2016(1/04/2016). Director: Quintanilla Ávila M.

Oyarzábal Sanz AL. Del gen a la patofisiología: nuevas enfermedades asociadas al catabolismo de los aminoácidos ramificados [dissertation]. Madrid: UAM: 2016(14/06/2016). Director: Rodríguez Pombo P.

de Velasco Oria de Rueda G. Análisis de un perfil de microARNs como factor pronóstico en cáncer de mama con afectación axilar [dissertation]. Madrid: UCM 2016(14/04/2016). Directors: Fresno Vara JA, Ciruelos Gil E, Paz-Ares L.

Palacios Ramírez R. Papel de ET-1 en la expresión de COX-2 y la contractilidad vascular en hipertensión. Modulación por PPARγ[dissertation]. Madrid: URJC: 2016(03/05/2016). Directors: Hernanz Martín R, Alonso Gordo MJ.

Díaz Agero P. Desarrollo de una técnica de terapia celular e ingeniería tisular con células troncales somáticas mesenquimales para el tratamiento de las fístulas traqueo-bronquiales postquirúrgicas y las de origen yatrogénico[dissertation]. Madrid: UAM: 2016(12/02/2016). Director: Álvarez-Sala Walther R.

Pandiella Dominique A. Aproximación cienciométrica a la Apnea del sueño (2006-2010)[dissertation]. Madrid: UAM: 2016(28/01/2016). Director: García Río F.

Fernández de Bobadilla J. Aspectos epidemiológicos, farmacoeconómicos, psicosociales y terapéuticos de la relación de la Enfermedad Cardiovascular y el Tabaquismo en España[dissertation]. Madrid: UAM: 2016(03/05/2016). Director: Álvarez-Sala Walther R. Fernández Fernández R. Resultados superiores del titanio frente al cromocobalto en cirugía primaria de cadera: resultados a largo plazo con el vástago Meridian[dissertation]. Madrid: UAM 2016(21/04/2016). Director: Gil Garay E. Ferrer Mayorga G. Efectos de la 1α,25-dihydroxyvitamin D3 en fibroblastos estromales de cáncer de colon[dissertation]. Madrid: UAM: 2016(25/11/2016). Directors: Muñoz Terol A, Larriba Muñoz MJ. Heredia Soto V. Identificación de biomarcadores relacionados con la transición epitelio mesénquima y carcaterización de modelos celulares tridimensionales in vitro en cáncer de ovario avanzado[dissertation]. Madrid: UAM: 2016(15/11/2016). Directors: Hardisson Hernáez D, Mendiola Sabio M. Hernández Esteban P. Técnica anatómica frente a técnica transtibial en la reconstrucción del LCA de la rodilla en pacientes futbolistas de alta demanda funcional.[dissertation]. Madrid: UAM: 2016(10/3/2016). Director: Gómez Barrena E. Hernández Jiménez E. Estudio de la inmunidad innata en pacientes con apnea obstructiva del sueño: un microambiente favorable para el progreso tumoral[dissertation]. Madrid: UAM: 2016(23/06/2016). Directors: López Collazo EM, García Río F. Jurado Camino MT. Tolerancia a Endotoxinas: Una explicación a las infecciones recurrentes en la Leucemia Linfática Crónica[dissertation]. Madrid: UAM: 2016(11/03/2016). Directors: López Collazo EM, Cubillos Zapata C. Linares Espinós EE. Valor predictivo del volumen-centro de los resultados de la cirugía de cáncer renal con extensión venosa. Impacto en el modelo asistencial[dissertation]. Madrid: UAM: 2016(22/11/2016). Director: Carballido Rodríguez J. Martín Salces M. Alteraciones de la hemostasia en los síndromes mielodisplásicos[dissertation]. Madrid: UAM: 2016(08/11/2016). Directors: Butta Coll NV, de Paz Arias R, Jiménez Yuste V. Mateos Pañero B.Valoración del Euroscore y SAPS III como predictor de mortalidad hospitalaria en el postoperatorio de cirugía cardiaca [dissertation]. Madrid: UAM: 2016(1/12/2016). Directors: Quintana Díaz M, Sánchez Casado M. Montejano Sánchez R. Impacto del tratamiento antirretroviral con y sin nucleós(t)idos sobre la densidad mineral ósea y los biomarcadores de remodelado óseo[dissertation]. Madrid: UAM: 2016 (18/05/2016). Directors: Arribas López JR, González García JJ, Arnalich Fernández F. Moreno García AC. Terapia celular con células troncales derivadas de tejido adiposo (ADSC) para mejorar el proceso de reparación de defectos óseos en un modelo animal[dissertation]. Madrid: UAM: 2016(04/07/2016). Director: Gil Garay E.

Paz Ramírez L. Utilidad del análisis molecular del ganglio centinela mediante técnica OSNA para la predicción intraoperatoria de afectación de ganglios no centinela en el cáncer de mama[dissertation]. Madrid: UAM: 2016(13/04/2016). Directors: Hardisson Hernáez D, Sánchez Méndez JI. Pérez Valero I. Deterioro cognitivo asociado al virus de inmunodeficiencia humana (VIH) e inhibidores de proteasa potenciados con ritonavir en monoterapia [dissertation]. Madrid: UAM:2016(01/02/2016). Directors: Arribas López JR, Arnalich Fernández F. Rodríguez Castellano E. Impacto del tratamiento del VHC sobre la infección VIH y la morbimortalidad no hepática en pacientes coinfectados VIH y VHC[dissertation]. Madrid: UAM: 2016(01/05/2016). Directors: Berenguer Berenguer J, Arnalich Fernández F. Rodríguez Fernández R. Evaluación de la eficacia de la funduplicatura Nissen laparoscópica mediante el uso de un cuestionario de calidad de vida y estudio esofagogástrico baritado[dissertation]. Madrid: UAM: 2016(12/9/2016). Directors: Quintana Díaz M, Martínez Cortijo S. Rodríguez Sanz AI. Selección de posibles inhibidores de FABP4: Efectos en la actividad proinflamatoria de monocitos/macrófagos y en las interacciones macrófago/adipocito[dissertation]. Madrid: UAM: 2016(28/10/2016). Directors: Bellón Heredia T, Selgas Gutiérrez R. Romero Ribate D. Valoración del Síndrome de Apneas-Hipopneas del sueño como factor de riesgo de la Enfermedad Tromboembólica[dissertation]. Madrid: UAM: 2016(14/09/2016). Director: García Río F. Ruano Encinar M. Efecto de la prescripción electrónica asistida en pacientes pediátricos hospitalizados: evaluación de errores de medicación[dissertation]. Madrid: UAM: 2016(03/11/2016). Director: Álvarez-Sala Walther R. Ruiz Carrascoso G. Características microbiológicas y clínico-epidemiológicas de enterobacterias productoras de carbapenemasa OXA-48 en el contexto de un brote hospitalario[dissertation]. Madrid: UCM: 2016(10/02/2016). Director: Mingorance Cruz J. Sendagorta Cudós E. Prevalencia, diagnóstico y tratamiento de la displasia de alto grado anal asociada a la infección por el Virus del Papiloma Humano en pacientes infectados por el VIH[dissertation]. Madrid: UAM: 2016 (31/01/2016). Directors: González García JJ, Herranz Pinto P. Tiana Cerrolaza M. Mechanisms underlying gene repression in hypoxia[dissertation]. Madrid: UAM: 2016 (01/12/2016). Director: del Peso Ovalle L. European Mention Utrilla Contreras C. Valor de la Tomografía Computarizada Volumétrica en el estudio de la Enfermedad Pulmonar Obstructiva Crónica[dissertation]. Madrid: UAM: 2016(13/04/2016). Director: García Río F. Valbuena Gómez I. Eficacia de los recuperadores de sangre postoperatorios. Factores de riesgo transfusional y de hemorragia en la artroplastia total de rodilla [dissertation]. Madrid: UAM: 2016(20/12/2016). Directors: Gilsanz Rodríguez F, Guasch Arévalo E.

Moreno Pérez A. Teoría y práctica de la supervisión. Análisis del discurso de supervisores y psicoterapeutas [dissertation]. Madrid: UAH: 2016 (14/04/2016). Director: Rodríguez Vega B, Fernández Liria A. Navarro Vidal B. Logro de objetivos cardiometabólicos en sujetos hipertensos y diabéticos [dissertation]. Madrid: UAM: 2016 (13/03/2016). Directors: Banegas Banegas JR, Graciani Pérez-Regadera MA. 20

Return to EXECUTIVE SUMMARY INDEX

21

2 EXECUTIVE SUMMARY

2.4 Innovation and Transfer Activities

• Boosting a fruitful collaboration among all entities that make up the ITEMAS Platform. In the last years the UAI has definitely consolidated its presence and visibility in the whole environment HospitalInstitute. Its impact in the Hospital has been strengthened by the creation of both the Innovation Platform and the Innovation Committee as two linked structures within the organisation. The Innovation Platform is an initiative launched from the Hospital’s Management Board in order to promote, extend, enhance and stimulate innovation throughout the Hospital. The main mission of the Innovation Platform is to build a culture of innovation among all Hospital and Institute staff. The Innovation Unit is integrated into this platform as its main driver and, as such, it establishes its objectives and marks its lines of action and will be responsible for channelling the entire workload. It also forms part of the Innovation Committee, a decisionmaking body on the ideas to be supported by FIBHULP. Among the greatest achievements of the Innovation Support Unit are the following:

2.4.1. Innovation and Transfer Activities The Innovation Support Unit (UAI) of FIBHULP was created in June 2010 within the framework of the ITEMAS Network – currently called ITEMAS Platform- of the Carlos III Institute of Health. Since its creation, the UAI has contributed to promoting and protecting innovative/ground breaking research conducted by IdiPAZ. The UAI also intends to harness our institute’s considerable innovative potential generated, as a step prior to its subsequent transfer to society. Therefore, one of the main commitments of the UAI is that researchers and health personnel perceive it as a resource at their service, to provide support and advice in all that relates to the identification, management, protection, transfer, marketing and dissemination of their research results.

ACTIVITIES

The main aim of the UAI is to identify the potential transferable research results generated within our institute and to accompany and support the researcher throughout the whole innovation process: from the birth of the idea to its placement on the market. Since the UAI has been in operation, several projects sponsored by the institute itself have been managed and different collaboration agreements have been signed with important private institutions and organisations to promote innovation.

22

Our main objectives are: • Promoting a culture of innovation and entrepreneurship within the institute by fostering the generation of innovative ideas and solutions that meet the needs of patients and society, in general, and supporting their development through various initiatives. • Actively searching and identifying knowledge and research results emerged within the institute and transferable to the market. • Fostering and managing the protection and transfer of knowledge and research results to society and promoting the current technology portfolio of the institute while getting an economic return which allows its reinvestment in research and development. • Promoting the participation of industry in the innovation process acting as a stakeholder actively involved in it. • Formalising business alliances, including technology companies as well as industrial and financial partners, to develop collaborative projects and to transfer the results to the market. • Generating resources that achieve the greatest impact on society, enabling a better quality health care and at the same time contributing to the sustainability of the National Health System.

1. The UAI has become one of IdiPAZ’s most in-demand and requested platforms as it is responsible for promoting, supporting and managing all innovation projects. At December 31 2016, the UAI had 164 innovation projects or ideas in active state, 28 of which were in the capture phase, 49 in the evaluation phase, 9 in development, 52 in transfer and 26 in the market. According to these data, it follows that 16% of the projects have been successfully exploited and positioned in the market, very positive percentage (although far lower than the aspired figure) given the precariousness of the times we go through and the resources (both human and financial) with which the UAI counts. Among the various types of projects handled by the UAI it is particularly noteworthy the volume of medical device-type projects, followed by projects such as “Bio”, “Health ICT” and “eHealth”. Although the UAI has more than six years of experience, most of the activity (134 projects) and its achievements have taken place in the last five years, period 2012-2016. 2.The UAI has built a wide and diverse technology portfolio. Each year the number of innovation projects managed by the UAI increases with respect to the previous year, also increasing the number of Hospital services, research groups and professionals in general who join IdiPAZ’s innovation community. During the period 2012-2016, the UAI filed 23 priority patents (20 Spanish patents and 3 European patents) and 17 PCT; 5 national or regional phase entry applications were filed (2 before the EPO, 2 before USPTO and 1 before CIPO (Canadian Intellectual Property Office)) and 26 patents were granted (2 of them European patents). UAI’s portfolio of patents in active state during period 2012-2016 reached the figure of 41 patent families and 1 utility model. As for the software, during the period 2012-2016 the UAI registered 13 new computer applications. Special mention should also be made to the UAI brand portfolio. During the period 2012-2016, 14 brands were requested and 14 were granted.

It is important to note that these brands, besides allowing IdiPAZ to distinguish its products or services from competitors’ products or services, are associated with the know-how of the institution, know-how that has been transferred along with the distinctive sign in the case of the license agreements signed by the institution in respect of trademarks. 3. The UAI has prepared a catalogue of technology offers -based on specification sheets- which includes the complete portfolio of exploitable IdiPAZ results. This catalogue aims to promote the transfer of IdiPAZ’s technology portfolio to the industrial sector, generate collaborative projects for technological development and foster the exploitation of research results. Those validated specification sheets are published on IdiPAZ’s website. The catalogue is updated as the Institute’s technology portfolio grows. 4. The UAI has been, is, and will continue to be the principal architect for the transfer and exploitation of IdiPAZ’s technology portfolio. During the period 20122016 the UAI succeeded in signing 8 license agreements of intellectual property rights (copyright) and bringing 9 patents, 7 software, and 7 brands into commercial exploitation, which has meant a significant achievement in terms of economic return. 5. Thanks to UAI’s support and management it has been possible to create and consolidate the first technologybased company of the Hospital (and also of the region of Madrid) according to the regulations established by the Department of Health of the Community of Madrid. The spin-off concerned, Biomedica Molecular Medicine, exploits the research results in oncology –specifically, a genomic test to determine whether breast cancer patients should have chemotherapy – designed by some members of IdiPAZ. 6. Through the promotion of a culture of innovation, the UAI has managed to create a large community of innovative professionals. Over the last year its promotional activity has consisted in the celebration of several working days, workshops, seminars, etc.: • “Oportunidades de financiación del programa ERC para investigadores de institutos de investigación biomedical” Workshop, April 6 2016 • “La compra pública innovadora en e­Health en el entorno sanitario” Workshop, June 3 2016 • “La innovación es posible: IdiPAZ te ayuda a lograrlo” Workshop, July 12 2016 • “Gestión de la Investigación FIBHULP-IdiPAZ” Workshop, December 13 2016 In addition, UAI has collaborated with important institutions and private entities to promote innovation, in particular it has participated in various forums and round tables organised by various stakeholders of the biomedical sector. 7.The UAI’s has succeeded in creating a wide-ranging network of contacts. By virtue of its membership in the ITEMAS Platform, the Unit has continued to strengthen ties and creating synergies with the members of this Platform in order to achieve its established objectives.

Continue

23

2.4 Innovation and Transfer Activities

2 EXECUTIVE SUMMARY Apart from the above results it is important to emphasize that several innovation projects managed by the Innovation Unit have been awarded with prestigious prizes over the last year: • Award obtained in the first edition of the Healthstart Program by two of our innovation projects, in particular DILUBIO project, led by Dr Jesús Manuel Muñoz Caro, and PROTO:DEVICES project (High precision rectoscope) led by Dr Mario Álvarez Gallego (first prize and accesit respectively). Healthstart is the program of the Madrimasd Knowledge Foundation (Madri+d Foundation) and the Medical Technology Innovation Platform (ITEMAS Platform), promoted by the Institute of Health Carlos III (ISCIII) for the acceleration of technological start-ups of the Community of Madrid in the healthcare sector, • Prize won by the app Vivir con EPOC -developed by IdiPAZ’s HEALTH CARE NURSES RESEARCH GROUP together with the company Navandu Technologies- in the first edition of the Andalusia Health Challenges initiative. This initiative was promoted by the Public Health Service of Andalusia (SSPA) in collaboration with the company

Vodafone and aims to promote the development of mobile applications (or apps) that improve user adherence to the treatment of chronic diseases. This first ‘Challenge’ was directed, in particular, to chronic obstructive pulmonary disease (COPD). This same app has been awarded with other prizes such as the 2017 SaluDigital Award organized by Grupo Mediforum, in the category of Best Health App.

ORGANISATION

Since its implementation, the UAI has been integrated into the organisational structure of FIBHULP, as one of the Support Platforms for IdiPAZ research. The Innovation Unit is directed by Dr. Javier de Castro Carpeño, M.D. and Ph.D. in Medicine and a member of the Medical Oncology Department of the La Paz University Hospital/ Autonomous University of Madrid and of the Translational Oncology Unit of IdiPAZ. The Innovation Unit also consists of a team of four experts in fostering innovation and protecting research results and technology transfer: Estela Sánchez Simón, Law Graduate; Marisa Tejedor Botello, Bachelor of Economic Sciences; María Dolores Pérez Garre, Bachelor of Chemical Sciences. and Adriana Varela Fernández, Bachelor of Economic Sciences;

CONTACT Coordinator

2.4.2. Patents and trademarks

Neuroscience Area Neurology and Cerebrovascular Diseases Group Valdivieso Amate F, Bullido Gómez-Heras MJ, Martínez García A, inventors; UAM, assignee. Method of identifying compounds that induce or inhibit endoplasmic reticulum stress or oxidative stress. P200702997, PCT/ES2008/000705, EP2221379, US20100304384; 2007 November 13. Vergés Milano J, García García A, Ruhí Roura R, Montell Bonaventura E, García López M, Aláez Versón CR, Escaich Ferrer J, Egea Máiquez J, Lorrio González S, Negredo Madrigal P, inventors; Bioibérica S.A., UAM, assignees. Sulphated disaccharides for the treatment of neurodegenerative and/or neurovascular diseases. P200902399, PCT/EP2010/070613, US20120309707, CA20102785237; 2010 December 22. Valdivieso Ámate F, Burgos Muñoz JS, Ramírez Moreno C, Sastre Merlín I, inventors; UAM, CSIC, assignees. Method of identifying therapeutic compounds which can be used for the treatment and/or prevention of infections and diseases caused by human herpes viruses. P200400965, PCT/ES2005/000209, EP1769677, US20070218004, AT447321, AU2005235319, CA2562787, JP2007533315; 2004 April 21. Valdivieso Ámate F, Montoliú JL, Pozueta Larios J, inventors; UAM, CSIC, assignees. Alzheimer’s disease animal model, method for obtaining same and uses thereof. P200503002, PCT/ES2006/000673, EP1956091, EP20060841725, US20090222932, CA2638983, JP2009517066; 2005 December 02. Ballesteros García P, López Larrubia P, Domínguez Mateo L, Marco Contelles JL, Cerdán García-Esteller S, inventors; Universidad Nacional de Educación a Distancia, CSIC, assignees. Set of magnetic resonance imaging and spectroscopy cell acidity extrinsic indicators comprise polyol derivatives based on alditols. P200300936; 2003 April 23.

Neuroprotective Strategies in Neurodegenerative Diseases Group Cuadrado Pastor A, Innamorato NG, inventors: CSIC, UAM. Use of sulforaphane as supplementary therapy for earlystage neurodegenerative disease. P201231693; 2012 November 06.

Javier de Castro Carpeño [email protected] Phone: (+34) 91 207 12 34

León Martínez R, Egea Maíquez J, Buendía Abaitua I, Parada Pérez E, Navarro González de Mesa E, inventors; Fundación para la Investigación Biomédica del Hospital Universitario de La Princesa, UAM, CSIC, DNS Neuroscience S.A., assignees. Use of 3-(2-isothiocyanatoethyl)-5-methoxy-1H-indole for the treatment of neurodegenerative diseases. P201300667; 2013 July 17.

Members

León Martínez R, Buendía Abaitua I, Navarro González de Mesa E, Michalska P, Gameiro Ros I, López Vivo A, Egea Maíquez J, García López M, García García A, inventors; Fundación para la Investigación Biomédica del Hospital Universitario de La Princesa, UAM, DNS Neuroscience S.A., assignees. Compounds derived from 3-alkylamine-1H-indolyl acrylate and its use for the treatment of neurodegenerative diseases. P201400810, PCT/ES2015/000139, CA2964309; 2014 October15.

Estela Sánchez Simón [email protected] Phone: (+34) 91 207 12 34 Marisa Tejedor Botello [email protected] Phone: (+34) 91 207 17 40 María Dolores Pérez Garre [email protected] Phone: (+34) 91 207 12 34 Adriana Varela Fernández [email protected] Phone: (+34) 91 207 17 90

Cardiovascular Area Research on Invasive Clinical Cardiology- ICCI-PAZ Group Riera del Moral LF, inventor; FIBHULP, assignee. Aortic endoprosthesis for the treatment of aneurysm. P201231638, PCT/ES2013/070712; 2012 October 24. Filgueiras Rama D, López de Sá y Areses E, Millet Roig J, Calvo Saiz CJ, inventors; Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), FIBHULP, Universidad Politécnica de Valencia, assignees. Method of predicting or prognosticating neurological performance in patients who have suffered a cardiac arrest and optionally comatose status due to ventricular fibrillation. PCT/EP2015/076893, EP3020333; 2014 November 17.

Vascular Physiology and Pharmacology Group Pérez Girón JV, Ruiz-Castellanos MJ, de Luis Jiménez O, Pérez Boto V, Sanz González R, Hernández Vélez MC, Mas Gutiérrez JA, Alonso Gordo MJ, Salaíces Sánchez M, Ros Pérez M, Coloma Jerez A, Asenjo Barahona A, Sanz Montaña JL, Puente Prieto J, Jensen J, inventors; Nanoate, S.L., assignee. Method for producing biosensors. P201031224, PCT/ES2011/070536; 2010 August 05. Miguel Castro M, López-Alonso Fandiño R, Recio Sánchez MI, Ramos González MM, Aleixandre de Artiñano A, 24

Continue

25

2.4 Innovation and Transfer Activities

2 EXECUTIVE SUMMARY inventors; CSIC, assignee. Bioactive peptides derived from the proteins of egg white by means of enzymatic hydrolysis. P200301829, PCT/ES2004/070059, EP1661913, US8227207, AT388166, DE602004012289, DK1661913, JP2007523045; 2003 July 31. Miguel Castro M, López-Alonso Fandiño R, Ramos González MM, Aleixandre de Artiñano A, inventors; CSIC, assignee. Production of and antihypertensive properties of peptides derived from egg white proteins. P200501246 PCT/ ES2006/070067; 2005 May 23. Recio Sánchez MI; Quirós del Bosque A, Hernández Ledesma B, Gómez Ruiz JA, Miguel Castro M, Amigo Garrido L, López Expósito I, Ramos González MM, Aleixandre de Artiñano A, (Contreras Gómez M), inventors; CSIC, assignee. Bioactive peptides identified in enzymatic hydrolyzates of milk caseins and method of obtaining same. P200501373, PCT/ES2006/070079, EP1905779, EP2495250, US8354502, AU2006256720, BRPI0611729, CA2611416, CN101305017, CN103254278, JP2008545774, KR20080045108, MX2007015528, NO20080103; 2005 June 08. Garcés Rimón M, Miguel Castro M, López-Alonso Fandiño R, López-Miranda González V, Uranga Ocio J, inventors; CSIC, Universidad Rey Juan Carlos, assignees; Use of multifunctional bioactive products derived from the enzymatic hydrolysis of egg white proteins for treating metabolic syndrome. P201331767, PCT/ES2014/070880; 2013 December 04. Miguel Castro M, Garcés Rimón M, López-Alonso Fandiño R, Sandoval Huertas M, inventors; CSIC, Mario Sandoval Huertas, assignees. Healthy food compositions having gel or foam textures and comprising hydrolyzed egg products. P201331886, PCT/ES2014/070902, EP3106042, US9648897, AR098685, JP2015130856, MX2014015135; 2013 December 20. González-Muñiz R, Pérez de Vega MJ, Miguel M, Balsera-Paredes B, Moreno S, inventors; CSIC, assignee. Triazolyl polyphenols with antioxidant activity and uses thereof; P201531450; 2015 November 08. González-Muñiz R, Miguel Castro M, Pérez de Vega MJ, Balsera-Paredes B, S Moreno, inventors; CSIC, assignee. Compounds with antioxidant activity and uses thereof. P201630362; 2016 March 29.

Diagnosis and Treatment of Diseases Associated with Abnormalities of the Complement System Group López Trascasa M, authors; FIBHULP, assignee. Brand name: COMPLEMENTest; CM 009.658.791; 2011, January 14.

Lumphocyte Pathophysiology in Immunodeficiencies Group Van Dongen JJM, Orfao de Matos Correia E Vale JA, Van Der Burg M, Pérez Andrés M, Van Zelm MC, Kalina T, Vlkova M, López Granados E, Blanco Álvarez E, Kienzler AK, inventors; Erasmus University Medical Center Rotterdam, assignee. Reagents, methods, and kits for diagnosing primary immunodeficiencies. PCT/NL2015/050762, US62/072,498; 2014 Oct 30.

Drug Hypersensibility and Innate Immune Response Group Selgas Gutiérrez R, Bellón Heredia T, Rodríguez Sanz AI, Álvarez Builla J, Vaquero López JJ, Sánchez Alonso P, Alajarín Fernández R, inventors; FIBHULP, Universidad de Alcalá, assignees. Use of compounds derived from salts of pyridazine[1’,6’:1,2]pyrido[3,4-b]indolinium as anti-inflammatory agents. P201331143, PCT/ES2014/070603; 2013 July 25. Selgas Gutiérrez R, Bellón Heredia T, Rodríguez Sanz AI, Álvarez Builla J, Vaquero López JJ, Sánchez Alonso P, Alajarín Fernández R, inventors; FIBHULP, Universidad de Alcalá, assignees. Use of compounds derived from salts of piridazine[3,2-b]benzimidazolium as anti-inflammatory agents. P201430411, PCT/ES2014/070603; 2013 July 25. Sánchez Niño MD, Ortiz Arduán A; FIBHULP, Instituto de Investigación Sanitaria Fundación Jiménez Díaz. Pharmaceutical composition and its use in the manufacture of a medicament for treating chronic kidney disease and method for screening compounds. P201430081, PCT/ES2015/070039; 2014 January 27.

Infectious Diseases and Immunity Area AIDS and Infectious Diseases Group Romero Gómez M, Solá Lamoglia R, González García JJ, inventors; Servicio Andaluz de Salud, Universidad de Sevilla, Fundació Institut Mar D’Investigacions Mèdiques, FIBHULP, assignees. Kit for decision making in patients with Hepatitis C genotypes 1 and 4. P201330731; 2013 May 21.

Molecular Microbiology Group

Large System Pathologies Area Organic Dysfunction and Failure in the Agression Group Herrero Ambrosio A, Ramírez García E, Ojeda Feo JJ, Pérez Rodríguez J, Asensio Martín MJ, González Sánchez ML, Moro Agud M, Lorente Romeo M, López Nieto M, Gómez Rioja R, authors; FIBHULP, assignee. Brand name: SINOIRES; CM 13.080.056; 2014 July 14.

Vicente Muñoz M, Mingorance Cruz J, Rueda González MS, inventors; CSIC, assignee. Method for determining state of growth and viability of bacterial FTsZ population, whether natural or cultivated, is based on determining existence of FTsZ rings in actively growing individual cells. P200200370; 2002 February 15. Mingorance Cruz J, Castán García P, Franco de Sarabia Rosado PM, inventors; Biotools Biotechnological & Medical Laboratories S.A., assignee. Composition, method and kit for detecting bacteria by means of sequencing. PCT/ ES2009/000507, EP2492352, US2013157265, CA2775273, MX2012004627; 2009 October 22. Mingorance Cruz J, Castán García P, Franco de Sarabia Rosado PM, inventors; 2B Blackbio S.L., assignee. Composition, method and kit for detecting fungi and yeasts by means of sequencing. PCT/ES2010/000248; 2010 June 02.

Immuno-Rheumatology Group Pascual-Salcedo Pascual MD, Balsa Criado A, Plasencia Rodríguez C, authors; FIBHULP, assignee. Brand name: BioDrug Analysis BIDA. CM 13.808.531, 2015 March 10.

Fernández Luna JL, Martínez Taboada VM, López Hoyos M, Torices del Val S, Muñoz Cacho P, Varela Egocheaga I, Juliá Cano A, Marsal Barril S, Balsa Criado A, inventors; FIBHULP, Fundación Instituto de Investigación Marqués de Valdecilla, Servicio Cántabro de Salud, Universidad de Cantabria, Fundació Hospital Universitari Vall D´Hebron - Institut de Recerca (VHIR), assignees. Method for predicting the clinical response to anti-inflammatory agent therapies. P201600636; 2016 July 26.

Innate Immune Response Group Llamas Matías MA, López-Collazo E, inventors; FIBHULP, Llamas Matías MA, Empireo S.L., assignees. Method for determine the risk of developing an infectious disease. P201330768, PCT/ES2014/070434, EP3006570; 2013 May 27. 26

Nephrology Group Selgas Gutiérrez R, Bellón Heredia T, Rodríguez Sanz AI, Álvarez Builla J, Vaquero López JJ, Sánchez Alonso P, Alajarín Fernández R, inventors; FIBHULP, Universidad de Alcalá, assignees. Use of compounds derived from salts of pyridazine[1’,6’:1,2]pyrido[3,4-b]indolinium as anti-inflammatory agents. P201331143, PCT/ES2014/070603; 2013 July 25. Selgas Gutiérrez R, Bellón Heredia T, Rodríguez Sanz AI, Álvarez Builla J, Vaquero López JJ, Sánchez Alonso P, Alajarín Fernández R, inventors; FIBHULP, Universidad de Alcalá, assignees. Use of compounds derived from salts of piridazine[3,2-b]benzimidazolium as anti-inflammatory agents. P201430411, PCT/ES2014/070603; 2013 July 25. Aguilera Peralta AI, López-Cabrera M, Selgas Gutiérrez R, Steppan S, Passlickdeetjen J, inventors; Fresenius Medical Care Deutschland GMBH, assignee. Pharmaceutical compositions containing steviosides. EP14191301.2, PCT/ EP2015/074955; 2014 October 31. López-Cabrera M, Aguilera Peralta AI, Selgas Gutiérrez R, Passlickdeetjen J. Buechel J, Steppan S, inventors; Fresenius Medical Care AG & Co. KGaA, assignee. Method and kit for diagnosing epitelial to mesenchymal transition of the peritoneum (EMT-Chip). DE102015115158.8; 2015. Sánchez Niño MD, Ortiz Arduán A; FIBHULP, Instituto de Investigación Sanitaria Fundación Jiménez Díaz. Pharmaceutical composition and its use in the manufacture of a medicament for treating chronic kidney disease and method for selecting compounds. P201430081, PCT/ES2015/070039; 2014 January 27.

Neonatology Group Segovia Iñigo C, Montes Bueno MT, inventors; Segovia Iñigo C, assignee. Positioning device for neonates (Utility model). U201330102; 2013 January 31.

Continue

27

2 EXECUTIVE SUMMARY

2.4 Innovation and Transfer Activities

Diagnosis and Treatment of Allergic Diseases Group Valenta R, Constantin C, Quirce Gancedo, SE, inventors; Phadia AB, assignee. Novel wheat allergens. PCT/SE2008/051377, EP2225266, US2010305049, AU2008330230, CA2707190, CN101932597, JP2011505134, RU2010126590; 2007 November 30. Caballero Molina MT, Prior Gómez N, Remor Bitencourt EA, authors, FIBHULP, assignee. Brand name: HAE-QoL HEREDITARY ANGIOEDEMA QUALITY OF LIFE. CM 13.083.068; 2014 July 15.

INGEMM, author; FIBHULP, assignee. Brand name: OncoArray; ESM 2.962.910, USM 85.363.107, CM 10.091.882; 2011 January 05, 2011 July 05, 2011 July 01. Sánchez Herreros R, Martínez Fernández J, Castro Morera A, Gasset Vega M, Rodríguez Pérez RM, Pedrosa Delgado M, Quirce Gancedo S, inventors; FIBHULP, CSIC, assignees. Food allergen extracts and methods of producing and using the same. EP16382413.9 (Publication Number pending); 2016 September 06.

Gynecologic Oncology Group Zapardiel Gutiérrez I, de Santiago García J, inventors; FIBHULP, assignee. Laparoscopic surgical instrument. P201230950, PCT/ES2013/000139; 2012 June 18.

Moreno JC, Moya CM, Vallespin E, Lapunzina P, Nevado J, authors; FIBHULP, assignee. Brand name: ThyroArray; USM 85.686.688, CM 10.904.951; 2012 July 25, 2012 May 23.

Zapardiel Gutiérrez I, de Santiago García J, inventors; FIBHULP, assignee. Surgical device. P201330532, PCT/ ES2014/070277; 2013 April, 15.

Associated Clinician

Lapunzina Badía P, Borobia Pérez AM, Carcas Sanjuán AJ, Tenorio Castaño JA, Arias Lajara P, Lubomirov Jristov R, authors; FIBHULP, UAM, assignees. Brand name: PharmArray; USM 86.004.412, CM 11.608.403; 2013 July 08, 2013 February 27.

de la Oliva Senovilla P, inventor; FIBHULP, Instituto de Salud Carlos III, assignees. Shut-off valve for the interruption technique used in the analysis of respiratory mechanics. PCT/ES2005/000271, EP1897578; 2005 May 16.

Translational Oncology Group

Cancer and Human Molecular Genetics Area INGEMM- Institute of Medical and Molecular Genetics Group Friedman S, Li D, Narla G, Martignetti J, Heath K, inventors; Mount Sinai School of Medicine, assignee; Kruppel-like factor 6 (klf6), a tumor suppressor protein, and diagnostics, therapeutics, and screening based on this protein. PCT/ US2001/025046, EP1332362, CA2419064, AU8479001, US2005181374, US2011059899; 2000 August 09. INGEMM, author; FIBHULP, assignee. Brand name: INGEMM Instituto de Genética Médica y Molecular del Hospital Universitario La Paz; ESM 2.884.849, USM 77.891.143, CM 8.746.869; 2009 July 16, 2009 December 11, 2009 December 10.

INGEMM, author; FIBHULP, assignee. Brand name: KaryoArray; USM 79.078.751, CM 8.512.907; 2010 January 07, 2009 August 27.

INGEMM, author; FIBHULP, assignee. Brand name: OverGrowthArray; ESM 2.958.709-3, USM 85.334.932, CM 10.009.256; 2010 December 02, 2011 June 01, 2011 May 31.

INGEMM, author; FIBHULP, assignee. Brand name: MetabolArray; ESM 2.958.711-5, USM 85.334.903, CM 10.009.348; 2010 December 02, 2011 June 01, 2011 May 31.

Palomares M, Lapunzina P, Nevado J, Vallespin E, Vallcorba I, Melero J, authors; FIBHULP, Hospital Infanta Cristina (Badajoz) Fundesalud, assignees. Brand name: OncoHematoArray; ESM 2.958.703-4, USM 85.334.842, CM 10.009.181; 2010 December 02, 2011 June 01, 2011 May 31.

28

Lapunzina P, Nevado J, Solera J, Vallespin E, Martínez P, Martínez-González V, authors; FIBHULP, assignee. Brand name: ONCOSeq; USM 85.457.843, CM 9.969.064; 2011 October 27, 2011 May 16.

Cejas Guerrero P, Belda Iniesta C, Feliú Batlle J, González Barón M, de Castro Carpeño J, Casado Sáenz E, Sánchez Hernández JJ, inventors; FIBHULP, UAM, assignees. Genomic fingerprint for the prognosis of the evolution of colorectal adenocarcinoma. P200703229, PCT/ES2008/000756, EP2236626; 2007 December 04. Cejas Guerrero P, González Barón M, Casado Sáenz E, Sánchez Hernández JJ, Perona Abellón R, inventors; FIBHULP, UAM, CSIC, assignees. Use of trefoil factor family 3 (TFF3) in the prognosis of patients diagnosed with colorectal cancer. P200703230, PCT/ES2008/000757, EP2236625; 2007 December 04. Espinosa Arranz E, Fresno Vara JA, Gámez Pozo A, Sánchez Navarro I, inventors; FIBHULP, assignee. Method for tumor subclassification. P200803509, PCT/ES2009/070533; 2008 December 11. Redondo Sánchez A, Hardisson Hernaéz D, Barriuso Feijoo J, Mendiola Sabio M, inventors; FIBHULP, assignee. Method to obtain useful data for the prediction of a patient’s clinical response to an anticancer treatment. P200930400; 2009 July 01. Redondo Sánchez A, Hardisson Hernaéz D, Barriuso Feijoo J, Mendiola Sabio M, inventors; FIBHULP, assignee. Method to obtain useful data for the prediction of a patient’s pathological response to an anticancer treatment. P200930438; 2009 July 10. Cejas Guerrero P, Belda Iniesta C, Feliú Batlle J, de Castro Carpeño J, Moreno García V, Burgos Lizalde E, Casado Sáenz E, Sánchez Hernández JJ, inventors; FIBHULP, UAM, Empresa Pública Hospital del Norte, assignees. Genomic fingerprint for predicting the clinical response to an antitumor therapy in colorectal cancer. P201130863, PCT/ ES2012/070379; 2011 May 26. Moreno Rubio J, Cejas Guerrero P, Feliú Batlle J, Ramírez de Molina AI, Reglero Rada G, Vargas Alonso T, Molina Arranz S, González-Vallinas Garrachón M, inventors; FIBHULP, Fundación Imdea Alimentacion, assignees. Methods and kits for the prognosis of colorectal cancer. P201231918, PCT/ES2013/070864; 2012 December 10. Espinosa Arranz E, Fresno Vara JA, Gámez Pozo A, López Vacas R, Berges Soria J, inventors; FIBHULP, assignee. Method for tumor subclassification. P201430887, 2014 June 09. Miranda Utrera N, Castellano D, Villacampa Aubá F, Fresno Vara JA, Gámez Pozo A, inventors; FIBH12O, FIBHULP, assignees. Prognostic method for determining the risk of relapse in renal cancer patients with a clear cell type of renal carcinoma, stages I and II, and kit for same. P201531360, PCT/EP2016/072723; 2015 September 23.

Experimental Therapies and Biomarkers in Cancer Group Perona Abellón R, Sánchez Pérez I, Machado Pinilla R, Sastre Garzón L, Murguía Ibáñez JR, inventors; CSIC, UAM, Universidad Politécnica de Valencia, assignees. Sequence of nucleotides and peptides GSE 24.2 of dyskerin, which can induce telomerase activity, method for obtaining same, therapeutic compositions and applications thereof. P200502511, PCT/ES2006/070152, EP1947175, US20090202503, US2015337022, AT469212, CA2625981, DK1947175, JP2009511036, JP5560398, PT1947175; 2005 October 14. Perona Abellón R, Sastre Garzón L, Machado Pinilla R, Sánchez Pérez I, inventors; CSIC, UAM, assignees. Use of inductor agents GSE24.2 for producing pharmaceutical compositions for treating illnesses relating to cellular senescence. P200703106, PCT/ES2008/070212, EP2216043, US2011300115, JP2011504483, CA2706467; 2007 November 23.

Continue

29

2.4 Innovation and Transfer Activities

2 EXECUTIVE SUMMARY Cejas Guerrero P, Belda Iniesta C, Feliú Batlle J, González Barón M, de Castro Carpeño J, Casado Sáenz E, Sánchez Hernández JJ, inventors; FIBHULP, UAM, assignees. Genomic fingerprint for the prognosis of the evolution of colorectal adenocarcinoma. P200703229, PCT/ES2008/000756, EP2236626; 2007 December 04. Cejas Guerrero P, González Barón M, Casado Sáenz E, Sánchez Hernández JJ, Perona Abellón R, inventors; FIBHULP, UAM, CSIC, assignees. Use of trefoil factor family 3 (TFF3) in the prognosis of patients diagnosed with colorectal cancer. P200703230, PCT/ES2008/000757, EP2236625; 2007 December 04. Cejas Guerrero P, Belda Iniesta C, Feliú Batlle J, de Castro Carpeño J, Moreno García V, Burgos Lizalde E, Casado Sáenz E, Sánchez Hernández JJ, inventors; FIBHULP, UAM, Empresa Pública Hospital del Norte, assignees. Genomic fingerprint for predicting the clinical response to an antitumor therapy in colorectal cáncer. P201130863, PCT/ ES2012/070379; 2011 May 26. Martínez Máñez R, Murguía Ibáñez JR, Perona Abellón R, Agostini A, Mondragón Martínez L, Moreno Torres M, Manguán García C, Marcos Martínez MD, Soto Camino J, Sancenón Galarza F, inventors; Universidad Politécnica de Valencia, CSIC, Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina (CIBERBBN), Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), assignees. Release of substances into senescent cells. P201231370, PCT/ES2013/070581, EP2893923, JP2015529216, US2015306037; 2012 September 04. Ibáñez de Cáceres I, Belda Iniesta C, Pernía Arias O, Perona Abellón R, Cortés Sempere M; inventors. FIBHULP, CSIC, UAM, Fundación Hospital de Madrid, assignees. Method for predicting the response to a treatment consisting of radiotherapy combined with cisplatin-based chemotherapy. P201330783, PCT/ES2014/070433, EP3006572, US20160122828; 2013 May 29. Perona Abellón R, Sastre Garzón L, Pintado Berninches L, Carrillo García J, Molina Pachón A, Irradiccio Silva L, Manguán García C, inventors; CSIC, UAM, Advanced Medical Projects, Centro de Investigación Biomédica en Red (CIBER), assignees. Peptides derived from GSE 24.2 for treating diseases caused by oxidative stress and damage to DNA. P201331573, AU2014338820, CA2931429, EP3061815 PCT/ES2014/070803; 2013 October 25. Ibáñez de Cáceres I, Pernía Arias O, de Castro Carpeño J, Vera Puente O, Jiménez Hernández J, Perona Abellón R, Rojo Todo F, inventors; FIBHULP, CSIC, UAM, Instituto de Investigación Sanitaria FJD, assignees. Determination of methylation and miRNA levels in response to a platinum-based antitumor compound. P201530997, PCT/ES2016/070516; 2015 July 09.

Hergueta Redondo M, Sanz PG, Rojo A, García JF, Moreno-Bueno G, inventors; UAM, CSIC, Fundación MD Anderson International España, assignees; Gasdermin B2 as a new biomarker of malignance and resistance of Trastuzumab inhibitor in Her2+ tumors. P201231560; 2012 October 10.

Animal and Cell Models for Detection and Characterisation of Leukemic Stem Cells Group Campanero García MR, Molina Privado I, inventors; CSIC, UAM, assignees. Method for identifying patients with sporadic Burkitt’s lymphoma, identification method and use of compounds for the treatment of sporadic Burkitt’s lymphoma. P200702595, PCT/ES2008/070182; 2007 October 03. Molina Privado I, Campanero García MR, Rodríguez Martínez M, inventors; CSIC, UAM, assignees; Method for the differential diagnosis between Burkitt lymphoma and diffuse large B-cell lymphoma. P200900651; 2009 March 09. Zapata Hernández JM, Pérez Chacón G, inventors; CSIC, UAM, assignees; Use of an indolic compound with nucleophilic substituents at C3 and the dimeric variants thereof in the production of a pharmaceutical composition that can be used in the treatment of B-lymphoid neoplasms. P201331397, PCT/ES2014/070726; 2013 September 25.

Research and Diagnosis of Inherited Metabolic Diseases Group Pérez González B, Ruiz Desviat L, Jorge Finnigan A, Ugarte Pérez M, Martínez Ruiz A, Underhaug J, Barnejee R, inventors; UAM, Universidad de Bergen, Universidad de Michigan, assignees; Compounds useful for the treatment of methylmalonic aciduria. P201330171; 2013 February 11. Pérez González B, Gámez Abascal A, Yuste Checa P, Arduim Brasil S, Ugarte Pérez M, Martínez Ruiz A, Underhaug J, inventors; UAM, Universidad de Bergen, assignees; Compounds for treating congenital disorders of glycosylation. EP16382373.5; 2016.

Associated Clinician Glaría Enríquez A, Mañas Rueda A, Velázquez Soto R, inventors; FIBHULP, assignee. Isolation and immobilization device for test animals. P201031519, PCT/ES2011/070709; 2010 October 14.

Oto-Neurosurgery Research Group Polak M, Roca-Ribas Serdá F, Gavilán Bouzas J, Lassaletta Atienza L, Miró Castillo N, Rodrigo Dacosta J, inventors; MED-EL Elektromedizinische Geraete GmbH, assignee. Hearing treatment in patients with questionable cochlear nerve functionality. US2011275953, PCT/US2011/035312; 2010 May 05. Cobo Parra P, Varela Nieto I, Murillo-Cuesta S, Navares Zaera R, Martínez Vega R, Cediel Algovia R, inventors; CSIC, UCM, assignees. Anechoic acoustic chamber for evaluating the auditory function in laboratory animals. P201031720; 2010 November 23. Cobo Parra P, Varela Nieto I, Murillo-Cuesta S, Cediel Algovia R, inventors; CSIC, UCM, assignees. Method for designing a reverberating acoustic chamber for hearing test with animals. Procedimiento para diseñar una cámara acústica reverberante para ensayos auditivos con animales. P200802895, PCT/ES2009/070433; 2008 October 14.

Cancer Molecular Pathology and Therapeutics Targets Group Redondo Sánchez A, Hardisson Hernaéz D, Barriuso Feijoo J, Mendiola Sabio M, inventors; FIBHULP, assignee. Method to obtain useful data for the prediction of a patient’s clinical response to an anticancer treatment. P200930400; 2009 July 01. Redondo Sánchez A, Hardisson Hernaéz D, Barriuso Feijoo J, Mendiola Sabio M, inventors; FIBHULP, assignee. Method to obtain useful data for the prediction of a patient’s pathological response to an anticancer treatment. P200930438; 2009 July 10.

Mechanisms of Tumour Progression Group Matías-Guiu Guía FJ, Dolcet Roca FJ, Reventós Puigjaner J, Colás Ortega E, Prat Díaz de Losada J, Palacios Calvo J, Abal Posada M, López López R, Moreno Bueno G, Gil Moreno A, inventors; Institut de Recerca Biomèdica de Lleida Fundació Doctor Pifarré, Universitat deLleida, Fundació Hospital Universitari Vall d’Hebron-Institut de Recerca, Fundació Institut de Recerca de L’Hospital de la Santa Creu i Sant Pau, Servicio Andaluz de Salud, Servizo Galego de Saúde, Fundación MD Anderson International España, assignees. Method to predict risk of recurrence in endometrial carcinoma. Annexin-A2 as predictor biomarker of recurrent disease in endometrial cancer. EP14155510.2, PCT/EP2015/053387; 2014 February 18. García García JF, Martín Moreno AM, Roncador G, Martínez Torrecuadra JL, Moreno Bueno G, inventors; Fundación MD Anderson International España, Fundación Centro Nacional de Investigaciones Oncológicas (CNIO), assignees; Method for the diagnosis and/or prognosis of lymphomas. P201231304; 2012 August 14. Olmeda Casadomé D, Peinado Selgas H, Portillo Pérez F, Nieto Toledano MA, Cano García A, inventors; UAM, assignee. Materials and methods for the derepression of the E-cadherin promoter. US20060003956; 2004 March 03. 30

Olmeda Casadomé D, Moreno Bueno G, Portillo Pérez F, Cano García A, inventors; UAM, CSIC, assignees. Method for the diagnosis and/or prognosis of breast cancer. P200702342, PCT/ES2008/000563; 2007 August 28.

Surgery, Transplant and Health Technologies Area Bone Pathophysiology and Biomaterials Group Vilaboa Díaz NE, González Carrasco JL, Saldaña Quero L, Frutos Torres E. inventors; FIBHULP, CSIC, CIBER-BBN, assignees. Method to obtain a metallic-coated biomaterial; P201030949, PCT/ES2011/070400; 2010 June 21. Vilaboa Díaz NE, Gónzalez Carrasco JL, Multigner Domínguez M, Lieblich Rodríguez M, Muñoz Hernández M, Frutos Torres E, Saldaña Quero L, inventors; FIBHULP, CSIC, CIBER-BBN, Universidad Alfonso X El Sabio, assignees. Magnesium/polymer composite biomaterial for biomedical applications; P201030950, PCT/ES2011/070440; 2010 June 21. Fabiilli M, Wilson C, Padilla F, Martín Saavedra FM, inventors; The regents of the University of Michigan, assignee. Ultrasound-triggerable agents for tissue engineering; PCT/US2013/044817, US2013/0330389; 2012 June 08. Vilaboa Díaz NE, Calzado Martín A, Crespo García L, Saldaña Quero L, Moreo Calvo P, Alastrué Vera V, inventors; FIBHULP, CIBER-BBN, assignees. Chamber device for dynamic cell culture on biomaterials; P201330040, PCT/ ES2013/070819; 2013 January 16. Martín Saavedra FM, Vilaboa Díaz NE, Cebrián Hernando V, Arruebo Gordo M, Santamaría Ramiro J, Gómez Navascués L, inventors; FIBHULP, CIBER-BBN, Universidad de Zaragoza, assignees. Fibrin hydrogel with plasmonic nanoparticles; P201330894, PCT/ES2014/070484; 2013 June 14. González Carrasco JL, Benavente Castro R, Cifuentes Cuellar SC, Lieblich Rodríguez M, Olalde Graells B, Atorrasagasti Goyalde G, Argarate Madariaga N, Pacha Olivenza MA, Fernández Calderón MC, Saldaña Quero L, González Martín ML, Pérez Giraldo C, Gallardo Moreno AM, inventors; CSIC, Fundación Tecnalia Research & Innovation, FIBHULP, Universidad de Extremadura, Centro de Investigación Biomédica en Red (CIBER). Moldable, biodegradable, biocompatible and bioresorbable implant material, method for its preparation and uses thereof. P201530683; 2015 May 18. Voellmy R, Vilaboa Díaz NE, inventors; HSF Pharmaceuticals S.A., assignee. Inhibitors of heat shock factor I and uses thereof. US 62/495,501; 2016 September 16.

Cellular Engineering Group de Miguel González MP, Arnalich Montiel F, Royuela MM, inventors; FIBHULP, Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal, Universidad de Alcalá, assignees. Corneal endothelium injector; P201131222, PCT/ES2012/070543; 2011 July 18.

Continue

31

2 EXECUTIVE SUMMARY

2.4 Innovation and Transfer Activities

Clinical Pharmacology Group Herrero Ambrosio A, Ramírez García E, Ojeda Feo JJ, Pérez Rodríguez J, Asensio Martín MJ, González Sánchez ML, Moro Agud M, Lorente Romeo M, López Nieto M, Gómez Rioja R, authors; FIBHULP, assignee. Brand name: SINOIRES; CM 13.080.056; 2014 July 14.

assignees. Composition for the protection of tissues from the digestive tract and the nervous system of radiotherapy patients; P200931189; 2009 December 17. Goldman Tarlovky L, inventor; FIBHULP, assignee. System and method to obtain data on a patient’s breathing cycle. P201030927, PCT/ES2011/070242; 2010 June 16. de Miguel del Campo E, Reglero Rada GJ, Largo Aramburu C, Fornari Reale T, Rodríguez García-Risco M, Jaime de Pablo L, Santoyo Díez S, Señorans Rodríguez FJ, García Grande A, Merino Martín J, Caz Bonillo JV, Posadas Mañanes SJ, inventors; FIBHULP, UAM, assignees. Composition for the reduction of symptoms associated with menopause; P201031225, PCT/ES2011/070586; 2010 August 05.

Carcas Sansuán AJ, author; Carcas Sansuán AJ, assignee. Brand name: IBJ IberoAmerican Journals; ESM 3.063.048; 2013 February 12.

Castell Gómez JT, inventor; FIBHULP, assignee. Surgical device for interrupted suture. P201031491, PCT/ES2011/002352, EP2626014, US13/878035; 2010 October 07. Álvarez Gallego M, inventor; FIBHULP, assignee. Device for the extraction of surgical specimens by insufflation and suction. P201031490, PCT/ES2011/002357; 2010 October 07.

Carcas Sansuán AJ, author; Carcas Sansuán AJ, assignee Brand name: IberoAmerican Journals Plus; ESM 3.063.052; 2013 February 12.

Carcas Sansuán AJ, author; Carcas Sansuán AJ, assignee Brand name: IberoAmerican Journals Clinical Pharmacology; ESM 3.063.053; 2013 February 12.

de Miguel del Campo E, Largo Aramburu C, Tabernero Urbieta M, Reglero Rada GJ, Marín Martín F, Fornari Reale T, Prodanov Prodanov M, Ruiz Rodríguez A, Ibáñez Ezequiel E, Jaime de Pablo L, Soler Rivas C, Rodríguez GarcíaRisco M, Santoyo Díez S, González Lorente M, Arranz Gutiérrez E, Gil Ramírez A, inventors; FIBHULP, UAM, CSIC, assignees. Functional heart-healthy beverage containing wine and extracts of hops; P201131014, PCT/ES2012/070443; 2011 June 16. Reglero Rada GJ, de Miguel del Campo E, Marín Martín F, Fornari Reale T, Prodanov Prodanov M, Ruiz Rodríguez A, Largo Aramburu C, Tabernero Urbieta M, Ibáñez Ezequiel E, Jaime de Pablo L, Soler Rivas C, Rodríguez GarcíaRisco M, Santoyo Díez S, González Lorente M, Arranz Gutiérrez E, Gil Ramírez A, inventors; FIBHULP, UAM, CSIC, assignees. Method to obtain extract of hop and the extract obtained. P201230584, PCT/ES2012/070443; 2011 June 16. Brian Gahan P, Stroun M, García del Olmo D, García Arranz M, Vega Clemente ML, inventors; Peter Brian Gahan, Maurice Stroun, FIBHULP, assignees. Method for blocking tumour growth. EP2808027; 2013 May 29.

Carcas Sansuán AJ, author; Carcas Sansuán AJ, assignee Brand name: IberoAmerican Journals Medicine; ESM 3.063.049; 2013 February 12.

Castell Gómez JT, Carrascal Morillo T, inventors; FIBHULP, UNED, assignees. Synthetic surgical mesh. P201331453, PCT/ ES2014/000161; 2013 October 03. Álvarez Gallego M, Castejón Sisamón C, García Prada JC, Meneses Alonso J, inventors; FIBHULP, UC3M, assignees. Rectoscope. P201630551, PCT/ES2017/070249; 2016 April 29.

Lapunzina Badía P, Borobia Pérez AM, Carcas Sansuán AJ, Tenorio Castaño JA, Arias Lajara P, Lubomirov Jristov R, authors; FIBHULP, UAM, assignees. Brand name: PharmArray; USM 86.004.412, CM 11.608.403; 2013 July 08, 2013 February 27.

Carcas Sansuán AJ, Borobia Pérez AM, authors; FIBHULP, assignee. Brand name: CRDataX; CM 13.681.614; 2015 May 28.

Lapunzina Badía PD, Borobia Pérez AM, Carcas Sansuán AJ, Tenorio Castaño JA, Arias Lajara P, Frías Iniesta J, Dapia García I, Muñoz M, authors; FIBHULP, UAM, assignees. Brand name: ClinPharmarray. USM87054978, CM15489511; 2016 May 31, 2016 September 07.

Other Trademarks of IdiPAZ FIBHULP, author; FIBHULP, assignee. Brand name: IdiPAZ Instituto de Investigación Hospital Universitario La Paz; USM 85.078.878, CM 8.871.873; 2010 July 06, 2010 February 10.

FIBHULP, author; FIBHULP, assignee. Brand name: CEASEC Centro Avanzado de Simulación y Entrenamiento Clínico; ESM 3.567.901-8; 2015 June 22.

Osteoarticular Surgery Research- GICOA Group Arenas Vara MA, Conde del Campo A, De Damborenea González JJ, Matykina E, Esteban Moreno J, Gómez Barrena E, Pérez-Jorge Peremarch C, Pérez Tanoira R, inventors; CSIC, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, assignees. Titanium materials anodised with fluorine. P201030720, PCT/ES2011/070342; 2010 May 14.

FIBHULP, author; FIBHULP, assignee. Brand name: InnoPAZ Plataforma de Innovación Hospital Universitario La Paz; ESM 3.572.575-3; 2015 July 27.

Emergency and Critical Pathology Group Carballo Cardona C; author; FIBHULP, assignee. Brand name: Diagether. CM15869911, 2016 September 29.

Associated Clinician Castell Gómez JT, inventor; FIBHULP, assignee. System of “partial” or “total” openings and buttonholes for patient pyjama or nightgown. P200401758; 2004 July 16. García Fernández J, inventor; FIBHULP, assignee. Anaesthesia machine simulator. P200702128, PCT/ES2008/070109, US20090044803; 2007 July 30. de Miguel del Campo E, Posadas Mañanes SJ, Reglero Rada GJ, Largo Aramburu C, García Grande A, Merino Martín JJ, Caz Bonillo V, Fornari Reale T, Rodríguez García-Risco M, Señorans Rodríguez FJ, inventors; FIBHULP, UAM,

32

Return to EXECUTIVE SUMMARY INDEX

33

2 EXECUTIVE SUMMARY

2.5 Quality Committe

The vision of IdiPAZ is to be a reference centre for multidisciplinary translational biomedical research at the national and European level. To achieve this objective, the institution combines its efforts to ensure the quality of all its processes, thus ensuring the provision of the best service, research and teaching. IdiPAZ is committed to a comprehensive quality model backed by the maturity of the quality management team of the IdiPAZ institutions.To support and facilitate quality, the institution maintains a Quality Committee. During 2016, the Quality Committee fostered these principles but also achieved specific quality goals. The quality management system has been adapted to the requirements of the ISO 9001:2015, including in the scope both the Technical Secretariat and the Quality Committee. By the end of 2016 IdiPAZ will be ready to meet the requirements of the UNE 166002:2014 for innovation activities within the management system; and has also started to further expand the scope to the Innovation Support Unit and the Central Research and Clinical Trials Unit. Moreover, considering that IdiPAZ is a con-

tinuously evolving organisation, the Quality activities of our institution has been enriched by the different achievements made by the Hospital Universitario La Paz and Universidad Autónoma de Madrid. The hospital, with its accumulative experience about quality of care improvement, has continued working intensively during this year. Protocols, clinical pathways and participation in clinical practice guidelines has been developed and reviewed. The attached tables show the clinical pathways reviewed in 2016 as well as the protocols developed or updated in the same period. In addition, the staff members continuously collaborate in the improvement of the institution by participating in clinical committees and creating improvement groups, as well as implementing satisfaction surveys for patients and professionals. Also during 2016 19 departments maintained the standards ISO 9001:2008, ISO 14001:2004, ISO 22000:2005 and IQNetSR10 of their individual quality management systems. The hospital has also 22 accredited units within the Spanish National Accreditation System.

Protocol/ Clinical pathway Abordaje quirúrgico en infarto con edema cerebral e hipertensión intracraneal Acogida de pacientes obesos Actuación del Fracaso Renal en la enfermedad de Ébola Actuación en cirugía de mediastino Actuación en Neonatología con el postoperatorio del paciente con cardiopatía congénita Actuación en Reanimación Infantil con el postoperatorio del paciente con cardiopatía congénita

34

Status Revised Revised Revised Revised Revised Revised

Protocol/ Clinical pathway Administración del hidroferol en ERCA Alergia al dializador Asepsia/antisepsia en los quirófanos de Cirugía Cardiaca de Adultos Atención a ACV agudo Atención a la TCA incluida en gestión de unidosis Atención a los trastornos de conducta alimentaria Atención a pacientes con bombas de infusión subcutánea continua de insulina (ISCI) Atención al niño politraumatizado Atención al paciente con riesgos suicida (ARSUIC) Atención de pacientes con golpes de calor Atención del paciente con agonía Atención Nutricional en Fibrosis Quística Atención Nutricional en Trastornos de la Conducta Alimentaria Atención quirúrgica a los pacientes adultos con cardiopatías congénitas Bronquiolitis aguda con criterio de ingreso en CIP Cateterismo de venas pancreáticas y vena hepática derecha para detección preoperatorio de insulinomas Cateterización de senos petrosos para determinación de ACTH Cateterización de venas cervicales y torácicas para toma de muestras de PTH Cateterización de venas suprarrenales en el hiperaldosteronismo Cirugía plástica en enfermo intervenido de cirugía bariátrica Comunicación de órdenes verbales en asa cerrada Conservación de medicamentos en las unidades clínicas Control metabólico de la diabetes gestacional Cuidados de enfermería en hemodiálisis y diálisis peritoneal Cuidados de enfermería en técnicas de recambio plasmático Derivación de pacientes a ERCA Derivación de pacientes con osteoporosis Desensibilización a cotrimoxazol en niños Diarrea en el niño viajero Diagnóstico diferencial de eosinofilias Educación nutricional y seguimiento grupal Evaluación hipotálamo-hipofisaria en los traumatismos craneoencefálicos Fiebre en el niño inmigrante Inclusión en lista de espera de trasplante Inmovilización terapéutica Intervención intensiva en obesidad (Programa EGO) Malnutrición Hospitalaria Manejo ambulatorio del debut de diabetes tipo 1 Manejo de Amebiasis Manejo de Chikungunya Manejo de Cólera Manejo de Dengue Manejo de Esquistosomiasis Manejo de Estrongyloidiasis Manejo de Giardiasis Manejo de la Anafilaxia

Status

Status

Protocol/ Clinical pathway Manejo de la anemia ferropénica en urgencias

Revised

Manejo de la Enfermedad de Chagas

Revised

Manejo de la Malaria

Revised

Manejo de Rabia

Revised

Manejo de Toxocariasis

Revised

Manejo de Triquinosis

Revised

Manejo de Trypanosomiasis

Revised

Manejo enfermedad tromboembólica venosa

Revised

Revised Revised Revised Revised Revised

Mantenimiento del carro de parada

Revised

Neumonía asociada a ventilación mecánica

Revised

Neumonía en Inmunodeprimido

Revised

Nutrición Artificial Domiciliaria

Revised

Nutrición en Hemodiálisis

Revised

Revised

Osteodistrofia en diálisis peritoneal Preparación para colonoscopia en los pacientes en diálisis Preparación para la colonoscopia en paciente ERCA Prevención de Endocarditis Infecciosa en Pacientes Portadores de Prótesis Valvulares Cardiacas y Dispositivos Intravasculares Prevención de lesiones de piel y tejidos blandos en pacientes sometidos a cirugía cardiaca. Prevención de riesgo suicida en la unidad breve de hospitalización psiquiátrica Prevención del cáncer de cuello de útero Prevención y tratamiento de la intoxicación por metotrexato intravenoso Protocolo de supresión salina para confirmación de hiperaldosteronismo primario Provocación nasal específica e inespecífica

Revised

Revised

Prueba de estimulación del cortisol con comida

Revised

Revised

RCP avanzada Recogida de lesiones detectadas en colonoscopia de cribado Score de evaluación del donante del trasplante renal Sepsis comunitaria sin foco en paciente con patología crónica Sepsis comunitaria sin foco en paciente sano Talleres de actividad física para el paciente con obesidad Talleres de dietética para el paciente con obesidad

Revised

Talleres de psicología para el paciente con obesidad

Revised

Test de ayuno prolongado

Revised

Test de restricción hídrica

Revised

New New Revised Revised Revised Revised New

Revised Revised Revised Revised Revised Revised Revised Revised Revised

New Revised New Revised Revised Revised Revised Revised Revised Revised Revised Revised Revised Revised Revised Revised Revised Revised Revised Revised Revised Revised

Transfusión segura en la unidad de quemados críticos

New Revised Revised Revised Revised Revised Revised Revised Revised

New New Revised Revised Revised Revised

New

Trasplante de miembro superior

Revised

Tratamiento de la Hipertensión Pulmonar

Revised

Tratamiento de la Leucemia Mieloide Crónica

Revised

Tratamiento de las peritonitis en CAPD

Revised

Tratamiento endovascular del Infarto cerebral agudo

Revised

Uso racional de antibióticos en infección de orina

New

Utilización de medicamentos de alto riesgo

Revised

Validación farmacéutica en Pacientes Externos

Revised

Valoración de orificio del catéter peritoneal

Revised

Verificación planificación tratamientos radioterapia 3D Revised Vuelta a diálisis tras fallo de trasplante renal

Revised

Return to EXECUTIVE SUMMARY INDEX

35

2 EXECUTIVE SUMMARY

2.6 Clinical Trials

Agrifoglio Rotaeche A. Estudio de fase II, multicéntrico, aleatorizado, doble ciego, controlado con comparador, para evaluar la eficacia, la seguridad y la farmacocinética de Ulimorelina (LP101) administrada por vía intravenosa en pacientes con intolerancia a la alimentación enteral. Type: clinical trial, phase II. HULP code: 4624. Sponsored´s protocol code: LP101-CL-201. Sponsored by: Ipsen Innovation. Signed date: 17/05/2016 Alonso Dorrego JM. Estudio en fase III, multicéntrico, aleatorizado, doble ciego, de grupos paralelos y controlado con placebo para evaluar la eficacia y la seguridad de uno o más tratamientos intradetrusor con 600 u 800 unidades de Dysport® para el tratamiento de la incontinencia urinaria en pacientes con hiperactividad neurógena del detrusor por lesión de la médula espinal o esclerosis múltiple. Type: clinical trial, phase III. HULP code: 4713. Sponsored´s protocol code: D-FR-52120-223. Sponsored by: Meditate Ltd. Signed date: 24/10/2016 Alonso Gregorio S. Estudio prospectivo, internacional, multicéntrico y de brazo único para evaluar la eficacia de Dispositivo Temporal Implantable de Nitinol (TIND) de medi-tate en sujetos con Hiperplasia Prostática Benigna (HPB). Type: Healthcare product. HULP code: 4537. Sponsored´s protocol code: MT-02. Sponsored by: Ipsen Pharma S.P.S. Signed date: 24/02/2016 Álvarez Escola C. Estudio observacional, multicéntrico internacional, para evaluar la efectividad en la práctica clínica cotidiana de la Lanreotida Autogel 120 mg, en intervalos posológicos prolongados (>4 semanas), para el tratamiento de la acromegalia: Estudio SOMACROL. Type: EPA-OD. HULP code: PI-2285. Sponsored´s protocol code: IPS-SOM-2015-01. Sponsored by: Csl Behring Gmbh Clinical. Signed date: 18/05/2016 Álvarez Román MT. Estudio de extensión de fase IIIb, abierto, multicéntrico, sobre la seguridad y eficacia de una proteína de fusión del factor IX recombinante de la coagulación con la albumina (RIXFP) en pacientes con Hemofilia B. Type: clinical trial, phase IIIb. HULP code: Anexo-II 4011. Sponsored´s protocol code: CSL654_3003. Sponsored by: Baxter Innovations Gmbh. Signed date: 23/02/2016 Álvarez Román MT. Estudio de extensión de fase III, abierto, multicéntrico para evaluar la seguridad y eficacia del factor de la coagulación VIII recombinante (RVIII-cadena sencilla, csl627) en pacientes con Hemofilia A severa. Type: clinical trial, phase III. HULP code: Anexo-I 4179. Sponsored´s protocol code: CSL-3001. Sponsored by: Grifols S.A. Signed date: 18/05/2016 Álvarez Román MT. Estudio de fase III prospectivo, multicéntrico y abierto para investigar la seguridad, la inmunogenicidad y la eficacia hemostática del factor VIII pegilado (BAX 855) en pacientes no tratados previamente (PNTP) y pacientes tratados mínimamente (PTM) < 6 años con hemofilia a grave (FVIII < 1 %. Type: clinical trial, phase III. HULP code: 4487. Sponsored´s protocol code: 261203. Sponsored by: Baxter Innovations Gmbh. Signed date: 19/01/2016 Álvarez Román MT. Estudio clínico de fase III, prospectivo, aleatorizado y multicéntrico para comparar la seguridad y la eficacia de BAX 855 tras la profilaxis guiada por FC dirigida a dos concentraciones mínimas de FVIII distintas en sujetos con Hemofilia A grave. Type: clinical trial, phase III. HULP code: 4547. Sponsored´s protocol code: 261303. Sponsored by: CSL Behring Gmbh Clinical. Signed date: 16/02/2016

36

Álvarez Román MT. Estudio multicéntrico, abierto y de administración repetida, para evaluar la seguridad y la eficacia de UCB7665 en sujetos con trombocitopenia inmune primaria” (TP0001. Type: clinical trial, phase II. HULP code: 4562. Sponsored´s protocol code: TP0001. Sponsored by: Asociación de Investigación de la Enfermedad Tromboembolica de la Región de Murcia. Signed date: 31/03/2016 Álvarez Román MT. Estudio de fase I, prospectivo, abierto, de dos periodos, secuencia fija y aumento escalonado de la dosis sobre la FC y la seguridad de BAX 826 (APS-FVIIIR) en pacientes con Hemofilia A grave (FVIII < 1 %) previamente tratados.Type: clinical trial, phase I. HULP code: 4563. Sponsored´s protocol code: 291501. Sponsored by: Bio Products Laboratory Ltd. Signed date: 16/03/2016 Álvarez Román MT. Estudio multicéntrico de fase II, abierto, de un solo brazo, prospectivo, intervencional, del factor derivado del plasma VIII/VWF (Alphanate®) en la terapia de inducción de tolerancia inmune en sujetos con Hemofilia Congénita A. Type: clinical trial, phase II. HULP code: 4655. Sponsored´s protocol code: GBI1406. Sponsored by: Baxter Innovations Gmbh. Signed date: 27/07/2016 Álvarez Román MT. Estudio multicéntrico de recogida de datos retrospectivos sobre el uso del factor x de alta pureza de BPL en el tratamiento de pacientes con deficiencia del factor X hereditaria. Type: EPA-OD. HULP code: PI-2192. Sponsored´s protocol code: TEN 05. Sponsored by: Ucb Biosciencies Gmbh. Signed date: 12/05/2016 Álvarez Román MT. Estudio retrospectivo para evaluar el uso de agonistas de los receptores de trombopoyetina en pacientes adultos con trombocitopenia inmune primaria en España. Type: EPA-OD. HULP code: PI-2517. Sponsored´s protocol code: VERTEX 2.0. Sponsored by: Melinta Therapeutics, Inc. Signed date: 18/10/2016 Álvarez-Sala Walther R. Estudio de fase III, multicéntrico, aleatorizado, doble ciego y controlado con comparador para evaluar la seguridad y la eficacia de Delafloxacino intravenoso con cambio a vía oral en sujetos adultos con neumonía bacteriana adquirida en la comunidad. Type: clinical trial, phase IIIa. HULP code: 4545. Sponsored´s protocol code: ML-3341-306. Sponsored by: Hospital Universitario De Gran Canaria. Signed date: 14/06/2016 Añón Elizalde JM. Estudio comparativo, aleatorio, controlado, para evaluar la eficacia de la administración de Dexametasona en el tratamiento de pacientes con el síndrome de distrés respiratorio agudo. Type: clinical trial, phase IV. HULP code: 4680. Sponsored´s protocol code: PI11-0143. Sponsored by: Medimmune. Signed date: 04/10/2016 Ares Segura S. Estudio de fase IIb aleatorizado, doble ciego, controlado con placebo para evaluar la seguridad y la eficacia de MEDI8897, un anticuerpo monoclonal con una semivida prolongada frente al virus respiratorio sincitial, en prematuros sanos. Type: clinical trial, phase II. HULP code: 4660. Sponsored´s protocol code: D5290C00003. Sponsored by: Janssen-Cilag España, S.A. Signed date: 03/10/2016 Arribas López JR. Estudio internacional, multicéntrico, observacional, prospectivo, sobre la seguridad de Maraviroc utilizado junto con la terapia de base optimizada en pacientes infectados por el VIH-1 que han recibido tratamiento. Type: EPA-SP. HULP code: Anexo-II 2754. Sponsored´s protocol code: A4001067. Sponsored by: Merck Sharp & Dhome Corp. Signed date: 31/05/2016 Arribas López JR. Estudio de fase III abierto para evaluar la seguridad del tratamiento en un solo comprimido de Elvitegravir/Cobicista/ Entricitabina/Tenofovir alafenamida en pacientes infectados por el VIH-1 con insuficiencia renal leve o moderada.Type: clinical trial, phase III. HULP code: Anexo-I 3947. Sponsored´s protocol code: GS-US-292-0112. Sponsored by: Gilead Sciences Inc. Signed date: 20/06/2016 Arribas López JR. Estudio de fase III, aleatorizado, controlado con tratamiento activo y abierto para evaluar el cambio de tratamiento a un régimen en un solo comprimido administrado una vez al día de Darunavir/Cobicistat/Emtricitabina/Tenofovir alafenamida (D/C/F/ TAF) frente a la continuación del régimen actual formado por un Inhibidor de la Proteasa Potenciado (IPP) combinado con Emtricitabina/Tenofovir disoproxil fumarato (FTC/TDF) en sujetos infectados por el Virus de la Inmunodeficiencia Humana de tipo 1 (VIH-1) con supresión virológica. Type: clinical trial, phase III. HULP code: Anexo-I 4300. Sponsored´s protocol code: TMC114IFD3013. Sponsored by: Bristol Myers Squibb International Corporation. Signed date: 27/05/2016 Arribas López JR. Estudio fase IIIb, aleatorizado, doble ciego, con cambio de tratamiento para evaluar la seguridad y eficacia de una combinación a dosis fija (CDF) de Emtricitabina/Rilpivirina/Tenofovir Alafenamida (FTC/RPV/TAF), en pacientes con VIH-1 positivo que presentan supresión virológica en tratamiento con Emtricitabina/Rilpivirina/Tenofovir Disoproxil Fumarato (FTC/RPV/TDF).Type: clinical trial, phase IIIb. HULP code: Anexo-I 4374. Sponsored´s protocol code: GS-US-366-1260. Sponsored by: Gilead Sciences Inc. Signed date: 20/09/2016 Arribas López JR. Estudio fase IIIb, aleatorizado, doble ciego, para evaluar el cambio de un tratamiento con una combinación a dosis fija (CDF) de Efavirenz/Emtricitabina/Tenofovir Disoproxil Fumarato (EFV/FTC/TDF) a una CDF de Emtricitabina/Rilpivirina/Tenofovir Alafenamida (FTC/RPV/TAF) en pacientes con infección por VIH 1 y supresión virológica. Type: clinical trial, phase IIIb. HULP code: 4375. Sponsored´s protocol code: GS-US-366-1160. Sponsored by: Sanofi Aventis S.A. Signed date: 20/09/2016 Arribas López JR. Ensayo clínico fase IIb, aleatorizado, controlado con principio activo, doble ciego, para investigar la seguridad, eficacia y dosis-respuesta de BMS-955176, administrado con Tenofovir/Emtricitabina en adultos infectados por VIH 1 Naive a tratamiento.Type: clinical trial, phase II. HULP code: Anexo-I 4424. Sponsored´s protocol code: AI468-038. Sponsored by: Gilead Sciences Inc. Signed date: 26/02/2016 Arribas López JR. Ensayo clínico de fase III, aleatorizado y controlado con placebo para evaluar la seguridad y la capacidad inmunógena de tres lotes de estabilidad y un lote de dosis alta de RVSV‑ZEBOV-GP (vacuna contra el virus del Ébola V920) en adultos sanos. Type: clinical trial, phase III. HULP code: Anexo-I 4431. Sponsored´s protocol code: V920-012. Sponsored by: Janssen-Cilag España, S.A. Signed date: 07/01/2016 Arribas López JR. Estudio fase III, multicéntrico, abierto, randomizado, para evaluar el cambio a MK 1439A en pacientes con supresión virológica infectados por el VIH-1 en un régimen de un inhibidor de proteasa potenciado con Ritonavir y dos inhibidores de la transcriptasa inversa análogos de nucleósido (nrtis. Type: clinical trial, phase III. HULP code: Anexo-I 4441. Sponsored´s protocol code: 1439A-024. Sponsored by: Gilead Sciences Inc. Signed date: 27/09/2016 Arribas López JR. Estudio fase II, aleatorizado, doble ciego, controlado con placebo para evaluar la farmacocinética, seguridad y actividad antiviral del JNJ-63623872 en combinación con Oseltamivir en pacientes adolescentes, adultos y ancianos hospitalizados por infección de gripe a. Type: clinical trial, phase II. HULP code: Anexo-I 4501. Sponsored´s protocol code: 63623872FLZ2002. Sponsored by: Gilead Sciences Inc. Signed date: 22/06/2016

Continue

37

2.6 Clinical Trials

2 EXECUTIVE SUMMARY

38

Arribas López JR. Estudio de fase III, aleatorizado y doble ciego para evaluar la seguridad y la eficacia de GS-9883/ Emtricitabina/ Tenofovir Alafenamida en comparación con Dolutegravir + Emtricitabina/Tenofovir Alafenamida en adultos infectados por el VIH1 sin tratamiento antirretroviral previo. Type: clinical trial, phase III. HULP code: Anexo-I 4573. Sponsored´s protocol code: GS-US-380-1490. Sponsored by: Gilead Sciences Inc. Signed date: 01/07/2016 Arribas López JR. Estudio de fase III, aleatorizado y doble ciego para evaluar la seguridad y la eficacia de GS-9883/ Emtricitabina/ Tenofovir Alafenamida en comparación con Dolutegravir + Emtricitabina/Tenofovir Alafenamida en adultos infectados por el VIH1 sin tratamiento antirretroviral previo. Type: clinical trial, phase III. HULP code: 4573. Sponsored´s protocol code: GS-US-380-1490. Sponsored by: Gilead Sciences Inc. Signed date: 01/03/2016 Arribas López JR. Estudio de fase III, aleatorizado y doble ciego para evaluar la seguridad y la eficacia de GS-9883/Emtricitabina/ Tenofovir Alafenamida en comparación con Abacavir/Dolutegravir/Lamivudina en adultos infectados por el VIH-1 sin tratamiento antirretroviral previo. Type: clinical trial, phase III. HULP code: 4574. Sponsored´s protocol code: GS-US-380-1489. Sponsored by: Gilead Sciences Inc. Signed date: 01/04/2016 Arribas López JR. Estudio de fase III, aleatorizado y doble ciego para evaluar la seguridad y la eficacia de GS-9883/Emtricitabina/ Tenofovir Alafenamida en comparación con Abacavir/Dolutegravir/Lamivudina en adultos infectados por el VIH-1 sin tratamiento antirretroviral previo. Type: clinical trial, phase III. HULP code: Anexo-I 4574. Sponsored´s protocol code: GS-US-380-1489. Sponsored by: Glaxosmithkline Research And Development Limited. Signed date: 01/07/2016 Arribas López JR. Estudio piloto de fase IIIb abierto para evaluar el cambio a la combinación de dosis fijas (CDF) Elvitegravir/ Cobicistat/Emtricitabina/Tenofovir Alafenamida (E/C/F/TAF) en sujetos adultos infectados por el VIH-1 con supresión virológica que tienen la mutación de resistencia a itian archivada aislada M184V/M184I. Type: clinical trial, phase IIIb. HULP code: 4575. Sponsored´s protocol code: GS-US-292-1824. Sponsored by: Merck Sharp And Dohme De España, S.A. Signed date: 04/02/2016 Arribas López JR. Reconstitución inmune en pacientes con infección por el VIH-1 no tratados previamente y con cifras de linfocitos CD4+ inferiores a 100 células/mm3 que reciben un régimen de fármacos. Type: clinical trial, phase IV. HULP code: 4641. Sponsored´s protocol code: ADVANZ 4. Sponsored by: Pfizer, S.L.U. Signed date: 27/07/2016 Arribas López JR. Estudio de fase III, aleatorizado, doble ciego, multicéntrico, con grupos paralelos, de ausencia de inferioridad, para evaluar la eficacia, seguridad y tolerabilidad de Dolutegravir + Lamivudina en comparación con Dolutegravir + Tenofovir/ Emtricitabina en adultos infectados por el VIH-1 no tratados previamente. Type: clinical trial, phase III. HULP code: 4645. Sponsored´s protocol code: 205543. Sponsored by: Fundacio Clinic Per A La Reçerca Biomedica. Signed date: 08/09/2016 Bajo Rubio MA. Estudio de fase III, aleatorizado, abierto y controlado con tratamiento activo para evaluar la eficacia y la seguridad de fg-4592 en el tratamiento de la enemia en pacientes con insuficiencia renal cronica no tratados con dialisis. Type: clinical trial, phase IIIb. HULP code: Anexo-I 4010. Sponsored´s protocol code: 1517-CL-0610. Sponsored by: Astellas Pharma Europe B.V. Signed date: 25/03/2016 Bajo Rubio MA. Estudio de fase III, aleatorizado, abierto y controlado con tratamiento activo para evaluar la eficacia y la seguridad de roxadustat en el tratamiento de mantenimiento de la anemia en sujetos en el estadio final de la insuficiencia renal que reciben diálisis estable. Type: clinical trial, phase III. HULP code: Anexo-I 4276. Sponsored´s protocol code: 1517-CL-0613. Sponsored by: Pfizer, S.L.U. Signed date: 18/04/2016 Bajo Rubio MA. Estudio de la enfermedad de fabry en pacientes en diálisis peritoneal. Type: Non EPA. HULP code: PI-1920. Sponsored´s protocol code: GSS-FBZ-2014-04. Sponsored by: Astellas Pharma Europe B.V. Signed date: 11/01/2016 Balsa Criado A. Estudio aleatorizado, doble ciego y con control activo para evaluar la eficacia y seguridad de denosumab comparado con risedronato en pacientes tratados con glucocorticoides. Type: clinical trial, phase III. HULP code: Anexo-I 3575. Sponsored´s protocol code: 20101217. Sponsored by: Progenika Biopharma S.A. Signed date: 08/03/2016 Balsa Criado A. Estudio multicéntrico, internacional, aleatorizado, doble ciego, controlado con alendronato para determinar la eficacia y seguridad de AMG 785 en el tratamiento de mujeres con osteoporosis postmenopáusica. Type: clinical trial, phase III. HULP code: Anexo-III 3576. Sponsored´s protocol code: 20110142. Sponsored by: Pfizer Inc. Signed date: 08/04/2016 Balsa Criado A. Estudio fase IIIb para evaluar la eficacia, seguridad y tolerabilidad de tocilizumab (TCZ) subcutaneo (SC) administrado en monoterapia o en combinación con metotrexato (MTX) u otros fames no biológicos en pacientes con artritis reumatoide. Type: clinical trial, phase III. HULP code: Anexo-I 3949. Sponsored´s protocol code: ML28709. Sponsored by: Amgen, S.A. Signed date: 03/06/2016 Balsa Criado A. Estudio doble ciego, randomizado, de grupos paralelos y controlado con producto activo para comparar la eficacia y la seguridad de chs-0214 frente a enbrel® en pacientes con artritis reumatoide y respuesta inadecuada al tratamiento con metotrexato. Type: clinical trial, phase III. HULP code: Anexo-I 4205. Sponsored´s protocol code: CHS-0214-02. Sponsored by: Coherus Bioscences Inc. Signed date: 05/05/2016 Balsa Criado A. Ensayo clínico multicéntrico en fase IIa, aleatorizado, doble ciego, controlado con placebo para evaluar la eficacia y la seguridad de Guselkumab en el tratamiento de pacientes con artritis psoriásica activa. Type: clinical trial, phase II. HULP code: Anexo-I 4399. Sponsored´s protocol code: CNTO1959PSA2001. Sponsored by: Astellas Pharma Europe B.V. Signed date: 19/04/2016 Balsa Criado A. Estudio de extensión abierto para evaluar la seguridad a largo plazo y la durabilidad de la respuesta de CHS-0214 (CHS-0214-05, olses). Type: clinical trial, phase III. HULP code: Anexo-I 4430. Sponsored´s protocol code: CHS-0214-05. Sponsored by: Novartis Farmaceutica, S.A. Signed date: 05/05/2016 Balsa Criado A. Estudio observacional a largo plazo, multicéntrico, fase III, en pacientes de Estudios con Tanezumab que se someten a una sustitución total de rodilla, cadera u hombro. Type: clinical trial, phase III. HULP code: 4453. Sponsored´s protocol code: A4091064. Sponsored by: Novartis Pharma Services Ag. Signed date: 14/06/2016 Balsa Criado A. Estudio de fase III, aleatorizado, doble ciego, con control activo y con placebo, multicéntrico y de grupos paralelos de la seguridad y eficacia analgésica de Tanezumab en adultos con lumbalgia crónica. Type: clinical trial, phase III. HULP code: Anexo-I 4469. Sponsored´s protocol code: A4091059. Sponsored by: Pfizer Inc. Signed date: 08/03/2016

Balsa Criado A. Ensayo fase IIIb, aleatorizado, doble ciego para evaluar la eficacia y seguridad de Abatacept SC en combinación con metotrexato comparado con metotrexato en monoterapia para conseguir la remisión clínica en adultos con artritis reumatoide temprana sin tratamiento previo con metotrexato. Type: clinical trial, phase IIIb. HULP code: Anexo-I 4470. Sponsored´s protocol code: IM101-550. Sponsored by: Roche Farma, S.A. Signed date: 19/05/2016 Balsa Criado A. Estudio de fase III, aleatorizado, doble ciego, controlado con placebo, multicéntrico de la seguridad y eficacia analgésicas de la administración subcutánea de Tanezumab en sujetos con artrosis de cadera o de rodilla. Type: clinical trial, phase III. HULP code: 4528. Sponsored´s protocol code: A4091057. Sponsored by: Inventiva Sas. Signed date: 17/03/2016 Balsa Criado A. Estudio fase IIa, aleatorizado, doble-ciego, paralelo, controlado con placebo y naproxeno para evaluar la eficacia analgésica de ASP7962 en pacientes con dolor secundario a osteoartritis en rodilla. Type: clinical trial, phase II. HULP code: 4561. Sponsored´s protocol code: 7962-CL-0022. Sponsored by: Amgen, S.A. Signed date: 08/04/2016 Balsa Criado A. Estudio aleatorizado, en doble ciego, controlado con placebo y multicéntrico, de evaluación preliminar de la eficacia de IVA337 en el tratamiento de la esclerosis sistémica cutánea difusa. Type: clinical trial, phase II. HULP code: 4589. Sponsored´s protocol code: IVA-01-337-HSSC-15-001. Sponsored by: Janssen-Cilag España, S.A. Signed date: 22/02/2016 Balsa Criado A. Estudio multicéntrico de 52 semanas para evaluar la evolución temporal de la respuesta a Secukinumab en la inflamación articular mediante ecografía power doppler en pacientes con artritis psoriásica activa. Type: clinical trial, phase III. HULP code: 4594. Sponsored´s protocol code: CAIN457F2354. Sponsored by: Bristol Myers Squibb International Corporation. Signed date: 15/06/2016 Balsa Criado A. Estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo para evaluar la seguridad, tolerabilidad y eficacia de Secukinumab en pacientes con spondiloartritis axial no radiográfica activa durante un periodo de 2 años. Type: clinical trial, phase III. HULP code: 4596. Sponsored´s protocol code: CAIN457H2315. Sponsored by: F.Hoffmann-La Roche Ltd. Signed date: 09/05/2016 Balsa Criado A. Estudio en fase II, aleatorizado, doble ciego, controlado con placebo, de prueba de concepto y búsqueda de dosis de BI 655066 en pacientes con artritis psoriásica activa. Type: clinical trial, phase II. HULP code: 4628. Sponsored´s protocol code: 1311.5. Sponsored by: Coherus Bioscences Inc. Signed date: 23/05/2016 Balsa Criado A. Comparación de las prestaciones de un test rápido de detección de anticuerpos anti-infliximab (promonitor quick) en pacientes de reumatología en tratamiento activo con Infliximab con la prueba estándar de laboratorio (Elisa promonitor.Type: EPA-SP. HULP code: PI-2254. Sponsored´s protocol code: PQ-EF2. Sponsored by: Boehringer Ingelheim España, S.A. Signed date: 14/07/2016 Baltasar Tello P. Ensayo clínico de fase III, aleatorizado, doble ciego, controlado, paralelo, de Volasertib intravenoso en combinación con dosis bajas de citarabina subcutánea vs placebo + dosis bajas de citarabina en pacientes > 65 años con leucemia mieloide aguda previamente no tratada, que no puedan recibir tratamiento intensivo de inducción de remisión. Type: clinical trial, phase III. HULP code: Anexo-I 3789. Sponsored´s protocol code: 1230.14. Sponsored by: Pfizer, S.L.U. Signed date: 23/03/2016 Baltasar Tello P. Ensayo en fase III aleatorizado, multincéntrico, abierto, prospectivo para comparar la eficacia y la seguridad de un régimen combinado de Obinutuzumab y GDC-0199 (ABT-199) versus Obinutuzumab y Clorambucil en pacientes previamente no tratados con CLL y condiciones médicas coexistentes. Type: clinical trial, phase IIIa. HULP code: Anexo-I 4341. Sponsored´s protocol code: BO25323/CLL14. Sponsored by: Boehringer Ingelheim España, S.A. Signed date: 16/03/2016 Baquero Artigao F. Estudio epidemiológico prospectivo para estimar el impacto de la enfermedad invasora por streptococcus pneumoniae en la población pediátrica, tras la implementación de la vacunación antineumocódica en la Comunidad de Madrid. Type: Non EPA. HULP code: Anexo-V PI-581. Sponsored´s protocol code: 101317. Sponsored by: Glaxosmithkline, S.A. Signed date: 18/05/2016 Barranco Sanz MEP. Carga del asma grave en España: Estudio observacional multicéntrico. Type: EPA-OD. HULP code: PI-2300. Sponsored´s protocol code: 205738(HO-15-16438). Sponsored by: Ptc Therapeutics Inc. Signed date: 09/06/2016 Barrio Gómez De Agüero I. Estudio abierto de seguridad y de eficacia en pacientes con fibrosis quística mediada por mutación terminadora tratados previamente con Ataluren (PTC124®. Type: clinical trial, phase III. HULP code: Anexo-II 4198. Sponsored´s protocol code: PTC124-GD-023-CF. Sponsored by: Vertex Pharmaceuticals Incorporated. Signed date: 25/01/2016 Barrio Gómez de Agüero I. Estudio de extensión, fase III, abierto para evaluar la seguridad y la eficacia del tratamiento a largo plazo con VX 661 en combinación con ivacaftor en sujetos a partir de 12 años con fibrosis quística, homocigóticos o heterocigóticos para la mutación F508DEL-CFTR. Type: clinical trial, phase III. HULP code: 4529. Sponsored´s protocol code: VX14-661-110. Sponsored by: Fundación Para La Formación E Investigación Sanitarias De La Región De Murcia. Signed date: 27/04/2016 Bartha Rasero JL. Ensayo clínico controlado, aleatorizado, doble ciego con prevastatina versus placebo para la prevención de Preclampsia Statin. Type: clinical trial, phase III. HULP code: 4716. Sponsored´s protocol code: FFIS/2015/01/ST. Sponsored by: Novo Nordisk A/S. Signed date: 02/11/2016 Beltrán Romero LM. Pioneer 6- resultados cardiovasculares ensayo para investigar la seguridad cardiovascular de semaglutida oral en sujetos con diabetes tipo 2. Type: clinical trial, phase III. HULP code: 4626. Sponsored´s protocol code: NN9924-4221. Sponsored by: Novo Nordisk A/S. Signed date: 06/06/2016 Beltrán Romero LM. Pioneer 6- resultados cardiovasculares ensayo para investigar la seguridad cardiovascular de semaglutida oral en sujetos con diabetes tipo 2. Type: clinical trial, phase III. HULP code: Anexo-I 4626. Sponsored´s protocol code: NN9924-4221. Sponsored by: Lilly, S.A. Signed date: 28/09/2016 Bernad Pineda M. Teriparatida y risedronato en el tratamiento de la ostoporósis severa posmenopáusica efectos comparativos en las fracturas vertebrales. Type: clinical trial, phase IV. HULP code: Anexo-I 3690. Sponsored´s protocol code: B3D-EW-GHDW. Sponsored by: Daiichi-Sankyo Development Limited. Signed date: 04/04/2016 Borobia Pérez A. Ensayo clínico Estudio en fase I, en abierto, de dosis única y no randomizado para evaluar la farmacocinética (FC) y la farmacodinámica (FD) de edoxabán en pacientes pediátricos. Type: clinical trial, phase I. HULP code: 4634. Sponsored´s protocol code: DU176B-A-U157. Sponsored by: Avizorex Pharma S.L. Signed date: 12/09/2016

Continue

39

2.6 Clinical Trials

2 EXECUTIVE SUMMARY

40

Boto de los Bueis A. Estudio fase I/II, doble ciego, controlado con placebo, para evaluar la eficacia y seguridad de la solución oftálmica de AVX012 en sujetos con ojo seco leve o moderado. Type: clinical trial, phase I. HULP code: 4678. Sponsored´s protocol code: AVX012 CT001. Sponsored by: Shire Viropharma, Inc. Signed date: 13/09/2016 Caballero Molina MT. Registro de pacientes de FIRAZYR-IOS (Icatibant Outcome Survey). Type: EPA-LA. HULP code: Anexo-II 3080. Sponsored´s protocol code: IOS. Sponsored by: Biocryst Pharmaceuticals Inc. Signed date: 04/03/2016 Caballero Molina MT. Estudio multicéntrico, abierto, no aleatorizado para evaluar la farmacocinética, tolerabilidad y seguridad de una única administración subcutánea de icatibant en niños y adolescentes con angioedema hereditario.Type: clinical trial, phase IV. HULP code: Anexo-II 3507. Sponsored´s protocol code: HGT-FIR-086. Sponsored by: Alexion Pharmaceutical Inc. Signed date: 27/10/2016 Caballero Molina MT. Estudio (registro) postautorización de tipo observacional, multicéntrico, en varios países europeos de pacientes con Angiodema Hereditario (AEH) que reciben cinryze (inhibidor de la C1 [humano]) para el tratamiento o la prevención de las crisis de AEH. Type: EPA-LA. HULP code: Anexo-I 3744. Sponsored´s protocol code: 0624-401. Sponsored by: Shire Pharmaceuticals Iberica, S.L. Signed date: 14/03/2016 Caballero Molina MT. Estudio de fase III, aleatorizado, doble ciego, controlado con placebo, cruzado parcialmente, de dos períodos y tres secuencias para evaluar la eficacia y la seguridad de la administración subcutánea de 2000 u de un inhibidor de la esterasa C1 (humana) en líquido inyectable para la prevención de las crisis de angioedema en adolescentes y adultos con angioedema hereditario. Type: clinical trial, phase III. HULP code: 4539. Sponsored´s protocol code: SHP-616-300. Sponsored by: Viropharma Sprl. Signed date: 16/02/2016 Caballero Molina MT. Estudio aleatorizado, doble ciego, controlado con placebo, de diferentes dosis y de grupos paralelos, para evaluar la eficacia, seguridad, tolerabilidad, propiedades farmacocinéticas y farmacodinámicas de BCX7353 como tratamiento preventivo para reducir la frecuencia de ataques en sujetos con angioedema hereditario. Type: clinical trial, phase II. HULP code: 4647. Sponsored´s protocol code: BCX7353-203. Sponsored by: Shire Human Genetic Therapies, Inc. Signed date: 05/09/2016 Camarena Grande C. Estudio multicéntrico, aleatorizado, controlado por placebo de SBC-102 en pacientes con deficiencia de lipasa ácida lisosomal. Type: clinical trial, phase III. HULP code: Anexo-II 3955. Sponsored´s protocol code: LAL-CL02. Sponsored by: Alexion Pharmaceutical Inc. Signed date: 22/06/2016 Camarena Grande C. Estudio abierto y multicéntrico de sebelipasa alfa en pacientes con déficit de lipasa ácida lisosómica. Type: clinical trial, phase II. HULP code: Anexo-I 4130. Sponsored´s protocol code: LAL-CL06. Sponsored by: F. Hoffmann-La Roche Ltd. Signed date: 30/05/2016 Canales Albendea MA. Estudio fase III multicéntrico, abierto, aleatorizado de ofatumumab añadido a clorambucilo en sujetos con leucemia linfocítica crónica no tratados previamente. Type: clinical trial, phase III. HULP code: Anexo-II 2774. Sponsored´s protocol code: OMB110911. Sponsored by: Sanofi Aventis S.A. Signed date: 17/05/2016 Canales Albendea MA. Estudio multicéntrico, fase III, abierto, aleatorizado, en pacientes con linfoma no-Hodgkin indolente avanzado, previamente no tratados para evaluar el beneficio de GA101 (RO5072759) más quimioterapia en comparación con Rituximab mas quimioterapia seguida de terapia de mantenimiento con ga101 o Rituximab en pacientes respondedores. Type: clinical trial, phase III. HULP code: Anexo-II 3352. Sponsored´s protocol code: BO21223. Sponsored by: Janssen-Cilag España, S.A. Signed date: 19/04/2016 Canales Albendea MA. Estudio abierto no aleatorizado de fase II en el que se estudia sar3419 un anticuerpo anti-CD19 conjugado con Maitansina administrado como monoterapia por infusión intravenosa a pacientes con linfoma B difuso de células grandes cd19+ recidivante o refractario al tratamiento. Type: clinical trial, phase II. HULP code: Anexo-II 3508. Sponsored´s protocol code: ARD10248. Sponsored by: Dominguez Rodríguez, Alberto. Signed date: 15/07/2016 Canales Albendea MA. Estudio fase IIb, comparativo, aleatorizado, de grupos paralelos, multicéntrico, para investigar la eficacia de Rituximab subcutáneo (SC) versus Rituximab intravenoso, ambos en combinación con CHOP (RCHOP), en pacientes con linfoma difuso de células b grandes (LDCBG) cd20 positivo, no tratados previamente. Type: clinical trial, phase III. HULP code: Anexo-I 3657. Sponsored´s protocol code: MO28107. Sponsored by: F.Hoffmann-La Roche Ltd. Signed date: 10/03/2016 Canales Albendea MA. Estudio de fase III, aleatorizado, doble ciego, de grupos paralelos y controlados con fármaco activo para comparar la eficacia y la seguridad de CT-p10 y Rituxan en pacientes con linfoma folicular con carga tumoral baja. Type: clinical trial, phase III. HULP code: Anexo-I 4511. Sponsored´s protocol code: CT-P10 3.4. Sponsored by: Pharmamar, S.A. Signed date: 04/04/2016 Canales Albendea MA. Clínico Estudio fase II de Plitidepsin en pacientes con linfoma angioinmunoblástico de células t en recaída o refractario. Type: clinical trial, phase II. HULP code: 4667. Sponsored´s protocol code: APL-B-021-13. Sponsored by: Novartis Farmaceutica, S.A. Signed date: 31/08/2016 Canales Albendea MA. Estudio observacional retrospectivo para describir el manejo de pacientes con linfoma de células del manto en recaída o refractario en la práctica clínica habitual (IMORS). Type: EPA-OD. HULP code: PI-2286. Sponsored´s protocol code: JAN-IBR-2015-01. Sponsored by: Celltrion Inc. Signed date: 04/04/2016 Carballo Cardona C. Ensayo clínico, multicéntrico, randomizado, abierto de la administración de Midazolam frente a morfina en pacientes con edema agudo de pulmón: “Estudio mimo. Type: Non EPA. HULP code: 4625. Sponsored´s protocol code: MIMO/2016. Sponsored by: Astrazeneca Ab. Signed date: 25/10/2016 Castelo Fernández B. Riftos MKI - Pacientes asintomáticos con cáncer diferenciado de tiroides refractario al yodo radioactivo. Estudio observacional para evaluar la utilización de inhibidores de multiquinasa. Type: EPA-SP. HULP code: 4413. Sponsored´s protocol code: BAY-SOR-2014-01. Sponsored by: Medpace Germany Gmbh. Signed date: 22/06/2016 Castelo Fernández B. Ensayo clínico abierto, randomizado, multicéntrico fase Ib/3 de talimogene laherparepvec en combinación con Pembrolizumab para el tratamiento de pacientes con carcinoma de células escamosas de cabeza y cuello metastásico o recurrente. Type: clinical trial, phase Ib. HULP code: 4538. Sponsored´s protocol code: 20130232. Sponsored by: Eisai Europe Limited. Signed date: 11/04/2016 Castelo Fernández B. Ensayo clínico de fase Ib/3 multicéntrico, aleatorizado, de Talimogene Laherparepvec en combinación con Pembrolizumab para el tratamiento de pacientes con carcinoma de células escamosas de cabeza y cuello metastásico o recurrente. Type: clinical trial, phase Ib. HULP code: Anexo-I 4538. Sponsored´s protocol code: 20130232. Sponsored by: Sociedad Española De Cardiologia (Sec). Signed date: 07/11/2016

Castelo Fernández B. Estudio de fase Ib-II, abierto y de un solo grupo de iph2201 preoperatorio en pacientes con carcinoma epidermoide de la cavidad bucal localmente avanzado y resecable. Type: clinical trial, phase II. HULP code: 4548. Sponsored´s protocol code: IPH2201. Sponsored by: Amgen, S.A. Signed date: 02/03/2016 Castelo Fernández B. Ensayo multicéntrico, aleatorizado, doble ciego de fase II de lenvatinib (e7080) en sujetos con cáncer tiroideo diferenciado resistente a 131i para determinar si una dosis oral inicial de 20 mg o 14 mg al día proporciona una eficacia comparable a la de una dosis inicial de 24 mg, pero con un mejor perfil de seguridad. Type: clinical trial, phase II. HULP code: 4588. Sponsored´s protocol code: E7080-G000-211. Sponsored by: Eisai Europe Limited. Signed date: 14/04/2016 Castelo Fernández B. Ensayo multicéntrico, aleatorizado, doble ciego de fase II de Lenvatinib (e7080) en sujetos con cáncer tiroideo diferenciado resistente a 131i para determinar si una dosis oral inicial de 20 mg o 14 mg al día proporciona una eficacia comparable a la de una dosis inicial de 24 mg, pero con un mejor perfil de seguridad. Type: clinical trial, phase II. HULP code: Anexo-I 4588. Sponsored´s protocol code: E7080-G000-211. Sponsored by: Amgen, S.A. Signed date: 22/07/2016 Castelo Fernández B. Estudio de fase III, aleatorizado, abierto, global, multicéntrico de monoterapia con medi4736 y medi4736 en combinación con Tremelimumab frente a terapia con tratamiento habitual en pacientes con carcinoma de células escamosas de cabeza y cuello recidivante o metastásico (ccecc. Type: clinical trial, phase III. HULP code: 4653. Sponsored´s protocol code: D4193C00002. Sponsored by: Bayer Hispania, S.L. Signed date: 15/06/2016 Castro Conde A. Registro de hipercolesterolemia familiar en el Síndrome Coronario Agudo. Type: Non EPA. HULP code: PI-067. Sponsored´s protocol code: HF-SCA. Sponsored by: Abscience. Signed date: 11/04/2016 Chaverri Rada D. Estudio prospectivo, fase II, multicéntrico, randomizado, doble ciego, controlado con placebo, de grupos paralelos para comparar la eficacia y seguridad de Masitinib versus placebo en el tratamiento de pacientes con esclerosis lateral amiotrofica (ELA). Type: clinical trial, phase II. HULP code: Anexo-I EC12/25. Sponsored´s protocol code: AB10015. Sponsored by: Grupo Español De Tumores Neuroendocrinos (Getne). Signed date: 01/03/2016 Custodio Carretero AB. Estudio fase II/III aleatorizado doble ciego de la combinación de Sandostatin LAR con Axitinib vs Sandostatin LAR con placebo en pacientes con tumores neuroendocrinos avanzados g1-g2 (OMS 2010) de origen no pancreático. Type: clinical trial, phase II. HULP code: Anexo-II 3398. Sponsored´s protocol code: AXI-IIG-02. Sponsored by: Grupo Español de Tumores Neuroendocrinos. Signed date: 15/02/2016 Custodio Carretero AB. Estudio fase II/III aleatorizado doble ciego de la combinación de Sandostatin lar con axitinib vs. Sandostatin lar con placebo en pacientes con tumores neuroendocrinos avanzados g1-g2 (oms 2010) de origen no pancreático. Type: clinical trial, phase II/III. HULP code: Anexo-III 3398. Sponsored´s protocol code: AXI-IIG-02. Sponsored by: Merck Sharp & Dhome Corp. Signed date: 20/07/2016 Custodio Carretero AB. Ensayo clínico de fase III, aleatorizado, controlado con tratamiento activo, con enmascaramiento parcial y con detección de biomarcadores, de Pembrolizumab en monoterapia y en combinación con Cisplatino + 5-fluorouracilo frente a placebo + Cisplatino + 5-Fluorouracilo como tratamiento de primera línea en sujetos con adenocarcinoma gástrico o de la unión gastroesofágica (UGE) avanzado. Type: clinical trial, phase III. HULP code: 4689. Sponsored´s protocol code: 3475-062. Sponsored by: Merck Kgaa. Signed date: 22/09/2016 Custodio Carretero AB. Ensayo en fase III, abierto y multicéntrico del Avelumab (msb0010718c) como tratamiento de tercera línea del adenocarcinoma de la unión gastroesofágica o gástrico, metastásico, recurrente o irresecable. Type: clinical trial, phase III. HULP code: 4704. Sponsored´s protocol code: EMR100070-008. Sponsored by: Sociedad Española de Cardiología. Signed date: 27/09/2016 Custodio Carretero AB. Evaluación de la respuesta radiológica de los tumores neuroendocrinos pancreáticos: comparación de los criterios CHOI y RECIST. Type: EPA-SP. HULP code: PI-2406. Sponsored´s protocol code: GET-SUN-2015-01. Sponsored by: Grupo Español De Tumores Neuroendocrinos. Signed date: 30/05/2016 Dalmau González-Gallerza R. Evaluación del control glucémico en pacientes con alto riesgo cardiovascular y Diabetes Mellitus Tipo 2 en consultas de atención primaria y cardiología Estudio ricard2. Type: EPA-OD. HULP code: PI-2409. Sponsored´s protocol code: RICARD2. Sponsored by: F.Hoffmann-La Roche Ltd. Signed date: 27/09/2016 de Castro Carpeño J. Estudio fase III multinacional, aleatorizado, abierto de custirsen (tv-1011/ogx-011) en combinación con docetaxel frente a docetaxel como tratamiento de segunda linea en pacientes con cancer de pulmon no microcitico avanzado o metastasico (estadio IV). Type: clinical trial, phase III. HULP code: Anexo-III 3757. Sponsored´s protocol code: TV1011-LC-303. Sponsored by: F.Hoffmann-La Roche Ltd. Signed date: 25/03/2016 de Castro Carpeño J. Estudio de fase III multicéntrico, abierto, randomizado, para investigar la eficacia y la seguridad de mpdl3280a (anticuerpo anti-pd-l1) comparado con Docetaxel, en pacientes con cáncer de pulmón no microcítico, tras fracaso de quimioterapia basada en platino. Type: clinical trial, phase III. HULP code: Anexo-I 072. Sponsored´s protocol code: GO28915. Sponsored by: Fundación Para La Formación e Investigación Sanitarias De La Región De Murcia. Signed date: 26/09/2016 de Castro Carpeño J. Ensayo clínico aleatorizado, doble ciego, controlado con placebo, de fase II, de Alisertib (mln8237) en combinación con Paclitaxel frente a placebo en combinación con Paclitaxel como tratamiento de segunda línea para el cáncer de pulmón microcítico (CPM). Type: clinical trial, phase II. HULP code: Anexo-I 4136. Sponsored´s protocol code: 4136 C14018. Sponsored by: Novartis Farmaceutica, S.A. Signed date: 19/05/2016 de Castro Carpeño J. Ensayo en fase IIb, abierto, multicéntrico y aleatorizado, para investigar la eficacia y la seguridad de Aldoxorrubicina en comparación con Topotecán en pacientes con cáncer de pulmón microcítico metastásico que o han sufrido una recidiva o no han respondido a quimioterapia previa. Type: clinical trial, phase II. HULP code: Anexo-I 4304. Sponsored´s protocol code: ALDOXORUBICIN-P2-SCLC-01. Sponsored by: Abbvie Deutschland Gmbh. Signed date: 25/04/2016 de Castro Carpeño J. Estudio de fase II, multicéntrico, aleatorizado y abierto que compara el tratamiento de veliparib más carboplatino y paclitaxel frente al tratamiento quimioterápico habitual elegido por el investigador en pacientes fumadores o ex fumadores

Continue

41

2.6 Clinical Trials

2 EXECUTIVE SUMMARY

42

con cáncer de pulmón no microcítico (CPNM), no epidermoide, avanzado o metastásico que reciben quimioterapia citotóxica por primera vez. Type: clinical trial, phase II. HULP code: Anexo-II 4329. Sponsored´s protocol code: M14-359. Sponsored by: Merrimack Pharmaceuticals. Signed date: 09/03/2016 de Castro Carpeño J. Estudio de fase II, multicéntrico, aleatorizado y abierto que compara el tratamiento de Veliparib más carboplatino y Paclitaxel frente al tratamiento quimioterápico habitual elegido por el investigador en pacientes fumadores o ex fumadores con cáncer de pulmón no microcítico (CPNM), no epidermoide, avanzado o metastásico que reciben quimioterapia citotóxica por primera vez”. Type: clinical trial, phase III. HULP code: Anexo-III 4329. Sponsored´s protocol code: M14-359. Sponsored by: F.Hoffmann-La Roche Ltd. Signed date: 10/05/2016 de Castro Carpeño J. Estudio aleatorizado en fase II comparando Vinorelbina oral como agente único administrada con dos esquemas diferentes en pacientes con cáncer de pulmón no microcítico avanzado no aptos para quimioterapia basada en platino/ Randomized phase II study comparing single agent oral vinorelbine administered with two different schedules in patients with advanced non small cell lung cancer unfit for a platinum-based chemotherapy. Type: clinical trial, phase II. HULP code: 4433. Sponsored´s protocol code: PM0259CA232J1. Sponsored by: Astellas Pharma, S.A. Signed date: 20/06/2016 de Castro Carpeño J. Estudio de fase II de mm-121 en combinación con Docetaxel o Pemetrexed en comparación con Docetaxel o Pemetrexed en monoterapia en pacientes con cáncer de pulmón no microcitico localmente avanzado o metastásico, positivo para heregulina. Type: clinical trial, phase II. HULP code: Anexo-I 4436. Sponsored´s protocol code: MM-121-01-01-09. Sponsored by: Novartis Farmacéutica, S.A. Signed date: 18/02/2016 de Castro Carpeño J. Ensayo internacional fase III, aleatorizado, abierto y multicéntrico, con medi4736 en combinación con Tremelimumab o medi4736 en monoterapia, frente a la quimioterapia habitual basada en platino, en el tratamiento de primera línea en pacientes con cáncer de pulmón no microcítico (NSCLC) avanzado o metastásico (MYSTIC). Type: clinical trial, phase III. HULP code: Anexo-I 4471. Sponsored´s protocol code: D419AC00001. Sponsored by: F.Hoffmann-La Roche Ltd. Signed date: 09/06/2016 de Castro Carpeño J. Estudio de fase III, multicéntrico, aleatorizado, doble ciego y con control activo para evaluar la seguridad y la eficacia de la combinación de Pro-netupitant/Palonosetrón (260 mg/0,25 mg) por vía intravenosa para la prevención de náuseas y vómitos inducidos por quimioterapia en ciclos repetidos de quimioterapia en pacientes que reciben quimioterapia altamente emetogénica. Type: clinical trial, phase III. HULP code: 4477. Sponsored´s protocol code: NEPA-15-18. Sponsored by: Astrazeneca Ab. Signed date: 07/03/2016 de Castro Carpeño J. Estudio en fase III, abierto y aleatorizado para investigar la eficacia y seguridad de Atezolizumab (anticuerpo anti-PD-l1) en comparación con el tratamiento de soporte óptimo. Type: clinical trial, phase III. HULP code: Anexo-I 4480. Sponsored´s protocol code: GO29527. Sponsored by: Kyowa Kirin Farmaceútica S.L.U. Signed date: 09/05/2016 de Castro Carpeño J. Seguridad y eficacia de Lonquex® (lipegfilgrastim) en comparación con Pegfilgrastim (Neulasta®, amgen inc) y placebo en pacientes con cáncer de pulmon no microcítico que reciben quimioterapia de primera linea. Type: clinical trial, phase IV. HULP code: 4490. Sponsored´s protocol code: XM22-ONC-40041. Sponsored by: Oncogenex Technologies Inc. Signed date: 29/04/2016 de Castro Carpeño J. Estudio en fase III, aleatorizado y doble ciego de pf-06439535 más Paclitaxel-carboplatino y Bevacizumab más Paclitaxel-carboplatino para el tratamiento de primera línea de pacientes con cáncer de pulmón no escamocelular no microcítico avanzado. Type: clinical trial, phase III. HULP code: 4512. Sponsored´s protocol code: B7391003. Sponsored by: Merck & Co. Inc. Signed date: 18/01/2016 de Castro Carpeño J. Estudio de fase III, abierto y aleatorizado, de la eficacia de asp8273 frente a Erlotinib o Gefitinib como tratamiento de primera línea de pacientes con cáncer de pulmón no microcítico y mutaciones de activación del egfr, en estadio IIIb/IV (Estudio solar). Type: clinical trial, phase III. HULP code: 4535. Sponsored´s protocol code: 8273-CL-0302. Sponsored by: Merckle Gmbh. Signed date: 04/04/2016 de Castro Carpeño J. Estudio de fase I, multicéntrico, abierto, de interacción farmacológica para evaluar el efecto de Ceritinib en la farmacocinética de Warfarina y Midazolam administrados como un coctel de dos fármacos en pacientes con tumores avanzados alk-positivo incluyendo cáncer de pulmón de células no pequeñas (nsclc. Type: clinical trial, phase I. HULP code: 4553. Sponsored´s protocol code: CLDK378A2103. Sponsored by: Abbvie Spain, S.L.U. Signed date: 27/01/2016 de Castro Carpeño J. Estudio de fase II, multicéntrico, de tres cohortes con el inhibidor oral de cmet, inc280, en pacientes adultos con cáncer de pulmón de células no pequeñas (NSCLC) avanzado y egfr wild type (WT), que han recibido una o dos líneas previas de terapia sistémica para enfermedad avanzada/metastásica. Type: clinical trial, phase II. HULP code: 4554. Sponsored´s protocol code: CINC280A2201. Sponsored by: Cytrx Corporation. Signed date: 11/01/2016 de Castro Carpeño J. Ensayo en fase III, aleatorizado, con el anticuerpo monoclonal anti-pd-1 pembrolizumab (MK-3475), en comparación con placebo para pacientes con CPNM en fase temprana después de resección y finalización del tratamiento complementario de referencia (PEARLS). Type: clinical trial, phase III. HULP code: 4558. Sponsored´s protocol code: EORTC 1416-LCG. Sponsored by: Helsinn Healthcare S.A. Signed date: 29/01/2016 de Castro Carpeño J. Estudio fase III, aleatorizado, doble ciego y controlado con placebo de carboplatino más etopósido con o sin atezolizumab (anticuerpo anti-pd-l1) en pacientes con cáncer de pulmón microcítico en etapa avanzada no tratado. Type: clinical trial, phase III. HULP code: 4615. Sponsored´s protocol code: GO30081. Sponsored by: Pierre Fabre Ibérica, S.A. Signed date: 22/04/2016 de Castro Carpeño J. Estudio fase III, aleatorizado, doble ciego y controlado con placebo de carboplatino más etopósido con o sin atezolizumab (anticuerpo anti-PD-l1) en pacientes con cáncer de pulmón microcítico en etapa avanzada no tratado. Type: clinical trial, phase I. HULP code: Anexo-I 4615. Sponsored´s protocol code: GO30081. Sponsored by: Ignyta, Inc. Signed date: 02/08/2016 de Castro Carpeño J. Estudio de extensión de un único brazo, abierto y multicéntrico en pacientes con tumores sólidos que reciben tratamiento con Bevacizumab en cualquiera de los Estudios esponsorizados por F. Hoffmann- La Roche y/o Genentech. Type: clinical trial, phase IV. HULP code: 4616. Sponsored´s protocol code: MO25757. Sponsored by: Millennium Pharmaceuticals, Inc. Signed date: 22/04/2016

de Castro Carpeño J. Estudio cesto, abierto, multicéntrico, global, en fase II con Entrectinib para el tratamiento de pacientes con tumores sólidos localmente avanzados o metastásicos que albergan reordenaciones en los genes ntrk1/2/3, ros1 o ALK.Type: clinical trial, phase II. HULP code: 4648. Sponsored´s protocol code: RXDX-101-02. Sponsored by: F. Hoffmann-La Roche Ltd. Signed date: 10/08/2016 de Castro Carpeño J. Estudio observacional sobre el manejo de la disnea diruptiva en pacientes oncológicos evaluación en la práctica clínica. Type: EPA-OD. HULP code: Anexo-I PI-2025. Sponsored´s protocol code: PI-2025. Sponsored by: Pfizer Inc. Signed date: 07/06/2016 de la Calle Fernández-Miranda M. Estudio de inmunogenicidad y seguridad de la vacuna DTPA de GSK biologicals, Boostrix® (263855), en mujeres embarazadas. Type: clinical trial, phase IV. HULP code: Anexo-I 4397. Sponsored´s protocol code: 116945. Sponsored by: Amgen Europe Gmbh. Signed date: 04/10/2016 de la Calle Fernández-Miranda M. Ensayo clínico uso precoz de progesterona para la prevención del parto pretérmino en la gestación gemelar. Estudio aleatorizado, doble ciego con placebo Events. Type: clinical trial, phase III. HULP code: 4690. Sponsored´s protocol code: FFIS/2015/02/EV. Sponsored by: Glaxosmithkline, S.A. Signed date: 20/09/2016 de Leciñana Cases MA. Pérdidas de productividad y gastos indirectos después de acontecimientos vasculares en Europa AMEV-COI. Type: EPA-OD. HULP code: PI-2382. Sponsored´s protocol code: AMG-SIM-2016-01. Sponsored by: Scioderm Inc. Signed date: 04/08/2016 de Lucas Laguna R. Estudio abierto y multicéntrico de fase II para evaluar la seguridad, tolerabilidad y farmacocinética de Apremilast (CC-10004) en pacientes pediátricos con psoriasis en placas entre moderada y grave. Type: clinical trial, phase II. HULP code: 4566. Sponsored´s protocol code: CC-10004-PPSO-001. Sponsored by: Glaxosmithkline, S.A. Signed date: 04/03/2016 de Lucas Laguna R. Estudio de fase III, multicéntrico, aleatorizado, doble ciego y controlado con placebo de la eficacia y seguridad de sd-101 crema en pacientes con epidermólisis ampollosa. Type: clinical trial, phase III. HULP code: 4672. Sponsored´s protocol code: SD-005. Sponsored by: Celgene International Sarl. Signed date: 10/10/2016 de Miguel Mendieta E. Estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo para demostrar la eficacia de Secukinumab subcutáneo hasta 1 año en el tratamiento de la entesitis del tendón de Aquiles en pacientes adultos con artritis psoriásica (APS) activa y espondiloartritis axial (ESPA AXIAL) (ACHILLES). Type: clinical trial, phase III. HULP code: 4673. Sponsored´s protocol code: CAIN457F3301. Sponsored by: Novartis Farmacéutica, S.A. Signed date: 27/09/2016 de Miguel Mendieta E. Estudio multicéntrico, observacional, no intervencionista, transversal y retrospectivo, para evaluar el control de la actividad de la enfermedad en condiciones de práctica clínica habitual en pacientes con espondilitis anquilosante y artritis psoriásica tratados en consultas de reumatología en España (Estudio midas). Type: EPA-OD. HULP code: PI-2457. Sponsored´s protocol code: CAIN457FES02. Sponsored by: Abbvie Spain, S.L.U. Signed date: 11/10/2016 de Paz Arias R. Estudio multicéntrico, de un único brazo, de remisión libre de tratamiento de Nilotinib, en pacientes con leucemia mieloide crónica en fase crónica con bcr-abl1 positivo, que han alcanzado un estado de enfermedad residual mínima (ERM) duradera con tratamiento de primera línea con nilotinib. Type: clinical trial, phase II. HULP code: Anexo-I 3807. Sponsored´s protocol code: CAMN107I2201. Sponsored by: Millennium Pharmaceuticals, Inc. Signed date: 14/01/2016 de Paz Arias R. Estudio fase III, multicéntrico doble ciego, controlado con placebo en combinación con Azacitidina en sujetos con síndromes mielodisplásicos (SMD) de riesgo intermedio-1, intermedio 2 o alto según el IPSS. Type: clinical trial, phase IIIa. HULP code: Anexo-IV 4134. Sponsored´s protocol code: TRC112121. Sponsored by: Ariad Pharmaceutical, Inc. Signed date: 16/06/2016 de Paz Arias R. Estudio aleatorizado y sin enmascaramiento de Ponatinib en comparación con Nilotinib en pacientes con leucemia mielógena crónica en fase crónica resistentes a Imatinib. Type: clinical trial, phase III. HULP code: 4526. Sponsored´s protocol code: AP24534-15-303. Sponsored by: Novartis Farmaceutica, S.A. Signed date: 12/01/2016 de Paz Arias R. Estudio clínico de fase II, aleatorizado, controlado y abierto para comparar la eficacia y la seguridad de Pevonedistat más Azacitidina frente a Azacitidina en monoterapia en pacientes con síndromes mielodisplásicos de alto riesgo, leucemia mielomonocítica crónica y leucemia mielógena aguda pobre en blastos. Type: clinical trial, phase II. HULP code: 4571. Sponsored´s protocol code: Pevonedistat-2001. Sponsored by: Lumena Paharmaceuticals Inc. Signed date: 17/08/2016 Díaz Fernández MC. Estudio abierto y a largo plazo con un periodo de retirada farmacológica aleatorizado, controlado con placebo y doble ciego de lum001, un inhibidor del trasportador apical de ácidos biliares dependiente de sodio (Asbti), en pacientes con Síndrome de Alagille. Type: clinical trial, phase III. HULP code: Anexo-II 4187. Sponsored´s protocol code: LUM001-304. Sponsored by: Sanofi Pasteur S.A. Signed date: 26/05/2016 Díaz González CC. Estudio de eficacia e inmunogeneicidad de una vacuna intramuscular a niños de 6 a 35 meses de edad en Europa y el resto del mundo. Type: clinical trial, phase III. HULP code: Anexo-II 4129. Sponsored´s protocol code: GQM05. Sponsored by: Alexion Pharmaceutical Inc. Signed date: 15/04/2016 Díez Tejedor E. Estudio multinacional, multicéntrico, aleatorizado, doble ciego, con grupos paralelos y controlado con placebo, seguido de un periodo de tratamiento activo, para evaluar la eficacia, la seguridad y la tolerabilidad de dos dosis de Laquinimod administradas por vía oral (0,6 mg/día o 1,2 mg/día9 en sujetos con esclerosis múltiple remitente-recurrente (EMRR). Type: clinical trial, phase III. HULP code: Anexo-I 3764. Sponsored´s protocol code: LAQ-MS-305. Sponsored by: Astrazeneca Farmaceutica Spain, S.A. Signed date: 26/08/2016 Díez Tejedor E. Ensayo de extensión, abierto, de fase III de ecu-mg-301 para evaluar la seguridad y la eficacia de Eculizumab en sujetos con Miastenia Gravis Generalizada (MGG) resistente al tratamiento. Type: clinical trial, phase III. HULP code: 4258. Sponsored´s protocol code: ECU-MG-302. Sponsored by: Bristol Myers Squibb International Corporation. Signed date: 05/01/2016 Díez Tejedor E. Estudio aleatorizado doble ciego controlado con placebo de fase II para investigar las posibles interacciones fármaco-fármaco entre Clobazam y Cannabidiol (GWP42003-p. Type: clinical trial, phase II. HULP code: 4508. Sponsored´s protocol code: GWEP1428. Sponsored by: GW Research Ltd. Signed date: 18/01/2016 Díez Tejedor E. Estudio aleatorizado doble ciego controlado con placebo, de dos partes para investigar las características farmacocinéticas, seguido de la eficacia y la seguridad de gwp42006 como terapia complementaria en pacientes con crisis epilépticas focales inadecuadamente controladas. Type: clinical trial, phase II. HULP code: 4509. Sponsored´s protocol code: GWEP1330. Sponsored by: Teva Branded Pharmaceutical Products R&D, Inc. Signed date: 24/05/2016

Continue

43

2.6 Clinical Trials

2 EXECUTIVE SUMMARY

44

Díez Tejedor E. Estudio de fase Ib, abierto y multicéntrico, para evaluar la seguridad y la tolerabilidad y para determinar la dosis máxima tolerada de pf-05230907 en sujetos con Hemorragia Intracerebral (HIC). Type: clinical trial, phase Ib. HULP code: 4600. Sponsored´s protocol code: B2341002. Sponsored by: Teva Branded Pharmaceutical Products R&D, Inc. Signed date: 11/07/2016 Díez Tejedor E. International corporation para la realización del ensayo clínico Estudio de fase II, controlado con placebo, aleatorizado, doble ciego y de grupos paralelos para evaluar la eficacia y la seguridad de bms-986141 en la prevención del infarto cerebral recurrente en sujetos que reciben ácido acetilsalicílico (AAS) después de un ictus isquémico agudo o de un accidente isquémico transitorio. Type: clinical trial, phase II. HULP code: 4612. Sponsored´s protocol code: CV006-004. Sponsored by: F. Hoffmann-La Roche Ltd. Signed date: 01/07/2016 Díez Tejedor E. Estudio multicéntrico, aleatorizado, de doble enmascaramiento, controlado por placebo y de grupos paralelos que compara la eficacia y la seguridad con pautas de 2 dosis de la administración subcutánea de TEV-48125 frente a placebo respecto al tratamiento preventivo de la migraña episódica. Type: clinical trial, phase III. HULP code: 4619. Sponsored´s protocol code: TV48125-CNS-30050. Sponsored by: Teva Branded Pharmaceutical Products R&D, Inc. Signed date: 04/08/2016 Díez Tejedor E. Estudio multicéntrico, aleatorizado, de doble enmascaramiento, controlado por placebo y de grupos paralelos que compara la eficacia y la seguridad con pautas de 2 dosis de la administración subcutánea de TEV-48125 frente a placebo respecto al tratamiento preventivo de la migraña crónica. Type: clinical trial, phase III. HULP code: 4620. Sponsored´s protocol code: TV48125-CNS-30049. Sponsored by: Pfizer Inc. Signed date: 12/07/2016 Díez Tejedor E. Estudio multicéntrico, aleatorizado, de doble enmascaramiento y con grupos paralelos que evalúa la seguridad, tolerabilidad y eficacia a largo plazo de la administración subcutánea de TEV-48125 para el tratamiento preventivo de la migraña. Type: clinical trial, phase III. HULP code: 4621. Sponsored´s protocol code: TV48125-CNS-30051. Sponsored by: Genzyme Europe Bv. Signed date: 04/08/2016 Díez Tejedor E. Estudio aleatorizado, con doble enmascaramiento, controlado con placebo y con grupos paralelos de la seguridad, la eficacia y la farmacodinámica de basmisanil (ro5186582) en adultos con deterioro motor grave tras un accidente isquémico. Type: clinical trial, phase II. HULP code: 4666. Sponsored´s protocol code: BP29937. Sponsored by: GW Research Ltd. Signed date: 17/10/2016 Díez Tejedor E. Estudio postautorización de seguridad, prospectivo, multicéntrico y observacional para evaluar el perfil de seguridad a largo plazo del tratamiento con Lemtrada® (alemtuzumab) en pacientes con formas recidivantes de esclerosis múltiple. Type: EPA-LA. HULP code: PI-2054. Sponsored´s protocol code: OBS13434. Sponsored by: Teva Pharmaceutical Industries Ltd. Signed date: 28/07/2016 Domínguez Ortega FJ. Estudio fase IV, observacional, multinacional sobre el control de la enfermedad y los resultados notificados por los pacientes en tratamiento con inhaladores de combinación a dosis fija para asma persistente y EPOC en la práctica clínica habitual (sprint). Type: EPA-OD. HULP code: Anexo-I PI-2002. Sponsored´s protocol code: BFS-AS-40087. Sponsored by: Chiesi Farmaceutici S.P.A. Signed date: 24/05/2016 Domínguez Ortega FJ. Estudio Marte- Estudio observacional sobre las características de los pacientes asmáticos en tratamiento de mantenimiento y rescate en España según práctica clínica habituallo. Type: EPA-OD. HULP code: PI-2281. Sponsored´s protocol code: CHI-FOR-2015-01. Sponsored by: Bayer Hispania, S.L. Signed date: 11/07/2016 Domínguez Ortega FJ. Estudio observacional para evaluar el uso de medicación de alivio en práctica clínica y su relación con el control del asma Estudio mistral. Type: EPA-OD. HULP code: PI-2405. Sponsored´s protocol code: AST-ASM-2016-01 y D589BR00035. Sponsored by: Teva Pharmaceutical Industries Ltd. Signed date: 08/07/2016 Elorza Fernández MD. Ensayo clínico para evaluar la seguridad, la eficacia y las propiedades farmacocinéticas y farmacodinámicas de Rivaroxaban oral, durante 7 días de tratamiento, en neonatos hasta menos de 6 meses con trombosis arterial o venosa. Type: clinical trial, phase I. HULP code: 4691. Sponsored´s protocol code: BAY59-7939/17618. Sponsored by: Chiesi Farmaceutici S.P.A. Signed date: 31/08/2016 Elorza Fernández MD. Evaluation of surfactant dose administered in clinical practice for the treatment of respiratory distress syndrome (RDS): retrospective observational study surprais study. Type: EPA-OD. HULP code: PI-2495. Sponsored´s protocol code: CHI-POR-2016-01. Sponsored by: Amgen Europe Gmbh. Signed date: 22/09/2016 Escobar Cervantes C. Pérdidas de productividad y gastos indirectos después de acontecimientos vasculares en Europa AMEVCOI. Type: EPA-OD. HULP code: PI-2382B. Sponsored´s protocol code: AMG-SIM-2016-01. Sponsored by: Fondazione Penta Onlus. Signed date: 04/08/2016 Escosa García L. Ensayo aleatorizado de tratamiento antirretroviral con dolutegravir (dtg) comparado con el tratamiento estándar (TE) en niños con infección VIH que inician tratamiento de primera línea o de segunda línea. Type: clinical trial, phase III. HULP code: 4582. Sponsored´s protocol code: PENTA 20-ODYSSEY. Sponsored by: F.Hoffmann-La Roche Ltd. Signed date: 15/04/2016 Espinosa Arranz E. Estudio de extensión (transferencia) abierto de Vemurafenib en pacientes con neoplasia maligna con la mutación brafv600 incluidos previamente en un protocolo anterior de vemurafenib. Type: clinical trial, phase IV. HULP code: Anexo-II 3871. Sponsored´s protocol code: GO28399. Sponsored by: Grupo Español Multidisciplinar De Melanoma Gem Gem. Signed date: 01/03/2016 Espinosa Arranz E. Ensayo de fase Ib/3 multicéntrico de Talimogene Laherparepvec en combinación con Pembrolizumab (mk3475) para el tratamiento del melanoma en estadio IIIb a ivm1c no resecable (masterkey-265. Type: clinical trial, phase IIIb. HULP code: 4636. Sponsored´s protocol code: 20110265. Sponsored by: Merck Sharp & Dhome Corp. Signed date: 12/05/2016 Espinosa Arranz E. Ensayo clínico abierto, multicéntrico, no aleatorizado en fase II para evaluar la eficacia de Nivolumab en combinación con Ipilimumab en pacientes con melanoma uveal metastásico no tratados previamente. Type: clinical trial, phase II. HULP code: 4655. Sponsored´s protocol code: GEM 1402. Sponsored by: Amgen, S.A. Signed date: 23/02/2016 Esteban Rodríguez I. Estudio observacional retrospectivo, multicéntrico, para evaluar la expresión de la proteína pd-l1 en pacientes con cáncer de pulmón no microcítico (CPNM) localmente avanzado o metastásico. Type: Healthcare product. HULP code: PI-2443. Sponsored´s protocol code: MK-3475-461. Sponsored by: Gilead Sciences Inc. Signed date: 13/10/2016

Feliú Batlle J. Estudio en fase III, aleatorizado, doble ciego, sobre el inhibidor jak1/2, Ruxolitinib o placebo combinado con Capecitabina en sujetos con adenocarcinoma de páncreas avanzado o metastásico que no respondieron o no toleran la quimioterapia en primera línea (Estudio JANUS 1). Type: clinical trial, phase III. HULP code: Anexo-I 4186. Sponsored´s protocol code: INCB 18424-362. Sponsored by: Fundación Centro Nacional de Investigaciones Oncológicas Carlos III. Signed date: 27/07/2016 Feliú Batlle J. Estudio aleatorizado, multicéntrico, doble ciego, controlado con placebo, de fase II/3 del inhibidor de la tirosina quinasa de bruton, Ibrutinib, en combinación con Nab-Paclitaxel y Gemcitabina frente a placebo en combinación con Nab-Paclitaxel y Gemcitabina, en el tratamiento de primera línea de pacientes con adenocarcinoma de páncreas metastásico. Type: clinical trial, phase II. HULP code: Anexo-I 4502. Sponsored´s protocol code: PCYC-1137-CA. Sponsored by: Pharmacyclis Llc. Signed date: 03/05/2016 Feliú Batlle J. Estudio aleatorizado, multicéntrico, doble ciego, controlado con placebo, de fase II/3 del inhibidor de la tirosina quinasa de bruton, Ibrutinib, en combinación con Nab-Paclitaxel y Gemcitabina frente a placebo en combinación con Nab-Paclitaxel y Gemcitabina, en el tratamiento de primera línea de pacientes con adenocarcinoma de páncreas metastásico. Type: clinical trial, phase II. HULP code: 4502. Sponsored´s protocol code: PCYC-1137-CA. Sponsored by: Pharmacyclics Llc. Signed date: 20/01/2016 Feliú Batlle J. Estudio de fase III aleatorizado y doble ciego para evaluar el uso de tas-102 más el mejor tratamiento sintomático frente a placebo más el mejor tratamiento sintomático en pacientes con cáncer gástrico metastásico resistente a los tratamientos de referencia. Type: clinical trial, phase III. HULP code: 4549. Sponsored´s protocol code: TO-TAS-102-302. Sponsored by: Pharmacyclis Llc. Signed date: 07/04/2016 Feliú Batlle J. Estudio en fase III, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y seguridad de gs-5745 en combinación con mfolfox6 como tratamiento de primera línea en pacientes con adenocarcinoma gástrico avanzado o de la unión gastroesofágica. Type: clinical trial, phase III. HULP code: 4569. Sponsored´s protocol code: GS-US-296-1080. Sponsored by: Incyte Corporation. Signed date: 15/03/2016 Feliú Batlle J. Estudio en fase III, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y seguridad de gs-5745 en combinación con mfolfox6 como tratamiento de primera línea en pacientes con adenocarcinoma gástrico avanzado o de la unión gastroesofágica. Type: clinical trial, phase III. HULP code: Anexo-I 4569. Sponsored´s protocol code: GS-US-296-1080. Sponsored by: Merck Kgaa. Signed date: 30/08/2016 Feliú Batlle J. Elección de terapias personalizadas en pacientes con carcinoma de páncreas metastásico de acuerdo al análisis genético del tumor y al modelo avatar. Type: clinical trial, phase III. HULP code: 4607. Sponsored´s protocol code: ERCAVATAR2015. Sponsored by: Taiho Oncology Usa Ine. Signed date: 12/05/2016 Feliú Batlle J. Estudio en fase Ib/2 del tratamiento combinado con Ibrutinib en tumores gastrointestinales y genitourinarios avanzados seleccionados. Type: clinical trial, phase I. HULP code: 4630. Sponsored´s protocol code: PCYC-1128-CA. Sponsored by: Gilead Sciences Inc. Signed date: 02/06/2016 Feliú Batlle J. Ensayo de fase III, multicéntrico y no enmascarado sobre el tratamiento de mantenimiento con Avelumab (msb0010718c) frente a la continuación de la quimioterapia de primera línea en sujetos con un adenocarcinoma gástrico, o de la zona de unión gastroesofágica, irresecable, localmente avanzado o metastásico. Type: clinical trial, phase III. HULP code: 4643. Sponsored´s protocol code: EMR100070-007. Sponsored by: Grunenthal Pharma S.A. Signed date: 20/09/2016 Fernández Dueñas E. Evaluación de la eficacia y seguridad de Tapentadol solución oral en el tratamiento del dolor agudo posoperatorio que requiere tratamiento opioide en pacientes pediátricos con edades desde el nacimiento hasta menos de 18 años. Type: clinical trial, phase III. HULP code: Anexo-II 4132. Sponsored´s protocol code: KF5503/65. Sponsored by: Grünenthal Gmbh. Signed date: 12/05/2016 Fernández Espla A. Estudio epidemiológico para estimar la prevalencia y evaluar la severidad, el abordaje y las estructuras organizativas empleadas para el manejo del dolor agudo postoperatorio tras cirugía mayor en pacientes ingresados en España (APOLO). Type: EPA-SP. HULP code: PI-2163. Sponsored´s protocol code: GRU-OPI-2015-01. Sponsored by: Astrazeneca Ab. Signed date: 10/02/2016 Figueira Iglesias JC. Ensayo clínico de fase II de demostración de viabilidad para evaluar la eficacia y la seguridad de medi3902 en la prevención de la neumonía nosocomial causada por pseudomonas aeruginosa en pacientes sujetos a ventilación mecánica. Type: clinical trial, phase II. HULP code: 4637. Sponsored´s protocol code: D5470C00004. Sponsored by: Axovant Sciences Ltd. Signed date: 25/05/2016 Frank García A. Estudio multicéntrico, randomizado, doble ciego, controlado con placebo, con grupos de tratamiento paralelos, de dos años de duración, para evaluar el efecto de RO4909832 administrado por vía subcutánea sobre la capacidad cognitiva y funcional en enfermedad de Alzheimer en fase prodromica. Type: clinical trial, phase II. HULP code: Anexo-III 3420. Sponsored´s protocol code: WN25203. Sponsored by: Janssen-Cilag España, S.A. Signed date: 25/01/2016 Frank García A. Estudio de fase IIa aleatorizado, doble ciego, controlado con placebo, de grupos paralelos, multicéntrico para estudiar la seguridad y tolerabilidad de jnj-54861911 en pacientes con enfermedad de Alzheimer temprana (pre-demencia). Type: clinical trial, phase II. HULP code: Anexo-I 4266. Sponsored´s protocol code: 54861911ALZ2002. Sponsored by: Janssen Cilag International NV. Signed date: 11/04/2016 Frank García A. Estudio de fase IIb/III, multicéntrico, aleatorizado, con doble ciego, controlado con placebo y de grupos paralelos para investigar la eficacia y la seguridad de JNJ-54861911 en sujetos asintomáticos con riesgo de desarrollar demencia de Alzheimer. Type: clinical trial, phase II. HULP code: 4448. Sponsored´s protocol code: 54861911ALZ2003. Sponsored by: Grupo Español de Trabajo en Enfermedad de Crhon y Colitis Ulcerosa. Signed date: 04/02/2016 Frank García A. Estudio de fase III, doble ciego y aleatorizado de rvt-101 frente a placebo cuando se añade al tratamiento estable con donepezilo ya existente, en pacientes con enfermedad de Alzheimer de leve a moderada. Type: clinical trial, phase III. HULP code: 4552. Sponsored´s protocol code: RVT-101-3001. Sponsored by: F.Hoffmann-La Roche Ltd. Signed date: 27/04/2016 Galve Martín ML. Estudio epidemiológico de la incidencia de enfermedad inflamatoria intestinal en población adulta en España. Type: Non EPA. HULP code: PI-068B. Sponsored´s protocol code: GIS-2015-INCIDENCIA. Sponsored by: Sociedad Española De Carburos Metálicos. Signed date: 28/04/2016

Continue

45

2.6 Clinical Trials

2 EXECUTIVE SUMMARY

46

García García S. Ensayo clínico de fase II de demostración de viabilidad para evaluar la eficacia y la seguridad de medi3902 en la prevención de la neumonía nosocomial causada por pseudomonas aeruginosa en pacientes sujetos a ventilación mecánica. Type: clinical trial, phase III. HULP code: 4540. Sponsored´s protocol code: HELIOS-AP. Sponsored by: Boehringer Ingelheim España, S.A. Signed date: 23/06/2016 García Martínez JR. Estudio exploratorio, aleatorizado, doble-enmascarado y controlado con placebo para evaluar la farmacodinámica, seguridad y tolerabilidad de BI 1026706 administrado de forma oral durante 12 semanas en pacientes con deficiencia visual leve debido a un edema macular diabético de predominio central. Type: clinical trial, phase II. HULP code: 4629. Sponsored´s protocol code: 1320.22. Sponsored by: Pfizer Inc. Signed date: 24/05/2016 García Puig J. Estudio de fase III multicéntrico, doble ciego, aleatorizado, controlado con placebo y con grupos paralelos para evaluar la eficacia, la seguridad y la tolerabilidad de PF-04950615 en la reducción del número de acontecimientos cardiovasculares graves en pacientes de alto riesgo. Type: clinical trial, phase III. HULP code: Anexo-II 4044. Sponsored´s protocol code: B1481022. Sponsored by: Pfizer Inc. Signed date: 30/06/2016 García Puig J. Ensayo clínico aleatorizado, controlado con placebo, para evaluar los resultados clínicos cardiovasculares tras el tratamiento con Exenatida una vez a la semana en pacientes con Diabetes Mellitus de Tipo 2. Type: clinical trial, phase III. HULP code: Anexo-I 4103. Sponsored´s protocol code: BCB109. Sponsored by: García Río, Francisco José. Signed date: 08/01/2016 García Puig J. Estudio de fase III multicéntrico, doble ciego, aleatorizado, controlado con placebo y con grupos paralelos para evaluar la eficacia, la seguridad y la tolerabilidad de PF-04950615 en la reducción del número de acontecimientos cardiovasculares mayores en pacientes de alto riesgo. Type: clinical trial, phase III. HULP code: Anexo-II 4219. Sponsored´s protocol code: B1481038. Sponsored by: Bristol Myers Squibb International Corporation. Signed date: 30/06/2016 García Río FJ. Efecto de la CPAP nasal sobre la reducción de la albuminuria en pacientes con nefropatía diabética y apnea obstructiva del sueño. Type: Healthcare product. HULP code: PI-2386. Sponsored´s protocol code: PI-2386. Sponsored by: Abbvie Spain, S.L.U. Signed date: 04/11/2016 García-Samaniego Rey FJ. Estudio abierto y multicéntrico para evaluar los resultados a largo plazo con ABT-450/ritonavir/ABT267 (ABT-450/r/ABT-267) y ABT 333 con o sin ribavirina (RBV) en adultos con infección crónica por el virus de la Hepatitis C (VHC) de genotipo 1 (topaz-i). Type: clinical trial, phase III. HULP code: Anexo-II 4272. Sponsored´s protocol code: M14-423. Sponsored by: Conatus Pharmaceuticals Inc. Signed date: 23/02/2016 García-Samaniego Rey FJ. Estudio abierto, multicéntrico y aleatorizado para evaluar la eficacia y la seguridad de abt-493/abt-530 en adultos con infección crónica por el virus de la hepatitis c genotipo 1 (endurance-1. Type: clinical trial, phase III. HULP code: 4505. Sponsored´s protocol code: M13-590. Sponsored by: Abbvie Spain, S.L.U. Signed date: 18/01/2016 García-Samaniego Rey FJ. Ensayo multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar Emricasán (IDN 6556), un inhibidor de la caspasa de administración oral, en sujetos con fibrosis por esteatohepatitis no alcohólica (EHNA). Type: clinical trial, phase II. HULP code: 4609. Sponsored´s protocol code: IDN-6556-12. Sponsored by: Gilead Sciences Inc. Signed date: 03/05/2016 García-Samaniego Rey FJ. Estudio de fase II, multicéntrico, aleatorizado, abierto, para evaluar la eficacia y seguridad de la combinación a dosis fija de Sofosbuvir/Velpatasvir (CDF) y Sofosbuvir/Velpatasvir en cdf y Ribavirina en pacientes con infección crónica por el genotipo 3 del VHC y cirrosis. Type: clinical trial, phase II. HULP code: 4622. Sponsored´s protocol code: GS-US-342-2097. Sponsored by: Amgen, S.A. Signed date: 15/07/2016 García-Samaniego Rey FJ. Eficacia y seguridad/tolerabilidad de Viekirax y Exviera en pacientes diagnosticados de VHC, coinfectados o no con VIH 1, GT 1 o 4, y enfermedad renal crónica en estadios de IIIb a V, incluyendo aquellos en diálisis, en práctica clínica habitual en España Estudio viekind. Type: EPA-OD. HULP code: PI-2303. Sponsored´s protocol code: ABB-OMB-2015-01. Sponsored by: Abbvie Deutschland Gmbh. Signed date: 09/05/2016 Gasior Kabat M. Seguridad de Romiplostim en el tratamiento de la trombocitopenia en pacientes con síndrome mielodisplásico de riesgo bajo o intermedio -1. Type: clinical trial , phase I. HULP code: Anexo-II 2709. Sponsored´s protocol code: 20060198. Sponsored by: Chu Saint Etienne. Signed date: 19/09/2016 Gómez Barrena E. Estudio en fase IIIb multicéntrico, aleatorizado, doble ciego y controlado, para evaluar la eficacia y seguridad de Rivaroxaban 10 mg frente a Enoxaparina 4000 UI para la profilaxis de TEV en cirugía ortopédica menor Estudio pronomos. Type: clinical trial, phase IIIb. HULP code: 4550. Sponsored´s protocol code: 1408143. Sponsored by: Anthera Pharmaceuticals Inc. Signed date: 12/05/2016 Gómez Candela C. Estudio fase III, aleatorizado, abierto, con evaluador enmascarado y comparador activo para evaluar la no inferioridad en la eficacia y seguridad de liprotamasa en sujetos con insuficiencia pancreática exocrina debida a fibrosis quística. Type: clinical trial, phase III. HULP code: 4530. Sponsored´s protocol code: AN-EPI3331. Sponsored by: Linical France Sarl. Signed date: 02/02/2016 Gómez Candela C. Estudio abierto para evaluar la eficacia y seguridad de Liprotamasa en sujetos con insuficiencia pancreática exocrina debida a fibrosis quística. Type: clinical trial, phase III. HULP code: 4686. Sponsored´s protocol code: AN-EPI3334. Sponsored by: Amgen, S.A. Signed date: 23/09/2016 Gómez Prieto P. Ensayo aleatorizado y doble ciego para evaluar la eficacia, la seguridad y la inmunogenicidad de abp 798 en comparacion con Rituximab en sujetos con linfoma no Hodgkin (LNH) de celulas b cd20+. Type: clinical trial, phase III. HULP code: Anexo-I 4216. Sponsored´s protocol code: 20130109. Sponsored by: Abbott Laboratories, S.A. Signed date: 12/04/2016 Gómez Senent S. Estudio postcomercialización observacional de cohortes en pacientes con enfermedad inflamatoria intestinal (EII) tratados con Inflectra (Infliximab) en la práctica clínica habitual (connect-ibd). Type: EPA-SP. HULP code: PI-2082. Sponsored´s protocol code: ZOB INF 1402. Sponsored by: Merck Kgaa. Signed date: 02/11/2016 Gómez Senent S. Estudio prospectivo observacional sobre una muestra de pacientes malnutridos con intolerancia gastrointestinal tras la administración de una formula peptídica alta en calorías y proteínas con MCT. Type: Non EPA. HULP code: PI-2410. Sponsored´s protocol code: DA13. Sponsored by: Hospira Productos Farmaceuticos Y Hospitalarios S.L. Signed date: 22/07/2016

González Casado I. Estudio observacional, prospectivo y multicéntrico a largo plazo en una cohorte de niños con talla baja nacidos pequeños para su edad gestacional (PEG) que han sido tratados con Saizen® / Prospective, single-cohort, multicentre observational long-term study in short children born small for Gestational Age (SGA) after treatment with Saizen®) (Estudio salto). Type: EPA-LA. HULP code: 3277. Sponsored´s protocol code: EMR200098_008 2016. Sponsored by: Agencia Nacional de Investigación sobre el Sida y las Hepatitis Víricas. Signed date: 05/09/2016 González García JJ. Ensayo clínico en fase III para optimizar la inmuno-estimulación con maraviroc, un antagonista CCR5, combinado con tratamiento antorretroviral (TAR) en pacientes con infeccion por VIH-1 avanzada, con diagnostico tardio, criterio de definición de SIDA y/o recuentos de Cd4 por debajo de 200 células/mm3. Type: clinical trial, phase IV. HULP code: Anexo-I 3680. Sponsored´s protocol code: ANRS 146 OPTIMA. Sponsored by: Laboratorios VIIV Healthcare, S.L. Signed date: 02/02/2016 González García JJ. Estudio abierto de fase III para evaluar la eficacia y la seguridad del tratamiento con Boceprevir en pacientes coinfectados por el VIH y VHC (genotipo 1 (subtipo A o B)), que han fracasado al tratamiento previo con Peginterferón y Ribavirina. Type: clinical trial, phase III. HULP code: Anexo-I 3788. Sponsored´s protocol code: BOC-HIV. Sponsored by: Espin Basany, Eloy. Signed date: 13/07/2016 González García JJ. Estudio fase III, aleatorizado, multicéntrico, abierto, de grupos paralelos, para evaluar la eficacia, seguridad y tolerabilidad de una pauta de tratamiento intramuscular de acción prolongada con Cabotegravir y Rilpivirina en el mantenimiento de la supresión virológica, tras una inducción con un tratamiento de comprimido único con un inhibidor de la integrasa en pacientes adultos infectados por el VIH-1 que no han recibido un tratamiento antirretroviral previo. Type: clinical trial, phase III. HULP code: 4679. Sponsored´s protocol code: 201584. Sponsored by: Fundacio Clinic Per A La Reçerca Biomedica. Signed date: 10/08/2016 González Gómez C. Profilaxis antibiótica parenteral vs oral + parenteral en cirugía colónica: ensayo clínico prospectivo, randomizado, controlado y multicéntrico. Type: clinical trial, phase IV. HULP code: 4693. Sponsored´s protocol code: 2011/001/PROF-ATB. Sponsored by: Sociedad Española de Oncología y Hematología Pediátricas. Signed date: 31/10/2016 González Martínez B. Estudio intergrupo para niños o addolescentes con linfoma no-hodkin b o leucemia linfoblástica de células b; evaluación de eficacia y seguridad de Rituximab en pacientes de alto riesgo. Type: clinical trial, phase II. HULP code: Anexo-I 3546. Sponsored´s protocol code: IGR2009/1593. Sponsored by: Janssen Cilag International Nv. Signed date: 06/07/2016 Gutiérrez-Larraya Aguado F. Estudio prospectivo, abierto, con control-activo, para evaluar la farmacocinética, farmacodinamia, seguridad y eficacia de Rivaroxaban para la tromboprofilaxis en sujetos pediátricos de 2 a 8 años de edad después del procedimiento Fonta. Type: clinical trial, phase III. HULP code: 4695. Sponsored´s protocol code: 39039039CHD3001. Sponsored by: Novartis Farmaceutica, S.A. Signed date: 23/09/2016 Herranz Pinto P. Estudio observacional para evaluar las recaídas en pacientes con psoriasis moderada - grave tratados con fármacos biológicos de acuerdo a la práctica clínica, en España Estudio biopres. Type: EPA-OD. HULP code: Anexo-I 4173. Sponsored´s protocol code: NOV-PSO-2013-01. Sponsored by: Novartis Farmaceutica, S.A. Signed date: 18/01/2016 Herranz Pinto P. Estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo, de 52 semanas de duración para demostrar la eficacia, seguridad y tolerabilidad de inyecciones subcutáneas de Secukinumab con jeringas precargadas de 2 ml (300 mg) en pacientes adultos con psoriasis en placas de moderada a grave- allure. Type: clinical trial, phase III. HULP code: 4665. Sponsored´s protocol code: CAIN457A2323. Sponsored by: Abbvie Deutschland Gmbh. Signed date: 22/09/2016 Hierro Llanillo L. Estudio abierto, multicéntrico para evaluar la farmacocinética, la seguridad y la eficacia de Ombitasvir (OBV), Paritaprevir (PTV), Ritonavir (RTV), con o sin Dasabuvir (DSV) y con o sin Ribavirina (RBV) en pacientes pediátricos con infección crónica por el virus de la Hepatitis C (VHC) genotipo 1 o 4 (zircon). Type: clinical trial, phase III. HULP code: 4533. Sponsored´s protocol code: M14-748. Sponsored by: Abbvie Deutschland Gmbh. Signed date: 18/01/2016 Hierro Llanillo L. Estudio abierto, multicéntrico para evaluar la farmacocinética, la seguridad y la eficacia de Ombitasvir (OBV), Paritaprevir (PTV), Ritonavir (RTV), con o sin Dasabuvir (DSV) y con o sin Ribavirina (RBV) en pacientes pediátricos con infección crónica por el virus de la Hepatitis C (VHC) genotipo 1 o 4 (zircon). Type: clinical trial, phase III. HULP code: Anexo-I 4533. Sponsored´s protocol code: M14-748. Sponsored by: Glaxosmithkline, S.A. Signed date: 19/07/2016 Hillman Gadea N. Estudio de 24 semanas, multicéntrico, aleatorizado, abierto, de dos brazos y grupos paralelos, para evaluar la eficacia y seguridad del ajuste de dosis de insulina glargina u300 manejada por el paciente frente a la manejada por el médico en Diabetes Mellitus Tipo 2 (LPS14409). Type: clinical trial, phase IV. HULP code: 4524. Sponsored´s protocol code: LPS14409. Sponsored by: Glaxosmithkline, S.A. Signed date: 25/01/2016 Hillman Gadea N. Ensayo clínico 200977: albiglutida + insulina glargina frente a insulina lispro + insulina glargina en el tratamiento de sujetos con Diabetes Mellitus Tipo 2: Estudio SWITCH. Type: clinical trial, phase III. HULP code: 4602. Sponsored´s protocol code: 200977. Sponsored by: Sanofi Aventis S.A. Signed date: 01/03/2016 Hillman Gadea N. Ensayo clínico 200977: albiglutida + insulina glargina frente a insulina lispro + insulina glargina en el tratamiento de sujetos con Diabetes Mellitus Tipo 2: Estudio SWITCH. Type: clinical trial, phase III. HULP code: Anexo-I 4602. Sponsored´s protocol code: 200977. Sponsored by: Novo Nordisk A/S. Signed date: 30/03/2016 Hillman Gadea N. Estudio internacional de cohortes, prospectivo, sin intervención, para evaluar la seguridad del tratamiento con Levemir® (insulina detemir) en embarazadas con Diabetes Mellitus registro de embarazos de pacientes diabéticas. Type: EPA-LA. HULP code: Anexo-I PI-2083. Sponsored´s protocol code: NOV-INS-2013-0. Sponsored by: Population Health Research Institute. Signed date: 21/08/2016 Iannuccelli F. Ensayo clínico internacional, aleatorizado, controlado con placebo para evaluar el efecto del Dabigatran (un inhibidor directo de la trombina) y Omeprazol (un inhibidor de la bomba de protones) en pacientes con daño miocárdico después de la cirugía. Type: clinical trial, phase IIIa. HULP code: 4481. Sponsored´s protocol code: 1160.143. Sponsored by: Astellas Pharma Europe B.V. Signed date: 07/07/2016 Jara Vega P. Estudio abierto, no comparativo, a largo plazo, para evaluar la eficacia y la seguridad de un régimen de inmunosupresor basado en Modigraf en pacientes pediátricos receptores de un aloinjerto de órgano solido. Type: clinical trial, phase IV. HULP code: Anexo-III 3252. Sponsored´s protocol code: F506-CL-0404. Sponsored by: Novo Nordisk A/S. Signed date: 10/02/2016

Continue

47

2.6 Clinical Trials

2 EXECUTIVE SUMMARY

48

Jiménez Yuste VM. Ensayo multinacional para evaluar la seguridad y la eficacia, junto con la farmacocinética, de NNC 0129-00001003 administrado para el tratamiento y la profilaxis de las hemorragias en pacientes con hemofilia a. Type: clinical trial, phase III. HULP code: Anexo-III 3526. Sponsored´s protocol code: NN7088-3859. Sponsored by: F.Hoffmann-La Roche Ltd. Signed date: 09/05/2016 Jiménez Yuste VM. Seguridad y eficacia de NNC0155-0000-0004 en la prevención y el tratamiento de las hemorragias en pacientes pediátricos con hemofilia a no tratados previamente. Type: clinical trial, phase III. HULP code: Anexo-II 3602. Sponsored´s protocol code: NN7008-3809. Sponsored by: F. Hoffmann-La Roche Ltd. Signed date: 15/03/2016 Jiménez Yuste VM. Ensayo clínico aleatorizado, multicéntrico, abierto de fase III para evaluar la eficacia, seguridad y farmacocinética del ro5534262 profiláctico frente a la no profilaxis en pacientes con hemofilia a con inhibidores. Type: clinical trial, phase III. HULP code: Anexo-I 4486. Sponsored´s protocol code: BH29884. Sponsored by: Novo Nordisk A/S. Signed date: 10/02/2016 Jiménez Yuste VM. Ensayo clínico de fase III multicéntrico, abierto y de un solo brazo para evaluar la eficacia, la seguridad y la farmacocinética de la administración subcutánea de Emicizumab una vez a la semana en pacientes pediátricos con hemofilia a con inhibidores. Type: clinical trial, phase III. HULP code: 4605. Sponsored´s protocol code: BH29992. Sponsored by: Novo Nordisk A/S. Signed date: 10/05/2016 Jiménez Yuste VM. Ensayo clínico de fase III, aleatorizado, multicéntrico y abierto para evaluar la eficacia, la seguridad y la farmacocinética del Emicizumab profiláctico, en comparación con la ausencia de profilaxis, en pacientes con hemofilia a sin inhibidores. Type: clinical trial, phase III. HULP code: 4606. Sponsored´s protocol code: BH30071. Sponsored by: Roche Farma, S.A. Signed date: 28/04/2016 Jiménez Yuste VM. Guardian 9- Ensayo abierto y multicéntrico para evaluar la farmacocinética de Novoeight® (turoctocog alfa) en relación con el IMC en sujetos con hemofilia a. Type: clinical trial, phase I. HULP code: 4618. Sponsored´s protocol code: NN7008-4239. Sponsored by: Fundación Publica Andaluza Progreso Y Salud. Signed date: 23/09/2016 Jiménez Yuste VM. Ensayo multicéntrico, comparativo, doble ciego, aleatorizado y cruzado para investigar la farmacocinética y la seguridad de dosis única de Turoctocog alfa pegol a partir del proceso pivotal y de Turoctocog alfa pegol a partir del proceso comercial en pacientes con hemofilia a grave. Type: clinical trial, phase I. HULP code: 4654. Sponsored´s protocol code: NN7088-4033. Sponsored by: F.Hoffmann-La Roche Ltd. Signed date: 02/09/2016 Jiménez Yuste VM. Ensayo clínico Estudio de fase III, multicéntrico y sin enmascaramiento para evaluar la eficacia, la seguridad, la farmacocinética y la farmacodinámica del Emicizumab administrado cada 4 semanas en pacientes con hemofilia a. Type: clinical trial, phase III. HULP code: 4674. Sponsored´s protocol code: BO39182. Sponsored by: Novo Nordisk A/S. Signed date: 29/08/2016 Loeches Yagüe B. Ensayo clínico aleatorizado, multicéntrico, abierto, controlado, en fase III, para demostrar la no inferioridad del tratamiento antibiótico dirigido de espectro reducido frente al tratamiento de amplio espectro con un betalactámico antipseudomónico en el tratamiento de pacientes con bacteriemia por enterobacteriaceae. Type: clinical trial, phase III. HULP code: 4583. Sponsored´s protocol code: SIMPLIFY. Sponsored by: Otsuka Pharmaceutical Development & Commercializacion, Inc. Signed date: 18/03/2016 López Arrieta JM. Un estudio de fase III, de 12 semanas de duración, multicéntrico, aleatorizado, doble ciego, controlado con placebo para evaluar la eficacia, seguridad y tolerabilidad de 3 dosis fijas de Brexpiprazol (opc-34712) en el tratamiento de sujetos con agitación asociada con la demencia del tipo Alzheimer. Type: clinical trial, phase III. HULP code: Anexo-II 4014. Sponsored´s protocol code: 331-12-283. Sponsored by: Novartis Farmaceutica, S.A. Signed date: 03/05/2016 López Arrieta JM. Estudio multicéntrico de faseIIa/IIb, aleatorizado, doble ciego, controlado con placebo, de 56 semanas de seguimiento, para evaluar la seguridad y la eficacia de bimagrumab IV sobre la masa corporal magra total y la actividad física en pacientes después de tratamiento quirúrgico de fractura de cadera. Type: clinical trial, phase II. HULP code: Anexo-II 4206. Sponsored´s protocol code: CBYM338D2201. Sponsored by: Glaxosmithkline Research And Development Limited. Signed date: 29/03/2016 López Arrieta JM. Estudio observacional de cohortes de la seguridad posterior a la autorización (PAS) para cuantificar la incidencia y la seguridad comparativa de acontecimientos cardiovasculares y cerebrovasculares específicos en pacientes con EPOC que utilizan la combinación Umec/vi por inhalación o Umec por inhalación en comparación con Tiotropio. Type: EPA-LA. HULP code: PI-2186. Sponsored´s protocol code: 201038. Sponsored by: Fundación De Investigación En Red En Enfermedades Cardiovasculares- Fircava. Signed date: 02/06/2016 López de Sá Areces E. Estudio prospectivo abierto del Andexanet alfa en pacientes tratados con un inhibidor de factor XA que presentan una hemorragia mayor aguda. Type: clinical trial, phase III. HULP code: 4523. Sponsored´s protocol code: 14-505. Sponsored by: Dalcor Pharma Uk Ltd. Signed date: 02/02/2016 López de Sá Areces E. Estudio observacional sobre el tratamiento oral antiplaquetario tras sindrome coronario agudo en España (Spanish Observational Study of Oapt after ACS). Type: EPA-SP. HULP code: PI-2206. Sponsored´s protocol code: FIR-ACS-2015-01. Sponsored by: Portola Pharmaceuticals Inc. Signed date: 02/03/2016 López-Sendón Hentschel JL. Estudio en fase III, aleatorizado, doble ciego y controlado con placebo para evaluar los efectos de Dalcetrapib sobre el riesgo cardiovascular (CV) en una población definida genéticamente con Síndrome Coronario Agudo reciente (SCA): el ensayo dal-gene. Type: clinical trial, phase III. HULP code: 4627. Sponsored´s protocol code: DAL-301. Sponsored by: Merck Sharp And Dohme De España, S.A. Signed date: 27/05/2016 López-Sendón Hentschel JL. Estudio de fase III fundamental, multicéntrico, aleatorizado, doble ciego, controlado con placebo, de grupos paralelos y determinado por los episodios para evaluar la eficacia y la seguridad de Vericiguat, un estimulador de la guanilato ciclasa soluble (GCS) por vía oral, en sujetos con insuficiencia cardíaca con fracción de eyección disminuida (ICFED): Estudio victoria (vericiguat global study in subjects with heart failure with reduced ejection fraction. Type: clinical trial, phase III. HULP code: 4685. Sponsored´s protocol code: 1242-001. Sponsored by: Iron Therapeutics UK. Limited. Signed date: 22/09/2016 Martín Arranz MD. Estudio doble ciego, aleatorizado, multicéntrico sobre una pauta posológica más alta de Adalimumab en comparación con una pauta estándar para el tratamiento de inducción y mantenimiento en pacientes con colitis ulcerosa moderada o muy activa. Type: clinical trial, phase III. HULP code: Anexo-I 4185. Sponsored´s protocol code: M14-033. Sponsored by: Grupo Español de Trabajo en Enfermedad de Crhon y Colitis Ulcerosa. Signed date: 03/02/2016

Martín Arranz MD. Estudio multicéntrico, aleatorizado, con doble enmascaramiento y controlado con placebo sobre abt-494 para inducir la remisión sintomática y endoscópica en pacientes con enfermedad de Crohn activa de intensidad moderada a grave que han respondido de forma insuficiente al tratamiento anti-TNF o que no toleran el tratamiento. Type: clinical trial, phase II. HULP code: Anexo-I 4417. Sponsored´s protocol code: M13-740. Sponsored by: Geteccu (Grupo Español De Trabajo En Enfermedad De Crhon Y Colitis Ulcerosa). Signed date: 27/04/2016 Martín Arranz MD. Estudio multicéntrico de fase II, aleatorizado, doble ciego y controlado con placebo de grupos paralelos para investigar la seguridad y la eficacia de apd334 en pacientes con colitis ulcerativa activa de moderada a grave.Type: clinical trial, phase II. HULP code: 4498. Sponsored´s protocol code: APD334-003. Sponsored by: Abbvie Spain, S.L.U. Signed date: 28/04/2016 Martín Arranz MD. Estudio de extensión del Estudio apd334-003 en pacientes con colitis ulcerosa activa moderada o grave. Type: clinical trial, phase II. HULP code: 4541. Sponsored´s protocol code: APD334-005. Sponsored by: Pfizer, S.L.U. Signed date: 28/06/2016 Martín Arranz MD. Estudio de fase IIIb, aleatorizado, controlado y multicéntrico con Maltol férrico oral (feraccru) o hierro intravenoso (carboximaltosa férrica; cmf), para el tratamiento de la anemia ferropénica en sujetos con enfermedad inflamatoria intestinal. Type: clinical trial, phase IIIb. HULP code: 4633. Sponsored´s protocol code: ST10-01-304. Sponsored by: Abbvie Spain, S.L.U. Signed date: 20/04/2016 Martín Arranz MD. Estudio epidemiológico de la incidencia de enfermedad inflamatoria intestinal en población adulta en España. Type: Non EPA. HULP code: PI-068A. Sponsored´s protocol code: GIS-2015-INCIDENCIA. Sponsored by: Arena Pharmaceuticals Inc. Signed date: 30/03/2016 Martín Arranz MD. Groupe d´etude thérapeutique des affections inflammatoires digestives); (Co-sponsor), GETECCU (Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa) para la realización del Estudio observacional titulado: IBD cancer and serious infections in Europe: I-CARE EII cancer e infecciones graves en Europa: I-CARE. Type: EPA-SP. HULP code: PI-2115. Sponsored´s protocol code: GET-EII-2015-01. Sponsored by: Arena Pharmaceuticals Inc. Signed date: 12/07/2016 Martín Mola E. Estudio de fase III, aleatorizado, doble ciego, con control activo y con placebo, multicéntrico y de grupos paralelos de la seguridad y eficacia analgésica de Tanezumab en adultos con lumbalgia crónica. Type: clinical trial, phase III. HULP code: 4469. Sponsored´s protocol code: A4091059. Sponsored by: Baxalta Innovations Gmhb. Signed date: 29/01/2016 Martín Salces M. Estudio de fase III, multicéntrico, abierto y no controlado para evaluar la seguridad y la eficacia de BAY 81-profilactico. Type: clinical trial, phase III. HULP code: Anexo-I 4099. Sponsored´s protocol code: 81-8973/13400. Sponsored by: Grupo Español De Investigación En Sarcomas. Signed date: 24/10/2016 Martín Salces M. Estudio de fase III, multicéntrico, de un solo brazo y abierto sobre la eficacia y la seguridad del factor VIII recombinante porcino con dominio b suprimido (BAX 802) en sujetos con hemofilia A congénita con inhibidores del factor VIII sometidos a intervenciones quirúrgicas u otros procedimientos invasivos. Type: clinical trial, phase III. HULP code: 4658. Sponsored´s protocol code: 241502. Sponsored by: Bayer Hispania, S.L. Signed date: 15/07/2016 Martínez Marín V. Determinantes clínicos y moleculares de respuesta y progresión a la inhibición de kit en pacientes con tumores del estroma gastrointestinal (GIST) con respuesta prolongada a Imatinib. Type: EPA-OD. HULP code: PI-2367. Sponsored´s protocol code: DETERMINANTES CLÍNICOS Y MOLECULARES DE RESPUESTA Y PROGRESIÓN A LA INHIBICIÓN DE KIT EN PACIENTES CON TUMORES DEL ESTROMA GASTROINTESTINAL (GIST) CON RESPUESTA PROLONGADA A IMATINIB. Sponsored by: Grupo Español de Investigación en Sarcomas. Signed date: 01/06/2016 Martínez Marín V. Estudio observacional, retrospectivo y multicéntrico para identificar el papel pronóstico y posibles implicaciones terapéuticas del receptor de la somatostatina (SSTR) en el tumor de estroma gastrointestinal (GIST) localizado (somagist). Type: Non EPA. HULP code: PI-2453. Sponsored´s protocol code: GEIS 46. Sponsored by: Chiltern International Spain, S.A. Signed date: 15/07/2016 Méndez Echevarría AM. Estudio multicéntrico, abierto, aleatorizado, de fase II/III para determinar la seguridad y eficacia de la Solitromicina en adolescentes (de 12 a 17 años de edad, ambos inclusive) y niños ( 2 meses a < 12 años de edad) con neumonía bacteriana adquirida en la comunidad sospechada o confirmada. Type: clinical trial, phase II. HULP code: 4599. Sponsored´s protocol code: CE01-203. Sponsored by: Biotronik Se&Co. Kg. Signed date: 13/06/2016 Merino Llorens JL. Estudio de la eficacia y la seguridad de f373280 para el mantenimiento del ritmo sinusal tras cardioversión eléctrica en pacientes con fibrilación auricular persistente e insuficiencia cardiaca crónica. Type: clinical trial, phase II. HULP code: Anexo-IV 3814. Sponsored´s protocol code: F373280CA201. Sponsored by: Biotronik Se&Co. Kg. Signed date: 28/03/2016 Merino Llorens JL. Triumph crt estimulacion biventricular trifocal para la optimización de la terapia de desincronización cardiaca (TRC). Type: Healthcare product. HULP code: 4519. Sponsored´s protocol code: ICSY02. Sponsored by: Pierre Fabre Medicament S.A.S. Signed date: 18/02/2016 Merino Llorens JL. Estudio clínico sobre las diferencias en la magnitud de la respuesta a la TRC en mujeres y hombres.Type: Healthcare product. HULP code: Anexo-1 4595. Sponsored´s protocol code: CR017. Sponsored by: Sorin Group España, S.L. Signed date: 08/09/2016 Merino Llorens JL. Estudio clínico sobre las diferencias en la magnitud de la respuesta a la TRC en mujeres y hombres, código de protocolo cr017, versión 10 de 3 de diciembre de 2014. Type: Healthcare product. HULP code: 4595. Sponsored´s protocol code: CR017. Sponsored by: Novartis Farmacéutica, S.A. Signed date: 14/06/2016 Merino Muñoz R. Estudio aleatorizado, doble ciego, controlado con placebo de Canakinumab en pacientes con fiebres periódicas hereditarias (TRAPS, HIDS o FMFRC) con retirada aleatorizada/reducción de la frecuencia de la dosis y posterior fase de tratamiento abierto a largo plazo. Type: clinical trial, phase III. HULP code: Anexo-III 4138. Sponsored´s protocol code: CACZ885N2301. Sponsored by: Novartis Farmacéutica, S.A. Signed date: 29/03/2016 Montes Ramírez ML. Estudio fase III aleatorizado, multicéntrico, abierto, de grupos paralelos, de no inferioridad, para evaluar la eficacia, seguridad y tolerabilidad del cambio de una terapia antirretroviral basada en INI, ITINN o IP a una pauta de tratamiento intramuscular de acción prolongada con Cabotegravir y Rilpivirina en pacientes adultos infectados por el VIH-1 con supresión virológica. Type: clinical trial, phase III. HULP code: 4681. Sponsored´s protocol code: 201585. Sponsored by: Sanofi Aventis S.A. Signed date: 10/08/2016

Continue

49

2.6 Clinical Trials

2 EXECUTIVE SUMMARY

50

Montes Ramírez ML. Eficacia y seguridad/tolerabilidad de Viekirax y Exviera en pacientes diagnosticados de VHC, coinfectados o no con VIH 1, GT 1 o 4, y enfermedad renal crónica en estadios de IIIb a V, incluyendo aquellos en diálisis, en práctica clínica habitual en España Estudio viekind. Type: EPA-OD. HULP code: PI-2303. Sponsored´s protocol code: ABB-OMB-2015-01. Sponsored by: Laboratorios VIIV Healthcare, S.L. Signed date: 09/05/2016 Montoya Lozano F. Cribado para la enfermedad de Gaucher en la población española con Esplenomegalia y/o Trombocitopenia de origen desconocido. Type: Non EPA. HULP code: PI-2241. Sponsored´s protocol code: GSS-GAU-20155-01. Sponsored by: Achaogen Inc. Signed date: 05/04/2016 Mora Rillo M. Estudio de fase III, multicéntrico, aleatorizado y abierto para evaluar la eficacia y la seguridad de Plazomicina en comparación con Colistina en pacientes con infección causada por enterobacterias resistentes a los carbapenémicos (CRE).Type: clinical trial, phase III. HULP code: Anexo-II 4039. Sponsored´s protocol code: 4039 ACHN-490-007. Sponsored by: Genzyme Europe Bv. Signed date: 23/05/2016 Morado Arias M. Protocolo de registro de la enfermedad de Gaucher. Type: EPA-SP. HULP code: 4122. Sponsored´s protocol code: GEN-GAU-2013-01. Sponsored by: Bayer Ag. Signed date: 27/05/2016 Moreno Gómez JR. Estudio multicéntrico, de ámbito global, abierto, aleatorizado, con control activo, dirigido por eventos, que para optimizar los resultados clínicos pretende comparar el tratamiento de Rivaroxaban con un tratamiento basado en antiagregantes plaquetarios tras el reemplazo por vía transcatéter de una válvula aórtica galileo. Type: clinical trial, phase III. HULP code: Anexo-I 4525. Sponsored´s protocol code: BAY17938. Sponsored by: Bayer Ag. Signed date: 30/09/2016 Moreno Gómez JR. Estudio multicéntrico, de ámbito global, abierto, aleatorizado, con control activo, dirigido por eventos, que para optimizar los resultados clínicos pretende comparar el tratamiento de Rivaroxaban con un tratamiento basado en antiagregantes plaquetarios tras el reemplazo por vía transcatéter de una válvula aórtica galileo. Type: clinical trial, phase III. HULP code: 4525. Sponsored´s protocol code: BAY 17938. Sponsored by: Fundación Casa Del Corazón. Signed date: 29/03/2016 Moreno Gómez JR. Registro de pacientes con dispositivo biorreabsorbible en la práctica clínica habitual: medida de costes, efectividad, qalys, y eficiencia- Estudio repara-qaly. Type: Healthcare product. HULP code: PI-2425. Sponsored´s protocol code: COR-BVS-2016-01 ESTUDIO REPARA-QALY. Sponsored by: Spherium Biomed S.L. Signed date: 15/07/2016 Morera López RM. Ensayo clínico fase Ib-II de gel de melatonina oral para la prevención y tratamiento de la mucositis oral en pacientes con cáncer de cabeza y cuello tratados con quimioradioterapia. Type: clinical trial, phase Ib. HULP code: 4638. Sponsored´s protocol code: JAN13004-30. Sponsored by: Ángelini Farmaceutica S.A. Signed date: 22/06/2016 Morera López RM. Estudio de calidad de vida en pacientes con dolor irruptivo oncológico atendidos en los servicios de oncología radioterápica con intención paliativa. Type: EPA-SP. HULP code: PI-2403. Sponsored´s protocol code: CAVIDIOR ANG-MOR-2016-01. Sponsored by: Bristol Myers Squibb International Corporation. Signed date: 27/05/2016 Murias Loza SM. Registro observacional de Abatacept en pacientes con artritis idiopática juvenil. Type: EPA-LA. HULP code: PI-2079. Sponsored´s protocol code: IM101240. Sponsored by: Glaxosmithkline, S.A. Signed date: 11/07/2016 Nuñez López MC. Estudio de vacunación cruzada con la formulación liofilizada de la vacuna de subunidades frente al herpes zóster (HZ/SU) de GSK biologicals (GSK 1437173a) en sujetos que previamente recibieron placebo en los Estudios zoster-006 y zoster-022. Type: clinical trial, phase III. HULP code: 4597. Sponsored´s protocol code: 204486. Sponsored by: Glaxosmithkline, S.A. Signed date: 27/04/2016 Nuñez López MC. Eficacia, seguridad e inmunogenicidad de la vacuna HZ/SU de GSK biologicals GSK1437173a en un estudio fase IIIb, abierto, de seguimiento a largo plazo (ZOE-LTFU) de los Estudios 110390/113077 (zoster-006/022) y evaluación de dosis adicionales en adultos de edad avanzada. Type: clinical trial, phase IIIb. HULP code: 4603. Sponsored´s protocol code: 201190ZOSTER-049. Sponsored by: Merck Sharp & Dhome Corp. Signed date: 13/05/2016 Olveira Martín A. Estudio observacional de carácter exploratorio, para describir el perfil de pacientes con hepatitis C con 18 años de edad o más tratados con regímenes sin Interferón según la adición de Ribavirina en España: evidencia de la práctica clínica real en 2015. Type: EPA-OD. HULP code: PI-2407. Sponsored´s protocol code: ID VEAP 6124. Sponsored by: Regeneron Pharmaceuticals, Inc. Signed date: 08/08/2016 Omeñaca Terés F. Estudio de seguimiento para evaluar la seguridad y los resultados a largo plazo en lactantes nacidos de madres que participaron en los Estudios de tratamiento con retosibán. Type: clinical trial, phase III. HULP code: Anexo-I 4322. Sponsored´s protocol code: 200722. Sponsored by: Glaxosmithkline, S.A. Signed date: 21/03/2016 Omeñaca Terés F. Estudio en fase III, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de un anticuerpo monoclonal humano, regn2222, para la prevención de la infección por el VRS bajo atención médica en lactantes prematuros. Type: clinical trial, phase III. HULP code: 4458. Sponsored´s protocol code: R2222-RSV-1332. Sponsored by: Glaxosmithkline Research and Development Limited. Signed date: 21/07/2016 Omeñaca Terés F. Inmunogenicidad y seguridad de una dosis de recuerdo de Infanrix Hexa® (217744) de GSK biologicals en niños sanos nacidos de madres vacunadas con Boostrix® en el embarazo o en el posparto inmediato. Type: clinical trial, phase IV. HULP code: 4613. Sponsored´s protocol code: 201334 BOOSTRIX-049. Sponsored by: Novavax, Inc. Signed date: 13/05/2016 Omeñaca Terés F. Estudio en fase III, aleatorizado, enmascarado para el observador, controlado con placebo y con grupos secuenciales para determinar la inmunogenicidad y la seguridad de una vacuna. Type: clinical trial, phase III. HULP code: 4663. Sponsored´s protocol code: RSV-M-301. Sponsored by: Ionis Pharmaceuticals Inc. Signed date: 19/10/2016 Pascual Pascual SI. Estudio en fase III, aleatorizado, doble ciego, controlado con placebo, multicéntrico e internacional que evalúa en grupos paralelos la eficacia y seguridad de 2 dosis de pxt3003 en pacientes con síndrome de Charcot-Marie-Tooth de tipo 1A tratados durante 15 meses. Type: clinical trial, phase III. HULP code: 4534. Sponsored´s protocol code: CLN-PXT3003-02. Sponsored by: Otsuka Pharmaceutical Development & Commercializacion, Inc. Signed date: 10/08/2016

Pascual Pascual SI. Estudio de extensión abierto para pacientes con atrofia muscular espinal que han participado previamente en Estudios experimentales de isis 396443. Type: clinical trial, phase III. HULP code: 4577. Sponsored´s protocol code: ISIS 396443-CS11. Sponsored by: Erydel S.P.A. Signed date: 07/04/2016 Pascual Pascual SI. Ensayo multicéntrico, aleatorizado, doble ciego, controlado con placebo para evaluar los efectos del fosfato sódico de dexametasona intra-eritrocito en los síntomas neurológicos de pacientes con ataxia telangiectasia.Type: clinical trial, phase III. HULP code: 4598. Sponsored´s protocol code: IEDAT-02-2015. Sponsored by: Pharnext ,. Signed date: 02/06/2016 Peces Serrano R. Ensayo de fase IIIb, multicéntrico y abierto para evaluar la seguridad a largo plazo de Tolvaptán de liberación inmediata (opc-41061, de 30 mg a 120 mg/día, dosis dividida) en sujetos con poliquistosis renal autosómica dominante. Type: clinical trial, phase IIIb. HULP code: 4473. Sponsored´s protocol code: 156-13-211. Sponsored by: Medtronic Iberica S.A. Signed date: 25/02/2016 Peinado Peinado R. RECABA-Registro Español de Crioablación con Balón. Type: Healthcare product. HULP code: PI-2454. Sponsored´s protocol code: RECABA. Sponsored by: Janssen Cilag International N.V. Signed date: 02/11/2016 Pérez Martínez A. Infusión de células natural killer como tratamiento de consolidación en niños y adolescentes con leucemia mieloblástica aguda. Type: Healthcare product. HULP code: 4489. Sponsored´s protocol code: NKCELL_LMA_2015. Sponsored by: Gilead Sciences Inc. Signed date: 20/04/2016 Pérez Martínez A. Estudio aleatorizado, abierto, de seguridad y eficacia de Ibrutinib en pacientes pediátricos y adultos jóvenes con linfoma no Hodgkin de células maduras b en recaída o refractario. Type: clinical trial, phase III. HULP code: 4644. Sponsored´s protocol code: 54179060LYM3003. Sponsored by: Pérez Martínez, Antonio. Signed date: 18/10/2016 Pérez Valero I. Estudio prospectivo, observacional de la utilización del medicamento Stribild® en adultos con infección por VIH. Type: EPA-LA. HULP code: PI-1975. Sponsored´s protocol code: GS-EU-236-0141. Sponsored by: Aveo Pharmaceuticals. Signed date: 20/05/2016 Pinto Marín Á. Estudio de fase III, aleatorizado, controlado, multicéntrico y abierto, para comparar el Tivozanib clorhidrato frente al Sorafenib en sujetos con carcinoma de células renales avanzado resistente al tratamiento. Type: clinical trial, phase III. HULP code: 4570. Sponsored´s protocol code: AV-951-15-303. Sponsored by: Pfizer, S.L.U. Signed date: 02/06/2016 Pinto Marín Á. Estudio exploratorio de fase II, abierto y con un solo grupo de tratamiento con Afatinib oral en monoterapia tras el fracaso a platino en pacientes con carcinoma urotelial avanzado/metastásico con desregulación de los receptores ERBB. Type: clinical trial, phase II. HULP code: 4632. Sponsored´s protocol code: 1200.261. Sponsored by: Sociedad Española De Oncologia Y Hematologia Pediatricas. Signed date: 15/07/2016 Pinto Marín Á. Estudio de fase III, multicéntrico, multinacional, aleatorizado, abierto, con grupos paralelos sobre Avelumab* (MSB0010718c) más los mejores cuidados paliativos frente a los mejores cuidados paliativos solos como tratamiento de mantenimiento en pacientes con cáncer urotelial localmente avanzado o mestastásico sin progresión de la enfermedad tras completar la quimioterapia de primera línea basada en platino. Type: clinical trial, phase III. HULP code: 4659. Sponsored´s protocol code: B9991001. Sponsored by: Grupo Grupo Sogug. Signed date: 04/07/2016 Pinto Marín Á. Estudio de fase III, Estudio multicéntrico, abierto, con un solo grupo de tratamiento para evaluar la seguridad de Atezolizumab en pacientes con carcinoma urotelial o no urotelial del tracto urinario localmente avanzado o metastásico. Type: clinical trial, phase III. HULP code: 4699. Sponsored´s protocol code: MO299833. Sponsored by: Boehringer Ingelheim España, S.A. Signed date: 05/10/2016 Pinto Marín Á. Validación del consorcio de la base de datos internacional de cáncer renal metastásico (IMDC) como clasificación pronóstica para terapias dirigidas (inhibidores de la ITC/MTOR) en segunda línea después del tratamiento con Pazopanib primera línea (spazo-2). Type: EPA-OD. HULP code: PI-2523. Sponsored´s protocol code: SOGUG-2016-A-IEC. Sponsored by: F.Hoffmann-La Roche Ltd. Signed date: 26/10/2016 Plaza López de Sabando D. Estudio prospectivo internacional de meduloblastoma riesgo estándar clínico en niños mayores de 3 a 5 años con perfil bajo de riesgo biológico (pnet 5 MB - LR) o perfil-medio de riesgo biológico (PNET 5-SR MB). Type: clinical trial, phase II. HULP code: 4556. Sponsored´s protocol code: PNET5MB. Sponsored by: Vertex Pharmaceuticals Incorporated. Signed date: 23/09/2016 Prados Sánchez C. Registro Observacional Europeo de pacientes con Fibrosis Quística (VOICE). Type: EPA-SP. HULP code: PI-2397. Sponsored´s protocol code: VX14-CFR-107. Sponsored by: Teva Pharma S.L.U. Signed date: 27/06/2016 Puertas Muñoz I. Registro Español de pacientes tratados con acetato de glatiramero (Copaxone®) 40 mg/ml . Type: EPA-SP. HULP code: PI-2216. Sponsored´s protocol code: TEV-ACE-2015-01. Sponsored by: Laboratoires Thea. Signed date: 05/04/2016 Ramos Castrillo A. ISY: Duokopt® satisfaction survey (Estudio de satisfacción de los pacientes de Duokopt®. Type: EPA-OD. HULP code: PI-2466. Sponsored´s protocol code: THE-DOR:2016-01. Sponsored by: Millennium Pharmaceuticals, Inc. Signed date: 13/09/2016 Redondo Sánchez A. Estudio de fase III, abierto, multicéntrico, randomizado para evaluar la eficacia y seguridad de Trastuzumab emtansine versus Trastuzumab como tratamiento adyuvante en pacientes con cáncer de mama primario HER2-positivo con presencia patológica de tumor residual en la mama o nodulo linfatico axilar tras tratamiento preoperatorio. Type: clinical trial, phase III. HULP code: Anexo-I 3783. Sponsored´s protocol code: BO27938. Sponsored by: Lilly, S.A. Signed date: 12/01/2016 Redondo Sánchez A. Estudio aleatorizado de fase III de Lubinectedin (pm01183) frente a Doxorrubicina liposomal pegilada o topotecán en pacientes con cáncer de ovario resistente a platino (Ensayo CORAIL). Type: clinical trial, phase III. HULP code: Anexo-I 4400. Sponsored´s protocol code: PM1183-C-004-14. Sponsored by: Tesaro Inc. Signed date: 13/07/2016 Redondo Sánchez A. Estudio fase II multicéntrico, abierto, de un solo brazo para evaluar la seguridad y eficacia de Bevacizumab en combinación con carboplatino y Paclitaxel en pacientes con cáncer de cérvix metastásico, recurrente o persistente. Type: clinical trial, phase II. HULP code: Anexo-I 4422. Sponsored´s protocol code: MO29594. Sponsored by: F. Hoffmann-La Roche Ltd. Signed date: 15/04/2016

Continue

51

2.6 Clinical Trials

2 EXECUTIVE SUMMARY

52

Redondo Sánchez A. Estudio de fase Ib (abierto) / fase II (aleatorizado, doble ciego) en el que se evalúan Gemcitabina y Docetaxel, con o sin Olaratumab, en el tratamiento del sarcoma de tejidos blandos en estadio avanzado. Type: clinical trial, phase II. HULP code: Anexo-I 4543. Sponsored´s protocol code: I5B-MC-JGDL. Sponsored by: Lilly, S.A. Signed date: 29/02/2016 Redondo Sánchez A. Estudio de fase Ib (abierto) / fase II (aleatorizado, doble ciego) en el que se evalúan Gemcitabina y Docetaxel, con o sin Olaratumab, en el tratamiento del sarcoma de tejidos blandos en estadio avanzado. Type: clinical trial, phase II. HULP code: 4543. Sponsored´s protocol code: I5B-MC-JGDL. Sponsored by: Pharmamar, S.A. Signed date: 27/01/2016 Redondo Sánchez A. Estudio en fase III, multicéntrico, aleatorizado y controlado con placebo de Atezolizumab (anticuerpo antipd-l1) combinado con Nab-Paclitaxel en comparación con placebo con Nab-Paclitaxel en pacientes con cáncer de mama triple negativo metastásico no tratado previamente. Type: clinical trial, phase III. HULP code: 4581. Sponsored´s protocol code: WO29522. Sponsored by: Pfizer Inc. Signed date: 20/04/2016 Redondo Sánchez A. Estudio de fase II aleatorizado de mln0128 (inhibidor doble de torc1/2), mln0128 + mln1117 (inhibidor de pi3k?), Paclitaxel semanal, o la combinación de Paclitaxel semanal y mln0128 en mujeres con cáncer de endometrio avanzado, recurrente o persistente. Type: clinical trial, phase II. HULP code: 4614. Sponsored´s protocol code: C31004. Sponsored by: Roche Farma, S.A. Signed date: 20/05/2016 Redondo Sánchez A. Estudio de fase III, aleatorizado, en doble ciego, controlado con placebo y multicéntrico, del tratamiento de mantenimiento con Niraparib en pacientes con cáncer de ovario avanzado portador de deficiencia de la recombinación homóloga (hrd) que han respondido a la quimioterapia de primera línea con platino. Type: clinical trial, phase III. HULP code: 4642. Sponsored´s protocol code: PR-30-5017-C. Sponsored by: Sanofi Aventis S.A. Signed date: 23/09/2016 Redondo Sánchez A. Estudio de fase III, multicéntrico, aleatorizado, abierto de Avelumab (msb0010718c) en monoterapia o en combinación con Doxorubicina liposomal pegilada frente a Doxorubicina liposomal pegilada en monoterapia en pacientes con cáncer de ovario refractario/resistente a platino. Type: clinical trial, phase III. HULP code: 4652. Sponsored´s protocol code: B9991009. Sponsored by: F.Hoffmann-La Roche Ltd. Signed date: 23/06/2016 Remesal Camba A. Estudio para evaluar la disminución de la frecuencia de dosis en pacientes con artritis idiopática juvenil sistemática activa (AIJS) que experimentan anomalías de laboratorio durante el tratamiento con Tocilizimab.Type: clinical trial, phase IV. HULP code: Anexo-II 3725. Sponsored´s protocol code: WA28029. Sponsored by: Sanofi-Aventis Recherche & Developpement. Signed date: 06/09/2016 Remesal Camba A. Estudio abierto, secuencial, de búsqueda de dosis ascendentes y repetidas de Sarilumab administrado con inyección subcutánea (SC) a niños y adolescentes con edades comprendidas entre 2 y 17 años con artritis idiopática juvenil de curso poliarticular (AIJP), seguido de una fase de extensión. Type: clinical trial, phase III. HULP code: 4604. Sponsored´s protocol code: DRI13925. Sponsored by: F.Hoffmann-La Roche Ltd. Signed date: 29/04/2016 Remesal Camba A. Estudio abierto, secuencial, de búsqueda de dosis ascendentes y repetidas de Sarilumab administrado con inyección subcutánea (SC) a niños y adolescentes con edades comprendidas entre 1 y 17 años con artritis idiopática juvenil sistémica (AIJS), seguido de una fase de extensión. Type: clinical trial, phase III. HULP code: 4705. Sponsored´s protocol code: DRI13926. Sponsored by: Boehringer Ingelheim International Gmbh. Signed date: 17/10/2016 Rios Blanco JJ. Estudio aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad del tratamiento oral con Nintedanib durante al menos 52 semanas en pacientes con enfermedad pulmonar intersticial asociada a esclerosis sistémica (SSC-ILD). Type: clinical trial, phase III. HULP code: 4504. Sponsored´s protocol code: 1.199.214. Sponsored by: Ucb Celltech. Signed date: 17/02/2016 Robles Marhuenda AJ. Estudio prueba de concepto aleatorizado, doble ciego, controlado con placebo, para evaluar la eficacia y seguridad de ucb5857 durante 12 semanas en pacientes con síndrome de Sjögren primario. Type: clinical trial, phase II. HULP code: Anexo-I 4429. Sponsored´s protocol code: SS0004. Sponsored by: Glaxosmithkline, S.A. Signed date: 02/11/2016 Robles Marhuenda AJ. Estudio aleatorizado, doble ciego (abierto para el promotor), comparativo, multicéntrico para evaluar la seguridad y la eficacia de la coadministración de Belimumab (gsk1550188) subcutáneo y rituximab intravenoso en sujetos con síndrome de Sjögren primario. Type: clinical trial, phase II. HULP code: 4488. Sponsored´s protocol code: 201842. Sponsored by: Baxter Innovations Gmbh. Signed date: 02/03/2016 Rodríguez de Rivera Garrido FJ. Estudio de fase III sobre la eficacia, la seguridad y la tolerabilidad de la infusión de inmunoglobulina (humana) al 10 % con hialuronidasa recombinante humana (HYQVIA/HYQVIA) y la infusión de inmunoglobulina (humana) al 10 % (gammagard liquid/kiovig) para el tratamiento de la polirradiculoneuropatía desmielinizante inflamatoria crónica (PDIC). Type: clinical trial, phase III. HULP code: 4497. Sponsored´s protocol code: 161403. Sponsored by: Sanofi Aventis S.A. Signed date: 17/02/2016 Rodríguez de Rivera Garrido FJ. Detención de enfermedad de Pompe en pacientes con miopatías de cinturas no definidas o hiperckemia asintomática. Type: Non EPA. HULP code: Anexo-I PI-823. Sponsored´s protocol code: L-GENZ-E-003. Sponsored by: Grupo Gemcad. Signed date: 27/07/2016 Rodríguez Salas N. Tratamiento de inducción con Folfox, con o sin aflibercept, seguido de quimio-radioterapia en carcinoma de recto localmente avanzado de alto riesgo un ensayo abierto, fase II randomizado. Type: clinical trial, phase II. HULP code: Anexo-I 4230. Sponsored´s protocol code: GEMCAD-1402. Sponsored by: Roche Farma, S.A. Signed date: 07/03/2016 Rodríguez Salas N. Estudio fase II, prospectivo, multicéntrico, abierto, randomizado, controlado con fármaco activo, de 3 grupos paralelos, para comparar la eficacia y seguridad de Masitinib en combinación con Folfiri (irinotecán, 5-fluorouracil y ácido folínico) frente al Masitinib solo, frente a mejores cuidados paliativos en pacientes con cáncer colorrectal metastásico en tercera o cuarta línea de tratamiento. Type: clinical trial, phase II. HULP code: Anexo-I 4426. Sponsored´s protocol code: AB12010. Sponsored by: Laboratorios Servier, S.L. Signed date: 12/04/2016 Rodríguez Salas N. Ensayo clínico multicéntrico randomizado, de tratamiento de mantenimiento basado en biomarcadores para primera línea de cáncer colorrectal metastásico (modul). Type: clinical trial, phase II. HULP code: 4532. Sponsored´s protocol code: MO29112. Sponsored by: Laboratorios Servier, S.L. Signed date: 04/01/2016

Rodríguez Salas N. Estudio abierto, aleatorizado, fase II que compara s95005 con Bevacizumab frente a Capecitabina con Bevacizumab en pacientes con cáncer colorrectal metastásico no tratado previamente que no son candidatos a terapia intensiva. Type: clinical trial, phase II. HULP code: 4580. Sponsored´s protocol code: CL2-95005-002. Sponsored by: Abscience. Signed date: 18/04/2016 Rodríguez Salas N. Estudio abierto, aleatorizado, fase II que compara s95005 con Bevacizumab frente a Capecitabina con Bevacizumab en pacientes con cáncer colorrectal metastásico no tratado previamente que no son candidatos a terapia intensiva. Type: clinical trial, phase II. HULP code: Anexo-I 4580. Sponsored´s protocol code: CL2-95005-002. Sponsored by: Instituto Investigación Sanitaria Hospital La Fe. Signed date: 23/09/2016 Rubio Aparicio PM. Protocolo Europeo de tratamiento para el neuroblastoma de riesgo bajo e intermedio.Type: clinical trial, phase III. HULP code: Anexo-I3353. Sponsored´s protocol code: LINES. Sponsored by: Amgen, S.A. Signed date: 31/05/2016 San Román Pacheco S. Estudio abierto, de un solo brazo para evaluar la seguridad y eficacia a largo plazo de Romiplostim en sujetos pediátricos trombocitopenicos con purpura trombocitopenica inmune (PTI). Type: clinical trial, phase III. HULP code: Anexo-I4211. Sponsored´s protocol code: 20101221. Sponsored by: Glaxosmithkline Research And Development Limited. Signed date: 01/02/2016 Sánchez Hernández I. Estudio observacional de cohortes de la seguridad posterior a la autorización (PAS) para cuantificar la incidencia y la seguridad comparativa de acontecimientos cardiovasculares y cerebrovasculares específicos en pacientes con EPOC que utilizan la combinación umec/vi por inhalación o umec por inhalación en comparación con tiotropio. Type: EPA-LA. HULP code: pi-2186B. Sponsored´s protocol code: 201038. Sponsored by: F.Hoffmann-La Roche Ltd. Signed date: 23/06/2016 Tallón Barranco A. Estudio abierto para evaluar la eficacia y la seguridad de Ocrelizumab en pacientes con esclerosis múltiple remitente-recidivante que tienen una respuesta subóptima a un ciclo adecuado de tratamiento modificador de la enfermedad. Type: clinical trial, phase III. HULP code: 4608. Sponsored´s protocol code: MA30005. Sponsored by: Novo Nordisk Pharma, S.A. Signed date: 25/04/2016 Torres Jiménez R. Ensayo para comparar la seguridad cardiovascular de la insulina Degludec frente a la insulina Glargina en pacientes con diabetes de tipo 2 y alto riesgo de episodios cardiovasculares. Type: clinical trial, phase III. HULP code: Anexo-II 4059. Sponsored´s protocol code: EX1250-4080. Sponsored by: Laboratorios Inibsa S.A. Signed date: 13/01/2016 Usandizaga Elio R. Estudio sobre las condiciones de uso de Caribán® y de otros antieméticos en el tratamiento de las náuseas y vómitos en el embarazo: Estudio prospectivo observacional longitudinal. Type: EPA-SP. HULP code: PI-2191. Sponsored´s protocol code: LIN-DOX-2015-01. Sponsored by: Fundación Seimc-Gesida. Signed date: 04/04/2016 Valencia Ortega E. Estudio prospectivo para la detección precoz de carcinoma pulmonar en pacientes con infección por VIH. Type: Non EPA. HULP code: PI-1820. Sponsored´s protocol code: GESIDA 8815. Sponsored by: Novartis Farmaceutica, S.A. Signed date: 08/06/2016 Valencia Ortega E. Estrategia de Switching con Raltegravir + abc/3tc en infección VIH-1 controlada, Estudio retrospectivo observacional a 48 semanas Estudio kiral. Type: EPA-OD. HULP code: PI-2424. Sponsored´s protocol code: LEO-RAL-2015-01 GESIDA 8715. Sponsored by: Fundación Seimc-Gesida. Signed date: 16/06/2016 Villasante Fernández-Montes C. Estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo de 52 semanas de duración para evaluar la eficacia y la seguridad de qaw039 añadido al tratamiento existente para el asma en pacientes con asma grave no controlada. Type: clinical trial, phase III. HULP code: 4507. Sponsored´s protocol code: CQAW039A2314. Sponsored by: Mundipharma Pharmaceuticals S.L. Signed date: 07/01/2016 Villasante Fernández-Montes C. Observacional, prospectivo, para evaluar la relación entre el grado de concordancia de las opiniones entre pacientes y médicos especialistas en el control sintomático y el riesgo futuro en pacientes con asma moderada. Type: Non EPA. HULP code: PI-1886. Sponsored´s protocol code: CONCORD-ASMA. Sponsored by: Novartis Farmaceutica, S.A. Signed date: 29/01/2016 Zamora Auñón P. Estudio aleatorizado, doble ciego, controlado con placebo, de lee011 en combinacion con Letrozol para el tratamiento de mujeres postmenopáusicas con cáncer de mama avanzado con receptor hormonal positivo, her2-negativo que no han recibido terapia previa para la enfermedad avanzada. Type: clinical trial, phase III. HULP code: Anexo-I 4070. Sponsored´s protocol code: CLEE011A2301. Sponsored by: Medica Scientia Innovation Research. Signed date: 04/03/2016 Zamora Auñón P. Estudio de fase II randomizado, multicéntrico, abierto para evaluar la eficacia y seguridad de Palbociclib en combinación con Fulvestrant o Letrozol en pacientes con cáncer de mama metastasico Her2 negativo, er+ (parsifal 1). Type: clinical trial, phase II. HULP code: Anexo-II 4390. Sponsored´s protocol code: MEDOPP067. Sponsored by: Medica Scientia Innovation Research. Signed date: 04/05/2016

Return to EXECUTIVE SUMMARY INDEX

53

2 EXECUTIVE SUMMARY Contact [email protected] [email protected] Phone: Biobank Laboratory (+34) 91 207 11 91

EQUIPMENT

2.7 Platforms

2.7.1. Biobank IdiPAZ’s Biobank main objective is to promote biomedical research, which will increase and enhance the quality of scientific production in Spain. Biobank’s work is specialized in the management of human biological samples for biomedical research (register, processing, storage and final assignment) in compliance with Spain’s present legislation Law14/2007 on Biomedical Research and the Royal Decree of Biobanks 1716/2011. Thus the confidentiality of the samples and associated data will be guaranteed. The Biobank participates through the central node and peripheral nodes in various cooperative network structures (IDINET Platform). It is also part of the Hospitals Network (RetBioH), created in January 2010, through which we participate in the European platform called Biobanking and Biomolecular Resources Research Infrastructure (BBMRI). IdiPAZ’s Biobank also offers the scientific community the use of its equipment and the support of its professionals through an extensive offer of samples and services.

COMPOSITION Science Coordinator Eugenia García Fernández Coordinator of Professionals/Experts Marina Arranz Álvarez Senior Experts in Pathology and Cytology Cristina Salinas Sánchez

54

• Eight -80ºC deep freezers equipped with remote alarm temperature control and a CO2 backup system. Seven of these are equipped with an open door control software • One tank of liquid nitrogen at its gas phase with an alarm temperature control and a lack of CO2 detector • W-2D tube system with a data matrix codification for liquids, with a scanner to read col boxes and reader for the identification and the traceability of the tubes • Combined refrigerator of 4º C y – 20º C • Cryostat to cut frozen samples • Microtome y bath/coating to cut paraffin samples • Laser Microdissector • Biological safety cabins IIA • Centrifuge with capacity to process samples in tubes and Eppendorfs • Automatic platform to manipulate and trace liquids • Automatic nucleoids acid extractors. DNA and ARN from blood and frozen tissue or in paraffin • Two mini coolers to freeze inclined biological samples below 1ºC • Two containers to freeze and transport Isopentane • One container for the transport of isopentame samples • Two pairs of gloves to work in low temperatures • Two pairs of cryogenic work gloves • Vortex Mixer /agitator • Spectrophotometer (Nanodrop) • One set of automatic micropipettes • One automatic electronic pipette • Fungibility: basically kits and the necessary products to process and preserve tissues, blood, cells, DNA and ARN • Printer/photocopier/scanner • 3 computers and a management computer system • Label printing system and a bar code reader connected to the management software

PORTFOLIO OF SERVICES Technical and scientific assessment • Collection and management of new collection • Work Methodology/ Methods • Quality control of DNA/ARN sample treatment • Expert training to use Biobank management system • Training and advice on the use of Biobank management software (Bio-e-Bank). • Information to the investigator on the custody, deposit, availability and transfer of samples associated with the biobank. • Training of trainees (FCTs) of training cycles. Sample/collection management • Coordinating a collection of samples in multiple study/research centers • Storage of pre-existing collections under LIB 14/2007. • Storage of preexisting samples in accordance with Spain’s Biobank laws LIB 14/2007 and 1716/2011 Royal Decree • Management and control of Informed Consent (CI) and/or clinic’s regarding samples • Aliquot of blood/salines/plasma/other liquids • Sample reception and codification Histology techniques • Making paraffin block • Making frozen tissue blocks • Paraffin/frozen cuts • Hematoxylin and eosin stain (H&E) • Other kinds of stains • Laser microdissection Cell techniques • Purifying and freezing of mononuclear cells of peripheral blood (PMBCs) Molecular Techniques • DNA and RNA blood extraction • DNA and RNA extraction from frozen tissue and paraffin • DNA and RNA quantification via spectrophotometer (NANODROP) Researchers who wish to deposit their collections in IdiPAZ’ Biobank will have to sign an agreement of sample deposit (in which the terms and conditions under which the Biobank will deposit the samples) and in agreement with the existing legislation on the subject. On the other hand researchers who wish to use our samples will have to sign a Transfer Agreement (Material Transfer Agreement) in which the terms and conditions under which the Biobank will grant the samples.

BIOBANK’S SCIENTIFIC INDICATORS In the year 2016, Biobank IdiPAZ has worked on 32 research projects funded by Spanish State aid, private foundations, industrial companies or cooperatives such as the National Network of Hospital Biobanks (RetBioH). The principal researchers of these projects belonged to IdiPAZ research groups and to external, national and international groups. Of these projects and together with the central node of the biobank, a total of 4,353 new samples have been stored, generating more than 15,400 aliquots. During the same period 20 requests for samples were processed and a total of 1,873 samples were assigned, showing an exponential increase in demand compared to previous years.

Continue

55

2.7 Platforms

2 EXECUTIVE SUMMARY

2.7.2. UCICEC La Paz Central Research and Clinical Trials Unit (Unidad Central de Investigación Clínica y Ensayos Clínicos de La Paz, HULP-UCICEC), is one of the IdiPAZ supported platforms of investigation. Its purpose is to promote and support clinical research at La Paz University Hospital and to establish collaboration links with other investigation centres. Presently HULP-UCICEC is integrated in the Spanish Clinical Research Network (SCReN). Its wide portfolio of services provides support to researchers in design, set-up (including IRBs and Competent Authority approvals), management, data analysis and report writing of clinical trials and research projects. As Trials Managers, assists the Principal Investigators in the preparation of feasibility and financial reports, administrative tasks (i.e., investigators coordination, schedule of visits), as well as projects development and research, particularly in the recruitment and follow-up of patients and data collection, assistance in audit, inspections and adverse drug reactions management according to regulatory procedures, among other tasks. We also perform nursing activities and laboratory management, obtaining, processing and shipping the samples to central laboratories. All operations are GCP compliant as needed. HULP-UCICEC also runs a Phase I-II Trial Unit; the facilities and equipment allows harbour early phase clinical trials both in healthy volunteers and patients (children and adults).

COMPOSITION

56

Scientific Coordinator Antonio J. Carcas (MD, PhD) [email protected] Safety and Pharmacovigilance Coordinators Antonio J. Carcas (MD, PhD) [email protected] Elena Ramírez (MD, PhD) [email protected] Responsible for Pharmacovigilance Hoi Y. Tong (MD) [email protected] Project Manager / Senior Monitor Maria Posada Novoa (MSc) [email protected] Clinical Research Associate Alicia Herranz Estellés (MD, MSc) [email protected] Clinical Trials Nurses Vega Mauleón Martínez [email protected] Raquel de Madariaga Castell [email protected] Laura Vitón Vara (MSc) [email protected]

Head Jesús Frías Iniesta (MD, PhD) [email protected]

Nursing supervisor Elena Martín de Castro [email protected]

UCICEC Manager Alberto M. Borobia (MD, PhD) [email protected] Phone: (+34) 91 207 14 66

Receptionist /Clinical Trials Assistant Cristina Miragall Roig [email protected] Phone: (+34) 91 207 14 66

FACILITIES • 3 Work offices (9 work stations) • 1 Meeting room (with audiovisual and teleconference systems) • 1 Archive room • Phase I/II Clinical Trial Unit: - A hospital ward with eight beds and four chairs (children and adults) - 1 Doctor’s office - 1 Central point for sample collection - 1 Sitting room • Carlos III Satellite Unit - 1 Work office and doctor’s office - 1 Laboratory

EQUIPMENT • 1 ECG • 1 Centrifuge (Carlos III Satellite Unit) • 2 Refrigerated centrifuge • 1 Refrigerator • 1 Room temperature chamber (Carlos III Satellite Unit) • 3 -20ºC freezers (1 in Carlos III Satellite Unit) • 2 -80ºC deep freezer • 4 Vital signs monitors • Defibrillator • Temperature recording system • Digital clocks synchronised by GPS • 2 medical scales (1 in Carlos III Satellite Unit) • Digital blood pressure monitors and pulse oximeters • Digital timers • Crash trolley • 2 Cure trolleys • Video surveillance system

• 11 patient calling devices • 4 patient surveillance cameras

SERVICE PORTFOLIO The portfolio of services includes more than 80 tasks grouped into: • Methodologic support • Clinical trial pre-study activities • Study development • Finalization and closure tasks • Pharmacovigilance • Statistics and data management • Medical and nursing tasks

RESEARCH ACTIVITY OF UCICEC During 2015, an important increase in UCICEC activity has taken place. The platform has provided assistance and support in start-up, coordination, datamanagement, laboratory management or nursing tasks in 74 commercial clinical trials of 21 IdiPAZ Research Groups and 19 independent clinical research projects of 11 IdiPAZ Research Groups. In this period, 4 audits and 1 inspection have been conducted and have been successfully overcome. HULP-UCICEC has also provided methodological support in almost 100 clinical independent projects, including advice on study requirements and documentation, protocol development and design and preparation of application reports for competitive projects. Finally, 6 early phase trials of the Neurology and Cerebrovascular Diseases, Oncology, Paediatrics Infectious Disease and Nutrition group have been conducted in our Phase I Unit.

Continue

57

2.7 Platforms

2 EXECUTIVE SUMMARY

2.7.3. Experimental

Surgery

The Experimental Surgery Section is a support unit for research and teaching. In the research field, the Section develops biomedical research projects and fine-tunes procedures for new diagnostic and therapeutic techniques that use laboratory animals. In the teaching field, the Section organises and supports training courses in surgical, microsurgical, laparoscopic and anaesthetic techniques.

COMPOSITION Section Head Juan José Vázquez Estévez [email protected] Phone: (+34) 91 207 15 81 Veterinarian Carlota Largo Aramburu [email protected] Phone: (+34) 91 207 15 81 Secretary Irene Cuevas Gordo [email protected] Phone: (+34) 91 727 71 54 Technicians and assistants Ángela Mora; Isabel Rodríguez, Mª Teresa Arranz; Pablo Llorente; Pedro Gallego; Domingo Ortega; Gonzalo Polo and Daniel Ruiz

EQUIPMENT The Section consists of one microsurgery room, an operating room and an animal facility. The microsurgery room has surgical microscopes, as well as inhalers anaesthesia systems for rodents. All experimental procedures with rodents are performed in this room. Its layout, with fixed and mobile posts, allows for the implementation of microsurgical and laparoscopic courses with simulators or live animals. The operating room is equipped with double team surgical tables and anaesthesia stations with monitoring equipment, which allow for two surgeries to be performed simulta-neously. It is also equipped with laparoscopic, ultrasound and C-Arm X-ray equipment. All procedures performed on large animals are carried out here, along with training courses on surgical, laparoscopic and anaesthetic techniques. Both microsurgery and operating room had an overhead camara, escreens and audio- video streaming between them and also with the auditorium. There is also an experimental room for neurological studies using Rotarod or Plus Maze.

ANIMAL FACILITY The research and teaching at IdiPAZ involving the use of laboratory animals is managed via the animal platform of IdiPAZ, and is overseen by Dr. Carlota Largo Aramburu. In this department we develop biomedical research projects, training courses specific to the va-

58

rious specialties as well as procedures for putting in place new diagnostic techniques or therapies that involve the use of experimental animals. In addition, the animal facility works with the Ethics Committee for Animal Wellbeing, whose authorisations is required for all procedures. The animal facility is located in basement 2 of the IdiPAZ building within the hospital complex. The facility provides a total of 10 rooms for animal housing, in both breeding and experimental phases, two rooms for animal handling and experimental procedures, a room for washing material, which includes a cage washer, an autoclave and a pressurebased washing system, and several storage rooms for clean materials, feed and wood shavings for cages. In addition, for its proper functioning, the animal facility is connected with the rest of the departments of Experimental Surgery where there is a double operating theatre, a microsurgery room and various additional rooms (dressing areas, offices, and store rooms).

The species typically used include: rodents (rats, mice and gerbils), rabbits, pigs, sheep and goats, and occasionally dogs, cats or guinea pigs. Recently, a fish housing unit has been established (zebra fish). To avoid contamination and permit a good workflow, the rooms for housing of large animals are physically separated from those for the rodents and the rest of the facilities (washing area, store rooms, or the handling room). In addition, all the rooms include an external video camera system to monitor the interior while avoiding the unnecessary entrance of unauthorised personnel. The cages provide the minimum dimensions required for housing pigs and/or small ruminants. The structure of each cage is includes stainless steel anchored to the wall, with sliding separators that allow the expansion of the space by uniting two cages. The rooms have the slope needed to encourage the elimination of solid residue via a drain located in the rear of the cage. All of the drains are equipped with protection systems to prevent the entrance of rodents or insects. For the cleanliness of the room and the animals, there are hot and cold water connections via a hose.

The rabbit room includes modular mobile crate racks of 3, 6 or 9 cages. The rabbits are kept in individual stainless steel cages with plastic grids. They also have a box structure inside that allows the animal to hide or go up to a higher position. The stainless steel feeders and drinking water are located in the cage door. Faeces and urine are collected in an extractible stainless steel tray. This room has a central drain with similar characteristics as those in the large animal room. The rodent area is separated from the rest of the facility via a gate system (without locking doors) where staff can dress appropriately before entering (boots, robe, gloves, hat and mask). In this area, 5 rooms are located for the housing of rats and mice in both breeding and experimental phases and a room for fish.There is a storeroom for feed and shavings and a room for handling and the performance of procedures. In addition to two large areas of animals, the animal facility includes: • A washroom equipped with a cage washer (Hobart), a stainless steel pool and an autoclave. It also has a pressure wash system for cleaning the cages and/or visits that require it. • A room for handling large animals for the performance of procedures with a table and surgical lamp, surgical cart, monitoring equipment and a C-arm X-Ray. • Store room (clean material). • Control room with computers for environmental control. The animal facility complies with all current legislation and is registered with number ES-280790001941.

CONTACT Carlota Largo Aramburu [email protected] Phone: (+34) 91 727 71 54

PORTAFOLIO OF SERVICE • Animals for experimentation (own breeding) • Housing and maintenance of animals • Leasing of spaces for conducting courses (microsurgery laboratories and operating room) • Performance of surgical procedures on large animals (leasing space and anaesthesia, does not include surgery)

Continue

59

2 EXECUTIVE SUMMARY

2.7 Platforms

2.7.4. Simulation

Platform

The IdiPAZ Simulation Centre offers professionals from various fields the following possibilities: • Learning and training on the approach for patients in critical clinical conditions: cardiopulmonary resuscitation, shock of various origins, acute respiratory failure of various aetiologies, multiple trauma, arrhythmias, complicated births, difficult airways, safety, and leadership. • Ongoing training of teams who treat patients in critical conditions: ICU, anaesthesia, emergency department, surgery. • Learning and training on managing patients with technology-dependent conditions: mechanical ventilation, extracorporeal membrane oxygenation, dialysis, haemodialysis and haemofiltration and external ventricular assistance. • Learning and training on managing technology for diagnostic and therapeutic use: echocardiography, abdominal ultrasonography, catheterisation, laparoscopic surgery, bronchoscopy, laryngoscopy, endoscopy and colonoscopy. • Learning the use of invasive techniques: arterial and central venous cannulation, nasogastric and vesical catheterisation, suturing, thoracentesis, paracentesis, tracheostomy, nerve blocks. • Learning to perform a correct medical history review and physical examination and communicating and contacting patients, using actors and advanced simulators.

COMPOSITION Governing Council Dr. Javier Cobas Gamallo Dª. Ana Coloma Zapatero Dra. Carlota Largo Aramburu Dª Elena Martín de Castro Dr. Juan Vázquez Estévez D. Juan José Pérez Blanco Dr. Manuel Quintana Díaz Dr. Pedro de la Oliva Senovilla Dr. Ramón Cantero Cid Dra. Ana Mª Sánchez Torres Dra. Emilia Guash Arévalo Dr. Esteban López de Sá y Areses Dr. Ignacio Zapardiel Gutiérrez Dª. Esther Rey Cuevas

Dr. Juan José Ríos Blanco Dª. Estela Sánchez Simón Chairman Governing Council Dr. Juan Vázquez Estévez Secretary Governing Council Dª Ana Coloma Zapatero Dª Estela Sánchez Simón Audiovisual technician D. Javier Rubio Bolívar

CONTACT Juan Vázquez Estévez [email protected] Phone: (+34) 91 207 71 54

Course Diplomado en Reanimación Cardiopulmonar Completa

Director AM Sánchez Torres

Date December, 19th-20th

Assistants 18

Jornada temática: Hipertermia Maligna-De la Teoría a la Práctica

N Brogly

December, 14th -15th

10

Terapias de depuración extracorpórea en críticos

MÁ Alcalá

December, 12nd

22

Actualización en el Manejo de niños con Patología Compleja

C Calvo Rey

December, 1st

25

60

M Quintana Díaz

November, 29th

Director MA Delgado

Date November, 23th-25th

Assistants 20

Máster UAM-UR

M Quintana Díaz

November, 22th

8

Curso de Asistencia Inicial al Trauma Pediátrico (AITP)

JA Ruíz Domínguez

November, 17th-18th

20

Taller de RCP Pediátrico Avanzada

JA Ruiz Domínguez

November, 10th

20

Máster UAM-UR

M Quintana Díaz

November, 8th

8

Proyecto de Innovación docente: Estrategias creativas para la simulación clínica en el grado de Enfermería: Simulación con marionetas y máscaras

MT González Gil

November, 7th

10

VIII Curso de Ecografía en el Paciente Pediátrico Crítico

JJ Menéndez Suso

November, 2th-4th

16

Curso de Cirugía de Control de Daños

J Murcia, JJ Vázquez

October, 27

12

RCP Avanzada Pediátrica y Neonatal

MA Delgado

October, 19th-21st

20

Soporte Vital Básico Instrumentalizado

C Fernández Carretero

June, 27th-28th

20

PhyMEL-LS: Diseño e implementación de una sesión de simulación clínica utilizando Learning Space y la metodología PhyMEL

JJ Vázquez Estévez, M del Río

June, 27th

9

Diplomado en Reanimación Cardiopulmonar Completa

AM Sánchez Torres

June, 14th-15th

18

Soporte Vital Básico Instrumentalizado

C Fernández Carretero

June, 13th

25

Soporte Vital Básico

C Fernández Carretero

June, 3

25

RCP Avanzada Pediátrica y Neonatal

M Ángel Delgado

May, 25th-27th

20

Microcirugía Vasculo Nerviosa y sus Aplicaciones Clínicas

C Casado Pérez

May, 23rd -27th

20

Soporte Vital

C Fernández Carretero

May: 19th, 23rd and 24th June: 24th, 27th and 28th October: 11st,13rd and 25th

40

Curso de RCP Básica Instrumentalizada Pediátrica

JA Ruiz Domínguez

May, 18th

20

Instructores en AITP

JJ Vázquez Estévez

May, 11st

th

th

9

SVA para Enfermería

M Quintana Díaz

May, 09 -13

25

Inmovilización Terapeútica

C Fernández Carretero

May, 4th

40

Inmovilización Terapeútica

C Fernández Carretero

May, 3rd

RCPB para Enfermería

M Quintana Díaz

April, 28

25

Microcirugía experimental y colgajos microvasculares en la rata

J Arias Gallardo, MJ Morán Soto, J González Martín-Moro

April, 25th-29th

200

Multidisciplinar en Anestiología

P Garrido

April, 21st-23rd

100

Formación de Formadores de Quirófano y Urgencias. Edición 1

L Gallego Morales

April, 18th -19th

20

Ecografía en el Paciente Pediátrico Clínico

JJ Menéndez Suso

April, 12 -14

16

Curso de Simulación en Terapias Continuas de Depuración Extrarenal

Reinoso-Barbero, P. Sanabria, L. Castro

April, 9th

16

Suturas en Urgencias Pediátricas

L Martínez

April, 6th

Curso Teórico Práctico de Cirugía Laparoscópica Avanzada en Urología: de la investigación a la práctica clínica

J Cisneros Ledo

March, 29 April, 1st May 24th-27th October, 18th-21th

20

Formación Instructores en Simulación

P de la Oliva

March,14th-17th

18

RCP Avanzada Pediátrica y Neonatal

MA Delgado

February, 24th -26th

15

Microcirugía Experimental y Colgajos Microvasculares en la Rata

J Arias, MJ Morán, J González

February, 22nd -26th

18

Asistencia Inicial al Trauma Pediátrico

JA Ruíz Domínguez

February, 18th-19th

20

Actualización RCP Adjuntos Urgencias

S García García

February, 10

12

Simulación en Vía Aérea

P Garrido

February, 5th -6th

100

th

rd

40 th

nd

th

20 th

COURSES SIMULATION PLATFORM

Máster UAM-UR

Course RCP Avanzada Pediátrica y Neonatal

8

th

Inmovilización Terapéutica

C Fernández Carretero

November, 29th

40

Inmovilización Terapéutica

C Fernández Carretero

November, 22

th

40

M Gutiérrez Fernández

January, 26th -27th

10

Curso CRM (Crisis Resource Management) en Urología Pediátrica

JJ Vázquez, MJ Martínez Urrutia, S Riva Vila

Puesta a punto de modelo animal experimental de infarto cerebral para proyecto europeo RESSTORE

November, 25th

12

Actualización RCP

JA Ruíz Domínguez

January, 26th

20

Actualización RCP Adjuntos Pediatría

S García García

January, 25th

20

Continue

61

2.7 Platforms

2 EXECUTIVE SUMMARY 2.7.5. Cell

Culture Unit

Cell culture techniques allow scientists to mimic maintenance and growth of cells under controlled and precise environmental conditions. This technology offers the employment and development of in vitro model systems aiming at elucidating the cellular and molecular mechanisms involved in certain disease processes, predicting cellular and tissue responses to a particular microenvironment and identifying and/or developing novel drugs and therapeutic targets. Therefore, cell culturing is considered as an essential tool in main aspects such as disease prevention and management, pre-clinical assessment of drug-based strategies and diagnosis of disorders and conditions that afflict human health. The main objective of the Cell Culture Unit, integrated into the Hospital La Paz Institute for Health Research (IdiPAZ) as core support platform, is to provide users with basic instrumental and technical assistance in cell culture-related experimental approaches. This Unit facilitates the proposal and development of translational research initiatives, providing a convenient basis for creativity, innovation, as well as acquisition and dissemination of the scientific knowledge. The multidisciplinar and dynamic environment established in the Unit incites and promotes the creation of synergies, innovative perspectives and networking opportunities which can be a source of inspiration, exploration and stimulation for new interests, ideas and collaborative research activities. Furthermore, Cell Culture Unit is tightly vinculated to other joint platforms such as the Imaging Core and Flow Cytometry Laboratory, in which researchers can upgrade their objectives and improve and refine their hypotheses.

COMPOSITION Head Gema Vallés Pérez, PhD [email protected] Phone: (+34) 91 207 15 76 Technical staff Beatriz Sanz Minguela Alexander Otero Guardia Telephone: (+34) 91 727 70 00 (ext 2142). Secretary Susana García Pérez [email protected] Telephone: (+34) 91 207 15 12

FACILITIES AND EQUIPMENT The Cell Culture Unit consists of an experimentation laboratory, a cryopreservation room and a warehouse. All facilities are located in the IdiPAZ building. The experimentation laboratory is fitted with the following equipment: Cabinets • 3 Faster BIO 48 vertical laminar flow cabinets • 1 Faster TWO 30 vertical laminar flow cabinet • 3 Telstar Bio-II-A biological safety cabinets 62

• 1 Faster BH-EN 2004 biological safety cabinet • 2 Nuaire NU-437-400E biological safety cabinets • 1 Heraeus HS-12 biological safety cabinets • 1 Gelaire BSB 4A biological safety cabinet • 1 Esco Class II BSC biological safety cabinet Incubators • 3 Thermo Forma Scientific incubators with temperature and CO2 control and saturated humidity environment • 2 HERAcell incubators with temperature and CO2 control and saturated humidity environment • 2 Biotech Galaxy S incubators with temperature and CO2 control and saturated humidity environment • 2 Nuaire Autoflow incubators with temperature and CO2 control and saturated humidity environment • 1 Sanyo O2/CO2 incubator with temperature and gas control and saturated humidity environment • This equipment is complemented with a centralized and alarmed gas system, which guarantees a constant and controlled supply of CO2 and N2. Microscopes • 1 Nikon DIAPHOT TMD inverted light microscope connected to a Nikon D80 digital camera. • 1 Leica DMIL inverted light microscope connected to a Canon Powershot S70 digital camera. • 1 Optika inverted light microscope • 1 Motic AE2000 inverted light microscope connected to an automatic counter Celeromics • 1 Lan Optics inverted light microscope Centrifuges • 2 Eppendorf 5810R refrigerated centrifuges • 2 Eppendorf 5804 centrifuge • 1 Hettich Universal 32R refrigerated centrifuge • 1 Kubota 2010 centrifuge Cell Separation System • 1 Milteny Biotec autoMACS cell separation system Freezing systems • 1 Liebherr refrigerator (4 ° C and -20 ° C) • 1 Balay refrigerator (4 ° C and -20 ° C) • 1 Whirlpool refrigerator (4 ° C and -20 ° C) • 1 Beko refrigerator (4 ° C and -20 ° C) Other equipment • 1 Presoclave 75 P-Selecta autoclave • 1 Millipore water purification system

• 1 Heidolph Reax 2000 vortex • 1 Raypa thermostatic waterbath • 1 Memmert thermostatic waterbath • 2 Precisterm thermostatic waterbath • 1 Grant JB Aqua 12 Plus thermostatic waterbath • Vacuum pumps, pipettes, counters, automatic pipettors, freezing containers, cell counting cameras, etc .... The cryopreservation room is equipped with • 2 Statebourne Biorack 3000 liquid nitrogen tank • 1 Thermo Locator 6 Plus liquid nitrogen tank • 1 10 K Taylor Wharton liquid nitrogen tank • 1 MVE cryosystem 4000 liquid nitrogen tank • 1 Cryo Diffusion B2016 liquid nitrogen tank • 1 Cryo diffusion B2048 liquid nitrogen tank • 1 Cryo Diffusion B2011 liquid nitrogen tank • 1 SEO GT40 liquid nitrogen tank • 1 MVE XLC 511 liquid nitrogen tank The infrastructure for cryopreservation is completed with a liquid nitrogen transfer device and an alarmed Oxygen O2 detector coupled to a mechanical ventilation system.

PORTFOLIO OF SERVICES • Scientific and technical advice, personalized support and consultation: guidance in experimental setup and design, study planning, optimization of techniques and protocols, reagents and material acquisition, cells supply, troubleshooting, analysis and interpretation of results… • Basic training and hands-on experiments (implementation of the self-service mode) according to biosafety, waste disposal and good laboratory practice guidelines. • Access to specific facilities including instrumentation, equipment, materials and reagents. • Preparation and supply of certain materials, reagents and sterile solutions. • Management and general supervision including good laboratory practices and work habits, maintenance, cleaning and waste disposal and operation and maintenance of the equipment. • Performance of experimental procedures: cell separation, cell isolation for cultivation, maintenance and propagation of cell lines and primary cultures, cryopreservation and resuscitation, viability and proliferation, etc... • Control and maintenance of cryopreserved stock cells. • Elaboration and management of protocols and guidelines, operating procedures, reports and other required mandatory documentation.

• Detection, identification and treatment of contaminations in cell cultures. • Access to technologies and common infrastructures as well as common standard equipment and other associated IdiPAZ facilities.

RESEARCH ACTIVITY INDICATORS During 2016, our platform has provided assistance and support to more than 70 users belonging to multidisciplinary IdiPAZ groups such as Neurology and Cerebrovascular Diseases, Innate immune response, Immuno-rheumatology, Drug hypersensibility, Experimental Therapies and Biomarkers in Cancer, Translational Oncology, Cancer Molecular Pathology and Therapeutic Targets, Molecular Hepatology, Diagnosis and Treatment of Allergic Diseases, Nephrology, Bone Pathophysiology and Biomaterials, Cellular Engineering and Experimental Surgery, Translational Research in Pediatric Oncology, Hematopoietic Transplantation and Cell Therapy, Respiratory Diseases and Urology. The contribution and efforts of the Cell Culture Unit to the scientific productivity of these groups throughout this year is reflected by a relevant output of more than 70 research projects funded by competitive national calls (ISCIII, MINECO, CIBER...), private foundations, organizations, societies or pharmaceutical companies (Roche Farma, Baxter, HSF Pharmaceuticals, Pfizer, Novartis farmacéutica, Janssen Cilag, Fundación Marató TV3, Vissum corporación, Óptica general SARL, Proteomika ...) and international initiatives sponsored by the European Framework Programme for Research and Innovation (H2020) and the International Olympic Committee (IOC). As additional indicators is relevant to mention the involvement of this platform in the development of 48 publications (mostly in top international journals), participation in 11 conferences and congresses, 2 book chapters, 13 doctoral theses, 10 patents and trademarks and its contribution to the basis or progress in numerous clinical trials. Moreover, this division has also promoted and stimulated the establishment of collaborative alliances between IdiPAZ scientists and international groups and institutions such as the Chang Gung Memorial Hospital in Taiwan, the University of Liverpool or Glasgow in UK, the Pasteur Institute or the Centre Hospitalier Universitaire Grenoble Alpes in France, the University of Eastern Finland, the University Hospital Brno in Czech Republic, the University of California, Florida or Wisconsin-Madison in USA, the Utrecht University in The Netherlands, the Trinity College in Ireland, the Reviva Regenerative Medicine Center in Lebanon or companies such as HSF Pharmaceuticals in Switzerland or Optica General in Lebanon.

Continue

63

2.7 Platforms

2 EXECUTIVE SUMMARY 2.7.6. Automatic

Sequencing Laboratory

The main role of the Automatic Sequencing Laboratory is to provide support for medical research and clinical routine. The goal is to increase the volume and quality of scientific results in a number of research and clinical groups inside our both Institute and elsewhere.

DESCRIPTION Our laboratory is located inside a renowned hospital. This allows for frequent interactions with the hospital’s various research groups, and thus allows for the laboratory members to stay up to date on state-of-theart techniques in genetics. Nowadays, the Sanger sequencing method is regarded it as the gold standard for validation of NextGeneration Sequencing variants. In order to achieve the goals stated above, our laboratory owns the necessary equipment and infrastructure for performing tasks such as conventional sequencing (Sanger method), marker DNA genotyping, and other molecular biology techniques based on capillary electrophoresis. The equipment can use up to five simultaneous colours on the same sample when it migrates into the genetic analysers.Therefore, we are able to detect more than 30 polymorphic markers per sample. In addition, the laboratory equipment allows us to carry out extractions of DNA and RNA. The laboratory is regularly involved in quality control audits on the Sanger sequencing and genotyping, as well as result homologation. Such audits are performed at both national and international levels (e.g., EMQN).

OFFERED TECHNIQUES • Sanger sequencing. • Marker DNA genotyping. • Analysis of single nucleotide polymorphisms (SNPs) by primer extension (SNaPshot TM). • Aneuploidies by quantitative fluorescence PCR detection (QF-PCR). • Short tandem repeats detection (TP-PCR). • Multiplex ligation-dependent probe amplification (MLPAs). • Microsatellite Instability (MSI). • Support for sample preparation workflow to maximise the quality of results. • On-demand training for the software analysing the result data.

COMPOSITION Lab manager Mª Rocío Mena de la Cruz [email protected] Technicians Inmaculada Rueda Arenas [email protected]

64

2.7.7. Image

María Victoria Gómez del Pozo [email protected] Phone: (+34) 91 207 10 10 (ext. 226/230)

EQUIPMENT Devices • Eppendrof 5415D Centrifuge • Veriti Thermocycler (Applied Biosystems) • EpMOTION Eppendorf automated pipetting • Genetic analysers 3130xl (x2) & 3730xl (Applied Biosystems - Life Technologies). Software • Sequencing Analysis 5.3.1 • Sequence Scanner 1.0 • GeneMapper 4.0 • Peak Scanner 1.0

RESEARCH ACTIVITIES During 2016 our laboratory supported to research groups as well internal groups as outside researches. Our close interaction with these users enabled a number of contributions to these groups at different levels: from initial brainstorming as research staff, to sample processing useful in fields such as rare disease, Microbiology, Genotyping cellular, Immunology, Oncology, etc. Our laboratory´s staff close collaboration with one of these groups has led to authorship of one original article, and contributing to about thirty more by offering sequencing services. In addition, our participation in several international and national congresses during last year, have allowed us to maintain training in new techniques.

Laboratory

The study, characterization and analysis of morphological and functional changes in cells and tissues is a very relevant discipline not only for the diagnosis in clinical pathology but also for a better understanding of the cause and mechanisms in various diseases studied by both basic and preclinical research. The mission of Image and Immunohistochemistry Laboratory Core is to provide a centralized service dedicated to assisting with the highest quality histology, immunohistochemistry and imaging equipment, as well as scientific and technical support to researchers. This core is open to all investigators, including; IdiPAZ and their affiliates, commercial and notfor-profit biotechnology companies, and other academic institutions. Specialized staff will support the researchers’ projects by evaluating the user’s needs in histology or immunohistochemistry, help with planning large-scale projects, advice on using the most appropriate techniques for the processing and interpretation of experimental or preclinical research samples results. Trained and authorized users have free access to the platform; IdiPAZ staff in a Do-Ityourself manner and in a fee-for-service manner to all the rest. For service requests, users must refer to the head of the core. To fulfil its mission of enabling cuttingedge research, the facility houses two platforms, Immunohistochemistry and Microscopy Laboratory with state of the art Histology, Immunohistochemistry and Digital Microscopy technologies.The histology laboratory offers advice, protocols and automated high-throughput equipment allowing citospines, fixation techniques (paraffined or freezed), sectioning of tissues (microtomes and cryostats), and classical or advanced immuno-staining (Dako Autostainer). The image laboratory offers users equipment to develop the most demanding processing requirements including conventional microscopy as bright field, phase contrast and fluorescence in addition of confocal and advanced microscopy for in vivo imaging with high-speed camera and incubation system of cultures with temperature and gas control. During 2016, Image unit maintained their quality standards in order to help users to get the excellence in their research by supporting projects (publics or privates, national or international grants), scientific dissemination (thesis) and high impact international publications. In addition core facility joins forces with other core facilities (Cell Culture, Biobank, Experimental Surgery..), to create a teamwork to combine technologies and applications for exchanging knowledge and expertise and working on common strategies for training and projects support. In the last year, we have extended the number of users inside Hospital La Paz (HULP, clinical and basic researchers), associated IdiPAZ groups (UAM), as well as other research groups (UCM, CSIC etc).

COMPOSITION Scientific head Maria Teresa Vallejo Cremades (PhD). [email protected] Phone: (+34) 91 727 75 26 Technical Paula Sánchez Guismera Phone: (+34) 91 727 70 00 (ext. 42148-Immunohistochemistry Lab.) (+34) 91 727 75 26- Microscopy Lab.

RESOURCES AND MANAGEMENT OF THE LABORATORY IdiPAZ researchers can use all equipment in the Image Core by themselves, but only once they have been trained. In addition, the lab provides fee-for-service to external institutions and private companies. An introduction to the lab with some safety regulations and the basic training for the usage of the required instrument is provided on by the lab staff at any time of the year. Basic safety regulations for the proper work in the lab will be explained also to new users. Users must schedule the time of work in any equipment and booking reserve it’s mandatory in all the facility. Standard protocols both equipment and techniques and general rules for biosafety and lab safety are available in a separate document provided by the laboratory staff. Access to the Immunohistochemistry Lab is free, but the magnetic individual card is required to entry into the Microscoy lab.

Continue

65

2.7 Platforms

2 EXECUTIVE SUMMARY

66

The equipment is housed in two different laboratories belonging to the Image platform; the Immunohistochemistry and the Microscopy laboratories: Immunohistochemistry Laboratory • Tissue processor providing effcient, reliable and timely processing of paraffn wax (Leica TP1020) • Embedding unit for high quality paraffn blocking (Leica EG1160) • Selecta Wax dispenser, paraffn wax dispenser with adjustable temperature from ambient to 100 ºC • 2 microtomes for specimen sectioning Leica RM2255 • 1 microtome for specimen sectioning Shandon AS325 • Leica EG 1150C Cold plate • 2 thermostatic water Leica HI 1210 baths • 1 thermostatic water Selecta Thermofn bath • Automated Immunohistochemistry stainer (Autostainer Plus DAKO) • 2 Cryostat for frozen sectioning (Leica CM 3050S and Leica CM1950) • PTLink DAKO • Crison pH meter • Liebher upright freezer (-20ºC and 4ºC) • Liebher economy freezer (-20ºC) • Shandon Cytospin 2 • Memmert BE 500 oven • Memmert UN 30 oven • Selecta Agimatic-E magnetic stirrer with heating • Pippetors • Olympus CH microscope, for practical laboratory applications • Gilson pipette sets • NUAIRE laboratory fume hood. Dissection equipped and staining area with manual options for Do-It-Yourself staining and cover-slipping. The laboratory is equipped with shared facilities from Translational Oncology and Anatomopathology Breast and Gynecological Cancer groups that use them for diagnostic and clinical research purpose (ESCO fume hood and Crison Microtome). Permission to use must be solicited to the head of these laboratories. The Image Analyses laboratory equipment includes: • Leica TCS SPE inverted confocal. Leica DMI4000B inverted microscope; Ilumination source, Lasers diode 405, Lasers diode 488, Lasers diode 532 and Lasers diode 635; Dishes, Standard microscope slides. • NIKON microscope ECIPSE IT to conventional and fluorescence microscopy, in vivo imaging and High Content (equipped with incubation chamber) • Camera IMAGING SOURCE • Camera Camera ANDOR Neo SCHOS refrigerated. • Lauda Ecoline Star incubator edition 003 • Hotplate (OKO LAB) • Doser gases (Okolab) • Adapter culture plates microscope • Leica DMI6000B inverted microscope. Filter cubes: A4(UV), L5 (green), N3 (red) and Y5 (far red) • Olympus BX41 (Bright feld) upright microscope with an attached Digital camera • Zeiss Axioplan 2 upright microscope with fve objectives

from 5x to 100x, phase contrast and fuorescent capabilities • Zeiss Axio Lab.Al microscope fve objectives from 5x to100x. ERC5S Axocan camera. • Nanosight LM10 viewing unit measures nanoparticles, exosomes, vesicles’s size based on the scattering of light, includes a microscope, a LM10 viewing unit, a Marlin camera, an objective x20 and is connected to a image analysis software. • Digital microscopy (photography with a Leica DFC 350 FXR2 digital camera attached) • Image ProPlus 5.0 image analysis software • Leica LAS AF image analysis software • Analysis station with Huygens deconvolution software, Image J, LASAF Lite programme and related image analysis software. • Nanosight NTA 3.1 analytical software

SERVICE PORTFOLIO • Collection and processing for fixing and decalcification of samples. • Sample processing in paraffin by hand or automatic. - Complete processing paraffin embedding. - Serial cut in microtome and tissue assembly. • Antibodies’ validation. • Buffer preparation and distribution of consumables. • Sample processing frozen. - Preparation of freeze blocks. - Serial sections of blocks freeze and cuts collected on slides or floating. • Staining. - Hematoxylin - eosin. - Masson trichrome. - Nissl. - PAS. - Acetylcholinesterase. - Cytochemical and immunohistochemical techniques. - Decalcification of samples required. - Dewaxing cuts, performing staining. - Immunohistochemical staining automated system Autostainer. - Immunofluorescence in frozen tissue and paraffin. Protocols. - Dehydration and slide assembly. • Image acquisition.Viewing and digital format acquisition. - Light microscopy. - Light microscopy with phase contrast. - Epifluorescence. - Confocal microscopy. - Advanced Micro scopy in living cell. • Fluorescence colocalization by confocal microscopy. • 3D reconstruction. • In vivo image acquisition of biological samples (incubation system for the temperature and CO 2). • Morphometry in biological samples. • Large images acquisitions (scanning the entire slide) for bright field and fluorescence. • Collaboration for sample processing protocols for microscopy (fastening, staining, marking, etc.) and advice for planning projects that could require the use of microscopy.

2.7.8. Flow

Cytometry Laboratory

Flow Cytometry Laboratory of IdiPAZ supports the scientific activity contributing to the advance in the research, at present benefit of different research groups of the Institute. The equipment allows for phenotypic analysis of subpopulations, quantification of soluble factors in biological samples and culture supernatants, cell cycle experiments.

COMPOSITION Head Víctor M. Toledano Real [email protected] Phone: (+34) 91 207 15 12 (ext. 2484) Secretary Susana García Pérez [email protected] Phone: (+34) 91 207 15 12

EQUIPMENT The Flow Cytometry Laboratory of IdiPAZ has the following facilities: • One Beckman Coulter Navios cytometer analyser is a clinical system that delivers analytical excellence by coupling extraordinary sensitivity, resolution and dynamic range with high-speed data collection. With superior detection capabilities, the Navios provides accurate measurements, especially for rare events, which is critical to clinical diagnosis and monitoring. The fully-featured, easy-to-use Navios software provides tools to improve the quality of results as well as optimize workflow efficiencies in a clinical lab. - This analyser has three lasers; Blue solid state Diode: 488nm, 22mwlaser output, Red solid state Diode: 638nm, 25mwlaser output and Violet solid state Diode: 405nm, 40mw laser output. The Navios can analyse ten colours simultaneously in samples marked with the following fluorochromes:• FL1: FITC, GFP, Cy2, Alexa 488 • FL2: PE, Cy3 • FL3: PI, ECD, PE-TEXAS RED, RED RFD • FL4: PE-Cy5, PerCP, PerCP5.5, TC 7AAD, SPRD • FL5:PECy7 • FL6: APC, Alexa 647 • FL7: APC-Alexa700, Alexa 700 • FL8: APC-Cy7, APC-Alexa750, APCAlexa780 • FL9: Pacific Blue, eFluor 450 Cyan, Cyan, Violet RFD • FL10: Pacific Orange, AmCyan. - The Navios is connected to computer using the Navios acquisition and analysis programme. • Two Becton Dickinson FACSCalibur™ cytometer analysers is a platform allows users to perform both cell analysis and cell sorting in a single benchtop system. The system supports a wide variety of research and clinical applications and is comple-

mented by a broad suite of intuitive software solutions to streamline analysis for a wide range of applications including enumeration of lymphocyte subsets, stem cells, residual white blood cells, and reticulocytes. - Each analyser has two lasers, a 488nm argon laser and a 635nm solid-state red diode laser. The FACSCalibur ™ can analyse four colours simultaneously in samples marked with the following fluorochromes: • FL1: FITC, Alexa 488 • FL2: PE, PI • FL3: PECy5, PerCP, Per-CP5.5 • FL4: APC, APCCy7, Alexa 647. - The two cytometers are connected to Macintosh G4 OS.9.2.2 computers using the CellQuest™ acquisition and analysis programme, and Macintosh G5 OSX with CellQuestPro™ acquisition and analysis software. • The laboratory also has an additional Mac G5 OSX analysis station with CellQuestPro™ acquisition and analysis software.

Continue

67

2.7 Platforms

2 EXECUTIVE SUMMARY 2.7.9. Radioisotope

Laboratory

The radioactive facility of IdiPAZ laboratories is authorised by the Nuclear Safety Council (Consejo de Seguridad Nuclear, CSN) to operate with non-encapsulated sources radioisotopes: 3H, 33P, 32P, 125I and 51Cr. Personnel of the Radiological Protection Department of HULP conduct radiological protection and periodically monitor laboratory contamination levels.They are also responsible for the removal and management of waste products and the management of users’ personal dosimeters.

COMPOSITION Head Nuria Vilaboa Díaz [email protected] Phone: (+34) 91 207 10 34 David Vicent López [email protected] Phone: (+34) 91 207 10 30

2.7.10. Biostatistcs Secretary Susana García Pérez [email protected] Phone: (+34) 91 207 15 12

EQUIPMENT Contains exclusive areas for the use of ß and γ isotopes; aliquot withdrawal and storage of radiolabeled compounds; and equipment for exclusive use with radioactive material. The laboratory has the following equipment: • CO2 incubator • Cell harvester • Beta counter • Hybridisation oven • Gel dryer • SpeedVac® concentrator • Screens and containers specifically for γ and β radiation emitters • High-energy γ and β contamination detectors (Geiger counter)

Section

Section of Biostatistics mission is to provide methodological support to professionals of the University Hospital La Paz and generally IdiPAZ professionals and provide technical solutions to optimize clinical processes by incorporating necessary for this technology.

DISTRIBUTION OF SUPPORT GRANTED ACCORDING TO DIFFERENT TYPES OF WORK IS:

COMPOSITION Clinical Biostatistics Rosario Madero Jarabo [email protected] Phone: (+34) 91 207 71 12 Mariana Díaz Almirón [email protected] Phone: (+34) 91 207 17 91

SUPPORT DISTRIBUTION ACCORDING TO CENTRES:

Bioengineer Francisco Gayá Moreno [email protected] Phone: (+34) 91 207 17 91 Clinical Epidemiologist Jesús Díez Sebastián [email protected] Phone: (+34) 91 207 17 91 (+34) 91 727 75 70

EQUIPMENT The main programs used for data analysis: • SAS 9.3 (Copyright © 2012, SAS Institute Inc., Cary, NC, USA). • SAS Enterprise Guide 5.1 (Copyright © 2012, SAS Institute Inc., Cary, NC, USA). • R version 3.2.5 R Core Team (2016). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL http://www.R-project.org/. • SPSS 9 (Copyright 1999 by SPSS Inc. ). • SYSTAT 11 (Copyright (c) 2004 by SYSTAT Software Inc., Richmon, CA, USA.) • nQuery Advisor 5.0 (Copyright (c) 1995-2002). • PEST 4.0 Planning and Evaluation of Sequential Trials (Medical and pharmaceutical Statistics Research Unit. The University of Readyng, UK). • Review Manager (RevMan) Version 5.0. (Metaanalysis) Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008.

SERVICE PORTFOLIO • Study design. • Creating systems to collect data (such as ms Access). • Technical Support in the development of studies. • Development of information processing systems (clinical imaging systems, reading of measurement systems, implementing statistics methods…). 68

SUPPORT DISTRIBUTION GRANTED ACCORDING TO PROFESSIONS:

• Results analysis: multivariate analysis (discriminant analysis, correspondence analysis, factor analysis, survival analysis, risk analysis, competing risks analysis...), generalized linear including models with mixed effects and generalized equations, risk models development for classification and prediction, building point system for risk evaluation, analysis of growth curves, clinical trial methodologies, sequencial analysis of data, analysis of high dimensions (microarrays analysis), bicluster analysis. Resampling methods (Bootstrap, Jacknife, …). • Results dissemination. • Training activities.

Continue

69

2.7 Platforms

2 EXECUTIVE SUMMARY 2.7.11. Documentalist The documentalist from IdiPAZ aims to support and assist all members of the Institute with regard to the access and use of databases, literature searches, bibliometric indicators or any other related matter. Another purpose of the documentalist is the development of control tools that are useful for making the registration of scientific production of the group belonging to the Institute. As a result of this register quarterly Bibliometric Reports are published showing the papers published by the researchers from IdiPAZ. These reports show provisional data that will later be submitted to the Directors of the Group for review and inclusion in the Annual Research Report. The Research Report is the official document published on an annual basis which includes all the information regarding the research activities of each of the research groups.

2.7.12. PAIN

Platform

The PAIN Platform-Early-Stage Researches Support Platform (Plataforma de Apoyo al Investigador Novel) from IdiPAZ is a recently created service that aims to promote the design and development of research projects in several health areas, with high methodological quality, to enable our professionals in early-stage research. Additionally, the mission of the PAIN Platform is to promote the training and development of early career researchers of IdiPAZ.

COMPOSITION Head Paloma Gómez Campelo (PhD) [email protected] Phone: (+34) 91 207 15 12

2.7.13. Internationalization COMPOSITION Head Raúl Román Cañizares [email protected] Phone: (+34) 91 207 15 12

SERVICE PORTFOLIO • Perform the Annual Research Report of IdiPAZ • Collaboration with researchers in the access and use of databases, literature searches, etc. • Creating tools of scientific production control • Development of Bibliometric Reports • Evaluation of researchers • Bibliometric assessment of Research Groups • Advice on literature search tools • Advice on the use of bibliometric techniques • Poster printing for congress

Platform

The IdiPAZ Internationalization Platform aims to become a fundamental tool to support IdiPAZ researchers to continue being a reference in the international arena. The main objective is to promote at international level the different research groups of IdiPAZ, identifying possible synergies between groups and centers, new partners and funding sources, as well as to forge strategic alliances.

• Supporting and encouraging participation in information events • Organising information and training sessions on specific required areas • Advising on the proposal preparation and the negotiation phase with the European Commission • Managing the approved projects.

PROGRAMMES:

SPECIFIC OBJECTIVES: • Conduct an active monitoring international funding programs for R & D + i • Identifying and disseminate interesting opportunities and calls for research groups • Identifying and actively participate in international networks interesting for the center • Introducing and disseminating the capabilities of the center and its research groups • Identifying, defining, validating and developing project ideas that emerged in the center

H2020 H2020 is the leading European program for funding research and innovation projects in various subject areas. For the period 2014-2020 it accounts with a budget of nearly € 80,000m. Most activities are implemented through competitive calls managed by the European Commission with preset priorities in work programs. The program structure can be seen reflected in the following figure:

Excellent Science

Industrial Leadership

Societal Challenges

European Research Council- ERC

Leadership in enabling and industrial technologies

Health, Demographic Change and Wellbeing

Marie Sklowdoska-Curie Actions Access to Risk Finance Future and Emerging Technologies-FET

Innovation in SMEs

Food Security, Sustainable, Agriculture and Forestry, Marine, Maritime and Inland Water Research and the Bioeconomy Secure, Clean and Efficient Energy Smart, Green and Integrated Transport Climate Action, Enviorement, Resource Efficiency and Raw Material

Research Infrastructures

Inclusive, innovative and reflective societies Secure societies- Protecting freedom and security of Europe and its citizens

Spreading Excellence and Widening Participation Science with and for Society

SERVICE PORTFOLIO • Methodological and epidemiological support to the study design of the professionals in early-stage research. • Technical and methodological support in developing a research protocol for a study. • Analysis of the grounds for refusal of rejected projects. • Methodological support to write grant proposals to access all available funding programs. • Technical support in writing other scientific documents.

70

Continue

71

2 EXECUTIVE SUMMARY

2.7 Platforms

EU HEALTH PROGRAMME The Health Program of the EU is the main instrument available to the European Commission to carry out the Health Strategy of the EU. It is implemented through annual work plans, in which the criteria and funding priorities are established. The total budget of the third program is 449.4 million euros for the period 2014-2020.

COST COST is the first and widest European intergovernmental framework for transnational Cooperation in Science and Technology.

Its aim is to enable break-through scientific developments leading to new concepts and products and thereby contributes to strengthen Europe’s research and innovation capacities. These networks, COST Actions, represent the main instrument available to the program for its implementation. The calls are continuously open with two court dates per year. Other programmes • IMI • INTERREG-SUDOE • AAL • ERA-NETs

Team Adriana Varela Fernández [email protected] Phone: (+34) 91207 17 90 José Luis Narro Villanueva [email protected] Phone: (+34) 91727 75 76 Marisa Tejedor Botello [email protected] Phone: (+34) 91727 75 76

DOCUMENTATION Active projects Project

72

COMPOSITION

Programme

SAPHeIN

Implementing SAPHetydoc for the wide adoption of eINvoicing

CEF TELECOM

WEAKID

Clinical validation of miniature wearable dialysis machine

H2020

ORTHOUNION

ORTHOpedic randomized clinical trial with expanded bone marrow MSC and bioceramics versus autograft in long bone nonUNIONs

H2020

ERN TransplantChild (Coordinated by the HULP)

European Reference Network on transplantation in children

EU Health Programme

ERN RARE-LIVER

European Reference Network on hepatological diseases

H2020

VIRUSCAN

Optomechanics for Virology

H2020

RESSTORE

REgenerative Stem cell therapy for STroke in Europe

H2020

ENABLE

European Gram-negative Antibacterial Engine

IMI

EPP eHealth

European Procurers Platform - eHealth Transforming the market for eHealth Solutions

H2020

NEO-CIRC

Dobutamine for NEOnatal CIRCulatory failure defined by novel biomarkers

FP7

Logo

Webs • Participant portal: it is the entry point for electronic administration of EU-funded research and innovation projects. • CORDIS: it is the European Commission’s primary public repository and portal to disseminate information on all EU-funded research projects and their results in the broadest sense. • Eshorizonte2020: it is the H2020 Spanish portal. • European IPR Helpdesk: it offers free of charge, first-line support on IP and IPR matters to beneficiaries of EU funded research projects and EU SMEs involved in transnational partnership agreements, especially within the Enterprise Europe Network (EEN). • EURAXESS – Researchers in Motion: it is a unique pan-European initiative providing access to a complete range of information and support services to researchers wishing to pursue their research careers in Europe or stay connected to it. • EATRIS: European Infrastructure for Translational Medicine, it provides a new development pathway,

open to researchers and companies in need of support for advancing biomedical innovations. • ECRIN: European Clinical Research Infrastructure Network, it is a public, non-profit organisation that links scientific partners and networks across Europe to facilitate multinational clinical research. Documents and Forms Project Abstract Research Group Profile Annotated Model Grant Agreement - AMGA July 2016 version Events organized by the Internationalization Platform Jornada de Formación Básica sobre el Programa HORIZON 2020 FET Infoday 2017

SERVICE PORTFOLIO • Participation in international networks of interest to the center • Targeted dissemination of funding and project involvement opportunities • Organization of information sessions and training courses • Preparation and dissemination of scientific and technological profiles of the research groups • Identification of project proposals under preparation in which the center can be involved. • Advice on the definition of the project idea and the preparation of proposals • Identification of partners for projects coordinated or participated by researchers at the center • Support in the negotiation phase with the European Commission - EC before the signing of the grant agreement- GA. • Management of funded projects.

Return to EXECUTIVE SUMMARY INDEX

73

2 EXECUTIVE SUMMARY

2.8. Scientific Production

74

Journal

ISSN

Total of documents

Impact factor

Quartile

Accident Analysis and Prevention Acta Diabetológica Acta Haematologica Acta Orthopaedica et Traumatologica Turcica Acta Oto-Laryngologica Acta Paediatrica Acta Tropica Actas Dermo-Sifiliográficas Actas Urológicas Españolas Advances in Skin & Wound Care Age and Ageing AIDS AIDS Care-Psychological and Socio-Medical Aspects of AIDS/HIV AIDS Research and Human Retroviruses AIDS Reviews Allergologia et Immunopathologia Allergologie Allergology International Allergy Allergy & Rhinology American Heart Journal American Journal of Cardiology American Journal of Case Reports American Journal of Clinical Nutrition American Journal of Human Genetics American Journal of Medical Genetics Part A American Journal of Medical Genetics Part C-Seminars in Medical Genetics American Journal of Medical Quality American Journal of Obstetrics and Gynecology American Journal of Physical Anthropology American Journal of Physiology-Renal Physiology American Journal of Respiratory and Critical Care Medicine American Journal of Transplantation Anales de Documentación Anales de Pediatría Anales del Sistema Sanitario de Navarra Analytical Chemistry Andrology Angiología Annals of Allergy Asthma & Immunology Annals of Burns and Fire Disasters Annals of Hematology Annals of Occupational Hygiene Annals of Oncology Annals of Otology Rhinology and Laryngology Annals of Surgical Oncology Annals of the Rheumatic Diseases Annals of Translational Medicine Anticancer Research Antimicrobial Agents and Chemotherapy Antioxidants & Redox Signaling Antiviral Therapy Applied Physiology Nutrition and Metabolism Applied Psychology-Health and Well Being Archives of Bone and JoInt Surgery-ABJS Archives of Clinical Neuropsychology Archives of Disease in Childhood-Fetal and Neonatal Edition Archives of Gynecology and Obstetrics Archives of Orthopaedic and Trauma Surgery

0001-4575 0940-5429 0001-5792 1017-995X 0001-6489 0803-5253 0001-706X 0001-7310 0210-4806 1527-7941 0002-0729 0269-9370 0954-0121 0889-2229 1139-6121 0301-0546 0344-5062 1323-8930 0105-4538 2152-6575 0002-8703 0002-9149 1941-5923 0002-9165 0002-9297 1552-4825 1552-4868 1062-8606 0002-9378 0002-9483 1931-857X 1073-449X 1600-6135 1575-2437 1695-4033 1137-6627 0003-2700 2047-2919 0003-3170 1081-1206 1592-9558 0939-5555 0003-4878 0923-7534 0003-4894 1068-9265 0003-4967 2305-5839 0250-7005 0066-4804 1523-0864 1359-6535 1715-5312 1758-0846 2345-4644 0887-6177 1359-2998 0932-0067 0936-8051

1 2 1 1 1 4 1 12 3 1 1 3 2 2 3 3 1 1 2 1 2 3 1 1 1 6 1 1 1 1 1 3 1 1 11 2 1 1 2 2 1 2 1 2 2 1 8 1 1 2 2 4 1 1 1 2 1 1 1

2.685 3.34 1.205 0.599 1.116 2.043 2.218

D1 Q2 Q4 Q4 Q3 Q2 Q2 Not Indexed

1.181 1.088 4.282 5.003 1.824 2.095 3.195 1.439 0.311 3.194 7.361

Q4 Q3 Q1 Q1 Q2 Q3 Q2 Q4 Q4 Q2 D1 Not Indexed

4.436 3.398 Not Indexed 6.926 9.025 2.259 5.6 1.688 5.574 2.552 3.611 13.204 6.165 Not Indexed 1.14 0.625 6.32 2.427 Not Indexed 3.728 Not Indexed 3.083 1.71 11.855 1.384 4.041 12.811 Not Indexed 1.937 4.302 6.337 2.594 2.023 2.722 Not Indexed 2.044 3.786 2.09 1.942

Q2 Q2 D1 D1 Q3 Q1 Q3 D1 Q2 Q1 D1 D1 Q3 Q4 D1 Q2 Q2 Q2 Q3 D1 Q2 D1 D1 Q3 Q1 D1 Q2 Q2 Q1 Q3 D1 Q2 Q2

Continue

75

2.8. Scientific Production

2 EXECUTIVE SUMMARY

76

Archivos de Bronconeumología Archivos de Cardiología de México Archivos de la Sociedad Española de Oftalmología Archivos Españoles de Urología Arthritis & Rheumatology Arthritis Care & Research Arthritis Research & Therapy Asian Spine Journal Atención Primaria Autoimmunity Reviews Autophagy Behavioral and Brain Functions Biochemical Pharmacology Biochimica et Biophysica Acta-Molecular and Cell Biology of Lipids Biochimica et Biophysica Acta-Molecular Basis of Disease Biomaterials Biomedical Materials Bioscience Reports BJU International Blood Blood Coagulation & Fibrinolysis Blood Reviews Blood Transfusion BMC Cancer BMC Medical Research Methodology BMC Microbiology BMC Neurology BMC Palliative Care BMC Pulmonary Medicine BMJ Open Bone Marrow Transplantation Brain Brain & Development Brain Research Brain Structure & Function Brazilian Journal of Anesthesiology (Elsevier) Brazilian Journal of Physical Therapy Breast Cancer Research and Treatment Breast Care Breastfeeding Medicine British Journal of Anaesthesia British Journal of Cancer British Journal of Dermatology British Journal of Haematology British Journal of Nutrition British Journal of Oral & Maxillofacial Surgery British Journal of Pharmacology Cancer Cell Cancer Epidemiology Cancer Epidemiology Biomarkers & Prevention Cancer Letters Cardiology Cardiology and Therapy Cardiology in The Young Cardiovascular & Hematological Disorders Drug Targets Cardiovascular Diabetology Case Reports in Hematology Catheterization and Cardiovascular Interventions Cell Death & Disease Cell Death and Differentiation Cellular and Molecular Life Sciences Central European Journal of Urology Cerebellum & Ataxias

0300-2896 1405-9940 1989-7286 0004-0614 2326-5191 2151-464X 1478-6354 1976-1902 0212-6567 1568-9972 1554-8627 1744-9081 0006-2952 1388-1981 0925-4439 0142-9612 1748-6041 0144-8463 1464-4096 0006-4971 0957-5235 0268-960X 1723-2007 1471-2407 1471-2288 1471-2180 1471-2377 1472-684X 1471-2466 2044-6055 0268-3369 0006-8950 0387-7604 0006-8993 1863-2653 0104-0014 1413-3555 0167-6806 1661-3791 1556-8253 0007-0912 0007-0920 0007-0963 0007-1048 0007-1145 0266-4356 0007-1188 1535-6108 1877-7821 1055-9965 0304-3835 0008-6312 2193-8261 1047-9511 2212-4063 1475-2840 2090-6560 1522-1946 2041-4889 1350-9047 1420-682X 2080-4806 2053-8871

9 1 4 6 2 2 1 1 2 1 2 1 1 1 4 1 2 1 1 1 4 1 2 2 1 1 1 1 1 1 1 2 1 1 1 1 1 1 1 1 2 3 4 3 2 1 3 1 2 1 1 1 1 2 1 1 1 1 2 1 1 5 1

2.979 Not Indexed Not Indexed 0.323 6.918 3.319 4.121 Not Indexed 1.042 8.961 8.593 2.207 4.581 5.547 5.476 8.402 2.469 2.906 4.338 13.164 1.367 6.342 1.607 3.288 3.295 2.644 2.006 1.602 2.435 2.369 3.874 10.292 1.52 2.746 Not Indexed Not Indexed 1.226 3.626 1.553 1.551 6.238 6.176 4.706 5.67 3.706 1.218 5.491 27.407 2.343 4.142 6.375 1.742 Not Indexed 0.905 Not Indexed 4.752 Not Indexed 2.602 5.965 8.339 5.788 Not Indexed Not Indexed

Q2

Q4 D1 Q2 Q2 Q3 D1 Q1 Q3 Q1 Q1 Q1 D1 Q2 Q2 Q1 D1 Q4 Q1 Q4 Q2 Q1 Q2 Q3 Q3 Q3 Q1 Q2 D1 Q4 Q3

Q3 Q2 Q3 Q3 D1 Q1 D1 Q1 Q1 Q3 D1 D1 Q2 Q1 Q1 Q3 Q4 Q1 Q2 Q1 D1 Q1

Cerebrovascular Diseases Circulation Circulation Journal Circulation-Cardiovascular Interventions Circulation-Cardiovascular Quality and Outcomes Cirugía Cardiovascular Cirugía Pediátrica Cirugía y Cirujanos Clinical & Translational Oncology Clinical and Applied Thrombosis-Hemostasis Clinical and Experimental Allergy Clinical and Experimental Hypertension Clinical and Experimental Immunology Clinical and Experimental Obstetrics & Gynecology Clinical and Experimental Pharmacology and Physiology Clinical and Experimental Rheumatology Clinical Cancer Research Clinical Cardiology Clinical Endocrinology Clinical Genetics Clinical Immunology Clinical Infectious Diseases Clinical Kidney Journal Clinical Microbiology and Infection Clinical Nutrition Clinical Rheumatology Clinical Sarcoma Research Clinical Science Cochlear Implants International Contemporary Nurse COPD-Journal of Chronic Obstructive Pulmonary Disease Córnea Critical Care Critical Care Medicine Critical Reviews in Oncology Hematology Current Allergy and Asthma Reports Current Cancer Drug Targets Current Medical Research and Opinion Current Opinion in Allergy and Clinical Immunology Cytotherapy Chest Chinese Journal of Cancer Research Chronic Respiratory Disease Data in Brief Dermatologic Therapy Diabetes Diabetes Care Diabetes-Metabolism Research and Reviews Disease Models & Mechanisms Drug and Alcohol Dependence Drug Safety Ebiomedicine Ecancermedicalscience Elife Embo Molecular Medicine E-Memoires de L Academie Nationale de Chirurgie Emergencias Emerging Infectious Diseases Endocrinología y Nutrición Endocrinology Diabetes and Metabolism Case Reports Energies Enfermedades Infecciosas y Microbiología Clínica Enfermería Clínica

1015-9770 0009-7322 1346-9843 1941-7640 1941-7705 1134-0096 0214-1221 0009-7411 1699-048X 1076-0296 0954-7894 1064-1963 0009-9104 0390-6663 1440-1681 0392-856X 1078-0432 0160-9289 0300-0664 0009-9163 1521-6616 1058-4838 1753-0784 1198-743X 0261-5614 0770-3198 2045-3329 0143-5221 1754-7628 1037-6178 1541-2555 0277-3740 1466-609X 0090-3493 1040-8428 1529-7322 1568-0096 0300-7995 1528-4050 1465-3249 0012-3692 1000-9604 1479-9723 2352-3409 1396-0296 0012-1797 0149-5992 1520-7560 1754-8403 0376-8716 0114-5916 2352-3964 1754-6605 2050-084X 1757-4676 1634-0647 1137-6821 1080-6040 1575-0922 2052-0573 1996-1073 0213-005X 1130-8621

1 3 3 1 1 9 3 1 11 1 1 1 1 1 1 4 2 1 2 2 3 1 1 2 2 2 1 1 2 1 1 1 1 1 3 1 1 1 1 2 3 1 1 1 1 1 1 1 2 1 1 3 3 1 1 1 2 1 2 1 1 20 1

2.974 19.309 3.544 7.198 4.524 Not Indexed Not Indexed 0.276 2.353 2.096 5.264 1.162 3.41 0.429 2.01 2.634 9.619 2.757 3.327 3.326 3.99 8.216 Not Indexed 5.292 4.548 2.365 Not Indexed 4.936 Not Indexed 0.836 2.576 2.01 5.358 7.05 4.971 3.735 2.992 2.757 3.463 3.203 6.044 3 1.818 Not Indexed 1.093 8.684 11.857 3.263 4.691 3.222 3.435 Not Indexed Not Indexed 7.725 9.249 Not Indexed 3.028 8.222 1.106 Not Indexed 2.262 1.714 Not Indexed

Q2 D1 Q2 D1 Q2

Q4 Q3 Q3 Q1 Q4 Q2 Q4 Q3 Q3 D1 Q2 Q2 Q2 Q2 D1 D1 Q1 Q3 Q1 Q3 Q3 Q2 Q1 Q1 Q1 Q2 Q3 Q1 Q2 Q2 Q1 Q2 Q3 Q4 D1 D1 Q2 Q1 Q1 Q1

D1 D1 Q1 D1 Q4 Q2 Q3

Continue

77

2.8. Scientific Production

2 EXECUTIVE SUMMARY

78

Environmental Research EuroIntervention Europace European Annals of Allergy and Clinical Immunology European Archives of Oto-Rhino-Laryngology European Food Research and Technology European Geriatric Medicine European Heart Journal European Heart Journal-Acute Cardiovascular Care European Heart Journal-Cardiovascular Pharmacotherapy European Journal of Anatomy European Journal of Cancer Prevention European Journal of Cardio-Thoracic Surgery European Journal of Cardiovascular Nursing European Journal of Clinical Investigation European Journal of Clinical Microbiology & Infectious Diseases European Journal of Clinical Pharmacology European Journal of Emergency Medicine European Journal of Endocrinology European Journal of Haematology European Journal of Heart Failure European Journal of Human Genetics European Journal of Internal Medicine European Journal of Medical Genetics European Journal of Neurology European Journal of Nutrition European Journal of Obstetrics & Gynecology and Reproductive Biology European Journal of Orthopaedic Surgery & Traumatology European Journal of Pediatric Surgery European Journal of Pharmacology European Journal of Preventive Cardiology European Neuropsychopharmacology European Spine Journal European Surgery-Acta Chirurgica Austriaca European Urology European Urology Supplements Eurosurveillance Experimental Gerontology Expert Opinion on Drug Metabolism & Toxicology Expert Opinion on Investigational Drugs Expert Opinion on Pharmacotherapy Expert Opinion on Therapeutic Targets Expert Review of Anticancer Therapy Expert Review of Anti-Infective Therapy Expert Review of Clinical Immunology Expert Review of Hematology Expert Review of Neurotherapeutics Farmacia Hospitalaria Febs Journal Food & Function Food & Nutrition Research Free Radical Biology and Medicine Frontiers in Aging Neuroscience Frontiers in Immunology Frontiers in Molecular Neuroscience Frontiers in Neuroanatomy Frontiers in Pharmacology Frontiers in Physiology Frontiers in Psychology Future Cardiology Future Medicinal Chemistry Future Oncology Future Virology

1096-0953 1774-024X 1099-5129 1764-1489 0937-4477 1438-2377 1878-7649 0195-668X 2048-8726 2055-6837 1136-4890 0959-8278 1010-7940 1474-5151 0014-2972 0934-9723 0031-6970 0969-9546 0804-4643 0902-4441 1388-9842 1018-4813 0953-6205 1769-7212 1351-5101 1436-6207 0301-2115 1633-8065 0939-7248 0014-2999 2047-4873 0924-977X 0940-6719 1682-8631 0302-2838 1569-9056 1560-7917 0531-5565 1742-5255 1354-3784 1465-6566 1472-8222 1473-7140 1478-7210 1744-666X 1747-4086 1473-7175 0214-753X 1742-464X 2042-6496 1654-6628 0891-5849 1663-4365 1664-3224 1662-5099 1662-5129 1663-9812 1664-042X 1664-1078 1479-6678 1756-8919 1479-6694 1746-0794

1 2 4 1 3 1 1 4 1 2 1 1 1 1 2 1 1 1 2 5 1 2 2 1 1 2 1 1 6 1 3 1 2 1 1 1 1 1 1 1 3 1 1 1 1 5 1 2 1 1 1 1 2 1 1 2 2 1 1 3 1 1 1

3.835 5.165 4.53 Not Indexed 1.66 1.664 1.336 19.651 Not Indexed Not Indexed Not Indexed 2.556 3.759 2.763 2.714 2.727 2.902 2.025 4.101 2.653 6.968 4.287 2.96 2.137 3.988 4.37 1.666 Not Indexed 1.313 2.896 3.606 4.239 2.563 0.287 16.265 3.462 7.202 3.34 3.027 4.716 3.894 4.873 2.212 3.139 3.27 2.246 3.149 Not Indexed 3.902 3.247 2.039 5.606 4.504 6.429 5.076 3.267 4.4 4.134 2.323 Not Indexed 3.556 2.131 0.958

Q1 Q1 Q1 Q2 Q2 Q4 D1

Q3 Q1 D1 Q1 Q2 Q2 Q2 Q1 Q2 D1 Q1 Q1 Q3 Q1 Q1 Q3 Q3 Q2 Q2 Q1 Q1 Q4 D1 Q1 D1 Q1 Q2 Q1 Q1 Q1 Q3 Q2 Q2 Q3 Q2 Q2 Q1 Q2 Q1 Q1 Q1 Q1 D1 Q1 Q1 Q2 Q1 Q3 Q4

Gastroenterología y Hepatología General Hospital Psychiatry Genetic Counseling Genetic Epidemiology Genetics and Molecular Biology Genetics in Medicine Genome Medicine Geriatrics & Gerontology International Gynecologic and Obstetric Investigation Gynecologic Oncology Haematologica Haemophilia Health & Place Heart Hepatology Hip International Hipertensión y Riesgo Vascular HIV Medicine Human Genetics Human Molecular Genetics Human Reproduction Update Hypertension IEEE Systems Journal IEEE Transactions on Vehicular Technology Immunotherapy Indian Journal of Plastic Surgery Inflammatory Bowel Diseases Internal Medicine Journal International Archives of Allergy and Immunology International Journal of Antimicrobial Agents International Journal of Cancer International Journal of Cardiology International Journal of Clinical Pharmacy International Journal of Chronic Obstructive Pulmonary Disease International Journal of Environmental Research and Public Health International Journal of Gastronomy and Food Science International Journal of Gynecological Cancer International Journal of Gynecology & Obstetrics International Journal of Immunogenetics International Journal of Infectious Diseases International Journal of Molecular Sciences International Journal of Pediatric Otorhinolaryngology International Journal of Stroke International Journal of Systematic and Evolutionary Microbiology International Journal of Tuberculosis and Lung Disease Investigacion Clínica JACC-Cardiovascular Interventions JAIDS-Journal of Acquired Immune Deficiency Syndromes JAMA Cardiology JAMA Dermatology JAMA-Journal of the American Medical Association JIMD Reports Journal of Acute Disease Journal of Aerosol Medicine and Pulmonary Drug Delivery Journal of Agricultural and Food Chemistry Journal of Alzheimers Disease Journal of Allergy and Clinical Immunology Journal of Allergy and Clinical Immunology-in Practice Journal of Antibiotics Journal of Antimicrobial Chemotherapy Journal of Applied Clinical Medical Physics Journal of Arthroplasty Journal of Back and Musculoskeletal Rehabilitation

0210-5705 0163-8343 1015-8146 0741-0395 1415-4757 1098-3600 1756-994X 1444-1586 1423-002X 0090-8258 0390-6078 1351-8216 1353-8292 1355-6037 0270-9139 1120-7000 1989-4805 1464-2662 0340-6717 0964-6906 1355-4786 0194-911X 1932-8184 0018-9545 1750-743X 0970-0358 1078-0998 1444-0903 1018-2438 0924-8579 0020-7136 0167-5273 2210-7703 1178-2005 1660-4601 1878-450X 1048-891X 0020-7292 1744-3121 1201-9712 1422-0067 0165-5876 1747-4930 1466-5026 1027-3719 0535-5133 1936-8798 1525-4135 2380-6583 2168-6068 0098-7484 2192-8312 2221-6189 1941-2711 0021-8561 1387-2877 0091-6749 2213-2198 0021-8820 0305-7453 1526-9914 0883-5403 1053-8127

1 1 1 1 1 1 1 1 1 3 1 7 1 4 3 1 2 3 2 2 1 1 1 1 1 1 2 1 1 1 1 6 1 1 1 1 4 2 1 1 1 1 1 1 1 1 1 2 1 1 1 1 1 1 2 2 2 3 1 3 1 1 1

0.917 2.279 0.236 1.884 1.147 8.229 7.071 2.351 1.415 4.959 7.702 3.569 2.541 6.059 13.246 1.055 Not Indexed 3.257 4.637 5.34 11.748 6.857 3.882 4.066 2.716 Not Indexed 4.525 1.902 2.72 4.307 6.513 6.189 1.555 3.157 2.101 Not Indexed 2.369 2.174 1.093 2.532 3.226 1.159 3.314 2.134 2.468 0.493 8.841 3.935 Not Indexed 5.817 44.405 Not Indexed Not Indexed 2.528 3.154 3.731 13.081 5.317 2.237 5.071 1.338 3.055 0.912

Q4 Q3 Q4 Q2 Q4 D1 D1 Q3 Q4 D1 D1 Q2 Q2 Q1 D1 Q3 Q2 Q1 Q2 D1 D1 D1 Q1 Q3 Q1 Q2 Q3 Q1 Q1 Q1 Q4 Q2 Q2 Q2 Q2 Q4 Q2 Q2 Q3 Q2 Q3 Q3 Q4 D1 Q1 D1 D1

Q3 D1 Q2 D1 Q1 Q2 D1 Q3 Q1 Q3

Continue

79

2.8. Scientific Production

2 EXECUTIVE SUMMARY

80

Journal of Biomedical Materials Research Part A Journal of Bone and Mineral Metabolism Journal of Cancer Research and Therapeutics Journal of Cardiology Journal of Cardiovascular Pharmacology and Therapeutics Journal of Cardiovascular Surgery Journal of Clinical and Experimental Dentistry Journal of Clinical Anesthesia Journal of Clinical Endocrinology & Metabolism Journal of Clinical Gastroenterology Journal of Clinical Hypertension Journal of Clinical Immunology Journal of Clinical Investigation Journal of Clinical Oncology Journal of Clinical Pathology Journal of Clinical Pharmacy and Therapeutics Journal of Clinical Sleep Medicine Journal of Clinical Virology Journal of Comparative Neurology Journal of Cystic Fibrosis Journal of Chemotherapy Journal of Diabetes and its Complications Journal of Endourology Journal of Epidemiology and Community Health Journal of Exercise Rehabilitation Journal of Functional Foods Journal of Gastroenterology and Hepatology Journal of General Virology Journal of Gynecologic Oncology Journal of Headache and Pain Journal of High Energy Physics Journal of Human Genetics Journal of Hypertension Journal of Immunotoxicology Journal of Infection Journal of Interventional Cardiology Journal of Investigational Allergology and Clinical Immunology Journal of Materials Science-Materials in Medicine Journal of Maternal-Fetal & Neonatal Medicine Journal of Medicinal Chemistry Journal of Minimal Access Surgery Journal of Molecular Diagnostics Journal of NeuroInterventional Surgery Journal of Nuclear Medicine Journal of Nutrition Health & Aging Journal of Obstetrics and Gynaecology Journal of Occupational Health Journal of Oncology Journal of Paediatrics and Child Health Journal of Parenteral and Enteral Nutrition Journal of Pediatric Ophthalmology & Strabismus Journal of Pediatrics Journal of Pediatrics Review Journal of Physical Chemistry Letters Journal of Reproductive Medicine Journal of Rheumatology Journal of Sexual Medicine Journal of Stroke & Cerebrovascular Diseases Journal of Surgical Oncology Journal of the American Association for Laboratory Animal Science Journal of the American College of Cardiology Journal of the American Heart Association

1549-3296 0914-8779 0973-1482 0914-5087 1074-2484 0021-9509 1989-5488 0952-8180 0021-972X 0192-0790 1524-6175 0271-9142 0021-9738 0732-183X 0021-9746 0269-4727 1550-9389 1386-6532 0021-9967 1569-1993 1120-009X 1056-8727 2152-4920 0143-005X 2288-176X 1756-4646 0815-9319 0022-1317 2005-0380 1129-2369 1029-8479 1434-5161 0263-6352 1547-691X 0163-4453 0896-4327 1018-9068 0957-4530 1476-7058 0022-2623 0972-9941 1525-1578 1759-8486 0161-5505 1279-7707 0144-3615 1341-9145 1687-8450 1034-4810 0148-6071 0191-3913 0022-3476 2322-4398 1948-7185 0024-7758 0315-162X 1743-6095 1052-3057 0022-4790 1559-6109 0735-1097 2047-9980

1 1 1 1 1 1 1 1 1 1 1 3 1 2 1 1 1 3 1 1 1 1 1 2 3 1 1 1 1 1 1 1 7 1 3 1 13 1 3 2 1 1 1 1 2 1 1 1 1 2 2 2 1 1 1 1 1 2 1 1 6 1

3.076 2.423 0.75 2.732 3 2.179 Not Indexed 1.667 5.455 3.328 3.242 3.253 12.784 24.008 2.687 1.679 3.429 3.051 3.266 4.727 1.577 2.734 Not Indexed 3.608 Not Indexed 3.144 3.452 2.838 3.14 2.141 6.063 2.471 4.085 2.021 4.201 1.88 3.094 2.325 1.826 6.259 1.282 4.526 3.551 6.646 2.772 0.629 1.848 Not Indexed 1.572 4.22 0.902 3.874 Not Indexed 9.353 0.848 3.15 2.978 1.517 2.993 1.195 19.896 4.863

Q2 Q3 Q4 Q2 Q2 Q2 Q3 Q1 Q2 Q2 Q2 D1 D1 Q2 Q3 Q2 Q2 D1 Q1 Q4 Q3 Q1 Q1 Q2 Q2 Q1 Q1 Q1 Q3 Q1 Q3 Q1 Q3 Q2 Q3 Q3 D1 Q3 Q1 Q1 D1 Q2 Q4 Q2 Q3 Q1 Q4 D1 D1 Q4 Q2 Q2 Q4 Q1 Q2 D1 Q1

Journal of the American Medical Directors Association Journal of the American Society of Hypertension Journal of the American Society of Nephrology Journal of the European Academy of Dermatology and Venereology Journal of the National Comprehensive Cancer Network Journal of the Neurological Sciences Journal of Thrombosis and Haemostasis Journal of Thrombosis and Thrombolysis Journal of Translational Medicine Journal of Trauma and Acute Care Surgery Journal of Ultrasound in Medicine Journal of Viral Hepatitis Journal of Virology Journal of Virus Eradication Journal of Womens Health Journals of Gerontology Series A-Biological Sciences and Medical Sciences JOVE-Journal of Visualized Experiments Kidney & Blood Pressure Research Kidney International Lancet Lancet Infectious Diseases Lancet Neurology Leukemia & Lymphoma Lipids in Health and Disease Liver International Lung Cancer Lung India Lymphatic Research and Biology Maturitas Mayo Clinic Proceedings Mechanisms of Ageing and Development Medchemcomm Medicina Clínica Medicina Intensiva Medicine Melanoma Research Methods in Molecular Biology Microbial Biotechnology Minerva Anestesiológica Mitochondrion Molecular and Cellular Biology Molecular Cancer Therapeutics Molecular Genetics & Genomic Medicine Molecular Genetics and Metabolism Molecular Immunology Molecular Neurobiology Molecular Psychiatry Molecular Vision Multiple Sclerosis Journal Muscle & Nerve Mycoses Nature Nature Communications Nature Genetics Nature Medicine Nature Reviews Rheumatology Nefrología Neonatology Nephrology Dialysis Transplantation Neurochemistry International Neuroimage-Clinical Neurologia

1525-8610 1933-1711 1046-6673 0926-9959 1540-1405 0022-510X 1538-7933 0929-5305 1479-5876 2163-0755 0278-4297 1352-0504 0022-538X 2055-6640 1540-9996 1079-5006 1940-087X 1420-4096 0085-2538 0140-6736 1473-3099 1474-4422 1042-8194 1476-511X 1478-3223 0169-5002 0970-2113 1539-6851 0378-5122 0025-6196 0047-6374 2040-2503 0025-7753 0210-5691 0025-7974 0960-8931 1940-6029 1751-7907 0375-9393 1567-7249 0270-7306 1535-7163 2324-9269 1096-7192 0161-5890 0893-7648 1359-4184 1090-0535 1352-4585 0148-639X 0933-7407 0028-0836 2041-1723 1061-4036 1078-8956 1759-4790 0211-6995 1661-7800 1460-2385 0197-0186 2213-1582 0213-4853

3 2 1 1 1 1 1 3 2 1 4 1 1 1 1 2 1 1 2 12 3 1 1 1 3 1 1 1 1 1 1 1 15 5 2 1 1 1 2 1 1 1 3 1 1 2 1 1 1 1 1 1 2 2 1 1 3 1 3 1 1 3

5.775 3.263 8.966 3.528 4.675 2.295 5.287 2.142 3.786 3.403 1.547 4.122 4.663

D1 Q2 D1 Q1 Q2 Q3 Q1 Q3 Q1 Q1 Q3 Q1 Q1

Not Indexed 2.322 5.957 1.232 3.104 8.395 47.831 19.864 26.284 2.755 2.073 4.116 4.294 Not Indexed 1.551 3.255 6.686 3.087 2.608 1.125 1.231 1.803 2.615 Not Indexed 3.513 2.623 3.704 4.398 5.764 Not Indexed 3.769 3.326 6.19 13.204 2.057 4.84 2.605 2.252 40.137 12.124 27.959 29.886 12.188 1.183 2.598 4.47 3.262 4.348 2.103

Q2 D1 Q2 Q2 D1 D1 D1 D1 Q2 Q3 Q1 Q1 Q3 Q1 D1 Q2 Q2 Q3 Q4 Q2 Q2 Q2 Q2 Q2 Q1 Q1 Q1 Q2 D1 D1 Q2 Q1 Q2 Q2 D1 D1 D1 D1 D1 Q4 Q1 Q1 Q2 Q1 Q3

Continue

81

2.8. Scientific Production

2 EXECUTIVE SUMMARY

82

Neurology-Neuroimmunology & NeuroInflammation Neuromuscular Disorders Neuropharmacology Neuroradiology Neurotoxicology New England Journal of Medicine NPJ Primary Care Respiratory Medicine Nucleic Acids Research Nucleosides Nucleotides & Nucleic Acids Nutrición Hospitalaria Nutrients Obesity Obesity Surgery Ocular Immunology and Inflammation Oncogene Oncogenesis Oncoimmunology Oncotarget Open Forum Infectious Diseases Open Orthopaedics Journal Ophthalmic Genetics Organic Geochemistry Orphanet Journal of Rare Diseases Orthopedics Osteoporosis International PACE-Pacing and Clinical Electrophysiology Pain Medicine Pain Physician Pain Practice Pain Research & Management Pain Research and Treatment Parasites & Vectors Patient Preference and Adherence Pediatric Allergy and Immunology Pediatric and Developmental Pathology Pediatric Dermatology Pediatric Hematology and Oncology Pediatric Infectious Disease Journal Pediatric Research Pediatric Surgery International Peritoneal Dialysis International Pflugers Archiv-European Journal of Physiology Pharmacoepidemiology and Drug Safety Pharmacogenetics and Genomics Pharmacogenomics Pharmacogenomics Journal Pharmacological Research Pharmacology & Therapeutics Pituitary Placenta Plastic and Reconstructive Surgery Plos Genetics Plos Neglected Tropical Diseases Plos One Pm&R Primary Care Diabetes Proceedings of the National Academy of Sciences of the United States of America Quality of Life Research Radiología Respiration Respiratory Care

2332-7812 0960-8966 0028-3908 0028-3940 0161-813X 0028-4793 2055-1010 0305-1048 1525-7770 0212-1611 2072-6643 1930-7381 0960-8923 0927-3948 0950-9232 2157-9024 2162-402X 1949-2553 2328-8957 1874-3250 1381-6810 0146-6380 1750-1172 0147-7447 0937-941X 0147-8389 1526-2375 1533-3159 1530-7085 1203-6765 2090-1542 1756-3305 1177-889X 0905-6157 1093-5266 0736-8046 0888-0018 0891-3668 0031-3998 0179-0358 0896-8608 0031-6768 1053-8569 1744-6872 1462-2416 1470-269X 1043-6618 0163-7258 1386-341X 0143-4004 0032-1052 1553-7404 1935-2735 1932-6203 1934-1482 1751-9918

1 1 1 1 2 5 1 1 3 4 1 1 1 1 3 1 3 10 4 1 1 1 2 1 2 1 2 1 1 1 1 1 2 1 15 2 2 7 4 1 1 1 6 1 2 1 2 1 1 1 1 1 1 24 1 1

Not Indexed 2.969 5.012 2.093 3.1 72.406 2.793 10.162 0.868 0.747 3.55 3.783 3.947 2.453 7.519 4.143 7.719 5.168 Not Indexed Not Indexed 1.277 3.081 3.507 1.143 3.591 1.486 2.82 2.84 2.495 2.027 Not Indexed 3.08 1.798 3.775 1.089 0.99 1.12 2.486 2.882 1.181 1.557 3.156 2.552 2.184 2.35 3.815 4.48 11.127 2.481 2.759 3.784 6.1 3.834 2.806 1.785 1.381

Q1 Q2 D1 Q4 Q4 Q3 Q1 Q1 Q3 Q3 Q2 Q2 Q2 Q3 Q1 Q1 D1 Q3 Q1 Q1 D1 D1 Q1 Q2 Q3

0027-8424

2

9.661

D1

0962-9343 1578-178X 0025-7931 0020-1324

1 1 1 1

2.344

Q2 D1 Q2 Q2 D1 D1 D1 Q4 Q4 Q2 Q1 D1 Q2 D1 Q2 D1 Q1

Q3 Q1 Q2 Q3 Q2 Q3 Q1 Q2 Q2 Q3

Q2 Not Indexed

2.772 1.733

Resuscitation Reumatología Clínica Revista Brasileira de Anestesiología Revista Clínica Española Revista de Calidad Asistencial Revista de Neurología Revista de Psiquiatría y Salud Mental Revista Española de Anestesiología Y Reanimación Revista Española de Cardiología Revista Española de Cirugía Ortopédica Y Traumatología Revista Española de Geriatría Y Gerontología Revista Española de Medicina Nuclear e Imagen Molecular Revista Española de Nutrición Humana Y Dietética Revista Española de Quimioterapia Revista Española de Salud Pública Revista Iberoamericana de Micologia Revista Portuguesa de Cardiología Rheumatology Rheumatology International RSC Advances Scandinavian Journal of Rheumatology Scientific Reports Semergen Seminars in Arthritis and Rheumatism Seminars in Nephrology Sleep Medicine Reviews Spanish Journal of Psychology Spine Spine Deformity Stem Cells International Stem Cells Translational Medicine Stroke Supportive Care in Cancer Taiwanese Journal of Obstetrics & Gynecology Targeted Oncology Techniques in Coloproctology Therapeutic Hypothermia and Temperature Management Thoracic and Cardiovascular Surgeon Thorax Thrombosis and Haemostasis Thrombosis Research Tobacco Control Torture Toxicology and Applied Pharmacology Translational Research Translational Stroke Research Transplant Immunology Transplantation Reviews Trends in Genetics Tumor Biology Ultrasound in Obstetrics & Gynecology Ultrasound International Open Urologic Oncology-Seminars and Original Investigations Urology Virus Research Viruses-Basel World Journal of Gastroenterology World Journal of GastroIntestinal Endoscopy World Journal of Orthopedics World Journal of Pediatrics

0300-9572 1699-258X 0034-7094 0014-2565 1887-1364 0210-0010 1888-9891 2340-3284 0300-8932 1988-8856 1578-1747 2253-654X 2173-1292 0214-3429 1135-5727 1130-1406 0870-2551 1462-0324 0172-8172 2046-2069 0300-9742 2045-2322 1578-8865 0049-0172 0270-9295 1087-0792 1138-7416 0362-2436 2212-1358 1687-966X 2157-6564 0039-2499 0941-4355 1028-4559 1776-2596 1123-6337 2153-7658 0171-6425 0040-6376 0340-6245 0049-3848 0964-4563 1997-3322 0041-008X 1931-5244 1868-4483 0966-3274 0955-470X 0168-9525 1010-4283 1469-0705 2509-596X 1078-1439 0090-4295 0168-1702 1999-4915 1007-9327 1948-5190 2218-5836 1708-8569

1 3 3 5 1 9 1 13 32 3 1 1 4 1 4 3 1 1 1 1 1 10 8 3 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 5 3 1 6 2 1 1 1 1 1 1 1 1 1 1 2 1 3 1 1 1

5.23

D1 Not Indexed

0.903 0.971

Q4 Q3 Not Indexed

0.743 2.227

Q4 Q3 Not Indexed

4.485

Q2 Not Indexed Not Indexed

0.951

Q4 Not Indexed

0.75 0.69 1.33 1.195 4.818 1.824 3.108 2.667 4.259

Q4 Q4 Q3 Q4 Q1 Q3 Q2 Q2 Q1 Not Indexed

4.498 3.598 8.958 0.502 2.499

Q1 Q1 D1 Q4 Q2 Not Indexed

3.54 4 6.032 2.698 0.925 3.438 2.342 1.787 1.424 8.272 5.627 2.65 5.469 Not Indexed 3.791 4.652 4.503 1.78 3.113 10.844 3.65 4.71 Not Indexed 3.767 2.309 2.628 3.465 3.365 Not Indexed Not Indexed 1.164

Q2 Q1 D1 Q1 Q4 Q2 Q2 Q4 Q3 D1 D1 Q2 Q1 Q1 Q1 Q1 Q3 Q2 D1 Q2 D1 Q1 Q2 Q3 Q2 Q2

Q3

Q2 Q4

Return to EXECUTIVE SUMMARY INDEX

83

2 EXECUTIVE SUMMARY 2.9.2. RECTICs-

Acronym

Network

Funding Organisation

Principal Researcher

IdiPAZ Group

End Date

RD12/0018/0023

RICET

Tropical Disease Cooperative Research Network

Instituto de Salud Carlos III

Díaz Menéndez, Marta

AIDS and Infectious Diseases

31/12/2017

RD12/0026/0004

SAMID

Research Network for Maternal and Child Health and Development

Instituto de Salud Carlos III

Cabañas González, Fernando

Congenital Malformation Surgery

31/12/2017

RD12/0036/007

RTICC

Cooperative Cancer Research Network

Instituto de Salud Carlos III

Cano García, Amparo

Mechanisms of Tumour Progression

30/06/2017

PT13/0006/0012

ITEMAS

Medical Technology Innovation Platform

Instituto de Salud Carlos III

de Castro Carpeño, Javier

Translational Oncology

31/12/2017

PT13/0010/0003

ReTBioH

Biobanks Platform

Instituto de Salud Carlos III

García Fernández, María Eugenia

Cellular Engineering

31/12/2017

RD12/0014/0006

INVICTUS

Vascular and Cerebral Diseases Network

Instituto de Salud Carlos III

Díez Tejedor, Exuperio

Neurology and Cerebrovascular Diseases

31/12/2016

PT13/0002/0015

UCICEC

Research and Clinical Trials Units Platform

Instituto de Salud Carlos III

Frías Iniesta, Jesús

Clinical Pharmacology

31/12/2017

RD12/0017/0016

RIS

Research Network for AIDS

Instituto de Salud Carlos III

González García, Juan

AIDS and Infectious Diseases

31/12/2017

RD12/0042/0063

RIC

Cardiovascular Research Network

Instituto de Salud Carlos III

López-Sendón Hentschel, José Luis

Research on Invasive Clinical Cardiology ICCI-Paz

31/12/2017

RD12/0026/0011

SAMID

Research Network for Maternal and Child Health and Development

Instituto de Salud Carlos III

Martínez Martínez, Leopoldo

Congenital Malformation Surgery

31/12/2017

RD12/0009/0012

RIER

Investigational Network in Inflammation and Rheumatic Diseases

Instituto de Salud Carlos III

Miranda Carús, María Eugenia

Immuno-Rheumatology

31/12/2017

RD12/0036/0021

RTICC

Cooperative Cancer Research Network

Instituto de Salud Carlos III

Muñoz Terol, Alberto

Mechanisms of Tumour Progression

30/06/2017

RD12/0043/0019

RETICEF

Cooperative Research Network in Aging and Fragility

Instituto de Salud Carlos III

Otero Puime, Ángel

Aging and Fragility in the Elderly

31/12/2017

RD12/0042/0024

RIC

Cardiovascular Research Network

Instituto de Salud Carlos III

Salaices Sánchez, Mercedes

Vascular Physiology and Pharmacology

30/06/2017

S2010-BMD2321

FIBROTEAM

Molecular mechanisms, experimental models and therapeutic approaches in the organic fibrosis: from the biological mediator to the clinical application

Comunidad de Madrid

Selgas Gutiérrez, Rafael

Nephrology

30/04/2016

RD12/0021/0004

REDINREN

Research Network for Renal Diseases

Instituto de Salud Carlos III

Selgas Gutiérrez, Rafael

Nephrology

31/12/2017

RD12/0026/0011

SAMID

Research Network for Maternal and Child Health and Development

Instituto de Salud Carlos III

Tovar Larrucea, Juan Antonio

Congenital Malformation Surgery

31/12/2016

MAT2014-52905REDT

BIOIMPLANT

Research Network for the development of titanium implants functionalized

Ministerio de Economía y Competitividad

Vilaboa Díaz, Nuria Elda

Bone Pathophysiology and Biomaterials

31/05/2017

P2013/MIT-2862

FIOBI

Research Network for multifunctional materials for the challenges of the Society

Comunidad de Madrid

Vilaboa Díaz, Nuria Elda

Bone Pathophysiology and Biomaterials

30/09/2018

Project

2.9 CIBERs and RETICs

2.9.1. CIBERAcronym

CIBER-bbn

CIBERehd

CIBERer

Network Biomedical Research Center CIBER

Funding Organisation

Networked Biomedical Research Center for Bio- Instituto de Salud engineering, Biomaterials Carlos III and Nanomedicine Networked Biomedical Research Center for Hepatic and Digestive Diseases

Principal Researcher

IdiPAZ Group

Vilaboa Díaz, Nuria Elda

Bone Pathophysiology and biomaterials

Instituto de Salud García-Samaniego Carlos III Rey, Javier

Networked Biomedical Instituto de Salud Research Center for Rare Carlos III Diseases

López Trascasa, Margarita Lapunzina Badía, Pablo

CIBEResp

CIBERned

84

Networked Biomedical Instituto de Salud Rodríguez Research Center for Public Carlos III Artalejo, Fernando Health and Epidemiology Networked Biomedical Research Center for Neurodegenerative Diseases

Instituto de Salud Cuadrado Pastor, Carlos III Antonio

Associated Clinician Diagnosis and Treatment of Diseases Associated with Abnormalities of the Complement System

Networks for Cooperative Research in Health

End Date

31/12/2017

31/12/2017

31/12/2017

Cell Therapy and Gene 31/12/2017 Metastasis Cardiovascular Epidemiology and Nutrition

31/12/2017

Neuroprotective strategies in neurodegenerative diseases

31/12/2017

Return to EXECUTIVE SUMMARY INDEX

85

2 EXECUTIVE SUMMARY

Members of the network

2.10 Institutional Projects

TransplantChild is integrated by 18 Healthcare Providers (HCP) institutions from 11 Members States. Together, ERN members advice on the patient’s diagnosis, treatment and support during the transplant process (pre-transplant, transplant surgery and post-transplant phases). Karolinska

Whilhelmina Children Hospital

Lund Hospital (Skane Univ Hospital)

Saint Luc Children's Memorial Health Institute

KCH (King's College Hospital NHS foundation Trust)

Paris Necker

Vilnius UH Santariskiu Klinikos

Bicetre

Hannover Medical School

Hospital Universitario la Paz

H Sta María

Hospital de Coimbra Papa Giovanni XXIII

Bambino Gesu

Ospiedaliera di Podova

ISMETT

Centro Hospitalario do Porto EPE (CHP)

Strategic areas TransplantChild (http://www.transplantchild.com) is an ERN for Paediatric transplantation (PT), both Solid Organ Transplantation (SOT) and Hematopoietic Stem Cell Transplantation (HSCT) which are low-prevalence and complex conditions that require highly specialized expertise and resources. It’s the only ERN coordinated by Spanish Center (Hospital Universitario La Paz-FIBHULP), and the only focused in a therapeutic process. The network scope is a cross-cutting approach to supports common areas in different types of transplants as immunosuppression, rejection, tolerance, risk of infection and psychosocial wellbeing.

Main lines of Action Mission

TransplantChild aims to improve life expectancy and quality of life for EU paediatric patients requiring transplantation, by: • Ensuring their access through the network to the best possible advice on diagnostic, care practices and support procedures, considering a cross-cutting approach. • Developing and joining efforts within the Network & stakeholders for integrative, innovative and better procedures, information, training, knowledge and expertise.

• To harmonise clinical best practices by the development of clinical practice guidelines. • Identifying, aligning and prioritising research and innovation focused on facilitating continuous improvement transplanted patient care.

Network organization Quality-safety

Improvement in healthcare

• To harmonise and spread knowledge exchanging and disseminating knowledge and best practices within and outside the network. • To Identify and fulfill education and training in PT, promoting the use of standardized continuous education training programmes. • TO facilitate the development of effective organisational structures and to define the mechanisms needed for planning-monitoring and organization, quality and safety.

Paediatric patient/families

Harmonise evidence-based and safe clinical practise

Research and Innovation

Spread Knowledge Professional education and training

Added value of the Network • The scarcity and fragmentation of specialist knowledge are the main reasons why patients may not find a satisfactory treatment and follow-up program. • TransplantChild aims to consolidate knowledge and expertise scattered across countries. This will result in:

Vision

To become a network of excellence for patients / families based on their health outcomes achieved throughout the life of the transplanted patient. • Is based on innovative monitoring techniques and evidence-based treatments. • Has highly specialized multidisciplinary teams committed to improving the quality of life of patients and their families, research, and dissemination of knowledge.

86

• To improve patient healthcare by facilitating the patient/family empowerment, access to information, experience and necessary knowledge to facilitate their decision-making and self-care.

- Better chances for patients to receive an accurate diagnosis and advice on the best treatment and support for their specific condition. - Giving healthcare providers access to a much larger pool of expertise. - Facilitating the patients’ access to care, improving their health care outcomes and the sustainability of this complex procedure for national healthcare systems.

Return to EXECUTIVE SUMMARY INDEX

87

2 EXECUTIVE SUMMARY

Canada USA

Minnesota Pennsylvania Massachusetts

2.11 Internationalization

Los Angeles Texas

Taiwan Singapore

Mexico

Denmark The Netherlands

Colombia Ecuador

Sweden Finland

United Kingdom

Germany

Brasil

Ireland Belgium

Czech Republic

Lille France

France Argentina Chile

Serbia

Switzerland

Lebanon

Italy

88

Return to EXECUTIVE SUMMARY INDEX

89

3

INFORMATION GROUPS BY AREA 3.1 Neuroscience Area 106 88 23

384.544 326.414 49

3.2 Cardiovascular Area 224 169 41

1,372.682 1,118.856 98

3.3 Infectious Diseases and Immunity Area 212 154 38

956.421 641.204 86

3.4 Large System Pathologies Area 291 219 44

1,309.496 1,089.056 108

3.5 Cancer and Human Molecular Genetics Area 120 102 20

581.068 522.905 58

3.6 Surgery, Transplant and Health Technologies Area 174 141 11 90

351.686 281.096 35 Return to INDEX

91

3 INFORMATION GROUPS BY AREA

PSYCHIATRY AND MENTAL HEALTH GROUP

3.1 Neuroscience Area Exuperio Díez Tejedor

106 88 23

384. 326.414 49 544

Psychiatry and Mental Health Group Neurology and Cerebrovascular Diseases Group Neuroprotective Strategies in Neurodegenerative Diseases Group Structure, Neurochemistry and Plasticity of Neural Circuits of the Cerebral Cortex and Thalamus Group Involvement of Glycinergic and Glutamatergic Systems in Central Nervous System Pathologies Group

92

Return to INFORMATION GROUPS BY AREA INDEX

9 16.947 2 Consuelo de Dios Perrino Facultativo Especialista de Área en Psiquiatría. HULP Blanca Amador Sastre Facultativo Especialista de Área en Psicología Clínica. HULP Elena Barbero Val Licenciada. HULP Carmen Bayón Pérez Facultativo Especialista de Área en Psiquiatría. HULP Profesora Asociada. Facultad de Medicina. UAM María Fe Bravo Ortiz Jefe de Servicio de Psiquiatría. HULP Profesora Asociada. Facultad de Medicina.UAM Rosa Calvo Sagardoy Psicóloga Clínica. Servicio de Psiquiatría. HULP Susana Cebolla Lorenzo Facultativo Especialista de Área en Psiquiatría. HULP María Teresa González Salvador Facultativo Especialista de Área en Psiquiatría. HULP Nieves González Suárez Facultativo Especialista de Área en Psiquiatría. HULP Ana Hospital Moreno Facultativo Especialista de Área en Psicología Clínica. HULP Eduardo Jiménez Sola Facultativo Especialista de Área en Psiquiatría. HULP Ángela Palao Tarrero Facultativo Especialista de Área en Psiquiatría. HULP Pau Pérez Sales Facultativo Especialista de Área en Psiquiatría. HULP Beatriz Rodríguez Vega Facultativo Especialista de Área en Psiquiatría. HULP Profesora Asociada. Facultad de Medicina. UAM Rosa Villanueva Peña Facultativo Especialista de Área en Psiquiatría. HULP

Strategic Objective The group is devoted to assess the efficacy of psychotherapeutic techniques as adjunctive to other therapeutic measures in mental disorders and other medical diseases. Their main areas of investigation are: research in bipolar disorder, severe mental disorder, and other medical disorders such as multiple sclerosis, cancer and chronic pain. We participate in clinical trials on new treatments and specific therapies in order to improve and the prognosis of these disorders We are specially focused in the assessment of the efficacy and effectiveness of techniques such as Mindfulness and we evaluate hypothetical mediators of response, such as neurotrophic factors or factors related to inflammatory response. Moreover, the group is involved in the evaluation of new treatments or new indications in mental disorders through the participation in clinical trials.

Research Lines Psychotherapeutic interventions in mental disorders.

Research Activity DOCTORAL THESES Moreno Pérez A. Teoría y práctica de la supervisión. Análisis del discurso de supervisores y psicoterapeutas [dissertation]. Madrid: UAH: 2016 (14/04/2016). Directors: Rodríguez Vega B, Fernández Liria A.

Continue

93

3 INFORMATION GROUPS BY AREA

3.1 Neuroscience Area

BOOKS AND BOOK CHAPTERS Roca M, García E, Bernardo M, Pérez V, Vieta E, de Dios C, Serrano M. Criterios de calidad en psiquiatría. Esquizofrenia. Depresión.Trastorno Bipolar. Madrid: Luzan 5, 2016. Pérez Sales P. Tortura psicológica: definición, evaluación y medida. Madrid: Desclee de Brower, 2016.

PUBLICATIONS • Bayón-Pérez C, Hernando A, Álvarez-Comino MJ, Cebolla S, Serrano L, Gutiérrez F, Montesinos F, Lagarde M, Bisbal O, Matarranz M, Rubio R, Pulido F. Toward a comprehensive care of HIV patients: Finding a strategy to detect depression in a Spanish HIV cohort. AIDS Care. 2016; 28(7):834-.41. Article. IF: 1.824; Q2. • Muñoz San José A, Oreja-Guevara C, Cebolla Lorenzo C, Carrillo Notario L, Rodríguez Vega B, Bayón Pérez C. Psychotherapeutic and psychosocial interventions for managing stress in multiple sclerosis: the contribution of mindfulness-based interventions. Neurología. 2016; 31(2):113-20. Review. IF: 2.103; Q3 • Lubrini G, Lago MR, Periánez JA, Barranco AT, de Dios C, Fernández-Fourier M, Tejedor ED, García AF. The contribution of depressive symptoms to slowness of information processing in relapsing remitting multiple sclerosis. Mult Scler. 2016; 22(12):1607-15. Article. IF: 4.84; Q1 • Medel-Herrero A, Gómez-Beneyto M, Saz-Parkinson Z, BravoOrtiz MF, Amate JM. Discordance between two national health statistics sources (EMH and EESCRI 1990-2009). Analysis of psychiatric morbidity. Rev Psiquiatr Salud Ment. 2016; 9(1):22-30. Article. IF: 2.227; Q3 • Navarro-Lashaya MA, Pérez-Sales P, López Neyr G, Martínez Maitane A, Morentín B. Incommunicado detention and torture in Spain part IV: Psychological and psychiatric consequences of ill-treatment and torture: trauma and human worldviews. Torture. 2016; 26(3):34-45. Article. Not Indexed • Pacchiarotti I, León-Caballero J, Murru A, Verdolini N, Furio MA, Pancheri C, Valentí M, Samalin L, Roige ES, González-Pinto A, Montes J, Benabarre A, Crespo JM, Perrino CD, Goikolea JM, Gutiérrez-Rojas L, Carvalho AF,Vieta E. Mood stabilizers and antipsychotics during breastfeeding: Focus on bipolar disorder. Eur Neuropsychopharm. 2016; 26(10):1562-78. Review. IF: 4.239; Q1 • Pérez-Sales P, Morentín B, Barrenetxea O, Navarro-Lashayas MA. Incommunicado detention and torture in Spain part II: Enhanced credibility assessment based on the Istanbul Protocol. Torture. 2016; 26(3):8-20. Article. Not Indexed • Pérez-Sales P, Navarro-Lashayas MA, Plaza A, Morentín B, Barrios Salinas O. Incommunicado detention and torture in Spain Part III: ‘Five days is enough’: the concept of torturing environments. Torture. 2016; 26(3):21-33. Article. Not Indexed • Polo R, Blanch J, Locutura J, Arazo P, Bachiller P, Bayón C, Estrada V, Fernández JL, Fumaz C, Galindo MJ,Tome MG, Iribarren JA, Lozano F, Marino A, Mellado MJ, Muñoz-Moreno JA, Navarro ML, Navines R, Prieto JFP, Rojo A, Rousaud A, Hernández JS, Santos J, Tuset M. Executive summary of the consensus document on psychiatric and psychological aspects in adults and children with HIV infection. Enferm Infec Micr Cl. 2016; 34(1):54-60. Article. IF: 1.714; Q3

94

Bravo Ortiz MF, Rodríguez Vega B. Desarrollo de habilidades y actitudes para el establecimiento de la relación médico paciente a través de un programa online de entrenamiento en mindfulness. UAM. 2016-2017. Management centre: UAM de Dios Perrino C. Terapia congnitiva basada en mindfulness frente a intervencion psicoeducativa en pacientes con trastorno bipolar con síntomas subsindrómicos depresivos: ensayo piloto randomizado (PI13/00352). ISCIII. 2014-2017. Management centre: FIBHULP

NEUROLOGY AND CEREBROVASCULAR DISEASES GROUP

PRIVATE PROJECTS Alcobendas Rueda RM. Registro de enfermedades autoinflamatorias en la Comunidad de Madrid. Swedish Orphan Biovitrum S.L. 2014-Ongoing. Management centre: FIBHULP Bayón Pérez C. Curso de investigación mindfulness en la práctica clínica. Astrazeneca Farmacéutica Spain S.A. 2012-Ongoing. Management centre: FIBHULP Bravo Ortiz MF. Jornadas de investigación en el ámbito de intervenciones grupales en salud mental. Astrazeneca Farmacéutica Spain S.A. 2011-Ongoing. Management centre: FIBHULP Bravo Ortiz MF. Programa de ayuda a la formación en investigación en centros de investigación. Fundacion Alicia Koplowitz. 2015-Ongoing. Management centre: FIBHULP Bravo Ortiz MF. XIV Jornadas de investigación en psiquiatría y salud mental: cognición, emoción y salud mental. Janssen-Cilag España S.A. 2014-Ongoing. Management centre: FIBHULP Bravo Ortiz MF. XVII Jornadas de investigación. Construyendo puentes entre la salud mental infarto-juvenil y de adultos. Janssen-Cilag España S.A. 2016-Ongoing. Management centre: FIBHULP Calvo Sagardoy R. Cambios biomagnéticos y cognitivoemocionales en el tratamiento de las alteraciones de la imagen corporal en pacientes con transtornos en la conducta alimentaria. Colegio Oficial de Psicólogos de Madrid. 2005-Ongoing. Management centre: FIBHULP de Dios Perrino C. Regulación epigenética del sistema oxitocina-vasopresina y prosociabilidad en la mania bipolar. FIBHULP. 2015-Ongoing. Management centre: FIBHULP

PUBLIC PROJECTS

Rodríguez Vega B. Comparación de dos estrategias de intervención para el tratamiento de los trastornos depresivos en pacientes oncológicos. Asociación Escuela Española de Psicoterapia. 2007-Ongoing. Management centre: FIBHULP

Bravo Ortiz MF, Arango López C. AGES: Ambiente y genes en esquizofrenia-grupos de investigación de la Comunidad de Madrid (AGES-S2010/BMD-2422). Consejería de Educación de la CAM. 2016-2017. Management centre: FIBHGM

Rodríguez Vega B. Evaluación cualitativa de dos estrategias de tratamiento para la depresión en un muestra de pacientes oncológicos. Asociación Escuela Española de Psicoterapia. 2007-Ongoing. Management centre: FIBHULP

Return to NEUROSCIENCE AREA INDEX

57 176.956 19 Exuperio Díez Tejedor Jefe de Servicio de Neurología. HULP Catedrático del Departamento de Neurología. Facultad de Medicina. UAM María José Aguilar-Amat Prior Facultativo Especialista de Área en Neurología. HULP María Alonso de Leciñana Cases Facultativo Especialista de Área en Neurología. HULP Joaquín Arcas Martínez Facultativo Especialista de Área en Neurología Pediátrica. HULP Juan José Arévalo Manso Enfermero. HULP Francisco Javier Arpa Gutiérrez Profesor Honorario. Facultad de Medicina. UAM María Jesús Bullido Gómez-Heras Profesor Titular. Departamento de Biología Molecular. Facultad de Ciencias. CBM “Severo Ochoa” Fernando Carceller Benito Jefe de Sección en Servicio de Neurocirugía. HULP Sebastián Cerdán García-Esteller Investigador Postdoctoral. Laboratorio de Imagen y Espectroscopia por Resonancia Magnética. IIB “Alberto Sols” Delia Chaverri Rada Facultativo Especialista de Área en Neurología. HULP Jorge Eduardo Collazos Castro Jefe de Laboratorio de Reparación Neural y Biomateriales. Hospital Nacional de Parapléjicos de Toledo Josué Fernández Carnero Profesor e Investigador Postdoctoral. Centro Superior de Estudios Universitaríos La Salle Andrés Francisco Fernández Prieto Facultativo Especialista de Área en Radiología. HULP Mireya Fernández-Fournier Fernández Facultativo Especialista de Área en Neurología. HULP

Ana Frank García Jefe de Sección en Servicio de Neurología. HULP Profesora Titular de Neurología. Facultad de Medicina. UAM Remedios Frutos Martínez Facultativo Especialista de Área en Radiología. HULP Blanca Fuentes Gimeno Jefe de Sección en Servicio de Neurología. HULP Profesor Asociado. UAM Alfonso Gil Martínez Fisioterapeuta. HULP David Gómez Andrés Investigador Predoctoral. Departamento de Anatomía, Histología y Neurociencia. UAM Ana Cristina Guadaño Ferraz Científico Titular. Departamento de Fisiopatología Endocrina y del Sistema Nervioso. IIB “Alberto Sols” María Dolores Gutiérrez Fernández Investigadora Postdoctoral. Laboratorio de Neurociencias y Enfermedades Cerebrovasculares. HULP María Hernández Barral Facultativo Especialista de Área en Neurología. HULP Rafael Herruzo Cabrera Jefe de Sección de Medicina Preventiva y Salud Pública. HULP Catedrático Facultad de Medicina. UAM Vicente Iváñez Mora Facultativo Especialista de Área en Neurología. HULP Roy La Touche Arbizu Profesor Titular. Centro Superior de Estudios Universitaríos La Salle Manuel Lara Lara Facultativo Especialista de Área en Neurología. HULP Jesús María López Arrieta Jefe de Sección de Geriatría. Hospital de Cantoblanco – HULP Profesor Asociado de Prácticas. Facultad de Psicología. UAM María Pilar López Larrubia Científica Titular. CSIC. IBB “Alberto Sols”

Continue

95

3.1 Neuroscience Area

3 INFORMATION GROUPS BY AREA

96

Ibai López de Uralde Villanueva Investigador Predoctoral. Centro Superior de Estudios Universitarios La Salle Genny Lubrini Investigadora Postdoctoral. Servicio de Neurología. HULP Begoña Marín Aguilera Facultativo Especialista de Área en Radiología. HULP Juan Andrés Martín Gonzalo Profesor Titular. Escuela Universitaria de Fisioterapia de la ONCE Ángel Martín Montes Facultativo Especialista de Área en Neurología. HULP Antonio Martínez Bermejo Jefe de Servicio de Neurología Pediátrica. HULP Profesor Asociado. Facultad de Medicina. UAM Mercedes Martínez Moreno Jefe de Sección en Servicio de Medicina Física y Rehabilitación. HULP Patricia Martínez Sánchez Facultativo Especialista de Área en Neurología. HULP Susana Moraleda Pérez Jefe de Sección de Medicina Física y Rehabilitación. HULP Pilar Negredo Madrigal Profesor Interino. Departamento de Anatomía, Histología y Neurociencia. UAM Susana Noval Martín Facultativo Especialista de Área en Oftalmología. HULP Jesús Oliván Palacios Facultativo Especialista de Área en Neurofisiología Clínica. HULP Laura Otero Ortega Investigadora Postdoctoral (Contrato Sara Borrell). HULP Joaquín Pardo Montero Profesor Titular. Centro Superior de Estudios Universitarios La Salle Alba París Alemany Profesora. Investigadora Predoctoral. Centro Superior de Estudios Universitarios La Salle Samuel Ignacio Pascual Pascual Jefe de Sección de Neurología Pediátrica. HULP Profesor Asociado. Facultad de Medicina. UAM José Francisco Paz Solís Facultativo Especialista de Área en Neurocirugía. HULP Inmaculada Puertas Muñoz Facultativo Especialista de Área en Neurología. HULP Irene Pulido Valdeolivas Investigadora Predoctoral. Departamento de Anatomía, Histiología y Neurociencia. HULP Estrella Rausell Tamayo Catedrática. Departamento de Anatomía, Histología y Neurociencias. Facultad de Medicina. UAM José María Roda Frade Jefe de Servicio de Neurocirugía. HULP Irene Rodríguez Andonaegui Profesor Ayudante. Escuela Universitaria de Fisioterapia de la ONCE Berta Rodríguez Frutos Investigadora Postdoctoral. Laboratorio de Neurociencias y Enfermedades Cerebrovasculares. HULP Francisco Javier Rodríguez de Rivera Garrido Facultativo Especialista de Área en Neurología. HULP Aranzazu Royo Orejas Jefe de Sección de Radiología. HULP Gerardo Ruiz Ares Facultativo Especialista de Área en Neurología. HULP

María Teresa Salas Campos Técnico Titulado Superior. Servicio de Neurología. HULP Patricia Sánchez García Técnico de Laboratorio. HULP Susana Santiago Pérez Facultativo Especialista de Área en Neurofisiología. HULP Borja Enrique Sanz Cuesta Facultativo Especialista de Área en Neurología (Contrato Río Hortega). HULP Antonio Tallón Barranco Facultativo Especialista de Área en Neurología. HULP Gema Torrijos Barbero Especialista en Neuropsicología. Unidad de Memoria y Demencias. Hospital de Cantoblanco-HULP Arturo Ugalde Canitrot Facultativo Especialista de Área en Neurofisiología Clínica. HULP Francisco Vivancos Matellano Facultativo Especialista de Área en Neurología. HULP

Strategic Objective The research of this group is distributed in the following areas:

CEREBROVASCULAR • Development of translational research studies (both animal and clinical studies) in cerebrovascular diseases, with the objectives of increasing the understanding of the pathogenesis of both cerebral infarction (with cortical and subcortical affectation) and cerebral hemorrhage. To identify prognostic biomarkers and therapeutic targets mainly aimed at the promotion of brain protection and repair, with a special interest on the development of cell therapy as well as in trophic factors, extracellular vesicles and remyelinizating drugs. Clinical trials of cell therapy in acute cerebral infarction (clinical trial AMASCIS and European Consortium RESSTORE-H2020). • Development of innovative strategies in the diagnosis and treatment of ischemic stroke, through the development of an independent operator-ultrasound device for brain visualization and for enhancement by ultrasound of drug therapies (BDNF, exosomes) in the ischemic area. • Evaluation of the benefit of the implementation of prehospital clinical scales able to identify of patients of cerebral artery occlusion susceptible to mechanical thrombectomy in order to shorten treatment delay and improve the prognosis of patients. Comparative analysis of benefit and risk of primary mechanical thrombectomy versus intravenous thrombolysis in patients with acute ischemic stroke within the first 4.5 hours from onset. • Study of the clinical (neurological and neuropsychological) and anthropological factors influencing functional recovery and reintegration of stroke patients as well as the compliance with the recommendations for secondary stroke prevention.

HEADACHES AND NEUROPATHIC PAIN • Analysis of the expression of the phenomenon central painful awareness in different primary and secondary headaches.

NEURODEGENERATION Amyotrophic Lateral Sclerosis • ECAS scale (Edinburgh Cognitive Assessment Scale) validation and adaptation to Spanish language. Analysis of the different profiles of cognitive impairment in ALS patients by means of the ECAS scale (Edimburgh Cognitive Assesment Scale). • SOPHIA Project: European Project on harmonization and optimization of the production and processing of samples for the study of biomarkers in ALS and other motor neuron diseases. • Functional study of Autonomic Nervous System in Amyotrophic Lateral Sclerosis. Identification of differential patterns of the disease presentation and their impact on clinical outcome. Alzheimer´s disease • Study of the lysosomal pathway involvement in a model of neurodegeneration and cholesterol dysregulation in Alzheimer’s disease. Parkinson´s disease • Tremor as a negative predictive factor in developing dementia associated with Parkinson’s disease. • Evaluation of the benefits and risks of continuous infusion of intraduodenal levodopa in idiopathic Parkinson’s disease. Hereditary ataxias • Assessment of therapeutic response to Frenkel training exercises enhanced by Wii game console in patients with cerebellar ataxia. • Participation in the Registry of the European Consortium EFACTS (European Friedreich’s Ataxia Consortium for Translational Studies) aimed at improve the knowledge of the epigenetic mechanisms related to silencing the expression of frataxin and the pathogenesis of the disease, identification of biomarkers and genes modifying the clinical expression of the disease, development of new therapies as well as cellular and animal models for the study of Friedrich’s Ataxia.

COGNITION, BEHAVIOR AND NEUROLOGICAL ANTHROPOLOGY • Analysis of the medium and long term results of workshops on post-stroke care attended by family and patients during the hospitalization time for an acute stroke on the degree of knowledge and acknowledge of stroke and its risk factors. • Evaluation of the perceived quality of physicianpatient-family communication in cerebrovascular diseases and dementias.

NEUROIMMUNOLOGY Multiple sclerosis • Study of remyelinizators substances as a biomarker white matter lesion in multiple sclerosis patients. • Analysis of white matter biomarkers in Theiler’s Mourine Encephalomyelitis Virus (TMEV) animal model. Development of new reparative therapies based on the enhancement of remyelinization in experimental animal model. • Analysis of molecular and neuroimaging biomarkers of brain damage and repair in Multiple Sclerosis.

AUTONOMIC NERVOUS SYSTEM • Evaluation of the Autonomic Nervous System in movement disorders. • Evaluation of the Autonomic Nervous System in focal autonomic neuropathies and in Fabry disease. • COMPASS-31 Study (collaboration with the Mayo Clinic): Registry of patients and controls with central and peripheral dysautonomia.

NEUROMUSCULAR DISEASES • Observational study of the clinical course of patients with Charcot-Marie-Tooth disease. Identification of prognostic factors. • Efficacy of evaluation of Eslicarbazepine acetate in neuropathic pain in patients with peripheral neuropathies.

SLEEP • Development and evaluation of intervention protocols in childhood insomnia treatment. • Analysis of sleep microstructure in newborns with Prader Willi Syndrome. • Study on the efficacy of child insomnia treatment with oral iron supplements against placebo.

EPILEPSY • Evaluation of the benefit of the implementation of an outpatient clinic for first seizures. • Analysis of factors influencing the recurrence of seizures, tolerance and adherences to drugs, during the first monotherapy in patients with epilepsia. • Analysis of neuropsychological disorders in the primary generalized epilepsy. • Evaluation of cognitive impact of antiepileptic treatment after the first seizure and at the start of the first monotherapy as well as in elderly patients with focal epilepsy. • Influence of stress as a trigger of seizures in epilepsy. • Depression and anxiety: impact on the therapeutic compliance of patients with epilepsy. • Registry of patients treated with i.v. antiepileptic drugs. Analysis of indications, response and adverse events.

BRAIN DEVELOPMENT DISORDERS • Study and functional classification of the gait of pediatric patients with cerebral palsy. • Study and functional classification of the gait of patients with familial spastic paraparesis. • Gait analysis as a tool for the differential diagnosis between child cerebral palsy and PEF in paediatric patients.

Continue

97

3 INFORMATION GROUPS BY AREA

3.1 Neuroscience Area

Research Lines • Cerebrovascular diseases. • Neurodegenerative diseases. • Neuroimmunology. Multiple Sclerosis. • Neuromuscular diseases and spinocerebellar ataxias. Motor neuron diseases Amyotrophic lateral sclerosis. • Headache and neuropathic pain. • Developmental disorders and neurological maturation (TRADESMA).

Research Activity BOOKS AND BOOK CHAPTERS Fuentes B, Martínez-Sánchez P, Ruiz-Ares G. Ictus por enfermedad carotídea. ¿De qué manera debo enfrentar esta situación? In: Agustín Godoy D. El libro de los interrogantes acerca del ACV. Colombia: Distribuna, 2016. Fernández-Fournier Fernández M, Reverté Villarosa S. Traumatismo craneoencefálico. In: Lendínez Mesa A (Ed.). Enfermería en nerorehabilitación. Madrid: Elsevier, 2016. p.60-65 Fernández-Fournier Fernández M. Treating spasticity ameliorates quality of life and social functioning. In: 55 Relevant clinical cases of spasticity management in MS with THC:CBD oromucosal spray. vol.VII. Mayence: Editec, 2016. p.14-16 Palau F, Arpa J. Differential diagnosis of cerebellar ataxias. In: Gruol DL, Koibuchi N, Manto M, Molinari M, Schmahmann JD, Shen Y, (Eds.). Essemtials of cerebellum and cerebellar disorders: a primer for graduate students. Switzerland: Springer International Publishing AG, 2016. p.523-529 Rodríguez de Rivera FJ. Patobiografía de Lou Gehrig. Esclerosis lateral amiotrófica. Madrid:You & Us S.A., 2016.

PUBLICATIONS • Alcalde-Cabero E, Almazán-Isla J, López FJG, Callizo JRA, Avellanal F, Casasnovas C, Cemillán C, Cuadrado JI, Duarte J, Fernández-Pérez MD, Fernández O, Merino JAG, Montero RG, Montero D, Pardo J, Rodríguez-Rivera FJ, Ruiz-Tovar M, de Pedro-Cuesta J. Guillain-Barre syndrome following the 2009 pandemic monovalent and seasonal trivalent influenza vaccination campaigns in Spain from 2009 to 2011: outcomes from active surveillance by a neurologist network, and records from a country-wide hospital discharge database. BMC Neurol. 2016;16:75. Article. IF: 2.006; Q3 • Anguita-Palacios MC,Talayero-San-Miguel M, Herrero-Cereceda S, Martín-Cadenas M, Pardo-Cuevas P, Gil-Martínez A. Fear and preoperative anxiety behaviour and pain intensity perceived after knee arthroscopy. Enferm Clin. 2016;26(4):227-33. Article. Not Indexed • Arévalo-Manso JJ, Martínez-Sánchez P, Fuentes B, Ruiz-Ares G, Sanz-Cuesta BE, Prefasi D, Juárez-Martín B, Navarro-Parias A, Parrilla-Novo P, Díez-Tejedor E. Can we improve the early detection of atrial fibrillation in a stroke unit? Detection rate of a monitor with integrated detection software. Eur J Cardiovasc Nur. 2016;15(1):64-71. Article. IF: 2.763; D1

98

• Buendía I, Parada E, Navarro E, León R, Negredo P, Egea J, López MG. Subthreshold concentrations of melatonin and galantamine improves pathological AD-Hallmarks in hippocampal organotypic cultures. Mol Neurobiol. 2016;53(5):3338-48. Article. IF: 6.19; D1 • Cea LA, Puebla C, Cisterna BA, Escamilla R, Vargas AA, Frank M, Martínez-Montero P, Prior C, Molano J, Esteban-Rodríguez I, Pascual I, Gallano P, Lorenzo G, Pian H, Barrio LC, Willecke K, Saez JC. Fast skeletal myofibers of mdx mouse, model of Duchenne muscular dystrophy, express connexin hemichannels that lead to apoptosis. Cell Mol Life Sci. 2016;73(13):2583-99. Article. IF: 5.788; Q1 • de Lecinana MA, Egido JA, Casado I, Ribo M, Dávalos A, Masjuan J, Caniego JL, Martínez-Vila E, Tejedor ED. Reply to letter “Remarks on cerebral infarct from anotherpoint of view”. Neurología. 2016;31(2):136. Letter. IF: 2.103; Q3 • de Lecinana MA, Fuentes B, Ximénez-Carrillo A, Vivancos J, Masjuan J, Gil-Núñez A, Martínez-Sánchez P, Zapata-Wainberg G, Cruz-Culebras A, García-Pastor A, Díaz-Otero F, Fandino E, Frutos R, Caniego JL, Méndez JC, Fernández-Prieto A, BarcenaRuiz E, Díez-Tejedor E. A collaborative system for endovascular treatment of acute ischaemic stroke: the Madrid Stroke Network experience. Eur J Neurol. 2016;23(2):297-303. Article. IF: 3.988; Q1 • de Munain LL, Juan-García FJ, Duarte E, Martín-Mourelle R, Rodríguez S, Moraleda-Pérez S. Early pharmacologic treatment with botulinum toxin A in post-stroke spasticity: consensus evidence-based recommendations. Rev Neurología. 2016;63(8):363-9. Review. IF: 0.743; Q4 • de-la-Puente-Ranea L, García-Calvo B, La Touche R, FernándezCarnero J, Gil-Martínez A. Influence of the actions observed on cervical motion in patients with chronic neck pain: a pilot study. J Exerc Rehabil. 2016;12(4):346-54. Article. Not Indexed • Elizagaray-García I, Muriente-González J, Gil-Martínez A. Education for patients with fibromyalgia. A systematic review of randomised clinical trials. Rev Neurología. 2016;62(2):49-60. Article. IF: 0.743; Q4 • Fernández-Alonso L, Muñoz-García D, La Touche R. The level of physical activity affects the health of older adults despite being active. J Exerc Rehabil. 2016;12(3):164-201. Article. Not Indexed • Fernández-Montoya J, Buendía I, Martín YB, Egea J, Negredo P, Avendaño C. Sensory input-dependent changes in glutamatergic neuro transmission-related genes and proteins in the adult rat trigeminal ganglion. Front Mol Neurosci. 2016;9:132. Article. IF: 5.076; Q1 • Ferrer-Peña R, Gil-Martínez A, Pardo-Montero J, Jiménez-Penick V, Gallego-Izquierdo T, La Touche R. Adaptation and validation of the Spanish version of the graded chronic pain scale. Reumatol Clin. 2016;12(3):130-8. Article. Not Indexed • Fiz-Pérez L,Velázquez-Fragua R, García-Guixot S, García-Romero M, Martínez-Bermejo A. Dissection of vertebral arteries as the cause of acute cerebrovascular event in children. Rev Neurología. 2016;62(8):382-3. Letter. IF: 0.743; Q4 • Freitas AE, Egea J, Buendía I, Gómez-Rangel V, Parada E, Navarro E, Casas AI, Wojnicz A, Ortiz JA, Cuadrado A, Ruiz-Nuno A, Rodrigues ALS, López MG. Agmatine, by improving neuroplasticity markers and inducing Nrf2, prevents corticosterone-induced depressive-like behavior in mice. Mol Neurobiol. 2016;53(5):3030-45. Article. IF: 6.19; D1 • Gil-Martínez A, Grande-Alonso M, La Touche R, Lara-Lara M, López-López A, Fernández-Carnero J. Psychosocial and soma-

tosensory factors in women with chronic migraine and painful temporomandibular disorders. Pain Res Manag. 2016; 3945673. Article. IF: 2.027; Q3 • Gil-Martínez A, Grande-Alonso M, López-de-Uralde-Villanueva I, López-López A, Fernández-Carnero J, La Touche R. Chronic temporomandibular disorders: disability, pain intensity and fear of movement. J Headache Pain. 2016;17:103. Article. IF: 2.141; Q1 • González-Suárez I, Arpa J, Ríos-Blanco JJ. Brain microvasculature involvement in ANCA positive vasculitis. Cerebrovasc Dis. 2016;41(42891):313-21. Article. IF: 2.974; Q2 • Illán-Gala I, Martínez-Sánchez P, Fuentes B, Llamas-Osorio Y, de Terán JD, Báez M, Ruiz-Ares G, Sanz-Cuesta BE, Lara-Lara M, Díez-Tejedor E. Effect of anticoagulation on cardioembolic stroke severity, outcomes and response to intravenous thrombolysis. J Thromb Thrombolys. 2016;42(1):99-106. Article. IF: 2.142; Q3 • Itzhaki RF, Lathe R, Balin BJ, Ball MJ, Bearer EL, Braak H, Bullido MJ, Carter C, Clerici M, Cosby SL, del Tredici K, Field H, Fulop T, Grassi C, Griffin WST, Haas J, Hudson AP, Kamer AR, Kell DB, Licastro F, Letenneur L, Lovheim H, Mancuso R, Miklossy J, Otth C, Palamara AT, Perry G, Preston C, Pretorius E, Strandberg T, Tabet N, Taylor-Robinson SD, Whittum-Hudson JA. Microbes and Alzheimer’s Disease. J Alzheimers Dis. 2016;51(4):979-84. Editorial Material. IF: 3.731; Q2 • Jun G, Ibrahim-Verbaas CA, Vronskaya M, Lambert JC, Chung J, Naj A, Kunkle BW, Wang LS, Bis JC, Bellénguez C, Harold D, Lunetta KL, Destefano AL, Grenier-Boley B, Sims R, Beecham GW, Smith AV, Chouraki V, Hamilton-Nelson KL, Ikram MA, Fievet N, Denning N, Martin ER, Schmidt H, Kamatani Y, Dunstan ML, Valladares O, Laza AR, Zelenika D, Ramírez A, Foroud TM, Choi SH, Boland A, Becker T, Kukull WA, van der Lee SJ, Pasquier F, Cruchaga C, Beekly D, Fitzpatrick AL, Hanon O, Gill M, Barber R, Gudnason V, Campion D, Love S, Bennett DA, Amin N, Berr C, Tsolaki M, Buxbaum JD, López OL, Deramecourt V, Fox NC, Cantwell LB, Tarraga L, Dufouil C, Hardy J, Crane PK, Eiriksdottir G, Hannequin D, Clarke R, Evans D, Mosley TH, Letenneur L, Brayne C, Maier W, De Jager P, Emilsson V, Dartigues JF, Hampel H, Kamboh MI, de Bruijn RFAG, Tzourio C, Pastor P, Larson EB, Rotter JI, O’Donovan MC, Montine TJ, Nalls MA, Mead S, Reiman EM, Jonsson PV, Holmes C, St George-Hyslop PH, Boada M, Passmore P, Wendland JR, Schmidt R, Morgan K, Winslow AR, Powell JF, Carasquillo M, Younkin SG, Jakobsdottir J, Kauwe JSK, Wilhelmsen KC, Rujescu D, Nothen MM, Hofman A, Jones L, Haines JL, Psaty BM, Van Broeckhoven C, Holmans P, Launer LJ, Mayeux R, Lathrop M, Goate AM, Escott-Price V, Seshadri S, Pericak-Vance MA, Amouyel P, Williams J, van Duijn CM, Schellenberg GD, Farrer LA, (Bullido MJ). A novel Alzheimer disease locus located near the gene encoding tau protein. Mol Psychiatr. 2016;21(1):108-17. Article. IF: 13.204; D1 • Kawiorski MM, Martínez-Sánchez P, García-Pastor A, Calleja P, Fuentes B, Sanz-Cuesta BE, Lourido D, Marín B, Díaz-Otero F, Vicente A, Sierra-Hidalgo F, Ruiz-Ares G, Díez-Tejedor E, Fandino E, de Lecinana MA. Alberta Stroke Program Early CT Score applied to CT angiography source images is a strong predictor of futile recanalization in acute ischemic stroke. Neuroradiology. 2016;58(5):487-93. Article. IF: 2.093; Q2 • Kawiorski MM, Vicente A, Lourido D, Muriel A, Fandino E, Méndez JC, Sánchez-Gonzalez V, Aguado A, Álvarez-Velasco R, de Lecinana MA. Good clinical and radiological correlation from standard perfusion computed tomography accurately identifies salvageable tissue in ischemic stroke. J Stroke Cerebrovasc. 2016;25(5):1062-9. Article. IF: 1.517; Q4

• León-Hernández JV, Martín-Pintado-Zugasti A, Frutos LG, Alguacil-Diego IM, de la Llave-Rincón AI, Fernández-Carnero J. Immediate and short-term effects of the combination of dry needling and percutaneous TENS on post-needling soreness in patients with chronic myofascial neck pain. Braz J Phys Ther. 2016;20(5):422-31. Article. IF: 1.226; Q3 • López-de-Uralde-Villanueva I, Beltrán-Alacreu H, FernándezCarnero J, Gil-Martínez A, La Touche R. Differences in neural mechanosensitivity between patients with chronic nonspecific neck pain with and without neuropathic features. A descriptive cross-sectional study. Pain Med. 2016;17(1):136-48. Article. IF: 2.82; Q1 • López-de-Uralde-Villanueva I, Beltrán-Alacreu H, FernándezCarnero J, Kindelan-Calvo P, La Touche R. Widespread pressure pain hyperalgesia in chronic nonspecific neck pain with neuropathic features: A descriptive cross-sectional study. Pain Physician. 2016;19(2):77-87. Article. IF: 2.84; Q2 • López-de-Uralde-Villanueva I, Muñoz-García D, Gil-Martínez A, Pardo-Montero J, Muñoz-Plata R, Angulo-Díaz-Parreno S, Gómez-Martínez M, La Touche R. A systematic review and meta-analysis on the effectiveness of graded activity and graded exposure for chronic nonspecific low back pain. Pain Med. 2016;17(1):172-88. Review. IF: 2.82; Q1 • Lubrini G, Lago MR, Periánez JA, Barranco AT, de Dios C, Fernández-Fourier M, Tejedor ED, García AF. The contribution of depressive symptoms to slowness of information processing in relapsing remitting multiple sclerosis. Mult Scler. 2016;22(12):1607-15. Article. IF: 4.84; Q1 • Lupo V, García-García F, Sancho P, Tello C, García-Romero M, Villarreal L, Alberti A, Sivera R, Dopazo J, Pascual-Pascual SI, Márquez-Infante C, Casasnovas C, Sevilla T, Espinos C. Assessment of targeted next-generation sequencing as a tool for the diagnosis of Charcot-Marie-Tooth disease and hereditary motor neuropathy. J Mol Diagn. 2016;18(2):225-34. Article. IF: 4.526; Q1 • Martí-Fabregas J, Prats-Sánchez L, Martínez-Domeno A, CampsRenom P, Marín R, Jiménez-Xarrie E, Fuentes B, Dorado L, Purroy F, Arias-Rivas S, Delgado-Mederos R. The H-ATOMIC criteria for the etiologic classification of patients with intracerebral Hemorrhage. Plos One. 2016;11(6):e0156992. Article. IF: 2.806; Q1 • Martín-Pintado-Zugasti A, Rodríguez-Fernández AL, FernándezCarnero J. Postneedling soreness after deep dry needling of a latent myofascial trigger point in the upper trapezius muscle: Characteristics, sex differences and associated factors. J Back Musculoskelet. 2016;29(2):301-8. Article. IF: 0.912; Q3 • Masjuan J, Álvarez-Sabín J, Arias-Rivas S, Blanco M, de Felipe A, Escudero-Martínez I, Fuentes B, Gallego-Cullere J, MonicheÁlvarez F, Muñoz L, de la Ossa-Herrero NP, Sahuquillo P, Santamarina E, Sanz B, Tembl JI, Zandio B. Urgent stroke care in hospitals with a stroke unit. Quick Project. Rev Neurología. 2016;62(7):303-10. Article. IF: 0.743; Q4 • Mayor-Ibarguren A, Roldán-Puchalt MC, Sancho-Bueso T, PérezLópez C, Álvarez-Linera J, Frutos R, Álvarez-Escola C, RegojoZapata R, Beato-Merino MJ, Herranz-Pinto P, Lecumberri B. Kaposi sarcoma secondary to endogenous adrenocorticotropic hormone-dependent Cushing syndrome. Brit J Dermatol. 2016;174(6):1370-4. Article. IF: 4.706; D1 • Mínguez-Zuazo A, Grande-Alonso M, Saiz Moral B, La Touche R, Lara Lerma S. Therapeutic patient education and exercise therapy in patients with cervicogenic dizziness: a prospective case series clinical study. J Exerc Rehabil. 2016;12(3):216-25. Article. Not Indexed

Continue

99

3.1 Neuroscience Area

3 INFORMATION GROUPS BY AREA • Muñoz-García D, Gil-Martínez A, López-López A, López-deUralde-Villanueva I, La Touche R, Fernández-Carnero J. Chronic neck pain and cervico-craniofacial pain patients express similar levels of neck pain-related disability, pain catastrophizing, and cervical range of motion. Pain Res Treat. 2016; 7296032. Article. Not Indexed • Ntaios G, Vemmos K, Lip GYH, Koroboki E, Manios E, Vemmou A, Rodríguez-Campello A, Cuadrado-Godia E, Giralt-Steinhauer E, Arnao V, Caso V, Paciaroni M, Díez-Tejedor E, Fuentes B, Pérez Lucas J, Arauz A, Ameriso SF, Hawkes MA, Pertierra L, GómezSchneider M, Bandini F, Chavarria Cano B, Iglesias Mohedano AM, García Pastor A, Gil-Núñez A, Putaala J, Tatlisumak T, Barboza MA, Athanasakis G, Makaritsis K, Papavasileiou V. Risk stratification for recurrence and mortality in embolic stroke of undetermined source. Stroke. 2016;47(9):2278-85. Article. IF: 6.032; D1 • Pardo-Maza A, Lassaletta L, González-Otero T, Roda JM, Moraleda S, Arbizu A, Gavilán J. Evolution of patients with immediate complete facial paralysis secondary to acoustic neuroma surgery. Ann Oto Rhinol Laryn. 2016;125(6):495-500. Article. IF: 1.384; Q2 • Pascual-Pascual SI, Nascimento A, Fernández-Llamazares CM, Medrano-López C, Villalobos-Pinto E, Martínez-Moreno M, Ley M, Manrique-Rodríguez S, Blasco-Alonso J. Clinical guidelines for infantile-onset Pompe disease. Rev Neurología. 2016;63(6):26979. Article. IF: 0.743; Q4 • Pastor P, Moreno F, Clarimón J, Ruiz A, Combarros O, Calero M, de Munain AL, Bullido MJ, de Pancorbo MM, Carro E, Antonell A, Coto E, Ortega-Cubero S, Hernández I,Tarraga L, Boada M, Lleo A, Dols-Icardo O, Kulisevsky J, Vázquez-Higuera JL, Infante J, Rabano A, Fernández-Blázquez MA, Valenti M, Indakoetxea B, Barandiaran M, Gorostidi A, Frank-García A, Sastre I, Lorenzo E, Pastor MA, Elcoroaristizabal X, Lennarz M, Maier W, Ramírez A, Serrano-Ríos M, Lee SE, Sánchez-Juan P. MAPT H1 haplotype is associated with late-onset Alzheimer’s disease risk in APOE epsilon 4 Noncarriers: Results from the Dementia Genetics Spanish Consortium. J Alzheimers Dis. 2016;49(2):343-52. Article. IF: 3.731; Q2 • Patino P, Parada E, Farre-Alins V, Molz S, Cacabelos R, MarcoContelles J, López MG, Tasca CI, Ramos E, Romero A, Egea J. Melatonin protects against oxygen and glucose deprivation by decreasing extracellular glutamate and Nox-derived ROS in rat hippocampal slices. Neurotoxicology. 2016;57:61-8. Article. IF: 3.1; Q2 • Pérez-Villena A, Soto-Insuga V, Castano-de la Mota C, Martín-del Valle F, Pons-Rodríguez M, Losada-del Pozo R, Moreno-Acero N, Alarcón-Martínez H, Rodrigo-Moreno M, Miravet-Fuster E, Monfort-Belenguer L, Polo-Antúnez A, Martínez-Bermejo A, Merino-Andreu M. The importance of sleep problems in children with headache and other neurodevelopmental disorders in neuropaediatric services. Rev Neurología. 2016;62(2):61-7. Article. IF: 0.743; Q4 • Pesántez-Ríos G, Martínez-Bermejo A, Pesántez-Cuesta G. Neuropsychological alterations are frequent in rolandic epilepsy and its atypical developments. Rev Neurología. 2016;63(3):125-9. Review. IF: 0.743; Q4 • Prefasi D, Martínez-Sánchez P, Fuentes B, Díez-Tejedor E. Severity and outcomes according to stroke etiology in patients under 50 years of age with ischemic stroke. J Thromb Thrombolys. 2016;42(2):272-82. Article. IF: 2.142; Q3 • Prefasi D, Martínez-Sánchez P, Fuentes B, Díez-Tejedor E. The utility of the RoPE score in cryptogenic stroke patients <= 50 years in predicting a stroke-related patent foramen ovale. Int J Stroke. 2016;11(1):NP7-NP8. Letter. IF: 3.314; Q2

100

• Pulido-Valdeolivas I, Gómez-Andrés D, Sanz-Gallego I, Rausell E, Arpa J. Patterns of motor signs in spinocerebellar ataxia type 3 at the start of follow-up in a reference unit. Cerebellum Ataxias. 2016;3:4. Article. Not Indexed • Reetz K, Dogan I, Hilgers RD, Giunti P, Mariotti C, Durr A, Boesch S, Klopstock T, de Rivera FJR, Schols L, Klockgether T, Burk K, Rai M, Pandolfo M, Schulz JB. Progression characteristics of the European Friedreich’s Ataxia Consortium for Translational Studies (EFACTS): a 2 year cohort study. Lancet Neurol. 2016;15(13):1346-54. Article. IF: 26.284; D1 • Ríos A, López-Navas AI, López-López AI, Gómez FJ, Iriarte J, Herruzo R, Blanco G, Llorca FJ, Asunsolo A, Sánchez-Gallegos P, Gutiérrez PR, Fernández A, de Jesús MT, Martínez-Alarcón L, Lana A, Fuentes L, Hernández JR, Virseda J, Yelamos J, Bondía JA, Hernández AM, Ayala MA, Ramírez P, Parrilla P. Acceptance of living liver donation among medical students: A multicenter stratified study from Spain. World J Gastroentero. 2016;22(25):5800-13. Article. IF: 3.365; Q2 • Rodríguez-Frutos B, Otero-Ortega L, Gutiérrez-Fernández M, Fuentes B, Ramos-Cejudo J, Díez-Tejedor E. Stem cell therapy and administration routes after stroke. Transl Stroke Res. 2016;7(5):378-87. Article. IF: 4.503; Q1 • Rodríguez-Frutos B, Otero-Ortega L, Ramos-Cejudo J, Martínez-Sánchez P, Barahona-Sanz I, Navarro-Hernanz T, Gómez-de Frutos MD, Díez-Tejedor E, Gutiérrez-Fernández M. Enhanced brain-derived neurotrophic factor delivery by ultrasound and microbubbles promotes white matter repair after stroke. Biomaterials. 2016;100:41-52. Article. IF: 8.402; D1 • Sánchez-Benavides G, Peña-Casanova J, Casals-Coll M, Gramunt N, Manero RM, Puig-Pijoan A, Aguilar M, Robles A, Antúnez C, Frank-García A, Fernández-Martínez M, Blesa R. One-year reference norms of cognitive change in Spanish old adults: data from the NEURONORMA Sample. Arch Clin Neuropsych. 2016;31(4):378-88. Article. IF: 2.044; Q3 • Sánchez-Herán A, Agudo-Carmona D, Ferrer-Pena R, López-deUralde-Villanueva I, Gil-Martínez A, Paris-Alemany A, La Touche R. Postural stability in osteoarthritis of the knee and hip: analysis of association with pain catastrophizing and fear-avoidance beliefs. PM&R. 2016;8(7):618-28. Article. IF: 1.785; Q2 • Secades JJ, Álvarez-Sabín J, Castillo J, Díez-Tejedor E, MartínezVila E, Ríos J, Oudovenko N. Citicoline for acute ischemic stroke: A systematic review and formal meta-analysis of randomized, double-blind, and placebo-controlled trials. J Stroke Cerebrovasc. 2016;25(8):1984-96. Review. IF: 1.517; Q4 • Sepulveda M, Armangue T, Sola-Valls N, Arrambide G, MecaLallana JE, Oreja-Guevara C, Mendibe M, de Arcaya AA, Aladro Y, Casanova B, Olascoaga J, Jiménez-Huete A, Fernández-Fournier M, Ramio-Torrenta L, Cobo-Calvo A, Vinals M, de Andrés C, Meca-Lallana V, Cervello A, Calles C, Rubio MB, Ramo-Tello C, Caminero A, Munteis E, Antigüedad AR, Blanco Y, Villoslada P, Montalbán X, Graus F, Saiz A. Neuromyelitis optica spectrum disorders comparison according to the phenotype and serostatus. Neurol Neuroimmunol Neuroinflamm. 2016;3(3):e225. Article. Not Indexed • Sevilla T, Lupo V, Martínez-Rubio D, Sancho P, Sivera R, Chumillas MJ, García-Romero M, Pascual-Pascual SI, Muelas N, Dopazo J, Vílchez JJ, Palau F, Espinos C. Mutations in the MORC2 gene cause axonal Charcot-Marie-Tooth disease. Brain. 2016;139:62-72. Article. IF: 10.292; D1 • Tapias G, García-Romero M, Crespo C, Cuesta M, Forne C, Pascual-Pascual SI. Cost-minimization analysis in the treatment of spasticity in children with cerebral palsy with botulinum toxin

type A: an observational, longitudinal, retrospective study. Farm Hosp. 2016;40(5):412-26. Article. Not Indexed • Ugalde-Canitrot A, García-Fernández M, García-Caballero J. Quality management in epileptology: can it really improve care for patients? Am J Med Qual. 2016;31(1):94. Letter. IF: 1.688; Q3 • Vivancos-Matellano F, García-Ruiz AJ, Soler NGA. Pharmacoeconomic study of the treatment of advanced Parkinson’s disease. Rev Neurología. 2016;63(12):529-36. Article. IF: 0.743; Q4

Pascual Pascual SM. Translational research, experimental medicine and therapeutics on charcot-marie-tooth disease (TREAT-CMT). ISCIII. 2012-2016. Management centre: FIBHULP

PRIVATE PROJECT

PUBLIC PROJECTS

Díez Tejedor E. Analysis of the protectiv effect of olmesartan administrated pre or post-cerebral infarction in an animal model. Pfizer, SLU. 2011-Ongoing. Management centre: FIBHULP

Bullido Gómez-Heras MJ. Identificacion de alteraciones funcionales en modelos patogénicos de la enfermedad de Alzheimer: implicación de la via lisosomal (SAF201453954-R). MINECO. 2015-2017. Management centre: UAM

Díez Tejedor E. Registro clínico para el seguimiento de tratamiento anticoagulante en prevención secundaria tras un ictus cardioembólico. Boehringer Ingelheim España, S.A. 2011-Ongoing. Management centre: FIBHULP

Cerdán García-Esteller S, López Larrubia P. Cerebral regulation of global energy balance in health and disease as detected by functional diffusion weighted MRI (SAF201453739-R). MINECO. 2015-2017. Management centre: CSIC

Díez Tejedor E. Pacientes con esclerosis múltiple: análisis de la respuesta a tratamientos biológicos. Fundación Biogen Idec. 2013-Ongoing. Management centre: FIBHULP

de Leciñana Cases MA. Identificación de proteínas implicadas en la neuroreparación tras la isquemia cerebral. Estudio clínico-experimental (PI14/00705). ISCIII. 2014-2016. Management centre: FIBHRYC Díez Tejedor E. Terapia reparadora con células madre mesenquimales alogénicas de tejido adiposo en el infarto cerebral agudo comparado con tratamiento convencional. Evaluacion de seguridad. Estudio piloto (EC10-171). MSSSI. 2011-2017. Management centre: FIBHULP Díez Tejedor E. Red de Enfermedades Vasculares Cerebrales (ICTUS) (RD12/0014/0006). ISCIII. 2013-2016. Management centre: FIBHULP Díez Tejedor E. Identificación de marcadores de daño de fibras (axonal y mielina) en sustancia blanca cerebral y nuevas dianas terapéuticas para potenciar la reparación y recuperación en el infarto subcortical. Estudio trasnacional (PI12/01754). ISCIII. 2013-2017. Management centre: FIBHULP Fuentes Gimeno B. Terapia reparadora con exosomas de células troncales mesenquimales en el infarto cerebral con daño subcortical en un modelo animal experimental (PI15/01318). ISCIII. 2016-2018. Management centre: FIBHULP Gil Martínez A. Sistema de interacción natural para análisis y rehabilitación de los trastornos de la marcha en la enfermedad de Parkinson (MOBEEZE) (RTC-2015-38701). MINECO. 2015-2017. Management centre: FIBHULP Gutiérrez Fernández MD. Exosomes as predictive biomarkers in acute ischemic stroke patients: a translational research approach (CP15/00069). ISCIII. 2016-2018. Management centre: FIBHULP Gutiérrez Fernández MD. Miguel Servet Tipo I (CP15/00069). ISCIII. 2016-2021. Management centre: FIBHULP

Díez Tejedor E. Informatización de la gestión de pacientes. Unidad de neuroinmunologia y esclerosis múltiple en el Hospital Universitario La Paz. Novartis Farmaceutica, S.A. 2014-Ongoing. Management centre: FIBHULP Díez Tejedor E. Brain repair therapy with exosomes derived mesenchymal stem cells in experimental intreacerebral hemorrhage model. Roche Farma, S.A. 2016-Ongoing. Management centre: FIBHULP Frank García A. Validación de los biomarcadores proteicos y metabolómicos en muestras de pacientes. Neuron Biopharma S.A. 2010-Ongoing. Management centre: FIBHULP Gil Martínez A. Sistema de interaccion natural para analisis y rehabilitacion de los trastornos de la marcha en la enfermedad de Parkinson (MOBEEZE). Fundación I+D del Software Libre. 2016-Ongoing. Management centre: FIBHULP Iváñez Mora V. Proyecto de creación de base de datos para la investigación clínica y epidemiológica en epilepsia. EISAI Farmacéutica S.A. 2009-Ongoing. Management centre: FIBHULP Jurado MJ. Traducción, adaptación cultural y validación del cuestionario de sueño sleep disturbance scale for children (SDSC) en población española infanto-juvenil de 6 a 16 años. 2014-Ongoing. Management centre: FIBHULP Moraleda Pérez S. Pacientes con parálisis facial periférica: registro de características clínicas antes y después del tratamiento con toxina botulínica tipo A y reeducación neuromuscular facial. Merz Pharma España. 2014-Ongoing. Management centre: FIBHULP Noval Martín S. Estudio multicéntrico de tres años de duración para evaluar la tomografía de coherencia óptica como medida de valoración en pacientes con esclerosis múltiple. Novartis Farmaceutica, S.A. 2012-Ongoing. Management centre: FIBHULP

Continue

101

3.1 Neuroscience Area

3 INFORMATION GROUPS BY AREA Pascual Pascual SI. Estudio de la eficacia de la toxina botulínica en el pie equino espástico de la parálisis cerebral y de los factores que influyen en la misma. Allergan, S.A. 2008-Ongoing. Management centre: FIBHULP Vivancos Matellano F. Análisis de la diferente evolución clínica de pacientes con enfermedad de parkinson con tratamiento adyuvante asociado de un inhibidor de la dopa decarboxilasa y un inhibidor de la COMT. Abbvie Spain, SLU. 2008-Ongoing. Management centre: FIBHULP

INTERNATIONAL PROJECTS Díez Tejedor E. Resstore Regenerative Stem Cell Therapy for stroke in Europe- RESSTORE. Therapeutic efficacy of allogenic adipose tissue derived mesenchymal stem cells for enhancing functional outcome in stroke patients (H2020 Topic PHC-15-2015). EU. 2016-2020. Management centre: FIBHULP Pascual Pascual SI. Traslational research, experimental medicineand therapeutic on Charcolt- Marie-Tooth Disease (TREAT). EU. 2012-2016. Management centre: FIBHULP Rodríguez de Rivera Garrido FJ. European Friedreich’s Ataxia Consortium Tor Translational Studies (EFACTS). EU. 2016-Ongoing. Management centre: FIBHULP

CLINICAL TRIALS de Leciñana Cases MA. Pérdidas de productividad y gastos indirectos después de acontecimientos vasculares en Europa AMEV-COI. Amgen Europe GMBH. HULP Code: PI-2382. Sponsored´s Protocol Code: AMGSIM-2016-01. Signature Date: 04/08/2016 Díez Tejedor E. Ensayo de extensión, abierto, de fase III de ECU-MG-301 para evaluar la seguridad y la eficacia de eculizumab en sujetos con Miastenia Gravis Generalizada (MGG) resistente al tratamiento. Alexion Pharmaceutical Inc. HULP Code: 4258. Sponsored´s Protocol Code: ECU-MG-302. Signature Date: 05/01/2016 Díez Tejedor E. Corporación internacional para la realización del ensayo clínico, estudio de fase 2, controlado con placebo, aleatorizado, doble ciego y de grupos paralelos para evaluar la eficacia y la seguridad de BMS-986141 en la prevención del infarto cerebral recurrente en sujetos que reciben Ácido Acetilsalicílico (AAS) después de un ictus isquémico agudo o de un accidente isquémico transitorio. Bristol Myers Squibb International Corporation. HULP Code: 4612. Sponsored´s Protocol Code: CV006-004. Signature Date: 01/07/2016 Díez Tejedor E. Estudio aleatorizado, con doble enmascaramiento, controlado con placebo y con grupos paralelos de la seguridad, la eficacia y la farmacodinámica de Basmi102

sanil (RO5186582) en adultos con deterioro motor grave tras un accidente isquémico. F Hoffmann-La Roche Ltd. HULP Code: 4666. Sponsored´s Protocol Code: BP29937. Signature Date: 17/10/2016 Díez Tejedor E. Estudio aleatorizado doble ciego controlado con placebo de fase II para investigar las posibles interacciones fármaco-fármaco entre clobazam y cannabidiol (GWP2003-P). GW Research Ltd. HULP Code: 4508. Sponsored´s Protocol Code: GWEP1428. Signature Date: 18/01/2016 Díez Tejedor E. Estudio aleatorizado doble ciego controlado con placebo, de dos partes para investigar las características farmacocinéticas, seguido de la eficacia y la seguridad de GWP42006 como terapia complementaria en pacientes con crisis epilépticas focales inadecuadamente controladas. GW Research Ltd. HULP Code: 4509. Sponsored´s Protocol Code: GWEP1330. Signature Date: 24/05/2016 Díez Tejedor E. Estudio multicéntrico, aleatorizado, de doble enmascaramiento, controlado por placebo y de grupos paralelos que compara la eficacia y la seguridad con pautas de 2 dosis de la administración subcutánea de tev-48125 frente a placebo respecto al tratamiento preventivo de la migraña crónica. Teva Branded Pharmaceutical Products R&D, Inc. HULP Code: 4620. Sponsored´s Protocol Code: TV48125CNS-30049. Signature Date: 12/07/2016 Díez Tejedor E. Estudio de fase 1b, abierto y multicéntrico, para evaluar la seguridad y la tolerabilidad y para determinar la dosis máxima tolerada de PF-05230907 en sujetos con hemorragia intracerebral. Pfizer Inc. HULP Code: 4600. Sponsored´s Protocol Code: B2341002. Signature Date: 11/07/2016 Díez Tejedor E. Estudio multicéntrico, aleatorizado, de doble enmascaramiento, controlado por placebo y de grupos paralelos que compara la eficacia y la seguridad con pautas de 2 dosis de la administración subcutánea de TEV-48125 frente a placebo respecto al tratamiento preventivo de la migraña episódica. Teva Branded Pharmaceutical Products R&D Inc. HULP Code: 4619. Sponsored´s Protocol Code: TV48125CNS-30050. Signature Date: 04/08/2016 Díez Tejedor E. Estudio multicéntrico, aleatorizado, de doble enmascaramiento y con grupos paralelos que evalúa la seguridad, tolerabilidad y eficacia a largo plazo de la administración subcutánea de TEV-48125 para el tratamiento preventivo de la migraña. Teva Branded Pharmaceutical Products R&D Inc. HULP Code: 4621. Sponsored´s Protocol Code: TV48125CNS-30051. Signature Date: 04/08/2016 Díez Tejedor E. Estudio postautorización de seguridad, prospectivo, multicéntrico y observacional para evaluar el perfil de seguridad a largo plazo del tratamiento con lemtrada® (alemtuzumab) en pacientes con formas reci-

divantes de esclerosis múltiple. Genzyme Europe BV. HULP Code: PI-2054. Sponsored´s Protocol Code: OBS13434. Signature Date: 28/07/2016 Díez Tejedor E. Estudio multinacional, multicéntrico, aleatorizado, doble ciego, con grupos paralelos y controlado con placebo, seguido de un periodo de tratamiento activo, para evaluar la eficacia, la seguridad y la tolerabilidad de dos dosis de laquinimod administradas por vía oral (0,6 mg/día o 1,2 mg/día9 en sujetos con Esclerosis múltiple Remitente-Recurrente (EMRR). Teva Pharmaceutical Industries Ltd. HULP Code: Anexo-I 3764. Sponsored´s Protocol Code: LAQMS-305. Signature Date: 26/08/2016 Frank García A. Estudio de fase III, doble ciego y aleatorizado de RVT-101 frente a placebo cuando se añade al tratamiento estable con donepezilo ya existente, en pacientes con enfermedad de Alzheimer de leve a moderada. Axovant Sciences Ltd. HULP Code: 4552. Sponsored´s Protocol Code: RVT-101-3001. Signature Date: 27/04/2016 Frank García A. Estudio multicéntrico, randomizado, doble ciego, controlado con placebo, con grupos de tratamiento paralelos, de dos años de duración, para evaluar el efecto de RO4909832 administrado por vía subcutánea sobre la capacidad cognitiva y funcional en enfermedad de Alzheimer en fase prodrómica. F Hoffmann-La Roche Ltd. HULP Code: Anexo-III 3420. Sponsored´s Protocol Code: WN25203. Signature Date: 25/01/2016 Frank García A. Estudio de fase 2A aleatorizado, doble ciego, controlado con placebo, de grupos paralelos, multicéntrico para estudiar la seguridad y tolerabilidad de JNJ-54861911 en pacientes con enfermedad de Alzheimer temprana (pre-demencia). Janssen-Cilag España S.A. HULP Code: Anexo-I 4266. Sponsored´s Protocol Code: 54861911ALZ2002. Signature Date: 11/04/2016 Frank García A. Estudio de fase IIb/III, multicéntrico, aleatorizado, con doble ciego, controlado con placebo y de grupos paralelos para investigar la eficacia y la seguridad de jnj-54861911 en sujetos asintomáticos con riesgo de desarrollar demencia de alzheimer. Janssen Cilag International Nv. HULP Code: 4448. Sponsored´s Protocol Code: 54861911ALZ2003. Signature Date: 04/02/2016 López Arrieta JM. Un estudio de fase 3, de 12 semanas de duración, multicéntrico, aleatorizado, doble ciego, controlado con placebo para evaluar la eficacia, seguridad y tolerabilidad de 3 dosis fijas de brexpiprazol (OPC-34712) en el tratamiento de sujetos con agitación asociada con la demencia del tipo Alzheimer. Otsuka Pharmaceutical Development & Commercializacion Inc. HULP Code: Anexo-II 4014. Sponsored´s Protocol Code: 331-12-283. Signature Date: 03/05/2016 López Arrieta JM. Estudio multicéntrico de fase IIA/IIB, aleatorizado, doble ciego, controlado con placebo, de 56

semanas de seguimiento, para evaluar la seguridad y la eficacia de bimagrumab i.v. sobre la masa corporal magra total y la actividad física en pacientes después de tratamiento quirúrgico de fractura de cadera. Novartis Farmaceutica S.A. HULP Code: Anexo-II 4206. Sponsored´s Protocol Code: CBYM338D2201. Signature Date: 29/03/2016 López Arrieta JM. Estudio observacional de cohortes de la seguridad posterior a la autorización (PAs) para cuantificar la incidencia y la seguridad comparativa de acontecimientos cardiovasculares y cerebrovasculares específicos en pacientes con EPOC que utilizan la combinación UMEC/VI por inhalación o UMEC por inhalación en comparación con tiotropio. Glaxosmithkline Research and Development Limited. HULP Code: PI-2186. Sponsored´s Protocol Code: 201038. Signature Date: 02/06/2016 Pascual Pascual SI. Estudio de extensión abierto para pacientes con atrofia muscular espinal que han participado previamente en estudios experimentales de ISIS 396443. Ionis Pharmaceuticals Inc. HULP Code: 4577. Sponsored´s Protocol Code: ISIS 396443-CS11. Signature Date: 07/04/2016 Pascual Pascual SI. Ensayo multicéntrico, aleatorizado, doble ciego, controlado con placebo para evaluar los efectos del fosfato sódico de dexametasona intra-eritrocito en los síntomas neurológicos de pacientes con ataxia telangiectasia. Erydel SPA. HULP Code: 4598. Sponsored´s Protocol Code: IEDAT-02-2015. Signature Date: 02/06/2016 Pascual Pascual SI. Estudio en fase III, aleatorizado, doble ciego, controlado con placebo, multicéntrico e internacional que evalúa en grupos paralelos la eficacia y seguridad de 2 dosis de PXT3003 en pacientes con síndrome de Charcot-Marie-Tooth de tipo 1A tratados durante 15 meses. Pharnext. HULP Code: 4534. Sponsored´s Protocol Code: CLN-PXT3003-02. Signature Date: 10/08/2016 Rodríguez de Rivera Garrido FJ. Estudio de fase III sobre la eficacia, la seguridad y la tolerabilidad de la infusión de inmunoglobulina (humana) al 10 % con hialuronidasa recombinante humana (HYQVIA/HYQVIA) y la infusión de inmunoglobulina (humana) al 10 % (gammagard liquid/ KIOVING) para el tratamiento de la polirradiculoneuropatía desmielinizante inflamatoria crónica (PDIC). Baxter Innovations GMBH. HULP Code: 4497. Sponsored´s Protocol Code: 161403. Signature Date: 17/02/2016 Rodríguez de Rivera Garrido FJ. Detención de enfermedad de Pompe en pacientes con miopatías de cinturas no definidas o hiperckemia asintomática. Sanofi Aventis S.A. HULP Code: Anexo-I PI-823. Sponsored´s Protocol Code: L-GENZ-E-003. Signature Date: 27/07/2016 Tallón Barranco A. Estudio abierto para evaluar la eficacia y la seguridad de ocrelizumab en pacientes con esclerosis múltiple remitente-recidivante que tienen una

Continue

103

3.1 Neuroscience Area

3 INFORMATION GROUPS BY AREA respuesta subóptima a un ciclo adecuado de tratamiento modificador de la enfermedad. F Hoffmann-La Roche Ltd. HULP Code: 4608. Sponsored´s Protocol Code: MA30005. Signature Date: 25/04/2016

PATENTS AND TRADEMARKS

Valdivieso Ámate F, Montoliú JL, Pozueta Larios J, inventors; UAM, CSIC, assignees. Alzheimer’s disease animal model, method for obtaining same and uses thereof. P200503002, PCT/ES2006/000673, EP1956091, EP20060841725, US20090222932, CA2638983, JP2009517066; 2005 December 02.

Ballesteros García P, López Larrubia P, Domínguez Mateo L, Marco Contelles JL, Cerdán García-Esteller S, inventors; Universidad Nacional de Educación a Distancia, CSIC, assignees. Set of magnetic resonance imaging and spectroscopy cell acidity extrinsic indicators comprise polyol derivatives based on alditols. P200300936; 2003 April 23.

Valdivieso Amate F, Bullido Gómez-Heras MJ, Martínez García A, inventors; UAM, assignee. Method of identifying compounds that induce or inhibit endoplasmic reticulum stress or oxidative stress. P200702997, PCT/ ES2008/000705, EP2221379, US20100304384; 2007 November 13.

Valdivieso Ámate F, Burgos Muñoz JS, Ramírez Moreno C, Sastre Merlín I, inventors; UAM, CSIC, assignees. Method of identifying therapeutic compounds which can be used for the treatment and/or prevention of infections and diseases caused by human herpes viruses. P200400965, PCT/ES2005/000209, EP1769677, US20070218004, AT447321, AU2005235319, CA2562787, JP2007533315; 2004 April 21.

Vergés Milano J, García García A, Ruhí Roura R, Montell Bonaventura E, García López M, Aláez Versón CR, Escaich Ferrer J, Egea Máiquez J, Lorrio González S, Negredo Madrigal P, inventors; BIOIBÉRICA S.A., UAM, assignees. Sulphated disaccharides for the treatment of neurodegenerative and/or neurovascular diseases. P200902399, PCT/EP2010/070613, US20120309707, CA20102785237; 2010 December 22.

NEUROPROTECTIVE STRATEGIES IN NEURODEGENERATIVE DISEASES GROUP

19 114.192 18 Antonio Cuadrado Pastor Catedrático. Facultad de Medicina. UAM Ángel Juan García Yagüe Investigador Postdoctoral. CIBERNED Nadia Giselle Innamorato Investigadora Predoctoral. UAM Isabel Lastres Becker Investigadora Senior (Contrato Ramón y Cajal). UAM Ángela Martínez Valverde Investigadora Postdoctoral. IIB “Alberto Sols” Patricia Rada Llano Investigadora Postdoctoral. IIB “Alberto Sols”

Strategic Objective Oxidative stress is a key element in the aetiopathogenesis of neurodegenerative diseases and their comorbidities. Our laboratory studies the antioxidant protection mechanisms activated by extracellular signals and how this response ould be regulated pharmacologically to provide a therapeutic benefit in these diseases. To meet these two objectives, we are studying signalling pathways that regulate antioxidant metabolism and provide a general protective response. An important finding of this group was the observation that the PI3K/AKT/GSK-3 survival pathway regulates the transcription factor Nrf2, guardian of cellular redox homeostasis, that provides protection against oxidative, inflammatory and proteotoxic stress. For the past year we have been working on the validation this transcription factor as a new therapeutic target to modify progression of Parkinson’s and Alzheimer’s disease as well as co-morbid retinopathy and type II diabetes. 104

Return to NEUROSCIENCE AREA INDEX

Research Lines • Role of oxidative stress in neuronal death and neuroinflammation. in neurodegenerative diseases. • The transcription factor Nrf2 as a new therapeutic target in Parkinson’s and Alzheimer’s disease. • Molecular basis of type 2 diabetes and its complications (diabetic retinopathy and nephropathy).

Research Activity PUBLICATIONS • Arroba AI, Alcalde-Estévez E, García-Ramírez M, Cazzoni D, de la Villa P, Sánchez-Fernández EM, Mellet CO, Fernández JMG, Hernández C, Simo R,Valverde AM. Modulation of microglia polarization dynamics during diabetic retinopathy in db/db mice. BBA-Mol Basis Dis. 2016;1862(9):1663-74. Article. IF: 5.476; Q1 • Arroba AI, Rodríguez-de la Rosa L, Murillo-Cuesta S, VaqueroVillanueva L, Hurle JM, Varela-Nieto I, Valverde AM. Autophagy resolves early retinal inflammation in Igf1-deficient mice. Dis Model Mech. 2016;9(9):965-74. Article. IF: 4.691; Q1 • Baquedano E, Burgos-Ramos E, Canelles S, González-Rodríguez A, Chowen JA, Argente J, Barrios V, Valverde AM, Frago LM. Increased oxidative stress and apoptosis in the hypothalamus of diabetic male mice in the insulin receptor substrate-2 knockout model. Dis Model Mech. 2016;9(5):573-83. Article. IF: 4.691; Q1 • Beltramo E, Lopatina T, Mazzeo A, Arroba AI, Valverde AM, Hernández C, Simo R, Porta M. Effects of the neuroprotective drugs somatostatin and brimonidine on retinal cell models of diabetic retinopathy. Acta Diabetol. 2016;53(6):957-64. Article. IF: 3.34; Q2 • Calderón-Domínguez M, Sebastián D, Fucho R, Weber M, Mir JF, García-Casarrubios E, Obregón MJ, Zorzano A, Valverde AM,

Continue

105

3.1 Neuroscience Area

3 INFORMATION GROUPS BY AREA Serra D, Herrero L. Carnitine palmitoyltransferase 1 increases lipolysis, UCP1 protein expression and mitochondrial activity in brown adipocytes. Plos One. 2016;11(7):e0159399. Article. IF: 2.806; Q1 • Freitas AE, Egea J, Buendía I, Gómez-Rangel V, Parada E, Navarro E, Casas AI, Wojnicz A, Ortiz JA, Cuadrado A, Ruiz-Nuno A, Rodrigues ALS, López MG. Agmatine, by improving neuroplasticity markers and inducing Nrf2, prevents corticosterone-induced depressive-like behavior in mice. Mol Neurobiol. 2016;53(5):3030-45. Article. IF: 6.19; D1 • García-Casarrubios E, de Moura C, Arroba AI, Pescador N, Calderón-Dominguez M, García L, Herrero L, Serra D, Cadenas S, Reis F, Carvalho E, Obregón MJ, Valverde AM. Rapamycin negatively impacts insulin signaling, glucose uptake and uncoupling protein-1 in brown adipocytes. BBA-Mol Cell Biol L. 2016;1861(12):1929-41. Article. IF: 5.547; Q1 • Gavito AL, Cabello R, Suárez J, Serrano A, Pavón FJ, Vida M, Romero M, Pardo V, Bautista D, Arrabal S, Decara J, Cuesta AL, Valverde AM, de Fonseca FR, Baixeras E. Single administration of recombinant IL-6 restores the gene expression of lipogenic enzymes in liver of fasting IL-6-deficient mice. Brit J Pharmacol. 2016;173(6):1070-84. Article. IF: 5.491; D1 • Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, Arozena AA, Adachi H, Adams CM, Adams PD, Adeli K, Adhihetty PJ, Adler SG, Agam G, Agarwal R, Aghi MK, Agnello M, Agostinis P, Aguilar PV, Aguirre-Ghiso J, Airoldi EM, Ait-Si-Ali S, Akematsu T, Akporiaye ET, Al-Rubeai M, Albaiceta GM, Albanese C, Albani D, Albert ML, Aldudo J, Algul H, Alirezaei M, Alloza I, Almasan A, Almonte-Beceril M, Alnemri ES, Alonso C, Altan-Bonnet N, Altieri DC, Álvarez S, Álvarez-Erviti L, Alves S, Amadoro G, Amano A, Amantini C, Ambrosio S, Amelio I, Amer AO, Amessou M, Amon A, An ZY, Anania FA, Andersen SU, Andley UP, Andreadi CK, Andrieu-Abadie N, Anel A, Ann DK, Anoopkumar-Dukie S, Antonioli M, Aoki H, Apostolova N, Aquila S, Aquilano K, Araki K, Arama E, Aranda A, Araya J, Arcaro A, Arias E, Arimoto H, Ariosa AR, Armstrong JL, Arnould T, Arsov I, Asanuma K, Askanas V, Asselin E, Atarashi R, Atherton SS, Atkin JD, Attardi LD, Auberger P, Auburger G,Aurelian L,Autelli R,Avagliano L,Avantaggiati ML,Avrahami L, Awale S, Azad N, Bachetti T, Backer JM, Bae DH, Bae JS, Bae ON, Bae SH, Baehrecke EH, Baek SH, Baghdiguian S, Bagniewska-Zadworna A, Bai H, Bai J, Bai XY, Bailly Y, Balaji KN, Balduini W, Ballabio A, Balzan R, Banerjee R, Banhegyi G, Bao HJ, Barbeau B, Barrachina MD, Barreiro E, Bartel B, Bartolome A, Bassham DC, Bassi MT, Bast RC, Basu A, Batista MT, Batoko H, Battino M, Bauckman K, Baumgarner BL, Bayer KU, Beale R, Beaulieu JF, Beck GR, Becker C, Beckham JD, Bedard PA, Bednarski PJ, Begley TJ, Behl C, Behrends C, Behrens GMN, Behrns KE, Bejarano E, Belaid A, Belleudi F, Benard G, Berchem G, Bergamaschi D, Bergami M, Berkhout B, Berliocchi L, Bernard A, Bernard M, Bernassola F, Bertolotti A, Bess AS, Besteiro S, Bettuzzi S, Bhalla S, Bhattacharyya S, Bhutia SK, Biagosch C, Bianchi MW, Biard-Piechaczyk M, Billes V, Bincoletto C, Bingol B, Bird SW, Bitoun M, Bjedov I, Blackstone C, Blanc L, Blanco GA, Blomhoff HK, Boada-Romero E, Bockler S, Boes M, Boesze-Battaglia K, Boise LH, Bolino A, Boman A, Bonaldo P, Bordi M, Bosch J, Botana LM, Botti J, Bou G, Bouche M, Bouchecareilh M, Boucher MJ, Boulton ME, Bouret SG, Boya P, Boyer-Guittaut M, Bozhkov PV, Brady N, Braga VMM, Brancolini C, Braus GH, BravoSan Pedro JM, Brennan LA, Bresnick EH, Brest P, Bridges D, Bringer MA, Brini M, Brito GC, Brodin B, Brookes PS, Brown EJ, Brown K, Broxmeyer HE, Bruhat A, Brum PC, Brumell JH, Brunetti-Pierri N, Bryson-Richardson RJ, Buch S, Buchan AM, Budak H, Bulavin DV, Bultman SJ, Bultman SJ, Bumbasirevic V, Burelle Y, Burke RE, Burmeister M, Butikofer P, Caberlotto L, Cadwell K, Cahova M, Cai DS, Cai JJ, Cai Q, Calatayud S, Camougrand N,

106

Campanella M, Campbell GR, Campbell M, Campello S, Candau R, Caniggia I, Cantoni L, Cao LZ, Caplan AB, Caraglia M, Cardinali C, Cardoso SM, Carew JS, Carleton LA, Carlin CR, Carloni S, Carlsson SR, Carmona-Gutiérrez D, Carneiro LAM, Carnevali O, Carra S, Carrier A, Carroll B, Casas C, Casas J, Cassinelli G, Castets P, Castro-Obregon S, Cavallini G, Ceccherini I, Cecconi F, Cederbaum AI, Cena V, Cenci S, Cerella C, Cervia D, Cetrullo S, Chaachouay H, Chae HJ, Chagin AS, Chai CY, Chakrabarti G, Chamilos G, Chan EYW, Chan MTV, Chandra D, Chandra P, Chang CP, Chang RCC, Chang TY, Chatham JC, Chatterjee S, Chauhan S, Che YS, Cheetham ME, Cheluvappa R, Chen CJ, Chen G, Chen GC, Chen GQ, Chen HZ, Chen JW, Chen JK, Chen M, Chen MZ, Chen PW, Chen Q, Chen Q, Chen SD, Chen S, Chen SSL, Chen W, Chen WJ, Chen WQ, Chen WL, Chen XM, Chen YH, Chen YG, Chen Y, Chen YY, Chen YS, Chen YJ, Chen YQ, Chen YJ, Chen Z, Chen Z, Cheng A, Cheng CHK, Cheng H, Cheong HS, Cherry S, Chesney J, Cheung CHA, Chevet E, Chi HC, Chi SG, Chiacchiera F, Chiang HL, Chiarelli R, Chiariello M, Chieppa M, Chin LS, Chiong M, Chiu GNC, Cho DH, Cho SG, Cho WC, Cho YY, Cho YS, Choi AMK, Choi EJ, Choi EK, Choi JY, Choi ME, Choi SI, Chou TF, Chouaib S, Choubey D, Choubey V, Chow KC, Chowdhury K, Chu CT, Chuang TH, Chun T, Chung HW, Chung TJ, Chung YL, Chwae YJ, Cianfanelli V, Ciarcia R, Ciechomska IA, Ciriolo MR, Cirone M, Claerhout S, Clague MJ, Claria J, Clarke PGH, Clarke R, Clementi E, Cleyrat C, Cnop M, Coccia EM, Cocco T, Codogno P, Coers J, Cohen EEW, Colecchia D, Coletto L, Coll NS, Colucci-Guyon E, Comincini S, Condello M, Cook KL, Coombs GH, Cooper CD, Cooper JM, Coppens I, Corasaniti MT, Corazzari M, Corbalan R, Corcelle-Termeau E, Cordero MD, Corral-Ramos C, Corti O, Cossarizza A, Costelli P, Costes S, Costes S, Coto-Montes A, Cottet S, Couve E, Covey LR, Cowart LA, Cox JS, Coxon FP, Coyne CB, Cragg MS, Craven RJ, Crepaldi T, Crespo JL, Criollo A, Crippa V, Cruz MT, Cuervo AM, Cuezva JM, Cui TX, Cutillas PR, Czaja MJ, Czyzyk-Krzeska MF, Dagda RK, Dahmen U, Dai CS, Dai WJ, Dai Y, Dalby KN,Valle LD, Dalmasso G, D’Amelio M, Damme M, Darfeuille-Michaud A, Dargemont C, Darley-Usmar VM, Dasarathy S, Dasgupta B, Dash S, Dass CR, Davey HM, Davids LM, Davila D, Davis RJ, Dawson TM, Dawson VL, Daza P, de Belleroche J, de Figueiredo P, de Figueiredo RCBQ, de la Fuente J, De Martino L, De Matteis A, De Meyer GRY, De Milito A, De Santi M, de Souza W, De Tata V, De Zio D, Debnath J, Dechant R, Decuypere JP, Deegan S, Dehay B, Del Bello B, Del Re DP, Delage-Mourroux R, Delbridge LMD, Deldicque L, Delorme-Axford E, Deng YZ, Dengjel J, Denizot M, Dent P, Der CJ, Deretic V, Derrien B, Deutsch E, Devarenne TP, Devenish RJ, Di Bartolomeo S, Di Daniele N, Di Domenico F, Di Nardo A, Di Paola S, Di Pietro A, Di Renzo L, DiAntonio A, DíazAraya G, Díaz-Laviada I, Díaz-Meco MT, Díaz-Nido J, Dickey CA, Dickson RC, Diederich M, Digard P, Dikic I, Dinesh-Kumar SP, Ding C, Ding WX, Ding ZF, Dini L, Distler JHW, Diwan A, Djavaheri-Mergny M, Dmytruk K, Dobson RCJ, Doetsch V, Dokladny K, Dokudovskaya S, Donadelli M, Dong XC, Dong XN, Dong Z, Donohue TM, Doran KS, D’Orazi G, Dorn GW, Dosenko V, Dridi S, Drucker L, Du J, Du LL, Du LH, du Toit A, Dua P, Duan L, Duann P, Dubey VK, Duchen MR, Duchosal MA, Duez H, Dugail I, Dumit VI, Duncan MC, Dunlop EA, Dunn WA, Dupont N, Dupuis L, Duran RV, Durcan TM, Duvezin-Caubet S, Duvvuri U, Eapen V, Ebrahimi-Fakhari D, Echard A, Eckhart L, Edelstein CL, Edinger AL, Eichinger L, Eisenberg T, Eisenberg-Lerner A, Eissa NT, El-Deiry WS, El-Khoury V, Elazar Z, Eldar-Finkelman H, Elliott CJH, Emanuele E, Emmenegger U, Engedal N, Engelbrecht AM, Engelender S, Enserink JM, Erdmann R, Erenpreisa J, Eri R, Eriksen JL, Erman A, Escalante R, Eskelinen EL, Espert L, EstebanMartínez L, Evans TJ, Fabri M, Fabrias G, Fabrizi C, Facchiano A, Faergeman NJ, Faggioni A, Fairlie WD, Fan CH, Fan DP, Fan J, Fang SY, Fanto M, Fanzani A, Farkas T, Faure M, Favier FB, Fearnhead H,

Federici M, Fei E, Felizardo TC, Feng H, Feng YB, Feng YC, Ferguson TA, Fernández AF, Fernández-Barrena MG, Fernández-Checa JC, Fernández-López A, Fernández-Zapico ME, Feron O, Ferraro E, Ferreira-Halder CV, Fesus L, Feuer R, Fiesel FC, Filippi-Chiela EC, Filomeni G, Fimia GM, Fingert JH, Finkbeiner S, Finkel T, Fiorito F, Fisher PB, Flajolet M, Flamigni F, Florey O, Florio S, Floto RA, Folini M, Follo C, Fon EA, Fornai F, Fortunato F, Fraldi A, Franco R, Francois A, Francois A, Frankel LB, Fraser IDC, Frey N, Freyssenet DG, Frezza C, Friedman SL, Frigo DE, Fu DX, Fuentes JM, Fueyo J, Fujitani Y, Fujiwara Y, Fujiya M, Fukuda M, Fulda S, Fusco C, Gabryel B, Gaestel M, Gailly P, Gajewska M, Galadari S, Galili G, Galindo I, Galindo MF, Galliciotti G, Galluzzi L, Galluzzi L, Galy V, Gammoh N, Gandy S, Ganesan AK, Ganesan S, Ganley IG, Gannage M, Gao FB, Gao F, Gao JX, Nannig LG, Vescovi EG, García-Macia M, García-Ruiz C, Garg AD, Garg PK, Gargini R, Gassen NC, Gatica D, Gatti E, Gavard J, Gavathiotis E, Ge L, Ge PF, Ge SF, Gean PW, Gelmetti V, Genazzani AA, Geng JF, Genschik P, Gerner L, Gestwicki JE, Gewirtz DA, Ghavami S, Ghigo E, Ghosh D, Giammarioli AM, Giampieri F, Giampietri C, Giatromanolaki A, Gibbings DJ, Gibellini L, Gibson SB, Ginet V, Giordano A, Giorgini F, Giovannetti E, Girardin SE, Gispert S, Giuliano S, Gladson CL, Glavic A, Gleave M, Godefroy N, Gogal RM, Gokulan K, Goldman GH, Goletti D, Goligorsky MS, Gomes AV, Gomes LC, Gómez H, Gómez-Manzano C, Gómez-Sánchez R, Goncalves DAP, Goncu E, Gong QQ, Gongora C, Gonzalez CB, Gonzalez-Alegre P, Gonzalez-Cabo P, Gonzalez-Polo RA, Goping IS, Gorbea C, Gorbunov NV, Goring DR, Gorman AM, Gorski SM, Goruppi S, Goto-Yamada S, Gotor C, Gottlieb RA, Gozes I, Gozuacik D, Graba Y, Graef M, Granato GE, Grant GD, Grant S, Gravina GL, Green DR, Greenhough A, Greenwood MT, Grimaldi B, Gros F, Grose C, Groulx JF, Gruber F, Grumati P, Grune T, Guan JL, Guan KL, Guerra B, Guillen C, Gulshan K, Gunst J, Guo CY, Guo L, Guo M, Guo WJ, Guo XG, Gust AA, Gustafsson AB, Gutierrez E, Gutierrez MG, Gwak HS, Haas A, Haber JE, Hadano S, Hagedorn M, Hahn DR, Halayko AJ, Hamacher-Brady A, Hamada K, Hamai A, Hamann A, Hamasaki M, Hamer I, Hamid Q, Hamid Q, Han F, Han WD, Handa JT, Hanover JA, Hansen M, Harada M, Harhaji-Trajkovic L, Harper JW, Harrath AH, Harris AL, Harris J, Hasler U, Hasselblatt P, Hasui K, Hawley RG, Hawley TS, He CC, He CY, He FT, He G, He RR, He XH, He YW, He YY, Heath JK, Hebert MJ, Heinzen RA, Helgason GV, Hensel M, Henske EP, Her CT, Herman PK, Hernández A, Hernández C, HernándezTiedra S, Hetz C, Hiesinger PR, Higaki K, Hilfiker S, Hill BG, Hill JA, Hill WD, Hino K, Hofius D, Hofman P, Hoglinger GU, Hohfeld J, Holz MK, Hong YG, Hood DA, Hoozemans JJM, Hoppe T, Hsu C, Hsu CY, Hsu LC, Hu D, Hu GC, Hu HM, Hu HB, Hu MC, Hu YC, Hu ZW, Hua F, Hua Y, Huang CH, Huang HL, Huang KH, Huang KY, Huang SL, Huang SQ, Huang WP, Huang YR, Huang Y, Huang YF, Huber TB, Huebbe P, Huh WK, Hulmi JJ, Hur GM, Hurley JH, Husak Z, Hussain SNA, Hussain S, Hwang JJ, Hwang SM, Hwang TIS, Ichihara A, Imai Y, Imbriano C, Inomata M, Into T, Iovane V, Iovanna JL, Iozzo RV, Ip NY, Irazoqui JE, Iribarren P, Isaka Y, Isakovic AJ, Ischiropoulos H, Isenberg JS, Ishaq M, Ishida H, Ishii I, Ishmael JE, Isidoro C, Isobe KI, Isono E, Issazadeh-Navikas S, Itahana K, Itakura E, Ivanov AI, Iyer AKV, Izquierdo JM, Izumi Y, Izzo V, Jaattela M, Jaber N, Jackson DJ, Jackson WT, Jacob TG, Jacques TS, Jagannath C, Jain A, Jana NR, Jang BK, Jani A, Janji B, Jannig PR, Jansson PJ, Jean S, Jendrach M, Jeon JH, Jessen N, Jeung EB, Jia KL, Jia LJ, Jiang H, Jiang HC, Jiang LW, Jiang T, Jiang XY, Jiang XJ, Jiang XJ, Jiang Y, Jiang YJ, Jimenez A, Jin C, Jin HC, Jin L, Jin MY, Jin SK, Jinwal UK, Jo EK, Johansen T, Johnson DE, Johnson GVW, Johnson JD, Jonasch E, Jones C, Joosten LAB, Jordan J, Joseph AM, Joseph B, Joubert AM, Ju DW, Ju JF, Juan HF, Juenemann K, Juhasz G, Jung HS, Jung JU, Jung YK, Jungbluth H, Justice MJ, Jutten B, Kaakoush NO, Kaarniranta K, Kaasik A, Kabuta T, Kaeffer B, Kagedal K, Kahana A, Kajimura S, Kakhlon O, Kalia M, Kalvakolanu DV, Ka-

mada Y, Kambas K, Kaminskyy VO, Kampinga HH, Kandouz M, Kang C, Kang R, Kang TC, Kanki T, Kanneganti TD, Kanno H, Kanthasamy AG, Kantorow M, Kaparakis-Liaskos M, Kapuy O, Karantza V, Karim MR, Karmakar P, Kaser A, Kaushik S, Kawula T, Kaynar AM, Ke PY, Ke ZJ, Kehrl JH, Keller KE, Kemper JK, Kenworthy AK, Kepp O, Kern A, Kesari S, Kessel D, Ketteler R, Kettelhut ID, Khambu B, Khan MM, Khandelwal VKM, Khare S, Kiang JG, Kiger AA, Kihara A, Kim AL, Kim CH, Kim DR, Kim DH, Kim EK, Kim HY, Kim HR, Kim JS, Kim JH, Kim JC, Kim JH, Kim KW, Kim MD, Kim MM, Kim PK, Kim SW, Kim SY, Kim YS, Kim Y, Kimchi A, Kimmelman AC, Kimura T, King JS, Kirkegaard K, Kirkin V, Kirshenbaum LA, Kishi S, Kitajima Y, Kitamoto K, Kitaoka Y, Kitazato K, Kley RA, Klimecki WT, Klinkenberg M, Klucken J, Knaevelsrud H, Knecht E, Knuppertz L, Ko JL, Kobayashi S, Koch JC, Koechlin-Ramonatxo C, Koenig U, Koh YH, Kohler K, Kohlwein SD, Koike M, Komatsu M, Kominami E, Kong DX, Kong HJ, Konstantakou EG, Kopp BT, Korcsmaros T, Korhonen L, Korolchuk VI, Koshkina NV, Kou YJ, Koukourakis MI, Koumenis C, Kovacs AL, Kovacs T, Kovacs WJ, Koya D, Kraft C, Krainc D, Kramer H, Kravic-Stevovic T, Krek W, Kretz-Remy C, Krick R, Krishnamurthy M, Kriston-Vizi J, Kroemer G, Kruer MC, Kruger R, Ktistakis NT, Kuchitsu K, Kuhn C, Kumar AP, Kumar A, Kumar A, Kumar D, Kumar D, Kumar R, Kumar S, Kundu M, Kung HJ, Kuno A, Kuo SH, Kuret J, Kurz T, Kwok T, Kwon TK, Kwon YT, Kyrmizi I, La Spada AR, Lafont F, Lahm T, Lakkaraju A, Lam T, Lamark T, Lancel S, Landowski TH, Lane DJR, Lane JD, Lanzi C, Lapaquette P, Lapierre LR, Laporte J, Laukkarinen J, Laurie GW, Lavandero S, Lavie L, LaVoie MJ, Law BYK, Law HKW, Law KB, Layfield R, Lazo PA, Le Cam L, Le Roch KG, Le Stunff H, Leardkamolkarn V, Lecuit M, Lee BH, Lee CH, Lee EF, Lee GM, Lee HJ, Lee H, Lee JK, Lee J, Lee JH, Lee JH, Lee M, Lee MS, Lee PJ, Lee SW, Lee SJ, Lee SJ, Lee SY, Lee SH, Lee SS, Lee SJ, Lee S, Lee YR, Lee YJ, Lee YH, Leeuwenburgh C, Lefort S, Legouis R, Lei JZ, Lei QY, Leib DA, Leibowitz G, Lekli I, Lemaire SD, Lemasters JJ, Lemberg MK, Lemoine A, Leng SL, Lenz G, Lenzi P, Lerman LO, Barbato DL, Leu JIJ, Leung HY, Levine B, Lewis PA, Lezoualc’h F, Li C, Li FQ, Li FJ, Li J, Li K, Li L, Li M, Li M, Li Q, Li R, Li S, Li W, Li W, Li XT, Li YM, Lian JQ, Liang CY, Liang QR, Liao YL, Liberal J, Liberski PP, Lie P, Lieberman AP, Lim HJ, Lim KL, Lim K, Lima RT, Lin CS, Lin CF, Lin F, Lin FM, Lin FC, Lin K, Lin KH, Lin PH, Lin TW, Lin WW, Lin YS, Lin Y, Linden R, Lindholm D, Lindqvist LM, Lingor P, Linkermann A, Liotta LA, Lipinski MM, Lira VA, Lisanti MP, Liton PB, Liu B, Liu C, Liu CF, Liu F, Liu HJ, Liu JX, Liu JJ, Liu JL, Liu K, Liu LY, Liu L, Liu QT, Liu RY, Liu SM, Liu SW, Liu W, Liu XD, Liu XG, Liu XH, Liu XF, Liu X, Liu XQ, Liu Y, Liu YL, Liu ZX, Liu Z, Liuzzi JP, Lizard G, Ljujic M, Lodhi IJ, Logue SE, Lokeshwar BL, Long YC, Lonial S, Loos B, LópezOtin C, López-Vicario C, Lorente M, Lorenzi PL, Lorincz P, Los M, Lotze MT, Lovat PE, Lu BF, Lu B, Lu J, Lu Q, Lu SM, Lu SY, Lu YY, Luciano F, Luckhart S, Lucocq JM, Ludovico P, Lugea A, Lukacs NW, Lum JJ, Lund AH, Luo HL, Luo J, Luo SQ, Luparello C, Lyons T, Ma JJ, Ma Y, Ma Y, Ma ZY, Machado J, Machado-Santelli GM, Macian F, MacIntosh GC, MacKeigan JP, Macleod KF, MacMicking JD, MacMillan-Crow LA, Madeo F, Madesh M, Madrigal-Matute J, Maeda A, Maeda T, Maegawa G, Maellaro E, Maes H, Magarinos M, Maiese K, Maiti TK, Maiuri L, Maiuri MC, Maki CG, Malli R, Malorni W, Maloyan A, Mami-Chouaib F, Man N, Mancias JD, Mandelkow EM, Mandell MA, Manfredi AA, Manie SN, Manzoni C, Mao K, Mao ZX, Mao ZW, Marambaud P, Marconi AM, Marelja Z, Marfe G, Margeta M, Margittai E, Mari M, Mariani FV, Marin C, Marinelli S, Marino G, Markovic I, Marquez R, Martelli AM, Martens S, Martin KR, Martin SJ, Martin S, Martin-Acebes MA, Martin-Sanz P, Martinand-Mari C, Martinet W, Martínez J, Martínez-López N, Martínez-Outschoorn U, Martínez-Velazquez M, Martínez-Vicente M, Martins WK, Mashima H, Mastrianni JA, Matarese G, Matarrese P, Mateo R, Matoba S, Matsumoto N, Matsushita T, Matsuura A, Matsuzawa T, Mattson MP, Matus S, Maugeri N, Mau-

Continue

107

3.1 Neuroscience Area

3 INFORMATION GROUPS BY AREA

108

vezin C, Mayer A, Maysinger D, Mazzolini GD, McBrayer MK, McCall K, McCormick C, McInerney GM, McIver SC, McKenna S, McMahon JJ, McNeish IA, Mechta-Grigoriou F, Medema JP, Medina DL, Megyeri K, Mehrpour M, Mehta JL, Mei YD, Meier UC, Meijer AJ, Melendez A, Melino G, Melino S, de Melo EJT, Mena MA, Meneghini MD, Menendez JA, Menezes R, Meng LS, Meng LH, Meng SS, Menghini R, Menko AS, Menna-Barreto RFS, Menon MB, Meraz-Rios MA, Merla G, Merlini L, Merlot AM, Meryk A, Meschini S, Meyer JN, Mi MT, Miao CY, Micale L, Michaeli S, Michiels C, Migliaccio AR, Mihailidou AS, Mijaljica D, Mikoshiba K, Milan E, Miller-Fleming L, Mills GB, Mills IG, Minakaki G, Minassian BA, Ming XF, Minibayeva F, Minina EA, Mintern JD, Minucci S, Miranda-Vizuete A, Mitchell CH, Miyamoto S, Miyazawa K, Mizushima N, Mnich K, Mograbi B, Mohseni S, Moita LF, Molinari M, Molinari M, Moller AB, Mollereau B, Mollinedo F, Monick MM, Monick MM, Montagnaro S, Montell C, Moore DJ, Moore MN, Mora-Rodríguez R, Moreira PI, Morel E, Morelli MB, Moreno S, Morgan MJ, Moris A, Moriyasu Y, Morrison JL, Morrison LA, Morselli E, Moscat J, Moseley PL, Mostowy S, Motori E, Mottet D, Mottram JC, Moussa CEH, Mpakou VE, Mukhtar H, Levy JMM, Muller S, Munoz-Moreno R, Munoz-Pinedo C, Munz C, Murphy ME, Murray JT, Murthy A, Mysorekar IU, Nabi IR, Nabissi M, Nader GA, Nagahara Y, Nagai Y, Nagata K, Nagelkerke A, Nagy P, Naidu SR, Nair S, Nakano H, Nakatogawa H, Nanjundan M, Napolitano G, Naqvi NI, Nardacci R, Narendra DP, Narita M, Nascimbeni AC, Natarajan R, Navegantes LC, Nawrocki ST, Nazarko TY, Nazarko VY, Neill T, Neri LM, Netea MG, Netea-Maier RT, Neves BM, Ney PA, Nezis IP, Nguyen HTT, Nguyen HP, Nicot AS, Nilsen H, Nilsson P, Nishimura M, Nishino I, Niso-Santano M, Niu H, Nixon RA, Njar VCO, Noda T, Noegel AA, Nolte EM, Norberg E, Norga KK, Noureini SK, Notomi S, Notterpek L, Nowikovsky K, Nukina N, Nurnberger T, O’Donnell VB, O’Donovan T, O’Dwyer PJ, Oehme I, Oeste CL, Ogawa M, Ogretmen B, Ogura Y, Oh YJ, Ohmuraya M, Ohshima T, Ojha R, Okamoto K, Okazaki T, Oliver FJ, Ollinger K, Olsson S, Orban DP, Ordonez P, Orhon I, Orosz L, O’Rourke EJ, Orozco H, Ortega AL, Ortona E, Osellame LD, Oshima J, Oshima S, Osiewacz HD, Otomo T, Otsu K, Ou JHJ, Outeiro TF, Ouyang DY, Ouyang HJ, Overholtzer M, Ozbun MA, Ozdinler PH, Ozpolat B, Pacelli C, Paganetti P, Page G, Pages G, Pagnini U, Pajak B, Pak SC, PakosZebrucka K, Pakpour N, Palkova Z, Palladino F, Pallauf K, Pallet N, Palmieri M, Paludan SR, Palumbo C, Palumbo S, Pampliega O, Pan HM, Pan W, Panaretakis T, Pandey A, Pantazopoulou A, Papackova Z, Papademetrio DL, Papassideri I, Papini A, Parajuli N, Pardo J, Parekh VV, Parenti G, Park JI, Park J, Park OK, Parker R, Parlato R, Parys JB, Parzych KR, Pasquet JM, Pasquier B, Pasumarthi KBS, Patschan D, Patterson C, Pattingre S, Pattison S, Pause A, Pavenstadt H, Pavone F, Pedrozo Z, Pena FJ, Penalva MA, Pende M, Peng JX, Penna F, Penninger JM, Pensalfini A, Pepe S, Pereira GJS, Pereira PC, la Cruz VP, Perez-Perez ME, Perez-Rodríguez D, Perez-Sala D, Perier C, Perl A, Perlmutter DH, Perrotta I, Pervaiz S, Pesonen M, Pessin JE, Peters GJ, Petersen M, Petrache I, Petrof BJ, Petrovski G, Phang JM, Piacentini M, Pierdominici M, Pierre P, Pierrefite-Carle V, Pietrocola F, Pimentel-Muinos FX, Pinar M, Pineda B, Pinkas-Kramarski R, Pinti M, Pinton P, Piperdi B, Piret JM, Platanias LC, Platta HW, Plowey ED, Poggeler S, Poirot M, Polcic P, Poletti A, Poon AH, Popelka H, Popova B, Poprawa I, Poulose SM, Poulton J, Powers SK, Powers T, Pozuelo-Rubio M, Prak K, Prange R, Prescott M, Priault M, Prince S, Proia RL, Proikas-Cezanne T, Prokisch H, Promponas VJ, Przyklenk K, Puertollano R, Pugazhenthi S, Puglielli L, Pujol A, Puyal J, Pyeon D, Qi X, Qian WB, Qin ZH, Qiu Y, Qu ZW, Quadrilatero J, Quinn F, Raben N, Rabinowich H, Radogna F, Ragusa MJ, Rahmani M, Raina K, Ramanadham S, Ramesh R, Rami A, Randall-Demllo S, Randow F, Rao H, Rao VA, Rasmussen BB, Rasse TM, Ratovitski EA, Rautou PE, Ray SK, Razani B, Reed BH, Reggiori F, Rehm M, Reichert AS, Rein

T, Reiner DJ, Reits E, Ren J, Ren XC, Renna M, Reusch JEB, Revuelta JL, Reyes L, Rezaie AR, Richards RI, Richardson DR, Richetta C, Riehle MA, Rihn BH, Rikihisa Y, Riley BE, Rimbach G, Rippo MR, Ritis K, Rizzi F, Rizzo E, Roach PJ, Robbins J, Roberge M, Roca G, Roccheri MC, Rocha S, Rodrigues CMP, Rodríguez CI, de Cordoba SR, Rodríguez-Muela N, Roelofs J, Rogov VV, Rohn TT, Rohrer B, Romanelli D, Romani L, Romano PS, Roncero MIG, Rosa JL, Rosello A, Rosen KV, Rosenstiel P, Rost-Roszkowska M, Roth KA, Roue G, Rouis M, Rouschop KM, Ruan DT, Ruano D, Rubinsztein DC, Rucker EB, Rudich A, Rudolf E, Rudolf R, Ruegg MA, RuizRoldan C, Ruparelia AA, Rusmini P, Russ DW, Russo GL, Russo G, Russo R, Rusten TE, Ryabovol V, Ryan KM, Ryter SW, Sabatini DM, Sacher M, Sachse C, Sack MN, Sadoshima J, Saftig P, Sagi-Eisenberg R, Sahni S, Saikumar P, Saito T, Saitoh T, Sakakura K, Sakoh-Nakatogawa M, Sakuraba Y, Salazar-Roa M, Salomoni P, Saluja AK, Salvaterra PM, Salvioli R, Samali A, Sánchez AMJ, Sánchez-Alcazar JA, Sánchez-Prieto R, Sandri M, Sanjuan MA, Santaguida S, Santambrogio L, Santoni G, dos Santos CN, Saran S, Sardiello M, Sargent G, Sarkar P, Sarkar S, Sarrias MR, Sarwal MM, Sasakawa C, Sasaki M, Sass M, Sato K, Sato M, Satriano J, Savaraj N, Saveljeva S, Schaefer L, Schaible UE, Scharl M, Schatzl HM, Schekman R, Scheper W, Schiavi A, Schipper HM, Schmeisser H, Schmidt J, Schmitz I, Schneider BE, Schneider EM, Schneider JL, Schon EA, Schonenberger MJ, Schonthal AH, Schorderet DF, Schroder B, Schuck S, Schulze RJ, Schwarten M, Schwarz TL, Sciarretta S, Scotto K, Scovassi AI, Screaton RA, Screen M, Seca H, Sedej S, Segatori L, Segev N, Seglen PO, Segui-Simarro JM, Segura-Aguilar J, Seiliez I, Seki E, Sell C, Semenkovich CF, Semenza GL, Sen U, Serra AL, Serrano-Puebla A, Sesaki H, Setoguchi T, Settembre C, Shacka JJ, Shajahan-Haq AN, Shapiro IM, Sharma S, She H, Shen CKJ, Shen CC, Shen HM, Shen SB, Shen WL, Sheng R, Sheng XY, Sheng ZH, Shepherd TG, Shi JY, Shi Q, Shi QH, Shi YG, Shibutani S, Shibuya K, Shidoji Y, Shieh JJ, Shih CM, Shimada Y, Shimizu S, Shin DW, Shinohara ML, Shintani M, Shintani T, Shioi T, Shirabe K, Shiri-Sverdlov R, Shirihai O, Shore GC, Shu CW, Shukla D, Sibirny AA, Sica V, Sigurdson CJ, Sigurdsson EM, Sijwali PS, Sikorska B, Silveira WA, Silvente-Poirot S, Silverman GA, Simak J, Simmet T, Simon AK, Simon HU, Simone C, Simons M, Simonsen A, Singh R, Singh SV, Singh SK, Sinha D, Sinha S, Sinicrope FA, Sirko A, Sirohi K, Sishi BJN, Sittler A, Siu PM, Sivridis E, Skwarska A, Slack R, Slaninova I, Slavov N, Smaili SS, Smalley KSM, Smith DR, Soenen SJ, Soleimanpour SA, Solhaug A, Somasundaram K, Son JH, Sonawane A, Song CJ, Song FY, Song HK, Song JX, Song W, Soo KY, Sood AK, Soong TW, Soontornniyomkij V, Sorice M, Sotgia F, Soto-Pantoja DR, Sotthibundhu A, Sousa MJ, Spaink HP, Span PN, Spang A, Sparks JD, Speck PG, Spector SA, Spies CD, Springer W, St Clair D, Stacchiotti A, Staels B, Stang MT, Starczynowski DT, Starokadomskyy P, Steegborn C, Steele JW, Stefanis L, Steffan J, Stellrecht CM, Stenmark H, Stepkowski TM, Stern ST, Stevens C, Stockwell BR, Stoka V, Storchova Z, Stork B, Stratoulias V, Stravopodis DJ, Strnad P, Strohecker AM, Strom AL, Stromhaug P, Stulik J, Su YX, Su ZL, Subauste CS, Subramaniam S, Sue CM, Suh SW, Sui XB, Sukseree S, Sulzer D, Sun FL, Sun JR, Sun J, Sun SY, Sun Y, Sun Y, Sun YJ, Sundaramoorthy V, Sung J, Suzuki H, Suzuki K, Suzuki N, Suzuki T, Suzuki YJ, Swanson MS, Swanton C, Sward K, Swarup G, Sweeney ST, Sylvester PW, Szatmari Z, Szegezdi E, Szlosarek PW, Taegtmeyer H, Tafani M, Taillebourg E, Tait SWG, Takacs-Vellai K, Takahashi Y, Takats S, Takemura G, Takigawa N, Talbot NJ, Tamagno E, Tamburini J, Tan CP, Tan L, Tan ML, Tan M, Tan YJ, Tanaka K, Tanaka M, Tang DL, Tang DZ, Tang GM, Tanida I, Tanji K, Tannous BA, Tapia JA, Tasset-Cuevas I, Tatar M, Tavassoly I, Tavernarakis N, Taylor A, Taylor GS, Taylor GA, Taylor JP, Taylor MJ, Tchetina EV, Tee AR, Teixeira-Clerc F, Telang S, Tencomnao T, Teng BB, Teng RJ, Terro F, Tettamanti G, Theiss AL, Theron AE, Thomas KJ, Thome MP, Thomes PG, Thorburn A, Thorner J, Thum T, Thumm M, Thurston TLM, Tian L, Till A, Ting JPY, Titorenko VI, Toker L, Toldo S, Tooze SA, Topisirovic I,

Torgersen ML, Torosantucci L, Torriglia A, Torrisi MR, Tournier C, Towns R,Trajkovic V,Travassos LH,Triola G,Tripathi DN,Trisciuoglio D, Troncoso R, Trougakos IP, Truttmann AC, Tsai KJ, Tschan MP, Tseng YH, Tsukuba T, Tsung A, Tsvetkov AS, Tu SP, Tuan HY, Tucci M, Tumbarello DA, Turk B, Turk V, Turner RFB, Tveita AA, Tyagi SC, Ubukata M, Uchiyama Y, Udelnow A, Ueno T, Umekawa M, Umemiya-Shirafuji R, Underwood BR, Ungermann C, Ureshino RP, Ushioda R, Uversky VN, Uzcategui NL, Vaccari T, Vaccaro MI, Vachova L, Vakifahmetoglu-Norberg H, Valdor R, Valente EM, Vallette F, Valverde AM, Van den Berghe G, Van Den Bosch L, van den Brink GR, van der Goot FG, van der Klei IJ, van der Laan LJW, van Doorn WG, van Egmond M, van Golen KL,Van Kaer L, Campagne MV,Vandenabeele P,Vandenberghe W,Vanhorebeek I,Varela-Nieto I, Vasconcelos MH, Vasko R, Vavvas DG, Vega-Naredo I, Velasco G,Velentzas AD,Velentzas PD,Vellai T,Vellenga E,Vendelbo MH, Venkatachalam K, Ventura N, Ventura S, Veras PST, Verdier M, Vertessy BG,Viale A,Vidal M,Vieira HLA,Vierstra RD,Vigneswaran N, Vij N, Vila M, Villar M, Villar VH, Villarroya J, Vindis C, Viola G, Viscomi MT,Vitale G,Vogl DT,Voitsekhovskaja OV, von Haefen C, von Schwarzenberg K, Voth DE, Vouret-Craviari V, Vuori K, Vyas JM, Waeber C, Walker CL, Walker MJ, Walter J, Wan L, Wan XB, Wang B, Wang CH, Wang CY, Wang CS, Wang CR, Wang CH, Wang D, Wang F, Wang FX, Wang GH, Wang HJ, Wang HC, Wang HG, Wang HM, Wang HD, Wang J, Wang JJ, Wang M, Wang MQ, Wang PY, Wang P, Wang RC, Wang S, Wang TF, Wang X, Wang XJ, Wang XW, Wang X, Wang XJ, Wang Y, Wang Y, Wang Y, Wang YJ, Wang YP,Wang Y,Wang YT,Wang YQ,Wang ZN,Wappner P,Ward C, Ward DM, Warnes G, Watada H, Watanabe Y, Watase K, Weaver TE, Weekes CD, Wei JW, Weide T, Weihl CC, Weindl G, Weis SN, Wen LP, Wen X, Wen YF, Westermann B, Weyand CM, White AR, White E, Whitton JL, Whitworth AJ, Wiels J, Wild F, Wildenberg ME, Wileman T, Wilkinson DS, Wilkinson S, Willbold D, Williams C, Williams K, Williamson PR, Winklhofer KF, Witkin SS, Wohlgemuth SE, Wollert T, Wolvetang EJ, Wong E, Wong GW, Wong RW,Wong VKW,Woodcock EA,Wright KL,Wu CL,Wu DF, Wu GS, Wu J, Wu JF, Wu M, Wu M, Wu SZ, Wu WKK, Wu YH, Wu ZL, Xavier CPR, Xavier RJ, Xia GX, Xia T, Xia WL, Xia Y, Xiao HY, Xiao J, Xiao S, Xiao WH, Xie CM, Xie ZP, Xie ZL, Xilouri M, Xiong YY, Xu CS, Xu CF, Xu F, Xu HX, Xu HW, Xu J, Xu JZ, Xu JX, Xu L, Xu XL, Xu YQ, Xu Y, Xu ZX, Xu ZH, Xue Y,Yamada T,Yamamoto A,Yamanaka K,Yamashina S,Yamashiro S,Yan B,Yan B,Yan X, Yan Z,Yanagi Y,Yang DS,Yang JM,Yang L,Yang MH,Yang PM,Yang P, Yang Q, Yang WN, Yang WY, Yang XS, Yang Y, Yang Y, Yang ZF, Yang ZH,Yao MC,Yao PJ,Yao XF,Yao ZY,Yao ZY,Yasui LS,Ye MX,Yedvobnick B,Yeganeh B,Yeh ES,Yeyati PL,Yi F,Yi L,Yin XM,Yip CK,Yoo YM,Yoo YH,Yoon SY,Yoshida KI,Yoshimori T,Young KH,Yu HM,Yu JJ, Yu JT, Yu J, Yu L, Yu WH, Yu XF, Yu ZP, Yuan JY, Yuan ZM, Yue BYJT, Yue JB, Yue ZY, Zacks DN, Zacksenhaus E, Zaffaroni N, Zaglia T, Zakeri Z, Zecchini V, Zeng JS, Zeng M, Zeng Q, Zervos AS, Zhang DD, Zhang F, Zhang G, Zhang GC, Zhang H, Zhang H, Zhang H, Zhang HB, Zhang J, Zhang J, Zhang JW, Zhang JH, Zhang JP, Zhang L, Zhang L, Zhang L, Zhang L, Zhang MY, Zhang XN, Zhang XD, Zhang Y, Zhang Y, Zhang YJ, Zhang YM, Zhang YJ, Zhao M, Zhao WL, Zhao XN, Zhao YG, Zhao Y, Zhao YC, Zhao YX, Zhao ZD, Zhao ZZJ, Zheng DX, Zheng XL, Zheng XX, Zhivotovsky B, Zhong Q, Zhou GZ, Zhou GF, Zhou HP, Zhou SF, Zhou XJ, Zhu HX, Zhu H, Zhu WG, Zhu WH, Zhu XF, Zhu YH, Zhuang SM, Zhuang XH, Ziparo E, Zois CE, Zoladek T, Zong WX, Zorzano A, Zughaier SM. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition).Autophagy. 2016;12(1):1222. Review. IF: 8.593; Q1 • Lastres-Becker I, García-Yagüe AJ, Scannevin RH, Casarejos MJ, Kugler S, Rabano A, Cuadrado A. Repurposing the NRF2 activator dimethyl fumarate as therapy against synucleinopathy in Parkinson’s disease. Antioxid Redox Sign. 2016;25(2):61-77. Article. IF: 6.337; D1

• Lastres-Becker I, Nonis D, Eich F, Klinkenberg M, Gorospe M, Kotter P, Klein FAC, Kedersha N, Auburger G. Mammalian ataxin-2 modulates translation control at the pre-initiation complex via PI3K/mTOR and is induced by starvation. BBA-Mol Basis Dis. 2016;1862(9):1558-69. Article. IF: 5.476; Q1 • López-Guadamillas E, Fernández-Marcos PJ, Pantoja C, MuñozMartín M, Martínez D, Gómez-López G, Campos-Olivas R, Valverde AM, Serrano M. p21(Cip1) plays a critical role in the physiological adaptation to fasting through activation of PPAR alpha. Sci Rep-Uk. 2016;6:34542. Article. IF: 4.259; Q1 • López-Luque J, Caballero-Díaz D, Martínez-Palacián A, Roncero C, Moreno-Cáceres J, García-Bravo M, Grueso E, Fernández A, Crosas-Molist E, García-Álvaro M, Addante A, Bertrán E, Valverde AM, González-Rodríguez A, Herrera B, Montoliú L, Serrano T, Segovia JC, Fernández M, Ramos E, Sánchez A, Fabregat I. Dissecting the role of epidermal growth factor receptor catalytic activity during liver regeneration and hepatocarcinogenesis. Hepatology. 2016;63(2):604-19. Article. IF: 13.246; D1 • Motino O, Agra N, Contreras RB, Domínguez-Moreno M, García-Monzón C, Vargas-Castrillón J, Carnovale CE, Boscá L, Casado M, Mayoral R, Valdecantos MP, Valverde AM, Francés DE, Martín-Sanz P. Cyclooxygenase-2 expression in hepatocytes attenuates non-alcoholic steatohepatitis and liver fibrosis in mice. BBA-Mol Basis Dis. 2016;1862(9):1710-23. Article. IF: 5.476; Q1 • Pajares M, Jiménez-Moreno N, García-Yagüe AJ, Escoll M, de Ceballos ML, Van Leuven F, Rabano A, Yamamoto M, Rojo AI, Cuadrado A. Transcription factor NFE2L2/NRF2 is a regulator of macroautophagy genes. Autophagy. 2016;12(10):1902-1916. Article. IF: 8.593; Q1 • Santacatterina F, Sánchez-Cenizo L, Formentini L, Mobasher MA, Casas E, Rueda CB, Martínez-Reyes I, de Arenas CN, GarcíaBermúdez J, Zapata JM, Sánchez-Arago M, Satrustegui J,Valverde AM, Cueva JM. Down-regulation of oxidative phosphorylation in the liver by expression of the ATPase inhibitory factor 1 induces a tumor-promoter metabolic state. Oncotarget. 2016;7(1):490508. Article. IF: 5.168; Q1 • Schmidt HHHW, Stocker R, Paulsen G, Ghezzi P, Riley D, Daiber A, Cuadrado A. Response to I. Batinic-Haberle et al. Antioxid Redox Sign. 2016;24(9):525-526. Letter. IF: 6.337; D1 • Villar-Lorenzo A, Ardiles AE, Arroba AI, Hernández-Jiménez E, Pardo V, López-Collazo E, Jiménez IA, Bazzocchi IL, GonzálezRodríguez A, Valverde AM. Friedelane-type triterpenoids as selective anti-inflammatory agents by regulation of differential signaling pathways in LPS-stimulated macrophages. Toxicol Appl Pharm. 2016;313:57-67. Article. IF: 3.791; Q1 • Zarei M, Barroso E, Leiva R, Barniol-Xicota M, Pujol E, Escolano C, Vázquez S, Palomer X, Pardo V, González-Rodríguez A, Valverde AM, Quesada-López T, Villarroya F, Wahli W, VázquezCarrera M. Heme-regulated eIF2 alpha kinase modulates hepatic FGF21 and is activated by PPAR beta/delta deficiency. Diabetes. 2016;65(10):3185-99. Article. IF: 8.684; D1

PUBLIC PROJECTS Martínez Valderde A. Estudio de los mecanismos de resistencia a la insulina: implicaciones en obesidad, diabetes y síndrome metabólico (S2010/BMD-2423). CAM. 20122016. Management centre: CSIC Cuadrado Pastor A. Papel de NRF2 como modulador antioxidante de la neuroinflamación en la enfermedad de Alzheimer (SAF2013-43271-R). MINECO. 2014-2016. Management centre: UAM

Continue

109

3.1 Neuroscience Area

3 INFORMATION GROUPS BY AREA Cuadrado Pastor A. Red de investigación en NRF2 como nodo del “patogenosoma” (SAF2015-71304-REDT). MINECO. 2015-2017. Management centre: UAM Martínez Valderde A. Inflammation associated with cronic metabolic damage in diabetes mellitus and its complications (SAF2015-65267-R). MINECO. 2016-2018. Management centre: CSIC

PRIVATE PROJECTS Cuadrado Pastor A. Targeting NRF2 with SFX-01 to modify parkinson’s disease progression in the AAV6-αsynuclein mouse model. Evgen. 2016-Ongoing. Management centre: UAM” Martínez Valverde A. Desarrollo de mecanismo de acción del glicinato de metformina en un modelo de hepatocitos. Laboratorios Silanes. 2015-Ongoing. Management centre: CSIC

INTERNATIONAL PROJECTS Martínez Valverde A. Neurodegeneration as an early event in the pathogenesis of diabetic retinopathy: a multicentric, prospective, phase II-III, double blind randomized controlled trial to assess the efficacy of neuroprotective administered topically to prevent or arrest diabetic retinopathy (EUROCONDOR) (FP7-HEALTH-2011-TWOSTAGE HEALTH.2011.2.4.3.1). EU. 2012-2016. Management centre: CSIC

Cuadrado Pastor A. Knowledge transfer in redox biology for developing advanced molecular tools in neurodegenerative diseases - focus on the signature of NRF2 transcription factor in diagnosis and therapy (P_37_732). EU. 2016-2020. Management centre: Victor Babes National Institute of Pathology (Bucharest)

PATENTS AND TRADEMARKS Cuadrado Pastor A, Innamorato NG, inventors; CSIC, UAM, assignees. Use of sulforaphane as supplementary therapy for early-stage neurodegenerative disease. P201231693; 2012 November 06. León Martínez R, Egea Maíquez J, Buendía Abaitua I, Parada Pérez E, Navarro González de Mesa E, inventors; Fundación para la Investigación Biomédica del Hospital Universitario de La Princesa, UAM, CSIC, DNS NEUROSCIENCE S.A., assignees. Use of 3-(2-isothiocyanatoethyl)5-methoxy-1H-indole for the treatment of neurodegenerative diseases. P201300667; 2013 July 17. León Martínez R, Buendía Abaitua I, Navarro González de Mesa E, Michalska P, Gameiro Ros I, López Vivo A, Egea Maíquez J, García López M, García García A, inventors; Fundación para la Investigación Biomédica del Hospital Universitario de La Princesa, UAM, DNS Neuroscience S.A., assignees. Compounds derived from 3-alkylamine-1H-indolyl acrylate and its use for the treatment of neurodegenerative diseases. P201400810, PCT/ES2015/000139, CA2964309; 2014 October15.

Cuadrado Pastor A. Aproximación teranóstica avanzada en cáncer combinando terapia fotodinámica y nanopartículas (PCIN-2016-071). MINECO-EU. 2016-2018. Management centre: UAM

110

Return to NEUROSCIENCE AREA INDEX

STRUCTURE, NEUROCHEMISTRY AND PLASTICITY OF NEURAL CIRCUITS OF THE CEREBRAL CORTEX AND THALAMUS GROUP 3 6.534 2

Francisco Clascá Cabré Catedrático. Facultad de de Medicina. UAM Juan Álvarez-Linera Prado Facultativo Especialista de Área en Radiodiagnóstico. HULP Carlos Avendaño Trueba Catedrático. Facultad de Medicina. UAM Marina Cabrizo Alonso Técnico de Laboratorio. UAM Guadalupe Camarero Calderón Investigadora Postdoctoral. IIB “Alberto Sols” Carmen Cavada Martínez Catedrática. Facultad de Medicina. UAM Miguel Ángel García Cabezas Profesor Asociado. Especialista en Anatomía Patológica. UAM María García-Amado Sancho Investigadora Predoctoral. UAM María José García-Miguel Piedras Ayudante de Universidad. Facultad de Medicina. UAM Agnieszka Krzyanowska Investigadora Predoctoral. UAM Raquel Márquez López Técnico de Laboratorio. UAM B.Yasmina Martín Martínez Investigadora Predoctoral. UAM Marta Miró Murillo Técnico de Laboratorio. UAM César Porrero Calzado Investigador Predoctoral. UAM Lucía Prensa Sepúlveda Profesora Titular. Facultad de Medicina. UAM Begoña Rodríguez Menéndez Técnico de Laboratorio. UAM

Pablo Rubio Garrido Profesor Contratado. Facultad de Medicina. Universidad San Pablo-CEU Rosa Sánchez Lozano Técnico de Laboratorio. UAM

Strategic Objective Our project is aimed towards identifying and quantifying the cellular microcircuits, neurochemistry and plasticity of neural networks that connect the cerebral cortex and the thalamus, as well as a number of systems afferent to the thalamus and its modification through stimulation or injury. These complex networks are the biological substrate of cognitive, perceptual and voluntary motor control capabilities. Although our objective is to advance understanding of the human brain, the implementation of the experimental techniques with the greatest problem-solving capacity must, in large part, be conducted in animal, primate and rodent models. The information that our studies provide is necessary to understanding the cellular basis of higher brain functions as the foundation for understanding its normal and pathological function.

Research Lines • Thalamocortical circuits: cellular and synaptic development and diversity in animal models. • Structure of neural systems and models of human neurological diseases (Parkinson’s and Alzheimer’s) in the brains of primates and rodents.

Continue

111

3.1 Neuroscience Area

3 INFORMATION GROUPS BY AREA • Plasticity of the somatosensory system. • Inhibitory mechanisms involved in neuropathic pain in animal models.

Research Activity

INVOLVEMENT OF GLYCINERGIC AND GLUTAMATERGIC SYSTEMS IN CENTRAL NERVOUS SYSTEM PATHOLOGIES GROUP

PUBLICATIONS • Cazemier JL, Clascá F, Tiesinga PHE. Connectomic analysis of brain networks: Novel techniques and future directions. Front Neuroanat. 2016;10:110. Review. IF: 3.267; D1 • de Manzo FP, Ingelmo I, Manzo A, Clascá F, Santamaría L. Quantitative changes in the V2 lateral visual cortex in developing rats with induced protein malnutrition. Eur J Anat. 2016;20(2):17184. Article. Not Indexed • Porrero C, Rodríguez-Moreno J, Quetglas JI, Smerdou C, Furuta T, Clascá F. A simple and efficient in vivo non-viral RNA transfection method for labeling the whole axonal tree of individual adult long-range projection neurons. Front Neuroanat. 2016;10:27. Article. IF: 3.267; D1

3 14.583 2

Cecilio Giménez Martín Catedrático. Facultad de Ciencias. UAM María del Carmen Aragón Rueda Catedrática. Facultad de Ciencias. UAM Esther Arribas González Investigadora Predoctoral. UAM Ignacio Ibáñez Sainz-Pardo Investigador Predoctoral. UAM Beatriz Fuensanta López Corcuera Profesora Titular. Facultad de Ciencias. UAM Enrique Núñez Balbuena Investigador Postdoctoral. UAM Francisco Zafra Gómez Catedrático. Facultad de Ciencias. UAM Eva Maria Porlan Alonso Investigador Postdoctoral. Ramón y Cajal. UAM

Strategic Objective The group studies the physiological and pathological aspects of the glycine transporters (GlyTs) in the central nervous system as emerging drug targets in transmission mediated glycine dysfunctions as hyperekplexia or pain. • Identification, analysis and classification of mutations in the gene of GlyT2 (SLC6A5) in human patients with hyperekplexia. • Effects of mutations of hyperekplexia on the molecular structure, biogenesis and intracellular trafficking of GlyT2. Study of the interaction of inhibitors 112

Return to NEUROSCIENCE AREA INDEX

with GlyT2 (dockings on 3D models) for selecting regions that facilitate folding or activity of hyperekplexia mutants. • Study of the interactome of GlyT2 with proteins already known or new mutants of human hyperekplexia. • Development of alternative cellular models for the study of hyperekplexia mutants such as infection of primary neurons with lentiviral particles or the generation of induced pluripotent stem cells (iPSC) from patient samples. • Regulation of GlyTs by receptors involved in pain signal processing in nociceptive pathways of the spinal cord.

Research Lines • Regulatory mechanisms of neurotransmitters flow between neurons and glia in the nervous system under physiological conditions and in ischemia. a) Regulation of intracellular trafficking of neurotransmitter transporter systems. b) Regulation of the expression of transporters, channels and receptors in the CNS by micro RNAs. • Molecular mechanisms of Dravet syndrome. Study of the intracellular trafficking and regulation of Nav1.1 sodium channel. • Molecular mechanisms underlying neurogenesis and its regulation by diverse kinases

Continue

113

3 INFORMATION GROUPS BY AREA

3.1 Neuroscience Area

Research Activity PUBLICATIONS • Ibáñez I, Díez-Guerra FJ, Giménez C, Zafra F. Activity dependent internalization of the glutamate transporter GLT-1 mediated by beta-arrestin 1 and ubiquitination. Neuropharmacology. 2016;107:376-86. Article. IF: 5.012; D1 • Quereda V, Porlán E, Canamero M, Dubus P, Malumbres M. An essential role for Ink4 and Cip/Kip cell-cycle inhibitors in preventing replicative stress. Cell Death Differ. 2016;23(3):430-41. Article. IF: 8.339; D1 • Porlán E, Martí-Prado B, Consiglio A, Farinas I. Stable and efficient genetic modification of cells in the adult mouse V-SVZ for the analysis of neural stem cell autonomous and non-autonomous effects. J Vis Exp. 2016;108:e53282. Article. IF: 1.232; Q2

PUBLIC PROJECTS López Corcuera B, Rueda Aragón C. Estructura, función y regulación del transportador neuronal de glicina GLYT2 en mutaciones asociadas a hiperplexia humana: desarrollo de nuevos modelos de estudio. (SAF2014-58045-R). MINECO. 2015-2017. Management centre: UAM Porlan Alonso EM. Control de la division celular asimétrica por reguladores mitóticos: implicaciones para procesos patológicos y regenerativos del sistema nervioso (SAF2015-67756-R). MINECO. 2016-2018. Management centre: UAM Zafra Gómez F. Regulación por microRNAs de las sinapsis glutamatérgicas en isquemia. Desarrollo de técnicas no invasivas para el estudio de la neurotransmisión mediada por glutamato (SAF2014-55686-R). MINECO. 2015-2017. Management centre: UAM

PRIVATE PROJECTS Zafra Gómez F. Mecanismos moleculares del síndrome de Dravet. Fundación Ramón Areces. 2015-2016. Management centre: UAM

114

Return to NEUROSCIENCE AREA INDEX

115

3 INFORMATION GROUPS BY AREA

RESEARCH ON INVASIVE CLINICAL CARDIOLOGY – ICCI-PAZ GROUP

3.2 Cardiovascular Area José Luis López-Sendón Hentschel

224 169 41

1,372.682 1,118.856 98

Research on Invasive Clinical Cardiology – ICCI-Paz Group Cardiovascular Epidemiology and Nutrition Group Coagulopathies and Alterations of Haemostasis Group Vascular Physiology and Pharmacology Group Vascular Pharmacology and Metabolism Group (FARMAVSM)

116

Return to INFORMATION GROUPS BY AREA INDEX

82 776.634 36 José Luis López-Sendón Hentschel Jefe de Servicio de Cardiología. HULP Isabel Antorrena Miranda Facultativo Especialista de Área en Cardiología. HULP Eduardo Armada Romero Facultativo Especialista de Área en Cardiología. HULP Almudena Castro Conde Facultativo Especialista de Área en Cardiología. HULP Regina Dalmáu González-Gallarza Facultativo Especialista de Área en Cardiología. HULP Francisco Javier Domínguez Melcón Facultativo Especialista de Área en Cardiología. HULP Carlos Escobar Cervantes Facultativo Especialista de Área en Cardiología. HULP Jaime Fernández de Bobadilla Osorio Facultativo Especialista de Área en Cardiología. HULP Javier Fuertes Beneítez Facultativo Especialista de Área en Cardiología. HULP Guillermo Galeote García Facultativo Especialista de Área en Cardiología. HULP Elvira Ana González García Facultativo Especialista de Área en Cardiología. HULP Teresa González Gallego Investigadora Senior (Contrato Ramón y Cajal). IIB “Alberto Sols” Gabriela Guzmán Martínez Facultativo Especialista de Área en Cardiología. HULP Ángel Manuel Iniesta Manjavacas Facultativo Especialista de Área en Cardiología. HULP Santiago Jiménez Valero Facultativo Especialista de Área en Cardiología. HULP Teresa López Fernández Facultativo Especialista de Área en Cardiología. HULP Esteban López de Sá y Areses Jefe de Sección de Cuidados Intensivos Cardiológicos. HULP

José Luis Merino Llorens Facultativo Especialista de Área en Cardiología. Director Unidad Investigación en Arritmias/Electrofisiología Robótica. HULP María del Carmen Monedero Martín Facultativo Especialista de Área en Cardiología. HULP José Raúl Moreno Gómez Jefe de Sección de Hemodinámica. HULP María del Mar Moreno Yangüela Jefe de Sección de Imagen Cardiaca. HULP Rafael Peinado Peinado Jefe de Sección de Arritmias y Electrofisiología. HULP Elena María Refoyo Salicio Facultativo Especialista de Área en Cardiología. HULP Juan Ramón Rey Blas Facultativo Especialista de Área en Cardiología. HULP Luis Riera del Moral Facultativo Especialista de Área en Angiología y Cirugía Vascular. HULP Profesor Asociado Departamento de Cirugía. UAM Inmaculada Roldán Rabadán Facultativo Especialista de Área en Cardiología. HULP José Ruiz Cantador Facultativo Especialista de Área en Cardiología. HULP Ángel Sánchez Recalde Facultativo Especialista de Área en Cardiología. HULP Silvia Cayetana Valbuena López Facultativo Especialista de Área en Cardiología. HULP

Strategic Objective The group consists of various healthcare units of the Department of Cardiology at Hospital La Paz: Clinic/ Coronary Unit, interventional cardiology, cardiac imaging, electrophysiology, rehabilitation and adult congenital heart disease.

Continue

117

3.2 Cardiovascular Area

3 INFORMATION GROUPS BY AREA The main research lines focus on providing clinical responses, with direct participation in clinical trials and international multicentre registries. Moreover, clinical translational potential is reinforced through an institutional relationship with the CNIC.

Research Lines • Myocardial ischaemia. Acute and chronic. Diagnosis, prognosis and treatment. • Cardiac arrhythmias. Catheter navigation systems. • Diagnosis and treatment. Post cardiac arrest hypothermia. • Heart Failure. Diagnosis and treatment. Cardiotoxicity of antineoplastic agents. • Cardiac diagnostic imaging. • Aortic stenosis. Diagnosis and treatment. • Adult congenital heart diseases.

Research Activity DOCTORAL THESES Fernández de Bobadilla J. Aspectos epidemiológicos, farmacoeconómicos, psicosociales y terapéuticos de la relación de la Enfermedad Cardiovascular y el Tabaquismo en España[dissertation]. Madrid: UAM: 2016(03/05/2016). Director: Álvarez-Sala Walther R.

BOOKS AND BOOK CHAPTERS Castro Conde A. Organización en la insuficiencia cardiaca. In: Marzal Martín D, López-Sendón Henschel JL, Rodríguez Padial L. Proceso asistencial simplificado de la insuficiencia cardiaca. Madrid: Sociedad Española de Cardiología, 2016. p.135-160 Kerkhove DG, Rigo F, Arpino G, Jerusalem G, LópezSendón J, Juanatey JR, Plana JC, Moonen M, ScherrerCrosbie M, Monaghan M, Maurea N, Cécile O, Erba PA, Coucke P, Frères P, Dulgheru R, Hinojar R, Sicari R, López-Fernández T, Marwick TH, Suter TM, Edvardsen T, Bours V, Sánchez V, González A, Cosyns D, BucciarelliDucci C, Cardinale D, Rodríguez Muñoz D. Cardiotoxicity: future research directions. In: Lancellotti P, Zamorano J, Galderisi M. Anticancer treatments and cardiotoxicity. San Diego: Elsevier, 2016. p.409-411

PUBLICATIONS • Ageno W, Buller HR, Falanga A, Hacke W, Hendriks J, Lobban T, Merino J, Milojevic IS, Moya F, van der Worp HB, Randall G, Tsioufis K, Verhamme P, Camm AJ. Managing reversal of direct oral anticoagulants in emergency situations Anticoagulation Education Task Force White Paper. Thromb Haemostasis. 2016;116(6):1003-10. Article. IF: 5.627; D1 • Akerstrom F, Pachon M, García-Fernández FJ, Salvador-Montañés O, Jensen-Urstad M, Puchol A, Peinado R, Salgado R, Insulander P, Rodríguez-Padial L, Arias MA. Number of beats in the transition zone with fixed SA interval during right ventricular overdrive pacing determines accessory pathway location in orthodromic reentrant tachycardia. Pace. 2016;39(1):21-7. Article. IF: 1.486; Q3 • Alfonso F, Pérez-Vizcaíno MJ, del Blanco BG, García-Touchard A, López-Mínguez JR, Masotti M, Zueco J, Melgares R, Mainar V, Moreno R, Domínguez A, Sanchis J, Bethencourt A, Moreu J, Cequier A, Martí V, Otaegui I, Bastante T, Gonzalo N, Jiménez-Quevedo P,

118

Cárdenas A, Fernández C. Everolimus-eluting stents in patients with bare-metal and drug-eluting in-stent restenosis results from a patient-level pooled analysis of the RIBS IV and V Trials. CircCardiovasc Inte. 2016;9(7):e003479. Article. IF: 7.198; D1 • Ambrosio G, Komajda M, Mugelli A, López-Sendón J, Tamargo J, Camm J. Management of stable angina: A commentary on the European Society of Cardiology guidelines. Eur J Prev Cardiol. 2016;23(13):1401-12. Editorial Material. IF: 3.606; Q2 • Anguera I, García-Alberola A, Dallaglio P, Toquero J, Pérez L, Martínez JG, Peinado R, Rubín JM, Brugada J, Cequier A. Shock reduction with long-term quinidine in patients with brugada syndrome and malignant ventricular arrhythmia episodes. J Am Coll Cardiol. 2016;67(13):1653-4. Letter. IF: 19.896; D1 • Arbel Y, FitzGerald G, Yan AT, Tan MK, Fox KAA, Gore JM, Steg PG, Eagle KA, Brieger D, Montalescot G, Budaj A, López-Sendón J, Avezum A, Granger CB, Goodman SG. Temporal trends in all-cause mortality according to smoking status: Insights from the Global Registry of Acute Coronary Events. Int J Cardiol. 2016;218:291-7. Article. IF: 6.189; Q1 • Aroca A, Polo L, Sánchez R, Bret M, González A, Rey J, Ruiz J, Peña N, Pérez N, González A, Sánchez-Recalde A, Villagrá F. Single ventricle surgery in adulthood. A considered decision. Cir Cardiov . 2016;23(2):80-6. Article. Not Indexed • Arroyo-Ucar E, Moreno R, del Prado S, López T, Sánchez-Recalde A, Orbe LC, Jiménez-Valero S, Galeote G, Ramírez MU, Davia RG, Plaza I, Mesa JM, López-Sendón JL. Echogenic mobile images in intraprocedural three-dimensional transesophageal echocardiographic monitoring during percutaneous aortic valve implantation: Incidence, characteristics and clinical implications. Rev Port Cardiol. 2016;35(3):133-8. Article. IF: 1.195; Q4 • Barrios V, Escobar C. Blood pressure goals revisited. J Hypertens. 2016;34(7):1444-5. Letter. IF: 4.085; Q1 • Barrios V, Escobar C. Clinical benefits of pitavastatin: focus on patients with diabetes or at risk of developing diabetes. Future Cardiol. 2016;12(4):449-66. Article. Not Indexed • Barrios V, Escobar C. Implications of edoxaban in the prevention and treatment of thromboembolic complications in clinical practice. Future Cardiol. 2016;12(4):419-33. Article. Not Indexed • Barrios V, Escobar C. Improving cardiovascular protection: focus on a cardiovascular polypill. Future Cardiol. 2016;12(2):181-96. Review. Not Indexed • Bohm M, Lloyd SM, Ford I, Borer JS, Ewen S, Laufs U, Mahfoud F, López-Sendón J, Ponikowski P, Tavazzi L, Swedberg K, Komajda M. Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT. Eur J Heart Fail. 2016;18(6):672-83. Article. IF: 6.968; D1 • Bonaca MP, Bhatt DL, Steg PG, Storey RF, Cohen M, Im K, Ophuis TO, Budaj A, Goto S, López-Sendón J, Díaz R, Dalby A,Van de Werf F, Ardissino D, Montalescot G, Aylward P, Magnani G, Jensen EC, Held P, Braunwald E, Sabatine MS. Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y(12) inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUSTIMI 54. Eur Heart J. 2016;37(14):1133-42. Article. IF: 19.651; D1 • Bonaca MP, Bhatt DL, Storey RF, Steg G, Cohen M, Kuder J, Goodrich E, Nicolau JC, Parkhomenko A, López-Sendón J, Dellborg M, Dalby A, Spinar J, Aylward P, Corbalaá R, Abola MTB, Jensen EC, Held P, Braunwald E, Sabatine MS. Ticagrelor for prevention of ischemic events after myocardial infarction in patients with peripheral artery disease. J Am Coll Cardiol. 2016;67(23):271928. Article. IF: 19.896; D1 • Cannon CP, Gropper S, Bhatt DL, Ellis SG, Kimura T, Lip GYH, Steg PG, ten Berg JM, Manassie J, Kreuzer J, Blatchford J, Massaro JM, Brueckmann M, Ripoll EF, Oldgren J, Hohnloser SH, (López Sendón JL). Design and rationale of the RE-DUAL PCI Trial: A prospective, randomized, phase 3b study comparing the safety and efficacy of dual antithrombotic therapy with dabigatran etexilate versus warfarin triple therapy in patients with nonval-

vular atrial fibrillation who have undergone percutaneous coronary intervention with stenting. Clin Cardiol. 2016;39(10):55564. Article. IF: 2.757; Q2 • Caro-Codón J, Galeote G, Álvarez-Ortega C, Moreno R, López-Sendón JL. A marble in the heart. JACC-Cardiovasc Inte. 2016;9(24):2573-4. Editorial Material. IF: 8.841; D1 • Caro-Codón J, Jiménez-Valero S, Galeote G, Sánchez-Recalde A, Moreno R. Radiation-induced coronary artery disease: Useful insights from OCT. Int J Cardiol. 2016;202:535-6. Letter. IF: 6.189; Q1 • Caro-Codón J, Valbuena-López S, Álvarez-Ortega C, MorenoYanguela M, Moreno R. Rapid pacing-induced massive mitral regurgitation during transcatheter aortic valve implantation. Circ J. 2016;80(3):748-9. Editorial Material. IF: 3.544; Q2 • Conde AC, Martín DM, González-Gallarza RD, Esteban VA, Bueno MM, Marimón XGM, Senén AB, Murga N, Abeytua M.Vascular risk and cardiac rehabilitation 2015: A selection of topical issues. Rev Esp Cardiol. 2016;69(3):294-9. Article. IF: 4.485; Q2 • Connolly SJ, Milling TJ, Eikelboom JW, Gibson CM, Curnutte JT, Gold A, Bronson MD, Lu GM, Conley PB, Verhamme P, Schmidt J, Middeldorp S, Cohen AT, Beyer-Westendorf J, Albaladejo P, López-Sendón J, Goodman S, Leeds J, Wiens BL, Siegal DM, Zotova E, Meeks B, Nakamya J, Lim WT, Crowther M. Andexanet alfa for acute major bleeding associated with factor XA Inhibitors. New Engl J Med. 2016;375(12):1131-41. Article. IF: 72.406; D1 • Chan WK, Goodman SG, Brieger D, Fox KAA, Gale CP, Chew DP, Udell JA, López-Sendon J, Huynh T, Yan RT, Singh SM, Yan AT. Clinical characteristics, management, and outcomes of acute coronary syndrome in patients with right bundle branch block on presentation. Am J Cardiol. 2016;117(5):754-9. Article. IF: 3.398; Q2 • Dallaglio PD, Anguera I, Jiménez-Candil J, Peinado R, García-Seara J, Arcocha MF, Macías R, Herreros B, Quesada A, HernándezMadrid A, Álvarez M, di Marco A, Filgueiras D, Matía R, Cequier A, Sabate X. Impact of previous cardiac surgery on long-term outcome of cavotricuspid isthmus-dependent atrial flutter ablation. Europace. 2016;18(6):873-80. Article. IF: 4.53; Q1 • Danchin N, Lettino M, Zeymer U, Widimsky P, Bardaji A, Barrabes JA, Cequier A, Claeys MJ, de Luca L, Dorler J, Erlinge D, Erne P, Goldstein P, Koul SM, Lemesle G, Luscher TF, Matter CM, Montalescot G, Radovanovic D, Sendón JL, Tousek P, Weidinger F, Weston CFM, Zaman A, Andell P, Li J, Jukema JW. Use, patient selection and outcomes of P2Y12 receptor inhibitor treatment in patients with STEMI based on contemporary European registries. Eur Heart J Cardiovasc Pharmacother. 2016;2(3):152-67. Article. Not Indexed • de Caterina R, Andersson U, Alexander JH, Al-Khatib SM, Bahit MC, Goto S, Hanna M, Held C, Hohnloser S, Hylek EM, Lanas F, Lopes RD, López-Sendon J, Renda G, Horowitz J, Granger CB, Wallentin L. History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation trial. Am Heart J. 2016;175:175-83. Article. IF: 4.436; Q2 • Díaz SD, Salicio ER, Valbuena-López SC, Peña MFV, RamírezValdiris U, Guzmán-Martínez G. Multidetector computed tomography usefulness in infective endocarditis. Rev Esp Cardiol. 2016;69(4):442-5. Letter. IF: 4.485; Q2 • Escobar C, Barrios V, Prieto L. Therapeutic behavior of primary care physicians in patients with atrial fibrillation taking vitamin K antagonists not adequately controlled. Eur J Intern Med. 2016;30:E17-8. Letter. IF: 2.96; Q1 • Esteve-Pastor MA, García-Fernández A, Macías M, Sogorb F, Valdés M, Roldán V, Muñiz J, Badimón L, Roldán I, BertomeuMartínez V, Cequier A, Lip GYH,Anguita M, Marín F. Is the ORBIT bleeding risk score superior to the HAS-BLED score in anticoagulated atrial fibrillation patients? Circ J. 2016;80(10):2102-8. Article. IF: 3.544; Q2 • Esteve-Pastor MA, Marín F, Bertoméu-Martínez V, Roldán-Rabadán I, Cequier-Fillat A, Badimón L, Muñiz-García J, Valdés M,

Anguita-Sánchez M. Do physicians correctly calculate thromboembolic risk scores? A comparison of concordance between manual and computer-based calculation of CHADS(2) and CHA(2)DS(2)-VASc scores. Intern Med J. 2016;46(5):583-9. Article. IF: 1.902; Q2 • Estrada A, Doiny D, Merino JL. Perimitral atrial flutter ablation by transaortic radiofrequency application. Europace. 2016;18(7):1037. Article. IF: 4.53; Q1 • Fernández-Lozano I, Brugada J, Alzueta J, Arbelo E, Arribas F, García-Bolao I, Merino JL, Olalla JJ, Osca J, Quesada A, Anguita M, Cequier A, Alfonso F, Badimón L, Barrabés JA, Lozano IF, de Diego JJG, Padial LR, San Román JA, Sánchez PL, Sanchis J, Sionis A. Comments on the 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Rev Esp Cardiol. 2016;69(2):94-101. Editorial Material. IF: 4.485; Q2 • Ferreira-González I, Abu-Assi E, Arias MA, Gallego P, SánchezRecalde A, Avanzas P, Bayes-Genis A, de Isla LP, Sanchis J. Revista Española de Cardiologia: Current position and future directions. Rev Esp Cardiol. 2016;69(3):327-36. Editorial Material. IF: 4.485; Q2 • Fontenla A, Martínez-Ferrer JB, Alzueta J, Vinolas X, GarcíaAlberola A, Brugada J, Peinado R, Sancho-Tello MJ, Cano A, Fernández-Lozano I. Incidence of arrhythmias in a large cohort of patients with current implantable cardioverter-defibrillators in Spain: results from the UMBRELLA Registry. Europace. 2016;18(11):1726-34. Article. IF: 4.53; Q1 • García-Gutiérrez V, Jiménez-Velasco A, Gómez-Casares MT, Sánchez-Guijo F, López-Sendón JL, Steegmann Olmedillas JL. Cardiovascular management of patients with chronic myeloid leukemia from a multidisciplinary perspective, and proposing action protocol by consensus meeting. Med Clin-Barcelona. 2016;146(12):561.e1-8. Article. IF: 1.125; Q3 • Gemma D, Gómez RM, de Bobadilla JF, García GG, Fernández TL, López-Mínguez JR, López-Sendón JL. Percutaneous balloon mitral valvuloplasty and closure of the left atrial appendage: Synergy of two procedures in one percutaneous intervention. Rev Port Cardiol. 2016;35(11):617. Article. IF: 1.195; Q4 • Goette A, Merino JL, Ezekowitz MD, Zamoryakhin D, Melino M, Jin J, Mercuri MF, Grosso MA, Fernández V, Al-Saady N, Pelekh N, Merkely B, Zenin S, Kushnir M, Spinar J, Batushkin V, de Groot JR, Lip GYH. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. Lancet. 2016;388(10055):1995-2003. Article. IF: 47.831; D1 • Gómez-Lara J, Salvatella N, Gonzalo N, Hernández-Hernández F, Fernández-Nofrerias E, Sánchez-Recalde A, Bastante T, Marcano A, Romaguera R, Ferreiro JL, Roura G, Teruel L, Ariza-Sole A, Miranda-Guardiola F, García-Abad VR, Gómez-Hospital JA, Alfonso F, Cequier A. IVUS-guided treatment strategies for definite late and very late stent thrombosis. Eurointervention. 2016;12(11):E1355-65. Article. IF: 5.165; Q1 • Green AS, Lorite NM, Bueno H, Payeras AC, Molina BD, Juanatey JRG, Urioste LMR, Gómez JLZ, Bonet LA, Sole AA, Freire RB, Rodríguez JLL, de Sa EL, Fernández SL, Asenjo RM, Pérez SM, Figal DP, Cubero JS, Román AV, Calvar JAS, Manterola FA,Ynsaurriaga FA, Masip AE, Gonzalez IF, Navarro MJ, Ortuno FM, de Isla LP, Padial LR, Fernández PLS, Green AS, García RV. Comments on the 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Rev Esp Cardiol. 2016;69(12):111925. Editorial Material. IF: 4.485; Q2 • Hagstrom E, James SK, Bertilsson M, Becker RC, Himmelmann A, Husted S, Katus HA, Steg PG, Storey RF, Siegbahn A,Wallentin L, (López Sendón JL). Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study. Eur Heart J. 2016;37(16):1325-33. Article. IF: 19.651; D1 • Hernández JMD, Moreno R, Lee DH, García del Blanco B, San Martín JC, García Blas S, Serra García V, Gaviria K, García I, Zue-

Continue

119

3.2 Cardiovascular Area

3 INFORMATION GROUPS BY AREA

120

co J.The routine use of surgical exposure approach for trans-femoral implantation of the balloon expandable aortic prosthesis is associated to a low rate of vascular complications. J Cardiovasc Surg. 2016;57(4):615-9. Article. IF: 2.179; Q2 • Hernández-Enríquez M, Andrea R, Brugaletta S, Jiménez-Quevedo P, Hernández-García JM,Trillo R, Larman M, Fernández-Avilés F, Vázquez-González N, Iñíguez A, Zueco J, Ruiz-Salmerón R, del Valle R, Molina E, del Blanco BG, Berenguer A,Valdés M, Moreno R, Urbano-Carrillo C, Hernández-Antolín R, Gimeno F, Cequier A, Cruz I, López-Mínguez JR, Aramendi JI, Sánchez A, Goicolea J, Albarran A, Díaz JF, Navarro F, Moreu J, Morist A, FernándezNofrerias E, Fernández-Vázquez F, Ten F, Mainar V, Mari B, Saenz A, Alfonso F, Diarte JA, Sancho M, Lezaun R, Arzamendi D, Sabate M. Puncture versus surgical cutdown complications of transfemoral aortic valve implantation (from the Spanish TAVI Registry). Am J Cardiol. 2016;118(4):578-84. Article. IF: 3.398; Q2 • Hijazi Z, Aulin J, Andersson U, Alexander JH, Gersh B, Granger CB, Hanna M, Horowitz J, Hylek EM, Lopes RD, Siegbahn A, Wallentin L, (López Sendón JL). Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation. Heart. 2016;102(7):508-17. Article. IF: 6.059; Q1 • Hijazi Z, Hohnloser SH, Andersson U, Alexander JH, Hanna M, Keltai M, Parkhomenko A, López-Sendón JL, Lopes RD, Siegbahn A, Granger CB,Wallentin L. Efficacy and safety of apixaban compared with warfarin in patients with atrial fibrillation in relation to renal function over time insights from the ARISTOTLE randomized clinical trial. JAMA Cardiol. 2016;1(4):451-60. Article. Not Indexed • Hori M, Matsumoto M, Tanahashi N, Momomura S, Uchiyama S, Goto S, Izumi T, Koretsune Y, Kajikawa M, Kato M, Cavaliere M, Iekushi K, Yamanaka S, (Merino JL). Predictive factors for bleeding during treatment with rivaroxaban and warfarin in Japanese patients with atrial fibrillation - Subgroup analysis of J-ROCKET AF. J Cardiol. 2016;68(42891):523-8. Article. IF: 2.732; Q2 • Hori M, Ohashi Y, Pan GH, Kato M, Kajikawa M, (Merino JL). Point-of-care device for warfarin monitoring used in the J-ROCKET AF Study. Circ J. 2016;80(6):1488-90. Letter. IF: 3.544; Q2 • Johansson A, Eriksson N, Lindholm D, Varenhorst C, James S, Syvanen AC, Axelsson T, Siegbahn A, Barratt BJ, Becker RC, Himmelmann A, Katus HA, Steg PG, Storey RF, Wallentin L, (López Sendón JL). Genome-wide association and Mendelian randomization study of NT-proBNP in patients with acute coronary syndrome. Hum Mol Genet. 2016;25(7):1447-56. Article. IF: 5.34; Q2 • Jolly SS, Caims JA, Yusuf S, Rokoss MJ, Gao P, Meeks B, Kedev S, Stankovic G, Moreno R, Gershlick A, Chowdhary S, Lavi S, Niemela K, Bernat I, Cantor WJ, Cheema AN, Steg PG, Welsh RC, Sheth T, Bertrand OF, Avezum A, Bhindi R, Natarajan MK, Horak D, Leung RCM, Kassam S, Rao SV, El-Omar M, Mehta SR,Velianou JL, Pancholy S, Dzavik V. Outcomes after thrombus aspiration for ST elevation myocardial infarction: 1-year follow-up of the prospective randomised TOTAL trial. Lancet. 2016;387(10014):12735. Article. IF: 47.831; D1 • Kotseva K, Wood D, de Bacquer D, de Backer G, Ryden L, Jennings C, Gyberg V, Amouyel P, Bruthans J, Conde AC, Cifkova R, Deckers JW, de Sutter J, Dilic M, Dolzhenko M, Erglis A, Fras Z, Gaita D, Gotcheva N, Goudevenos J, Heuschmann P, Laucevicius A, Lehto S, Lovic D, Milicic D, Moore D, Nicolaides E, Oganov R, Pajak A, Pogosova N, Reiner Z, Stagmo M, Stork S, Tokgozoglu L, Vulic D. EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol. 2016;23(6):636-48. Article. IF: 3.606; Q2 • Lesiak M, Araszkiewicz A, Grajek S, Colombo A, Lalmand J, Carstensen S, Namiki A, Tobaru T, Merkely B, Moreno R, Barbato E, Wijns W, Saito S. Long coronary lesions treated with thin strut bioresorbable polymer drug eluting stent: Experience from multicentre randomized CENTURY II study. J Interv Cardiol. 2016;29(1):47-56. Article. IF: 1.88; Q3

• Lillo-Castellano JM, Marina-Breysse M, Gómez-Gallanti A, Martínez-Ferrer JB, Alzueta J, Pérez-Álvarez L, Alberola A, FernándezLozano I, Rodríguez A, Porro R, Anguera I, Fontenla A, GonzálezFerrer JJ, Canadas-Godoy V, Pérez-Castellano N, Garofalo D, Salvador-Montañés O, Calvo CJ, Quintanilla JG, Peinado R, MoraJiménez I, Pérez-Villacastín J, Rojo-Álvarez JL, Filgueiras-Rama D. Safety threshold of R-wave amplitudes in patients with implantable cardioverter defibrillator. Heart. 2016;102(20):1662-70. Article. IF: 6.059; Q1 • Lincoff AM, Mehran R, Povsic TJ, Zelenkofske SL, Huang Z, Armstrong PW, Steg PG, Bode C, Cohen MG, Buller C, Laanmets P, Valgimigli M, Marandi T, Fridrich V, Cantor WJ, Merkely B, López-Sendón J, Cornel JH, Kasprzak JD, Aschermann M, Guetta V, Morais J, Sinnaeve PR, Huber K, Stables R, Sellers MA, Borgman M, Glenn L, Levinson AI, Lopes RD, Hasselblad V, Becker RC, Alexander JH. Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial. Lancet. 2016;387(10016):349-56. Article. IF: 47.831; D1 • Lobos-Bejarano JM, Barrios V, Polo-García J, Escobar C, VargasOrtega D, Marín-Montanes N, Prieto-Valiente L, Fuentes S, Prieto MA, García-Ortiz L. Evaluation of SAMe-TT2R2 score and other clinical factors influencing the quality of anticoagulation therapy in non-valvular atrial fibrillation: a nationwide study in Spain. Curr Med Res Opin. 2016;32(7):1201-7. Article. IF: 2.757; Q1 • López MLP, Peinado AA, Rocafort AG, Zurita MB, Lois JR, Blanco FV, Ruiz JMO, Recalde AS. Surgical correction in adults with Fallot previously unoperated or just palliated: Fiction or reality? Cir Cardiov . 2016;23(1):24-30. Article. Not Indexed • López MLP, Peinado AA, Rocafort AG, Zurita MB, Lois JR, Pérez RS, Blanco FV, Ruiz JMO, Recalde AS. Surgical reinterventions in Fallot patients during adulthood: An emerging population. Cir Cardiov . 2016;23(5):220-8. Article. Not Indexed • López-Sendón JL, González-Juanatey JR, Pinto F, Castillo JC, Badimón L, Dalmau R,Torrecilla EG, Mínguez JRL, Maceira AM, Pascual-Figal D, Moya-Prats JLP, Sionis A, Zamorano JL. Quality markers in cardiology: measures of outcomes and clinical practice-a perspective of the Spanish Society of Cardiology and of Thoracic and Cardiovascular Surgery. Eur Heart J. 2016;37(1):12-23. Article. IF: 19.651; D1 • Lozano IF, Urkia C, Mesa JBL, Escudier JM, Manrique I, García ND, Vázquez AP, Sionis A, Osorio PL, Núñez M, de Sa EL. European resuscitation council guidelines for resuscitation 2015: Key points. Rev Esp Cardiol. 2016;69(6):588-94. Editorial Material. IF: 4.485; Q2 • Lyden PD, López-de-Sa E, Nichol G, Kiragu AW. Current advances in the use of therapeutic hypothermia. Ther Hypothermia Temp Manag. 2016;6(1):2-5. Editorial Material. IF: 1.787; Q4 • Manolis AJ, Poulimenos LE, Ambrosio G, Kallistratos MS, LópezSendón J, Dechend R, Mancia G, Camm AJ. Medical treatment of stable angina: A tailored therapeutic approach. Int J Cardiol. 2016;220:445-53. Review. IF: 6.189; Q1 • Martín-Reyes R, Hernández JMD, Franco-Peláez J, López-Palop R, Arrieta MT, Santos IJA, Sáez PC, Sánchez-Recalde A, Peña JCS, Camarero TG, Brugaletta S, de Carlos FG, Piñero A, Sánchez DCS, Frutos A, Larraya GL, Navarro F, Farre J. The use of the acute Pd/ Pa drop after intracoronary nitroglycerin infusion to rule out significant FFR: CANICA (Can intracoronary nitroglycerin predict fractional flow reserve without adenosine?) multicenter study. Catheter Cardio Inte. 2016;87(2):262-9. Article. IF: 2.602; Q2 • McMurray JJV, Krum H, Abraham WT, Dickstein K, Kober LV, Desai AS, Solomon SD, Greenlaw N, Ali MA, Chiang YT, Shao Q, Tarnesby G, Massie BM, (Castro Conde A) . Aliskiren, enalapril, or aliskiren and enalapril in heart failure. New Engl J Med. 2016;374(16):1521-32. Article. IF: 72.406; D1 • Merino JL, Arceluz M, Delgado R, Falconi E, Cruz F, Vásquez CC, Ortega M. Sensitivity and accuracy of Sensitherm/Esotherm oesophageal temperature probe. Europace. 2016;18(3):468-9. Letter. IF: 4.53; Q1

• Murphy SA, Cannon CP, Blazing MA, Giugliano RP, White JA, Lokhnygina Y, Reist C, Im K, Bohula EA, Isaza D, López-Sendón J, Dellborg M, Kher U, Tershakovec AM, Braunwald E. Reduction in total cardiovascular events with Ezetimibe/Simvastatin postacute coronary syndrome the IMPROVE-IT Trial. J Am Coll Cardiol. 2016;67(4):353-61. Article. IF: 19.896; D1 • O’Donoghue ML, Glaser R, Cavender MA, Aylward PE, Bonaca MP, Budaj A, Davies RY, Dellborg M, Fox KAA, Gutiérrez JAT, Hamm C, Kiss RG, Kovar F, Kuder JF, Im KA, Lepore JJ, LópezSendón JL, Ophuis TO, Parkhomenko A, Shannon JB, Spinar J, Tanguay JF, Ruda M, Steg PG, Theroux P, Wiviott SD, Laws I, Sabatine MS, Morrow DA. Effect of losmapimod on cardiovascular outcomes in patients hospitalized with acute myocardial infarction a randomized clinical trial. JAMA-J Am Med Assoc. 2016;315(15):1591-9. Article. IF: 44.405; D1 • Oldgren J, Hijazi Z, Lindback J,Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Granger CB, Hylek EM, Lopes RD, Siegbahn A, Yusuf S,Wallentin L, (López Sendón JL). Performance and validation of a novel biomarker-based stroke risk score for atrial fibrillation. Circulation. 2016;134(22):1697-707. Article. IF: 19.309; D1 • Ortiz MR, Roldán I, Bertoméu V, Muñiz J, Marín F, Anguita M. Structural heart disease in anticoagulated patients with nonvalvular atrial fibrillation: Prevalence and clinical profile in a Spanish Sample. Rev Esp Cardiol. 2016;69(10):986-90. Letter. IF: 4.485; Q2 • Peinado R, Ruiz-Mateos F, Izquierdo M, Arana E, Robledo M, Arias MA, Jiménez-Jáimez J, Rodríguez-Manero M, Chimeno J. Cardiac arrhythmias and pacing 2015: A selection of topical issues. Rev Esp Cardiol. 2016;69(2):167-75. Editorial Material. IF: 4.485; Q2 • Pokorney SD, Piccini JP, Stevens SR, Patel MR, Pieper KS, Halperin JL, Breithardt G, Singer DE, Hankey GJ, Hacke W, Becker RC, Berkowitz SD, Nessel CC, Mahaffey KW, Fox KAA, Califf RM, (Merino JL). Cause of death and predictors of all-cause mortality in anticoagulated patients with nonvalvular atrial fibrillation: Data from ROCKET AF. J Am Heart Assoc. 2016;5(3):e002197. Article. IF: 4.863; Q1 • Ponz I, López-de-Sa E, Armada E, Caro J, Blázquez Z, Rosillo S, González O, Rey JR, Monedero MD, López-Sendón JL. Influence of the temperature on the moment of awakening in patients treated with therapeutic hypothermia after cardiac arrest. Resuscitation. 2016;103:32-6. Article. IF: 5.23; D1 • Rabadán IR, Sánchez MA, Marín F, Quesada MA, Siles JC, Peinado R, Bertomeu V, Fillat AC, Badimón L, Muñiz J. Current antiarrhythmic therapy for nonvalvular atrial fibrillation in Spain. Data from the FANTASIIA Registry. Rev Esp Cardiol. 2016;69(1):5460. Article. IF: 4.485; Q2 • Rao SV, Zeymer U, Douglas PS, Al-Khalidi H, White JA, Liu JY, Levy H, Guetta V, Gibson CM, Tanguay JF, Vermeersch P, Roncalli J, Kasprzak JD, Henry TD, Frey N, Kracoff O, Traverse JH, Chew DP, López-Sendón J, Heyrman R, Krucoff MW. Bioabsorbable intracoronary matrix for prevention of ventricular remodeling after myocardial infarction. J Am Coll Cardiol. 2016;68(7):71523. Article. IF: 19.896; D1 • Rodríguez-Manero M, Abu Assi E, Sánchez-Gómez JM, Fernández-Armenta J, Díaz-Infante E, García-Bolao I, Benezet-Mazuecos J, Lahuerta AA, Expósito-García V, Bertomeu-González V, Arce-León A, Barrio-López MT, Peinado R, Martínez-Sande L, Arias MA. Comparative evaluation of four risk scores for predicting mortality in patients with implantable cardioverter-defibrillator for primary prevention. Rev Esp Cardiol. 2016;69(11):1033-41. Article. IF: 4.485; Q2 • Rodríguez-Manero M, Barrio-López MT, Abu Assi E, ExpósitoGarcía V, Bertomeu-González V, Sánchez-Gómez JM, GonzálezTorres L, García-Bolao I, Gaztanaga L, Cabañas-Grandio P, Iglesias-Bravo JA, Arce-León A, la Huerta AA, Fernández-Armenta J, Peinado R, Arias MA, Díaz-Infante E. Primary prevention of sudden death in patients with valvular cardiomyopathy. Rev Esp Cardiol. 2016;69(3):272-8. Article. IF: 4.485; Q2

• Salinas P, Moreno R, Calvo L, Sánchez-Recalde A, Jiménez-Valero S, Galeote G, López-Fernández T, Ramírez U, Riera L, Plaza I, Moreno I, Mesa JM, López-Sendon JL. Long-term follow-up after transcatheter aortic valve implantation for severe aortic stenosis. Rev Esp Cardiol. 2016;69(1):37-44. Article. IF: 4.485; Q2 • Sánchez MA, Conde AC, Fort AC, Marimón XGM, Doblás JJG, González-Juanatey JR, Corbi RML, López-Sendón JL, Prieto JM, Padial LR. Challenges in oral lipid-lowering therapy: position document of the Spanish Society of Cardiology. Rev Esp Cardiol. 2016;69(11):1083-7. Editorial Material. IF: 4.485; Q2 • Sánchez-Recalde A, Moreno R, Flores BE, Jiménez-Valero S, Mateos AGDY, López-Sendón JL. Percutaneous transcatheter treatment for massive pulmonary embolism. Rev Esp Cardiol. 2016;69(3):340-2. Letter. IF: 4.485; Q2 • Sánchez-Recalde A, Moreno R, Jiménez-Valero S, Galeote G. Systemic thrombolysis for high-risk pulmonary embolism versus percutaneous transcatheter treatment. Response. Rev Esp Cardiol. 2016;69(8):801-2. Letter. IF: 4.485; Q2 • Sanjuán P, Montalbetti T, Pérez-García AM, Bermédez J, Arranz H, Castro A. A Randomised trial of a positive intervention to promote well-being in cardiac patients.Appl Psychol Health Well Being. 2016;8(1):64-84. Article. IF: 2.722; Q1 • Shimada YJ, Bansilal S, Wiviott SD, Becker RC, Harrington RA, Himmelmann A, Neely B, Husted S, James SK, Katus HA, Lopes RD, Steg PG, Storey RF, Wallentin L, Cannon CP, (López-Sendón JL). Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Am Heart J. 2016;177:1-8. Article. IF: 4.436; Q2 • Velders MA, Abtan J, Angiolillo DJ, Ardissino D, Harrington RA, Hellkamp A, Himmelmann A, Husted S, Katus HA, Meier B, Schulte PJ, Storey RF, Wallentin L, Steg PG, James SK, (López Sendón JL). Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention. Heart. 2016;102(8):61725. Article. IF: 6.059; Q1 • Weisz G, Genereux P, Iniguez A, Zurakowski A, Shechter M, Alexander KP, Dressler O, Osmukhina A, James S, Ohman EM, Ben-Yehuda O, Farzaneh-Far R, Stone GW (Moreno Gómez R). Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2016;387(10014):136-45. Article. IF: 47.831; D1 • Zeymer U, Montalescot G, Ardissino D, Bolognese L, Clemmensen P, Collet JP, López-Sendón J, Widimsky P. Optimal timing of initiation of oral P2Y12-receptor antagonist therapy in patients with non-ST elevation acute coronary syndromes. Lessons learnt from the ACCOAST-trial. Eur Heart J Acute Cardiovasc Care. 2016;5(3):282-8. Article. Not Indexed • Zeymer U, Widimsky P, Danchin N, Lettino M, Bardaji A, Barrabes JA, Cequier A, Claeys MJ, de Luca L, Dorler J, Erlinge D, Erne P, Goldstein P, Koul SM, Lemesle G, Luscher TF, Matter CM, Montalescot G, Radovanovic D, Sendón JL,Tousek P,Weidinger F, Weston CFM, Zaman A, Andell P, Li J, Jukema JW. P2Y12 receptor inhibitors in patients with non-ST-elevation acute coronary syndrome in the real world: use, patient selection, and outcomes from contemporary European registries. Eur Heart J Cardiovasc Pharmacother. 2016;2(4):229-43. Article. Not Indexed

PUBLIC PROJECTS Jiménez Valero S. ABLAVIEW - Un sistema innovador de ablacion por radio-frecuencia guiado por imagen para el tratamiento de la fibrilación auricular (RTC-2016-20165445-1). MINECO. 2016-2019. Management centre: FIBHULP

Continue

121

3.2 Cardiovascular Area

3 INFORMATION GROUPS BY AREA López-Sendón Hentschel JL. Red de Enfermedades Cardiovasculares (RECAVA) (RD12/0042/0063). ISCIII. 2013-2017. Management centre: FIBHULP López-Sendón Hentschel JL. Toxicidad cardiovascular por fármacos antitumorales. Valoración del riesgo y diagnóstico precoz (PI13/00559). ISCIII. 2014-2017. Management centre: FIBHULP

PRIVATE PROJECTS Castro Conde A. Tecnologías disruptivas para la rehabilitación del futuro paquete de trabajo 1: modelado de sitemas biónicos híbridos para escenarios de rehabilitación virtuales y ubicuos basados en la evidencia. Paquete de trabajo 6: adaptación inteligente de terapia. Laboratorios Servier S.L. 2011-Ongoing. Management centre: FIBHULP Castro Conde A. Curso de rehabilitación cardiaca. 2012-Ongoing. Management centre: FIBHULP Castro Conde A. Jornadas de formación en investigación en la prevención secundaria y rehabilitación. Astrazeneca Farmacéutica Spain S.A. 2013-Ongoing. Management centre: FIBHULP Castro Conde A. II Encuentro nacional de investigación en Rehabilitación Cardiaca. Laboratorio Menarini S.A. 2015-Ongoing. Management centre: FIBHULP Dalmáu González-Gallerza R. Estudio de los beneficios de la marcha nórdica dentro de un programa de rehabilitación cardíaca en pacientes con Síndrome Coronario Agudo Reciente. Laboratorio Menarini S.A. 2011-Ongoing. Management centre: FIBHULP Jiménez Valero S. Estudio en modelo porcino para evaluar la utilidad de la tomografía de coherencia óptica en el análisis de las lesiones endocárdicas producidas por radiofrecuencia. Medlumics S.L. 2015-Ongoing. Management centre: FIBHULP Jiménez Valero S. Análisis de correlación entre los marcadores de inflamación y morfología de placas coronarias mediante tomografía de coherencia óptica y tec multicorte: estudio IVI. Abbott Laboratories S.A. 2009-Ongoing. Management centre: FIBHULP López-Sendón Hentschel JL. Sesiones clínicas de Cardiología. Astrazeneca Farmacéutica Spain S.A. 2006-Ongoing. Management centre: FIBHULP López-Sendón Hentschel JL. International study of comparative health effectiveness with medical and invasive approaches - estudio internacional comparativo de la eficacia sanitaria con enfoques médicos e invasivos. 2013-Ongoing. Management centre: FIBHULP López-Sendón Hentschel JL. Biomarcadores en la cardiotoxicidad por agentes antineoplás: rendimiento dianóstico. Bayer Hispania S.L. 2015-Ongoing. Management centre: FIBHULP

122

López-Sendón Hentschel JL. Sesiones interhospitalarias de formación en investigación en Cardiología. Astrazeneca Farmacéutica Spain S.A. 2016-Ongoing. Management centre: FIBHULP Merino Llorens JL. Actividades formativas de investigación en Cirugía Cardiaca Pediátrica. Bayer Hispania S.L. 2006-Ongoing. Management centre: FIBHULP Merino Llorens JL. Innovación tecnológica en cardiología: mapas tridimensionales de ciclo de retorno para la ablación de taquicardias macroreentrantes. Bayer Hispania S.L. 2007-Ongoing. Management centre: FIBHULP Merino Llorens JL. Formación en investigación en Electrofisiología Cardiaca. European Society of Cardiology. 2015-Ongoing. Management centre: FIBHULP Moreno Gómez JR. Evaluacion clínica y seguimiento de los pacientes con cardiopatía estructural sometidos a procedimientos de tratamiento percutáneo. Subproyecto: análisis de expresión de miRNAs relacionados con el proceso angiogénico en cáncer mama. Abbott Laboratories S.A. 2011-Ongoing. Management centre: FIBHULP Peinado Peinado R. Síndrome de apneas-hipopneas obstructivas del sueño y arritmias ventriculares en pacientes con disfunción ventricular sistólica portadores de DAI. Boston Scientific Ibérica S.A. 2008-Ongoing. Management centre: FIBHULP Peinado Peinado R. Utilidad de la estimulación programada ventricular izquierda para la inducción de la taquicardia ventricular monomórfica clínica en pacientes con infarto previo-Boston. Boston Scientific Ibérica S.A. 2009-Ongoing. Management centre: FIBHULP Peinado Peinado R. Influencia del remodelado eléctrico del miocardio auricular en la recurrencia de fibrilación auricular tras el aislamiento eléctrico de las venas pulmonares por fibrilación auricular paroxística. Medtronic Iberica S.A. 2009-Ongoing. Management centre: FIBHULP

HULP Code: PI-2382B. Sponsored´s Protocol Code: AMGSIM-2016-01. Signature Date: 04/08/2016 López de Sá Areces E. Estudio prospectivo abierto del andexanet alfa en pacientes tratados con un inhibidor de factor XA que presentan una hemorragia mayor aguda. Portola Pharmaceuticals Inc. HULP Code: 4523. Sponsored´s Protocol Code: 14-505. Signature Date: 02/02/2016 López de Sa Areces E. Estudio observacional sobre el tratamiento oral antiplaquetario tras síndrome coronario agudo en España (spanish observational study of oapt after ACS). Fundación de Investigación en Red en Enfermedades Cardiovasculares-FIRCAVA. HULP Code: PI-2206. Sponsored´s Protocol Code: FIRACS-2015-01. Signature Date: 02/03/2016 López-Sendón Hentschel JL. Estudio en fase III, aleatorizado, doble ciego y controlado con placebo para evaluar los efectos de dalcetrapib sobre el riesgo cardiovascular (CV) en una población definida genéticamente con síndrome coronario agudo reciente (SCA): el ensayo DALGENE. Dalcor Pharma UK Ltd. HULP Code: 4627. Sponsored´s Protocol Code: DAL-301. Signature Date: 27/05/2016 López-Sendón Hentschel JL. Estudio de fase III fundamental, multicéntrico, aleatorizado, doble ciego, controlado con placebo, de grupos paralelos y determinado por los episodios para evaluar la eficacia y la seguridad de vericiguat, un estimulador de la guanilato ciclasa soluble (GCS) por vía oral, en sujetos con insuficiencia cardíaca con fracción de eyección disminuida (ICFED): estudio victoria (vericiguat global study in subjects with heart failure with reduced ejection fraction). Merck Sharp and Dohme de España S.A. HULP Code: 4685. Sponsored´s Protocol Code: 1242-001. Signature Date: 22/09/2016 Merino Llorens JL. Estudio de la eficacia y la seguridad de F373280 para el mantenimiento del ritmo sinusal tras cardioversión eléctrica en pacientes con fibrilación auricular persistente e insuficiencia cardiaca crónica. Pierre Fabre Medicament S.A.S. HULP Code: Anexo-4 3814. Sponsored´s Protocol Code: F373280CA201. Signature Date: 28/03/2016

HULP Code: Anexo-1 4595. Sponsored´s Protocol Code: CR017. Signature Date: 08/09/2016 Merino Llorens JL. Estudio clínico sobre las diferencias en la magnitud de la respuesta a la TRC en mujeres y hombres, código de protocolo CR017, versión 1.0 de 3 de diciembre de 2014. Biotronik Se&Co KG. HULP Code: 4595. Sponsored´s Protocol Code: CR017. Signature Date: 14/06/2016 Moreno Gómez JR. Estudio multicéntrico, de ámbito global, abierto, aleatorizado, con control activo, dirigido por eventos, que para optimizar los resultados clínicos pretende comparar el tratamiento de rivaroxaban con un tratamiento basado en antiagregantes plaquetarios tras el reemplazo por vía transcatéter de una válvula aórticaGalileo. Bayer AG. HULP Code: Anexo-1 4525. Sponsored´s Protocol Code: BAY17938. Signature Date: 30/09/2016 Moreno Gómez JR. Estudio multicéntrico, de ámbito global, abierto, aleatorizado, con control activo, dirigido por eventos, que para optimizar los resultados clínicos pretende comparar el tratamiento de rivaroxaban con un tratamiento basado en antiagregantes plaquetarios tras el reemplazo por vía transcatéter de una válvula aórticaGalileo. Bayer AG. HULP Code: 4525. Sponsored´s Protocol Code: BAY 17938. Signature Date: 29/03/2016 Moreno Gómez JR. Registro de pacientes con dispositivo biorreabsorbible en la práctica clínica habitual: medida de costes, efectividad, QALYS, y eficiencia. Fundación Casa del Corazón. HULP Code: PI-2425. Sponsored´s Protocol Code: CORBVS-2016-01 ESTUDIO REPARA-QALY. Signature Date: 15/07/2016 Peinado Peinado R. RECABA, Registro Español de Crioablación con Balón. Medtronic Ibérica S.A. HULP Code: PI-2454. Sponsored´s Protocol Code: RECABA. Signature Date: 02/11/2016

PATENTS AND TRADEMARKS

Castro Conde A. Registro de hipercolesterolemia familiar en el síndrome coronario agudo. Sociedad Española de Cardiología. HULP Code: PI-067. Sponsored´s Protocol Code: HF-SCA. Signature Date: 11/04/2016

Merino Llorens JL. Triumph CRT. Estimulación biventricular trifocal para la optimización de la terapia de resincronización cardiaca(TRC). Sorin Group España S.L. HULP Code: 4519. Sponsored´s Protocol Code: ICSY02. Signature Date: 18/02/2016

Filgueiras Rama D, López de Sá y Areses E, Millet Roig J, Calvo Saiz CJ, inventors; Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), FIBHULP, Universidad Politécnica de Valencia, assignees. Method of predicting or prognosticating neurological performance in patients who have suffered a cardiac arrest and optionally comatose status due to ventricular fibrillation. PCT/ EP2015/076893, EP3020333; 2014 November 17.

Dalmau González-Gallerza R. Evaluación del control glucémico en pacientes con alto riesgo cardiovascular y diabetes mellitus tipo 2 en consultas de atención primaria y cardiología. Sociedad Española de Cardiología. HULP Code: PI-2409. Sponsored´s Protocol Code: RICARD2. Signature Date: 27/09/2016

Merino Llorens JL. Estudio clínico sobre las diferencias en la magnitud de la respuesta a la TRV en mujeres y hombres. Biotronik Se&Co KG.

Riera del Moral LF, inventor; FIBHULP, assignee. Aortic endoprosthesis for the treatment of aneurysm. P201231638, PCT/ES2013/070712; 2012 October 24.

CLINICAL TRIALS

Escobar Cervantes C. Pérdidas de productividad y gastos indirectos después de acontecimientos vasculares en Europa AMEV-COI. Amgen Europe GMBH.

Return to C ARDIOVASCULAR AREA INDEX

123

3.2 Cardiovascular Area

3 INFORMATION GROUPS BY AREA

CARDIOVASCULAR EPIDEMIOLOGY AND NUTRITION GROUP

39 266.281 29

Fernando Rodríguez Artalejo Catedrático de Medicina Preventiva y Salud Pública. Facultad de Medicina. UAM José Ramón Banegas Banegas Catedrático de Medicina Preventiva y Salud Pública. Facultad de Medicina. UAM Auxiliadora Graciani Pérez-Regadera Profesora Contratada de Medicina Preventiva y Salud Pública. Facultad de Medicina. UAM Pilar Guallar Castillón Profesora Titular de Medicina Preventiva y Salud Pública. Facultad de Medicina. UAM Juan Luis Gutiérrez Fisac Profesor Asociado de Medicina Preventiva y Salud Pública. Facultad de Medicina. UAM Luz María León Muñoz Colaboradora Docente de Medicina Preventiva y Salud Pública. Facultad de Medicina. UAM Esther López García Profesora Contratada de Medicina Preventiva y Salud Pública. Facultad de Medicina. UAM Fernando Villar Álvarez Profesor Asociado de Medicina Preventiva y Salud Pública. Facultad de Medicina. UAM

Strategic Objective Our strategic objective is to produce relevant information to support clinical and populationbased policies aimed at controlling CVD. The results of our studies have been explicitly incorporated into the National Strategy for Ische124

mic Heart Disease Control and into the National Strategy for Obesity Prevention and Control, elaborated by the Ministry of Health. Moreover, our research results have also supported the development of clinical guidelines in this field; specifically, the guidelines of the Spanish Society for Arterial Hypertension, and guidelines of the Spanish Society of Family Medicine, the leading society devoted to primary health care in Spain.

Research Lines • Cardiovascular and Nutritional Epidemiology.

Research Activity DOCTORAL THESES Navarro Vidal B. Logro de objetivos cardiometabólicos en sujetos hipertensos y diabéticos [dissertation]. Madrid: UAM: 2016 (13/03/2016). Directors: Banegas Banegas JR, Graciani Pérez-Regadera MA.

PUBLICATIONS • Bentham J, Cesare M, Stevens GA, Zhou B, Bixby H, Cowan M, Fortunato L, Bennett JE, Danaei G, Hajifathalian K, Lu Y, Riley LM, Laxmaiah A, Kontis V, Paciorek CJ, Riboli E, Ezzati M, Abdeen ZA, Hamid ZA, Abu-Rmeileh NM, Acosta-Cazares B, Adams R, Aekplakorn W, Aguilar-Salinas CA, Agyemang C, Ah-

madvand A, Ahrens W, Al-Hazzaa HM, Al-Othman AR, Al Raddadi R, Ali MM, Alkerwi A, Álvarez-Pedrerol M, Aly E, Amouyel P, Amuzu A,Andersen LB,Anderssen SA,Anjana RM,Aounallah-Skhiri H, Ariansen I, Aris T, Arlappa N, Arveiler D, Assah FK, Avdicova M, Azizi F, Babu BV, Bahijri S, Balakrishna N, Bandosz P, Banegas JR, Barbagallo CM, Barcelo A, Barkat A, Barros MV, Bata I, Batieha AM, Batista RL, Baur LA, Beaglehole R, Ben Romdhane H, Benet M, Bennett JE, Bernabé-Ortiz A, Bernotine G, Bettiol H, Bhagyalaxmi A, Bharadwaj S, Bhargava SK, Bhatti Z, Bhutta ZA, Bi HS, Bi YF, Bjerregaard P, Bjertness E, Bjertness MB, Bjorkelund C, Blokstra A, Bo S, Bobak M, Boddy LM, Boehm BO, Boeing H, Boissonnet CP, Bongard V, Bovet P, Braeckman L, Bragt MCE, Brajkovich I, Branca F, Breckenkamp J, Brenner H, Brewster LM, Brian GR, Bruno G, Bueno-de-Mesquita HB, Bugge A, Burns C, de León AC, Cacciottolo J, Cama T, Cameron C, Camolas J, Can G, Candido APC, Capuano V, Cardoso VC, Carlsson AC, Carvalho MJ, Casanueva FF, Casas JP, Caserta CA, Chamukuttan S, Chan AW, Chan Q, Chaturvedi HK, Chaturvedi N, Chen CJ, Chen FF, Chen HS, Chen SH, Chen ZM, Cheng CY, Chetrit A, Chiolero A, Chiou ST, Chirita-Emandi A, Cho B, Cho Y, Christensen K, Chudek J, Cifkova R, Claessens F, Clays E, Concin H, Cooper C, Cooper R, Coppinger TC, Costanzo S, Cottel D, Cowell C, Craig CL, Crujeiras AB, D’Arrigo G, d’Orsi E, Dallongeville J, Damasceno A, Damsgaard CT, Danaei G, Dankner R, Dauchet L, De Backer G, De Bacque D, de Gaetano G, De Hanauw S, De Smedt D, Deepa M, Deev AD, Dehghan A, Delisle H, Delpeuch F, Deschamps V, Dhana K, Di Castelnuovo AF, Dias-Da-Costa JS, Díaz A, Djalalinia S, Do HTP, Dobson AJ, Donfrancesco C, Donoso SP, Doring A, Doua K, Drygas W, Dzerve V, Egbagbe EE, Eggertsen R, Ekelund U, El Ati J, Elliott P, Engle-Stone R, Erasmus RT, Erem C, Eriksen L, Escobedo-de la Pena J, Evans A, Faeh D, Fall CH, Farzadfar F, Felix-Redondo FJ, Ferguson TS, Fernández-Berges D, Ferrante D, Ferrari M, Ferreccio C, Ferrieres J, Finn JD, Fischer K, Flores EM, Foger B, Foo LH, Forslund AS, Forsner M, Fortmann SP, Francis HM, Francis DK, Franco MD, Franco OH, Frontera G, Fuchs FD, Fuchs SC, Fujita Y, Furusawa T, Furusawa T, Gaciong Z, Gafencu M, Gareta D, Garnett SP, Gaspoz JM, Gasull M, Gates L, Geleijnse JM, Ghasemian A, Giampaoli S, Gianfagna F, Giovannelli J, Giwercman A, Goldsmith RA, Goncalves H, Gross MG, Rivas JPG, Gorbea MB, Gottrand F, Graff-Iversen S, Grafnetter D, Grajda A, Grammatikopoulou MG, Gregor RD, Grodzicki T, Grontved A, Gruden G, Grujic V, Gu DF, Gualdi-Russo E, Guan OP, Gudnason V, Guerrero R, Guessous I, Guimaraes AL, Gulliford MC, Gunnlaugsdottir J, Gunter M, Guo XH, Guo Y, Gupta PC, Gureje O, Gurzkowska B, Gutierrez L, Gutzwiller F, Halkjaer J, Hambleton IR, Hardy R, Kumar RH, Hata J, Hayes AJ, He J, Hendriks ME, Cadena LH, Herrala S, Heshmat R, Hihtaniemi IT, Ho SY, Ho SC, Hobbs M, Hofman A, Hormiga CM, Horta BL, Houti L, Howitt C, Htay TT, Htet AS, Htike MMT, Hu YH, Husseini A, Huu CN, Huybrechts I, Hwalla N, Iacoviello L, Iannone AG, Ibrahim MM, Ikeda N, Ikram MA, Irazola VE, Islam M, Ivkovic V, Iwasaki M, Jackson RT, Jacobs JM, Jafar T, Jamil KM, Jamrozik K, Janszky I, Jasienska G, Jelakovic B, Jiang CQ, Joffres M, Johansson M, Jonas JB, Jorgensen T, Joshi P, Juolevi A, Jurak G, Juresa V, Kaaks R, Kafatos A, KalterLeibovici O, Kapantais E, Kasaeian A, Katz J, Kaur P, Kavousi M, Keil U, Boker LK, Keinanen-Kiukaanniemi S, Kelishadi R, Kemper HCG, Kengne AP, Kersting M, Key T, Khader YS, Khalili D, Khang YH, Khaw KTH, Khouw IMSL, Kiechl S, Killewo J, Kim J, Klimont J, Klumbiene J, Koirala B, Kolle E, Kolsteren P, Korrovits P, Koskinen S, Kouda K, Koziel S, Kratzer W, Krokstad S, Kromhout D, Kruger HS, Kubinova R, Kujala UM, Kula K, Kulaga Z, Kumar RK, Kurjata P, Kusuma YS, Kuulasmaa K, Kyobutungi C, Laamiri FZ, Laatikainen T, Lachat C, Laid Y, Lam TH, Landrove O, Lanska V, Lappas G, Larijani B, Laugsand LE, Laxmaiah A, Bao KLN, Le TD, Leclercq C, Lee J, Lee J, Lehtimaki T, Lekhraj R, León-Muñoz LM, Li YP, Lilly CL, Lim WY, Lima-Costa MF, Lin HH, Lin X, Linneberg A, Lissner L, Litwin M, Liu J, Lorbeer R, Lotufo PA, Lozano JE,

Luksiene D, Lundqvist A, Lunet N, Ma GH, Ma J, Machado-Coelho GLL, Machi S, Maggi S, Magliano DJ, Maire B, Makdisse M, Malekzadeh R, Malhotra R, Rao KM, Malyutina S, Manios Y, Mann JI, Manzato E, Margozzini P, Markey O, Marqués-Vidal P, Marrugat J, Martín-Prevel Y, Martorell R, Masoodi SR, Mathiesen EB, Matsha TE, Mazur A, Mbanya JCN, McFarlane SR, McGarvey ST, Mckee M, McLachlan S, McLean RM, McNulty BA, Yusof SM, MedieneBenchekor S, Meirhaeghe A, Meisinger C, Menezes AMB, Mensink GBM, Meshram II, Metspalu A, Mi J, Michaelsen KF, Mikkel K, Miller JC, Miquel JF, Miranda JJ, Misigoj-Durakovic M, Mohamed MK, Mohammad K, Mohammadifard N, Mohan V, Yusoff MFM, Molbo D, Moller NC, Molnar D, Mondo CK, Monterrubio EA, Monyeki KDK, Moreira LB, Morejon A, Moreno LA, Morgan K, Mortensen EL, Moschonis G, Mossakowska M, Mostafa A, Mota J, Motlagh ME, Motta J, Mu TT, Muiesan ML, Muller-Nurasyid M, Murphy N, Mursu J, Murtagh EM, Musa KI, Musil V, Nagel G, Nakamura H, Namesna J, Nang EEK, Nangia VB, Nankap M, Narake S, Navarrete-Muñoz EM, Neal WA, Nenko I, Neovius M, Nervi F, Neuhauser HK, Nguyen ND, Nguyen QN, Nieto-Martínez RE, Ning G, Ninomiya T, Nishtar S, Noale M, Norat T, Noto D, Al Nsour M, O’Reilly D, Oh K, Olayan IH, Olinto MTA, Oltarzewski M, Omar MA, Onat A, Ordunez P, Ortiz AP, Osler M, Osmond C, Ostojic SM, Otero JA, Overvad K, Owusu-Dabo E, Paccaud FM, Padez C, Pahomova E, Pajak A, Palli D, Palloni A, Palmieri L, Panda-Jonas S, Panza F, Parnell WR, Parsaeian M, Pecin I, Pednekar MS, Peeters PH, Peixoto SV, Peltonen M, Pereira AC, Pérez CM, Peters A, Petkeviciene J, Peykari N, Pham ST, Pigeot I, Pikhart H, Pilav A, Pilotto L, Pistelli F, Pitakaka F, Piwonska A, Plans-Rubio P, Poh BK, Porta M, Portegies MLP, Poulimeneas D, Pradeepa R, Prashant M, Price JF, Puiu M, Punab M, Qasrawi RF, Qorbani M, Bao TQ, Radic I, Radisauskas R, Rahman M, Raitakari O, Raj M, Rao SR, Ramachandran A, Ramke J, Ramos R, Rampal S, Rasmussen F, Redon J, Reganit PFM, Ribeiro R, Riboli E, Rigo F, de Wit TFR, Ritti-Dias RM, Rivera JA, Robinson SM, Robitaille C, Rodri-Guez-Artalejo F, Rodríguez-Pérez MD, Rodríguez-Villamizar LA, Rojas-Martínez R, Rojroongwasinkul N, Romaguera D, Ronkainen K, Rosengren A, Rouse I, Rubinstein A, Ruhli FJ, Rui O, Ruiz-Betancourt BS, Horimoto ARVR, Rutkowski M, Sabanayagam C, Sachdev HS, Saidi O, Salanave B, Martínez ES, Salomaa V, Salonen JT, Salvetti M, Sánchez-Abanto J, Sandjaja, Sans S, Santos DA, Santos O, dos Santos RN, Santos R, Saramies JL, Sardinha LB, Sarrafzadegan N, Saum KU, Savva SC, Scazufca M, Rosario AS, Schargrodsky H, Schienkiewitz A, Schmidt IM, Schneider IJ, Schultsz C, Schutte AE, Sein AA, Sen A, Senbanjo IO, Sepanlou SG, Shalnova SA, Sharma SK, Shaw JE, Shibuya K, Shin DW, Shin Y, Shiri R, Siantar R, Sibai AM, Silva AM, Silva DAS, Simon M, Simons J, Simons LA, Sjostrom M, Slowikowska-Hilczer J, Slusarczyk P, Smeeth L, Smith MC, Snijder MB, So HK, Sobngwi E, Soderberg S, Soekatri MYE, Solfrizzi V, Sonestedt E, Song Y, Sorensen TIA, Soric M, Jerome CS, Soumare A, Staessen JA, Starc G, Stathopoulou MG, Staub K, Stavreski B, Steene-Johannessen J, Stehle P, Stein AD, Stergiou GS, Stessman J, Stieber J, Stockl D, Stocks T, Stokwiszewski J, Stratton G, Stronks K, Strufaldi MW, Sun CA, Sundstrom J, Sung YT, Sunyer J, Suriyawongpaisal P, Swinburn BA, Sy RG, Szponar L, Tai ES, Tammesoo ML, Tamosiunas A, Tang LN, Tang X, Tanser F, Tao Y, Tarawneh MR, Tarp J, Tarqui-Mamani CB, Taylor A, Tchibindat F, Theobald H, Thijs L, Thuesen BH, Tjonneland A, Tolonen HK, Tolstrup JS, Topbas M, Topor-Madry R, Torrent M, Toselli S, Traissac P, Trichopoulou A, Trichopoulos D, Trinh OTH, Trivedi A, Tshepo L, Tulloch-Reid MK, Tuomainen TP, Tuomilehto J, Turley ML, Tynelius P, Tzotzas T, Tzourio C, Ueda P, Ukoli FAM, Ulmer H, Unal B, Uusitalo HMT, Valdivia G, Vale S, Valvi D, van der Schouw YT, Van Herck K, Van Minh H, van Rossem L, van Valkengoed IGM,Vanderschueren D,Vanuzzo D,Vatten L, Vega T, Velasquez-Melendez G, Veronesi G, Verschuren WMM, Verstraeten R,Victora CG,Viegi G,Viet L,Viikari-Juntura E,Vineis P,Vioque J,Virtanen JK,Visvikis-Siest S,Viswanathan B,Vollenwei-

Continue

125

3.2 Cardiovascular Area

3 INFORMATION GROUPS BY AREA der P, Voutilainen S, Vrdoljak A, Vrijheid M, Wade AN, Wagner A, Walton J, Mohamud WNW, Wang MD, Wang Q, Wang YX, Wannamethee SG, Wareham N, Weerasekera D, Whincup PH, Widhalm K, Widyahening IS, Wiecek A, Wijga AH, Wilks RJ, Willeit J, Wilsgaard T, Wojtyniak B, Wong JE, Wong TY, Woo J, Woodward M, Wu FC, Wu JF, Wu SL, Xu HQ, Xu L, Yamborisut U, Yan WL, Yang XG, Yardim N, Ye XW, Yiallouros PK, Yoshihara A, You QS, Younger-Coleman NO, Yusoff AF, Zainuddin AA, Zambon S, Zdrojewski T, Zeng Y, Zhao D, Zhao WH, Zheng YF, Zhou MG, Zhu D, Zimmermann E, Cisneros JZ. A century of trends in adult human height. Elife. 2016;5:e13410. Article. IF: 7.725; D1 • Borghi C, Rodríguez-Artalejo F, de Backer G, Dallongeville J, Medina J, Guallar E, Perk J, Banegas JR, Tubach F, Roy C, Halcox JP. The association between blood pressure and lipid levels in Europe: European study on cardiovascular risk prevention and management in usual daily practice. J Hypertens. 2016;34(11):215563. Article. IF: 4.085; Q1 • Borghi C, Tubach F, de Backer G, Dallongeville J, Guallar E, Medina J, Perk J, Roy C, Banegas JR, Rodríguez-Artalejo F, Halcox JP. Lack of control of hypertension in primary cardiovascular disease prevention in Europe: Results from the EURIKA study. Int J Cardiol. 2016;218:83-8. Article. IF: 6.189; Q1 • Castro-Rodríguez M, Carnicero JA, García-García FJ, Walter S, Morley JE, Rodríguez-Artalejo F, Sinclair AJ, Rodríguez-Mañas L. Frailty as a major factor in the increased risk of death and disability in older people with diabetes. J Am Med Dir Assoc. 2016;17(10):949-55. Article. IF: 5.775; D1 • Cavero-Redondo I, Peleteiro B, Álvarez-Bueno C, RodríguezArtalejo F, Martínez-Vizcaino V. Glycosylated haemoglobin as a predictor of cardiovascular events and mortality: a protocol for a systematic review and meta-analysis. BMJ Open. 2016;6(7):e012229. Review. IF: 2.369; Q1 • Christofaro DGD, Andrade SM, Fernandes RA, Cabrera MAS, Rodríguez-Artalejo F, Mesas AE. Overweight parents are twice as likely to underestimate the weight of their teenage children, regardless of their sociodemographic characteristics. Acta Paediatr. 2016;105(10):e474-9. Article. IF: 2.043; Q2 • de la Sierra A, Banegas JR, Divisón JA, Gorostidi M,Vinyoles E, de la Cruz JJ, Segura J, Ruilope LM. Ambulatory blood pressure in hypertensive patients with inclusion criteria for the SPRINT trial. J Am Soc Hypertens. 2016;10(12):947-53. Article. IF: 3.263; Q2 • de la Sierra A, Banegas JR,Vinyoles E, Gorostidi M, Segura J, de la Cruz JJ, Ruilope LM. Office and ambulatory blood pressure control in hypertensive patients treated with different two-drug and three-drug combinations. Clin Exp Hypertens. 2016;38(4):40914. Article. IF: 1.162; Q4 • de la Sierra A, Vinyoles E, Banegas JR, Parati G, de la Cruz JJ, Gorostidi M, Segura J, Ruilope LM. Short-term and long-term reproducibility of hypertension phenotypes obtained by office and ambulatory blood pressure measurements. J Clin Hypertens. 2016;18(9):927-33. Article. IF: 3.242; Q2 • di Cesare M, Bentham J, Stevens GA, Zhou B, Danaei G, Lu Y, Bixby H, Cowan MJ, Riley LM, Hajifathalian K, Fortunato L,Taddei C, Bennett JE, Ikeda N, Khang YH, Kyobutungi C, Laxmaiah A, Li YP, Lin HH, Miranda JJ, Mostafa A,Turley ML, Paciorek CJ, Gunter M, Ezzati M, Abdeen ZA, Hamid ZA, Abu-Rmeileh NM, AcostaCazares B, Adams R, Aekplakorn W, Aguilar-Salinas CA, Ahmadvand A, Ahrens W, Ali MM, Alkerwi A, Álvarez-Pedrerol M, Aly E, Amouyel P, Amuzu A, Andersen LB, Anderssen SA, Andrade DS, Anjana RM, Aounallah-Skhiri H, Ariansen I, Aris T, Arlappa N, Arveiler D, Assah FK, Avdicova M, Azizi F, Babu BV, Balakrishna N, Bandosz P, Banegas JR, Barbagallo CM, Barcelo A, Barkat A, Barros MV, Bata I, Batieha AM, Batista RL, Baur LA, Beaglehole R, Ben Romdhane H, Benet M, Bernabe-Ortiz A, Bernotiene G, Bettiol H, Bhagyalaxmi A, Bharadwaj S, Bhargava SK, Bhatti Z,

126

Bhutta ZA, Bi HS, Bi YF, Bjerregaard P, Bjertness E, Bjertness MB, Bjorkelund C, Blake M, Blokstra A, Bo S, Bobak M, Boddy LM, Boehm BO, Boeing H, Boissonnet CP, Bongard V, Bovet P, Braeckman L, Bragt MCE, Brajkovich I, Branca F, Breckenkamp J, Brenner H, Brewster LM, Brian GR, Bruno G, Bueno-de-Mesquita HB, Bugge A, Burns C, de León AC, Cacciottolo J, Cama T, Cameron C, Camolas J, Can G, Candido APC, Capuano V, Cardoso VC, Carvalho MJ, Casanueva FF, Casas JP, Caserta CA, Castetbon K, Chamukuttan S, Chan AW, Chan Q, Chaturvedi HK, Chaturvedi N, Chen CJ, Chen FF, Chen HS, Chen SH, Chen ZM, Cheng CY, Chetrit A, Chiolero A, Chiou ST, Chirita-Emandi A, Cho Y, Christensen K, Chudek J, Cifkova R, Claessens F, Clays E, Concin H, Cooper C, Cooper R, Coppinger TC, Costanzo S, Cottel D, Cowell C, Craig CL, Crujeiras AB, D’Arrigo G, d’Orsi E, Dallongeville J, Damasceno A, Damsgaard CT, Danaei G, Dankner R, Dauchet L, De Backer G, De Bacquer D, de Gaetano G, De Henauw S, De Smedt D, Deepa M, Deev AD, Dehghan A, Delisle H, Delpeuch F, Dhana K, Di Castelnuovo AF, Dias-da-Costa JS, Díaz A, Djalalinia S, Do HTP, Dobson AJ, Donfrancesco C, Doring A, Doua K, Drygas W, Egbagbe EE, Eggertsen R, Ekelund U, El Ati J, Elliott P, Engle-Stone R, Erasmus RT, Erem C, Eriksen L, Escobedo-de la Pena J, Evans A, Faeh D, Fall CH, Farzadfar F, FelixRedondo FJ, Ferguson TS, Fernández-Berges D, Ferrante D, Ferrari M, Ferreccio C, Ferrieres J, Finn JD, Fischer K, Flores EM, Foger B, Foo LH, Forslund AS, Fortmann SP, Fouad HM, Francis DK, Franco MD, Franco OH, Frontera G, Fuchs FD, Fuchs SC, Fujita Y, Furusawa T, Gaciong Z, Gafencu M, Gareta D, Garnett SP, Gaspoz JM, Gasull M, Gates L, Geleijnse JM, Ghasemian A, Giampaoli S, Gianfagna F, Giovannelli J, Giwercman A, Goldsmith RA, Gross MG, Rivas JPG, Gorbea MB, Gottrand F, -Iversen SG, Grafnetter D, Grajda A, Grammatikopoulou MG, Gregor RD, Grodzicki T, Grontved A, Gruden G, Grujic V, Gu DF, Guan OP, Gudnason V, Guerrero R, Guessous I, Guimaraes AL, Gulliford MC, Gunnlaugsdottir J, Gunter M, Guo XH, Guo Y, Gupta PC, Gureje O, Gurzkowska B, Gutierrez L, Gutzwiller F, Halkjaer J, Hardy R, Kumar RH, Hayes AJ, He J, Hendriks ME, Cadena LH, Heshmat R, Hihtaniemi IT, Ho SY, Ho SC, Hobbs M, Hofman A, Hormiga CM, Horta BL, Houti L, Htay TT, Htet AS, Htike MMT, Hu YH, Hussieni AS, Huu CN, Huybrechts I, Hwalla N, Iacoviello L, Iannone AG, Ibrahim MM, Ikeda N, Ikram MA, Irazola VE, Islam M, Iwasaki M, Jackson RT, Jacobs JM, Jafar T, Jamil KM, Jamrozik K, Jasienska G, Jiang CQ, Joffres M, Johansson M, Jonas JB, Jorgensen T, Joshi P, Juolevi A, Jurak G, Juresa V, Kaaks R, Kafatos A, Kalter-Leibovici O, Kapantais E, Kasaeian A, Katz J, Kaur P, Kavousi M, Keil U, Boker LK, Kelishadi R, Kemper HHCG, Kengne AP, Kersting M, Key T, Khader YS, Khalili D, Khang YH, Khaw KTH, Khouw IMSL, Kiechl S, Killewo J, Kim J, Kiyohara Y, Klimont J, Kolle E, Kolsteren P, Korrovits P, Koskinen S, Kouda K, Koziel S, Kratzer W, Krokstad S, Kromhout D, Kruger HS, Kula K, Kulaga Z, Kumar RK, Kusuma YS, Kuulasmaa K, Kyobutungi C, Laamiri FZ, Laatikainen T, Lachat C, Laid Y, Lam TH, Landrove O, Lanska V, Lappas G, Laugsand LE, Laxmaiah A, Bao KLN, Le TD, Leclercq C, Lee J, Lee J, Lehtimaki T, Lekhraj R, León-Muñoz LM, Li YP, Lim WY, Lima-Costa MF, Lin HH, Lin X, Linneberg A, Lissner L, Litwin M, Liu J, Lorbeer R, Lotufo PA, Lozano JE, Luksiene D, Lundqvist A, Lunet N, Lytsy P, Ma GS, Machi S, Maggi S, Magliano DJ, Makdisse M, Malekzadeh R, Malhotra R, Rao KM, Manios Y, Mann JI, Manzato E, Margozzini P, Markey O, Marques-Vidal P, Marrugat J, Martín-Prevel Y, Martorell R, Masoodi SR, Matsha TE, Mazur A, Mbanya JCN, McFarlane SR, McGarvey ST, McKee M, McLachlan S, McLean RM, McNulty BA,Yusof SM, Mediene-Benchekor S, Meirhaeghe A, Meisinger C, Mendes LL, Menezes AMB, Mensink GBM, Meshram II, Metspalu A, Mi J, Michaelsen KF, Mikkel K, Miller JC, Miquel JF, Miranda JJ, Misigoj-Durakovic M, Mohamed MK, Mohammad K, Mohammadifard N, Mohan V, Yusoff MFM, Molbo D, Moller NC, Molnar D, Mondo CK, Monterrubio EA, Monyeki KDK, Moreira LB, Morejon A, Moreno LA, Morgan K, Mortensen EL, Moschonis G,

Mossakowska M, Mostafa A, Mota J, Motlagh ME, Motta J, Mu TT, Muiesan ML, Muller-Nurasyid M, Murphy N, Mursu J, Murtagh EM, Musa KI, Musil V, Nagel G, Nakamura H, Namesna J, Nang EEK, Nangia VB, Nankap M, Narake S, Navarrete-Muñoz EM, Nenko I, Neovius M, Nervi F, Neuhauser HK, Nguyen ND, Nguyen QN, Nieto-Martínez RE, Ning G, Ninomiya T, Nishtar S, Noale M, Norat T, Noto D,Al Nsour M, O’Reilly D, Ochoa-Aviles AM, Oh K, Olayan IH, Olinto MTA, Oltarzewski M, Omar MA, Onat A, Ordunez P, Ortiz AP, Osler M, Osmond C, Ostojic SM, Otero JA, Overvad K, Paccaud FM, Padez C, Pajak A, Palli D, Palloni A, Palmieri L, Panda-Jonas S, Panza F, Parnell WR, Parsaeian M, Pednekar MS, Peeters PH, Peixoto SV, Pereira AC, Pérez CM, Peters A, Peykari N, Pham ST, Pigeot I, Pikhart H, Pilav A, Pilotto L, Pistelli F, Pitakaka F, Piwonska A, Piwonski J, Plans-Rubio P, Poh BK, Porta M, Portegies MLP, Poulimeneas D, Pradeepa R, Prashant M, Price JF, Puiu M, Punab M, Qasrawi RF, Qorbani M, Bao TQ, Radic I, Radisauskas R, Rahman M, Raitakari O, Raj M, Rao SR, Ramachandran A, Ramke J, Ramos R, Rampal S, Rasmussen F, Redon J, Reganit PFM, Ribeiro R, Riboli E, Rigo F, de Wit TFR, Ritti-Dias RM, Rivera JA, Robinson SM, Robitaille C, RodríguezArtalejo F, Rodríguez-Pérez MD, Rodríguez-Villamizar LA, RojasMartínez R, Rojroongwasinkul N, Romaguera D, Ronkainen K, Rosengren A, Rouse I, Rubinstein A, Ruhli FJ, Rui O, Ruiz-Betancourt BS, Horimoto ARVR, Rutkowski M, Sabanayagam C, Sachdev HS, Saidi O, Salanave B, Martínez ES, Salomaa V, Salonen JT, Salvetti M, Sánchez-Abanto J, Sandjaja, Sans S, Santos DA, Santos O, dos Santos RN, Santos R, Sardinha LB, Sarrafzadegan N, Saum KU, Savva SC, Scazufca M, Rosario AS, Schargrodsky H, Schienkiewitz A, Schmidt IM, Schneider IJ, Schultsz C, Schutte AE, Sein AA, Senbanjo IO, Sepanlou SG, Shalnova SA, Shaw JE, Shibuya K, Shin YC, Shiri R, Siantar R, Sibai AM, Silva AM, Silva DAS, Simon M, Simons J, Simons LA, Sjostrom M, Slowikowska-Hilczer J, Slusarczyk P, Smeeth L, Smith MC, Snijder MB, So HK, Sobngwi E, Soderberg S, Soekatri MYE, Solfrizzi V, Sonestedt E, Sorensen TIA, Soric M, Jerome CS, Soumare A, Staessen JA, Starc G, Stathopoulou MG, Staub K, Stavreski B, Steene-Johannessen J, Stehle P, Stein AD, Stergiou GS, Stessman J, Stieber J, Stockl D, Stocks T, Stokwiszewski J, Stratton G, Strufaldi MW, Sun CA, Sundstrom J, Sung YT, Sunyer J, Suriyawongpaisal P, Swinburn BA, Sy RG, Szponar L, Tai ES, Tammesoo ML, Tamosiunas A, Tang L, Tang X, Tanser F, Tao Y, Tarp J, Tarqui-Mamani CB, Taylor A, Tchibindat F, Thijs L, Thuesen BH, Tjonneland A, Tolonen HK, Tolstrup JS, Topbas M, Topor-Madry R, Torrent M, Traissac P, Trichopoulou A, Trichopoulos D, Trinh OTH, Trivedi A, Tshepo L, Tulloch-Reid MK, Tuomainen TP, Tuomilehto J, Turley ML, Tynelius P, Tzotzas T, Tzourio C, Ueda P, Ukoli FAM, Ulmer H, Unal B, Valdivia G, Vale S,Valvi D, van der Schouw YT,Van Herck K, Minh HV, van Valkengoed IGM, Vanderschueren D, Vanuzzo D, Vatten L, Vega T, Velasquez-Melendez G, Veronesi G, Verschuren WMM, Viegi G, Viet L, Viikari-Juntura E, Vineis P, Vioque J, Virtanen JK, Visvikis-Siest S, Viswanathan B, Vollenweider P, Voutilainen S, Vrijheid M, Wade AN, Wagner A, Walton J, Mohamud WNW, Wang MD, Wang Q, Wang YX, Wannamethee SG, Wareham N, Weerasekera D, Whincup PH, Widhalm K, Widyahening IS, Wiecek A, Wilks RJ, Willeit J, Wojtyniak B, Wong JE, Wong TY, Woo J, Woodward M, Wu FC, Wu JF, Wu SL, Xu HQ, Xu L, Yamborisut U, Yan WL, Yang XG, Yardim N, Ye XW, Yiallouros PK, Yoshihara A, You QS, Younger-Coleman NO,Yusoff AF, Zainuddin AA, Zambon S, Zdrojewski T, Zeng Y, Zhao D, Zhao WH, Zheng YF, Zhou MG, Zhu D, Zimmermann E, Cisneros JZ. Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19.2 million participants. Lancet. 2016;387(10026):1377-96. Article. IF: 47.831; D1 • Ding M, Satija A, Bhupathiraju SN, Hu Y, Sun Q, Han JL, LópezGarcía E,Willett W, van Dam RM, Hu FB. Response to Letter Regarding Article, “Association of Coffee Consumption With Total and Cause-Specific Mortality in 3 Large Prospective Cohorts”.

Circulation. 2016;133(20):e660. Letter. IF: 19.309; D1 • Divisón-Garrote JA, Banegas JR, de la Cruz JJ, Escobar-Cervantes C, de la Sierra A, Gorostidi M, Vinyoles E, Abellán-Alemán J, Segura J, Ruilope LM. Hypotension based on office and ambulatory monitoring blood pressure. Prevalence and clinical profile among a cohort of 70,997 treated hypertensives. J Am Soc Hypertens. 2016;10(9):714-23. Article. IF: 3.263; Q2 • García-Esquinas E, Guallar-Castillón P, Carnicero JA, Buño A, García-García FJ, Rodríguez-Mañas L, Rodríguez-Artalejo F. Serum uric acid concentrations and risk of frailty in older adults. Exp Gerontol. 2016;82:160-5. Article. IF: 3.34; Q1 • García-Esquinas E, Pérez-Hernández B, Guallar-Castillón P, Banegas JR, Ayuso-Mateos JL, Rodríguez-Artalejo F. Housing conditions and limitations in physical function among older adults. J Epidemiol Commun H. 2016;70(10):954-60.Article. IF: 3.608; Q1 • García-Esquinas E, Rahi B, Peres K, Colpo M, Dartigues JF, Bandinelli S, Feart C, Rodríguez-Artalejo F. Consumption of fruit and vegetables and risk of frailty: a dose-response analysis of 3 prospective cohorts of community-dwelling older adults. Am J Clin Nutr. 2016;104(1):132-42. Article. IF: 6.926; D1 • González-Parra E, Acena A, Lorenzo O, Tarín N, González-Casaus M, Cristóbal C, Huelmos A, Mahillo-Fernández I, Pello A, Carda R, Hernández-González I, Alonso J, Rodríguez-Artalejo F, López-Bescos L, Ortiz A, Egido J, Tuñón J. Important abnormalities of bone mineral metabolism are present in patients with coronary artery disease with a mild decrease of the estimated glomerular filtration rate. J Bone Miner Metab. 2016;34(5):58798. Article. IF: 2.423; Q3 • Gorostidi M, Banegas JR, de la Sierra A, Vinyoles E, Segura J, Ruilope LM. Ambulatory blood pressure monitoring in daily clinical practice - the Spanish ABPM Registry experience. Eur J Clin Invest. 2016;46(1):92-8. Review. IF: 2.714; Q1 • Graciani A, García-Esquinas E, López-García E, Banegas JR, Rodríguez-Artalejo F. Ideal cardiovascular health and risk of frailty in older adults. Circ-Cardiovasc Qual. 2016;9(3):239-45. Article. IF: 4.524; Q2 • Hermengildo Y, López-García E, García-Esquinas E, Pérez-Tasigchana RF, Rodríguez-Artalejo F, Guallar-Castillón P. Distribution of energy intake throughout the day and weight gain: a population-based cohort study in Spain. Brit J Nutr. 2016;115(11):200310. Article. IF: 3,706; Q1 • Lana A, Struijk E, Guallar-Castillón P, Martín-Moreno JM, Artalejo FR, López-García E. Leptin concentration and risk of impaired physical function in older adults: the Seniors-ENRICA cohort. Age Ageing. 2016;45(6):819-26. Article. IF: 4.282; Q1 • León-Muñoz LM, García-Esquinas E, Soler-Vila H, Guallar-Castillón P, Banegas JR, Rodríguez-Artalejo F. Unhealthy eating behaviors and weight gain: A prospective study in young and middleage adults. Obesity. 2016;24(5):1178-84. Article. IF: 3.783; Q1 • López-García E, Orozco-Arbeláez E, León-Muñoz LM, GuallarCastillón P, Graciani A, Banegas JR, Rodríguez-Artalejo F. Habitual coffee consumption and 24-h blood pressure control in older adults with hypertension. Clin Nutr. 2016;35(6):1457-63. Article. IF: 4.548; Q1 • Martínez-Gómez D, Guallar-Castillón P, Higueras-Fresnillo S, Rodríguez-Artalejo F. Concurrent validity of the historical leisure-time physical activity question of the Spanish National Health Survey in Older Adults. Rev Esp Cardiol (Engl Ed). 2016;Supl(16):30284-5. Article. IF: 4.485; Q2 • Martínez-Gómez D, Guallar-Castillón P, Rodríguez-Artalejo F, Bandinelli S. Attenuation of the effect of multimorbidity on cardiovascular mortality by physical activity in older adults. J Am Med Dir Assoc. 2016;17(12):1161-2. Letter. IF: 5.775; D1 • Martínez-Gómez D, Guallar-Castillón P, Rodríguez-Artalejo F.

Continue

127

3.2 Cardiovascular Area

3 INFORMATION GROUPS BY AREA Sitting time and mortality in older adults with disability: A national cohort study. J Am Med Dir Assoc. 2016;17(10):960.e15. Article. IF: 5.775; D1 • Martínez-Vizcaino V, Cavero-Redondo I, Álvarez-Bueno C, Rodríguez-Artalejo F. The accuracy of diagnostic methods for diabetic retinopathy: A systematic review and meta-analysis. Plos One. 2016;11(4):e0154411. Review. IF: 2.806; Q1 • Martín-Maria N, Caballero FF, Olaya B, Rodríguez-Artalejo F, Haro JM, Miret M, Ayuso-Mateos JL. Positive affect is inversely associated with mortality in individuals without depression. Front Psychol. 2016;7:1040. Article. IF: 2.323; Q2 • Monroy-Parada DX, Moya MA, Bosqued MJ, López L, RodríguezArtalejo F, Royo-Bordonada MA. Vending machines of food and beverages and nutritional profile of their products at schools in madrid, Spain, 2014-2015. Rev Esp Salud Publica. 2016;90:E1-9. Article. IF: 0.69; Q4 • Ortola R, García-Esquinas E, Galán I, Rodríguez-Artalejo F. Patterns of alcohol consumption and health-related quality of life in older adults. Drug Alcohol Depen. 2016;159:166-73. Article. IF: 3.222; Q1 • Ortola R, García-Esquinas E, León-Muñoz LM, Guallar-Castillón P, Valencia-Martín JL, Galán I, Rodríguez-Artalejo F. Patterns of alcohol consumption and risk of frailty in community-dwelling older adults. J Gerontol A-Biol. 2016;71(2):251-258. Article. IF: 5.957; D1 • Padrón A, Galán I, García-Esquinas E, Fernández E, Ballbe M, Rodríguez-Artalejo F. Exposure to secondhand smoke in the home and mental health in children: a population-based study. Tob Control. 2016;25(3):307-12. Article. IF: 5.469; Q1 • Pérez-Tasigchana RF, León-Muñoz LM, López-García E, Banegas JR, Rodríguez-Artalejo F, Guallar-Castillón P. Mediterranean diet and health-related quality of life in two cohorts of communitydwelling older adults. Plos One. 2016;11(3):e0151596. Article. IF: 2.806; Q1 • Rodríguez-Pascual C, Paredes-Galán E, Ferrero-Martínez AI, Baz-Alonso JA, Durán-Muñoz D, González-Babarro E, SanMartín M, Parajes T, Torres-Torres I, Piñón-Esteban M, Calvo-Iglesias F, Olcoz-Chiva MT, Rodríguez-Artalejo F. The frailty syndrome and mortality among very old patients with symptomatic severe aortic stenosis under different treatments. Int J Cardiol. 2016;224:125-31. Article. IF: 6.189; Q1 • Ruiz-Hurtado G, Ruilope LM, de la Sierra A, Sarafidis P, de la Cruz JJ, Gorostidi M, Segura J,Vinyoles E, Banegas JR. Association between high and very high albuminuria and nighttime blood pressure: Influence of diabetes and chronic kidney disease. Diabetes Care. 2016;39(10):1729-37. Article. IF: 11.857; D1 • Sánchez-Martínez M, Castell MV, González-Montalvo JI, de la Cruz JJ, Banegas JR, Otero A. Transitions in functional status of community dwelling older adults: Impact of physical performance, depression and cognition. Eur Geriatr Med. 2016;7(2):111-6. Article. IF: 1.336; Q4 • Sánchez-Martínez M, López-García E, Guallar-Castillón P, Cruz JJ, Orozco E, García-Esquinas E, Rodríguez-Artalejo F, Banegas JR. Social support and ambulatory blood pressure in older people. J Hypertens. 2016;34(10):2045-52. Article. IF: 4.085; Q1 • Sandoval-Insausti H, Pérez-Tasigchana RF, López-García E, García-Esquinas E, Rodríguez-Artalejo F, Guallar-Castillón P. Macronutrients intake and incident frailty in older adults: A prospective cohort study. J Gerontol A-Biol. 2016;71(10):1329-34. Article. IF: 5.957; D1 • Soler-Vila H, García-Esquinas E, León-Muñoz LM, López-García E, Banegas JR, Rodríguez-Artalejo F. Contribution of health behaviours and clinical factors to socioeconomic differences in frailty among older adults. J Epidemiol Commun H. 2016;70(4):354-60. Article. IF: 3.608; Q1

128

• Zhou B, Lu Y, Hajifathalian K, Bentham J, Di Cesare M, Danaei G, Bixby H, Cowan MJ, Ali MK, Taddei C, Lo WC, Reis-Santos B, Stevens GA, Riley LM, Miranda JJ, Bjerregaard P, Rivera JA, Fouad HM, Ma GS, Mbanya JCN, McGarvey ST, Mohan V, Onat A, Ramachandran A, Ben Romdhane H, Paciorek CJ, Bennett JE, Ezzati M, Abdeen ZA, Kadir KA, Abu-Rmeileh NM, Acosta-Cazares B, Adams R, Aekplakorn W, Aguilar-Salinas CA, Agyemang C, Ahmadvand A, Al-Othman AR, Alkerwi A, Amouyel P, Amuzu A, Andersen LB, Anderssen SA, Anjana RM, Aounallah-Skhiri H, Aris T, Arlappa N, Arveiler D, Assah FK, Avdicova M, Azizi F, Balakrishna N, Bandosz P, Barbagallo CM, Barcelo A, Batieha AM, Baur LA, Ben Romdhane H, Benet M, Bernabe-Ortiz A, Bharadwaj S, Bhargava SK, Bi YF, Bjerregaard P, Bjertness E, Bjertness MB, Bjokelund C, Blokstra A, Bo S, Boehm BO, Boissonnet CP, Bovet P, Brajkovich I, Breckenkamp J, Brenner H, Brewster LM, Brian GR, Bruno G, Bugge A, de León AC, Can G, Candido APC, Capuano V, Carlsson AC, Carvalho MJ, Casanueva FF, Casas JP, Caserta CA, Castetbon K, Chamukuttan S, Chaturvedi N, Chen CJ, Chen FF, Chen SH, Cheng CY, Chetrit A, Chiou ST, Cho Y, Chudek J, Cifkova R, Claessens F, Concin H, Cooper C, Cooper R, Costanzo S, Cottel D, Cowell C, Crujeiras AB, D’Arrigo G, Dallongeville J, Dankner R, Dauchet L, de Gaetano G, De Henauw S, Deepa M, Dehghan A, Deschamps V, Dhana K, Di Castelnuovo AF, Djalalinia S, Doua K, Drygas W, Du Y, Dzerve V, Egbagbe EE, Eggertsen R, El Ati J, Elosua R, Erasmus RT, Erem C, Ergor G, Eriksen L, Escobedo-de la Pena J, Fall CH, Farzadfar F, Felix-Redondo FJ, Ferguson TS, Fernández-Berges D, Ferrari M, Ferreccio C, Feskens EJM, Finn JD, Foger B, Foo LH, Forslund AS, Fouad HM, Francis DK, Franco MD, Franco OH, Frontera G, Furusawa T, Gaciong Z, Garnett SP, Gaspoz JM, Gasull M, Gates L, Geleijnse JM, Ghasemian A, Ghimire A, Giampaoli S, Gianfagna F, Giovannelli J, Giwercman A, Gross MG, Rivas JPG, Gorbea MB, Gottrand F, Grafnetter D, Grodzicki T, Grontved A, Gruden G, Gu DF, Guan OP, Guerrero R, Guessous I, Guimaraes AL, Gutierrez L, Hambleton IR, Hardy R, Kumar RH, Hata J, Heidemann C, Herrala S, Hihtaniemi IT, Ho SY, Ho SC, Hofman A, Hormiga CM, Horta BL, Houti L, Howitt C, Htay TT, Htet AS, Htike MMT, Htike MMT, Hu Y, Hussieni AS, Huybrechts I, Hwalla N, Iacoviello L, Iannone AG, Ibrahim MM, Ikeda N, Ikram MA, Irazola VE, Islam M, Iwasaki M, Jacobs JM, Jafar T, Jamil KM, Jasienska G, Jiang CQ, Jonas JB, Joshi P, Kafatos A, Kalter-Leibovici O, Kasaeian A, Katz J, Kaur P, Kavousi M, Kelishadi R, Kengne AP, Kersting M, Khader YS, Khalili D, Khang YH, Kiechl S, Kim J, Kolsteren P, Kratzer W, Kromhout D, Kujala UM, Kula K, Kyobutungi C, Laatikainen T, Lachat C, Laid Y, Lam TH, Landrove O, Lanska V, Lappas G, Laxmaiah A, Leclercq C, Lee J, Lee J, Lehtimaki T, Lekhraj R, LeónMuñoz LM, Li YP, Lim WY, Lima-Costa MF, Lin HH, Lin X, Lissner L, Lorbeer R, Lozano JE, Luksiene D, Lundqvist A, Lytsy P, Ma GS, Machado-Coelho GLL, Machi S, Maggi S, Magliano DJ, Makdisse M, Rao KM, Manios Y, Manzato E, Margozzini P, Marques-Vidal P, Martorell R, Masoodi SR, Mathiesen EB, Matsha TE, Mbanya JCN, McFarlane SR, McGarvey ST, McLachlan S, McNulty BA, Mediene-Benchekor S, Meirhaeghe A, Menezes AMB, Merat S, Meshram II, Mi J, Miquel JF, Miranda JJ, Mohamed MK, Mohammad K, Mohammadifard N, Mohan V, Yusoff MFM, Moller NC, Molnar D, Mondo CK, Morejon A, Moreno LA, Morgan K, Moschonis G, Mossakowska M, Mostafa A, Mota J, Motta J, Mu TT, Muiesan ML, Muller-Nurasyid M, Mursu J, Nagel G, Namesna J, Nang EEK, Nangia VB, Navarrete-Muñoz EM, Ndiaye NC, Nenko I, Nervi F, Nguyen ND, Nguyen QN, Nieto-Martínez RSE, Ning G, Ninomiya T, Noale M, Noto D, Al Nsour M, Ochoa-Aviles AM, Oh K, Onat A, Ordunez P, Osmond C, Otero JA, Owusu-Dabo E, Pahomova E, Palmieri L, Panda-Jonas S, Panza F, Parsaeian M, Peixoto SV, Peltonen M, Peters A, Peykari N, Pham ST, Pilav A, Pitakaka F, Piwonska A, Piwonski J, Plans-Rubio P, Porta M, Portegies MLP, Poustchi H, Pradeepa R, Price JF, Punab M, Qasrawi RF, Qorbani M, Radisauskas R, Rahman M, Raitakari O, Rao SR,

Ramachandran A, Ramke J, Ramos R, Rampal S, Rathmann W, Redon J, Reganit PFM, Rigo F, Robinson SM, Robitaille C, Rodríguez-Artalejo F, Rodríguez-Pérez MD, Rodríguez-Villamizar LA, Rojas-Martínez R, Ronkainen K, Rosengren A, Rubinstein A, Rui O, Ruiz-Betancourt BS, Horimoto ARVR, Rutkowski M, Sabanayagam C, Sachdev HS, Saidi O, Sakarya S, Salanave B, Salonen JT, Salvetti M, Sánchez-Abanto J, Santos D, dos Santos RN, Santos R, Saramies JL, Sardinha LB, Sarrafzadegan N, Saum KU, Scazufca M, Schargrodsky H, Scheidt-Nave C, Sein AA, Sharma SK, Shaw JE, Shibuya K, Shin Y, Shiri R, Siantar R, Sibai AM, Simon M, Simons J, Simons LA, Sjostrom M, Slowikowska-Hilczer J, Slusarczyk P, Smeeth L, Snijder MB, So HK, Sobngwi E, Soderberg S, Solfrizzi V, Sonestedt E, Soumare A, Staessen JA, Stathopoulou MG, SteeneJohannessen J, Stehle P, Stein AD, Stessman J, Stockl D, Stokwiszewski J, Stronks K, Strufaldi MW, Sun CA, Sundstrom J, Sung YT, Suriyawongpaisal P, Sy RG, Tai ES, Tamosiunas A, Tang L, Tarawneh M, Tarqui-Mamani CB, Taylor A, Theobald H, Thijs L, Thuesen BH, Tolonen HK, Tolstrup JS, Topbas M, Torrent M, Traissac P, Trinh OTH, Tulloch-Reid MK, Tuomainen TP, Turley ML, Tzourio C, Ueda P, Ukoli FAM, Ulmer H, Uusitalo HMT, Valdivia G, Valvi D, van Rossem L, van Valkengoed IGM, Vanderschueren D, Vanuzzo D, Vega T, Velasquez-Melendez G, Veronesi G, Verschuren WMM, Verstraeten R, Viet L, Vioque J, Virtanen JK, Viswanathan B, Vollenweider P, Voutilainen S, Vrijheid M, Wade AN, Wagner A, Walton J, Mohamud WNW, Wang F, Wang MD, Wang Q, Wang YX, Wannamethee SG, Weerasekera D, Whincup PH, Widhalm K, Wijga AH, Wilks RJ, Willeit J, Wilsgaard T, Wojtyniak B, Wong TY, Woo J, Woodward M, Wu FC, Wu SL, Xu HQ, Yan WL, Yang XG, Ye XW, Yoshihara A, Younger-Coleman NO, Zambon S, Zargar AH, Zdrojewski T, Zhao WH, Zheng YF, Cisneros JZ. Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet. 2016;387(10027):1513-30. Article. IF: 47.831; D1

Rodríguez Artalejo F. Centro de investigación biomédica en red de epidemiologíay salud pública (CIBEResp). ISCIII. 2006-2017. Management centre: UAM Rodríguez Artalejo F. Impacto de los principales patrones de consumo de bebidas alcohólicas sobre la salud de los adultos mayores en españa (2014/002). Plan Nacional sobre Drogas. 2015-2017. Management centre: UAM

INTERNATIONAL PROJECTS Rodríguez Artalejo F. Utility of OMIC-based biomarkers in characterizing older individuals at risk for frailty, its progression to disability and general consequences to health and well-being - the frailomic initiative (FP7-HEALTH2012-No 305483-2). EU. 2013-2017. Management centre: UAM Rodríguez Artalejo F. Ageing trajectories of health: longitudinal opportunities and synergies (ATHLOS) (H2020PHC-2014. 635316-2.). EU. 2015-2019. Management centre: UAM

PUBLIC PROJECTS Banegas Banegas JR. Estimación de la presión arterial central de 24 horas y determinación de umbrales diagnósticos de la presión arterial central en hipertensos atendidos en Atención Primaria (PI13/02321). ISCIII. 20142016. Management centre: UAM López García E. Impacto de la dieta en indicadores globales de bienestar en la población mayor española (PI13/00288). ISCIII. 2014-2016. Management centre: UAM Rodríguez Artalejo F. Conductas alimentarias, dieta mediterránea, obesidad sarcopénica y precursores modificables de la discapacidad en los ancianos (PI12/01166). ISCIII. 2013-2016. Management centre: UAM Rodríguez Artalejo F. El Síndrome de Fragilidad y los factores psicosociales en las trayectorias de envejecimiento saludable: una cohorte comunitaria de adultos mayores en españa. Proyectos de cohortes CIBER, en el marco de las Estrategias en Salud del Sistema Nacional de Salud (SBS). ISCIII. 2016-Ongoing. Management centre: UAM

Return to C ARDIOVASCULAR AREA INDEX

129

3 INFORMATION GROUPS BY AREA

3.2 Cardiovascular Area

PUBLICATIONS • Álvarez-Román MT, Fernández-Bello I, Jiménez-Yuste V, MartínSalces M, Arias-Salgado EG, Pollmar MIR, Sanz RJ, Butta NV. Procoagulant profile in patients with immune thrombocytopenia. Brit J Haematol. 2016;175(5):925-34. Article. IF: 5.67; Q1 • Álvarez-Román MT, Pollmar MIR, Bernardino JI, Lozano ML, Martín-Salces M, Fernández-Bello I, Jiménez-Yuste V, Butta NV. Thrombopoietin receptor agonists in conjunction with oseltamivir for immune thrombocytopenia. AIDS. 2016;30(7):1141-2. Letter. IF: 5.003; Q1

COAGULOPATHIES AND ALTERATIONS OF HAEMOSTASIS GROUP

• Auerswald G, Dolan G, Duffy A, Hermans C, Jiménez-Yuste V, Ljung R, Morfini M, Lambert T, Salek SZ. Pain and pain management in haemophilia. Blood Coagul Fibrin. 2016;27(8):845-54. Review. IF: 1.367; Q4

17 70.37 7

Víctor Manuel Jiménez Yuste Jefe de Servicio de Hematología. HULP María Teresa Álvarez Román Facultativo Especialista de Área en Hematología y Hemoterapia. HULP Nora Viviana Butta Coll Investigadora Senior (Contrato Miguel Servet- Tipo 2). Jefe de Laboratorio. HULP Ihosvany Fernández Bello Investigador Postdoctoral. HULP Raquel Fernández Morata Técnico de Laboratorio. HULP Elena García Arias-Salgado Investigadora asociada. Advanced Medical Projects Madrid Sara García Barcenilla Coordinadora de Estudios. HULP Mónica Martín Salces Facultativo Especialista de Área en Hematología y Hemoterapia. HULP Isabel Rivas Pollmar Médico Adjunto en Hematología. HULP

Strategic Objective This group’s research activities address various relevant questions in the area of haematology and focus on the characterisation of the genetic and molecular basis of coagulation and haemostatic function. Our group investigates physiological processes such as coagulation, haemostasis, innate immunity, inflammation, cell adhesion and migration, and cell signalling, with special emphasis on their relevance to pathological processes. 130

In addition, we perform epidemiological studies to facilitate patient data analysis and therapeutic treatment.

Research Lines 1- Haemophilia A and B: • Genetic and molecular studies in patients with haemophilia A and B. • Risk factors for the development of factor FVIII/ FIX inhibitors in patients with haemophilia A and B. Individualised treatment adaptation based on the nature of antigenic epitopes. • Epidemiological studies of congenital haemophilia A and B, acquired haemophilia A and von Willebrand’s disease. 2- Haemostasis disorders: • Haemostasis in thrombocytopenic diseases (immune thrombocytopenia and myelodysplastic syndromes). • Haemostasis in inflammatory diseases.

Research Activity DOCTORAL THESES Martín Salces M. Alteraciones de la hemostasia en los síndromes mielodisplásicos[dissertation]. Madrid: UAM: 2016(08/11/2016). Directors: Butta Coll NV, de Paz Arias R, Jiménez Yuste V.

• Batlle J, Pérez-Rodríguez A, Corrales I, López-Fernández MF, Rodríguez-Trillo A, Loures E, Cid AR, Bonanad S, Cabrera N, Moret A, Parra R, Mingot-Castellano ME, Balda I, Altisent C, Pérez-Montes R, Fisac RM, Iruin G, Herrero S, Soto I, de Rueda B, Jiménez-Yuste V, Alonso N,Vilarino D, Arija O, Campos R, Paloma MJ, Bermejo N, Toll T, Mateo J, Arribalzaga K, Marco P, Palomo A, Sarmiento L, Inigo B, Nieto MD, Vidal R, Martínez MP, Aguinaco R, Cesar JM, Ferreiro M, García-Frade J, Rodríguez-Huerta AM, Cuesta J, Rodríguez-González R, García-Candel F, Cornudella R, Aguilar C, Borras N,Vidal F. Molecular and clinical profile of von Willebrand disease in Spain (PCM-EVW-ES): Proposal for a new diagnostic paradigm. Thromb Haemostasis. 2016;115(1):40-50. Article. IF: 5.627; D1 • de la Corte-Rodríguez H, Rodríguez-Merchán EC, ÁlvarezRomán MT, Hernández-Moreno AL. Coexistence of factor VII deficiency and hereditary spastic paraplegia in two siblings. Case Rep Hematol. 2016; 1351873. Article. Not Indexed • González-López TJ, Álvarez-Román MT, Pascual C, SánchezGonzález B, Fernández-Fuentes F, Jarque I, Pérez-Rus G, PérezCrespo S, Bernat S, Hernández-Rivas JA, Andrade MM, Cortés M, Gómez-Núñez M, Olivera P, Martínez-Robles V, FernándezRodríguez A, Fuertes-Palacio MA, Fernández-Minano C, de Cabo E, Fisac R, Aguilar C, Bárez A, Penarrubia MJ, García-Frade LJ, González-Porras JR. Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice. Eur J Haematol. 2016;97(3):297-302. Article. IF: 2.653; Q2 • Holstein K, Batorova A, Carvalho M, Fijnvandraat K, Holme P, Kavakli K, Lambert T, Rocino A, Jiménez-Yuste V, Astermark J. Current view and outcome of ITI therapy - A change over time? Thromb Res. 2016;148:38-44. Article. IF: 2.65; Q2 • Jiménez-Yuste V, Kruse-Jarres R, Rangarajan S, Altisent C. The evolving role and future relevance of plasma-derived therapies in the management of bleeding disorders. Thromb Haemostasis. 2016;116:S1. Editorial Material. IF: 5.627; D1. • Jiménez-Yuste V, Oldenburg J, Rangarajan S, Kurth MH, Bozzo J, Santagostino E. Clinical overview of Fanhdi/Alphanate (plasmaderived, VWF-containing FVIII concentrate) in immune tolerance induction in haemophilia A patients with inhibitors. Haemophilia. 2016;22(1):E71-4. Letter. IF: 3.569; Q2 • Jiménez-Yuste V, Oldenburg J, Rangarajan S, Peiró-Jordán R, Santagostino E. Long-term outcome of haemophilia A patients after successful immune tolerance induction therapy using a single plasma-derived FVIII/VWF product: the long-term ITI study. Haemophilia. 2016;22(6):859-65. Article. IF: 3.569; Q2 • Kreuz W, Ettingshausen CE, Vdovin V, Zozulya N, Plyushch O, Svirin P, Andreeva T, Bubanska E, Campos M, Benedik-Dolnicar M, Jiménez-Yuste V, Kitanovski L, Klukowska A, Momot A, Osmulskaya N, Prieto M, Salek SZ, Velasco F, Pavlova A, Oldenburg J, Knaub S, Jansen M, Belyanskaya L, Walter O. First prospective report on immune tolerance in poor risk haemophilia A inhibi-

tor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study. Haemophilia. 2016;22(1):87-95. Article. IF: 3.569; Q2 • López-Fernández MF, Roca CA, Álvarez-Román MT, Hirnyk MIC, Mingot-Castellanos ME, Jiménez-Yuste V, Haro ARC, PérezGarrido R, Balbas CS. Spanish Consensus Guidelines on prophylaxis with bypassing agents in patients with haemophilia and inhibitors. Thromb Haemostasis. 2016;115(5):872-95. Article. IF: 5.627; D1 • Luczkowiak J, Arribas JR, Gómez S, Jiménez-Yuste V, de la Calle F, Viejo A, Delgado R. Specific neutralizing response in plasma from convalescent patients of Ebola Virus Disease against the West Africa Makona variant of Ebola virus. Virus Res. 2016;213:224-9. Article. IF: 2.628; Q3 • Mingot-Castellano ME, Álvarez-Román MT, López-Fernández MF, Altisent-Roca C, Canaro-Hirnyk MI, Jiménez-Yuste V, CidHaro AR, Pérez-Garrido R, Sedano-Balbás C. Spanish consensus guidelines on prophylaxis with bypassing agents for surgery in patients with haemophilia and inhibitors. Eur J Haematol. 2016;96(5):461-74. Review. IF: 2.653; Q2 • Santagostino E, Martinowitz U, Lissitchkov T, Pan-Petesch B, Hanabusa H, Oldenburg J, Boggio L, Negrier C, Pabinger I, Prondzinski MV, Altisent C, Castaman G, Yamamoto K, Álvarez-Román MT,Voigt C, Blackman N, Jacobs I. Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial. Blood. 2016;127(14):1761-9. Article. IF: 13.164; D1 • Walshl CE, Jiménez-Yuste V, Auerswald G, Grancha S. The burden of inhibitors in haemophilia patients. Thromb Haemostasis. 2016;116:S10-S17. Article. IF: 5.627; D1 • Wang M, Álvarez-Román MT, Chowdary P, Quon DV, Schafer K. Physical activity in individuals with haemophilia and experience with recombinant factor VIII Fc fusion protein and recombinant factor IX FC fusion protein for the treatment of active patients: a literature review and case reports. Blood Coagul Fibrin. 2016;27(7):737-44. Review. IF: 1.367; Q4

PUBLIC PROJECTS Butta Coll NV. Diferencias en la hemostasia de pacientes con trombocitopenia: identificación de mecanismos procoagulantes compensatorios del efecto de la disminución del numero de plaquetas (PI12/01831). ISCIII. 2013-2016. Management centre: FIBHULP Butta Coll NV. Estudio prospectivo de pacientes con trombocitopenia inmune: identificación de mecanismos fisiopatológicos que condicionan el fenotipo clínico y la respuesta a la terapia (PI15/01457). ISCIII. 2016-2018. Management centre: FIBHULP Butta Coll NV. Contrato Miguel Servet Tipo II (MSII11/ 000024). ISCIII. 2015-2017. Management centre: FIBHULP

PRIVATE PROJECTS Álvarez Román MT. Manejo de la patología urgente en pacientes con hemofilia en el ambito extrahospitalario. Desarrollo de un protocolo de actuación extrahospitalario. Desarrollo de un protocolo de actuación coordinado entre el summa 112 y el Servicio de Trombosis y Hemosta. Antares Consulting S.A. 2014-Ongoing. Management centre: FIBHULP

Continue

131

3.2 Cardiovascular Area

3 INFORMATION GROUPS BY AREA Butta Coll NV. Estudio de la hemostasia en la enfermedad de Behçet. Antares Consulting S.A. 2011-Ongoing. Management centre: FIBHULP Jiménez Yuste VM. Alteraciones citogenéticas en donantes de sangre sanos. FIBHULP. 2004-Ongoing. Management centre: FIBHULP Jiménez Yuste VM. Monitorización del tratamiento con agentes bypass, en pacientes con hemofilia e inhibidor mediante tres métodos de evaluación global de la hemostasia. Antares Consulting S.A. 2007-Ongoing. Management centre: FIBHULP Jiménez Yuste VM. Estudio retrospectivo de utilización de Fanhdi en enfermedad de Von Willebrand y hemofilia A. Baxter S.L. 2008-Ongoing. Management centre: FIBHULP Jiménez Yuste VM. Desarrollo de un nuevo método de laboratorio de alta sensibilidad para la detección cuantitativa de anticuerpos contra el factor VIII. Pfizer S.L.U. 2012-Ongoing. Management centre: FIBHULP Jiménez Yuste VM. Sinovitis post-hemartros. Estudio clínico, biológico y ecográfico. Post-hemarthrosis sinovitis markers on patients with haemophilia on prophilaxis. Clinical, biological and ultrasonographic stuyd. CAM. 2012. Management centre: FIBHULP Jiménez Yuste VM. Estudio in vitro del efecto procoagulante de factor VII recombinante activado y vatreptacog alfa en sangre de pacientes con hemofilia grave mediante tromboelastografía y test de generación de tromina. Novo Nordisk A.S. 2012-Ongoing. Management centre: FIBHULP Jiménez Yuste VM. Case-control pilot study of the immune modulating effect of feiba on patients with haemophilia A and inhibitors. Baxter Healthcare Corporation. 2013-Ongoing. Management centre: FIBHULP Jiménez Yuste VM. Evaluación de la disfunción endotelial e identificación de factores de riesgo asociados a la enfermedad cardiovascular en el paciente con hemofilia. Antares Consulting S.A. 2013-Ongoing. Management centre: FIBHULP Jiménez Yuste VM. Curso de Hematología: investigación y clínica. Glaxosmithkline S.A. 2014-Ongoing. Management centre: FIBHULP Jiménez Yuste VM. Field study to evaluate the assay variability of bay 81-8973 measurements with methodologies, reference standards and reagents routinely used in clinical laboratories. Bayer Hispania S.L. 2015-Ongoing. Management centre: FIBHULP Jiménez Yuste VM. Field study to evaluate the activity a site specific of B-domain deleted (BDD) pegylated recombinant FVIII protein (BAY 94-9024) in plasma samples measured with both chromogenic and one stage assays used in clinical laboratories. Bayer Hispania S.L. 2015-Ongoing. Management centre: FIBHULP Jiménez Yuste VM. Estudio del papel de los biomarcado132

res de daño endotelial, hepatocelular y fibrosis hepática y la elastografía de transición en el diagnóstico del síndrome de obstrucción sinusoidal. Eusa Pharma Iberia S.L.U. 2015-Ongoing. Management centre: FIBHULP Jiménez Yuste VM. One-year training and research scholarship programme in haemophilia and other haemostatic disorders. Novo Nordiks Health Care AG. 2015-Ongoing. Management centre: FIBHULP Jiménez Yuste VM. Individualización del régimen profiláctico con agentes biapás en pacientes con hemofilia e inhibidor de alta respuesta mediante tromboelastometría y trominografía. Antares Consulting S.A. 2014-Ongoing. Management centre: FIBHULP Jiménez Yuste VM. Tailoring prophylaxis in children with severe haemophilia: impact of the trough procoagulant state on the incidence of breakthrough bleeding. Novo Nordiks Health Care AG. 2015-Ongoing. Management centre: FIBHULP Jiménez Yuste VM. Curso en investigación y tratamiento de la hemofilia. Laboratorios Pfizer Ltda. 2015-Ongoing. Management centre: FIBHULP Jiménez Yuste VM. Individualizacion de la profilaxis: estudio de los niveles valles mediante técnicas globales e impacto de la actividad fisica. Baxalta GMBH. 2015-Ongoing. Management centre: FIBHULP Jiménez Yuste VM. Formación orientada a la investigación en el área de hematología. Profármaco-2 S.L. 2015-Ongoing. Management centre: FIBHULP

CLINICAL TRIALS Álvarez Román MT. Estudio de extension de fase III, abierto, multicéntrico para evaluar la seguridad y eficacia del factor de la coagulacion VIII recombinante (RVIII-cadena sencilla, CSL627) en pacientes con hemofilia a severa. CSL Behring GMBH Clinical. HULP Code: Anexo-I 4179. Sponsored´s Protocol Code: CSL-3001. Signature Date: 18/05/2016 Álvarez Román MT. Estudio multicéntrico de fase II, abierto, de un solo brazo, prospectivo, intervencional, del factor derivado del plasma VIII/VWF (Alphanate®) en la terapia de inducción de tolerancia inmune en sujetos con hemofilia congénita A. Grifols S.A. HULP Code: 4655. Sponsored´s Protocol Code: GBI1406. Signature Date: 27/07/2016 Álvarez Román MT. Estudio de fase III prospectivo, multicéntrico y abierto para investigar la seguridad, la inmunogenicidad y la eficacia hemostática del factor VIII pegilado (BAX 855) en pacientes no tratados previamente (PNTP) y pacientes tratados mínimamente (PTM) < 6 años con hemofilia a grave (FVIII < 1 %). Baxter Innovations GMBH. HULP Code: 4487. Sponsored´s Protocol Code: 261203. Signature Date: 19/01/2016 Álvarez Román MT. Estudio clínico de fase III, prospectivo, aleatorizado y multicéntrico para comparar la seguridad y la eficacia de BAX 855 tras la profilaxis guiada por FC di-

rigida a dos concentraciones mínimas de FVIII distintas en sujetos con hemofilia A grave. Baxter Innovations GMBH. HULP Code: 4547. Sponsored´s Protocol Code: 261303. Signature Date: 16/02/2016 Álvarez Román MT. Estudio de extensión de fase IIIB, abierto, multicéntrico, sobre la seguridad y eficacia de una proteína de fusion del factor IX recombinante de la coagulación con la albumina (RIXFP) en pacientes con hemofilia B. CSL Behring GMBH Clinical. HULP Code: Anexo-II 4011. Sponsored´s Protocol Code: CSL654_3003. Signature Date: 23/02/2016 Álvarez Román MT. Estudio de fase 1, prospectivo, abierto, de dos periodos, secuencia fija y aumento escalonado de la dosis sobre la FC y la seguridad de BAX 826 (APSFVIIIR) en pacientes con hemofilia a grave (FVIII < 1 %) previamente tratados. Baxter Innovations GMBH. HULP Code: 4563. Sponsored´s Protocol Code: 291501. Signature Date: 16/03/2016 Álvarez Román MT. Estudio multicéntrico de recogida de datos retrospectivos sobre el uso del factor X de alta pureza de BPL en el tratamiento de pacientes con deficiencia del factor X hereditaria. Bio Products Laboratory Ltd. HULP Code: PI-2192. Sponsored´s Protocol Code: TEN 05. Signature Date: 12/05/2016 Álvarez Román MT. Estudio multicéntrico, abierto y de administración repetida, para evaluar la seguridad y la eficacia de UCB7665 en sujetos con trombocitopenia inmune primaria (tp0001). UCB Biosciencies GMBH. HULP Code: 4562. Sponsored´s Protocol Code: TP0001. Signature Date: 31/03/2016 Álvarez Román MT. Estudio retrospectivo para evaluar el uso de agonistas de los receptores de trombopoyetina en pacientes adultos con trombocitopenia inmune primaria en España. Asociación de Investigación de la Enfermedad Tromboembólica de la Región de Murcia. HULP Code: PI-2517. Sponsored´s Protocol Code: VERTEX 2.0. Signature Date: 18/10/2016 Jiménez Yuste VM. Ensayo multinacional para evaluar la seguridad y la eficacia, junto con la farmacocinética, de NNC 0129-0000-1003 administrado para el tratamiento y la profilaxis de las hemorragias en pacientes con hemofilia A. Novo Nordisk AS. HULP Code: Anexo-IIII 3526. Sponsored´s Protocol Code: NN7088-3859. Signature Date: 09/05/2016 Jiménez Yuste VM. Ensayo clínico de fase III, aleatorizado, multicéntrico y abierto para evaluar la eficacia, la seguridad y la farmacocinética del emicizumab profiláctico, en comparación con la ausencia de profilaxis, en pacientes con hemofilia A sin inhibidores. F Hoffmann-La Roche Ltd. HULP Code: 4606. Sponsored´s Protocol Code: BH30071. Signature Date: 28/04/2016 Jiménez Yuste VM. Ensayo clínico aleatorizado, multicéntrico, abierto de fase III para evaluar la eficacia, seguridad y farmacocinética del RO5534262 profilactico frente a la no profilaxis en pacientes con hemofilia A con inhibidores. Roche Farma S.A.

HULP Code: Anexo-I 4486. Sponsored´s Protocol Code: BH29884. Signature Date: 10/02/2016 Jiménez Yuste VM. Seguridad y eficacia de NNC01550000-0004 en la prevención y el tratamiento de las hemorragias en pacientes pediátricos con hemofilia A no tratados previamente. Novo Nordisk AS. HULP Code: Anexo-II 3602. Sponsored´s Protocol Code: NN70083809. Signature Date: 15/03/2016 Jiménez Yuste VM. Ensayo clínico de fase III multicéntrico, abierto y de un solo brazo para evaluar la eficacia, la seguridad y la farmacocinética de la administración subcutánea de emicizumab una vez a la semana en pacientes pediátricos con hemofilia A con inhibidores. F HoffmannLa Roche Ltd. HULP Code: 4605. Sponsored´s Protocol Code: BH29992. Signature Date: 10/05/2016 Jiménez Yuste VM. Ensayo multicéntrico, comparativo, doble ciego, aleatorizado y cruzado para investigar la farmacocinética y la seguridad de dosis única de turoctocog alfa pegol a partir del proceso pivotal y de turoctocog alfa pegol a partir del proceso comercial en pacientes con hemofilia A grave. Novo Nordisk AS. HULP Code: 4654. Sponsored´s Protocol Code: NN7088-4033. Signature Date: 02/09/2016 Jiménez Yuste VM. Ensayo clínico estudio de fase III, multicéntrico y sin enmascaramiento para evaluar la eficacia, la seguridad, la farmacocinética y la farmacodinámica del emicizumab administrado cada 4 semanas en pacientes con hemofilia A. F Hoffmann-La Roche Ltd. HULP Code: 4674. Sponsored´s Protocol Code: BO39182. Signature Date: 29/08/2016 Jiménez Yuste VM. Guardian 9. Ensayo abierto y multicéntrico para evaluar la farmacocinética de Novoeight® (turoctocog alfa) en relación con el IMC en sujetos con hemofilia A. Novo Nordisk AS. HULP Code: 4618. Sponsored´s Protocol Code: NN7008-4239. Signature Date: 23/09/2016 Martín Salces M. Estudio de fase III, multicéntrico, de un solo brazo y abierto sobre la eficacia y la seguridad del factor VIII recombinante porcino con dominio B suprimido (BAX 802) en sujetos con hemofilia A congénita con inhibidores del factor VIII sometidos a intervenciones quirúrgicas u otros procedimientos invasivos. Baxalta Innovations GMBH. HULP Code: 4658. Sponsored´s Protocol Code: 241502. Signature Date: 15/07/2016 Martín Salces M. Estudio de fase III, multicéntrico, abierto y no controlado para evaluar la seguridad y la eficacia de BAY81-profilactico. Bayer Hispania SL. HULP Code: Anexo-I 4099. Sponsored´s Protocol Code: 818973/13400. Signature Date: 24/10/2016

Return to C ARDIOVASCULAR AREA INDEX

133

3.2 Cardiovascular Area

3 INFORMATION GROUPS BY AREA cies (and their interaction among each other or with other mediators such as nitric oxide) in inflammatory conditions that resemble those found in cardiovascular pathologies. This research is important given the essential role these mediators play in the control of vascular smooth muscle tone and vascular structure.

Research Lines

VASCULAR PHYSIOLOGY AND PHARMACOLOGY GROUP

• Oxidative stress, COX-derived products and vascular function and remodelling. Changes with hypertension and other cardiovascular pathologies. • Adipose tissue and vascular alterations in cardiovascular pathologies. • Neural control of vascular tone. • Cardiovascular effects of heavy metals. • Antioxidant and antihypertensive properties of bioactive peptides.

21 73.617 13

Mercedes Salaices Sánchez Catedrática. Departamento de Farmacología. Facultad de Medicina. UAM Andrea Aguado Martínez Investigadora Postdoctoral. UAM María Jesús Alonso Gordo Catedrática. Departamento de Ciencias Básicas de la Salud. Facultad de Ciencias de la Salud. Universidad Rey Juan Carlos María Soledad Avendaño Herrador Investigador Postdoctoral. UAM Gloria Balfagón Calvo Catedrática. Departamento de Fisiología. Facultad de Medicina. UAM Javier Blanco Rivero Profesor Contratado. Departamento de Fisiología. Facultad de Medicina. UAM Ana María Briones Alonso Investigadora Senior (Contrato Ramón y Cajal). UAM Laura Caracuel Cano Investigadora Postdoctoral. UAM Ana Belén García Redondo Investigadora Postdoctoral. UAM María González Amor Investigadora Predoctoral. UAM Raquel Hernanz Martín Profesora Contratada. Departamento de Ciencias Básicas de la Salud. Facultad de Ciencias de la Salud. Universidad Rey Juan Carlos Ángela Martín Cortes Profesora Contratada. Departamento de Ciencias Básicas de la Salud. Facultad de Ciencias de la Salud. Universidad Rey Juan Carlos 134

Marta Miguel Castro Científico Titular. Instituto de Investigación en Ciencias de la Alimentación. Consejo Superior de Investigaciones Científicas (CIAL, CSIC-UAM) Roberto Palacios Ramírez Investigador Predoctoral. Universidad Rey Juan Carlos Raquel Rodrígues Díez Investigadora Postdoctoral. UAM

Strategic Objective Our group is a well-established research group with more than 30 years of experience in the study of the mechanisms involved in the functional, structural and mechanical alterations of the vasculature in various cardiovascular pathologies such as ageing, diabetes and, in particular, hypertension. The group is located at the Faculty of Medicine (UAM) and maintains research collaborations with investigators at various universities in Spain and in other countries. Our main objective is to gain further insight into the physiological and molecular mechanisms involved in alterations of resistance and conductance arteries in cardiovascular pathologies. To conduct our research, we generally use various experimental approaches including in vivo animal models, ex vivo experiments and in vitro cell based studies combined with physiological, pharmacological and molecular biology techniques. In addition, we have begun to translate this knowledge into human studies. In terms of the mediators involved, we have a particular interest in the role of prostanoids derived from the inducible isoform of cyclooxygenase (COX-2) and reactive oxygen spe-

Research Activity DOCTORAL THESES Brose Piotrowicz IB. Avaliação das propriedades antioxidantes e anti-hipertensivas de peptídeos obtidos do concentrado proteico de farelo de arroz[dissertation]. Rio Grande: Universidade Federal do Rio Grande: 2016(27/05/2016). Directors: Salas Mellado M, Miguel Castro M. Palacios Ramírez R. Papel de ET-1 en la expresión de COX-2 y la contractilidad vascular en hipertensión. Modulación por PPARγ[dissertation]. Madrid: URJC: 2016(03/05/2016). Directors: Hernanz Martín R, Alonso Gordo MJ.

PUBLICATIONS • Aguado A, Fischer T, Rodríguez C, Manea A, Martínez-González J, Touyz RM, Hernanz R, Alonso MJ, Dixon DA, Briones AM, Salaices M. Hu antigen R is required for NOX-1 but not NOX-4 regulation by inflammatory stimuli in vascular smooth muscle cells. J Hypertens. 2016;34(2):253-65. Article. IF: 4.085; Q1 • Aleixandre A, Miguel M. Dietary fiber and blood pressure control. Food Funct. 2016;7(4):1864-71. Review. IF: 3.247; Q1 • Avendaño MS, Martínez-Revelles S, Aguado A, Simoes MR, González-Amor M, Palacios R, Guillem-Llobat P,Vassallo DV,Vila L, García-Puig J, Beltrán LM, Alonso MJ, Cachofeiro MV, Salaices M, Briones AM. J Role of COX-2-derived PGE(2) on vascular stiffness and function in hypertension. Brit J Pharmacol. 2016;173(9):1541-55. Article. IF: 5.491; D1

• Criado M, Balsera B, Mulet J, Sala S, Sala F, de la Torre-Martínez R, Fernández-Carvajal A, Ferrer-Montiel A, Moreno-Fernández S, Miguel M, de Vega MJP, González-Muñiz R. 1,3-diphenylpropan1-ones as allosteric modulators of alpha 7 nACh receptors with analgesic and antioxidant properties. Future Med Chem. 2016;8(7):731-49. Article. IF: 3.556; Q1 • Fernández-Vallinas S, Miguel M, Aleixandre A. Long-term antihypertensive effect of a soluble cocoa fiber product in spontaneously hypertensive rats. Food Nutr Res. 2016;60:29418. Article. IF: 2.039; Q2 • Galán M, Salaices M. T-regulatory cells and vascular function: the importance of their immunosuppressive action in hypertensive disease. J Hypertens. 2016;34(1):36-8. Editorial Material. IF: 4.085; Q1 • Garces-Rimón M, González C, Uranga JA, López-Miranda V, López-Fandino R, Miguel M. Pepsin egg white hydrolysate ameliorates obesity-related oxidative stress, inflammation and steatosis in zucker fatty rats. Plos One. 2016;11(3):e0151193. Article. IF: 2.806; Q1 • Garcés-Rimón M, López-Exposito I, López-Fandino R, Miguel M. Egg white hydrolysates with in vitro biological multiactivities to control complications associated with the metabolic syndrome. Eur Food Res Technol. 2016;242(1):61-9. Article. IF: 1.664; Q2 • Garcés-Rimón M, Sandoval M, Molina E, López-Fandino R, Miguela M. Egg protein hydrolysates: New culinary textures. Int J Gastronomy Food Sci. 2016;3:17-22. Article. Not Indexed • García-Redondo AB, Aguado A, Briones AM, Salaices M. NADPH oxidases and vascular remodeling in cardiovascular diseases. Pharmacol Res. 2016;114:110-20. Review. IF: 4.48; Q1 • Morales-Cano D, Moreno L, Barreira B, Briones AM, Pandolfi R, Moral-Sanz J, Callejo M, Mondéjar-Parreno G, Cortijo J, Salaices M, Duarte J, Pérez-Vizcaíno F, Cogolludo A. Activation of PPAR beta/delta prevents hyperglycaemia-induced impairment of Kv7 channels and cAMP-mediated relaxation in rat coronary arteries. Clin Sci. 2016;130(20):1823-36. Article. IF: 4.936; Q1 • Rizzetti DA, Altermann CD, Martínez CS, Pecanha FM, Vassallo DV, Uranga-Ocio JA, Castro MM, Wiggers GA, Mello-Carpes PB. Ameliorative effects of egg white hydrolysate on recognition memory impairments associated with chronic exposure to low mercury concentration. Neurochem Int. 2016;101:30-7. Article. IF: 3.262; Q2 • Rizzetti DA, Fernández F, Moreno S, Ocio JAU, Pecanha FM,Vera G, Vassallo DV, Castro MM, Wiggers GA. Egg white hydrolysate promotes neuroprotection for neuropathic disorders induced by chronic exposure to low concentrations of mercury. Brain Res. 2016;1646:482-9. Article. IF: 2.746; Q3 • Santiago E, Martínez MP, Climent B, Muñoz M, Briones AM, Salaices M, García-Sacristán A, Rivera L, Prieto D. Augmented oxidative stress and preserved vasoconstriction induced by hydrogen peroxide in coronary arteries in obesity: role of COX-2. Brit J Pharmacol. 2016;173(22):3176-95. Article. IF: 5.491; D1 • Sastre E, Caracuel L, Blanco-Rivero J, Callejo M, Xavier FE, Balfagón G. Biphasic effect of diabetes on neuronal nitric oxide release in rat mesenteric arteries. Plos One. 2016;11(6):e0156793. Article. IF: 2.806; Q1

• Azevedo BF, Simoes MR, Fiorim J, Botelho T, Angeli JK, Vieira JVA, Alonso MJ, Salaices M, dos Santos L, Vassallo DV. Chronic mercury exposure at different concentrations produces opposed vascular responses in rat aorta. Clin Exp Pharmacol P. 2016;43(7):712-9. Article. IF: 2.01; Q3

• Sastre E, Caracuel L, Prieto I, Llevenes P, Aller MA, Arias J, Balfagón G, Blanco-Rivero J. Decompensated liver cirrhosis and neural regulation of mesenteric vascular tone in rats: role of sympathetic, nitrergic and sensory innervations. Sci Rep-Uk. 2016;6:31076. Article. IF: 4.259; Q1

• Callera GE, Antunes TT, Correa JW, Moorman D, Gutsol A, He Y, Cat AND, Briones AM, Montezano AC, Burns KD, Touyz RM. Differential renal effects of candesartan at high and ultra-high doses in diabetic mice-potential role of the ACE2/AT2R/Mas axis. Bioscience Rep. 2016;36:e00398. Article. IF: 2.906; Q2

• Schmidt PM, Escobar AG, Torres JGD, Martínez CS, Rizzetti DA, Kunz SN, Vassallo DV, Alonso MJ, Pecanha FM, Wiggers GA. Aluminum exposure for one hour decreases vascular reactivity in conductance and resistance arteries in rats. Toxicol Appl Pharm. 2016;313:109-18. Article. IF: 3.791; Q1

Continue

135

3.2 Cardiovascular Area

3 INFORMATION GROUPS BY AREA • Victorio JA, Clerici SP, Palacios R, Alonso MJ,Vassallo DV, Jaffe IZ, Rossoni LV, Davel AP. Spironolactone prevents endothelial nitric oxide synthase uncoupling and vascular dysfunction induced by beta-adrenergic overstimulation role of perivascular adipose tissue. Hypertension. 2016;68(3):726. Article. IF: 6.857; D1 • Wiggers GA, Furieri LB, Briones AM, Avendaño MS, Pecanha FM, Vassallo DV, Salaices M, Alonso MJ. Cerebrovascular endothelial dysfunction induced by mercury exposure at low concentrations. Neurotoxicology. 2016;53:282-9. Article. IF: 3.1; Q2

PUBLIC PROJECTS Alonso Gordo MJ. Effect of exposure to lead and cadmium on cardiovascular system in animal models (PHBP1400001). MECD. 2015-2016. Management centre: URJC Alonso Gordo MJ. Modulation by NRF2 of hypertension-associated vascular damage. Relationship with TLR4 (SAF2015-69294-R). MINECO. 2016. Management centre: UAM Balfagón Calvo G. Sexual dimorphism in vascular nitrergic neuropathy in diabetes: analysis of the pathway involved and effects of its modulation. (SAF2012-38530). MINECO. 2013-2016. Management centre: UAM Briones Alonso AM. Relación entre postanoides, especies reactivas de oxígeno y aldosterona del tejido adiposo y su papel en las alteraciones cardiovasculares asociadas a hipertensión y obesidad (PI13/01488). ISCIII. 2014-2016. Management centre: FIBHULP Miguel Castro M. Efecto de un hidrolizado de proteínas de huevo con pepsina en un modelo experimental de síndrome metabólico inducido por dieta (INTRAMURAL 201570I028). CSIC. 2015-2016. Management centre: CSIC

y su papel en las alteraciones cardiovasculares asociadas a hipertensión y obesidad. Roche Farma, S.A. 2014-Ongoing. Management centre: FIBHULP Miguel Castro M. Estudio de los procesos de proteolisis en el desarrollo de aromas y sabores en el jamón puro ibérico de bellota y caracterización de péptidos bioactivos. Arturo Sanchez e Hijos. 2016-Ongoing. Management centre: CSIC Miguel Castro M. Participación en comité de expertos y asesoramiento científico en materia de alimentación y bebidas: cerveza 0,0% isotónica. Farfara Lab. 2016-Ongoing. Management centre: CSIC

PATENTS AND TRADEMARKS Pérez Girón JV, Ruiz-Castellanos MJ, de Luis Jiménez O, Pérez Boto V, Sanz González R, Hernández Vélez MC, Mas Gutiérrez JA, Alonso Gordo MJ, Salaíces Sánchez M, Ros Pérez M, Coloma Jerez A, Asenjo Barahona A, Sanz Montaña JL, Puente Prieto J, Jensen J, inventors; Nanoate, S.L., assignee. Method for producing biosensors. P201031224, PCT/ES2011/070536; 2010 August 05.

INTERNATIONAL PROJECTS

Miguel Castro M, López-Alonso Fandiño R, Recio Sánchez MI, Ramos González MM, Aleixandre de Artiñano A, inventors; CSIC, assignee. Bioactive peptides derived from the proteins of egg white by means of enzymatic hydrolysis. P200301829, PCT/ES2004/070059, EP1661913, US8227207, AT388166, DE602004012289, DK1661913, JP2007523045; 2003 July 31.

Alonso Gordo MJ. Efecto de la exposición a los metales tóxicos plomo y cadmio sobre el sistema cardiovascular en modelos animales (PHBP14-00001). MECyD. 20152016. Management centre: UAM

Miguel Castro M, López-Alonso Fandiño R, Ramos González MM, Aleixandre de Artiñano A, inventors; CSIC, assignee. Production of and antihypertensive properties of peptides derived from egg white proteins. P200501246 PCT/ES2006/070067; 2005 May 23.

Briones Alonso AM. ADMIRE - Aldosterone and mineralocorticoid receptor: pathophysiology, clinical implication and therapeutic innovations (COST BM1301). EU. 20142017. Management centre: UAM

Recio Sánchez MI; Quirós del Bosque A, Hernández Ledesma B, Gómez Ruiz JA, Miguel Castro M, Amigo Garrido L, López Expósito I, Ramos González MM, Aleixandre de Artiñano A, (Contreras Gómez M), inventors; CSIC, assignee. Bioactive peptides identified in enzymatic hydrolyzates of milk caseins and method of obtaining same. P200501373, PCT/ES2006/070079, EP1905779,

Miguel Castro M. Egg white hydrolysates as functional food ingredients to control the cardiometabolic complications associated to oxidative stress induced by heavy metals exposure (406715/2013-0). Conselho Nacional de Desenvolvimento Científico e Tecnológico del Gobierno de Brasil. 2014-2017. Management centre: Universidad Federal do Espirito Santo

EP2495250, US8354502, AU2006256720, BRPI0611729, C A2611416, CN101305017, CN103254278, JP2008545774, KR20080045108, MX2007015528, NO20080103; 2005 June 08. Garcés Rimón M, Miguel Castro M, López-Alonso Fandiño R, López-Miranda González V, Uranga Ocio J, inventors; CSIC, Universidad Rey Juan Carlos, assignees; Use of multifunctional bioactive products derived from the enzymatic hydrolysis of egg white proteins for treating metabolic syndrome. P201331767, PCT/ES2014/070880; 2013 December 04. Miguel Castro M, Garcés Rimón M, López-Alonso Fandiño R, Sandoval Huertas M, inventors; CSIC, Mario Sandoval Huertas, assignees. Healthy food compositions having gel or foam textures and comprising hydrolyzed egg products. P201331886, PCT/ES2014/070902, EP3106042, US9648897, AR098685, JP2015130856, MX2014015135; 2013 December 20. González-Muñiz R, Pérez de Vega MJ, Miguel M, Balsera-Paredes B, Moreno S, inventors; CSIC, assignee. Triazolyl polyphenols with antioxidant activity and uses thereof; P201531450; 2015 November 08. González-Muñiz R, Miguel Castro M, Pérez de Vega MJ, Balsera-Paredes B, S Moreno, inventors; CSIC, assignee. Compounds with antioxidant activity and uses thereof. P201630362; 2016 March 29.

Miguel Castro M. Obtención de hidrolizados de proteínas de huevo para controlar las distintas alteraciones asociadas al Síndrome Metabólico. Evaluación de su eficacia y seguridad en humanos (AGL-2012-32387). MINECO. 2015-2016. Management centre: CSIC Salaices Sánchez M. CIBER Enfermedades Cardiovasculares (CB16/11/00286). ISCIII. 2016-2017. Management centre: UAM Salaices Sánchez M. Hypertension and reciprocal regulation of reactive oxygen species and prostanoids in vascular cells. Role of angiotensin II/TLR4 pathway on the production of both mediators. (SAF2012-36400). MINECO. 2013-2016. Management centre: UAM Salaices Sánchez M. Red de Investigación Cardiovascular (RIC) (RD12/0042/0024). ISCIII. 2013-2017. Management centre: UAM

PRIVATE PROJECTS Briones Alonso AM. Relación entre postranoides, especies reactivas de oxígeno y aldosterona del tejido adiposo 136

Return to C ARDIOVASCULAR AREA INDEX

137

3.2 Cardiovascular Area

3 INFORMATION GROUPS BY AREA tanding the pathways involved in vascular damage and premature ageing associated to diabesity should help to delay vascular complications. Furthermore, preservation of vascular function in ageing should not only reduce deaths and disabilities secondary to cardiovascular events but should attenuate other negative aspects of the ageing process that lead to loss of function and/or disability, such as motor capacity and cognitive frailty. Indeed, it seems now quite evident that robustness in advanced age cannot be achieved without preservation of vascular function.

VASCULAR PHARMACOLOGY AND METABOLISM GROUP (FARMAVSM)

Research Lines The main objective of FARMAVASM for the next 5 years is to determine how those called progeric cardiometabolic diseases, particularly obesity, diabetes mellitus and/or metabolic syndrome, can favour the vascular aging process. In particular, we will analyse the role for selected adipokines over-produced and released by the inflamed adipose tissue in the development of premature vascular ageing. We aim to characterize the cellular and molecular mechanisms of action of selected adipokines that may lead to alterations in the vascular function and/or structure, as well as their interaction with other key factors influencing cardiometabolic diseases such is high glucose. Moreover, as pharmacologists, we aspire to characterize new pharmacological targets that could be relevant to prevent or delay accelerated vascular ageing and the associated cardiovascular risk. To achieve this global objective, we have now an active grant by the Plan Nacional de I+D covering 2015 to 2017, and we expect to obtain further financial support for the period 2018 to 2020. Furthermore, we have active projects with pharmaceutical companies (Boehringer Ingelgeim). Our strategy will also include our incorporation to national networks (CIBER or RETICS), and international programmes (Horizon 2020). Indeed, this is in fact one of the reasons for asking our inclusion in IdiPAZ. Additionally, we aimed

3 13.237 3

Carlos Félix Sánchez Ferrer Catedrático de Farmacología. UAM Elena Cercas Alonso Técnico Especialista en Análisis Clínico. UAM Jorge Francisco Gómez Cerezo Jefe de Servicio de Medicina Interna. Hospital Universitario Infanta Sofía Concepción Peiró Vallejo Profesora Titular de Farmacología. UAM Mariella Ramos González Investigador Predoctoral. UAM Susana Vallejo Fernán Investigador Postdoctoral. UAM

to include new researchers into FARMAVASM, both at pre- and postdoctoral level (FPU-MEC, FPU-UAM, Marie Sklodowska-Curie Actions, Juan de La Cierva, Ramón y Cajal).

Research Activity PUBLICATIONS • Peiró C, Romacho T, Azcutia V,Villalobos L, Fernández E, Bolaños JP, Moncada S, Sánchez-Ferrer CF. Inflammation, glucose, and vascular cell damage: the role of the pentose phosphate pathway. Cardiovasc Diabetol. 2016;15:82. Article. IF: 4.752; Q1 • Romacho T,Vallejo S,Villalobos LA, Wronkowitz N, Indrakusuma I, Sell H, Eckel J, Sánchez-Ferrer CF, Peiró C. Soluble dipeptidyl peptidase-4 induces microvascular endothelial dysfunction through proteinase-activated receptor-2 and thromboxane A(2) release. J Hypertens. 2016;34(5):869-76. Article. IF: 4.085; Q1 • Villalobos LA, Hipólito- Luengo AS, Ramos-González M, Cercas E, Vallejo S, Romero A, Romacho T, Carraro R, Sánchez-Ferrer CF, Peiró C. The angiotensin-(1-7)/mas axis counteracts angiotensin II-dependent and -independent pro-inflammatory signaling in human vascular smooth muscle cells. Front Pharmacol. 2016;7:482. Article. IF: 4.4; Q1

PUBLIC PROJECTS Peiró Vallejo CM, Sánchez Ferrer CF. Adipoquinas y envejecimiento vascular: mecanismos implicados y modulación farmacológica (SAF2014-52762-R). MINECO. 2015-2017. Management centre: UAM

PRIVATE PROJECTS Sánchez-Ferrer CF. Endothelial dysfunction induced by the adipokine dipeptidyl peptidase 4 (DPP-4) in human mesenteric microvessels and its prevention by linagliptin. Boehringer Ingelheim España. 2015-2016. Management centre: UAM

Strategic Objective Our research deals with the challenge 1 of the Spanish Strategy for Science and Technology and for Innovation: “Health, demographic change and wellbeing”. The main goal is to improve our understanding of vascular ageing, both in healthy and pathological conditions, like obesity and type 2 diabetes mellitus. Vascular ageing is associated with complex vascular structural and functional changes. It represents a crucial process for the health status of elderly people and the main risk factor for the development of cardiovascular diseases. Obesity and type 2 diabetes mellitus are extremely prevalent and closely related diseases, so that the term “diabesity” has 138

been coined. Diabesity is among the highest health and socioeconomic challenge in Western countries, especially due to cardiovascular complications. Epidemiological studies indicate that these patients have reduced life expectancy, in close relation to the development of diseases, such as hypertension and atherosclerosis. Diabesity is also considered an age-related disease, as well as a progeric entity, sharing similar cellular and molecular mechanisms than the age-induced vascular dysfunction. Unders-

Return to C ARDIOVASCULAR AREA INDEX

139

3 INFORMATION GROUPS BY AREA

AIDS AND INFECTIOUS DISEASES GROUP

3.3

Infectious Diseases and Immunity Area Eduardo López-Collazo

212 154 38

956.421 641.204 86

AIDS and Infectious Diseases Group Molecular Microbiology Group Immuno-Rheumatology Group Innate Immune Response Group Diagnosis and Treatment of Diseases associated with Abnormalities of the Complement System Group Lymphocyte Pathophysiology in Immunodeficiencies Group Drug Hypersensibility and Innate Immune Response Group Pediatric Respiratory, Systemic and Neurological Infections & Host Immune Response Group Pediatric Systemic Infections; HIV, tuberculosis, Imported and Emergent Diseases Group Translational Research in Pediatric Oncology, Hematopoietic Transplantation and Cell Therapy Group 140

Return to INFORMATION GROUPS BY AREA INDEX

43 292.427 19

José Ramón Arribas López Jefe de Sección de Enfermedades Infecciosas. HULP Profesor Asociado. UAM Marta Arsuaga Vicente Médico Adjunto en Medicina Interna. Unidad de Medicina Tropical. Hospital Carlos III - HULP José Ignacio Bernardino de la Serna Facultativo Especialista de Área en Medicina Interna. Unidad VIH. HULP Lara Crespillo Andújar Médico Ajunto en Medicina Interna. Unidad de Medicina Tropical. Hospital Carlos III - HULP Fernando de la Calle Prieto Médico Adjunto en Medicina Interna. Unidad de Medicina Tropical. Hospital Carlos III - HULP Profesor Colaborador. UAM Alicia de Pablo Olaiz Técnico de Laboratorio (Contrato de Técnico de Apoyo). HULP Marta Díaz Menéndez Médico Adjunto en Medicina Interna. Unidad de Medicina Tropical. HULP Marta Gálvez Charro Enfermera. Unidad de VIH. HULP Francisco Gayá Moreno Investigador Predoctoral (Contrato de Estabilización de Técnicos de Apoyo). HULP Alicia González Baeza Investigadora colaboradora. HULP Juan Julián González García Jefe de Sección. Unidad de VIH. HULP Pedro Herranz Pinto Facultativo Especialista de Área en Dermatología. Jefe de Sección. HULP

Víctor Hontañón Antoñana Investigador contratado. RIS María Concepción Ladrón de Guevara García Facultativo Especialista de Área en Microbiología y Parasitología. Hospital Carlos III- HULP María del Mar Lago Núñez Facultativo Especialista de Área en Medicina Interna. Unidad de Medicina Tropical. Hospital Carlos III - HULP Raquel Martín Jara Enfermera. Unidad de VIH. HULP Mario Mayoral Muñoz Enfermero. HULP Juan José Miguel Castro Enfermero. HULP Rocío Montejano Sánchez Facultativo Especialista de Área de Medicina Interna. Unidad de Enfermedades Infecciosas y Microbiología Clínica. HULP María Luisa Montes Ramírez Facultativo Especialista de Área de Medicina Interna. Unidad de VIH. HULP Marta Mora Rillo Facultativo Especialista de Área de Medicina Interna. Unidad de Enfermedades Infecciosas y Microbiología Clínica. HULP Francisco Moreno Ramos Farmacéutico. HULP José Francisco Pascual Pareja Facultativo Especialista de Área de Medicina Interna. Hospital de Cantoblanco – HULP José María Peña Sánchez de Rivera Jefe de Sección de Medicina Interna. HULP Catedrático. UAM Ignacio Pérez Valero Facultativo Especialista de Área de Medicina Interna. Unidad de VIH. HULP

Continue

141

3.3 Infectious Diseases and Immunity Area

3 INFORMATION GROUPS BY AREA Juan Carlos Ramos Ramos Facultativo Especialista de Área de Medicina Interna. Unidad de Enfermedades Infecciosas y Microbiología Clínica. HULP Berta Rodés Soldevila Investigadora Senior (Contrato Miguel Servet- I2). HULP Elena Sendagorta Cudós Facultativo Especialista de Área de Dermatología. HULP Lucía Serrano Morago Investigadora colaboradora. Elena Trigo Esteban Médico Ajunto en Medicina Interna. Unidad de Medicina Tropical. Hospital Carlos III - HULP

Strategic Objective Worldwide projections of global mortality and the burden of disease from 2002 to 2030 estimate that by 2030 HIV infection will be the number one disease in terms of overall burden and third in terms of overall mortality (Mathers, C. D.; Loncar, D. Projections of global mortality and burden of disease from 2002 to 2030. PLOS MEDICINE. 2006; 3(11): e442.). Although great progress has been made, HIV infection remains an incurable disease. Even under the best circumstances, HIV-infected patients who receive current antiretroviral therapy have a survival disadvantage compared with the general non-infected population, which is estimated to be a life expectancy of 15 years less than the general population. HIV infection is highly prevalent in Spain. Among western European countries, Spain has the second highest prevalence. An important local characteristic of the HIV-infected population in Spain is the high prevalence of hepatitis C coinfection. This research line covers four main topics of research in HIV infection: antiretroviral treatment, HIV-HCV coinfection, metabolic complications and HIV-resistance to antiretroviral drugs. The dramatic increase of antibacterial resistance makes imperative to perform research in this topic. We have added a new research line about carbapenemase producing enterobacteria in collaboration with the Molecular Microbiology Group. After the merge with Carlos III hospital we have included in our group researchers from the Tropical Diseases Unit and we have now the goal of doing research in this area.The availability of a highly infectious diseases unit make also possible to performe research in emerigng diseases with high mortality.

Research Lines • Antiretroviral therapy & resistance. • Metabolic complications of antiretroviral therapy. • Liver disease. • Neurocognitive impairment. • Paediatric HIV infection and MTCT. • Epigenetic and cellular factors related to HIV progression. • Optimisation of antibiotic therapy (ID no HIV). 142

• Carbapenemase producing enterobaceria. • Tropical diseases. • Emerging virusues.

Research Activity DOCTORAL THESES Montejano Sánchez R. Impacto del tratamiento antirretroviral con y sin nucleós(t)idos sobre la densidad mineral ósea y los biomarcadores de remodelado óseo[dissertation]. Madrid: UAM: 2016 (18/05/2016). Directors: Arribas López JR, González García JJ, Arnalich Fernández F. Pérez Valero I. Deterioro cognitivo asociado al Virus de Inmunodeficiencia Humana (VIH) e inhibidores de proteasa potenciados con ritonavir en monoterapia[dissertation]. Madrid: UAM: 2016 (14/06/2016). Directors: Arribas López JR, Arnalich Fernández F. Sendagorta Cudós E. Prevalencia, diagnóstico y tratamiento de la displasia de alto grado anal asociada a la infección por el Virus del Papiloma Humano en pacientes infectados por el VIH[dissertation]. Madrid: UAM: 2016 (31/01/2016). Directors: González García JJ, Herranz Pinto P.

PUBLICATIONS • Alejos B, Hernando V, Iribarren J, González-García J, Hernando A, Santos J, Asensi V, Gómez-Berrocal A, del Amo J, Jarrin I. Overall and cause-specific excess mortality in HIV-positive persons compared with the general population: Role of HCV coinfection. Medicine. 2016;95(36):e4727. Article. IF: 1.803; Q2 • Álvarez-Román MT, Pollmar MIR, Bernardino JI, Lozano ML, Martín-Salces M, Fernández-Bello I, Jiménez-Yuste V, Butta NV. Thrombopoietin receptor agonists in conjunction with oseltamivir for immune thrombocytopenia. AIDS. 2016;30(7):1141-2. Letter. IF: 5.003; Q1 • Arribas JR, Girard PM, Paton N, Winston A, Marcelin AG, Elbirt D, Hill A, Hadacek MB. Efficacy of protease inhibitor monotherapy vs. triple therapy: meta-analysis of data from 2303 patients in 13 randomized trials. HIV Med. 2016;17(5):358-67. Article. IF: 3.257; Q2 • Arribas JR, Luczkowiak J, Delgado R. Convalescent plasma for ebola virus disease. New Engl J Med. 2016;374(25):2498-9. Letter. IF: 72.406; D1 • Arsuaga M, Bujalance SG, Díaz-Menéndez M,Vázquez A, Arribas JR. Probable sexual transmission of Zika virus from a vasectomised man. Lancet Infect Dis. 2016;16(10):1107. Letter. IF: 19.864; D1

Domingo P, González-García J, Knobel H, Lázaro P, López JC, Llibre JM, Lozano F, Miro JM, Podzamczer D, Tuset M, Gatell JM. Costs and cost-effectiveness analysis of 2015 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. Enferm Infec Micr Cl. 2016;34(6):361-71. Article. IF: 1.714; Q3 • Berenguer J, Rivero A, Jarrin I, Núñez MJ,Vivancos MJ, Crespo M, Téllez MJ, Domingo P, Iribarren JA, Artero A, Márquez M, Santos I, Moreno J, Montero M, González-García J. Human immunodeficiency virus/hepatitis C virus coinfection in Spain: Prevalence and patient characteristics. Open Forum Infect Dis. 2016;3(2): ofw059. Article. Not Indexed • Concha PMT,Vélez P, Lafoz M, Arribas JR. Passenger exposure to magnetic fields due to the batteries of an electric vehicle. IEEE T Veh Technol. 2016;65(6):4564-71. Article. IF: 4.066; Q1 • de la Calle-Prieto F, Arsuaga-Vicente M, Mora-Rillo M, ArnalichFernández F, Arribas JR. Ebola virus disease: Update. Enferm Infec Micr Cl. 2016;34(7):452-60. Review. IF: 1.714; Q3 • de Pablo A, Bogoi R, Bejarano I, Toro C, Valencia E, Moreno V, Martín-Carbonero L, Gómez-Hernando C, Rodes B. Short communication: p21/CDKN1A expression shows broad interindividual diversity in a subset of HIV-1 elite controllers. AIDS Res Hum Retrov. 2016;32(3):232-6. Article. IF: 2.095; Q3 • Estebánez M, Bernardino JI, Serrano L, Pérez-Valero I, Zamora FX, Montes-Ramírez ML, González-García JJ, Arribas JR. Switching from tenofovir containing regimens to boosted protease inhibitor monotherapy: Impact on renal function. Enferm Infec Micr Cl. 2016;34(1):29-32. Article. IF: 1.714; Q3 • Fragoso PL, de los Buéis AB, Ljubetic LB, Zarzuelo AD, Gómez MPR, Rillo MM. Herpes simplex keratitis in rheumatoid arthritis patients. Ocul Immunol Inflamm. 2016;24(3):282-7. Article. IF: 2.453; Q2 • García ET, Sanz GY, Llácer-Delicado T, García RR, González-García J, García FG, López-Aldeguere J, Álvarez VA, Fernández AH. Clinical, epidemiological and treatment failure data among HIV-1 non-B-infected patients in the Spanish AIDS Research Network Cohort. Enferm Infec Micr Cl. 2016;34(6):353-60. Article. IF: 1.714; Q3 • González-Baeza A, Carvajal F, Bayón C, Pérez-Valero I, MontesRamírez M, Arribas JR. Facial emotion processing in aviremic HIV-infected Adults. Arch Clin Neuropsych. 2016;31(5):401-10. Article. IF: 2.044; Q3 • Gutiérrez-Gutiérrez B, Bonomo RA, Carmeli Y, Paterson DL, Almirante B, Martínez-Martínez L, Oliver A, Calbo E, Peña C, Akova M, Pitout J, Origuen J, Pintado V, García-Vázquez E, Gasch O, Hamprecht A, Prim N, Tumbarello M, Bou G, Viale P, Tacconelli E, Almela M, Pérez F, Giamarellou H, Cisneros JM, Schwaber MJ, Venditti M, Lowman W, Bermejo J, Hsueh PR, Mora-Rillo M, Gracia-Ahulfinger I, Pascual A, Rodríguez-Bano J. Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study. J Antimicrob Chemoth. 2016;71(6):1672-80.Article. IF: 5.071; D1

• Beraud G, Pulcini C, Paño-Pardo JR, Hoen B, Beovic B, Nathwani D. How do physicians cope with controversial topics in existing guidelines for the management of infective endocarditis? Results of an international survey. Clin Microbiol Infec. 2016;22(2):16370. Article. IF: 5.292; D1

• Gutiérrez-Gutiérrez B, Pérez-Galera S, Salamanca E, de Cueto M, Calbo E, Almirante B, Viale P, Oliver A, Pintado V, Gasch O, Martínez-Martínez L, Pitout J, Akova M, Peña C, Molina J, Hernández A, Venditti M, Prim N, Origuen J, Bou G, Tacconelli E, Tumbarello M, Hamprecht A, Giamarellou H, Almela M, Pérez F, Schwaber MJ, Bermejo J, Lowman W, Hsueh PR, Mora-Rillo M, Natera C, Souli M, Bonomo RA, Carmeli Y, Paterson DL, Pascual A, Rodríguez-Bano J. A Multinational, preregistered cohort study of beta-lactam/beta-lactamase inhibitor combinations for treatment of bloodstream infections due to extended-spectrum-beta-lactamase-producing enterobacteriaceae. Antimicrob Agents Ch. 2016;60(7):4159-69. Article. IF: 4.302; Q1

• Berenguer J, Rivero A, Blasco AJ, Arribas JR, Boix V, Clotet B,

• Iribarren JA, Rubio R, Aguirrebengoa K, Arribas JR, Baraia-Etxa-

• Artigas JMG, López JRA, de Mercado PLY, Bravo AJB. Cost/efficacy analysis of preferred Spanish AIDS study group regimens and the dual therapy with lopinavir/ritonavir plus lamivudine for initial ART in HIV infected adults. Enferm Infec Micr Cl. 2016;34(7):427-30. Article. IF: 1.714; Q3

buru J, Gutiérrez F, de Quirós JCLB, Losa JE, Miro JM, Moreno S, Molina JP, Podzamczer D, Pulido F, Riera M, Rivero A, Moreno JS, Amador C, Antela A, Arazo P, Arrizabalaga J, Bachiller P, Barros C, Berenguer J, Cayla J, Domingo P, Estrada V, Knobel H, Locutura J, Aldeguer JL, Llibre JM, Lozano F, Mallolas J, Malmierca E, Miralles C, Miralles P, Muñoz A, Ocampo A, Olalla J, Pérez I, Elías MJP, Arellano JLP, Portilla J, Ribera E, Rodríguez F, Santin M, Sanz JS, Téllez MJ, Torralba M, Valencia E, Von Wichmann MA. Executive summary: Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015. Enferm Infec Micr Cl. 2016;34(8):517-23. Article. IF: 1.714; Q3 • Iribarren JA, Rubio R, Aguirrebengoa K, Arribas JR, Baraia-Etxaburu J, Gutiérrez F, López Bernaldo de Quirós JC, Losa JE, Miró JM, Moreno S, Pérez Molina J, Podzamczer D, Pulido F, Riera M, Rivero A, Sanz Moreno J, Amador C, Antela A, Arazo P, Arrizabalaga J, Bachiller P, Barros C, Berenguer J, Cayla J, Domingo P, Estrada V, Knobel H, Locutura J, López Aldeguer J, Llibre JM, Lozano F, Mallolas J, Malmierca E, Miralles C, Miralles Pr, Muñoz A, Ocampo A, Olalla J, Pérez I, Pérez Elias MJ, Pérez Arellano JL, Portilla J, Ribera E, Rodríguez F, Santin M, Sanz Sanz J, Téllez MJ, Torralba M, Valencia E, Von Wichmann MA. Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015. Enferm Infec Micr Cl. 2016;34(8):516.e1516.e18. Article. IF: 1.714; Q3 • Joseph J, Cinque P, Colosi D, Dravid A, Ene L, Fox H, Gabuzda D, Gisslen M, Beth S, Letendre S, Mukerji SS, Nath A, Pérez-Valero I, Persaud D, Price RW, Rao VR, Sacktor N, Swanstrom R, Winston A, Wojna V, Wright E, Spudich S. Highlights of the Global HIV-1 CSF Escape Consortium Meeting, 9 June 2016, Bethesda, MD, USA. J Virus Erad. 2016;2(4):243-50-. Editorial Material. Not Indexed • Khachatryan V, Sirunyan AM, Tumasyan A, Adam W, Asilar E, Bergauer T, Brandstetter J, Brondolin E, Dragicevic M, Ero J, Flechl M, Friedl M, Fruhwirth R, Ghete VM, Hartl C, Hormann N, Hrubec J, Jeitler M, Konig A, Krammer M, Kratschmer I, Liko D, Matsushita T, Mikulec I, Rabady D, Rad N, Rahbaran B, Rohringer H, Schieck J, Schofbeck R, Strauss J, Treberer-Treberspurg W, Waltenberger W, Wulz CE, Mossolov V, Shumeiko N, González JS, Alderweireldt S, Cornelis T, De Wolf EA, Janssen X, Knutsson A, Lauwers J, Luyckx S, De Klundert MV, Van Haevermaet H, Van Mechelen P, Van Remortel N, Van Spilbeeck A, Abu Zeid S, Blekman F, D’Hondt J, Daci N, De Bruyn I, Deroover K, Heracleous N, Keaveney J, Lowette S, Moortgat S, Moreels L, Olbrechts A, Python Q, Strom D, Tavernier S, Van Doninck W, Van Mulders P, Van Parijs I, Brun H, Caillol C, Clerbaux B, De Lentdecker G, Fasanella G, Favart L, Goldouzian R, Grebenyuk A, Karapostoli G, Lenzi T, Leonard A, Maerschalk T, Marinov A, Randle-conde A, Seva T,Velde CV,Vanlaer P,Yonamine R, Zenoni F, Zhang F, Benucci L, Cimmino A, Crucy S, Dobur D, Fagot A, García G, Gul M, Mccartin J, Rios AAO, Poyraz D, Ryckbosch D, Salva S, Sigamani M, Tytgat M,Van Driessche W,Yazgan E, Zaganidis N, Basegmez S, Beluffi C, Bondu O, Brochet S, Bruno G, Caudron A, Ceard L, De Visscher S, Delaere C, Delcourt M, Favart D, Forthomme L, Giammanco A, Jafari A, Jez P, Komm M, Lemaitre V, Mertens A, Musich M, Nuttens C, Piotrzkowski K, Quertenmont L, Selvaggi M, Marono MV, Beliy N, Hammad GH, Alda WL, Alves FL, Alves GA, Brito L, Martins MC, Hamer M, Hensel C, Moraes A, Pol ME, Teles PR, Das Chagas EBB, Carvalho W, Chinellato J, Custodio A, Da Costa EM, Damiao DDJ, Martins CDO, De Souza SF, Guativa LMH, Malbouisson H, Figueiredo DM, Herrera CM, Mundim L, Nogima H, Da Silva WLP, Santoro A, Sznajder A, Manganote EJT, Pereira AV, Ahuja S, Bernardes CA, Santos AD, Dogra S, Tomei TRFP, Gregores EM, Mercadante PG, Moon CS, Novaes SF, Padula SS, Abad DR,Vargas JCR, Aleksandrov A, Hadjiiska R, Iaydjiev P, Rodozov M, Stoykova S, Sultanov G,Vutova M, Dimitrov A, Glushkov I, Litov L, Pavlov B, Petkov P, Fang W, Ahmad M, Bian JG,

Continue

143

3.3 Infectious Diseases and Immunity Area

3 INFORMATION GROUPS BY AREA

144

Chen GM, Chen HS, Chen M, Cheng T, Du R, Jiang CH, Leggat D, Plestina R, Romeo F, Shaheen SM, Spiezia A, Tao J, Wang C, Wang Z, Zhang H, Asawatangtrakuldee C, Ban Y, Li Q, Liu S, Mao Y, Qian SJ, Wang D, Xu Z, Avila C, Cabrera A, Sierra LFC, Florez C, Gómez JP, Moreno BG, Sanabria JC, Godinovic N, Lelas D, Puljak I, Cipriano PMR, Antunovic Z, Kovac M, Brigljevic V, Kadija K, Luetic J, Micanovic S, Sudic L, Attikis A, MavRománolakis G, Mousa J, Nicolaou C, Ptochos F, Razis PA, Rykaczewski H, Finger M, Finger M, Jarrin EC, Assran Y, Kamel AE, Mahrous A, Radi A, Calpas B, Kadastik M, Murumaa M, Perrini L, Raidal M, Tiko A, Veelken C, Eerola P, Pekkanen J, Voutilainen M, Harkonen J, Karimaki V, Kinnunen R, Lampen T, Lassila-Perini K, Lehti S, Linden T, Luukka P, Peltola T, Tuominiemi J, Tuovinen E, Wendland L, Talvitie J, Tuuva T, Besancon M, Couderc F, Dejardin M, Denegri D, Fabbro B, Faure JL, Favaro C, Ferri F, Ganjour S, Givernaud A, Gras P, de Monchenault GH, Jarry P, Locci E, Machet M, Malcles J, Rander J, Rosowsky A, Titov M, Zghiche A, Abdulsalam A, Antropov I, Baffioni S, Beaudette F, Busson P, Cadamuro L, Chapon E, Charlot C, Davignon O, de Cassagnac RG, Jo M, Lisniak S, Mine P, Naranjo IN, Nguyen M, Ochando C, Ortona G, Paganini P, Pigard P, Regnard S, Salerno R, Sirois Y, Strebler T,Yilmaz Y, Zabi A, Agram JL, Andrea J, Aubin A, Bloch D, Brom JM, Buttignol M, Chabert EC, Chanon N, Collard C, Conte E, Coubez X, Fontaine JC, Gele D, Goerlach U, Goetzmann C, Le Bihan AC, Merlin JA, Skovpen K, Van Hove P, Gadrat S, Beauceron S, Bernet C, Boudoul G, Bouvier E, Montoya CAC, Chierici R, Contardo D, Courbon B, Depasse P, El Mamouni H, Fan J, Fay J, Gascon S, Gouzevitch M, Ille B, Lagarde F, Laktineh IB, Lethuillier M, Mirabito L, Pequegnot AL, Perries S, Popov A, Álvarez JDR, Sabes D, Sordini V, Donckt MV, Verdier P, Viret S, Toriashvili T, Tsamalaidze Z, Autermann C, Beranek S, Feld L, Heister A, Kiesel MK, Klein K, Lipinski M, Ostapchuk A, Preuten M, Raupach F, Schael S, Schulte JF, Verlage T, Weber H, Zhukov V, Ata M, Brodski M, Dietz-Laursonn E, Duchardt D, Endres M, Erdmann M, Erdweg S, Esch T, Fischer R, Guth A, Hebbeker T, Heidemann C, Hoepfner K, Knutzen S, Merschmeyer M, Meyer A, Millet P, Mukherjee S, Olschewski M, Padeken K, Papacz P, Pook T, Radziej M, Reithler H, Rieger M, Scheuch F, Sonnenschein L, Teyssier D, Thuer S, Cherepanov V, Erdogan Y, Flugge G, Geenen H, Geisler M, Hoehle F, Kargoll B, Kress T, Kunsken A, Lingemann J, Nehrkorn A, Nowack A, Nugent IM, Pistone C, Pooth O, Stahl A, Martin MA, Asin I, Beernaert K, Behnke O, Behrens U, Borras K, Burgmeier A, Campbell A, Contreras-Campana C, Costanza F, Pardos CD, Dolinska G, Dooling S, Eckerlin G, Eckstein D, Eichhorn T, Gallo E, García JG, Geiser A, Gizhko A, Gunnellini P, Harb A, Hauk J, Hempel M, Jung H, Kalogeropoulos A, Karacheban O, Kasemann M, Katsas P, Kieseler J, Kleinwort C, Korol I, Lange W, Leonard J, Lipka K, Lobanov A, Lohmann W, Mankel R, Melzer-Pellmann IA, Meyer AB, Mittag G, Mnich J, Mussgiller A, Ntomari E, Pitzl D, Placakyte R, Raspereza A, Roland B, Sahin MO, Saxena P, Schoerner-Sadenius T, Seitz C, Spannagel S, Stefaniuk N, Trippkewitz KD, Van Onsem GP, Walsh R, Wissing C, Blobel V, Vignali MC, Draeger AR, Dreyer T, Ere J, Garutti E, Goebel K, González D, Gorner M, Haller J, Hoffmann M, Hoing RS, Junkes A, Klanner R, Kogler R, Kovalchuk N, Lapsien T, Lenz T, Marchesini I, Marconi D, Meyer M, Niedziela M, Nowatschin D, Ott J, Pantaleo F, Peiffer T, Perieanu A, Pietsch N, Poehlsen J, Sander C, Scharf C, Schleper P, Schlieckau E, Schmidt A, Schumann S, Schwandt J, Stadie H, Steinbruck G, Stober FM, Tholen H, Troendle D, Usai E, Vanelderen L, Vanhoefer A, Vormwald B, Barth C, Baus C, Berger J, Boser C, Butz E, Chwalek T, Colombo F, De Boer W, Descroix A, Dierlamm A, Fink S, Frensch F, Friese R, Giffels M, Gilbert A, Haitz D, Hartmann F, Heindl SM, Husemann U, Katkov I, Kornmayer A, Pardo PL, Maier B, Mildner H, Mozer MU, Muller T, Muller T, Plagge M, Quast G, Rabbertz K, Rocker S, Roscher F, Schroder M, Sieber G, Simonis HJ, Ulrich R, Wagner-Kuhr J, Wayand S, Weber M, Weiler T, Williamson S, Wohrmann C, Wolf R, Anagnostou G, Daskalakis G, Geralis T,

Giakoumopoulou VA, Kyriakis A, Loukas D, Psallidas A, TopsisGiotis I, Agapitos A, Kesisoglou S, Panagiotou A, Saoulidou N, Tziaferi E, Evangelou I, Flouris G, Foudas C, Kokkas P, Loukas N, Manthos N, Papadopoulos I, Paradas E, Strologas J, Filipovic N, Bencze G, Hajdu C, Hidas P, Horvath D, Sikler F, Veszpremi V, Vesztergombi G, Zsigmond AJ, Beni N, Czellar S, Karancsi J, Molnar J, Szillasi Z, Bartok M, Makovec A, Raics P, Trocsanyi ZL, Ujvari B, Choudhury S, Mal P, Mandal K, Nayak A, Sahoo DK, Sahoo N, Swain SK, Bansal S, Beri SB, Bhatnagar V, Chawla R, Dhingra N, Gupta R, Bhawandeep U, Kalsi AK, Kaur A, Kaur M, Kumar R, Mehta A, Mittal M, Singh JB,Walia G, Kumar A, Bhardwaj A, Choudhary BC, Garg RB, Keshri S, Kumar A, Malhotra S, Naimuddin M, Nishu N, Ranjan K, Sharma R, Sharma V, Bhattacharya R, Bhattacharya S, Chatterjee K, Dey S, Dutta S, Ghosh S, Majumdar N, Modak A, Mondal K, Mukhopadhyay S, Nandan S, Purohit A, Roy A, Roy D, Chowdhury SR, Sarkar S, Sharan M, Chudasama R, Dutta D, Jha V, Kumar V, Mohanty AK, Pant LM, Shukla P,Topkar A, Aziz T, Banerjee S, Bhowmik S, Chatterjee RM, Dewanjee RK, Dugad S, Ganguly S, Ghosh S, Guchait M, Gurtu A, Jain S, Kole G, Kumar S, Mahakud B, Maity M, Majumder G, Mazumdar K, Mitra S, Mohanty GB, Parida B, Sarkar T, Sur N, Sutar B,Wickramage N, Chauhan S, Dube S, Kapoor A, Kothekar K, Rane A, Sharma S, Bakhshiansohi H, Behnamian H, Etesami SM, Fahim A, Khakzad M, Najafabadi MM, Naseri M, Mehdiabadi SP, Hosseinabadi FR, Safarzadeh B, Zeinali M, Felcini M, Grunewald M, Abbrescia M, Calabria C, Caputo C, Colaleo A, Creanza D, Cristella L, De Filippis N, De Palma M, Fiore L, Iaselli G, Maggi G, Maggi M, Miniello G, My S, Nuzzo S, Pompili A, Pugliese G, Radogna R, Ranieri A, Selvaggi G, Silvestris L, Venditti R, Abbiendi G, Battilana C, Bonacorsi D, Braibant-Giacomelli S, Brigliadori L, Campanini R, Capiluppi P, Castro A, Cavallo FR, Chhibra SS, Codispoti G, Cuffiani M, Dallavalle GM, Fabbri F, Fanfani A, Fasanella D, Giacomelli P, Grandi C, Guiducci L, Marcellini S, Masetti G, Montanari A, Navarria FL, Perrotta A, Rossi AM, Rovelli T, Siroli GP, Tosi N, Cappello G, Chiorboli M, Costa S, Di Mattia A, Giordano F, Potenza R,Tricomi A,Tuve C, Barbagli G, Ciulli V, Civinini C, D’Alessandro R, Focardi E, Gori V, Lenzi P, Meschini M, Paoletti S, Sguazzoni G, Viliani L, Benussi L, Bianco S, Fabbri F, Piccolo D, Primavera F, Calvelli V, Ferro F, Lo Vetere M, Monge MR, Robutti E, Tosi S, Brianza L, Dinardo ME, Fiorendi S, Gennai S, Gerosa R, Ghezzi A, Govoni P, Malvezzi S, Manzoni RA, Marzocchi B, Menasce D, Moroni L, Paganoni M, Pedrini D, Pigazzini S, Ragazzi S, Redaelli N, de Fatis TT, Buontempo S, Cavallo N, Di Guida S, Esposito M, Fabozzi F, Iorio AOM, Lanza G, Lista L, Meola S, Merola M, Paolucci P, Sciacca C, Thyssen F, Azzi P, Bacchetta N, Benato L, Bisello D, Boletti A, Carlin R, Checchia P, Dall’Osso M, Dorigo T, Dosselli U, Gasparini F, Gasparini U, Gozzelino A, Lacaprara S, Margoni M, Meneguzzo AT, Montecassiano F, Passaseo M, Pazzini J, Pegoraro M, Pozzobon N, Ronchese P, Simonetto F, Torassa E, Tosi M, Zanetti M, Zotto P, Zucchetta A, Zumerle G, Braghieri A, Magnani A, Montagna P, Ratti SP, Re V, Riccardi C, Salvini P, Vai I, Vitulo P, Solestizi LA, Bilei GM, Ciangottini D, Fano L, Lariccia P, Leonardi R, Mantovani G, Menichelli M, Saha A, Santocchia A, Androsov K, Azzurri P, Bagliesi G, Bernardini J, Boccali T, Castaldi R, Ciocci MA, Dell’Orso R, Donato S, Fedi G, Foa L, Giassi A, Grippo MT, Ligabue F, Lomtadze T, Martini L, Messineo A, Palla F, Rizzi A, Savoy-Navarro A, Spagnolo P, Tenchini R, Tonelli G,Venturi A,Verdini PG, Barone L, Cavallari F, D’imperio G, Del Re D, Diemoz M, Gelli S, Jorda C, Longo E, Margaroli F, Meridiani P, Organtini G, Paramatti R, Preiato F, Rahatlou S, Rovelli C, Santanastasio F, Amapane N, Arcidiacono R, Argiro S, Arneodo M, Bartosik N, Bellan R, Biino C, Cartiglia N, Costa M, Covarelli R, Degano A, Demaria N, Finco L, Kiani B, Mariotti C, Maselli S, Migliore E, Mónaco V, Monteil E, Obertino MM, Pacher L, Pastrone N, Pelliccioni M,Angioni GLP, Ravera F, Romero A, Ruspa M, Sacchi R, Sola V, Solano A, Staiano A, Belforte S, Candelise V, Casarsa M, Cossutti F, Della Ricca G, Gobbo B, La Licata C, Schizzi A, Zanetti A,

Nam SK, Butanov K, Kim DH, Kim GN, Kim MS, Kong DJ, Lee S, Lee SW, Oh YD, Sekmen S, Son DC, Cifuentes JAB, Kim H, Kim TJ, Song S, Cho S, Choi S, Go Y, Gyun D, Hong B, Kim Y, Lee B, Lee K, Lee KS, Lee S, Lim J, Park SK, Roh Y, Yoo HD, Choi M, Kim H, Kim H, Kim JH, Lee JSH, Park IC, Ryu G, Ryu MS, Choi Y, Goh J, Kim D, Kwon E, Lee J, Yu I, Dudenas V, Juodagalvis A, Vaitkus J, Ahmed I, Ibrahim ZA, Komaragiri JR, Ali MABM, Idris FM, Abdullah WATW, Yusli MN, Zolkapli Z, Linares EC, Castilla-Valdez H, de la Cruz-Burelo E, la Cruz IHD, Hernández-Almada A, LópezFernández R, Guisao JM, Sánchez-Hernández A, Moreno SC, Valencia FV, Pedraza I, Ibarguen HAS, Estrada CU, Pineda AM, Krofcheck D, Butler PH, Ahmad A, Ahmad M, Hassan Q, Hoorani HR, Khan WA, Khurshid T, Shoaib M, Waqas M, Bialkowska H, Bluj M, Boimska B, Frueboes T, Gorski M, Kazana M, Nawrocki K, Románowska-Rybinska K, Szleper M, Traczyk P, Zalewski P, Brona G, Bunkowski K, Byszuk A, Doroba K, Kalinowski A, Konecki M, Krolikowski J, Misiura M, Olszewski M, Walczak M, Bargassa P, Silva CBD, Di Francesco A, Faccioli P, Parracho PGF, Gallinaro M, Hollar J, Leonardo N, Iglesias LL, Nemallapudi MV, Nguyen F, Antunes JR, Seixas J, Toldaiev O, Vadruccio D, Varela J, Vischia P, Bunin P, Gavrilenko M, Golutvin I, Gorbunov I, Kamenev A, Karjavin V, Lanev A, Malakhov A, Matveev V, Moisenz P, Palichik V, Perelygin V, Savina M, Shmatov S, Shulha S, Skatchkov N, Smirnov V, Yuldashev BS, Zarubin A, Golovtsov V, Ivanov Y, Kim V, Kuznetsova E, Levchenko P, Murzin V, Oreshkin V, Smirnov I, Sulimov V, Uvarov L, Vavilov S, Vorobyev A, Andreev Y, Dermenev A, Gninenko S, Golubev N, Karneyeu A, Kirsanov M, Krasnikov N, Pashenkov A, Tlisov D, Toropin A, Epshteyn V, Gavrilov V, Lychkovskaya N, Popov V, Pozdnyakov I, Safronov G, Spiridonov A, Toms M, Vlasov E, Zhokin A, Chadeeva M, Chistov R, Danilov M, Markin O, Rusinov V, Andreev V, Azarkin M, Dremin I, Kirakosyan M, Leonidov A, Mesyats G, Rusakov SV, Baskakov A, Belyaev A, Boos E, Bunichev V, Dubinin M, Dudko L, Ershov A, Gribushin A, Klyukhin V, Kodolova O, Lokhtin I, Miagkov I, Obraztsov S, Petrushanko S, Savrin V, Azhgirey I, Bayshev I, Bitioukov S, Kachanov V, Kalinin A, Konstantinov D, Krychkine V, Petrov V, Ryutin R, Sobol A,Tourtchanovitch L, Troshin S, Tyurin N, Uzunian A, Volkov A, Adzic P, Cirkovic P, Devetak D, Milosevic J, Rekovic V, Maestre JA, Calvo E, Cerrada M, Llatas MC, Colino N, De la Cruz B, Peris AD, Del Valle AE, Bedoya CF, Ramos JPF, Flix J, Fouz MC, García-Abia P, López OG, López SG, Hernández JM, Josa MI, De Martino EN, Yzquierdo APC, Pelayo JP, Olmeda AQ, Redondo I, Romero L, Soares MS, de Troconiz JF, Missiroli M, Moran D, Cuevas J, Menndez JF, Folgueras S, Caballero IG, Cortezon EP, García JMV, Cabrillo IJ, Calderon A, De Saa JRC, Curras E, Manzano PD, Fernández M, GarcíaFerrero J, Gómez G, Virto AL, Marco J, Marco R, Rivero CM, Matorras F, Gómez JP, Rodrigo T, Rodríguez-Marrero AY, Ruiz-Jimeno A, Scodellaro L, Trevisani N, Vila I, Cortabitarte RV, Abbaneo D, Auffray E, Auzinger G, Bachtis M, Baillon P, Ball AH, Barney D, Benaglia A, Benhabib L, Berruti GM, Bloch P, Bocci A, Bonato A, Botta C, Breuker H, Camporesi T, Castello R, Cepeda M, Cerminara G, D’Alfonso M, d’Enterria D, Dabrowski A, Daponte V, David A, De Gruttola M, De Guio F, De Roeck A, Di Marco E, Dobson M, Dordevic M, Dorney B, du Pree T, Duggan D, Dunser M, Dupont N, Elliott-Peisert A, Franzoni G, Fulcher J, Funk W, Gigi D, Gill K, Girone M, Glege F, Guida R, Gundacker S, Guthoff M, Hammer J, Harris P, Hegeman J, Innocente V, Janot P, Kirschenmann H, Knunz V, Kortelainen MJ, Kousouris K, Lecoq P, Lourenco C, Lucchini MT, Magini N, Malgeri L, Mannelli M, Martelli A, Masetti L, Meijers F, Mersi S, Meschi E, Moortgat F, Morovic S, Mulders M, Neugebauer H, Orfanelli S, Orsini L, Pape L, Perez E, Peruzzi M, Petrilli A, Petrucciani G, Pfeiffer A, Pierini M, Piparo D, Racz A, Reis T, Rolandi G, Rovere M, Ruan M, Sakulin H, Sauvan JB, Schafer C, Schwick C, Seidel M, Sharma A, Silva P, Simon M, Sphicas P, Steggemann J, Stoye M, Takahashi Y, Treille D, Triossi A, Tsirou A,Veckalns V,Veres GI, Wardle N, Wohri HK, Zagozdzinska A, Zeuner WD, Bertl W, Deiters K, Erdmann W, Horisberger

R, Ingram Q, Kaestli HC, Kotlinski D, Langenegger U, Rohe T, Bachmair F, Bani L, Bianchini L, Casal B, Dissertori G, Dittmar M, Donega M, Eller P, Grab C, Heidegger C, Hits D, Hoss J, Kasieczka G, Lecomte P, Lustermann W, Mangano B, Marionneau M, del Arbol PMR, Masciovecchio M, Meinhard MT, Meister D, Micheli F, Musella P, Nessi-Tedaldi F, Pandolfi F, Pata J, Pauss F, Perrin G, Perrozzi L, Quittnat M, Rossini M, Schonenberger M, Starodumov A,Takahashi M,Tavolaro VR,Theofilatos K,Wallny R, Aarrestad TK, Amsler C, Caminada L, Canelli MF, Chiochia V, De Cosa A, Galloni C, Hinzmann A, Hreus T, Kilminster B, Lange C, Ngadiuba J, Pinna D, Rauco G, Robmann P, Salerno D, Yang Y, Chen KH, Doan TH, Jain S, Khurana R, Konyushikhin M, Kuo CM, Lin W, Lu YJ, Pozdnyakov A, Yu SS, Kumar A, Chang P, Chang YH, Chang YW, Chao Y, Chen KF, Chen PH, Dietz C, Fiori F, Grundler U, Hou WS, Hsiung Y, Liu YF, Lu RS, Moya MM, Petrakou E, Tsai JF, Tzeng YM, Asavapibhop B, Kovitanggoon K, Singh G, Srimanobhas N, Suwonjandee N, Adiguzel A, Bakirci MN, Damarseckin S, Demiroglu ZS, Dozen C, Eskut E, Girgis S, Gokbulut G, Guler Y, Gurpinar E, Hos I, Kangal EE, Onengut G, Ozdemir K, Polatoz A, Cerci DS, Tali B, Topakli H, Zorbilmez C, Bilin B, Bilmis S, Isildak B, Karapinar G, Yalvac M, Zeyrek M, Gulmez E, Kaya M, Kaya O, Yetkin EA,Yetkin T, Cakir A, Cankocak K, Sen S,Vardarl FI, Grynyov B, Levchuk L, Sorokin P, Aggleton R, Ball F, Beck L, Brooke JJ, Burns D, Clement E, Cussans D, Flacher H, Goldstein J, Grimes M, Heath GP, Heath HF, Jacob J, Kreczko L, Lucas C, Meng Z, Newbold DM, Paramesvaran S, Poll A, Sakuma T, El Nasr-Storey SS, Senkin S, Smith D, Smith VJ, Bell KW, Belyaev A, Brew C, Brown RM, Calligaris L, Cieri D, Cockerill DJA, Coughlan JA, Harder K, Harper S, Olaiya E, Petyt D, Shepherd-Themistocleous CH, Thea A, Tomalin IR, Williams T, Worm SD, Baber M, Bainbridge R, Buchmuller O, Bundock A, Burton D, Casasso S, Citron M, Colling D, Corpe L, Dauncey P, Davies G, De Wit A, Della Negra M, Dunne P, Elwood A, Futyan D, Haddad Y, Hall G, Iles G, Lane R, Lucas R, Lyons L, Magnan AM, Malik S, Mastrolorenzo L, Nash J, Nikitenko A, Pela J, Penning B, Pesaresi M, Raymond DM, Richards A, Rose A, Seez C, Tapper A, Uchida K, Acosta MV,Virdee T, Zenz SC, Cole JE, Hobson PR, Khan A, Kyberd P, Leslie D, Reid ID, Symonds P, Teodorescu L, Turner M, Borzou A, Call K, Dittmann J, Hatakeyama K, Liu H, Pastika N, Charaf O, Cooper SI, Henderson C, Rumerio P, Arcaro D, Avetisyan A, Bose T, Gastler D, Rankin D, Richardson C, Rohlf J, Sulak L, Zou D, Alimena J, Benelli G, Berry E, Cutts D, Ferapontov A, Garabedian A, Hakala J, Heintz U, Jesus O, Laird E, Landsberg G, Mao Z, Narain M, Piperov S, Sagir S, Syarif R, Breedon R, Breto G, Sanchez MCD, Chauhan S, Chertok M, Conway J, Conway R, Cox PT, Erbacher R, Funk G, Gardner M, Ko W, Lander R, Mclean C, Mulhearn M, Pellett D, Pilot J, Ricci-Tam F, Shalhout S, Smith J, Squires M, Stolp D, Tripathi M, Wilbur S, Yohay R, Cousins R, Everaerts P, Florent A, Hauser J, Ignatenko M, Saltzberg D, Takasugi E,Valuev V, Weber M, Burt K, Clare R, Ellison J, Gary JW, Hanson G, Heilman J, Paneva MI, Jandir P, Kennedy E, Lacroix F, Long OR, Malberti M, Negrete MO, Shrinivas A,Wei H,Wimpenny S,Yates BR, Branson JG, Cerati GB, Cittolin S, D’Agnolo RT, Derdzinski M, Holzner A, Kelley R, Klein D, Letts J, Macneill I, Olivito D, Padhi S, Pieri M, Sani M, Sharma V, Simon S, Tadel M, Vartak A, Wasserbaech S, Welke C, Wurthwein F,Yagil A, Della Porta GZ, Bradmiller-Feld J, Campagnari C, Dishaw A, Dutta V, Flowers K, Sevilla MF, Geffert P, George C, Golf F, Gouskos L, Gran J, Incandela J, Mccoll N, Mullin SD, Richman J, Stuart D, Suarez I, West C,Yoo J, Anderson D, Apresyan A, Bendavid J, Bornheim A, Bunn J, Chen Y, Duarte J, Mott A, Newman HB, Pena C, Spiropulu M,Vlimant JR, Xie S, Zhu RY, Andrews MB, Azzolini V, Calamba A, Carlson B, Ferguson T, Paulini M, Russ J, Sun M,Vogel H,Vorobiev I, Cumalat JP, Ford WT, Gaz A, Jensen F, Johnson A, Krohn M, Mulholland T, Nauenberg U, Stenson K, Wagner SR, Alexander J, Chatterjee A, Chaves J, Chu J, Dittmer S, Eggert N, Mirman N, Kaufman GN, Patterson JR, Rinkevicius A, Ryd A, Skinnari L, Soffi L, Sun W, Tan SM, Teo WD,

Continue

145

3.3 Infectious Diseases and Immunity Area

3 INFORMATION GROUPS BY AREA

146

Thom J, Thompson J, Tucker J, Weng Y, Wittich P, Abdullin S, Albrow M, Apollinari G, Banerjee S, Bauerdick LAT, Beretvas A, Berryhill J, Bhat PC, Bolla G, Burkett K, Butler JN, Cheung HWK, Chlebana F, Cihangir S, Elvira VD, Fisk I, Freeman J, Gottschalk E, Gray L, Green D, Grunendahl S, Gutsche O, Hanlon J, Hare D, Harris RM, Hasegawa S, Hirschauer J, Hu Z, Jayatilaka B, Jindariani S, Johnson M, Joshi U, Klima B, Kreis B, Lammel S, Lewis J, Linacre J, Lincoln D, Lipton R, Liu T, De Sa R, Lykken J, Maeshima K, Marraffino JM, Maruyama S, Mason D, McBride P, Merkel P, Mrenna S, Nahn S, Newman-Holmes C, O’Dell V, Pedro K, Prokofyev O, Rakness G, Sexton-Kennedy E, Soha A, Spalding WJ, Spiegel L, Stoynev S, Strobbe N, Taylor L, Tkaczyk S, Tran NV, Uplegger L, Vaandering EW,Vernieri C,Verzocchi M,Vidal R, Wang M, Weber HA, Whitbeck A, Acosta D, Avery P, Bortignon P, Bourilkov D, Brinkerhoff A, Carnes A, Carver M, Curry D, Das S, Field RD, Furic IK, Konigsberg J, Korytov A, Kotov K, Ma P, Matchev K, Mei H, Milenovic P, Mitselmakher G, Rank D, Rossin R, Shchutska L, Snowball M, Sperka D, Terentyev N, Thomas L, Wang J, Wang S, Yelton J, Linn S, Markowitz P, Martínez G, Rodríguez JL, Ackert A, Adams JR, Adams T, Askew A, Bein S, Bochenek J, Diamond B, Haas J, Hagopian S, Hagopian V, Johnson KF, Khatiwada A, Prosper H, Weinberg M, Baarmand MM, Bhopatkar V, Colafranceschi S, Hohlmann M, Kalakhety H, Noonan D, Roy T, Yumiceva F, Adams MR, Apanasevich L, Berry D, Betts RR, Bucinskaite I, Cavanaugh R, Evdokimov O, Gauthier L, Gerber CE, Hofman DJ, Kurt P, O’Brien C, González IDS, Turner P, Varelas N, Wu Z, Zakaria M, Zhang J, Bilki B, Clarida W, Dilsiz K, Durgut S, Gandrajula RP, Haytmyradov M, Khristenko V, Merlo JP, Mermerkaya H, Mestvirishvili A, Moeller A, Nachtman J, Ogul H, Onel Y, Ozok F, Penzo A, Snyder C, Tiras E, Wetzel J, Yi K, Anderson I, Barnett BA, Blumenfeld B, Cocoros A, Eminizer N, Fehling D, Feng L, Gritsan AV, Maksimovic P, Osherson M, Roskes J, Sarica U, Swartz M, Xiao M, Xin Y, You C, Baringer P, Bean A, Bruner C, Castle J, Kenny RP, Kropivnitskaya A, Majumder D, Malek M, Mcbrayer W, Murray M, Sanders S, Stringer R, Wang Q, Ivanov A, Kaadze K, Khalil S, Makouski M, Maravin Y, Mohammadi A, Saini LK, Skhirtladze N, Toda S, Lange D, Rebassoo F, Wright D, Anelli C, Baden A, Baron O, Belloni A, Calvert B, Eno SC, Ferraioli C, Gómez JA, Hadley NJ, Jabeen S, Kellogg RG, Kolberg T, Kunkle J, Lu Y, Mignerey AC, Shin YH, Skuja A,Tonjes MB,Tonwar SC, Apyan A, Barbieri R, Baty A, Bi R, Bierwagen K, Brandt S, Busza W, Cali IA, Demiragli Z, Di Matteo L, Ceballos GG, Goncharov M, Gulhan D, Hsu D, Iiyama Y, Innocenti GM, Klute M, Kovalskyi D, Krajczar K, Lai YS, Lee YJ, Levin A, Luckey PD, Marini AC, Mcginn C, Mironov C, Narayanan S, Niu X, Paus C, Roland C, Roland G, Salfeld-Nebgen J, Stephans GSF, Sumorok K, Tatar K, Varma M, Velicanu D, Veverka J, Wang J, Wang TW, Wyslouch B, Yang M, Zhukova V, Benvenuti AC, Dahmes B, Evans A, Finkel A, Gude A, Hansen P, Kalafut S, Kao SC, Klapoetke K, Kubota Y, Lesko Z, Mans J, Nourbakhsh S, Ruckstuhl N, Rusack R, Tambe N, Turkewitz J, Acosta JG, Oliveros S, Avdeeva E, Bartek R, Bloom K, Bose S, Claes DR, Dominguez A, Fangmeier C, Suárez RG, Kamalieddin R, Knowlton D, Kravchenko I, Meier F, Monroy J, Ratnikov F, Siado JE, Snow GR, Stieger B, Alyari M, Dolen J, George J, Godshalk A, Harrington C, Iashvili I, Kaisen J, Kharchilava A, Kumar A, Parker A, Rappoccio S, Roozbahani B, Alverson G, Barberis E, Baumgartel D, Chasco M, Hortiangtham A, Massironi A, Morse DM, Nash D, Orimoto T, De Lima RT, Trocino D, Wang RJ, Wood D, Zhang J, Bhattacharya S, Hahn KA, Kubik A, Low JF, Mucia N, Odell N, Pollack B, Schmitt MH, Sung K, Trovato M, Velasco M, Dev N, Hildreth M, Jessop C, Karmgard DJ, Kellams N, Lannon K, Marinelli N, Meng F, Mueller C, Musienko Y, Planer M, Reinsvold A, Ruchti R, Rupprecht N, Smith G,Taroni S,Valls N,Wayne M,Wolf M,Woodard A, Antonelli L, Brinson J, Bylsma B, Durkin LS, Flowers S, Hart A, Hill C, Hughes R, Ji W, Ling TY, Liu B, Luo W, Puigh D, Rodenburg M, Winer BL, Wulsin HW, Driga O, Elmer P, Hardenbrook J, Hebda P, Koay SA, Lujan P, Marlow D, Medvedeva T, Mooney M, Olsen J,

Palmer C, Piroue P, Stickland D, Tully C, Zuranski A, Malik S, Barker A, Barnes VE, Benedetti D, Bortoletto D, Gutay L, Jha MK, Jones M, Jung AW, Jung K, Miller DH, Neumeister N, RadburnSmith BC, Shi X, Shipsey I, Silvers D, Sun J, Svyatkovskiy A, Wang F, Xie W, Xu L, Parashar N, Stupak J, Adair A, Akgun B, Chen Z, Ecklund KM, Geurts FJM, Guilbaud M, Li W, Michlin B, Northup M, Padley BP, Redjimi R, Roberts J, Rorie J, Tu Z, Zabel J, Betchart B, Bodek A, de Barbaro P, Demina R, Duh YT, Eshaq Y, Ferbel T, Galanti M, García-Bellido A, Han J, Hindrichs O, Khukhunaishvili A, Lo KH, Tan P, Verzetti M, Chou JP, Contreras-Campana E, Ferencek D, Gershtein Y, Halkiadakis E, Heindl M, Hidas D, Hughes E, Kaplan S, Elayavalli RK, Lath A, Nash K, Saka H, Salur S, Schnetzer S, Sheffield D, Somalwar S, Stone R, Thomas S, Thomassen P, Walker M, Foerster M, Heideman J, Riley G, Rose K, Spanier S, Thapa K, Bouhali O, Hernández AC, Celik A, Dalchenko M, De Mattia M, Delgado A, Dildick S, Eusebi R, Gilmore J, Huang T, Kamon T, Krutelyov V, Mueller R, Osipenkov I, Pakhotin Y, Patel R, Perloff A, Pernie L, Rathjens D, Rose A, Safonov A, Tatarinov A, Ulmer KA, Akchurin N, Cowden C, Damgov J, Dragoiu C, Dudero PR, Faulkner J, Kunori S, Lamichhane K, Lee SW, Libeiro T, Undleeb S,Volobouev I, Wang Z, Appelt E, Delannoy AG, Greene S, Gurrola A, Janjam R, Johns W, Maguire C, Mao Y, Melo A, Ni H, Sheldon P,Tuo S,Velkovska J, Xu Q, Arenton MW, Barria P, Cox B, Francis B, Goodell J, Hirosky R, Ledovskoy A, Li H, Neu C, Sinthuprasith T, Sun X, Wang Y, Wolfe E, Wood J, Xia F, Clarke C, Harr R, Karchin PE, Don CKK, Lamichhane P, Sturdy J, Belknap DA, Carlsmith D, Dasu S, Dodd L, Duric S, Gomber B, Grothe M, Herndon M, Herve A, Klabbers P, Lanaro A, Levine A, Long K, Loveless R, Mohapatra A, Ojalvo I, Perry T, Pierro GA, Polese G, Ruggles T, Sarangi T, Savin A, Sharma A, Smith N, Smith WH,Taylor D, Verwilligen P, Woods N. Search for Higgs boson off-shell production in proton-proton collisions at 7 and 8 TeV and derivation of constraints on its total decay width. J High Energy Phys. 2016;(9):51. Article. IF: 6.063; Q1 • Luczkowiak J, Arribas JR, Gómez S, Jiménez-Yuste V, de la Calle F, Viejo A, Delgado R. Specific neutralizing response in plasma from convalescent patients of Ebola virus disease against the West Africa Makona variant of Ebola virus. Virus Res. 2016;213:224-9. Article. IF: 2.628; Q3 • Mills A, Arribas JR, Andrade-Villanueva J, di Perri G,Van Lunzen J, Koenig E, Elion R, Cavassini M, Madruga JV, Brunetta J, Shamblaw D, de Jesus E, Orkin C, Wohl DA, Brar I, Stephens JL, Girard PM, Huhn G, Plummer A, Liu YP, Cheng AK, McCallister S. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. Lancet Infect Dis. 2016;16(1):43-52. Article. IF: 19.864; D1 • Montes ML, Nelson M, Girard PM, Sasadeusz J, Horban A, Grinsztejn B, Zakharova N, Rivero A, Durant J, Ortega-González E, Lathouwers E, Janssen K, Ouwerkerk-Mahadevan S, Witek J, González-García J. Telaprevir-based therapy in patients coinfected with chronic hepatitis C virus infection and HIV: INSIGHT study. J Antimicrob Chemoth. 2016;71(1):244-50. Article. IF: 5.071; D1 • Palacios-Baena ZR, Oteo J, Conejo C, Larrosa MN, Bou G, Fernández-Martínez M, González-López JJ, Pintado V, MartínezMartínez L, Merino M, Pomar V, Mora-Rillo M, Rivera MA, Oliver A, Ruiz-Carrascoso G, Ruiz-Garbajosa P, Zamorano L, Bautista V, Ortega A, Morales I, Pascual A, Campos J, Rodríguez-Baño J. Comprehensive clinical and epidemiological assessment of colonisation and infection due to carbapenemase-producing Enterobacteriaceae in Spain. J Infection. 2016;72(2):152-60. Article. IF: 4.201; Q1 • Paño-Pardo JR, Quintana BL, Perona FL, Carrascoso GR, Romero-Gómez MP, Yagüe BL, Díaz-Pollan B, Martínez-Virto A,

Mingorance J, Rodríguez JG, Arribas JR, Gómez-Gil R. Community-onset bloodstream and other infections, caused by carbapenemase-producing enterobacteriaceae: Epidemiological, microbiological, and clinical features. Open Forum Infect Dis. 2016;3(3):ofw136. Article. Not Indexed • Paño-Pardo JR, Schuffelmann-Gutiérrez C, Escosa-García L, Laplaza-González M, Moreno-Ramos F, Gómez-Gil R, López JD, Jordán I, Téllez C, de la Oliva P. Opportunities to improve antimicrobial use in paediatric intensive care units: a nationwide survey in Spain. Clin Microbiol Infec. 2016;22(2):171-7. Article. IF: 5.292; D1 • Pérez-Latorre L, Rivero-Juárez A, Hontañón V, Déez C, Cuenca F, Martín-Carbonero ML, Montes ML, Bellón JM, Aldámiz-Echevarría T, Carrero A, Rivero A, González-García J, Berenguer J. Prognostic value of transient elastography in human immunodeficiency virus-infected patients with chronic hepatitis C. Open Forum Infect Dis. 2016;3(4): ofw212. Article. Not Indexed • Pozniak A, Arribas JR, Gathe J, Gupta SK, Post FA, Bloch M, Avihingsanon A, Crofoot G, Benson P, Lichtenstein K, Ramgopal M, Chetchotisakd P, Custodio JM, Abram ME, Wei XL, Cheng A, McCallister S, SenGupta D, Fordyce MW. Switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected patients with renal impairment: 48-week results from a single-arm, multicenter, open-label phase 3 study. JAIDS-J Acq Imm Def. 2016;71(5):530-7. Article. IF: 3.935; Q1 • Raffi F, Esser S, Nunnari G, Pérez-Valero I, Waters L. Switching regimens in virologically suppressed HIV-1-infected patients: evidence base and rationale for integrase strand transfer inhibitor (INSTI)-containing regimens. HIV Med. 2016;17:3-16. Article. IF: 3.257; Q2 • Ramírez-Lapausa M, Pareja JFP, Gómez R, Martínez-Prieto M, Pérez PR, Asensio AN. Retrospective study of tolerability and efficacy of linezolid in patients with multidrug-resistant tuberculosis (1998-2014). Enferm Infec Micr Cl. 2016;34(2):85-90. Article. IF: 1.714; Q3 • Ramos A, Romero Y, Sánchez-Romero I, Fortun J, Paño JR, Peman J, Gurgui M, Rodríguez-Baño J, Padilla B. Risk factors, clinical presentation and prognosis of mixed candidaemia: a populationbased surveillance in Spain. Mycoses. 2016;59(10):636-43. Article. IF: 2.252; Q2 • Rivero A, Polo R, Aldeguer JL, Lozano F, Antela A, Aguirrebengoa K, Arribas JR, Asensi V, Berenguer J, Blanco JR, Boix V, Casado JL, Clotet B, Crespo M, Domingo P, Dueñas C, Estrada V, García F, Gatell JM, Gómez-Sirvent JL, González-García J, Gutiérrez F, Iribarren JA, Knobel H, Llibre JM, Losa JE, Mallolas J, Marino A, Miro JM, Moreno S, Palacios R, Pineda JA, Pulido F, Ribera E, Rubio R, Moreno JS, Sanz JS, Téllez MJ, de la Torre J, Tuset M, Molina JAP. Executive summary of the GESIDA/National AIDS plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (Updated January 2016). Enferm Infec Micr Cl. 2016;34(7):439-51. Article. IF: 1.714; Q3 • Sendagorta E, Bernardino JI, Álvarez-Gallego M, Feito M, Feltes R, Beato MJ, Pérez-Molina JA, Yllescas M, Díaz-Almiron M, Arribas JR, González-García J, Herranz P. Topical cidofovir to treat high-grade anal intraepithelial neoplasia in HIV-infected patients: a pilot clinical trial. AIDS. 2016;30(1):75-82. Article. IF: 5.003; Q1 • Sobrino-Vegas P, Moreno S, Rubio R, Viciana P, Bernardino JI, Blanco JR, Bernal E, Asensi V, Pulido F, del Amo J, Hernando V. Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004-2013. J Infection. 2016;72(5):587-96. Article. IF: 4.201; Q1 • Sotillo A, Paño-Pardo JR, López-Quintana B, Gómez-Gil R. Development of daptomycin resistance during therapy in a patient with methicillin-resistant Staphylococcus aureus endocarditis: A case report. Enferm Infec Micr Cl. 2016;34(8):534-5. Letter. IF:

1.714; Q3 • Stella-Ascariz N, Montejano R, Martín-Vicente M, Mingorance J, Pérez-Valero I, Bernardino JI, Arribas JR. Long-term control of human immunodeficiency virus-1 replication despite extensive resistance to current antiretroviral regimens: clonal analysis of resistance mutations in proviral deoxyribonucleic acid. Open Forum Infect Dis. 2016;3(1): ofw041. Article. Not Indexed • Troya J, Ryan P, Ribera E, Podzamczer D, Hontañón V, Terrón JA, Boix V, Moreno S, Barrufee P, Castaño M, Carrero A, Galindo MJ, Suárez-Lozano I, Knobel H, Raffo M, Solis J,Yllescas M, Esteban H, González-García J, Berenguer J, Imaz A. Abacavir/lamivudine plus Rilpivirine is an effective and safe strategy for HIV-1 suppressed patients: 48 week results of the SIMRIKI retrospective study. Plos One. 2016;11(10):e0164455. Article. IF: 2.806; Q1 • Uyeki TM, Mehta AK, Davey RT, Liddell AM, Wolf T, Vetter P, Schmiedel S, Grunewald T, Jacobs M, Arribas JR, Evans L, Hewlett AL, Brantsaeter AB, Ippolito G, Rapp C, Hoepelman AIM, Rapp C, Hoepelman AIM, Gutman J. Clinical management of Ebola virus disease in the United States and Europe. New Engl J Med. 2016;374(7):636-46. Article. IF: 72.406; D1 • van Lunzen J, Antinori A, Cohen CJ, Arribas JR, Wohl DA, Rieger A, Rachlis A, Bloch M, Segal-Maurer S, Garner W, Porter D, Bosse M, Piontkowsky D, Chuck SK, De-Oertel S. Rilpivirine vs. efavirenz-based single-tablet regimens in treatment-naive adults: week 96 efficacy and safety from a randomized phase 3b study. AIDS. 2016;30(2):251-9. Article. IF: 5.003; Q1 • Velasco C, Pérez I, Podzamczer D, Llibre JM, Domingo P, González-García J, Puig I, Ayala P, Martín M, Trilla A, Lázaro P, Gatell JM. Prediction of higher cost of antiretroviral therapy (ART) according to clinical complexity. A validated clinical index. Enferm Infec Micr Cl. 2016;34(3):149-58. Article. IF: 1.714; Q3 • Wohl D, Oka S, Clumeck N, Clarke A, Brinson C, Stephens J, Tashima K, Arribas JR, Rashbaum B, Cheret A, Brunetta J, Mussini C, Tebas P, Sax PE, Cheng A, Zhong LJ, Callebaut C, Das M, Fordyce M. A Randomized, double-blind comparison of tenofovir alafenamide versus tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine for initial HIV-1 treatment: Week 96 results. JAIDS-J Acq Imm Def. 2016;72(1):58-64. Article. IF: 3.935; Q1

PUBLIC PROJECTS Arribas López JR. Ensayo clínico, randomizado, piloto, diseñado para comparar, en sujetos infectados por el virus de inmunodeficiencia humana que nunca han recibido tratamiento antirretroviral, la evolución del funcionamiento cerebral y del rendimiento neurocognitivo tras 24 semanas de tratamiento (EC11-217). MSSSI. 2012-2017. Management centre: FIBHULP Arribas López JR. Envejecimiento prematuro de pacientes VIH+: evaluación in vivo e in vitro del impacto del tratamiento con análogos nucleósidos en la longitud de los telómeros (PI13/01467). ISCIII. 2014-2017. Management centre: FIBHULP Arribas López JR. Contrato de intenfisicación. ISCIII. 2015-2016. Management centre: FIBHULP Arribas López JR. Identificación y caracterización de anticuerpos monoclonales frente al virus ébola para aplicaciones diagnósticas y terapéuticas (DTS15/00143). ISCIII. 2016-2017. Management centre: FIBHULP

Continue

147

3.3 Infectious Diseases and Immunity Area

3 INFORMATION GROUPS BY AREA de Pablo Olaiz A. Contrato de técnico de apoyo (CA12/00333). ISCIII. 2013-2016. Management centre: FIBHULP

Madrid (Cohorte VIH-La Paz) PI-890. Janssen-Cilag España S.A. 2010-Ongoing. Management centre: FIBHULP

Gayá Moreno F. Contrato de técnico de apoyo. ISCIII, CAM. 2008-Ongoing. Management centre: FIBHULP

Arribas López JR. Reparación y asesoramiento para el desarrollo del curso de investigación sobre VIH y deterioro neurocognitivo, a través del grupo “SIDA y enfermedades infecciosas”. Bristol Myers Squibb S.A.U. 2012-Ongoing. Management centre: FIBHULP

González García JJ. Erradicación del VHC en pacientes coinfectados por VIH/VHC: efectos sobre la inflamación, el daño endotelial, la activación inmune y la aterosclerosis preclínica (EC11-241). MSSSI. 2012-2017. Management centre: FIBHULP González García JJ. Red de SIDA (RIS) (RD12/0017/0016). ISCIII. 2013-2017. Management centre: FIBHULP González García JJ. Efectos de la erradicación del VHC en pacientes con cirrosis avanzada por VHC. Una aproximación translacional (PI14/01581). ISCIII. 2015-2017. Management centre: FIBHULP Montejano Sanchez R. Contrato (CM14/00034). ISCIII. 2015-2017. Management centre: FIBHULP

Río

Hortega.

Mora Rillo M. Red de Investigación Cooperativa en Enfermedades Tropicales (RICET) (RD12/0018/0023). ISCIII. 2013-2017. Management centre: FIBHULP Paño Pardo JR. Cohorte ambispectiva de pacientes con infecciones por enterobacterias productoras de carbapenemasa (PI14/01832). ISCIII. 2015-2016. Management centre: FIBHULP Pérez Valero I. Contrato Juan Rodés (JR13/00016). ISCIII. 2014-2016. Management centre: FIBHULP Pérez Valero I. Seguridad neurocognitiva de terapias antirretrovirales no convencionales con inhibidores de proteasa (IPS) (PI14/01876). ISCIII. 2015-2017. Management centre: FIBHULP Rodés Soldevila B. Contrato de estabilización I2 (CES11/021). ISCIII, CAM. 2012-Ongoing. Management centre: FIBHULP Rodés Soldevila B. Análisis de la expresión de los niveles de proteínas modificadoras y otros mecanismos epigenéticos asociados a la regulación de la transcripción del VIH en pacientes LTNP/EC (PI12/00850). ISCIII. 2013-2017. Management centre: FIBHULP

PRIVATE PROJECTS Arribas López JR. Aplicación de la secuenciación de genomas individuales (SGI) al estudio de la resistencia a antirretrovirales en poblaciones minoritarias celulares y plasmáticas en pacientes infectados por VIH. Fundación para la Investigación y la Prevención del SIDA. 2009-Ongoing. Management centre: FIBHULP Arribas López JR. Registro descriptivo longitudinal retrospectivo de los pacientes Naïve incluidos en la cohorte de pacientes con infección por VIH del Hospital La Paz de 148

Arribas López JR. VIII Jornadas de actualización científica en enfermedades infecciosas. 27 y 28 de septiembre de 2012. Novartis Farmacéutica S.A. 2012-Ongoing. Management centre: FIBHULP Arribas López JR. Research in boosted PI monotherapy. 2012-Ongoing. Management centre: FIBHULP Arribas López JR. Curso de actualización de la investigación en simplificación con inhubidores de proteasa. Janssen Cilag S.A. Colombia. 2014-Ongoing. Management centre: FIBHULP

González García JJ. Características clínicas y epidemiológicas de la coinfección VHC-VIH en la población española en 2008. 2008-Ongoing. Management centre: FIBHULP González García JJ. Erradicación del virus de la hepatitis C en pacientes infectados por el VIH: efectos a largo plazo sobre la morbilidad y mortalidad no relacionada con la hepatopatía, sobre la activación inmune y sobre marcadores metabólicos, de inflamación y de baño Enot. Fundación para la Investigación y la Prevención del SIDA. 2011-Ongoing. Management centre: FIBHULP Herranz Pinto P. Terapia biológica con artritis psoriásica y psoriasis y su investigación asociada. Merck Sharp and Dohme de España S.A. 2005-Ongoing. Management centre: FIBHULP Herranz Pinto P. Curso manejo global de la toxicidad mucocutánea de las terapias antineoplásicas. De la investigación a la práctica clínica. Merck S.L. 2016-Ongoing. Management centre: FIBHULP

Arribas López JR. Curso de actualización en investigación en VIH: aprendizajes pasados y nuevos conceptos. Janssen Cilag S.A. Colombia. 2014-Ongoing. Management centre: FIBHULP

Herranz Pinto P. Jornada científica: lucha antivenérea en el siglo XXI. Gilead Sciences S.L. 2016-Ongoing. Management centre: FIBHULP

Arribas López JR. Curso de avances en la investigación en el tratamiento con inhibidores de proteasa. Janssen Cilag S.A. Colombia. 2015-Ongoing. Management centre: FIBHULP

Montes Ramírez ML. Estudio de hepatopatías en pacientes infectados por VIH sin hepatitis víricas que reciben tratamiento antirretroviral. Abbvie Spain S.L.U. 2016-Ongoing. Management centre: FIBHULP

Arribas López JR. XI Jornadas de actualización en enfermedades infecciosas: de la investigación a la práctica clínica. Gilead Sciences S.L. 2015-Ongoing. Management centre: FIBHULP Arribas López JR. Estudio de longitud telomérica en pacientes infectados por el VIH expuestos a dos estrategias de tratamiento antirretroviral diferente (Telomere Lenght Substudy). The European Treatment Network For HIV, Hepatitis and Global Infectious Diseases. 2016-Ongoing. Management centre: FIBHULP Arribas López JR. XI Jornadas de actualización en enfermdedades infecciosas: de la investigación a la práctica clínica. 2016-Ongoing. Management centre: FIBHULP Bernardino de la Serna JI. Cohorte observacional internacional coordinada por la cohorte Suiza de VIH (SHCS) sobre la contribución de las variables genéticas asociadas a la aparición de la enfermedad coronaria en pacientes infectados por el virus de la inmunodeficiencia humana. VIH Kantonsspital Bruderholz. 2011-Ongoing. Management centre: FIBHULP de la Calle Prieto F. Curso de consejo integral al viajero: de la investigación a la práctica clínica. Clientes Varios. 2016-Ongoing. Management centre: FIBHULP González García JJ. Estudio de cohorte de pacientes con infección por VIH del Hospital La Paz de Madrid (cohorte VIH-La Paz). Gilead Sciences S.L. 2008-Ongoing. Management centre: FIBHULP

Paño Pardo JR. Evaluación de la utilización de antifúngicos a través de datos agregados de consumo: elaboración de un modelo. Gilead Sciences S.L. 2010-Ongoing. Management centre: FIBHULP Peña Sánchez de Rivera JM. Estudio de cohorte de pacientes con infección por VIH del Hospital La Paz de Madrid (cohorte VIH-La Paz). Glaxosmithkline S.A. 2008-Ongoing. Management centre: FIBHULP Pérez Valero I. Jornada de actualización en infecciones de transmisión sexual para Atención Primaria: de la investigación a la práctica clínica. Gilead Sciences S.L. 2015-Ongoing. Management centre: FIBHULP

INTERNATIONAL PROJECTS Pérez Valero I. CNS HIV anti-retroviral therapy effects research (HHS-N-271-2010-00036C). National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS). 2002-2016. Management centre: National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS)

CLINICAL TRIALS Arribas López JR. Estudio internacional, multicéntrico, observacional, prospectivo, sobre la seguridad de mara-

viroc utilizado junto con la terapia de base optimizada en pacientes infectados por el VIH-1 que han recibido tratamiento. Pfizer S.L.U. HULP Code: Anexo-2 2754. Sponsored´s Protocol Code: A4001067. Signature Date: 31/05/2016 Arribas López JR. Estudio de fase 3 abierto para evaluar la seguridad del tratamiento en un solo comprimido de elvitegravir/cobicista/entricitabina/tenofovir alafenamida en pacientes infectados por el VIH-1 con insuficiencia renal leve o moderada. Gilead Sciences Inc. HULP Code: Anexo-1 3947. Sponsored´s Protocol Code: GSUS-292-0112. Signature Date: 20/06/2016 Arribas López JR. Estudio de fase 3, aleatorizado, controlado con tratamiento activo y abierto para evaluar el cambio de tratamiento a un régimen en un solo comprimido administrado una vez al día de darunavir/cobicistat/emtricitabina/tenofovir alafenamida (D/C/F/TAF) frente a la continuación del régimen actual formado por un inhibidor de la proteasa potenciado (IPP) combinado con emtricitabina/tenofovir disoproxil fumarato (FTC/TDF) en sujetos infectados por el virus de la inmunodeficiencia humana de tipo 1 (VIH-1) con supresión virológica. Janssen-Cilag España S.A. HULP Code: Anexo-1 4300. Sponsored´s Protocol Code: TMC114IFD3013. Signature Date: 27/05/2016 Arribas López JR. Estudio fase 3b, aleatorizado, doble ciego, para evaluar el cambio de un tratamiento con una combinación a dosis fija (CDF) de efavirenz/emtricitabina/ tenofovir disoproxil fumarato (EFV/FTC/FDF) a una CDF de emtricitabina/rilpivirina/tenofovir alafenamida (FTC/ RPV/TAF) en pacientes con infección por VIH 1 y supresión virológica. Gilead Sciences Inc. HULP Code: 4375. Sponsored´s Protocol Code: GS-US-366-1160. Signature Date: 20/09/2016 Arribas López JR. Ensayo clínico fase 2b, aleatorizado, controlado con principio activo, doble ciego, para investigar la seguridad, eficacia y dosis-respuesta de BMS955176, administrado con tenofovir/emtricitabina en adultos infectados por VIH 1 naive a tratamiento. Bristol Myers Squibb International Corporation. HULP Code: Anexo-1 4424. Sponsored´s Protocol Code: AI468038. Signature Date: 27/05/2016 Arribas López JR. Ensayo clínico de fase III, aleatorizado y controlado con placebo para evaluar la seguridad y la capacidad inmunógena de tres lotes de estabilidad y un lote de dosis alta de RVSV-ZEBOV-GP (vacuna contra el virus del ébola V920) en adultos sanos. Merck Sharp And Dohme de España S.A. HULP Code: Anexo-1 4431. Sponsored´s Protocol Code: V920-012. Signature Date: 07/01/2016 Arribas López JR. Estudio fase III, multicéntrico, abierto, randomizado, para evaluar el cambio a MK 1439A en pacientes con supresión virológica infectados por el VIH-1 en un régimen de un inhibidor de proteasa potenciado con ritonavir y dos inhibidores de la transcriptasa inversa

Continue

149

3.3 Infectious Diseases and Immunity Area

3 INFORMATION GROUPS BY AREA análogos de nucleósido. Merck Sharp & Dhome Corp. HULP Code: Anexo-1 4441. Sponsored´s Protocol Code: 1439A024. Signature Date: 27/09/2016 Arribas López JR. Estudio fase 2, aleatorizado, doble ciego, controlado con placebo para evaluar la farmacocinética, seguridad y actividad antiviral del JNJ-63623872 en combinación con oseltamivir en pacientes adolescentes, adultos y ancianos hospitalizados por infección de gripe A. Janssen-Cilag España S.A. HULP Code: Anexo-1 4501. Sponsored´s Protocol Code: 63623872FLZ2002. Signature Date: 22/06/2016 Arribas López JR. Estudio de fase 3, aleatorizado y doble ciego para evaluar la seguridad y la eficácia de GS-9883/ emtricitabina/tenofovir alafenamida en comparación con dolutegravir + emtricitabina/tenofovir alafenamida en adultos infectados por el VIH-1 sin tratamiento antirretroviral previo. Gilead Sciences Inc. HULP Code: Anexo-1 4573. Sponsored´s Protocol Code: GSUS-380-1490. Signature Date: 01/07/2016 Arribas López JR. Estudio de fase 3, aleatorizado y doble ciego para evaluar la seguridad y la eficácia de GS-9883/ emtricitabina/tenofovir alafenamida en comparación con dolutegravir + emtricitabina/tenofovir alafenamida en adultos infectados por el VIH-1 sin tratamiento antirretroviral previo. Gilead Sciences Inc. HULP Code: 4573. Sponsored´s Protocol Code: GS-US-380-1490. Signature Date: 01/03/2016 Arribas López JR. Estudio de fase 3, aleatorizado y doble ciego para evaluar la seguridad y la eficacia de GS-9883/ emtricitabina/tenofovir alafenamida en comparación con abacavir/dolutegravir/lamivudina en adultos infectados por el VIH-1 sin tratamiento antirretroviral previo. Gilead Sciences Inc. HULP Code: 4574. Sponsored´s Protocol Code: GS-US-380-1489. Signature Date: 01/04/2016 Arribas López JR. Estudio de fase 3, aleatorizado y doble ciego para evaluar la seguridad y la eficacia de GS-9883/ emtricitabina/tenofovir alafenamida en comparación con abacavir/dolutegravir/lamivudina en adultos infectados por el VIH-1 sin tratamiento antirretroviral previo. Gilead Sciences Inc. HULP Code: Anexo-1 4574. Sponsored´s Protocol Code: GSUS-380-1489. Signature Date: 01/07/2016 Arribas López JR. Estudio piloto de fase 3b abierto para evaluar el cambio a la combinación de dosis fijas (CDF) elvitegravir/cobicistat/emtricitabina/tenofovir alafenamida (E/C/F/TAF) en sujetos adultos infectados por el VIH-1 con supresión virológica que tienen la mutación de resistencia a itian archivada aislada M184V/M184I. Gilead Sciences Inc. HULP Code: 4575. Sponsored´s Protocol Code: GS-US-292-1824. Signature Date: 04/02/2016 Arribas López JR. Estudio de fase III, aleatorizado, doble ciego, multicéntrico, con grupos paralelos, de ausencia de inferioridad, para evaluar la eficacia, seguridad y tolera150

bilidad de dolutegravir más lamivudina en comparación con dolutegravir más tenofovir/emtricitabina en adultos infectados por el VIH-1 no tratados previamente. Glaxosmithkline Research and Development Limited. HULP Code: 4645. Sponsored´s Protocol Code: 205543. Signature Date: 08/09/2016 Arribas López JR. Reconstitución inmune en pacientes con infección por el VIH-1 no tratados previamente y con cifras de linfocitos CD4+ inferiores a 100 céls/mm3 que reciben un régimen de fármacos. Fundacio Clinic per a la Reçerca Biomedica. HULP Code: 4641. Sponsored´s Protocol Code: ADVANZ 4. Signature Date: 27/07/2016 Arribas López JR. Estudio fase 3b, aleatorizado, doble ciego, con cambio de tratamiento para evaluar la seguridad y eficacia de una combinación a dosis fija (CDF) de emtricitabina/rilpivirina/tenofovir alafenamida (FTC/ RPV/TAF), en pacientes con VIH-1 positivo que presentan supresión virológica en tratamiento con emtricitabina/ rilpivirina/tenofovir disoproxil fumarato (FTC/RPV/TDF). Gilead Sciences Inc. HULP Code: Anexo-1 4374. Sponsored´s Protocol Code: GSUS-366-1260. Signature Date: 20/09/2016 González García JJ. Ensayo clínico en fase III para optimizar la inmuno-estimulación con maraviroc, un antagonista CCR5, combinado con tratamiento antorretroviral (TAR) en pacientes con infeccion por VIH-1 avanzada, con diagnóstico tardío, criterio de definición de SIDA y/o recuentos de CD4 por debajo de 200 celulas/mm3. Agencia Nacional de Investigación sobre El SIDA y las Hepatitis Víricas (Inserm-Anrs). HULP Code: Anexo-1 3680. Sponsored´s Protocol Code: ANRS 146 OPTIMA. Signature Date: 02/02/2016

HULP Code: Anexo-1 4173. Sponsored´s Protocol Code: NOVPSO-2013-01. Signature Date: 18/01/2016 Herranz Pinto P. Estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo, de 52 semanas de duración para demostrar la eficacia, seguridad y tolerabilidad de inyecciones subcutáneas de secukinumab con jeringas precargadas de 2 ml (300 mg) en pacientes adultos con psoriasis en placas de moderada a grave- allure. Novartis Farmacéutica S.A. HULP Code: 4665. Sponsored´s Protocol Code: CAIN457A2323. Signature Date: 22/09/2016 Montes Ramírez ML. Eficacia y seguridad/tolerabilidad de viekirax y exviera en pacientes diagnosticados de VHC, coinfectados o no con VIH 1, GT 1 o 4, y enfermedad renal crónica en estadios de IIIb A V, incluyendo aquellos en diálisis, en práctica clínica habitual en España. Estudio Viekind. Abbvie Spain S.L.U. HULP Code: PI-2303. Sponsored´s Protocol Code: ABBOMB-2015-01. Signature Date: 09/05/2016 Montes Ramírez ML. Estudio fase III aleatorizado, multicéntrico, abierto, de grupos paralelos, de no inferioridad, para evaluar la eficacia, seguridad y tolerabilidad del cambio de una terapia antirretroviral basada en INI, ITINN o IP a una pauta de tratamiento intramuscular de acción prolongada con cabotegravir y rilpivirina en pacientes adultos infectados por el VIH-1 con supresión virológica. Laboratorios VIIV Healthcare S.L. HULP Code: 4681. Sponsored´s Protocol Code: 201585. Signature Date: 10/08/2016

causada por enterobacterias resistentes a los carbapenémicos (CRE). Achaogen Inc. HULP Code: Anexo-2 4039. Sponsored´s Protocol Code: 4039 ACHN-490-007. Signature Date: 23/05/2016 Pérez Valero I. Estudio prospectivo, observacional de la utilización del medicamento stribild® en adultos con infección por VIH. Gilead Sciences Inc. HULP Code: PI-1975. Sponsored´s Protocol Code: GSEU-236-0141. Signature Date: 20/05/2016 Ríos Blanco JJ. Estudio aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad del tratamiento oral con nintedanib durante al menos 52 semanas en pacientes con «enfermedad pulmonar intersticial asociada a esclerosis sistémica» (SSC-ILD). Boehringer Ingelheim International GMBH. HULP Code: 4504. Sponsored´s Protocol Code: 1.199.214. Signature Date: 17/02/2016

PATENTS AND TRADEMARKS Romero Gómez M, Solá Lamoglia R, González García JJ, inventors; Servicio Andaluz de Salud, Universidad de Sevilla, Fundació Institut Mar D’Investigacions Mèdiques, FIBHULP, assignees. Kit for decision making in patients with Hepatitis C genotypes 1 and 4. P201330731; 2013 May 21.

Mora Rillo M. Estudio de fase 3, multicéntrico, aleatorizado y abierto para evaluar la eficacia y la seguridad de plazomicina en comparación con colistina en pacientes con infección

González García JJ. Estudio fase III, aleatorizado, multicéntrico, abierto, de grupos paralelos, para evaluar la eficacia, seguridad y tolerabilidad de una pauta de tratamiento intramuscular de acción prolongada con cabotegravir y rilpivirina en el mantenimiento de la supresión virológica, tras una inducción con un tratamiento de comprimido único con un inhibidor de la integrasa en pacientes adultos infectados por el VIH-1 que no han recibido un tratamiento antirretroviral previo. Laboratorios VIIV Healthcare S.L. HULP Code: 4679. Sponsored´s Protocol Code: 201584. Signature Date: 10/08/2016 González García JJ. Estudio abierto de fase III para evaluar la eficacia y la seguridad del tratamiento con boceprevir en pacientes coinfectados por el VIH y VHC (genotipo 1 (subtipo A o B)), que han fracasado al tratamiento previo con peginterferón y ribavirina. Fundacio Clinic per a la Reçerca Biomédica. HULP Code: Anexo-1 3788. Sponsored´s Protocol Code: BOCHIV. Signature Date: 13/07/2016 Herranz Pinto P. Estudio observacional para evaluar las recaídas en pacientes con psoriasis moderada - grave tratados con fármacos biológicos de acuerdo a la práctica clínica en España. Estudio Biopres. Novartis Farmacéutica S.A.

Return to INFECTIOUS DISEASES AND IMMUNITY AREA INDEX

151

3.3 Infectious Diseases and Immunity Area

3 INFORMATION GROUPS BY AREA

152

MOLECULAR MICROBIOLOGY GROUP

32 113.016 9 Jesús Mingorance Cruz Investigador Senior (Contrato Ramón y Cajal - I3). HULP Emilio Cendejas Bueno Investigador Postdoctoral (Contrato Juan Rodés). HULP María Teresa Corcuera Pindado Técnico Grado Superior. HULP Manuela de Pablos Gómez Facultativo Especialista de Área en Microbiología. HULP Francisca Natalia Fernández Romero Investigadora Predoctoral. HULP Silvia García Bujalance Facultativo Especialista de Área en Microbiología. HULP María Jesús García García Profesor Titular del Departamento de Medicina Preventiva y Salud Pública y Microbiología. Facultad de Medicina. UAM Adelaida García Perea Facultativo Especialista de Área en Microbiología. HULP Julio García Rodríguez Jefe de Servicio de Microbiología. HULP Paulino Gómez Puertas Científico Titular CSIC. CBM “Severo Ochoa” Profesor Honorario. UAM María Rosa Gómez-Gil Mira Facultativo Especialista de Área en Microbiología. HULP María Belén Loeches Yagüe Médico Adjunto. Unidad de Enfermedades Infecciosas. HULP Elena López Camacho Investigadora Postdoctoral. HULP Carmen Menéndez Gómez Profesora Honoraria del Departamento de Medicina Preventiva y Salud Pública y Microbiología. Facultad de Medicina. UAM Dolores Montero Vega Facultativo Especialista de Área en Microbiología. HULP

Arturo Noguerado Asensio Jefe de Servicio de Medicina Interna. Hospital Universitario del Sureste Verónica Pérez Blanco Facultativo Especialista de Área en Medicina Preventiva. HULP María Inmaculada Quiles Melero Facultativo Especialista de Área en Microbiología. HULP Alicia Rico Nieto Facultativo Especialista de Área en Microbiología. HULP María Pilar Romero Gómez Facultativo Especialista de Área en Microbiología. HULP Guillermo Ruiz Carrascoso Facultativo Especialista de Área en Microbiología. HULP Alma María Sotillo Torquemada Investigadora Predoctoral. HULP Natalia Stella Ascariz Investigadora Predoctoral. HULP Carlos Toro Rueda Facultativo Especialista de Área en Microbiología. Hospital Carlos III-HULP

Strategic Objective The Molecular Microbiology research group is integrated into the Department of Microbiology at Hospital La Paz, and a significant number of its members are physicians in the department devoted to microbiological diagnostic work. This integration determines the group’s strategic approach and therefore, the different lines of research revolve around several aspects of clinical microbiology and infectious diseases. An important line of activity (Clinical Microbiology) is the result of the routine activities provided

by the department, but goes further and deeper into the methodological, epidemiological and pathological challenges encountered in the daily routine. One research line derived from the former is the development of methods for the molecular characterisation of pathogenic microorganisms, including microbiological diagnosis and epidemiological analysis, and more recently, microbial genomics. Another line focuses on the study of the evolution of pathogenic microorganisms. As a model of opportunistic pathogens, we study Escherichia coli, a microorganism that is well characterised at the genetic level and that is clinically relevant as the primary cause of urinary tract infections and one of the most frequently involved in bacteraemia. As a model of viral pathogens, we study the dynamics of HIV viral populations over time and in terms of the response to antiretroviral treatment. Another important focus, given the scarcity of new antibiotics, is the search for new therapeutic targets. In this line, we study bacterial division as a promising target for the development of new antibiotics.

Research Lines • Molecular epidemiology and evolution of pathogens. • Molecular methods for diagnostics of infectious diseases. • Microbial genomics. • Biochemistry and molecular biology of bacterial cell division. • Clinical Microbiology.

Research Activity DOCTORAL THESES Ruiz Carrascoso G. Características microbiológicas y clínico-epidemiológicas de enterobacterias productoras de carbapenemasa OXA-48 en el contexto de un brote hospitalario[dissertation]. Madrid: UCM: 2016 (10/02/2016). Director: Mingorance Cruz J.

BOOKS AND BOOK CHAPTERS de la Vega E, Corcuera MT, Gómez F. Técnicas de análisis hematológico: Altamar Editorial, 2016. Hernández B, Corcuera MT, Gómez F, Domínguez P, Simón F, Lorenzo MI. Microbiología Clínica: Altamar Editorial, 2016.

PUBLICATIONS

• Cendejas-Bueno E, Borobia AM, Gómez-López A, Escosa-García L, Río-García M, Plaza D, García-Rodríguez J, Carcas-Sansuán A. Invasive aspergillosis in a paediatric allogeneic stem cell transplantation recipient owing to a susceptible Aspergillus fumigatus: Treatment failure with high doses of voriconazole and influence of CYP2C19 polymorphisms. Int J Antimicrob Ag. 2016;47(5):410-1. Letter. IF: 4.307; Q1 • Dahdouh E, Orgaz B, Gómez-Gil R, Mingorance J, Daoud Z, Suárez M, San José C. Patterns of biofilm structure and formation kinetics among Acinetobacter baumannii clinical isolates with different antibiotic resistance profiles. Medchemcomm. 2016;7(1):157-63. Article. IF: 2.608; Q2 • de Pablo A, Bogoi R, Bejarano I, Toro C, Valencia E, Moreno V, Martín-Carbonero L, Gómez-Hernando C, Rodes B. Short communication: p21/CDKN1A expression shows broad interindividual diversity in a subset of HIV-1 elite controllers. AIDS Res Hum Retrov. 2016;32(3):232-6. Article. IF: 2.095; Q3 • Estrada V, Monge S, Gómez-Garre MD, Sobrino P, Masia M, Berenguer J, Portilla J, Vilades C, Martínez E, Blanco JR, (Mingorance J). Relationship between plasma bilirubin level and oxidative stress markers in HIV-infected patients on atazanavir- vs. efavirenz-based antiretroviral therapy. HIV Med. 2016;17(9):653-61. Article. IF: 3.257; Q2 • Falcés-Romero I, Gutiérrez-Arroyo A, Romero-Gómez MP. Catheter-associated bacteremia by Pandoraea pnomenusa in an infant with acute lymphoblastic leukemia. Med Clin-Barcelona. 2016;147(3):132. Letter. IF: 1.125; Q3 • Fortún J, Martín-Dávila P, de la Pedrosa EGG, Silva JT, GarcíaRodríguez J, Benito D, Venanzi E, Castaño F, Fernández-Ruiz M, Lázaro F, García-Luján R, Quiles I, Cabanillas JJ, Moreno S, Aguado JM. Galactomannan in bronchoalveolar lavage fluid for diagnosis of invasive aspergillosis in non-hematological patients. J Infection. 2016;72(6):738-44. Article. IF: 4.201; Q1 • Fragoso PL, de los Buéis AB, Ljubetic LB, Zarzuelo AD, Gómez MPR, Rillo MM. Herpes simplex keratitis in rheumatoid arthritis patients. Ocul Immunol Inflamm. 2016;24(3):282-7. Article. IF: 2.453; Q2 • García JL, Salgado T, Nieto AR. Subacute back pain. Rev Clin Esp. 2016;216(3):165-6. Editorial Material. IF: 0.971; Q3 • García MJ, Gola S. Gene and whole genome analyses reveal that the mycobacterial strain JS623 is not a member of the species Mycobacterium smegmatis. Microb Biotechnol. 2016;9(2):26974. Article. IF: 3.513; Q2 • García MJ, López MR. Do we have strategies to improve the preventive treatment of latent tuberculosis infection? Clin Infect Dis. 2016;62(11):1401-2. Editorial Material. IF: 8.216; D1 • García V, Escosa L, Cabrerizo M, Romero-Gómez MP. Sepsis-like syndrome and acute meningoencephalitis due to parechovirus type 3. Enferm Infec Micr Cl. 2016;34(1):73-4. Letter. IF: 1.714; Q3 • García-Rodríguez J, Quiles-Melero MI. Primary fungal peritonitis: A pending subject. Enferm Infec Micr Cl. 2016;34(8):469-70. Editorial Material. IF: 1.714; Q3 • Kartashev V, Doring M, Nieto L, Coletta E, Kaiser R, Sierra S, (García Bujalance S). New findings in HCV genotype distribution in selected West European, Russian and Israeli regions. J Clin Virol. 2016;81:82-9. Article. IF: 3.051; Q2

• Arroyo-Fajardo A, Troyano-Hernández P, Sotillo A, Romero-Gómez MP. Nocardia veterana bacteraemia after a lung infection in a patient with acute myeloid leukaemia. Enferm Infec Micr Cl. 2016;34(7):463-4. Letter. IF: 1.714; Q3

• Mendieta-Moreno JI, Trabada DG, Mendieta J, Lewis JP, GómezPuertas P, Ortega J. Quantum mechanics/molecular mechanics free energy maps and nonadiabatic simulations for a photochemical reaction in DNA: Cyclobutane thymine dimer. J Phys Chem Lett. 2016;7(21):4391-7. Article. IF: 9.353; D1

• Arsuaga M, Bujalance SG, Díaz-Menéndez M,Vázquez A, Arribas JR. Probable sexual transmission of Zika virus from a vasectomised man. Lancet Infect Dis. 2016;16(10):1107. Letter. IF: 19.864; D1

• Mingorance J, Regueiro B, Muñoz-Bellido JL. Historical perspective of mass spectrometry in microbiology. Enferm Infec Micr Cl. 2016;34 Suppl 2:3-7. Article. IF: 1.714; Q3

Continue

153

3.3 Infectious Diseases and Immunity Area

3 INFORMATION GROUPS BY AREA • Monteserin J, Paul R, López B, Cnockaert M, Tortoli E, Menéndez C, García MJ, Palomino JC, Vandamme P, Ritacco V, Martín A. Combined approach to the identification of clinically infrequent non-tuberculous mycobacteria in Argentina. Int J Tuberc Lung D. 2016;20(9):1257-62. Article. IF: 2.468; Q3 • Muñiz FDM, Redondo MM, Sánchez CP, Rodríguez JG. Chronic lung infection caused by Trichosporon mycotoxinivorans and tricosporin mucoides in an immunocompetent cystic fibrosis patient. Arch Bronconeumol. 2016;52(7):400. Letter. IF: 2.979; Q2 • Paño-Pardo JR, Quintana BL, Perona FL, Carrascoso GR, Romero-Gómez MP, Yagüe BL, Díaz-Pollán B, Martínez-Virto A, Mingorance J, Rodríguez JG, Arribas JR, Gómez-Gil R. Community-onset bloodstream and other infections, caused by carbapenemase-producing enterobacteriaceae: Epidemiological, microbiological, and clinical features. Open Forum Infect Dis. 2016;3(3): ofw136. Article. IF: Not Indexed • Paño-Pardo JR, Schuffelmann-Gutiérrez C, Escosa-García L, Laplaza-González M, Moreno-Ramos F, Gómez-Gil R, López JD, Jordán I, Téllez C, de la Oliva P. Opportunities to improve antimicrobial use in paediatric intensive care units: a nationwide survey in Spain. Clin Microbiol Infec. 2016;22(2):171-7. Article. IF: 5.292; D1 • Pescador P, Romero-Gómez MP, Gil RG, Mingorance J. Evaluation of combined use of the MALDI-TOF and GenomEra MRSA/ SA assay for the direct detection of methicillin resistance in Staphylococcus aureus from positive blood culture bottles. Enferm Infec Micr Cl. 2016;34(10):687-8. Letter. IF: 1.714; Q3

• Tortoli E, Kohl TA, Brown-Elliott BA, Trovato A, Leao SC, García MJ, Vasireddy S, Turenne CY, Griffith DE, PhiIley JV, Baldan R, Campana S, Cariani L, Colombo C,Taccetti G,Teri A, Niemann S, Wallace RJ, Cirillo DM. Emended description of mycobacterium abscessus, mycobacterium abscessus subsp abscessus and mycobacterium abscessus subsp bolletii and designation of mycobacterium abscessus subsp massiliense comb. nov. Int J Syst Evol Micr. 2016;66:4471-9. Article. IF: 2.134; Q3 • Valencia ME, Quiles MI. Urinary infection through Mycobacterium fortuitum in patient with infection by HIV. Rev Esp Quim. 2016;29(4):226-7. Letter. IF: 0.75; Q4

PUBLIC PROJECTS Menéndez Gómez MC. Micobacterias: carácter patógeno y relación con el entorno. Centro de estudios de América Latina (UAM-BSCH). 2015-2016. Management centre: UAM Mingorance Cruz J. Contrato de estabilización Ramón y Cajal (I3). ISCIII, CAM. 2011-Ongoing. Management centre: FIBHULP

• Pie J, Puisac B, Hernández-Marcos M, Teresa-Rodrigo ME, GilRodríguez M, Baquero-Montoya C, Ramos-Cáceres M, Bernal M, Ayerza-Casas A, Bueno I, Gómez-Puertas P, Ramos FJ. Special cases in cornelia de lange syndrome: the Spanish experience. Am J Med Genet C. 2016;172(2):198-205. Review. IF: 5.6; Q1

Mingorance Cruz J. Trazabilidad de microorganismos patógenos: tipificación de alta resolución mediante identificación de sitios de inserción de elementos móviles por secuenciación masiva dirigida (PI13/01218). ISCIII. 20142016. Management centre: FIBHULP

• Quiles Melero I, Peláez T, Rezusta López A, García-Rodríguez J. Application of mass spectrometry in mycology. Enferm Infec Micr Cl. 2016;34 Suppl 2:26-30. Article. IF: 1.714; Q3

Stella Ascariz N. Contrato predoctoral (FI14/00391). ISCIII. 2015-2018. Management centre: FIBHULP

• Robles-Marhuenda A, Romero-Gómez MP, García-Rodríguez J, Arnalich-Fernández F. Native valve endocarditis caused by Kocuria kristinae. Enferm Infec Micr Cl. 2016;34(7):464-5. Letter. IF: 1.714; Q3 • Rossi CGA, Gómez-Puertas P, Serrano JAA. In vivo functional and molecular characterization of the Penicillin-Binding Protein 4 (DacB) of Pseudomonas aeruginosa. BMC Microbiol. 2016;16:234. Article. IF: 2.644; Q2 • San-Juan R, Viedma E, Chaves F, Lalueza A, Fortún J, Loza E, Pujol M, Ardanuy C, Morales I, de Cueto M, Resino-Foz E, MoralesCartagena A, Rico A, Romero MP, Oreliana MA, López-Medrano F, Fernández-Ruiz M, Aguado JM. High MICs for vancomycin and daptomycin and complicated catheter-related bloodstream infections with methicillin-sensitive staphylococcus aureus. Emerg Infect Dis. 2016;22(6):1057-66. Article. IF: 8.222; D1 • Sobrino-Vegas P, Moreno S, Rubio R, Viciana P, Bernardino JI, Blanco JR, Bernal E, Asensi V, Pulido F, del Amo J, Hernando V, (Alcáriz NS, Mingorance J). Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004-2013. J Infection. 2016;72(5):587-96. Article. IF: 4.201; Q1 • Sotillo A, Paño-Pardo JR, López-Quintana B, Gómez-Gil R. Development of daptomycin resistance during therapy in a patient with methicillin-resistant Staphylococcus aureus endocarditis: A case report. Enferm Infec Micr Cl. 2016;34(8):534-5. Letter. IF: 1.714; Q3 • Stella-Ascariz N, Montejano R, Martín-Vicente M, Mingorance J, Pérez-Valero I, Bernardino JI, Arribas JR. Long-Term control of human immunodeficiency virus-1 replication despite extensive resistance to current antiretroviral regimens: Clonal analysis of

154

resistance mutations in proviral deoxyribonucleic acid. Open Forum Infect Dis. 2016;3(1): ofw041. Article. IF: Not Indexed

PRIVATE PROJECTS García Bujalance S. Detección de variantes minoritarias de mutaciones de resistencia del VIH-1 mediante pirosecuenciación y evaluación de su impacto sobre la eficacia de los tratamientos antirretrovirales PI-686. Laboratorios VIIV Healthcare S.L. 2010-Ongoing. Management centre: FIBHULP García Bujalance S. Evaluación del rendimiento del ensayo aptima HIV-1 Quant para la detección y cuantificación del HIV-1 en muestras de plasma. Hologic Deuschland GMBH. 2016-Ongoing. Management centre: FIBHULP García Rodríguez J. Estudio poblacional de las especies de candida invasoras. Astellas Pharma S.A. 2010-Ongoing. Management centre: FIBHULP García Rodríguez J. Estudio de la sensibilidad in vitro y sinergia de anidulafungina y voriconazol frente a aislamientos clínicos de especies de aspergillus del Hospital Universitario La Paz. 2010-Ongoing. Management centre: FIBHULP

García Rodríguez J. Identificación de aspergillus a través del sistema Malditof. Maldifumi. 2012-Ongoing. Management centre: FIBHULP García Rodríguez J. Colaboracion para el desarrollo de proyectos especificos entre el grupo de investigación de microbiología molecular del IdiPAZ en contreto: el desarrollo de soluciones en el ámbito de la microbiología molecular para atención en el punto de necesidad (POC). Epistem Ltd. 2016-Ongoing. Management centre: FIBHULP Gómez-Gil Mira MR. In vitro activities of ceftaroline, daptomycin, linezolid, and vancomycin against bacteremic methicillin-resistant staphylococcus aureus isolates. Astrazeneca Farmaceutica Spain S.A. 2013-Ongoing. Management centre: FIBHULP Gómez-Gil Mira MR. Aislamiento, identificación, estudio de sensibilidad, control de calidad y envio al laboratorio central de enterobacterias productoras de carbapenemasas. Astrazeneca Farmaceutica Spain S.A. 2016-Ongoing. Management centre: FIBHULP Mingorance Cruz J. Identificación y caracterización de patógenos con interés intrahospitalario bajos sistemas automatizables con potencial implantación hospitalaria. Biotools-Biotechnological Medical Laboratori. 2009-Ongoing. Management centre: FIBHULP Mingorance Cruz J. Molecular epidemiology of resistance to linezolid in gram positive cocci in a tertiary hospital. 2009-Ongoing. Management centre: FIBHULP Mingorance Cruz J. La utilidad clínica de septifast para el diagnóstico de sepsis en pacientes nefrológicos. Roche Diagnostics S.L. 2010-Ongoing. Management centre: FIBHULP Mingorance Cruz J. Idi-20101176-kits de diagnóstico basados en pirosecuenciación. Laboratorios VIIV Healthcare S.L. 2011-Ongoing. Management centre: FIBHULP Mingorance Cruz J. Aplicación de los métodos de tipado genómico y molecular a la elaboración del mapa microbiológico del Hospital Universitario La Paz. Epistem Ltd. 2012-Ongoing. Management centre: FIBHULP Mingorance Cruz J. Septidrive. Development and evaluation of a new sepsis test. 2012-Ongoing. Management centre: FIBHULP Mingorance Cruz J. Validación clínica de un biosensor para la identificación de streptococcus pneumoniae. CISC. 2013-Ongoing. Management centre: FIBHULP

Mingorance Cruz J. Desarrollo de un dispositivo lab on a chip para la detección en POCT (Points of Care Testing) de la resistencia a antibióticos de muestras de orina. Diagnochip Spa. 2014-Ongoing. Management centre: FIBHULP Toro Rueda C. Evaluación del rendimiento de una prueba en el punto de atención (POCT) de QPCR para el diagnóstico microbilógico. Epistem Ltd. 2012-Ongoing. Management centre: FIBHULP Toro Rueda C. Evaluación del rendimiento de una prueba en el punto de atención (POCT) de QPCR para diagnóstico biológico. Arcis Biotechnology Holdings Ltd. 2012-Ongoing. Management centre: FIBHULP

INTERNATIONAL PROJECTS Mingorance Cruz J. Optomechanics for virology - Viruscan (VIRUSCAN). EU. 2016-2021. Management centre: FIBHULP

CLINICAL TRIALS Loeches Yagüe B. Ensayo clínico aleatorizado, multicéntrico, abierto, controlado, en fase III, para demostrar la no inferioridad del tratamiento antibiótico dirigido de espectro reducido frente al tratamiento de amplio espectro con un betalactámico antipseudomónico en el tratamiento de pacientes con bacteriemia por enterobacteriaceae. Fundación Pública Andaluza Progreso y Salud. HULP Code: 4583. Sponsored´s Protocol Code: SIMPLIFY. Signature Date: 18/03/2016

PATENTS AND TRADEMARKS Mingorance Cruz J, Castán García P, Franco de Sarabia Rosado PM, inventors; Biotools Biotechnological & Medical Laboratories S.A., assignee. Composition, method and kit for detecting bacteria by means of sequencing. PCT/ ES2009/000507, EP2492352, US2013157265, CA2775273, MX2012004627; 2009 October 22. Mingorance Cruz J, Castán García P, Franco de Sarabia Rosado PM, inventors; 2B Blackbio S.L., assignee. Composition, method and kit for detecting fungi and yeasts by means of sequencing. PCT/ES2010/000248; 2010 June 02. Vicente Muñoz M, Mingorance Cruz J, Rueda González MS, inventors; CSIC, assignee. Method for determining state of growth and viability of bacterial FTsZ population, whether natural or cultivated, is based on determining existence of FTsZ rings in actively growing individual cells. P200200370; 2002 February 15.

García Rodríguez J. Diagnóstico de aspergilosis invasora mediante detección de ácidos nucleicos de aspergillus SPP en sangre. Gilead Sciences S.L. 2011-Ongoing. Management centre: FIBHULP

Return to INFECTIOUS DISEASES AND IMMUNITY AREA INDEX

155

3 INFORMATION GROUPS BY AREA

3.3 Infectious Diseases and Immunity Area

Research Activity

156

DOCTORAL THESES Arroyo Villa I. Estudio de las poblaciones celulares Th17 y Thf en la patogenia de la artritis reumatoide[dissertation]. Madrid: UAM: 2016(13/01/2016). Directors: Miranda Carús ME, Martín Mola E.

IMMUNORHEUMATOLOGY GROUP

Bautista Caro MB. Estudio sobre la biología de las células Th17 y Thf en espondiloartritis[dissertation]. Madrid: UAM: 2016(04/02/2016). Directors: Miranda Carús ME, Martín Mola E.

PUBLICATIONS • Alcobendas R, Rodríguez-Vidal A, Pascual-Salcedo D, Murias S, Remesal A, Diego C, Merino R. Monitoring serum etanercept levels in juvenile idiopathic arthritis: a pilot study. Clin Exp Rheumatol. 2016;34(5):955-6. Letter. IF: 2.634; Q3

24 132.042 11

María Eugenia Miranda Carús Facultativo Especialista de Área en Reumatología. HULP Pilar Aguado Acín Facultativo Especialista de Área en Reumatología. HULP Alejandro Balsa Criado Jefe de Sección en Reumatología. HULP Profesor Asociado. Facultad de Medicina. UAM Paula Fortea Gordo Investigadora predoctoral María Gema Bonilla Hernán Facultativo Especialista de Área en Reumatología. HULP Ana Castilla Plaza Facultativo Especialista de Área en Reumatología. HULP Eugenio de Miguel Mendieta Facultativo Especialista de Área en Reumatología. HULP Sara García Carazo Facultativo Especialista de Área en Reumatología. HULP María Teresa Jurado Camino Investigadora Postdoctoral. HULP Emilio Martín Mola Jefe de Servicio de Reumatología. HULP Profesor Asociado. Facultad de Medicina. UAM Ana Martínez Feito Investigadora Predoctoral. HULP Irene Monjo Henry Facultativo Especialista de Área en Reumatología. HULP Francisco de Borja Hernández Breijo Investigador post doctoral María Victoria Navarro Compán Facultativo Especialista de Área en Reumatología. HULP

Laura Nuño Nuño Médico Adjunto Interino en Reumatología. HULP Eva Olariaga Mérida Investigador en Inmunología. HULP María Dora Pascual-Salcedo Pascual Químico Adjunto en Inmunología. HULP Chamaida Plasencia Rodríguez Facultativo Especialista de Área en Reumatología. HULP Diana Peiteado López Facultativo Especialista de Área en Reumatología. HULP Lorena Valdeolivas de Opazo Investigadora predoctoral Alejandro Villalba Yllán Facultativo Especialista de Área en Reumatología. HULP

Strategic Objective Our objective is to investigate the pathogenesis of rheumatic diseases, specifically focusing on genetics, metabolic pathways and immunopathogenesis.

Research Lines • Immunopathogenesis and genetics of inflammatory and autoimmune arthritis. • Imaging of inflammatory and autoimmune arthritis. • Immunopathogenesis and genetics of osteoporosis. • Immunogenicity of biological therapies with monoclonal antibodies.

• Almodóvar R, Navarro-Compán V, Fernández-Carballido C, Hernández A, de Miguel E, Zarco P. Differences between familial and sporadic early spondyloarthritis: results from the ESPERANZA cohort. Clin Exp Rheumatol. 2016;34(4):575-80. Article. IF: 2.634; Q3 • Baron R, Likar R, Martín-Mola E, Blanco FJ, Kennes L, Mueller M, Falke D, Steigerwald I. Effectiveness of tapentadol prolonged release (PR) compared with Oxycodone/Naloxone PR for the management of severe chronic low back pain with a neuropathic component: A randomized, controlled, open-label, phase 3b/4 study. Pain Pract. 2016;16(5):580-99. Article. IF: 2.495; Q2 • de Hooge M, van den Berg R, Navarro-Compán V, Reijnierse M, van Gaalen F, Fagerli K, Landewe R, van Oosterhout M, Ramonda R, Huizinga T, van der Heijde D. Patients with chronic back pain of short duration from the SPACE cohort: which MRI structural lesions in the sacroiliac joints and inflammatory and structural lesions in the spine are most specific for axial spondyloarthritis? Ann Rheum Dis. 2016;75(7):1308-14. Article. IF: 12.811; D1 • del Río-Martínez P, Navarro-Compán V, Díaz-Miguel C, Almodovar R, Mulero J, de Miguel E. Similarities and differences between patients fulfilling axial and peripheral ASAS criteria for spondyloarthritis: Results from the Esperanza Cohort. Semin Arthritis Rheu. 2016;45(4):400-3. Review. IF: 4.498; Q1 • Ferreiro-Iglesias A, Montes A, Pérez-Pampín E, Canete JD, Raya E, Magro-Checa C, Vasilopoulos Y, Sarafidou T, Cáliz R, Ferrer MA, Joven B, Carreira P, Balsa A, Pascual-Salcedo D, Blanco FJ, Moreno-Ramos MJ, Fernández-Nebro A, Ordóñez MC, AlegreSancho JJ, Narváez J, Navarro-Sarabia F, Moreira V, Valor L, García-Portales R, Márquez A, Martín J, Gómez-Reino JJ, González A. Replication of PTPRC as genetic biomarker of response to TNF inhibitors in patients with rheumatoid arthritis. Pharmacogenomics J. 2016;16(2):137-40. Article. IF: 3.815; Q1 • Gossec L, Portier A, Landewe R, Etcheto A, Navarro-Compán V, Kroon F, van der Heijde D, Dougados M. Preliminary definitions of ‘flare’ in axial spondyloarthritis, based on pain, BASDAI and ASDAS-CRP: an ASAS initiative.Ann Rheum Dis. 2016;75(6):9916. Article. IF: 12.811; D1 • Koski JM, Kamel A, Waris P, Waris V, Tarkiainen I, Karvanen E, Szkudlarek M, Aydin SZ, Alasaarela E, Schmidt W, de Miguel E, Mandl P, Filippucci E, Ziswiler H, Terslev L, Ats K, Kurucz R, Naredo E, Balint P, Iagnocco A, Lepojarvi S, Elseoud A, Fouda M, Saarakkala S. Atlas-based knee osteophyte assessment with ultrasonography and radiography: relationship to arthrosco-

pic degeneration of articular cartilage. Scand J Rheumatol. 2016;45(2):158-64. Article. IF: 2.667; Q2 • Kviatkovsky MJ, Ramiro S, Landewe R, Dougados M, Tubach F, Bellamy N, Hochberg M, Ravaud P, Martín-Mola E, Awada H, Bombardier C, Felson D, Hajjaj-Hassouni N, Logeart I, MatucciCerinic M, van de Laar M, van der Heijde D. The minimum clinically important improvement and patient-acceptable symptom state in the BASDAI and BASFI for patients with ankylosing spondylitis. J Rheumatol. 2016;43(9):1680-6. Article. IF: 3.15; Q2 • López-Isac E, Martín JE, Assassi S, Simeón CP, Carreira P, Ortego-Centeno N, Freire M, Beltrán E, Narváez J, Alegre-Sancho JJ, Fernández-Gutiérrez B, Balsa A, Ortiz AM, González-Gay MA, Beretta L, Santaniello A, Bellocchi C, Lunardi C, Moroncini G, Gabrielli A, Witte T, Hunzelmann N, Distler JHW, Riekemasten G, van der Helm-Van Mil AH, de Vries-Bouwstra J, Magro-Checa C,Voskuyl AE,Vonk MC, Molberg O, Merriman T, Hesselstrand R, Nordin A, Padyukov L, Herrick A, Eyre S, Koeleman BPC, Denton CP, Fonseca C, Radstake TRDJ,Worthington J, Mayes MD, Martín J. IRF4 Newly identified as a common susceptibility locus for systemic sclerosis and rheumatoid arthritis in a cross-disease meta-analysis of genome-wide association studies. Arthritis Rheumatol. 2016;68(9):2338-44. Article. IF: 6.918; D1 • López-Mejías R, Genre F, Remuzgo-Martínez S, González-Juanatey C, Robustillo-Villarino M, Llorca J, Corrales A, Vicente E, Miranda-Filloy JA, Magro C, Tejera-Segura B, Huaranga MAR, Pina T, Blanco R, Alegre-Sancho JJ, Raya E, Mijares V, Ubilla B, Sánchez MDM, Gómez-Vaquero C, Balsa A, Pascual-Salcedo D, LópezLongo FJ, Carreira P, González-Álvaro I, Rodríguez-Rodríguez L, Fernández-Gutiérrez B, Ferraz-Amaro I, Castañeda S, Martín J, González-Gay MA. Influence of elevated-CRP level-related polymorphisms in non-rheumatic Caucasians on the risk of subclinical atherosclerosis and cardiovascular disease in rheumatoid arthritis. Sci Rep-Uk. 2016;6:31979. Article. IF: 4.259; Q1 • Martín-Mola E, Balsa A, García-Vicuña R, Gómez-Reino J, González-Gay MA, Sanmartí R, Loza E. Anti-citrullinated peptide antibodies and their value for predicting responses to biologic agents: a review. Rheumatol Int. 2016;36(8):1043-63. Article. IF: 1.824; Q3 • Moots RJ, Balsa A, Wolbink G. Reporting of potential immunogenicity with biologic drugs: clarity and accuracy required. Ann Rheum Dis. 2016;75(5):E24. Letter. IF: 12.811; D1 • Navarro-Compán V, Machado PM. Sacroiliac joint radiographic progression - speed and determinants. Nat Rev Rheumatol. 2016;12(7):380-1. Editorial Material. IF: 12.188; D1 • Navarro-Compán V, Plasencia-Rodríguez C, de Miguel E, Balsa A, Martín-Mola E, Seoane-Mato D, Canete JD. Anti-TNF discontinuation and tapering strategies in patients with axial spondyloarthritis: a systematic literature review. Rheumatology. 2016;55(7):1188-94. Article. IF: 4.818; Q1 • Navarro-Compán V, Ramiro S, Landewe R, Dougados M, MiceliRichard C, Richette P, van der Heijde D. Disease activity is longitudinally related to sacroiliac inflammation on MRI in male patients with axial spondyloarthritis: 2-years of the DESIR cohort. Ann Rheum Dis. 2016;75(5):874-8. Article. IF: 12.811; D1 • Nolla JM, Rodríguez M, Martín-Mola E, Raya E, Ibero I, Nocea G, Aragón B, Lizan L, Prades M. Patients’ and rheumatologists’ preferences for the attributes of biological agents used in the treatment of rheumatic diseases in Spain. Patient Prefer Adher. 2016;10:1101-13. Article. IF: 1.798; Q2 • Plasencia C, Wolbink G, Krieckaert CLM, Kneepkens EL, Turk S, Jurado T, Martínez-Feito A, Navarro-Compán V, Bonilla G,Villalba A, Peiteado D, Nuno L, Martín-Mola E, Nurmohamed MT, van der Kleij D, Rispens T, Pascual-Salcedo D, Balsa A. Comparing a tapering strategy to the standard dosing regimen of TNF inhi-

Continue

157

3 INFORMATION GROUPS BY AREA

3.3 Infectious Diseases and Immunity Area

bitors in rheumatoid arthritis patients with low disease activity. Clin Exp Rheumatol. 2016;34(4):655-62. Article. IF: 2.634; Q3 • Puig JG, de Miguel E. Hyperuricemia and gout: The impact of ultrasonography. Med Clin-Barcelona. 2016;146(2):67-8. Editorial Material. IF: 1.125; Q3 • Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, Kvien TK, Navarro-Compán MV, Oliver S, Schoels M, Scholte-Voshaar M, Stamm T, Stoffer M, Takeuchi T, Aletaha D, Andreu JL, Aringer M, Bergman M, Betteridge N, Bijlsma H, Burkhardt H, Cardiel M, Combe B, Durez P, Fonseca JE, Gibofsky A, Gómez-Reino JJ, Graninger W, Hannonen P, Haraoui B, Kouloumas M, Landewe R, Martín-Mola E, Nash P, Ostergaard M, Ostor A, Richards P, Sokka-Isler T, Thorne C, Tzioufas AG, van Vollenhoven R, de Wit M, van der Heijde D. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016;75(1):3-15. Review. IF: 12.811; D1 • Torices S, Julia A, Muñoz P, Varela I, Balsa A, Marsal S, FernándezNebro A, Blanco F, López-Hoyos M, Martínez-Taboada V, Fernández-Luna JL. A functional variant of TLR10 modifies the activity of NF kappa B and may help predict a worse prognosis in patients with rheumatoid arthritis. Arthritis Res Ther. 2016;18:221. Article. IF: 4.121; Q2 • Varela H, Villamañán E, Plasencia C, Romero JA, Ruano M, Balsa A, Herrero A. Safety of antitumour necrosis factor treatments in chronic rheumatic diseases: therapy discontinuations related to side effects. J Clin Pharm Ther. 2016;41(3):306-9. Article. IF: 1,679; Q3 • Ventura-Ríos L, Navarro-Compán V, Aliste M, Linares MA, Areny R, Audisio M, Bertoli AM, Cazenave T, Cerón C, Díaz ME, Gutiérrez M, Hernández C, Navarta D, Pineda C, Py GE, Reginato AM, Rosa J, Saaibi DL, Sedano O, Solano C, Castillo-Gallego C, Falcao S, de Miguel E. Is entheses ultrasound reliable? A reading Latin American exercise. Clin Rheumatol. 2016;35(5):1353-7. Article. IF: 2.365; Q3 • Ventura-Ríos L, Sánchez-Bringas G, Pineda C, Hernández-Díaz C, Reginato A, Alva M, Audisio M, Bertoli A, Cazenave T, Gutiérrez M, Mora C, Py G, Sedano O, Solano C, de Miguel E. Tendon involvement in patients with gout: an ultrasound study of prevalence. Clin Rheumatol. 2016;35(8):2039-44. Article. IF: 2.365; Q3

PUBLIC PROJECTS de Miguel Mendieta E. Curso natural y factores predictivos de la espondiloartritis de inicio (PI13/02034). ISCIII. 2014-2017. Management centre: FIBHULP Miranda Carus ME. Red de Investigación en Inflamacion y Enfermedades Reumaticas (RIER) (RD12/0009/0012). ISCIII. 2013-2017. Management centre: FIBHULP Miranda Carus ME. Frecuencia, fenotipo y funcion de las celulas T helper foliculares en sangre periférica de pacientes con artritis reumatoide (PI13/00084). ISCIII. 20142017. Management centre: FIBHULP Pascual-Salcedo Pascual MD. Desarrollo y validación de herramientas para la monitorización del tratamiento de la enfermedad inflamatoria intestinal con fármacos biológicos. (IBD-monitor) (RTC-2015-4004-1). MINECO. 2015-2018. Management centre: FIBHULP 158

PRIVATE PROJECTS Balsa Criado A. Relación entre los niveles de fármaco circulante, la aparición de anticuerpos anti-idiotipo y la respuesta clínica, en pacientes con enfermedades articulares inflamatorias (artritis reumatoide, artritis idiopática juvenil, artritis psoriática, enfermedad de Stilly espondiloartropatías). Pfizer S.L.U. 2011-Ongoing. Management centre: FIBHULP Balsa Criado A. Estudio para determinar la correlación entre la calprotectina sérica y la actividad de la artritis reumatoide. AREPAZ. 2010-Ongoing. Management centre: FIBHULP Balsa Criado A. Estudio de las comorbilidades en la artritis reumatoide. Roche Farma S.A. 2011-Ongoing. Management centre: FIBHULP Balsa Criado A. Preceptorship de investigación: individualized medicine: anti-TFN monitoring and clinical practice. Proteomika S.L. 2013-Ongoing. Management centre: FIBHULP Balsa Criado A. Preceptorship excelencia en reumatología. Synergy Medical Comunications Ltd. 2013-Ongoing. Management centre: FIBHULP Balsa Criado A. Actualización y renovación de la actividad investigadora en el Servicio de Reumatología del Hospital Universitario La Paz.Varios. 2016-Ongoing. Management centre: FIBHULP de Miguel Mendieta E. Carga de la enfermedad en pacientes con espondiloartritis de reciente comienzo. Assessment In Spondyloarthritis International Society. 2014-Ongoing. Management centre: FIBHULP Martín Mola E. Formación en investigación en pacientes con artritis de reciente comienzo, factores diagnósticos y pronósticos a tener en cuenta. Bristol Myers Squibb S.A.U. 2016-Ongoing. Management centre: FIBHULP Martín Mola E. Estudio COP. AREPAZ. 2007-Ongoing. Management centre: FIBHULP Martín Mola E. Proyecto COP. Hoffman La Roche. 2010-Ongoing. Management centre: FIBHULP Martín Mola E. Formación en investigación en el Área de Inmunología/Reumatología. Jannsen Cilaj-Bélgica. 2014-Ongoing. Management centre: FIBHULP Martín Mola E. Preceptoship on immunogenicity. Pfizer APS. 2014-Ongoing. Management centre: FIBHULP Martín Mola E. Preceptorship excelencia en reumatología. Janssen Cilag S.A. Colombia. 2012-Ongoing. Management centre: FIBHULP Miranda Carús ME. Frequency and function of B cells with regulatory capacity present in the peripheral blood

and synovial tissues of RA patients. Roche Farma S.A. 2009-Ongoing. Management centre: FIBHULP Pascual-Salcedo Pascual MD. Relación entre los niveles de fármaco circulantes, la aparición de anticuerpos antiidiotipo y la respuesta clínica, en pacientes con artritis reumatoide tratados con biológicos anti-TNF. Proteomika S.L. 2008-Ongoing. Management centre: FIBHULP Pascual-Salcedo Pascual MD. Estudio de los niveles de fármacos biológicos en la cohorte española con enfermedades inflamatorias sistémicas. Establecimiento de los rangos terapéuticos óptimos.Varios. 2015-Ongoing. Management centre: FIBHULP Pascual-Salcedo Pascual MD. Identificación precoz de buenos respondedores primarios a las terapias biológicas en la psoriasis moderada a grave. Novartis Farmaceutica S.A. 2014-Ongoing. Management centre: FIBHULP

CLINICAL TRIALS Balsa Criado A. Estudio aleatorizado, doble ciego y con control activo para evaluar la eficacia y seguridad de denosumab comparado con risedronato en pacientes tratados con glucocorticoides. Amgen S.A. HULP Code: Anexo-1 3575. Sponsored´s Protocol Code: 20101217. Signature Date: 08/03/2016 Balsa Criado A. Estudio fase IIIB para evaluar la eficacia, seguridad y tolerabilidad de tocilizumab (TCZ) subcutaneo (SC) administrado en monoterapia o en combinacion con metotrexato (MTX) u otros fames no biológicos en pacientes con artritis reumatoide. Roche Farma S.A. HULP Code: Anexo-1 3949. Sponsored´s Protocol Code: ML28709. Signature Date: 03/06/2016 Balsa Criado A. Estudio multicéntrico, internacional, aleatorizado, doble ciego, controlado con alendronato para determinar la eficacia y seguridad de AMG 785 en el tratamiento de mujeres con osteoporosis postmenopáusica. Amgen S.A. HULP Code: Anexo-3 3576. Sponsored´s Protocol Code: 20110142. Signature Date: 08/04/2016 Balsa Criado A. Estudio doble ciego, randomizado, de grupos paralelos y controlado con producto activo para comparar la eficacia y la seguridad de CHS-0214 frente a enbrel® en pacientes con artritis reumatoide y respuesta inadecuada al tratamiento con metotrexato. Coherus Bioscences Inc. HULP Code: Anexo-1 4205. Sponsored´s Protocol Code: CHS0214-02. Signature Date: 05/05/2016 Balsa Criado A. Ensayo clínico multicéntrico en fase 2A, aleatorizado, doble ciego, controlado con placebo para evaluar la eficacia y la seguridad de guselkumab en el tratamiento de pacientes con artritis psoriásica activa. Janssen-Cilag España S.A. HULP Code: Anexo-1 4399. Sponsored´s Protocol Code: CNTO1959PSA2001.

Signature Date: 19/04/2016 Balsa Criado A. Estudio de extensión abierto para evaluar la seguridad a largo plazo y la durabilidad de la respuesta de CHS-0214 (CHS-0214-05). Coherus Bioscences Inc. HULP Code: Anexo-1 4430. Sponsored´s Protocol Code: CHS0214-05. Signature Date: 05/05/2016 Balsa Criado A. Estudio de fase 3, aleatorizado, doble ciego, con control activo y con placebo, multicéntrico y de grupos paralelos de la seguridad y eficacia analgésica de tanezumab en adultos con lumbalgia crónica. Pfizer S.L.U. HULP Code: Anexo-1 4469. Sponsored´s Protocol Code: A4091059. Signature Date: 08/03/2016 Balsa Criado A. Ensayo fase 3b, aleatorizado, doble ciego para evaluar la eficacia y seguridad de abatacept SC en combinación con metotrexato comparado con metotrexato en monoterapia para conseguir la remisión clínica en adultos con artritis reumatoide temprana sin tratamiento previo con metotrexato. Bristol Myers Squibb International Corporation. HULP Code: Anexo-1 4470. Sponsored´s Protocol Code: IM101550. Signature Date: 19/05/2016 Balsa Criado A. Estudio observacional a largo plazo, multicéntrico, fase III, en pacientes de estudios con tanezumab que se someten a una sustitución total de rodilla, cadera u hombro. Pfizer Inc. HULP Code: 4453. Sponsored´s Protocol Code: A4091064. Signature Date: 14/06/2016 Balsa Criado A. Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo, multicéntrico de la seguridad y eficacia analgésicas de la administración subcutánea de tanezumab en sujetos con artrosis de cadera o de rodilla. Pfizer Inc. HULP Code: 4528. Sponsored´s Protocol Code: A4091057. Signature Date: 17/03/2016 Balsa Criado A. Estudio aleatorizado, en doble ciego, controlado con placebo y multicéntrico, de evaluación preliminar de la eficacia de IVA337 en el tratamiento de la esclerosis sistémica cutánea difusa. Inventiva S.A.S. HULP Code: 4589. Sponsored´s Protocol Code: IVA-01-337HSSC-15-001. Signature Date: 22/02/2016 Balsa Criado A. Estudio multicéntrico de 52 semanas para evaluar la evolución temporal de la respuesta a secukinumab en la inflamación articular mediante ecografía power doppler en pacientes con artritis psoriásica activa. Novartis Pharma Services AG. HULP Code: 4594. Sponsored´s Protocol Code: CAIN457F2354. Signature Date: 15/06/2016 Balsa Criado A. Estudio fase IIA, aleatorizado, doble-ciego, paralelo, controlado con placebo y naproxeno para evaluar la eficacia analgésica de ASP7962 en pacientes con dolor secundario a osteoartritis en rodilla. Astellas Pharma Europe BV. HULP Code: 4561. Sponsored´s Protocol Code: 7962-CL-0022. Signature Date: 08/04/2016

Continue

159

3.3 Infectious Diseases and Immunity Area

3 INFORMATION GROUPS BY AREA Balsa Criado A. Estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo para evaluar la seguridad, tolerabilidad y eficacia de secukinumab en pacientes con spondiloartritis axial no radiográfica activa durante un periodo de 2 años. Novartis Farmaceutica S.A. HULP Code: 4596. Sponsored´s Protocol Code: CAIN457H2315. Signature Date: 09/05/2016 Balsa Criado A. Estudio en fase II, aleatorizado, doble ciego, controlado con placebo, de prueba de concepto y búsqueda de dosis de BI 655066 en pacientes con artritis psoriásica activa. Boehringer Ingelheim España S.A. HULP Code: 4628. Sponsored´s Protocol Code: 1311.5. Signature Date: 23/05/2016 Balsa Criado A. Comparación de las prestaciones de un test rápido de detección de anticuerpos anti-infliximab (promonitor quick) en pacientes de reumatología en tratamiento activo con infliximab con la prueba estándar de laboratorio (elisa promonitor). Progenika Biopharma S.A . HULP Code: PI-2254. Sponsored´s Protocol Code: PQ-EF2. Signature Date: 42565 de Miguel Mendieta E. Estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo para demostrar la eficacia de secukinumab subcutáneo hasta 1 año en el tratamiento de la entesitis del tendón de aquiles en pacientes adultos con artritis psoriásica (APS) activa y espondiloartritis axial (Espa Axial). Novartis Farmacéutica S.A. HULP Code: 4673. Sponsored´s Protocol Code: CAIN457F3301. Signature Date: 27/09/2016 de Miguel Mendieta E. Estudio multicéntrico, observacional, no intervencionista, transversal y retrospectivo, para evaluar el control de la actividad de la enfermedad en condiciones de práctica clínica habitual en pacientes con espondilitis anquilosante y artritis psoriásica trata-

160

dos en consultas de reumatología en España (estudio Midas). Novartis Farmaceutica S.A. HULP Code: Contrato PI-2457. Sponsored´s Protocol Code: CAIN457FES02. Signature Date: 11/10/2016 Martín Mola E. Estudio de fase 3, aleatorizado, doble ciego, con control activo y con placebo, multicéntrico y de grupos paralelos de la seguridad y eficacia analgésica de tanezumab en adultos con lumbalgia crónica. Pfizer S.L.U. HULP Code: 4469. Sponsored´s Protocol Code: A4091059. Signature Date: 29/01/2016

PATENTS AND TRADEMARKS

INNATE IMMUNE RESPONSE GROUP

Pascual-Salcedo Pascual MD, Balsa Criado A, Plasencia Rodríguez C, authors; FIBHULP, assignee. Brand name: BioDrug Analysis BIDA. CM 13.808.531; 2015 March 10.

20 108.78 14 Fernández Luna JL, Martínez Taboada VM, López Hoyos M, Torices del Val S, Muñoz Cacho P, Varela Egocheaga I, Juliá Cano A, Marsal Barril S, Balsa Criado A, inventors; FIBHULP, Fundación Instituto de Investigación Marqués de Valdecilla, Servicio Cántabro de Salud, Universidad de Cantabria, Fundació Hospital Universitari Vall D´Hebron - Institut de Recerca (VHIR), assignees. Method for predicting the clinical response to anti-inflammatory agent therapies. P201600636; 2016 July 26.

Return to INFECTIOUS DISEASES AND IMMUNITY AREA INDEX

Eduardo López-Collazo Director Científico. IdiPAZ Investigador Senior (Contrato Miguel Servet - I2). Jefe de Laboratorio. HULP Luis Augusto Aguirre Perez Investigador Senior. HULP Susana Alemany de la Peña Investigadora Senior. Jefe de Laboratorio IIB “Alberto Sols” José Avendaño Ortiz Ayudante de Investigación. HULP Lisardo Boscá Gomar Investigador Senior. Jefe de Laboratorio. IIB “Alberto Sols” Ramón Cantero Cid Facultativo Especialista de Área en Cirugía General y de Aparato Digestivo. HULP José Germán Casas Martín Investigador Predoctoral. HULP Antonio Castrillo Viguera Investigador Senior. Jefe de Laboratorio. IIB “Alberto Sols” María Fernández Velasco Investigadora Senior (Contrato Miguel Servet- Tipo I). IIB “Alberto Sols” Santiago Gómez Ruiz Profesor Titular. Universidad Rey Juan Carlos María Susana Guerra García Investigadora Postdoctoral. UAM Enrique Hernández Jiménez Investigador Predoctoral (Contrato Predoctoral). HULP Charbel Antonio Maroun Eid Facultativo especialista de área en urgencias. HULP Paloma Martín Sanz Investigadora Senior. Jefe de Laboratorio. IIB “Alberto Sols”

Aurora Muñoz Jiménez Técnico de Laboratorio. HULP Rebeca Pérez de Diego Investigadora Senior (Contrato Ramón y Cajal). HULP Sanjiv Prashar Profesor Titular. Universidad Rey Juan Carlos Víctor Manuel Toledano Real Técnico de Laboratorio (Contrato de Técnico de Apoyo). HULP Aníbal Ramón Varela Serrano Técnico de Laboratorio. HULP

Strategic Objective This group focuses on the study of the reprogramming of the innate immune response in the context of inflammatory diseases (e.g., sepsis, cystic fibrosis, acute coronary syndrome, lung cancer) using the description of the various molecular mechanisms that underlie the reprogramming of monocytes/macrophages during refractory states. The innate immune response is activated in various clinical contexts that can be modelled in vitro.The initial reaction of the Innate Immune System is marked by an inflammatory response that is similar in different contexts. However, after the initial response, a “deviation” is produced towards an “alternative” response that may, in many cases, lead to refractory states such as endotoxin and tumour tolerance. These refractory states may have undesirable clinical consequences and their study is the objective of our research.

Continue

161

3 INFORMATION GROUPS BY AREA

3.3 Infectious Diseases and Immunity Area

Research Lines • Molecular mechanisms of endotoxin tolerance in several clinical contexts: respiratory diseases (OSA and cystic fibrosis), acute coronary syndrome, sepsis, septic shock and leukaemias. • Molecular mechanisms of the innate immune system tolerance to tumours in several clinical contexts. • Role of the innate immune system in metastasis.

Research Activity DOCTORAL THESES Hernández Jiménez E. Estudio de la inmunidad innata en pacientes con apnea obstructiva del sueño: un microambiente favorable para el progreso tumoral[dissertation]. Madrid: UAM: 2016(23/06/2016). Directors: López Collazo EM, García Río F. Jurado Camino MT.Tolerancia a Endotoxinas: Una explicación a las infecciones recurrentes en la Leucemia Linfática Crónica[dissertation]. Madrid: UAM: 2016(11/03/2016). Directors: López Collazo EM, Cubillos Zapata C.

PUBLICATIONS • Al Ali S, Baldanta S, Fernández-Escobar M, Guerra S. Use of reporter genes in the generation of vaccinia virus-derived vectors.Viruses-Basel. 2016;8(5):134. Review. IF: 3.465; Q2

• Leivas A, Pérez-Martínez A, Blanchard MJ, Martín-Clavero E, Fernández L, Lahuerta JJ, Martínez-López J. Novel treatment strategy with autologous activated and expanded natural killer cells plus anti-myeloma drugs for multiple myeloma. Oncoimmunology. 2016;5(12):e1250051. Article. IF: 7.719; D1 • Moreno-Cáceres J, Máinez J, Mayoral R, Martín-Sanz P, Egea G, Fabregat I. Caveolin-1-dependent activation of the metalloprotease TACE/ADAM17 by TGF-beta in hepatocytes requires activation of SRC and the NADPH oxidase NOX1. Febs J. 2016;283(7):1300-10. Article. IF: 3.902; Q2 • Motino O, Agra N, Contreras RB, Domínguez-Moreno M, García-Monzón C, Vargas-Castrillón J, Carnovale CE, Boscá L, Casado M, Mayoral R, Valdecantos MP, Valverde AM, Francés DE, Martín-Sanz P. Cyclooxygenase-2 expression in hepatocytes attenuates non-alcoholic steatohepatitis and liver fibrosis in mice. BBA-Mol Basis Dis. 2016;1862(9):1710-23. Article. IF: 5.476; Q1 • Pintor-Tortolero J, García JC, Cantero R. Transanal minimally invasive surgery approach for rectal GIST. Tech Coloproctol. 2016;20(5):321-2. Editorial Material. IF: 2.342; Q2 • Pourcet B, Gage MC, León TE, Waddington KE, Pello OM, Steffensen KR, Castrillo A, Valledor AF, Pineda-Torra I. The nuclear receptor LXR modulates interleukin-18 levels in macrophages through multiple mechanisms. SCI Rep-Uk. 2016;6:25481. Article. IF: 4.259; Q1 • Prieto P, Fernández-Velasco M, Fernández-Santos ME, Sánchez PL, Terrón V, Martín-Sanz P, Fernández-Avilés F, Boscá L. Cell expansion-dependent inflammatory and metabolic profile of human bone marrow mesenchymal stem cells. Front Physiol. 2016;7:548. Article. IF: 4.134; Q1

• Bonastre J, Landín L, Bolado P, Casado-Sánchez C, López-Collazo E, Díez J. Effect of cold preservation on chronic rejection in a rat hindlimb transplantation model. Plast Reconstr Surg. 2016;138(3):628-37. Article. IF: 3.784; Q1

• Rackov G, Hernández-Jiménez E, Shokri R, Carmona-Rodríguez L, Manes S, Álvarez-Mon M, López-Collazo E, Martínez C, Balomenos D. p21 mediates macrophage reprogramming through regulation of p50-p50 NF-kappa B and IFN-beta. J Clin Invest. 2016;126(8):3089-103. Article. IF: 12.784; D1

• Contreras-Jurado C, Alonso-Merino E, Saiz-Ladera C,Valino AJ, Regadera J, Alemany S, Aranda A. The thyroid hormone receptors inhibit hepatic interleukin-6 signaling suring endotoxemia. SCI Rep-Uk. 2016;6:30990. Article. IF: 4.259; Q1

• Rudnicki M, Tripodi GL, Ferrer R, Boscá L, Pitta MGR, Pitta IR, Abdalla DSP. New thiazolidinediones affect endothelial cell activation and angiogenesis. Eur J Pharmacol. 2016;782:98-106. Article. IF: 2.896; Q2

• Cubillos-Zapata C, Avendaño-Ortiz J, Córdoba R, Hernández-Jiménez E, Toledano V, de Diego RP, López-Collazo E. Ibrutinib as an antitumor immunomodulator in patients with refractory chronic lymphocytic leukemia. Oncoimmunology. 2016;5(12):e1242544. Article. IF: 7.719; D1

• Silva JC, César FA, de Oliveira EM, Turato WM, Tripodi GL, Castilho G, Machado-Lima A, de las Heras B, Boscá L, Rabello MM, Hernándes MZ, Pitta MGR, Pitta IR, Passarelli M, Rudnicki M, Abdalla DSP. New PPAR gamma partial agonist improves obesity-induced metabolic alterations and atherosclerosis in LDLr-/mice. Pharmacol Res. 2016;104:49-60. Article. IF: 4.48; Q1

• Cubillos-Zapata C, Córdoba R, Avendaño-Ortiz J, Arribas-Jiménez C, Hernández-Jiménez E, Toledano V, Villaescusa T, Moreno V, López-Collazo E. CC-122 immunomodulatory effects in refractory patients with diffuse large B-cell lymphoma. Oncoimmunology. 2016;5(12):e1231290. Article. IF: 7.719; D1 • Fernández-Escobar M, Baldanta S, Reyburn H, Guerra S. Use of functional genomics to understand replication deficient poxvirus-host interactions. Virus Res. 2016;216:1-15. Article. IF: 2.628; Q3

162

blasts is BCL10 independent. Clin Immunol. 2016;163:120-2. Letter. IF: 3.99; Q2

• Singh P, González-Ramos S, Mojena M, Rosales-Mendoza CE, Emami H, Swanson J, Morss A, Fayad ZA, Rudd JHF, Gelfand J, Paz-García M, Martín-Sanz P, Boscá L, Tawakol A. GM-CSF enhances macrophage glycolytic activity in vitro and improves detection of inflammation in vivo. J Nucl Med. 2016;57(9):1428-35. Article. IF: 6.646; D1

• Fernández-Escobar M, Nájera JL, Baldanta S, Rodríguez D, Way M, Esteban M, Guerra S. Suppression of NYVAC infection in HeLa cells requires Rnase l but is independent of protein kinase R activity. J Virol. 2016;90(4):2135-41. Article. IF: 4.663; Q1

• Villar-Lorenzo A, Ardiles AE, Arroba AI, Hernández-Jiménez E, Pardo V, López-Collazo E, Jiménez IA, Bazzocchi IL, GonzálezRodríguez A, Valverde AM. Friedelane-type triterpenoids as selective anti-inflammatory agents by regulation of differential signaling pathways in LPS-stimulated macrophages. Toxicol Appl Pharm. 2016;313:57-67. Article. IF: 3.791; Q1

• García-Gómez S, Doforno RA, Martínez-Barricarte R, Torres JM, Cerdán AF, Dávila M, Hernández-Jiménez E, Toledano V, Cubillos-Zapata C, Vallejo-Cremades MT, López-Collazo E, Arquero MF, Sánchez-Ramón S, Casanova JL, de Diego RP. Actin polymerisation after FC gamma R stimulation of human fibro-

• Villarroya-Beltri C, Baixauli F, Mittelbrunn M, Fernández-Delgado I, Torralba D, Moreno-Gonzalo O, Baldanta S, Enrich C, Guerra S, Sánchez-Madrid F. ISGylation controls exosome secretion by promoting lysosomal degradation of MVB proteins. Nat Commun. 2016;7:13588. Article. IF: 12.124; D1

PUBLIC PROJECTS Fernández Velasco M. Contratos (CD12/00542). ISCIII. 2013-2016. Management centre: FIBHULP

Sara

Borrell

Ferández Velasco M. NLR-NOD1 contribution to diabetic cardiomyopathy (CP11/00197). ISCIII. 2012-2016. Management centre: FIBHULP Fernández Velasco M. Implicación de los receptores NOD1 en el desarrollo de la insuficiencia cardiaca (PI14/01078). ISCIII. 2015-2017. Management centre: FIBHULP Fernández Velasco M. Contrato Miguel Servet tipo I (MS11/00197). ISCIII. 2012-2016. Management centre: FIBHULP Hernández Jiménez E. Contrato (FI12/00284). ISCIII. 2012-2016. Management centre: FIBHULP

predoctoral

López Collazo EM. Tolerancia a endotoxinas: ¿Una puerta hacia el tratamiento eficaz de la sepsis? (PI14/01234). ISCIII. 2015-2017. Management centre: FIBHULP López Collazo EM. The risk of infections in severalpathologies: a thorough study with clinical tools development for personalised medicine (PIE15/00065). ISCIII. 20162018. Management centre: FIBHULP López Collazo EM. Contrato de estabilización Miguel Servet (I2). ISCIII, CAM. 2009-Ongoing. Management centre: FIBHULP Pérez de Diego R. Respuesta inmune celular y humoral de la enfermedad inflamatoria intestinal. Papel de los patrones moleculares asociados a patógenos en la etiología y evolución clínica (PI14/00616). ISCIII. 2015-2017. Management centre: FIBHULP Pérez de Diego R. Contrato Ramón y Cajal (RyC 201107597). MINECO. 2011-2017. Management centre: FIBHULP Pérez Martínez A. Infusión de células natural killer activadas y expandidas en combinación con quimioterapia en pacientes pediátricos con leucemia/linfoma T refractaria (EC11-057). MSSSI. 2013-2016. Management centre: FIBHULP Pérez Martínez A. Diseño del receptor antigénico quimérico NKG2D (CAR-NKG2D) como terapia celular en los sarcomas infantiles (PI15/00973). ISCIII. 2016-2018. Management centre: FIBHULP Toledano Real VM. Contrato PTA (PTA2013-8265-I). MINECO. 2015-2018. Management centre: FIBHULP

PRIVATE PROJECTS Cantero Cid R. Cultivo y estudio de células troncales (STEM) de adenocarcinoma de recto humano pre y post-

tratamiento con radiobioquimioterapia. Usos potenciales en terapia oncológica. Fundación Mutua Madrileña. 2014-Ongoing. Management centre: FIBHULP Cantero Cid R. Premio por la publicación del artículo: Negative pressure therapy to reduce risk of wound infection following diverting loop ileostomy reversal. An initial study. KCI UK Holdings Limited. 2016-Ongoing. Management centre: FIBHULP Gómez Ruiz S. Phosphorus-rich early transition metal and rare earth metal complexes as precursors for metal phosphides. DAAD-Fundación Universidad. 2014-Ongoing. Management centre: URJC López Collazo EM. Estudio del sistema inmune infiltrado en el cáncer de pulmón y búsqueda de marcadores pronósticos en células circulantes de pacientes que sufren esta enfermedad. Encinar. 2014-Ongoing. Management centre: FIBHULP López Collazo EM. Programa específico de investigación para la obtención y validación de un método de muestreo (Screening) masivo para descartar el dopaje en el deporte. Fundación Hospital de Madrid. 2013-Ongoing. Management centre: FIBHULP López Collazo EM. Transplantation (SOT & HSCT) in children transchild. FIBHULP. 2016-Ongoing. Management centre: FIBHULP Perez de Diego R. Medicina de precisión en inmunodeficiencias primarias: desentrañando nuevas etiologías genéticas mediante aproximaciones “ómicas”. Fundación Mutua Madrileña. 2015-Ongoing. Management centre: FIBHULP Pérez Martínez A. Infusión de células natual killer como tratamiento de consolidación en niños y adolescentes con leucemia mieloblástica aguda. Fundación Mutua Madrileña. 2015-Ongoing. Management centre: FIBHULP Pérez Martínez A. Inmunoterapia con células natural killer en el cancer infantil. Fundación Cris contra el Cáncer. 2015-Ongoing. Management centre: FIBHULP Pérez Martínez A. Inmunoterapia en sarcomas: combinación del anticuerpo antiCXCR4 y la terapia celular NK. Fundación la Sonrisa de Alex. 2016-Ongoing. Management centre: FIBHULP Pérez Martínez A. NK cell team-2: inmunoterapia con células natural killer en el niño. Fundación Cris contra el Cáncer. 2014-Ongoing. Management centre: FIBHULP Pérez Martínez A. Optimización de la terapia celular NK en sarcomas pediátricos mediante el uso nanopartículas multifuncionalizadas. PI-1567. Fundación Cris contra el Cáncer. 2013-Ongoing. Management centre: FIBHULP Pérez Martínez A. Terapia celular basada en el receptor

Continue

163

3.3 Infectious Diseases and Immunity Area

3 INFORMATION GROUPS BY AREA quimérico NKG2D (CAR-NKG2D) para la leucemia infantil. Fundación Uno entre Cien Mil. 2015-Ongoing. Management centre: FIBHULP Pérez Martínez A. Terapia celular con el receptor antigénico quimérico NKG2D(CAR-NKG2D) para los tumores sólidos infantiles. Fundación Asociación Española contra el Cáncer. 2016-Ongoing. Management centre: FIBHULP Pérez Martínez A. Unidad de Investigación y de terapias avanzadas en Hematooncología infantil. Fundación Cris contra el Cáncer. 2016-Ongoing. Management centre: FIBHULP

INTERNATIONAL PROJECTS López Collazo EM, Belda Iniesta C. Massive screening methodology to discard doping. COI. 2015-Ongoing. Management centre: COE.

CLINICAL TRIALS

y adolescentes con leucemia mieloblástica aguda. Pérez Martínez A. HULP Code: 4489. Sponsored´s Protocol Code: NKCELL_ LMA_2015. Signature Date: 20/04/2016 Pérez Martínez A. Estudio aleatorizado, abierto, de seguridad y eficacia de ibrutinib en pacientes pediátricos y adultos jóvenes con linfoma No Hodgkin de células maduras B en recaída o refractario. Janssen Cilag International NV. HULP Code: 4644. Sponsored´s Protocol Code: 54179060LYM3003. Signature Date: 18/10/2016

PATENTS AND TRADEMARKS Llamas Matías MA, López-Collazo E, inventors; FIBHULP, Llamas Matías MA, Empireo S.L., assignees. Method for determine the risk of developing an infectious disease. P201330768, PCT/ES2014/070434, EP3006570; 2013 May 27.

DIAGNOSIS AND TREATMENT OF DISEASES ASSOCIATED WITH ABNORMALITIES GROUP 7 17.655 0

Pérez Martínez A. Infusión de células natural killer como tratamiento de consolidación en niños

Margarita López Trascasa Jefa de Sección en Inmunología. HULP Profesor Asociado de la Facultad de Medicina. UAM Pilar Sánchez-Corral Gómez Investigadora Senior (Contrato Miguel Servet - I3SNS). Jefa de Laboratorio. HULP Fernando Corvillo Rodríguez Investigador Predoctoral. HULP Sofía Garrido Herrero Técnico de Laboratorio. HULP Alberto López Lera Investigador Postdoctoral. Contratado CIBERER. HULP Marta Melgosa Hijosa Facultativo Especialista de Área en Nefrología Infantil. HULP Rocío Mena de la Cruz Responsable de Laboratorio de Secuenciación. HULP Pilar Nozal Aranda Investigadora Predoctoral. HULP Antonia Peña Carrión Facultativo Especialista de Área en Nefrología Infantil. HULP

Strategic Objective This is a national reference group for the study of primary or acquired defects in the complement system. The main aim is to gain an understanding of the molecular mechanisms underlying in complement deficiency or dysregulation in several human diseases, the majority of which are classified as rare diseases. In this context, the group implements and applies various methodological strategies (immunological, biochemical, proteomic and genetic) to detect clinically relevant deficiencies or functional defects in complement 164

Return to INFECTIOUS DISEASES AND IMMUNITY AREA INDEX

components. By following a clearly translational approach, the group also develops new diagnostic tests which are implemented in the clinical practice, especially for treatment adjustment and patient follow-up. The research lines could be classified as: screening and characterization of genetic or acquired complement defects that cause renal pathology (I), functional and molecular diagnosis of deficiencies affecting individual components of the complement system (II), diagnosis and molecular studies in Hereditary Angioedema and screening for disease modifying genes (III).

Research Lines • Screening and characterization of genetic and acquired Complement defects in renal disease. • Biochemical and molecular diagnosis of isolated Complement deficiencies. • Screening and molecular characterization of diseasemodifying genes in Hereditary Angioedema. • Genetic and immunological mechanisms associated with Complement dysregulation in partial lipodistrophy.

Research Activity DOCTORAL THESES Bernabéu Herrero ME. Defects in complement factor H-related proteins (FHRs) in renal pathology[dissertation]. Madrid: UAM: 2016 (09/09/2016). Director: Sánchez-Corral Gómez P. European Mention

Continue

165

3.3 Infectious Diseases and Immunity Area

3 INFORMATION GROUPS BY AREA Nozal Aranda P. Autoantibodies against proteins of the alternative complement pathway in renal diseases [dissertation]. Madrid: UAM: 2016(13/09/2016). Director: López Trascasa M.

López Trascasa M. Nuevos biomarcadores en enfermedades mediadas por el sistema del complemento (PI15/00255). MINECO. 2016-2018. Management centre: FIBHULP

PUBLICATIONS

Sánchez-Corral Gómez P. Línea de incorporación estable de investigadores (I3). ISCIII, CAM. 2008-Ongoing. Management centre: FIBHULP

• Blom AM, Corvillo F, Magda M, Stasilojc G, Nozal P, Pérez-Valdivia MA, Cabello-Chaves V, de Córdoba SR, López-Trascasa M, Okroj M.Testing the activity of complement convertases in serum/plasma for diagnosis of C4NeF-Mediated C3 glomerulonephritis. J Clin Immunol. 2016;36(5):517-27. Article. IF: 3.253; Q2 • Corvillo F, García-Morato MB, Nozal P, Garrido S, Tortajada A, de Córdoba SR, López-Trascasa M. Serum properdin consumption as a biomarker of C5 convertase dysregulation in C3 glomerulopathy. Clin Exp Immunol. 2016;184(1):118-25. Article. IF: 3.41; Q2

Sánchez-Corral Gómez P. Diagnóstico, caracterización y relevancia clínica de defectos en la familia factor H/ CFHRS del complemento en patología renal (PI12/00597). ISCIII. 2013-2017. Management centre: FIBHULP

• García-Morato MB, Padilla-Merlano B, Nozal P, Espino M, Juárez C, Villar LM, López-Trascasa M. Laboratory guidelines for the diagnosis and follow-up of patients with monoclonal gammopathies. Rev Clin Esp. 2016;216(3):128-34. Article. IF: 0.971; Q3

Sánchez-Corral Gómez P. Mecanismos patogénicos en enfermedades raras y comunes asociadas con desregulación del complemento (CIBERer-ER16P1AC754). ISCIII. 2016-2016. Management centre: CIB-CSIC

• Nozal P, Bernabéu-Herrero ME, Uzonyi B, Szilagyi A, Hyvarinen S, Prohaszka Z, Jokiranta TS, Sánchez-Corral P, López-Trascasa M, Jozsi M. Heterogeneity but individual constancy of epitopes isotypes and avidity of factor H autoantibodies in atypical hemolytic uremic syndrome. Mol Immunol. 2016;70:47-55. Article. IF: 3.326; Q2

Sánchez-Corral Gómez P. Nefropatías asociadas con desregulación del complemento: estudio de factores de riesgo y evolución mediante proteómica traslacional (PI16/00723). ISCIII. 2017-2019. Management centre: FIBHULP

• Nozal P, López-Trascasa M. Autoantibodies against alternative complement pathway proteins in renal pathologies. Nefrología. 2016;36(5):489-95. Review. IF: 1.183; Q4

PRIVATE PROJECTS

• Pedrosa M, Phillips-Angles E, López-Lera A, López-Trascasa M, Caballero T. Complement study versus CINH gene testing for the diagnosis of type I hereditary angioedema in children. J Clin Immunol. 2016;36(1):16-8. Letter. IF: 3.253; Q2 • Tenorio J, Romanelli V, Martín-Trujillo A, Fernández GM, Segovia M, Perandones C, Jurado LAP, Esteller M, Fraga M, Arias P, Gordo G, Dapia I, Mena R, Palomares M, de Nanclares GP, Nevado J, García-Miñaur S, Santos-Simarro F, Martínez-Glez V, Vallespín E, Monk D, Lapunzina P. Clinical and molecular analyses of Beckwith-Wiedemann syndrome: Comparison between spontaneous conception and assisted reproduction techniques. Am J Med Genet A. 2016;170(10):2740-9. Article. IF: 2.259; Q3

PUBLIC PROJECTS López Trascasa M. Networked Biomedical Research Center for Rare Diseases (CIBERer). ISCIII. 2010-2016. Management centre: FIBHULP

López Trascasa M. Complementest. Déficits y alteraciones del sistema del complemento en patología humana. Secugen S.L. 2011-Ongoing. Management centre: FIBHULP López Trascasa M. Estudio de las bases moleculares del síndrome hemolítico urémico atípico y creación de un Registro Español de SHU-atípico. Secugen S.L. 2011-Ongoing. Management centre: FIBHULP

PATENTS AND TRADEMARKS López Trascasa M, authors; FIBHULP, assignee. Brand name: COMPLEMENTest. CM 009.658.791; 2011, January 14.

López Trascasa M. Implicaciones del Sistema del Complemento en la patología humana (SAF2012-38636). MINECO. 2013-2016. Management centre: FIBHULP

166

Return to INFECTIOUS DISEASES AND IMMUNITY AREA INDEX

LYMPHOCYTE PATHOPHYSIOLOGY IN IMMUNODEFICIENCIES GROUP

11 41.919 3

Eduardo López Granados Coordinador de Inmunología. HULP Rita Francisca Álvarez Doforno Facultativo Especialista de Área en Inmunología. HULP Francisco Javier Alves Ferreira Facultativo Especialista de Área en Anatomía Patológica. HULP Lucía del Pino Molina Investigadora Predoctoral. HULP Antonio Ferreira Cerdán Facultativo Especialista de Área en Inmunología. HULP María Cruz García Rodríguez Facultativo Especialista de Área en Inmunología. HULP Julia Leal de la Rosa Facultativo Especialista de Área en Pediatría General. HULP Montserrat Lozano Doncel Técnico de Laboratorio. HULP Diego Plaza López de Sabando Facultativo Especialista de Área en Hemato-Oncología Pediátrica. HULP Ángel Julián Robles Marhuenda Facultativo Especialista de Área en Medicina Interna. HULP Rebeca Rodríguez Pena Facultativo Especialista de Área en Inmunología. HULP María Carmen Salcedo Moreno Técnico de Laboratorio. HULP Ana Sastre Urguelles Facultativo Especialista de Área en Hemato-Oncología Pediátrica. HULP Esther Tato Gutiérrez Técnico de Laboratorio. HULP Juan Manuel Torres Canizales Médico Interno Residente en Inmunología. HULP

Strategic Objective Defective molecular events driving the differentiation, activation and homeostasis of lymphocytes underline the pathophysiology of numerous immunological and haematological diseases. In primary immunodeficiencies (PIDs), intrinsic impairments of immune cells lead to infection and, in some cases, autoimmunity and cancer. Common variable immunodeficiency disorders (CVIDs) are the most frequent but least understood types of PID and are a major focus of our research. Our group attempts to unravel the molecular basis for functional defects of lymphocytes in several PIDs as well as the basis for autoimmune and lymphoproliferative complications. We take a multidisciplinary clinical, anatomic, genetic, epigenetic and functional approach. By correlating clinical and experimental data, we aim to achieve a better understanding of the syndromes and lay the groundwork for new, more effective treatments. We have recently been concentrating our efforts on understanding differentiation and survival cell signalling pathways and the control of gene transcription in B cells from affected individuals.The B cell receptor (BCR), the TNF-R family members and the Toll-like receptors (TLRs) are fundamental to the synergistic action of B cell function. It is increasingly evident that innate and adaptive pathways intersect and reinforce each other and that TLRs play a fundamental role in this relationship. Methodological and conceptual approaches applied to the study of PIDs can be applied to monitoring

Continue

167

3.3 Infectious Diseases and Immunity Area

3 INFORMATION GROUPS BY AREA more prevalent secondary immunodeficiency states such as immunological reconstitution in haematopoietic stem cell transplantation (HSCT), acute viral infection, and use of immunosuppressive treatments in transplantation and autoimmunity. We validate new biological markers and assays for a patient-based rather than a disease-based therapeutic approach in the latest clinical scenarios, to facilitate clinical decisions and to maximise the clinical efficiency and safety of treatments.

Research Lines • The study of the anatomical, genetic, epigenetic and biochemical bases for lymphoid function deficiency in immunodeficiencies of antibody formation and their autoimmune and lymphoproliferative complications. • Role of Toll Like Receptors (TLRs) and signalling pathways in lymphoid maturation and immune response to infection in primary immunodeficiencies. • Identification of new biomarkers for lymphoid function for monitoring in states of immunodeficiency secondary to: acute viral infection, immune reconstitution after transplantation of haematopoietic progenitors and use of immunosuppressive therapies in transplantation, autoimmunity and chronic inflammation.

Research Activity PUBLICATIONS • Bautista F, Gallego S, Cañete A, Mora J, Heredia CD, Cruz O, Fernández JM, Rives S, Madero L, Castel V, Cela ME, Ramírez G, Sábado C, Acha T, Astigarraga I, Sastre A, Muñoz A, Guibelalde M, Moreno L. Landscape of early clinical trials for childhood and adolescence cancer in Spain. Clin Transl Oncol. 2016;18(7):70813. Article. IF: 2.353; Q3 • Calvo C, Gallardo P, Torija P, Bellón S, Méndez-Echeverría A, del Rosal T, Baquero-Artigao F, Sainz T, Romero M, Cabrerizo M. Enterovirus neurological disease and bacterial coinfection in very young infants with fever. J Clin Virol. 2016;85:37-9. Article. IF: 3.051; Q2 • Gallego-Bustos F, Gotea V, Ramos-Amador JT, Rodríguez-Peña R, Gil-Herrera J, Sastre A, Delmiro A, Rai G, Elnitski L, GonzálezGranado LI, Allende LM. A Case of IL-7R deficiency caused by a novel synonymous mutation and implications for mutation screening in SCID diagnosis. Front Immunol. 2016;7:443. Article. IF: 6.429; Q1 • García-Gómez S, Doforno RA, Martínez-Barricarte R, Torres JM, Cerdán AF, Dávila M, Hernández-Jiménez E,Toledano V, CubillosZapata C, Vallejo-Cremades MT, López-Collazo E, Arquero MF, Sánchez-Ramón S, Casanova JL, de Diego RP. Actin polymerisation after FC gamma R stimulation of human fibroblasts is BCL10 independent. Clin Immunol. 2016;163:120-2. Letter. IF: 3.99; Q2 • González B, Bueno D, Rubio PM, Román SS, Plaza D, Sastre A, García-Miguel P, Fernández L, Valentín J, Martínez I, Pérez-Martínez A. An immunological approach to acute myeloid leukaemia. An Pediatr. 2016;84(4):195-202. Article. IF: 1.14; Q3 • Iparraguirre L, Gutiérrez-Camino A, Umérez M, Martín-Guerre-

168

ro I, Astigarraga I, Navajas A, Sastre A, de Andoin NG, GarcíaOrad A. MiR-pharmacogenetics of methotrexate in childhood B-cell acute lymphoblastic leukemia. Pharmacogenet Genom. 2016;26(11):517-25. Article. IF: 2.184; Q2 • López-Rodríguez M, Herrera-Ramos E, Sole-Violán J, Ruiz-Hernández JJ, Borderías L, Horcajada JP, Lerma-Chippirraz E, Rajas O, Briones M, Pérez-González MC, García-Bello MA, López-Granados E, de Castro FR, Rodríguez-Gallego C. IFITM3 and severe influenza virus infection. No evidence of genetic association. Eur J Clin Microbiol. 2016;35(11):1811-7. Article. IF: 2.727; Q2 • Méndez-Echevarría A, del Rosal T, Pérez-Costa E, RodríguezPeña R, Zarauza A, Ferreira-Cerdán A, Bravo M, Mellado MJ, López-Granados E. Clinical features before hematopoietic stem cell transplantation or enzyme replacement therapy of children with combined immunodeficiency. Pediatr Infect Dis J. 2016;35(7):794-8. Article. IF: 2.486; Q1 • Robles-Marhuenda A, Romero-Gómez MP, García-Rodríguez J, Arnalich-Fernández F. Native valve endocarditis caused by Kocuria kristinae. Enferm Infec Micr Cl. 2016;34(7):464-5. Letter. IF: 1.714; Q3 • Ruiz-Pinto S, Pita G, Patino-García A, García-Miguel P, Alonso J, Pérez-Martínez A, Sastre A, Gómez-Mariano G, Lissat A, Scotlandi K, Serra M, Ladenstein R, Lapouble E, Pierron G, Kontny U, Picci P, Kovar H, Delattre O, González-Neira A. Identification of genetic variants in pharmacokinetic genes associated with Ewing Sarcoma treatment outcome. Ann Oncol. 2016;27(9):1788-93. Article. IF: 11.855; D1

López Granados E. Estudio de la respuesa antiviral T mediante ensayo de OX40 y su correlacion con la terapia inmunosupresora para una monitorizacion individualizada del niño trasplantado. Cytognos. 2015-Ongoing. Management centre: FIBHULP López Granados E. XII Reunión del Registro Español Inmunodeficiencias Primaria. CAM. 2015-Ongoing. Management centre: FIBHULP Robles Marhuenda AJ. Relevancia clínica y problemática terapéutica del síndrome de los anticuerpos antifosfolípidos. Sanofi Aventis S.A. 2006-Ongoing. Management centre: FIBHULP

CLINICAL TRIALS Méndez Echevarría AM. Estudio multicéntrico, abierto, aleatorizado, de fase II/III para determinar la seguridad y eficacia de la solitromicina en adolescentes (de 12 a 17 años de edad, ambos inclusive) y niños (> 2 meses a < 12 años de edad) con neumonía bacteriana adquirida en la comunidad sospechada o confirmada. Chiltern International Spain S.A. HULP Code: 4599. Sponsored´s Protocol Code: CE01-203. Signature Date: 13/06/2016

Robles Marhuenda AJ. Estudio aleatorizado, doble ciego (abierto para el promotor), comparativo, multicéntrico para evaluar la seguridad y la eficacia de la coadministración de belimumab (GSK1550188) subcutáneo y rituximab intravenoso en sujetos con Síndrome de Sjögren primario. Glaxosmithkline S.A. HULP Code: 4488. Sponsored´s Protocol Code: 201842. Signature Date: 02/03/2016

PATENTS AND TRADEMARKS Van Dongen JJM, Orfao de Matos Correia E Vale JA, Van Der Burg M, Pérez Andrés M, Van Zelm MC, Kalina T, Vlkova M, López Granados E, Blanco Álvarez E, Kienzler AK, inventors; Erasmus University Medical Center Rotterdam, assignee. Reagents, methods, and kits for diagnosing primary immunodeficiencies. PCT/NL2015/050762, US62/072,498; 2014 October 30.

• Sánchez-Ramón S, de Gracia J, García-Alonso AM, Molina JJR, Melero J, de Andrés A, de Morales JMGR, Ferreira A, Ocejo-Vinyals JG, Cid JJ, Martínez JMG, Lasheras T, Vargas ML, Gil-Herrera J, Rodríguez MCG, Castaner JL, Granado LIG, Allende LM, SolerPalacín P, Herraiz L, Hoyos ML, Bellón JM, Silva G, Gurbindo DM, Carbone J, Rodríguez-Sainz C, Matamoros N, Parker AR, Fernández-Cruz E. Multicenter study for the evaluation of the antibody response against salmonella typhi VI vaccination (EMPATHY) for the diagnosis of Anti-polysaccharide antibody production deficiency in patients with primary immunodeficiency. Clin Immunol. 2016;169:80-4. Article. IF: 3.99; Q2

PUBLIC PROJECTS López Granados E. Evaluación de protocolos avanzados de monitorización inmunológica para un mejor manejo terapéutico en trasplante de progenitores hematopoyéticos e intestinal (PI13/02296). ISCIII. 2014-2017 Management centre: FIBHULP

PRIVATE PROJECTS López Granados E. Actualización y renovación de la actividad en el Servicio de Inmunologia del Hospital Universitario La Paz. CSL Behring S.A. 2012-Ongoing. Management centre: FIBHULP López Granados E. Aplicaciones clínicas de la monitorización inmunológica avanzada en el trasplante de órgano sólido infantil. Fundación Mutua Madrileña. 2014-Ongoing. Management centre: FIBHULP López Granados E. Cáncer, fallo medular e inmunodeficiencia en niños, un esfuerzo integrado para comprender sus bases moleculares y mejorar su diagnóstico y pronóstico clínico. Fundación Asociación Española contra el Cáncer. 2014-Ongoing. Management centre: FIBHULP

Return to INFECTIOUS DISEASES AND IMMUNITY AREA INDEX

169

3.3 Infectious Diseases and Immunity Area

3 INFORMATION GROUPS BY AREA

DRUG HYPERSENSIBILITY AND INNATE IMMUNE RESPONSE GROUP 24 59.765 4 Teresa Bellón Heredia Investigadora Senior (Contrato Miguel Servet -I2). Jefe de laboratorio. HULP María del Rosario Cabañas Moreno Facultativo Especialista de Área en Alergología. HULP Francisco José de Abajo Iglesias Facultativo Especialista de Área en Farmacología. Hospital Universitario Príncipe de Asturias Profesor Titular. Facultad de Medicina. Universidad de Alcalá Jessica González Ramos Médico Interno Residente en Dermatología. HULP Victoria Lerma Hambleton Coordinadora de casos del estudio PIELenRed. Hospital Universitario Príncipe de Asturias Aranzazu Isabel Rodríguez Sanz Investigador Postdoctoral. HULP Gastón Roustan Gullón Facultativo Especialista de Área en Dermatología. Hospital Universitario Puerta de Hierro Profesor Asociado. Facultad de Medicina. UAM

Strategic Objective Cutaneous adverse drug reactions are unpredictable and represent a plethora of skin diseases with various degrees of severity. The spectrum ranges from mild to potentially fatal multisystem maladies. Those of most concern are usually referred to as severe cutaneous adverse reactions (SCARs), and include acute generalized exanthematous pustulosis (AGEP), drug reaction with eosinophilia and systemic symptoms (DRESS), also known as drug induced hypersensitivity syndrome or hypersensitivity syndrome (DIHS/HSS), Stevens-Johnson’s syndrome (SJS), and toxic epider170

se reactions to medications (DRESS, AGEP and SJS/ TEN) associated to the registry PIELenRed, and integrated in the international registry RegiSCAR. • To investigate in vitro test for drug causality assessement. • To explore the involvement of the innate immune response (in particular natural cytotoxic activity) during the development of SCARs. • Identification of biomarkers of susceptibility. • To find biomarkers for disease and response to treatments. • To explore the potential of microRNAs in SJS/TEN as biomarkers of disease and of response to treatments, as well as their relationship with pathogenic mechanisms. • To analyze the evolution of the cytotoxic response in patients with CMV replication. • Compare the innate immune response in patients with CMV replication after kidney transplant and in patients with SCARs.

mal necrolysis (TEN). Among them, SJS and TEN are the most severe clinical entities and are nowadays considered as variants of the same disease characterized by keratinocyte necrosis and epidermal detachment with the formation of subepidermal bullae. From the immunopatohogenic point of view, SCARs are T-cell mediated type IV hypersensitivity reactions. However, T cells can orchestrate different types of immune responses and this functional heterogeneity has led to a further sub-classification into type IVaIVd hypersensitivity that considers the distinct cytokine production pattern by T cell subpopulations, and emphasizes the participation of different effector cells causing inflammation and tissue damage. Current knowledge supports the active participation of cytotoxic lymphocytes in different clinical entities. Our project aims to a better understanding of the immune mechanisms underlying the etiopathogenesis of these diseases. The study is performed in the framework of the consortium PIELenRed (Plataforma interdisciplinar para el estudio de reacciones cutáneas graves en Red) integrated by researchers belonging to different hospitals in Madrid. Reactivation of latent herpesvirus has been described during the development of some of the previously mentioned clinical entities. In order to improve our understanding of the behaviour of the immune system during viral replication, collaboration has been established with the Kidney Transplant Unit (Nephrology Service, HULP). Kidney transplant recipients are being followed immediately before and after transplant in order to identify patients with active cytomegalovirus (CMV/HHV-5) replication. General objectives for the next 5 years The main objectives are: • Biobanking of samples of severe cutaneous adver-

Research Lines • Biobanking of biological samples from patients with severe cutaneous adverse reactions to medications (DRESS, AGEP and SJS/TEN). • Development and evaluation of in vtro tests for drug causality assessment. • Identification of biomarkers of susceptibility. • Involvement of NK receptors in the etiopathogenesis of Stevens-Johnson syndrome /Toxic epidermal necrolysis (SJS/TEN). • Differential analysis of the cytokine pattern involved in different SCARs (AGEP, DRESS and SJS/TEN) • Analysis of miRNAs as biomarkers of disease and response to treatments.

zález IJ, Jáuregui Presa I, Olaguibel Rivera JM, Zubeldia Ortuño JM. Tratado de Alergología. Madrid: Ergón, 2016. p.1415-50

PUBLICATIONS • Alfageme F, Cerezo E, Fernández I S, Aguilo R, Vilas-Sueiro A, Roustan G. Introduction of basic dermatologic ultrasound in undergraduate medical education. Ultrasound Int Open. 2016;2(4):E136-9. Article. Not Indexed • Arruti N,Villarreal O, Bernedo N, Audicana MT,Velasco M, Uriel O, Martínez A, Bellón T. Positive allergy study (Intradermal, Patch, and Lymphocyte Transformation Tests) in a case of isoniazid-induced DRESS. J Invest Allerg Clin. 2016;26(2):119-20. Editorial Material. IF: 3.094; Q2 • Bellón T, Lerma V, González-Valle O, Herrada CG, de Abajo FJ. Vemurafenib-induced toxic epidermal necrolysis: possible crossreactivity with other sulfonamide compounds. Brit J Dermatol. 2016;174(3):621-4. Article. IF: 4.706; D1 • Bellón T, Ramírez E, Borobia AM, Lerma V, Moreno-Hidalgo MA, Laosa O, Aramburu JA, González-Herrada C, de Abajo FJ. The HLA-B*15:02 allele in a Spanish Romani patient with carbamazepine-induced Stevens-Johnson syndrome. Pharmacogenomics. 2016;17(6):541-5. Article. IF: 2.35; Q3 • Brauer R, Douglas I, Rodríguez LAG, Downey G, Huerta C, de Abajo F, Bate A, Tepie MF, de Groot MCH, Schlienger R, Reynolds R, Smeeth L, Klungel O, Ruigómez A. Risk of acute liver injury associated with use of antibiotics. Comparative cohort and nested case-control studies using two primary care databases in Europe. Pharmacoepidem Dr S. 2016;25:29-38. Article. IF: 2.552; Q2 • Brauer R, Ruigómez A, Downey G, Bate A, Rodríguez LAG, Huerta C, Gil M, de Abajo F, Requena G, Álvarez Y, Slattery J, de Groot M, Souverein P, Hesse U, Rottenkolber M, Schmiedl S, de Vries F, Tepie MF, Schlienger R, Smeeth L, Douglas I, Reynolds R, Klungel O. Prevalence of antibiotic use: a comparison across various European health care data sources. Pharmacoepidem Dr S. 2016;25:11-20. Article. IF: 2.552; Q2 • Caballero T, Maurer M, Longhurst HJ, Aberer W, Bouillet L, Fabien V, (Cabañas R). Triggers and prodromal symptoms of angioedema attacks in patients with hereditary angioedema. J Invest Allerg Clin. 2016;26(6):383-6. Article. IF: 3.094; Q2

Research Activity

• Canabal J, Caballero T, Caminoa M, Fiandor A, Quirce S, Cabañas R. Anaphylactic shock caused by a hidden allergen in blood sausage. J Invest Allerg Clin. 2016;26(3):200-1. Editorial Material. IF: 3.094; Q2

DOCTORAL THESES

• Carrascosa R,Alfageme F, Roustan G, Suárez MD. Skin ultrasound in Kaposi sarcoma. Actas Dermosifiliogr. 2016;107(4):E19-E22. Article. Not Indexed

Rodríguez Sanz AI. Selección de posibles inhibidores de FABP4: efectos en la actividad proinflamatoria de monocitos/macrófagos y en las interacciones macrófago-adipocito [dissertation]. Madrid: UAM: 2016(28/10/2016). Directors: Bellón Heredia T, Selgas Gutiérrez R

BOOKS AND BOOK CHAPTERS Cabañas Moreno R. Fisiopatología y genética del angioedema. In: Caballero Molina T, Cabañas Moreno R. Angioedema. Madrid: Comunicación y Ediciones Sanitarias S.L., 2016. p.27-52 Cabañas Moreno R. Angioedema histaminérgico. In: Caballero Molina T, Cabañas Moreno R.Angioedema. Madrid: Comunicación y Ediciones Sanitarias S.L., 2016. p.53-72 Cabañas Moreno R. Manifestaciones clínicas por órganos y sistemas de las reacciones de hipersensibilidad inducidas por fármacos. Reacciones cutáneas graves. In: Dávila Gon-

• González-Ramos J, Noguera-Morel L, Tong HY, Ramírez E, RuizBravo E, Bellón T, Cabanas R, Cachafeiro L, Herranz-Pinto P. Two cases of overlap severe cutaneous adverse reactions to benznidazole treatment for asymptomatic Chagas disease in a nonendemic country. Brit J Dermatol. 2016;175(3):604-7. Article. IF: 4.706; D1 • Huerta C, Abbing-Karahagopian V, Requena G, Oliva B, Álvarez Y, Gardarsdottir H, Miret M, Schneider C, Gil M, Souverein PC, de Bruin ML, Slattery J, de Groot MCH, Hesse U, Rottenkolber M, Schmiedl S, Montero D, Bate A, Ruigómez A, García-Rodríguez LA, Johansson S, de Vries F, Schlienger RG, Reynolds RF, Klungel OH, de Abajo FJ. Exposure to benzodiazepines (anxiolytics, hypnotics and related drugs) in seven European electronic healthcare databases: a cross-national descriptive study from the PROTECT-EU Project. Pharmacoepidem Dr S. 2016;25:56-65.Article. IF: 2.552; Q2 • Ingelmo AR, Díaz ID, Moreno RC, Quesada MCM, García-Avilés C, Núñez IG, Tadeo JIM, Ballesteros RM, Ortega-Rodríguez N, Vílchez MAP, Sánchez-Morillas L, Albelda CV, Rodilla EM, Jaén

Continue

171

3.3 Infectious Diseases and Immunity Area

3 INFORMATION GROUPS BY AREA MJT. Clinical practice guidelines for diagnosis and management of hypersensitivity reactions to contrast media. J Invest Allerg Clin. 2016;26(3):144-55. Review. IF: 3.094; Q2 • Macía-Martínez MA, de Abajo FJ, Roberts G, Slattery J, Thakrar B, Wisniewski AFZ. An empirical approach to explore the relationship between measures of disproportionate reporting and relative risks from analytical studies. Drug Safety. 2016;39(1):29-43. Article. IF: 3.435; Q1 • Phillips-Angles E, González-Muñoz M, Domínguez-Ortega J, Cabañas R, Quirce S. Usefulness of basophil activation test in diagnosis of hypersensitivity to etoricoxib. J Allergy Clin Immunol Pract. 2016;4(2):350-1. Letter. IF: 5.317; Q1 • Porrino-Bustamante ML, Alfageme F, Suárez L, de Domingo MAG, Hospital M, Roustan G. High-frequency color doppler sonography of bullous pemphigoid correlation with histologic findings. J Ultras Med. 2016;35(8):1821-25. Article. IF: 1.547; Q3 • Prieto-García A, Marcos C, Caballero T. Classification of angioedema without wheals. Ann Allerg Asthma Im. 2016;116(2):177-177. Letter. IF: 3.728; Q2 • Requena G, Huerta C, Gardarsdottir H, Logie J, González-González R, Abbing-Karahagopian V, Miret M, Schneider C, Souverein PC, Webb D, Afonso A, Boudiaf N, Martín E, Oliva B, Álvarez A, de Groot MCH, Bate A, Johansson S, Schlienger R, Reynolds R, Klungel OH, de Abajo FJ. Hip/femur fractures associated with the use of benzodiazepines (anxiolytics, hypnotics and related drugs): a methodological approach to assess consistencies across databases from the PROTECT-EU project. Pharmacoepidem Dr S. 2016;25:66-78. Article. IF: 2.552; Q2 • Requena G, Logie J, Martín E, Boudiaf N, González RG, Huerta C, Álvarez A,Webb D, Bate A, Rodríguez LAG, Reynolds R, Schlienger R, Gardarsdottir H, de Groot M, Klungel OH, de Abajo F, Douglas IJ. Do case-only designs yield consistent results across design and different databases? A case study of hip fractures and benzodiazepines. Pharmacoepidem Dr S. 2016;25:79-87. Article. IF: 2.552; Q2 • Roldán FA, Fernández IS, Garza FZM, Gullon GR. Update on the use of ultrasound in vascular anomalies. Actas Dermosifiliogr. 2016;107(4):284-93. Review. Not Indexed • Sanchéz-González MJ, Barbarroja-Escudero J, Antolín-Amerigo D, Rodríguez-Rodríguez M, Pericet-Fernández L, Vélez D, BellónHeredia T, Álvarez-Mon M. Flare-up reaction in the inoculation drug sites by glatiramer acetate: First case described. Allergol Int. 2016;65(4):469-71. Letter. IF: 3.194; Q2 • Souverein PC, Abbing-Karahagopian V, Martín E, Huerta C, de Abajo F, Leufkens HGM, Candore G, Álvarez Y, Slattery J, Miret M, Requena G, Gil MJ, Groenwold RHH, Reynolds R, Schlienger RG, Logie JW, de Groot MCH, Klungel OH, van Staa TP, Egberts TCG, de Bruin ML, Gardarsdottir H. Understanding inconsistency in the results from observational pharmacoepidemiological studies: the case of antidepressant use and risk of hip/femur fractures. Pharmacoepidem Dr S. 2016;25:88-102. Article. IF: 2.552; Q2 • Urrutia S, Roustan G, Plazas MJ, Armengol S, Paz S, Lizan L. Oral alitretinoin in the treatment of sovere refractory chronic hand eczema in the Spanish National Health Systes: Description and analysis of current clinical practice. Actas Dermosifiliogr. 2016;107(2):142-8. Article. Not Indexed • Wortsman X, Alfageme F, Roustan G, Arias-Santiago S, Martorell A, Catalano O, di Santolo MS, Zarchi K, Bouer M, González C, Bard R, Mandava A, Crisan M, Crisan D, Gaitini D. Proposal for an assessment training program in dermatologic ultrasound by the DERMUS Group. J Ultras Med. 2016;35(11):2305-9. Editorial Material. IF: 1.547; Q3 • Wortsman X, Alfageme F, Roustan G, Arias-Santiago S, Martorell A, Catalano O, di Santolo MS, Zarchi K, Bouer M, González C, Bard R, Mandava A, Gaitini D. Guidelines for performing derma-

tologic ultrasound examinations by the DERMUS Group. J Ultras Med. 2016;35(3):577-80. Article. IF: 1.547; Q3

PUBLIC PROJECTS Bellón Heredia T. Lesiones cutáneas graves asociadas a medicamentos. Mantenimiento de un biobanco de muestras e identificación de posibles marcadores biológicos: análisis de microRNAs como biomarcadores de enfermedad (PI13/01768). ISCIII. 2014-2017. Management centre: FIBHULP Bellón Heredia T. Contrato de Estabilización Miguel Servet (I2). ISCIII. 2007-Ongoing. Management centre: FIBHULP

PRIVATE PROJECTS Bellón Heredia T. Enfermedad por CMV después del transplante renal. Importancia de la monitorización inmunológica: respuesta específica t CD8 y expresión de CD94/NKG2C en relación con el rechazo. Roche Farma. 2010-Ongoing. Management centre: FIBHULP Bellón Heredia T. Reacciones de hipersensibilidad cutánea graves asociadas a medicamentos: biobanco de muestras biológicas asociadas a un registro de casos para el estudio de los determinantes y mecanismos biológicos y realización del test de transformación linfocitaria. Fundación para la Investigación Biomédica del Hospital Universitario Principe de Asturias. 2014-Ongoing. Management centre: FIBHULP Bellón Heredia T. Formación en la investigación. SYF Galenus Center S.L. 2015-Ongoing. Management centre: FIBHULP de Abajo Iglesias FJ. Cáncer colorrectal y medicamentos: estudio de casos y controles en la base de datos BiFAP. Instituto Teófilo Hernando. 2014-2017. Management centre: FIB-HUPA de Abajo Iglesias FJ. Convenios de colaboración Registro poblacional de trastornos cutáneos graves asociados a medicamentos. Agenca Española de Medicamentos y Productos Sanitarios. 2015-2016. Management centre: FIB-HUPA

PATENTS AND TRADEMARKS Selgas Gutiérrez R, Bellón Heredia T, Rodríguez Sanz AI, Álvarez Builla J, Vaquero López JJ, Sánchez Alonso P, Alajarín Fernández R, inventors; FIBHULP, Universidad de Alcalá, assignees. Use of compounds derived from salts of pyridazine[1’,6’:1,2]pyrido[3,4-b]indolinium as antiinflammatory agents. P201331143, PCT/ES2014/070603; 2013 July 25. Selgas Gutiérrez R, Bellón Heredia T, Rodríguez Sanz AI, Álvarez Builla J, Vaquero López JJ, Sánchez Alonso P, Alajarín Fernández R, inventors; FIBHULP, Universidad de Alcalá, assignees. Use of compounds derived from salts of piridazine[3,2-b]benzimidazolium as anti-inflammatory agents. P201430411, PCT/ES2014/070603; 2013 July 25.

PEDIATRIC RESPIRATORY, SYSTEMIC AND NEUROLOGICAL INFECTIONS & HOST GROUP*

Cristina Calvo Rey Jefe de Sección del Servicio de Pediatría Hospitalaria, Enfermedades Infecciosas y Tropicales. HULP María Rosa Albañil Ballesteros Pediatra Titular. Centro de Salud de Cuzco. Atención Primaria María Mercedes Bueno Campaña Facultativo Especialista de Área en Pediatría. Hospital Fundación de Alcorcón María Cabrerizo Sanz Investigador titular. ISCIII Ana María Calderón Reyón Ayudante de Investigación. ISCIII Inmaculada Casas Flechas Cientifico Titular de OPIs. ISCIII Teresa del Rosal Rabes Médico Adjunto de Pediatría Hospitalaria y Enfermedades Infecciosas y Tropicales. HULP María Luz García  García Jefe de Servicio de Pediatría. Hospital Universitario Severo Ochoa Mónica González Esguevillas Ayudante de Investigación. Centro Nacional de Microbiología. ISCIII María de la Montaña Iglesias Caballero Titulado Superior ATP. Centro Nacional de Microbiología. ISCIII Ana María Méndez Echevarría Facultativo Especialista de Área en Pediatría General. HULP Mar Molinero Calamita Colaboradora I+D+I.Centro Nacional de Microbiología. ISCIII Almudena Otero Sánchez Centro Nacional de Microbiología. ISCIII Juan Francisco Pozo Sánchez Investigador Titular de OPIs. Unidad de Virus Respiratorios y Gripe. ISCIII

Strategic Objective Infectious diseases are the most frequent pathology in childhood. Our group is focused in the study of paediatric infections with special attention to those associated to viruses. The acute respiratory infections (ARIs) of lower respiratory tract are the most frequent infectious diseases in humans and these suppose at least 4 million of deaths yearly in the world. A high proportion of these infections are related with viral aetiology and particularly in children. In our country, the viral ARIs are one of the most frequent causes of hospitalization in children less than 2 years old. Using the metagenomics and applying an adapted method designed and developed for ARIs study, we will have achieve an increased knowledge of viral infections in hospitalized children of all ages, as well as in outpatients. Metagenomics could allow recognizing new viruses and also permits a deeper knowledge of traditional respiratory virus groups. Any new technological tool and its application to respiratory infection will mean an improvement in the diagnosis and monitoring of these types of infections and their immediate use is specified for resolving alerts in public health associated with respiratory viral infections is like the case of MERS-CoV, avian flu, or other influenza pandemics. We are also interested in the study of the immunological response of the infants to the viral infections, and the mechanisms that allow develop recurrent wheezing, or asthma (the most frequent chronic disease in children). Emerging viral infections have also an important role

* Group recently created: february 2017 172

Return to INFECTIOUS DISEASES AND IMMUNITY AREA INDEX

Continue

173

3.3 Infectious Diseases and Immunity Area

3 INFORMATION GROUPS BY AREA in the pathology in childhood. Recently picornaviruses, mainly human parechovirus and enterovirus are causing outbreaks and several neurological infections, morbidity and mortality. They were associated with a wide range of pathologies, from febrile syndrome to respiratory, neurological or systemic diseases. In newborns, these infections can be severe, even fatal. Surveillance of these polio-like diseases is a public health concern and it is one of our group objectives. Finally, to study viral infections in high risk group of children (newborn, chronic lung diseases, immunodefiencies, oncologic patients…) is also a priority in our group.

Research Lines • Respiratory viral infections in hospitalized children. Viral metagenomic methods applied to the severe infections of the lower respiratory tract. 

• Respiratory viral infections in children in Primary Care. • Respiratory viral infections in high risk group of children (newborn, chronic lung diseases, immunodefiencies, oncologic patients…). • Applying of new technologies as echography to value risk conditions in viral infections. • Immune response of the children and interleukins profile in infants with respiratory viral infections and correlation with the development of recurrent wheezing in the first years of life. • Detection and characterization of enterovirus (EV) and parechovirus (PeV) systemic and neurological infections in children.  • Neurological development in children with EV and PeV infections.

PEDIATRIC SYSTEMIC INFECTIONS; HIV, TUBERCULOSIS, IMPORTED AND EMERGENT GROUP*

• Kawasaki disease.

María José Mellado Peña Jefe de Servicio. HULP Fernando Baquero Artigao Facultativo Especialista de Área de Pediatría. HULP Profesor asociado. UAM Francisco José Climent Alcalá Facultativo Especialista de Área en Pediatría. Unidad de Patología Compleja. HULP Colaborador docente. UAM Luis Escosa García Facultativo Especialista de Área de Pediatría. HULP Marta García Fernández de Villalta Facultativo Especialista de Área en Pediatría. HULP Colaborador Clínico Docente. UAM María Milagros García López de Hortelano Médico Adjunto de Pediatría Hospitalaria y Enfermedades Infecciosas y Tropicales. HULP Roi Piñeiro Pérez Jefe Asociado del Servicio de Pediatría. Hospital General de Villalba Talía Sainz Acosta Facultativo Especialista de Área en Pediatría. HULP Profesor colaborador. UCM

Strategic Objective • Vertically acquired HIV infection in children: Comorbidities, biomarkers, HIV reservoir, new therapeutic approaches. • Epidemiology of Paediatric Tuberculosis is Spain: molecular epidemiology of drug resistant strains, new diagnostic tools and new drugs for TB: Pharmacodynamics in children and TB-drugs Off-label use in paediatrics.

• Congenital infections: burden of disease, prompt diagnosis and in-utero and postnatal management, host immune response. • Epidemiology of imported and emergent diseases in children: Identification and management of emergent outbreaks. Immuno-pathogenesis, preventive measures and management. • Immunization strategies in children: immune response in high risk patient’s vaccine effectiveness and barriers.

Research Lines • Vertically acquired HIV infection in children - Immuno-pathogenesis: Immune-activation, inflammation and biomarkers. - Epidemiology, immuno-virological factors. - Comorbidities, long term follow-up, cardiovascular risk, bone disorders, metabolic abnormalities, neurocognitive impairment, renal dysfunction. - Antiretroviral treatment: new drugs, resistances, dosage, toxicity in children, simplification strategies. - HIV eradication: barriers, HIV reservoir, new antiretroviral drugs and other strategies to achieve HIV replication control. - Gut Microbiota and bacterial traslocation intestinal as modulating factors for inflammation and immune-activation in HIV-infected  children. - Transition to adult care: barriers, strategies to maintain adherence to care.

* Group recently created: february 2017 174

Return to INFECTIOUS DISEASES AND IMMUNITY AREA INDEX

Continue

175

3 INFORMATION GROUPS BY AREA

3.3 Infectious Diseases and Immunity Area

• Epidemiology of paediatric Tuberculosis (TB). - Epidemiology of paediatric TB. Paediatric cases as as a sentinel for burden of diseases.

• Epidemiology of imported and emergent diseases in children

- Molecular epidemiology of paediatric TB: resistant strains.

- Paediatric International Outbreaks: Epidemiology and public health impact:  Zika. Rabies. Dengue. Chikungunya. Haemorragic fevers, Mers-co.

- Immuno-pathogenesis: New diagnostic tools in special Populations: HIV-infected, ID patients, migrants and Internationally adopted childre

- Imported diseases in Spain: epidemiology and special populations: adopted, migrant, refugees, travelers and ID children.

- Management of critical situations. Neonatal TB, multidrug resistant and extra-pulmonary TB.

• Immunization strategies in children, including high risk patients

- New fixed-dosed combinations. Off label drugs in children. Pharmacodinamic and pharmacokinetic.

- Immunization and vaccine response in special populations: immunocompromised children, transplant recipients, chronic patients, HIV-infected, migrants.

• Congenital infectious diseases - Congenital Citomegalovirus and Toxoplasma infections: diagnostic barriers, prognostic factors, new therapeutic approaches.  - CHAGAS disease and congenital TB: diagnostic barriers, prognostic factors, pharmacokinetics in newborns and new drugs.

- Vaccine immunogenicity: barriers in paediatric populations.

TRANSLATIONAL RESEARCH IN PEDIATRIC ONCOLOGY, HEMATOPOIETIC GROUP*

Antonio Pérez Martínez Facultativo Especialista de Área en Pediatría, Oncología Hematología. HULP David Bueno Sánchez Facultativo Especialista de Área en Pediatría, Oncología Hematología. HULP Pilar Carrasco Salas Diagnóstico Molecular. HULP Adela Escudero López Investigadora Postdoctoral. HULP Berta González Martínez Facultativo Especialista de Área en Pediatría. HULP Pablo González Navarro Técnico en Laboratorio. HULP Irene González Magro Investigador Predoctoral. HULP  Pedro María Rubio Aparicio Facultativo Especialista de Área en Pediatría, Oncología Hematología. HULP Sonsoles San Román Pacheco Facultativo Especialista de Área en Pediatría, Oncología Hematología. HULP Jaime Valentín Quiroga Investigador Predoctoral. HULP  María Vela Cuenca Investigador Postdoctoral. HULP 

y

y

through the susceptibility of tumor cells to Natural Killer cells; and the optimization of hematopoietic stem cells transplantation.

Research Lines • Analysis of solid / hematological tumors samples to determine their susceptibility to cell therapy, at functional, protein expression and genetic level. • Cell therapy with activated NK cells in childhood cancer. • Hematopoietic progenitor transplantation as a platform for cell therapy. • Cell therapy with memory T lymphocytes as adoptive immunotherapy in transplantation of haematopoietic progenitors.

y

y

Strategic Objective Our research program focuses on the molecular and immunological characterization of childhood cancer; the development of cell therapies, primarily

• Optimization of cell therapy by the generation of an NKG2D antigenic chimeric receptor (NKG2DCAR). Evaluation of its specificity, persistence and activity (in vitro and in vivo) for the treatment of childhood cancer. • Optimization of NK cell therapy using nanotechnology and antigenic chimeric receptors (CAR). • Induction of immunological tolerance in solid organ transplantation through the induction of hematopoietic mixed chimerism by cell therapy • Development of academic clinical trials and collaborations with the pharmaceutical industry as a strategy for the development of new therapies more effective and with fewer side effects in childhood cancer.

* Group recently created: february 2017

176

Return to INFECTIOUS DISEASES AND IMMUNITY AREA INDEX

Return to INFECTIOUS DISEASES AND IMMUNITY AREA INDEX

177

3 INFORMATION GROUPS BY AREA

INTERNAL MEDICINE AND SYSTEMIC DISEASES GROUP

System 3.4 Large Pathology Area Francisco García Río

291 219 44

1,309.496 1,089.056 108

Internal Medicine and Systemic Diseases Group Organic Dysfunction and Failure in the Aggression Group Respiratory Diseases Group Regulation of Gene Expression and by Hypoxia Group Nephrology Group Neonatology Group Aging and Fragility in the Elderly Group Molecular Hepatology Group Diagnosis and Treatment of Allergic Diseases Group Gynecologic Oncology Group Patient Blood Management Group Endocrine Diseases Group Urology Group Health Care Nurses Research Group Maternal and Fetal Medicine Group Emergency and Critical Pathology Group 178

Return to INFORMATION GROUPS BY AREA INDEX

18 150.429 9 Francisco Arnalich Fernández Jefe de Servicio de Medicina Interna. HULP Catedrático. Facultad de Medicina. UAM Gema Atienza Toledo Técnico de Laboratorio. UAM Anna Bordas Sánchez Investigadora Predoctoral. UAM José Luis Cedillo Mireles Becario Predoctoral (Contrato FPU). UAM María del Carmen Fernández Capitán Jefe de Sección de Medicina Interna. HULP Profesora asociada de Medicina, UAM Carolina Martín Sánchez Becaria Predoctoral (Contrato FPI). UAM Carmen Montiel López Catedrática de Universidad. Facultad de Medicina. UAM María Angustias Quesada Simón Facultativo Especialista de Área en Medicina Interna. HULP Profesora Honoraria de Medicina. UAM Jaime Renart Pita Investigador Científico. IIB “Alberto Sols” Juan José Ríos Blanco Facultativo Especialista de Área en Medicina Interna. HULP Profesor Aociado de Medicina. UAM

Strategic Objective In the setting of the systemic response frequently found in patients attended in Internal Medicine wards, our group has studied some regulatory mechanisms of the innate immune response in patients with sepsis and other inflammatory states such as acute coronary syndromes (ACS), cystic fibrosis and cancer.

The first line of our research is the link between the parasympathetic and innate immune systems, that is the molecular mechanisms by which acetylcholine can influence the immune system via the ‘cholinergic anti-inflammatory pathway’. This pathway is mediated by the vagus nerve which releases acetylcholine to interact with the α7 subunit of the nicotinic acetylcholine receptor (α7nAChR). We firstly reported that the neuronal α7 nicotinic receptor subunit gene (CHRNA7) is partially duplicated in the human genome forming a hybrid gene (CHRFAM7A) with the novel FAM7A gene, and provided experimental data showing that dupα7 could modulate α7 receptor-mediated synaptic transmission and cholinergic anti-inflammatory response (J Biol Chem 2011). The Toll-like receptor (TLR) plays an important role in the induction of the hyperinflammatory response and tissue injury in sepsis. We found that the α7 gene expression level in septic patients’ peripheral blood mononuclear cells (PBMC) is a clinically relevant marker to assess the magnitude of the patient’s inflammatory state, disease severity, and clinical outcome (J Infect Dis 2015). Another exciting line of our research is the involvement of the α7-nicotinic receptor and its endogenous modulator dupα7 in human smoking-related tumors, and particularly their involvement in tobacco carcinogen-induced tumor development and chemotherapy resistence. This topic has attracted a grant from the Ministerio de Economia y Competitividad from 2014-2017. Besides, profesor Jaime Renart who works in our team group, is doing new research on the molecular mechanisms of podoplanin, a type I transmembrane mucin widely known as a marker for lymphatic endothelial cells that

Continue

179

3.4 Large System Pathology Area

3 INFORMATION GROUPS BY AREA has a critical role during development of the heart, lungs and lymphatic endothelial system. The expression of podoplanin is significantly enhanced during tissue-remodelling processes and in several types of human cancer, including squamous cell carcinomas.

Research Lines Applied research lines: • Molecular mechanisms involved in the innate immune response. • Link between the parasympathetic and innate immune systems. Collaborative research line: • Adaptative imnune response in human immunodeficiency virus (HIV) infection. • Multicentric group: RIETE group (Registro Español de Enfermedad Trombo-Embólica). • Molecular mechanisms of podoplanin during tissueremodelling processes and in several types of human cancer. • Mechanisms and clinical features of systemic autoimmne diseases. Lines of study framed in basic research projects: • Study of the pathophysiological role of nicotinica7 and dup-a7 receptors expressed in human macrophages, neurons and lung carcinoma cells. • Identification of signalling pathways connecting nicotinic alpha7 receptors and negative regulators of TLR-mediated inflammation in human macrophages.

Research Activity DOCTORAL THESES Montejano Sánchez R. Impacto del tratamiento del tratamiento antiretroviral con y sin nucleosidos sobre la densidad mineral ósea y los biomarcadores de remodelado oseo [dissertation]. Madrid: UAM: 2016(01/04/2016). Directors: Arribas López JR, Arnalich Fernández F. Pérez Valero I. Deterioro cognitivo asociado al virus de inmunodeficiencia humana (VIH) e inhibidores de proteasa potenciados con ritonavir en monoterapia [dissertation]. Madrid: UAM:2016(01/02/2016). Directors: Arribas López JR, Arnalich Fernández F. Rodríguez Castellano E. Impacto del tratamiento del VHC sobre la infección VIH y la morbimortalidad no hepática en pacientes coinfectados VIH y VHC[dissertation]. Madrid: UAM: 2016(01/05/2016). Directors: Berenguer Berenguer J, Arnalich Fernández F.

PUBLICATIONS • Alonso-Fernández A, Suquía AG, de la Peña M, Casitas R, Pierola J, Barcelo A, Soriano JB, Fernández-Capitan C, Martínez-Cerón E, Carrera M, García-Rio F. OSA is a risk factor for recurrent VTE. Chest. 2016;150(6):1291-301. Article. IF: 6.044; Q1

180

• Brito-Zerón P, Bosch X, Pérez-de-Lis M, Pérez-Álvarez R, Fraile G, Gheitasi H, Retamozo S, Bove A, Monclus E, Escoda O, Moreno A, López-Guillermo A, Khamashta MA, Ramos-Casals M, (Ríos-Blanco JJ). Infection is the major trigger of hemophagocytic syndrome in adult patients treated with biological therapies. Semin Arthritis Rheu. 2016;45(4):391-9. Review. IF: 4.498; Q1 • Carrasco-Ramírez P, Greening DW, Andrés G, Gopal SK, MartínVillar E, Renart J, Simpson RJ, Quintanilla M. Podoplanin is a component of extracellular vesicles that reprograms cell-derived exosomal proteins and modulates lymphatic vessel formation. Oncotarget. 2016;7(13):16070-89. Article. IF: 5.168; Q1 • Comín-Colet J, Anguita M, Formiga F, Almenar L, Crespo-Leiro MG, Manzano L, Muñiz J, Chaves J, de Frutos T, Enjuanes C, (Quesada Simón MA). Health-related quality of life of patients with chronic systolic heart failure in Spain: Results of the VIDA-IC Study. Rev Esp Cardiol. 2016;69(3):256-71. Article. IF: 4.485; Q2 • Chew CRM, Batres SA, Blanco JJR. Update in pulmonary arterial hypertension. Rev Clin Esp. 2016;216(8):436-44. Review. IF: 0.971; Q3 • de la Calle-Prieto F, Arsuaga-Vicente M, Mora-Rillo M, ArnalichFernández F, Arribas JR. Ebola virus disease: Update. Enferm Infec Micr Cl. 2016;34(7):452-60. Review. IF: 1.714; Q3 • Frasson S, Gussoni G, Di Micco P, Barba R, Bertoletti L, Núñez MJ, Valero B, Sampériz AL, Rivas A, Monreal M, (FernándezCapitán C). Infection as cause of immobility and occurrence of venous thromboembolism: analysis of 1635 medical cases from the RIETE registry. J Thromb Thrombolys. 2016;41(3):404-12. Article. IF: 2.142; Q3 • González-Suárez I, Arpa J, Ríos-Blanco JJ. Brain microvasculature involvement in ANCA positive vasculitis. Cerebrovasc Dis. 2016;41(42891):313-21. Article. IF: 2.974; Q2 • Jiménez D, de Miguel-Díez J, Guijarro R, Trujillo-Santos J, Otero R, Barba R, Muriel A, Meyer G,Yusen RD, Monreal M, (FernándezCapitán C). Trends in the management and outcomes of acute pulmonary èmbolism analysis from the RIETE Registry. J Am Coll Cardiol. 2016;67(2):162-70. Article. IF: 19.896; D1 • Montes R, Guruceaga E, González-Porrás JR, Reverter JC, Marco P, Pina E, Páramo JA, Hermida J, Lecumberri R, (Fernández-Capitán C). Identification of new markers of recurrence in patients with unprovoked deep vein thrombosis by gene expression profiling: the retro study. Eur J Haematol. 2016;97(2):128-36. Article. IF: 2.653; Q2 • Morillo R, Jiménez D, Aibar MA, Mastroiacovo D, Wells PS, Sampériz A, de Sousa MS, Muriel A, Yusen RD, Monreal M, (Fernández-Capitán C). DVT management and outcome trends, 2001 to 2014. Chest. 2016;150(2):374-83. Article. IF: 6.044; Q1 • Rabadán IR, Sánchez MA, Marín F, Quesada MA, Siles JC, Peinado R, Bertoméu V, Fillat AC, Badimón L, Muñiz J. Current antiarrhythmic therapy for nonvalvular atrial fibrillation in Spain. Data From the FANTASIIA Registry. Rev Esp Cardiol. 2016;69(1):5460. Article. IF: 4.485; Q2 • Robles-Marhuenda A, Romero-Gómez MP, García-Rodríguez J, Arnalich-Fernández F. Native valve endocarditis caused by Kocuria kristinae. Enferm Infec Micr Cl. 2016;34(7):464-5. Letter. IF: 1.714; Q3 • Salamanca-Bautista P, Conde-Martel A, Aramburu-Bodas O, Formiga F, Trullás JC, Quesada-Simón MA, Casado-Cerrada J, RuizLaiglesia F, Manzano L, Montero-Pérez-Barquero M. Precipitating factors of heart failure admission: Differences related to age and left ventricular ejection fraction. Int J Cardiol. 2016;219:150-5. Article. IF: 6.189; Q1

Freire-Dapena M, Guillén-del Castillo A, Iniesta-Arandia N, Castillo-Palma MJ, Egurbide-Arberas M, Trapiellla-Martínez L, Vargas-Hitos JA, Todoli-Parra JA, Rodríguez-Carballeira M, Marín-Ballve A, Pla-Salas X, Ríos-Blanco JJ, FonollosaPla V. Digital ulcers and cutaneous subsets of systemic sclerosis: Clinical, immunological, nailfold capillaroscopy, and survival differences in the Spanish RESCLE Registry. Semin Arthritis Rheu. 2016;46(2):200-8. Review. IF: 4.498; Q1 • Tong HY, Dávila-Fajardo CL, Borobia AM, Martínez-González LJ, Lubomirov R, León LMP, Banares MJB, Díaz-Villamarín X, Fernández-Capitan C, Barrera JC, Carcas AJ. A new pharmacogenetic algorithm to predict the most appropriate dosage of acenocoumarol for stable anticoagulation in a mixed spanish population. Plos One. 2016;11(3):e0150456. Article. IF: 2.806; Q1 • Trullas JC, Manzano L, Formiga F, AramburuBodas O, Quesada-Simón MA, Arias-Jiménez JL, García-Escriva D, Romero-Requena JM, Jordana-Comajuncosa R, Montero-PérezBarquero M. Heart failure with recovered ejection fraction in a cohort of elderly patients with chronic heart failure. Cardiology. 2016;135(3):196-201. Article. IF: 1.742; Q3 • Uyeki TM, Mehta AK, Davey RT, Liddell AM, Wolf T, Vetter P, Schmiedel S, Grunewald T, Jacobs M, Arribas JR, Evans L, Hewlett AL, Brantsaeter AB, Ippolito G, Rapp C, Hoepelman AIM, Rapp C, Hoepelman AIM, Gutman J, (Arnalich Fernández F). Clinical Management of ebola virus disease in the United States and Europe. New Engl J Med. 2016;374(7):636-46. Article. IF: 72.406; D1

PUBLIC PROJECTS Montiel López C, Arnalich Montiel F. The α7-nicotinic receptor and its endogenous modulator dupa7 in human smoking-related tumors: their involvement in tobacco carcinogen-induced tumor development and chemotherapy resistence (SAF2014-56623-R). MINECO. 2014-2017. Management centre: UAM

PRIVATE PROJECTS Arnalich Fernández F. Gestión multidisciplinar de la asistencia al paciente con insuficiencia cardíaca. Academia de Estudios MIR S.L. 2008-Ongoing. Management centre: FIBHULP Arnalich Fernández F. Papel del DUP-ALFA7, un duplicado parcial de la subunidad ALFA7 del receptor nicotínico humano, en el desarrollo tumoral asociado al consumo de tabaco. Fundación Mutua Madrileña. 2011-Ongoing. Management centre: FIBHULP Arnalich Fernández F. Plan de difusion de la enfermedad de Fabry. Almirall S.A. 2015-Ongoing. Management centre: FIBHULP

Arnalich Fernández F. Servicio de Urgencias. 2016-Ongoing. Management centre: FIBHULP Fernández Capitán MC. Estudio longitudinal predictivo de hipertensión pulmonar postrombótica basado en la creacion de una red de biobancos vinculados a datos clínicos de Embolismo Pulmonar (Estudio Osiris). Laboratorios Farmaceúticos Rovi S.A. 2015-Ongoing. Management centre: FIBHULP Ríos Blanco JJ. Estudio de disfunción ventricular precoz en pacientes con Esclerodermia. Glaxosmithkline S.A. 2011-Ongoing. Management centre: FIBHULP Ríos Blanco JJ. Estudio de hipertensión pulmonar en la cohorte de pacientes con infección VIH del Hospital La Paz. Glaxosmithkline S.A. 2010-Ongoing. Management centre: FIBHULP Ríos Blanco JJ. PI-674 Estudio de la relación entre la rigidez arterial y la función endotelial en pacientes con hipertensión de bata blanca. Menarini Diagnósticos S.A. 2009-Ongoing. Management centre: FIBHULP

• Tolosa-Vilella C, Morera-Morales ML, Simeón-Aznar CP, MariAlfonso B, Colunga-Argüelles D, Rubio JLC, Rubio-Rivas M,

Return to LARGE SYSTEM PATHOLOGIES AREA INDEX

181

3 INFORMATION GROUPS BY AREA

3.4 Large System Pathology Area

Research Lines • Biomarkers. • Resuscitation outcome. • Therapeutic support.

Research Activity

ORGANIC DYSFUNCTION AND FAILURE IN THE AGGRESSION GROUP

CLINICAL TRIALS

PUBLICATIONS • Bauzano E, Estebánez B, García-Morales I, Muñoz VF. Collaborative human-robot system for HALS suture procedures. IEEEE Syst J. 2016;10(3):957-66. Article. IF: 3.882; D1 • Cuerda C, Álvarez J, Ramos P, Abanades JC, García-de-Lorenzo A, Gil P, de-la-Cruz JJ. Prevalence of malnutrition in subjects over 65 years of age in the Community of Madrid. The DREAM + 65 Study. Nutr Hosp. 2016;33(2):263-9. Article. IF: 0.747; Q4

11 39.682 7

Abelardo García de Lorenzo y Mateos Jefe de Servicio de Medicina Intensiva. HULP Profesor Titular. Facultad de Medicina. UAM Alexander Agrifoglio Rotaeche Facultativo Especialista de Área en Medicina Intensiva. HULP José Manuel Añón Elizalde Jefe de Sección en Medicina Intensiva. HULP María Antonia Arce Mendiburu Facultativo Especialista de Área en Medicina Intensiva. HULP María José Asensio Martín Facultativo Especialista de Área en Medicina Intensiva. HULP Lucía Cachafeiro Fuciños Facultativo Especialista de Área en Medicina Intensiva. HULP Belén Civantos Martín Facultativo Especialista de Área en Medicina Intensiva. HULP María Belén Estebánez Montiel Facultativo Especialista de Área en Medicina Intensiva. Coordinador de Trasplante. HULP Juan Carlos Figueira Iglesias Facultativo Especialista de Área en Medicina Intensiva. HULP Eva Mercedes Flores Cabeza Facultativo Especialista de Área en Medicina Intensiva. HULP Ricardo García Hernández Facultativo Especialista de Área en Medicina Intensiva. HULP Eva Herrero de Lucas Facultativo Especialista de Área en Medicina Intensiva. HULP Jesús Javier Manzanares Gómez Facultativo Especialista de Área en Medicina Intensiva. HULP Eva Perales Ferrera Facultativo Especialista de Área en Medicina Intensiva. HULP

182

• Villar J, Ambros A, Soler JA, Martínez D, Ferrando C, Solano R, Mosteiro F, Blanco J, Martín-Rodríguez C, Fernández MD, López J, Díaz-Domínguez FJ,Andaluz-Ojeda D, Merayo E, Pérez-Méndez L, Fernández RL, Kacmarek RM, (Civantos B). Age, Pao(2)/Fio(2), and plateau pressure score: A proposal for a simple outcome score in patients with the acute respiratory distress syndrome. Crit Care Med. 2016;44(7):1361-9. Article. IF: 7.05; Q1

Itziar Pozuelo Echegaray Facultativo Especialista de Área en Medicina Intensiva. HULP Santos Manuel Sánchez Sánchez Jefe de Sección de Medicina Intensiva. HULP Santiago Yus Teruel Facultativo Especialista de Área en Medicina Intensiva. HULP

Strategic Objective The global objective of the investigation team on Dysfunction and Organ Failure in Aggression is the optimization of the patient management in the really critical ill patients who can develop Organ Dysfunction or Organ Failure. Multiorgan Dysfuntion & Multiorgan Failure Syndrome (MOF-MOD Syndrome) are correlated with bad prognostic and high mortality rates. D-FMO Syndrome is correlated both with the disease severity and the therapeutic efforts. The therapeutic management of the patient must be early and directed to specific objectives. Otherwise, the support measures must be directed to the specific situations (like sepsis, trauma …) and to the Organs or Systems in Dysfunction or Failure (coagulation, haemodynamic, respiratory or renal...). Finally, the detection or D-FMO syndrome employing not only single markers (clinic) but early and organ specific biomarkers (basic or advanced biochemical markers, molecular markers…) can bring a higher efficacy and better results.

• Frasson S, Gussoni G, Di Micco P, Barba R, Bertoletti L, Nunez MJ,Valero B, Samperiz AL, Rivas A, Monreal M (García de Lorenzo y Mateos A). Infection as cause of immobility and occurrence of venous thromboembolism: analysis of 1635 medical cases from the RIETE registry. J Thromb Thrombolys. 2016;41(3):40412. Article. IF: 2.142; Q3 • García-de-Lorenzo A, Luque S, Grau S, Agrifoglio A, Cachafeiro L, Herrero E, Asensio MJ, Sánchez SM, Roberts JA. Comparative population plasma and tissue pharmacokinetics of micafungin in critically Ill patients with severe burn injuries and patients with complicated intra-abdominal infection. Antimicrob Agents Ch. 2016;60(10):5914-21. Article. IF: 4.302; Q1 • Garzotto F, Ostermann M, Martín-Langerwerf D, Sánchez-Sánchez M, Teng J, Robert R, Marinho A, Herrera-Gutiérrez ME, Mao HJ, Benavente D, Kipnis E, Lorenzin A, Marcelli D, Tetta C, Ronco C. The dose response multicentre investigation on fluid assessment (DoReMIFA) in critically ill patients. Crit Care. 2016;20:196. Article. IF: 5.358; Q1 • González-Ramos J, Noguera-Morel L, Tong HY, Ramírez E, RuizBravo E, Bellón T, Cabañas R, Cachafeiro L, Herranz-Pinto P. Two cases of overlap severe cutaneous adverse reactions to benznidazole treatment for asymptomatic Chagas disease in a nonendemic country. Brit J Dermatol. 2016;175(3):604-7. Article. IF: 4.706; D1 • Ortiz JE, Borrego AG, Gallego JLR, Sánchez-Palencia Y, Urbanczyk J,Torres T, Domingo L, Estebánez B. Biomarkers and inorganic proxies in the paleoenvironmental reconstruction of mires: The importance of landscape in Las Conchas (Asturias, Northern Spain). Org Geochem. 2016;95:41-54. Article. IF: 3.081; Q1 • Planas M, Álvarez-Hernández J, León-Sanz M, Celaya-Pérez S, Araujo K, de Lorenzo AG. Prevalence of hospital malnutrition in cancer patients: a sub-analysis of the PREDyCESA (R) study. Support Care Cancer. 2016;24(1):429-35. Article. IF: 2.698; Q1

Agrifoglio Rotaeche A. Estudio de fase II, multicéntrico, aleatorizado, doble ciego, controlado con comparador, para evaluar la eficacia, la seguridad y la farmacocinética de ulimorelina (lp101) administrada por vía intravenosa en pacientes con intolerancia a la alimentación enteral. Lyric Pharmaceuticals IncII. HULP Code: 4624. Sponsored´s Protocol Code: LP101-CL-201. Signature Date: 17/5/2016 Añón Elizalde JM. Estudio comparativo, aleatorio, controlado, para evaluar la eficacia de la administración de dexametasona en el tratamiento de pacientes con el síndrome de distrés respiratorio agudo. Hospital Universitario de Gran Canaria. HULP Code: 4680. Sponsored´s Protocol Code: PI11-0143. Signature Date: 4/10/2016 Fernández Dueñas E. Evaluación de la eficacia y seguridad de tapentadol solución oral en el tratamiento del dolor agudo posoperatorio que requiere tratamiento opioide en pacientes pediátricos con edades desde el nacimiento hasta menos de 18 años. Grunenthal Pharma S.A. HULP Code: Anexo-II 4132. Sponsored´s Protocol Code: KF5503/65. Signature Date: 12/5/2016 Figueira Iglesias JC. Ensayo clínico de fase II de demostración de viabilidad para evaluar la eficacia y la seguridad de medi3902 en la prevención de la neumonía nosocomial causada por pseudomonas aeruginosa en pacientes sujetos a ventilación mecánica. Astrazeneca Ab. HULP Code: 4637. Sponsored´s Protocol Code: D5470C00004. Signature Date: 25/5/2016

PATENTS AND TRADEMARKS Herrero Ambrosio A, Ramírez García E, Ojeda Feo JJ, Pérez Rodríguez J, Asensio Martín MJ, González Sánchez ML, Moro Agud M, Lorente Romeo M, López Nieto M, Gómez Rioja R, authors; FIBHULP, assignee. Brand name: SINOIRES. CM 13.080.056; 2014 July 14.

• Sánchez-Recalde A, Moreno R, Flores BE, Jiménez-Valero S, Mateos AGDY, López-Sendon JL. Percutaneous transcatheter treatment for massive pulmonary embolism. Rev Esp Cardiol. 2016;69(3):340-42. Letter. IF: 4.485; Q2 • Sánchez-Sánchez M, García-de-Lorenzo A, Asensio MJ. First resuscitation of critical burn patients: progresses and problems. Med Intensiva. 2016;40(2):118-24. Article. IF: 1.231; Q4

Return to LARGE SYSTEM PATHOLOGIES AREA INDEX

183

3 INFORMATION GROUPS BY AREA

3.4 Large System Pathology Area

methodological aspects of the measurement of exhaled breath condensate and nitric oxide.

Research Lines

RESPIRATORY DISEASES GROUP

Research Activity DOCTORAL THESES

29 141.729 11 Francisco José García Río Jefe de Sección de Neumología (Contrato de Intensificación). HULP Profesor Titular. Facultad de Medicina. UAMP Cristina Aguado Cruz Investigador Predoctoral. HULP Sergio Alcolea Batres Facultativo Especialista de Área en Neumología. HULP Rodolfo Álvarez-Sala Walther Jefe de Servicio de Neumología. HULP Catedrático. Facultad de Medicina. UAM Juan José Cabanillas Martín Facultativo Especialista de Área en Neumología. HULP Carlos Javier Carpio Segura Facultativo Especialista de Área en Neumología. HULP Raquel Casitas Mateo Facultativo Especialista de Área en Neumología. HULP Carolina Cubillos Zapata Investigadora Posdoctoral (Contrato Sara Borrell). HULP Raúl Galera Martínez Facultativo Especialista de Área en Neumología. HULP Luis Gómez Carrera Facultativo Especialista de Área en Neumología. HULP María Antonia Gómez Mendieta Facultativo Especialista de Área en Neumología. HULP Elisabet Martínez Cerón Facultativo Especialista de Área en Neumología. HULP José María Pino García Facultativo Especialista de Área en Neumología. HULP Concepción Prados Sánchez Jefe de Sección de Neumología. HULP David Romero Ribate Facultativo Especialista de Área en Neumología. HULP

184

• Cardiovascular morbidity of sleep-disordered breathing. • Pathogenesis of airflow limitation. • Systematization of lung function testing.

Ana Santiago Recuerda Facultativo Especialista de Área en Neumología. HULP Carlos Villasante Fernández-Montes Jefe de Sección de Neumología. HULP

Strategic Objective Our group studies the molecular mechanisms of cardiovascular morbidity associated with sleep breathing disorders, in particular, the sleep apnoeahypopnea syndrome (SAHS). We also provide evidence for making clinical decisions on patients with these disorders. We conduct studies to evaluate the mechanisms involved in the development of arterial hypertension, arrhythmias, heart failure, ischaemic heart disease, pulmonary hypertension, pulmonary embolism, and carbohydrate metabolism disorders. In terms of the pathogenesis of airflow limitations, several of our projects have focused on small airway function, bronchial hyperresponsiveness and exercise adaptation in a number of obstructive diseases, particularly COPD, asthma and cystic fibrosis. We also evaluate the objective measurement of daily physical activity in these patients and contribute to the best definition of its determinants and its clinical and prognostic usefulness. We collaborate with other research groups to study the contribution of the innate immune system to the evolution of these diseases and the relationship between the response to hypoxia and the clinical expression of COPD and SAHS. Finally, in the field of the systematisation of lung function testing, we create reference values for various population groups and define the

Díaz Agero P. Desarrollo de una técnica de terapia celular e ingeniería tisular con células troncales somáticas mesenquimales para el tratamiento de las fístulas traqueo-bronquiales postquirúrgicas y las de origen yatrogénico[dissertation]. Madrid: UAM: 2016(12/02/2016). Director: Álvarez-Sala Walther R. Fernández de Bobadilla J. Aspectos epidemiológicos, farmacoeconómicos, psicosociales y terapéuticos de la relación de la Enfermedad Cardiovascular y el Tabaquismo en España[dissertation]. Madrid: UAM: 2016(03/05/2016). Director: Álvarez-Sala Walther R. Hernández Jiménez E. Estudio de la inmunidad innata en pacientes con apnea obstructiva del sueño: un microambiente favorable para el progreso tumoral[dissertation]. Madrid: UAM: 2016(23/06/2016). Directors: López-Collazo EM, García Río F. Pandiella Dominique A. Aproximación cienciométrica a la Apnea del sueño (2006-2010)[dissertation]. Madrid: UAM: 2016(28/01/2016). Director: García Río F. Romero Ribate D. Valoración del Síndrome de ApneasHipopneas del sueño como factor de riesgo de la Enfermedad Tromboembólica[dissertation]. Madrid: UAM: 2016(14/09/2016). Director: García Río F. Ruano Encinar M. Efecto de la prescripción electrónica asistida en pacientes pediátricos hospitalizados: evaluación de errores de medicación[dissertation]. Madrid: UAM: 2016(03/11/2016). Director: Álvarez-Sala Walther R. Utrilla Contreras C. Valor de la Tomografía Computarizada Volumétrica en el estudio de la Enfermedad Pulmonar Obstructiva Crónica[dissertation]. Madrid: UAM: 2016(13/04/2016). Director: García Río F.

PUBLICATIONS • Alonso-Fernández A, Suquia AG, de la Peña M, Casitas R, Pierola J, Barcelo A, Soriano JB, Fernández-Capitán C, Martínez-Cerón E, Carrera M, García-Río F. OSA is a risk factor for recurrent VTE. Chest. 2016;150(6):1291-301. Article. IF: 6.044; Q1 • Caballero JD, del Campo R, Royuela A, Sole A, Maiz L, Olveira C,

Quintana-Gallego E, de Gracia J, Cobo M, de la Pedrosa EGG, Oliver A, Cantón R, Sole A, Cortell I, Asensio O, García G, Martínez MT, Cols M, Salcedo A, Vázquez C, Baranda F, Girón R, Quintana E, Delgado I, de Miguel MA, García M, Oliva C, Prados MC, Barrio MI, Pastor MD, Olveira C, de Gracia J, Álvarez A, Escribano A, Castillo S, Figuerola J, Togores B, Oliver A, López C, Caballero JD, Tato M, Maiz L, Suarez L, Canton R. Bronchopulmonary infection-colonization patterns in Spanish cystic fibrosis patients: Results from a national multicenter study. J Cyst Fibros. 2016;15(3):357-65. Article. IF: 4.727; Q1 • Carpio C, Villasante C, Galera R, Romero D, de Cos A, Hernanz A, García-Río F. Systemic inflammation and higher perception of dyspnea mimicking asthma in obese subjects. J Allergy Clin Immun. 2016;137(3):718-26. Article. IF: 13.081; D1 • Carrera LG, Walther RAS. Pulmonary fibrosis. Med Clin-Barcelona. 2016;146(3):115-6. Editorial Material. IF: 1.125; Q3 • Cubillos-Zapata C, Córdoba R, Avendaño-Ortiz J, Arribas-Jiménez C, Hernández-Jiménez E, Toledano V,Villaescusa T, Moreno V, López-Collazo E. CC-122 immunomodulatory effects in refractory patients with diffuse large B-cell lymphoma. Oncoimmunology. 2016;5(12):e1231290. Article. IF: 7.719; D1 • Chew CRM, Batres SA, Blanco JJR. Update in pulmonary arterial hypertension. Rev Clin Esp. 2016;216(8):436-44. Review. IF: 0.971; Q3 • de la Rosa D, Martínez-García MA, Olveira C, Girón R, Maiz L, Prados C. Annual direct medical costs of bronchiectasis treatment: Impact of severity, exacerbations, chronic bronchial colonization and chronic obstructive pulmonary disease coexistence. Chron Resp Dis. 2016;13(4):361-71. Article. IF: 1.818; Q3 • Franssen FME, Soriano JB, Roche N, Bloomfield PH, Brusselle G, Fabbri LM, García-Río F, Kearney MT, Kwon N, Lundback B, Rabe KF, Raillard A, Muellerova H, Cockcroft JR. Lung function abnormalities in smokers with ischemic heart disease.Am J Resp Crit Care. 2016;194(5):568-76. Article. IF: 13.204; D1 • García-Martínez D, Torres-Tamayo N, Torres-Sánchez I, GarcíaRío F, Bastir M. Morphological and functional implications of sexual dimorphism in the human skeletal thorax. Am J Phys Anthropol. 2016;161(3):467-77. Article. IF: 2.552; Q2 • García-Sánchez A, Fernández-Navarro I, García-Río F. Central apneas and REM sleep behavior disorder as an initial presentation of multiple system atrophy. J Clin Sleep Med. 2016;12(2):267-70. Article. IF: 3.429; Q2 • Guzmán E, Taylor G, Hope J, Herbert R, Cubillos-Zapata C, Charleston B. Transduction of skin-migrating dendritic cells by human adenovirus 5 occurs via an actin-dependent phagocytic pathway. J Gen Virol. 2016;97:2703-18. Article. IF: 2.838; Q2 • López-Jiménez MJ, Masa JF, Corral J, Terán J, Ordaz E, Troncoso MF, González-Mangado N, González M, López-Martínez S, de Lucas P, Marín JM, Martí S, Díaz-Cambriles T, Díaz-de-Atauri J, Chiner E, Aizpuru F, Egea C, Romero A, Benítez JM, SánchezGómez J, Golpe R, Santiago-Recuerda A, Gómez S, Barbe F, Bengoa M. Mid- and long-term efficacy of non-invasive ventilation in obesity hypoventilation syndrome: The Pickwick’s Study. Arch Bronconeumol. 2016;52(3):158-65. Article. IF: 2.979; Q2 • Martínez-Cerón E, Barquiel B, Bezos AM, Casitas R, Galera R, García-Benito C, Hernanz A, Alonso-Fernández A, GarcíaRío F. Effect of continuous positive airway pressure on glycemic control in patients with obstructive sleep apnea and type 2 diabetes A randomized clinical trial. Am J Resp Crit Care. 2016;194(4):476-85. Article. IF: 13.204; D1 • Martínez-Cerón E, Buño A, García-Río F. Analytical performance requirements for biomarker-based studies evaluating continuous positive airway pressure effects in obstructive sleep apnea reply. Am J Resp Crit Care. 2016;194(4):523-4. Letter. IF: 13.204; D1

Continue

185

3.4 Large System Pathology Area

3 INFORMATION GROUPS BY AREA • Martínez-Cerón E, Fernández-Navarro I, García-Río F. Effects of continuous positive airway pressure treatment on glucose metabolism in patients with obstructive sleep apnea. Sleep Med Rev. 2016;25:121-30. Review. IF: 8.958; D1 • Martínez-Cerón E, García A, Casitas R, Galera R, García-Río F. Cost-effectiveness analysis of 3 methacholine challenge tests: importance of simplified protocols. J Invest Allerg Clin. 2016;26(2):121-4. Editorial Material. IF: 3.094; Q2 • Masa JF, Corral J, Caballero C, Barrot E, Terán-Santos J, AlonsoÁlvarez ML, Gómez-García T, González M, López-Martín S, de Lucas P, Marín JM, Martí S, Díaz-Cambriles T, Chiner E, Egea C, Miranda E, Mokhlesi B, García-Ledesma E, Sánchez-Quiroga MA, Ordax E, González-Mangado N, Troncoso MF, Martínez-Martínez MA, Cantalejo O, Ojeda E, Carrizo SJ, Gallego B, Pallero M, Ramón MA, Díaz-de-Atauri J, Mñoz-Méndez J, Senent C, SanchoChust JN, Ribas-Solis FJ, Romero A, Benítez JM, Sánchez-Gómez J, Golpe R, Santiago-Recuerda A, Gómez S, Bengoa M. Non-invasive ventilation in obesity hypoventilation syndrome without severe obstructive sleep apnoea. Thorax. 2016;71(10):899-906. Article. IF: 8.272; D1 • Masa JF, Utrabo I, de Terreros JG, Aburto M, Esteban C, Prats E, Núñez B, Ortega-González A, Jara-Palomares L, Martín-Vicente MJ, Farrero E, Binimelis A, Sala E, Serrano-Rebollo JC, Barrot E, Sánchez-Oro-Gómez R, Fernández-Álvarez R, Rodríguez-Jerez F, Sayas J, Benavides P, Catalá R, Rivas FJ, Egea CJ, Antón A, Penacoba P, Santiago-Recuerda A, Gómez-Mendieta MA, Méndez L, Cebrían JJ, Pina JA, Zamora E, Segrelles G. Noninvasive ventilation for severely acidotic patients in respiratory intermediate care units Precision medicine in intermediate care units. BMC Pulm Med. 2016;16:97. Article. IF: 2.435; Q3 • Miranda DG, Peces EMS, Babarro AA, Sánchez MCP, Cerdeira MV. HOLD study (Home care Obstructive Lung Disease): natural history of patients with advanced COPD. BMC Palliat Care. 2016;15:35. Article. IF: 1.602; Q3 • Miravitlles M, Galdiz JB, Huerta A, Villacampa A, Carcedo D, García-Río F. Cost-effectiveness of combination therapy umeclidinium/vilanterol versus tiotropium in symptomatic COPD Spanish patients. Int J Chron Obstruct Pulmon Dis. 2016;11:123-32. Article. IF: 3.157; Q2 • Olveira C, Sole A, Girón RM, Quintana-Gallego E, Mondéjar P, Baranda F, Álvarez A, Prados C, Rodríguez-González J, Herrero-Labarga I, Quittner A, Olveira G. Depression and anxiety symptoms in Spanish adult patients with cystic fibrosis: associations with health-related quality of life. Gen Hosp Psychiat. 2016;40:39-46. Article. IF: 2.279; Q3 • Pomares X, Montón C, Bare M, Pont M, Estirado C, Gea J, Quintana JM, Vidal S, Santiago A. Emergency hospital care for exacerbation of COPD: Is inhaled maintenance therapy modified? COPD. 2016;13(1):11-8. Article. IF: 2.576; Q3 • Roche O, Déguiz ML, Tiana M, Galiana-Ribote C, MartínezAlcázar D, Rey-Serra C, Ranz-Ribeiro B, Casitas R, Galera R, Fernández-Navarro I, Sánchez-Cuellar S, Bernard V, Ancochea J, Wasserman WW, García-Río F, Jiménez B, del Peso L. Identification of non-coding genetic variants in samples from hypoxemic respiratory disease patients that affect the transcriptional response to hypoxia. Nucleic Acids Res. 2016;44(19):9315-30. Article. IF: 10.162; D1 • Ruano M,ViIlamañán E, Pérez E, Herrero A, Álvarez-Sala R. New technologies as a strategy to decrease medication errors: how do they affect adults and children differently? World J Pediatr. 2016;12(1):28-34. Review. IF: 1.164; Q3 • Ruiz-Pérez D, Largo C, García-Río F. Technical aspects and benefits of experimental mouse lung transplantation. Arch Bronconeumol. 2016;52(12):596-604. Review. IF: 2.979; Q2 • Soriano JB, García-Río F. Global lung function initiative equations:

186

The legacy starts. Respiration. 2016;92(3):131-3. Editorial Material. IF: 2.772; Q2 • Torres-Capelli M, Marsboom G, Li QOY, Tello D, Rodríguez FM, Alonso T, Sánchez-Madrid F, García-Río F, Ancochea J, Aragonés J. Role of Hif2 alpha oxygen sensing pathway in bronchial epithelial club cell proliferation. Sci Rep-Uk. 2016;6:25357. Article. IF: 4.259; Q1 • Villamañán E, González D, Armada E, Ruano M, Álvarez-Sala R, Herrero A. The patents game. Generic and biosimilar drugs. Rev Calid Asist. 2016;31(2):99-105. Article. Not Indexed • Zamarrón-de Lucas E, García-Fernández E, Carpio C, Alcolea S, Martínez-Abad Y, Álvarez-Sala R. Massive cardiac lipomatosis, an autopsy finding in a patient with sudden death. Med ClinBarcelona. 2016;146(12):541-3. Article. IF: 1.125; Q3

PUBLIC PROJECTS García Río FJ. Contrato de Intensificación (INT15/00076). ISCIII. 2016-2017. Management centre: FIBHULP García Río FJ. Papel de las alteraciones de las dianas génicas de HIF y del Sistema Inmune Innato en el desarrollo del SAHS. Su implicación en cáncer y cardiopatía hisquémica (PI13/01512). ISCIII. 2014-2017. Management centre: FIBHULP Ruiz Pérez D. Predoctoral contract (FPU13/01638). MINECO. 2014-2017. Management centre: FIBHULP

PRIVATE PROJECTS

ñola de Neumología y Cirugía Torácica. 2014-2016. Management centre: Fundación RESPIRA García Río FJ. Valores de referencia para el consumo de oxígeno máximo, umbral de acidosis, reserva ventilatoria y reserva cardiaca en la población madrileña de ascendientes europeos. Sociedad Española de Neumología y cirugía torácica. 2014-2016. Management centre: Fundación RESPIRA Gómez Carrera L. Auditoría clínica sobre manejo de Fibrosis Pulmonar Idiopatica (FPI) en el área sanitaria del Hospital La Paz. Boehringer Ingelheim España S.A. 2016-Ongoing. Management centre: FIBHULP Santiago Recuerda A. Efecto del tratamiento con ventilación mecánica no invasora y humidificación en las complicaciones infecciosas respiratorias. Menarini Diagnósticos S.A. 2014-Ongoing. Management centre: FIBHULP

CLINICAL TRIALS Álvarez-Sala Walther R. Estudio de fase 3, multicéntrico, aleatorizado, doble ciego y controlado con comparador para evaluar la seguridad y la eficacia de delafloxacino intravenoso con cambio a vía oral en sujetos adultos con neumonía bacteriana adquirida en la comunidad. Melinta Therapeutics Inc. HULP Code: 4545. Sponsored´s Protocol Code: ML-3341-306. Signature Date: 14/06/2016

García Río FJ. Efecto de la CPAP nasal sobre la reducción de la albuminuria en pacientes con nefropatía diabética y apnea obstructiva del sueño. Francisco José García Río . HULP Code: PI-2386. Sponsored´s Protocol Code: PI-2386. Signature Date: 04/11/2016 Prados Sánchez C. Registro observacional europeo de pacientes con fibrosis quística (VOICE). Vertex Pharmaceuticals Incorporated. EPA-SP. 42548. HULP Code: Contrato PI-2397. Sponsored´s Protocol Code: VX14-CFR-107. Signature Date: 27/06/2016 Villasante Fernández-Montes C. Estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo de 52 semanas de duración para evaluar la eficacia y la seguridad de QAW039 añadido al tratamiento existente para el asma en pacientes con asma grave no controlada. Novartis Farmacéutica S.A. HULP Code: Contrato 4507. Sponsored´s Protocol Code: CQAW039A2314. Signature Date: 07/01/2016 Villasante Fernández-Montes C. Observacional, prospectivo, para evaluar la relación entre el grado de concordancia de las opiniones entre pacientes y médicos especialistas en el control sintomático y el riesgo futuro en pacientes con asma moderada. Mundipharma Pharmaceuticals S.L. HULP Code: Contrato PI-1886. Sponsored´s Protocol Code: CONCORD-ASMA. Signature Date: 29/01/2016

Álvarez-Sala Walther R. Actualización y renovación de la actividad investigadora en el Servicio de Neumologia del Hospital Universitario La Paz. Chiesi España S.A. 2015-Ongoing. Management centre: FIBHULP Álvarez-Sala Walther R. Puesta al día en asma grave para Atención Primaria: de la investigación a la práctica clinica. Sandoz Farmaceutica S.A. 2016-Ongoing. Management centre: FIBHULP García Río FJ. Análisis de la actividad del Sistema Inmune Innato en pacientes con Síndrome de Apneas-Hipopneas del sueño grave. Roche Pharma S.A. 2014-Ongoing. Management centre: FIBHULP García Río FJ. Caracterización clínica de distintos fenotipos de exacerbación de EPOC. Evaluación de sus factores de riesgo, pronóstico y persistencia a medio plazo. Sociedad Madrileña de Neumología y Cirugía Torácica. 2016. Management centre: Fundación NEUMOMADRID García Río FJ. Contribución de las alteraciones de la percepción de la disnea al diagnóstico de asma ficticio en obesos. PI-795. Astrazeneca Farmaceutica Spain S.A. 2009-Ongoing. Management centre: FIBHULP García Río FJ. Regulación de la expresión génica por Hipoxia: identificación de polimorfismos que afectan a los sitios de unión del Factor Inducible por Hipoxia (HIF) en pacientes de EPOC y pacientes de SAHS. Sociedad Espa-

Return to LARGE SYSTEM PATHOLOGIES AREA INDEX

187

3.4 Large System Pathology Area

3 INFORMATION GROUPS BY AREA

REGULATION OF GENE EXPRESSION AND BY HYPOXIA GROUP

NEPHROLOGY GROUP

1 10.162 1 Luis del Peso Ovalle Profesor Titular. Departamento de Bioquímica. Facultad de Medicina. UAM Benilde Jiménez Cuenca Profesor Titular. Departamento de Bioquímica Facultad de Medicina. UAM María Tiana Cerrolaza Investigador Postdoctoral. UAMf

Strategic Objective The elucidation of the cellular and molecular responses to changes in oxygen tension constitutes an exciting research topic given the dependence of virtually all human tissues on appropriate oxygen supply and the involvement of hypoxia in high-incidence pathologies such as cardiopulmonary diseases and cancer. The Hypoxia Inducible transcription Factor (HIF) plays a pivotal role in this response by controlling the expression of most of the genes involved in the adaptation to hypoxia. Our research group aims to provide novel insight into transcriptional response to hypoxia and to exploit this knowledge to improve clinical management of pathologies in which hypoxia is a common feature. To this end we are currently involved in the following.

Research Activity DOCTORAL THESES Tiana Cerrolaza M. Mechanisms underlying gene repression in hypoxia[dissertation]. Madrid: UAM: 2016(01/12/2016). Director: del Peso Ovalle L. European Mention.

PUBLICATIONS • Roche O, Deguiz ML, Tiana M, Galiana-Ribote C, MartínezAlcázar D, Rey-Serra C, Ranz-Ribeiro B, Casitas R, Galera R, Fernández-Navarro I, Sánchez-Cuellar S, Bernard V, Ancochea J, Wasserman WW, García-Río F, Jiménez B, del Peso L. Identification of non-coding genetic variants in samples from hypoxemic respiratory disease patients that affect the transcriptional response to hypoxia. Nucleic Acids Res. 2016;44(19):9315-30. Article. IF: 10.162; D1

PUBLIC PROJECTS

Research Lines • Identification of network motifs within the gene regulatory network regulated by HIF and study of their role in the adaptation to hypoxia. • Characterization of the effect of hypoxia/HIF 188

on endothelial cell proliferation and integration of this response in the induction of angiogenesis. • Analysis of the functional effect of polymorphisms affecting HIF binding and investigation of their correlation with the different phenotypes in chronic respiratory diseases and cancer.

del Peso Ovalle L. Estudio genómico, bioinfomático y funcional del papel de la hipoxia en angiogénesis y el Síndrome de Von Hippel-Lindau (SAF2014-53819-R). MINECO. 2015-2017. Management centre: UAM

Return to LARGE SYSTEM PATHOLOGIES AREA INDEX

26 375.556 22

Rafael Selgas Gutiérrez Jefe de Servicio de Nefrología. HULP Profesor Asociado. Facultad de Medicina. UAM María Auxiliadora Bajo Rubio Jefe de Sección de Nefrología. HULP Profesora Asociado. Facultad de Medicina. UAM María José Castro Notario Enfermera. HULP Olga Costero Fernández Facultativo Especialista de Área en Nefrología. HULP Gloria del Peso Gilsanz Facultativo Especialista de Área en Nefrología. HULP María José Fernández Reyes Facultativo Especialista de Área en Nefrología. Hospital de Segovia Helena García LLana Psicóloga Investigadora. HULP María Elena González García Facultativo Especialista de Área en Nefrología. HULP Guadalupe González Mateo Investigadora Postdoctoral. HULP Carlos Jiménez Martín Jefe de Sección de Nefrología. HULP María Ovidia López Oliva Facultativo Especialista de Área en Nefrología. HULP Virginia Martínez Cabeza Técnico de Laboratorio. HULP Teresa Olea Tejero Facultativo Especialista de Área en Nefrología. HULP Ramón Peces Serrano Facultativo Especialista de Área en Nefrología. HULP Begoña Rivas Becerra Facultativo Especialista de Área en Nefrología. HULP

María Dolores Sánchez Niño Investigadora Postdoctoral (Contrato Sara Borrell). HULP Rafael Jesús Sánchez Villanueva Facultativo Especialista de Área en Nefrología. HULP Maximino Alberto Torre Carballada Facultativo Especialista de Área en Nefrología. HULP

Strategic Objective The strategic objective of this medical scientific group is to enable, by developing a deep understanding of the various components that make up nephrology (kidney diseases in initial stages, progression of kidney disease, particular and general complications of dialysis and kidney transplantation), access by affected patients to the best diagnostic and therapeutic interventions available at any time. Each of the areas must ensure a minimum level of research and development activity representing the innovation in these areas.

Research Lines The lines of research are occasionally cross-sectional to the four components indicated for nephrology as a whole. A) Incipient nephropaties and kidney disease progression: • Glomerular and tubular nephropathies. New diagnostic markers and interventions. • Organisational Research (computerisation, organization of generational change in the department and network).

Continue

189

3.4 Large System Pathology Area

3 INFORMATION GROUPS BY AREA • Morbidity, mortality and progression of Diabetic Nephropathy and other glomerular nephropathies. • Autosomal Dominant Polycystic Kidney Disease. Family Studies and treatment approaches. • Association of cardiovascular disease with the progress of nephropathies (NEFRONA multicenter study, REDinREN). • Incorporation of a psychologist into the department of nephrology: criteria and process. Issues on monitoring therapeutic adherence. • Occult Hepatits C virus in different kidney disease situations. B) Complications of dialysis: • Establishment of normal peritoneal functional in humans. Implications for patient survival and long-term treatment. Aquaporin 1 (AQP1) and its genetic polymorphisms: relationship with peritoneal transport of water (Multicentre European study). • The alternatively activated macrophage of peritoneal effluent (AAM): its relationship with defence and peritoneal fibrosis. CCL18 as a chemokine of AAM and mediator of peritoneal fibrosis. • Peritoneal biopsy for the complete evaluation of the peritoneal membrane. A correspondence study with cell and components findings in peritoneal effluent during kidney transplantation (Multicenter). • Cardiovascular risk in patients with advanced kidney disease and on dialysis. Endocrinological aspects. The abdominal adipocyte and adipocytokines. FABP antagonists as blockers of the adipocyte-macrophage response. Non-thyroideal diseases, influence on CKD patients. FGF 21 role in uremic insulin resistance. • Mouse model for peritoneal dialysis: exploration of the effects of dialysis fluids, pharmacological interventions and genetic manipulation (KO, transgenic). • Allergic reactions to hemodialysis membranes: mechanisms and alternatives. C) Complications of kidney transplantation: • Toxicity due to immunosuppressors. Ultrasound contrast in the analysis of renal microvasculature in kidney transplantation and complications. • The involvement of CMV in the renal graft response: anticipated diagnosis. • Kidney graft response. Thymoglobulin administered to a cadaver donor: effects on the expression of HLA antigens by tubular cells (clinical trial). • Post-transplant monitorization of anti-HLA antibodies. Local development. • The transplantation career since the values of the patient: health outcome repercussion.

Research Activity DOCTORAL THESES Rodríguez Sanz AI. Selección de posibles inhibidores de FABP4: Efectos en la actividad proinflamatoria de monocitos/macrófagos y en las interacciones macrófago/ 190

adipocito[dissertation]. Madrid: UAM: 2016(28/10/2016). Directors: Bellón Heredia T, Selgas Gutiérrez R. Ossorio González M. CCL18 y su implicación en esclerosis peritoneal: validación clínica de un nuevo marcador diagnóstico y pronóstico de alteración de la función peritoneal[dissertation]. Madrid: UAM: 2016(13/12/2016). Directors: Selgas Gutiérrez R, Bajo Rubio MA.

PUBLICATIONS • del Peso G, Jiménez-Heffernan JA, Selgas R, Remón C, Ossorio M, Fernández-Perpén A, Sánchez-Tomero JA, Cirugeda A, de Sousa E, Sandoval P, Díaz R, López-Cabrera M, Bajo MA. biocompatible dialysis solutions preserve peritoneal mesothelial cell and vessel wall integrity. A case-control study on human biopsies. Periton Dialysis Int. 2016;36(2):129-34. Article. IF: 1.557; Q3 • Elewa U, Fernández-Fernández B, Mahillo-Fernández I, MartínCleary C, Sanz AB, Sánchez-Niño MD, Ortiz A. PCSK9 in diabetic kidney disease. Eur J Clin Invest. 2016;46(9):779-86. Article. IF: 2.714; Q1 • Elewa U, Sánchez-Niño MD, Mahillo-Fernández I, Martín-Cleary C, Ana BS, Pérez-Gómez MV, Fernández-Fernández B, Ortiz A. Circulating CXCL16 in diabetic kidney disease. Kidney Blood Press R. 2016;41(5):663-71. Article. IF: 3.104; Q2 • Forouzanfar MH, Afshin A, Alexander LT, Anderson HR, Bhutta ZA, Biryukov S, Brauer M, Burnett R, Cercy K, Charlson FJ, Cohen AJ, Dandona L, Estep K, Ferrari AJ, Frostad JJ, Fullman N, Gething PW, Godwin WW, Griswold M, Kinfu Y, Kyu HH, Larson HJ, Liang X, Lim SS, Liu PY, López AD, Lozano R, Marczak L, Mensah GA, Mokdad AH, Moradi-Lakeh M, Naghavi M, Neal B, Reitsma MB, Roth GA, Salomón JA, Sur PJ, Vos T, Wagner JA, Wang H, Zhao Y, Zhou M, Aasvang GM, Abajobir AA, Abate KH, Abbafati C, Abbas KM, Abd-Allah F, Abdulle AM, Abera SF, Abraham B, Abu-Raddad LJ, Abyu GY, Adebiyi AO, Adedeji IA, Ademi Z, Adou AK, Adsuar JC, Agardh EE, Agarwal A, Agrawal A, Kiadaliri AA, Ajala ON, Akinyemiju TF, Al-Aly Z, Alam K, Alam NKM, Aldhahri SF, Aldridge RW, Alemu ZA, Ali R, Alkerwi A, Alla F, Allebeck P, Alsharif U, Altirkawi KA, Martin EA, Alvis-Guzmán N, Amare AT, Amberbir A, Amegah AK, Amini H, Ammar W, Amrock SM, Andersen HH, Anderson BO, Antonio CAT, Anwar P, Arnlov J, Al Artaman, Asayesh H, Asghar RJ, Assadi R, Atique S, Avokpaho EFGA, Awasthi A, Quintanilla BPA, Azzopardi P, Bacha U, Badawi A, Bahit MC, Balakrishnan K, Barac A, Barber RM, Barker-Collo SL, Barnighausen T, Barquera S, Barregard L, Barrero LH, Basu S, Bans C, Bazargan-Hejazi S, Beardsley J, Bedi N, Beghi E, Bell ML, Bello AK, Bennett DA, Bensenor IM, Berhane A, Bernabe E, Betsu BD, Beyene AS, Bhala N, Bhansali A, Bhatt S, Biadgilign S, Bikbov B, Bisanzio D, Bjertness E, Blore JD, Borschmann R, Boufous S, Bourne RRA, Brainin M, Brazinova A, Breitborde NJK, Brenner H, Broday DM, Brugha TS, Brunekreef B, Butt ZA, Cahill LE, Calabria B, Campos-Nonato IR, Cárdenas R, Carpenter D, Casey DC, Castaneda-Oquela CA, Rivas JC, Castro RE, Catala-López F, Chang JC, Chiang PPC, Chibalabala M, Chimed-Ochir O, Chisumpa VH, Chitheer AA, Choi JYJ, Christensen H, Christopher DJ, Ciobanu LG, Coates MM, Colquhoun SM, Cooper LT, Cooperrider K, Cornaby L, Cortinovis M, Crump JA, Cuevas-Nasu L, Damasceno A, Dandona R, Darby SC, Dargan PI, das Neves J, Davis AC, Davletov K, de Castro EF, de la Cruz-Góngora V, De Leo D, Degenhardt L, del Gobbo LC, del Pozo-Cruz B, Dellavalle RP, Deribew A, Des Jarlais DC, Dharmaratne SD, Dhillon PK, Díaz-Tome C, Dicker D, Ding EL, Dorsey ER, Doyle KE, Driscoll TR, Duan L, Dubey M, Duncan BB, Elyazar I, Endries AY, Ermakov SP, Erskine HE, Eshrati B, Esteghamati A, Fahimi S, Faraon EJA, Farid TA, Farinha CSES, Faro A, Farvid MS, Farzadfar F, Feigin VL, Fereshtehnejad SM, Fernandes JG, Fischer F, Fitchett JRA, Fleming T, Foigt N, Foreman K, Fowkes FGR, Franklin RC, Furst

T, Futran ND, Gakidou E, García-Basteiro AL, Gebrehiwot TT, Gebremedhin AT, Geleijnse JM, Gessner BD, Giref AZ, Giroud M, Gishu MD, Goenka S, Gómez-Cabrera MC, Gómez-Dantes H, Gona P, Goodridge A, Gopalani SV, Gotay CC, Goto A, Gouda HN, Gugnani HC, Guillemin F, Guo YM, Gupta R, Gupta R, Gutierrez RA, Haagsma JA, Hafezi-Nejad N, Haile D, Hailu GB, Halasa YA, Hamadeh RR, Hamidi S, Handal AJ, Hankey GJ, Hao YT, Harb HL, Harikrishnan S, Haro JM, Hassanvand MS, Hassen TA, Havmoeller R, Heredia-Pi IB, Hernández-Llanes NF, Heydarpour P, Hoek HW, Hoffman HJ, Horino M, Horita N, Hosgood HD, Hoy DG, Hsairi M, Htet AS, Hu G, Huang JJ, Husseini A, Hutchings SJ, Huybrechts I, Iburg KM, Idrisov BT, Ileanu BV, Inoue M, Jacobs TA, Jacobsen KH, Jahanmehr N, Jakovljevic MB, Jansen HAFM, Jassal SK, Javanbakht M, Jayatilleke AU, Jee SH, Jeemon P, Jha V, Jiang Y, Jibat T, Jin Y, Johnson CO, Jonas JB, Kabir Z, Kalkonde Y, Kamal R, Kan H, Karch A, Karema CK, Karimkhani C, Kasaeian A, Kaul A, Kawakami N, Kazi DS, Keiyoro PN, Kemp AH, Kengne AP, Keren A, Kesavachandran CN, Khader YS, Khan AR, Khan EA, Khan G, Khang YH, Khatibzadeh S, Khera S, Khoja TAM, Khubchandani J, Kieling C, Kim CI, Kim D, Kimokoti RW, Kissoon N, Kivipelto M, Knibbs LD, Kokubo Y, Kopec JA, Koul PA, Koyanagi A, Kravchenko M, Kromhout H, Krueger H, Ku T, Defo BK, Kuchenbecker RS, Bicer BK, Kuipers EJ, Kumar GA, Kwan GF, Lal DK, Lalloo R, Lallukka T, Lan Q, Larsson A, Latif AA, Lawrynowicz AEB, Leasher JL, Leigh J, Leung J, Levi M, Li XH, Li YC, Liang J, Liu SW, Lloyd BK, Logroscino G, Lotufo PA, Lunevicius R, Maclntyre M, Mahdavi M, Majdan M, Majeed A, Malekzadeh R, Malta DC, Manamo WAA, Mapoma CC, Marcenes W, Martin RV, Martínez-Raga J, Masiye F, Matsushita K, Matzopoulos R, Mayosi BM, McGrath JJ, McKee M, Meaney PA, Medina C, Mehari A, Mena-Rodríguez F, Mekonnen AB, Melaku YA, Memish ZA, Mendoza W, Mensink GBM, Meretoja A, Meretoja TJ, Mesfin YM, Mhimbira FA, Miller TR, Mills EJ, Mirarefin M, Misganaw A, Mock CN, Mohammadi A, Mohammed S, Mola GLD, Monasta L, Hernández JCM, Montico M, Morawska L, Mori R, Mozaffarian D, Mueller UO, Mullany E, Mumford JE, Murthy GVS, Nachega JB, Naheed A, Nangia V, Nassiri N, Newton JN, Ng M, Nguyen Q, Nisar MI, Pete PMN, Norheim OF, Norman RE, Norrving B, Nyakarahuka L, Obermeyer CM, Ogbo FA, Oh IH, Oladimeji O, Olivares PR, Olsen H, Olusanya BO, Olusanya JO, Opio JN, Oren E, Orozco R, Ortiz A, Ota E, Mahesh PA, Pana A, Park EK, Parry CD, Parsaeian M, Patel T, Caicedo AJP, Patil ST, Patten SB, Patton GC, Pearce N, Pereira DM, Perico N, Pesudovs K, Petzold M, Phillips MR, Piel FB, Pillay JD, Plass D, Polinder S, Pond CD, Pope CA, Pope D, Popova S, Poulton RG, Pourmalek F, Prasad NM, Qorbani M, Rabiee RHS, Radfar A, Rafay A, Rahimi-Movaghar V, Rahman M, Rahman MHU, Rahman SU, Rai RK, Rajsic S, Raju M, Ram U, Rana SM, Ranganathan K, Rao P, García CAR, Refaat AH, Rehm CD, Rehm J, Reinig N, Remuzzi G, Resnikoff S, Ribeiro AL, Rivera JA, Rolm HS, Rodríguez A, Rodríguez-Ramírez S, Rojas-Rueda D, Román Y, Ronfani L, Roshandel G, Rothenbacher D, Roy A, Saleh MM, Sanabria JR, Sánchez-Niño MD, Sánchez-Pimienta TG, Sandar L, Santomauro DF, Santos IS, Sarmiento-Suarez R, Sartorius B, Satpathy M, Savic M, Sawhney M, Schmidhuber J, Schmidt MI, Schneider IJC, Schottker B, Schutte AE, Schwebel DC, Scott JG, Seedat S, Sepanlou SG, Servan-Mori EE, Shaheen A, Shahraz S, Shaikh MA, Levy TS, Sharma R, She J, Sheikhbahaei S, Shen J, Sheth KN, Shi PL, Shibuya K, Shigematsu M, Shin MJ, Shiri R, Shishani K, Shiue I, Shrime MG, Sigfusdottir ID, Silva DAS, Silveira DGA, Silverberg JI, Simard EP, Sindi S, Singh A, Singh JA, Singh PK, Slepak EL, Soljak M, Soneji S, Sorensen RJD, Sposato LA, Sreeramareddy CT, Stathopoulou V, Steckling N, Steel N, Stein DJ, Stein MB, Stockl H, Stranges S, Stroumpoulis K, Sunguya BF, Swaminathan S, Sykes BL, Szoeke CEI, Tabares-Seisdedos R, Takahashi K, Talongwa RT, Landon N, Tanne D, Tavakkoli M, Taye BW, Taylor HR, Tedla BA, Tefera WM, Tegegne TK, Tekle DY, Terkawi AS, Thakur JS, Thomas BA, Thomas ML, Thomson AJ, Thorne-Lyman AL, Thrift AG, Thurston GD, Tillmann T, Tobe-Gai R, Tobollik M, Topor-Madry R,

Topouzis F,Towbin JA,Tran BX, Dimbuene ZT,Tsilimparis N,Tura AK,Tuzcu EM,Tyrovolas S, Ukwaja KN, Undurraga EA, Uneke CJ, Uthman OA, van Donkelaar A, van Os J, Varakin YY, Vasankari T, Veerman JL, Venketasubramanian N, Violante FS, Vollset SE, Wagner GR, Waller SG, Wang JL, Wang LH, Wang YP, Weichenthal S, Weiderpass E, Weintraub RG, Werdecker A, Westerman R, Whiteford HA,Wijeratne T,Wiysonge CS,Wolfe CDA,Won S,Woolf AD, Wubshet M, Xavier D, Xu GL, Yadav AK, Yakob B, Yalew AZ, Yano Y, Yaseri M, Ye PP, Yip P, Yonemoto N, Yoon SJ, Younis MZ, Yu CH, Zaidi Z, Zaki MES, Zhu J, Zipkin B, Zodpey S, Zuhlke LJ, Murray CJL. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1659-24. Article. IF: 47.831; D1 • González E, Díez JJ, Bajo MA, del Peso G, Grande C, Rodríguez O, Díaz-Almirón M, Iglesias P, Selgas R. Fibroblast growth factor 21 (FGF-21) in peritoneal dialysis patients: Natural history and metabolic implications. Plos One. 2016;11(3):e0151698. Article. IF: 2.806; Q1 • Henaut L, Sánchez-Niño MD, Castillo GAE, Sanz AB, Ortiz A.Targeting local vascular and systemic consequences of inflammation on vascular and cardiac valve calcification. Expert Opin Ther Tar. 2016;20(1):89-105. Review. IF: 4.873; Q1 • Henaut L, Sanz AB, Martín-Sánchez D, Carrasco S, Villa-Bellosta R, Aldámiz-Echevarría G, Massy ZA, Sánchez-Niño MD, Ortiz A. TWEAK favors phosphate-induced calcification of vascular smooth muscle cells through canonical and non-canonical activation of NF kappa B. Cell Death Dis. 2016;7:e2305. Article. IF: 5.965; Q1 • Janeiro D, Portoles J, López-Sánchez P, Tornero F, Felipe C, Castellano I, Rivera M, Fernández-Cusicanqui J, Cirugeda A, Fernández-Reyes MJ, Rodríguez-Palomares JR, Bajo MA, Caparros G, Ortiz A. How should we analyze and present mortality in our patients?: A multicentre GCDP experience. Nefrología. 2016;36(2):149-55. Article. IF: 1.183; Q4 • Jiménez C, López MO, Ros A, Aguilar A, Menéndez D, Rivas B, Santana MJ, Vaca MA, Escuín F, Madero R, Selgas R. The natural history of kidney graft cortical microcirculation determined by real-time contrast-enhanced sonography (RT-CES). Plos One. 2016;11(3):e0150384. Article. IF: 2.806; Q1 • Kassebaum NJ, Arora M, Barber RM, Bhutta ZA, Carter A, Casey DC, Charlson FJ, Coates MM, Coggeshall M, Cornaby L, Dandona L, Dicker DJ, Erskine HE, Ferrari AJ, Fitzmaurice C, Foreman K, Forouzanfar MH, Fullman N, Gething PW, Goldberg EM, Graetz N, Haagsma JA, Johnson C, Kemmer L, Khalil IA, Kinfu Y, Kutz MJ, Kyu HH, Leung J, Liang XF, Lim SS, Lim SS, Lozano R, Mensah GA, Mikesell J, Mokdad AH, Mooney MD, Naghavi M, Nguyen G, Nsoesie E, Pigott DM, Pinho C, Rankin Z, Reinig N, Salomon JA, Sandar L, Smith A, Sorensen RJD, Stanaway J, Steiner C, Teeple S, Thomas BA, Troeger C,VanderZanden A, Wagner JA, Wanga V, Whiteford HA, Zhou M, Zoeckler L, Abajobir AA, Abate KH, Abbafati C, Abbas KM, Abd-Allah F, Abraham B, Abubakar I, Abu-Raddad LJ, Abu-Rmeileh NME, Achoki T, Ackerman IN, Adebiyi AO, Adedeji IA, Adsuar JC, Afanvi KA, Afshin A, Agardh EE, Agarwal A, Kumar S, Ahmed MB, Kiadaliri AA, Ahmadieh H, Akseer N, Al-Aly Z, Alam K, Alam NKM, Aldhahri SF, Alegretti MA, Aleman AV, Alemu ZA, Alexander LT, Raghib A, Alkerwi A, Alla F, Allebeck P, Alsharif U, Altirkawi KA, Martin EA, Alvis-Guzmán N, Amare AT, Amberbir A, Amegah AK, Amini H, Ammar W, Amrock SM, Anderson GM, Anderson BO, Antonio CAT, Anwari P, Arnlov J, Arsenijevic VSA, Artaman A, Asayesh H, Asghar RJ, Avokpaho EFGA, Awasthi A, Quintanilla BPA, Azzopardi P, Bacha U, Badawi A, Balakrishnan K, Banerjee A, Barac A, Barker-Collo SL, Barnighausen T, Barregard L, Barrero LH, Basu S, Bayou TA, Beardsley J, Bedi N, Beghi E, Bell B, Bell ML, Benjet C, Bennett

Continue

191

3.4 Large System Pathology Area

3 INFORMATION GROUPS BY AREA

192

DA, Bensenor IM, Berhane A, Bernabe E, Betsu BD, Beyene AS, Bhala N, Bhansali A, Bhatt S, Biadgilign S, Bienhofff K, Bikbov B, Bin Abdulhak AA, Bisanzio D, Bjertness E, Blore JD, Borschmann R, Boufous S, Bourne RRA, Brainin M, Brazinova A, Breitborde NJK, Brugha TS, Buchbinder R, Buckle GC, Butt ZA, Calabria B, Campos-Nonato IR, Campuzano JC, Carabin H, Carapetis JR, Cárdenas R, Carrero JJ, Castañeda-Orjuela CA, Rivas JC, CataláLópez F, Cavalleri F, Chang JC, Chiang PPC, Chibalabala M, Chibueze CE, Chisumpa VH, Choi JYJ, Choudhury L, Christensen H, Ciobanu LG, Colistro V, Colomar M, Colquhoun SM, Cortinovis M, Crump JA, Damasceno A, Dandona R, Dargan PI, Das Neves J, Davey G, Davis AC, De Leo D, Degenhardt L, Del Gobbo LC, Derrett S, Des Jarlais DC, Deveber GA, Dharmaratne SD, Dhillon PK, Ding EL, Doyle KE, Driscoll TR, Duan L, Dubey M, Duncan BB, Ebrahimi H, Ellenbogen RG, Elyazar I, Endries AY, Ermakov SP, Eshrati B, Esteghamati A, Estep K, Fahimi S, Farid TA, Farinha CSES, Faro A, Farvid MS, Farzadfar F, Feigin VL, Fereshtehnejad SM, Fernandes JG, Fernandes JC, Fischer F, Fitchett JRA, Foigt N, Fowkes FGR, Franklin RC, Friedman J, Frostad J, Furst T, Futran ND, Gabbe B, Gankpe FG, García-Basteiro AL, Gebrehiwot TT, Gebremedhin AT, Geleijnse JM, Gibney KB, Gillum RF, Ginawi IAM, Giref AZ, Giroud M, Gishu MD, Godwin WW, Gómez-Dantes H, Gona P, Goodridge A, Gopalani SV, Gotay CC, Goto A, Gouda HN, Guo Y, Gupta R, Gupta R, Gupta V, Gutiérrez RA, Hafezi-Nejad N, Haile D, Hailu AD, Hailu GB, Halasa YA, Ribhi R, Hamadeh, Hamidi S, Hammami M, Handal AJ, Hankey GJ, Harb HL, Harikrishnan S, Haro JM, Hassanvand MS, Hassen TA, Havmoeller R, Hay RJ, Hedayati MT, Heredia-Pi IB, Heydarpour P, Hoek HW, Hoffman DJ, Horino M, Horita N, Hosgood HD, Hoy DG, Hsairi M, Huang H, Huang JJ, Iburg KM, Idrisov BT, Innos K, Inoue M, Jacobsen KH, Jauregui A, Jayatilleke AU, Jeemon P, Jha V, Jiang GH, Jiang Y, Jibat T, Jiménez-Corona A, Jin Y, Jonas JB, Kabir Z, Kajungu DK, Kalkonde Y, Kamal R, Kan HD, Kandel A, Karch A, Karema CK, Karimkhani C, Kasaeian A, Katibeh M, Kaul A, Kawakami N, Kazi DS, Keiyoro PN, Kemp AH, Kengne AP, Keren A, Kesavachandran CN, Khader YS, Khan AR, Khan EA, Khang YH, Khoja TAM, Khubchandani J, Kieling C, Kim CI, Kim D, Kim YJ, Kissoon N, Kivipelto M, Knibbs LD, Knudsen AK, Kokubo Y, Kolte D, Kopec JA, Koul PA, Koyanagi A, Defo BK, Kuchenbecker RS, Bicer BK, Kuipers EJ, Kumar GA, Kwan GF, Lalloo R, Lallukka T, Larsson A, Latif AA, Lavados PM, Lawrynowicz AEB, Leasher JL, Leigh J, Leung R, Li YC, Li YM, Lipshultz SE, Liu PY, Liu Y, Lloyd BK, Logroscino G, Looker KJ, Lotufo PA, Lucas RM, Lunevicius R, Lyons RA, El Razek HMA, Mandavi M, Majdan M, Majeed A, Malekzadeh R, Malta DC, Marcenes W, Martínez-Raga J, Masiye F, Mason-Jones AJ, Matzopoulos R, Mayosi BM, McGrath JJ, Mckee M, Meaney PA, Mehari A, Melaku YA, Memiah P, Memish ZA, Mendoza W, Meretoja A, Meretoja TJ, Mesfin YM, Mhimbira FA, Miller TR, Mills EJ, Mirarefin M, Mirrakhimov EM, Mitchell PB, Mock CN, Mohammad KA, Mohammadi A, Mohammed S, Monasta L, Hernández JCM, Montico M, Moradi-Lakeh M, Mori R, Mueller UO, Mumford JE, Murdoch ME, Murthy GVS, Nachega JB, Naheed A, Naldi L, Nangia V, Newton JN, Ng M, Ngalesoni FN, Le Nguyen Q, Nisar MI, Pete PMN, Nolla JM, Norheim OF, Norman RE, Norrving B, Obermeyer CM, Ogbo FA, Oh IH, Oladimeji O, Olivares PR, Olusanya BO, Olusanya JO, Oren E, Ortiz A, Ota E, Oyekale AS, Pa M, Park EK, Parsaeian M, Patten SB, Patton GC, Pedro JM, Pereira DM, Perico N, Pesudovs K, Petzold M, Phillips MR, Piel FB, Pillay JD, Pishgar F, Plass D, Polinder S, Popova S, Poulton RG, Pourmalek F, Prasad NM, Qorbani M, Rabiee RHS, Radfar A, Rafay A, Rahimi K, Rahimi-Movaghar V, Rahman M, Rahman MHU, Rahman SU, Rai D, Rai RK, Rajsic S, Raju M, Ram U, Ranganathan K, Refaat AH, Reitsma MB, Remuzzi G, Resnikoff S, Reynolds A, Ribeiro AL, Ricci S, Roba HS, Rojas-Rueda D, Ronfani L, Roshandel G, Roth GA, Roy A, Sackey BB, Sagar R, Sanabria JR, Sánchez-Niño MD, Santos IS, Santos JV, Sarmiento-Suárez R, Sartorius B, Satpathy M, Savic M, Sawhney M, Schmidt MI, Schneider IJC, Schutte AE, Schwebel DC, Seedat

S, Sepanlou SG, Servan-Mori EE, Shahraz S, Shaikh MA, Sharma R, She J, Sheikhbahaei S, Shen J, Sheth KN, Shibuya K, Shigematsu M, Shin MJ, Shin R, Sigfusdottir ID, Silva DAS, Silverberg JI, Simard EP, Singh A, Singh JA, Singh PK, Skirbekk V, Skogen JC, Soljak M, Soreide K, Sorensen RJD, Sreeramareddy CT, Stathopoulou V, Steel N, Stein DJ, Stein MB, Steiner TJ, Stovner LJ, Stranges S, Stroumpoulis K, Sunguya BF, Sur PJ, Swaminathan S, Sykes BL, Szoeke CEI, Tabares-Seisdedos R, Landon N, Tanne D, Tavakkoli M, Taye B, Taylor HR, Ao BJT, Tegegne TK, Tekle DY, Terkawi AS, Tessema GA, Thakur JS, Thomson AJ, Thorne-Lyman AL, Thrift AG, Thurston GD, Tobe-Gai R, Tonelli M, Topor-Madry R, Topouzis F, Tran BX, Dimbuene ZT, Tsilimbaris M, Tura AK, Tuzcu EM, Tyrovolas S, Ukwaja KN, Undurraga EA, Uneke CJ, Uthman OA, van Gool CH, van Os J, Vasankari T, Vasconcelos AMN, Venketasubramanian N,Violante FS,Vlassov VV,Vollset SE, Wagner GR, Wallin MT, Wang LH, Weichenthal S, Weiderpass E, Weintraub RG, Werdecker A, WestermaM R, Wijeratne T, Wilkinson JD, Williams HC, Wiysonge CS, Woldeyohannes SM, Wolfe CDA, Won S, Xu G, Yadav AK, Yakob B, Yan LL, Yan Y, Yaseri M, Ye P, Yip P, Yonemoto N, Yoon SJ, Younis MZ, Yu C, Zaidi Z, Zaki MES, Zeeb H, Zodpey S, Zonies D, Zuhlke LJ, Zeeb H, Zodpey S, Zonies D, Zuhlke LJ, Vos T, López AD, Murray CJL. Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1603-58. Article. IF: 47.831; D1 • Kassebaum NJ, Barber RM, Bhutta ZA, Dandona L, Gething PW, Hay SI, Kinfu Y, Larson HJ, Liang X, Lim SS, López AD, Lozano R, Mensah GA, Mokdad AH, Naghavi M, Pinho C, Salomon JA, Steiner C, Vos T, Wang H, Abajobir AA, Abate KH, Abbas KM, Abd-Allah F, Abdallat MA, Abdulle AM, Abera SF, Aboyans V, Abubakar I, Abu-Rmeileh NME, Achoki T, Adebiyi AO, Adedeji IA, Adelekan AL, Adou AK, Afanvi KA, Agarwal A, Kiadaliri AA, Ajala ON, Akinyemiju TF, Akseer N, Al-Aly Z, Alam K, Alam NKM, Alasfoor D, Aldhahri SF, Aldridge RW, Alhabib S, Ali R, Alkerwi A, Alla F, Al-Raddadi R, Alsharif U, Martín EA, Alvis-Guzmán N, Amare AT, Amberbir A, Amegah AK, Ammar W, Amrock SM, Andersen HH, Anderson GM, Antoine RM, Antonio CAT, Aregay AF, Arnlov J, Arora M, Arsenijevic VSA, Al Artaman, Asayesh H, Atique S, Avokpaho EFGA, Awasthi A, Quintanilla BPA, Azzopardi P, Bacha U, Badawi A, Bahit MC, Balakrishnan K, Banerjee A, Barac A, Barker-Collo SL, Barnighausen T, Basu S, Bayou TA, Bayou YT, Bazargan-Hejazi S, Beardsley J, Bedi NW, Bekele T, Bell ML, Bennett DA, Bensenor IM, Berhane A, Bernabe E, Betsu BD, Beyene AS, Biadgilign S, Bikbov B, Bin Abdulhak AA, Biroscak BJ, Biryukov S, Bisanzio D, Bjertness E, Blore JD, Brainin M, Brazinova A, Breitborde NJK, Brugha TS, Butt ZA, Campos-Nonato IR, Campuzano JC, Cárdenas R, Carrero JJ, Carter A, Casey DC, Castaneda-Oquela CA, Castro RE, Catala-López F, Cavalleri F, Chang HY, Chang JC, Chavan L, Chibueze CE, Chisumpa VH, Choi JYJ, Chowdhury R, Christopher DJ, Ciobanu LG, Cirillo M, Coates MM, Coggeshall M, Colistro V, Colquhoun SM, Cooper C, Cooper LT, Cortinovis M, Dahiru T, Damasceno A, Danawi H, Dandona R, Das Neves J, De Leo D, Dellavalle RP, Deribe K, Deribew A, Jarlais DCD, Dharmaratne SD, Dicker DJ, Ding EL, Dossou E, Dubey M, Ebel BE, Ellingsen CL, Elyazar I, Endries AY, Ermakov SP, Eshrati B, Esteghamati A, Faraon EJA, Farid TA, Farinha CSES, Faro A, Farvid MS, Farzadfar F, Fereshtehnejad SM, Fernandes JC, Fischer F, Fitchett JRA, Fleming T, Gt NF, Franca EB, Franklin RC, Fraser MS, Friedman J, Pullman N, Furst T, Futran ND, Gambashidze K, Gamkrelidze A, Gebre T, Gebrehiwot TT, Gebremedhin AT, Gebremedhin M, Gebru AA, Geleijnse JM, Gibney KB, Giref AZ, Giroud M, Gishu MD, Glaser E, Goenka S, Gómez-Dantes H, Gona P, Goodridge A, Gopalani SV, Goto A, Graetz N, Gugnani HC, Guo Y, Gupta R, Gupta R, Gupta V, Hafezi-Nejad N, Hailu AD, Hailu GB, Hamadeh RR, Hamidi S, Hancock J, Handal AJ, Hankey GJ, Harb HL, Harikrishnan S, Harun KM, Havmoeller R,

Hoek HW, Horino M, Horita N, Hosgood HD, Hoy DG, Htet AS, Hu G, Huang H, Huang JJ, Huybrechts I, Huynh C, Iannarone M, Iburg KM, Idrisov BT, Iyer VJ, Jacobsen KH, Jahanmehr N, Jakovljevic MB, Javanbakht M, Jayatilleke AU, Jee SH, Jeemon P, Jha V, Jiang G, Jiang Y, Jibat T, Jonas JB, Kabir Z, Kamal R, Kan H, Karch A, Karletsos D, Kasaeian A, Kaul A, Kawakami N, Kayibanda JF, Kazanjan K, Kazi DS, Keiyoro PN, Kemmer L, Kemp AH, Kengne AP, Keren A, Kereselidze M, Kesavachandran CN, Khader YS, Khan AR, Khan EA, Khang YH, Khonelidze I, Khosravi A, Khubchandani J, Kim YJ, Kivipelto M, Knibbs LD, Kokubo Y, Kosen S, Koul PA, Koyanagi A, Krishnaswami S, Defo BK, Bicer BK, Kudom AA, Kulikoff XR, Kulkarni C, Kumar GA, Kutz MJ, Lal DK, Lalloo R, Lam H, Lamadrid-Figueroa H, Lan Q, Larsson A, Laryea DO, Leigh J, Leung R, Li Y, Li Y, Lipshultz SE, Liu PY, Liu S, Liu Y, Lloyd BK, Lotufo PA, Lunevicius R, Ma S, El Razek HMA, El Razek MMA, Majdan M, Majeed A, Malekzadeh R, Mapoma CC, Marcenes W, Margolis DJ, Marquez N, Masiye F, Marzan MB, Mason-Jones AJ, Mazorodze TT, Meaney PA, Mehari A, Mehndiratta MM, MenaRodríguez F, Mekonnen AB, Melaku YA, Memish ZA, Mendoza W, Meretoja A, Meretoja TJ, Mhimbira FA, Miller TR, Mills EJ, Mirarefin M, Misganaw A, Ibrahim NM, Mohammad KA, Mohammadi A, Mohammed S, Mola GLD, Monasta L, Monis JDLC, Hernández JCM, Montero P, Montico M, Mooney MD, Moore AR, MoradiLakeh M, Morawska L, Mori R, Mueller U, Murthy GVS, Murthy S, Nachega JB, Naheed A, Naldi L, Nand D, Nangia V, Nash D, Neupane S, Newton JN, Ng M, Ngalesoni FN, Nguhiu P, Nguyen G, Le Nguyen Q, Nisar MI, Nomura M, Norheim OF, Norman RE, Nyakarahuka L, Obermeyer CM, Ogbo FA, Oh IH, Ojelabi FA, Olivares PR, Olusanya BO, Olusanya JO, Opio JN, Oren E, Ota E, Oyekale AS, Pa M, Pain A, Papantoniou N, Park EK, Park HY, Caicedo AJP, Patten SB, Paul VK, Pereira DM, Perico N, Pesudovs K, Petzold M, Phillips MR, Pillay JD, Pishgar F, Polinder S, Pope D, Pourmalek F, Qorbani M, Rafay A, Rahimi K, Rahimi-Movaghar V, Rahman M, Rahman MHU, Rahman SU, Rai RK, Ram U, Ranabhat CL, Rangaswamy T, Rao PV, Refaat AH, Remuzzi G, Resnikoff S, Rojas-Rueda D, Ronfani L, Roshandel G, Roy A, Ruhago GM, Sagar R, Saleh MM, Sanabria JR, Sánchez-Niño MD, Santos IS, Santos JV, Sarmiento-Suárez R, Sartorius B, Satpathy M, Savic M, Sawhney M, Saylan MI, Schneider IJ, Schwebel DC, Seedat S, Sepanlou SG, Servan-Mori EE, Setegn T, Shackelford KA, Shaikh MA, Shakh-Nazarova M, Sharma R, She J, Sheikhbahaei S, Shen J, Shibuya K, Shin MJ, Shiri R, Shishani K, Shiue I, Sigfusdottir ID, Silpakit N, Silva DA, Silveira DG, Silverberg JI, Simard EP, Sindi S, Singh A, Singh JA, Singh OP, Singh PK, Singh V, Skirbekk V, Sligar A, Sliwa K, Smith JM, Soneji S, Sorensen RJ, Soriano JB, Soshnikov S, Sposato LA, Sreeramareddy CT, Stathopoulou V, Stroumpoulis K, Sturua L, Sunguya BF, Swaminathan S, Sykes BL, Szoeke CE, Tabarés-Seisdedos R, Tabb KM, Talongwa RT, Tavakkoli M, Taye B, Tedla BA, Tefera WM, Tekle T, Shifa GT, Terkawi AS, Tesfay FH, Tessema GA, Thomson AJ, Thorne-Lyman AL, Tobe-Gai R, ToporMadry R, Towbin JA, Tran BX, Dimbuene ZT, Tura AK, Tyrovolas S, Ukwaja KN, Uthman OA, Vasankari T, Venketasubramanian N, Violante FS, Vladimirov SK, Vlassov VV, Vollset SE, Wagner JA, Wang L, Weichenthal S, Weiderpass E, Weintraub RG, Werdecker A, Westerman R, Wijeratne T, Wilkinson JD, Wiysonge CS, Woldeyohannes SM, Wolfe CD, Wolock T, Won S, Wubshet M, Xiao Q, Xu G,Yadav AK,Yakob B,Yalew AZ,Yano Y,Yebyo HG,Yip P, Yonemoto N, Yoon SJ, Younis MZ, Yu C, Yu S, Zaidi Z, Zaki ME, Zeeb H, Zhao Y, Zhao Y, Zhou M, Zodpey S, Zuhlke LJ, Murray CJ. Global, regional, and national levels of maternal mortality, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1775-812. Article. IF: 47.831; D1 • Liappas G, González-Mateo G, Aguirre AR, Abensur H, AlbarVizcaíno P, Parra EG, Sandoval P, Ramírez LG, del Peso G, Acedo JM, Bajo MA, Selgas R, Tomero JAS, López-Cabrera M, Aguilera A. Nebivolol, a beta(1)-adrenergic blocker, protects from pe-

ritoneal membrane damage induced during peritoneal dialysis. Oncotarget. 2016;7(21):30133-46. Article. IF: 5.168; Q1 • Liappas G, González-Mateo GT, Sánchez-Díaz R, Lazcano JJ, Lasarte S, Matesanz-Marín A, Zur R, Ferrantelli E, Ramírez LG, Aguilera A, Fernández-Ruiz E, Belén RHJ, Selgas R, SánchezMadrid F, Martín P, López-Cabrera M. Immune-regulatory molecule CD69 controls peritoneal fibrosis. J Am Soc Nephrol. 2016;27(12):3561-76. Article. IF: 8.966; D1 • Pérez-Gómez MV, Sánchez-Niño MD, Sanz AB, Zheng BB, Martín-Cleary C, Ruiz-Ortega M, Ortiz A, Fernández-Fernández B. Targeting inflammation in diabetic kidney disease: early clinical trials. Expert Opin Inv Drug. 2016;25(9):1045-58. Review. IF: 4.716; Q1 • Robles NR, Peces R, Gómez-Ferrer A, Villacampa F, Álvarez-Ossorio JL, Pérez-Segura P, Morote J, Herrera-Imbroda B, Nieto J, Carballido J, Anido U,Valero M, Meseguer C,Torra R. Everolimus safety and efficacy for renal angiomyolipomas associated with tuberous sclerosis complex: a Spanish expanded access trial. Orphanet J Rare Dis. 2016;11:128. Article. IF: 3.507; Q2 • Ruiz-Andrés O, Sánchez-Niño MD, Cannata-Ortiz P, Ruiz-Ortega M, Egido J, Ortiz A, Sanz AB. Histone lysine crotonylation during acute kidney injury in mice. Dis Model Mech. 2016;9(6):63345. Article. IF: 4.691; Q1 • Ruiz-Andrés O, Sánchez-Niño MD, Moreno JA, Ruiz-Ortega M, Ramos AM, Sanz AB, Ortiz A. Downregulation of kidney protective factors by inflammation: role of transcription factors and epigenetic mechanisms. Am J Physiol-Renal. 2016;311(6):F132940. Review. IF: 3.611; Q1 • Ruiz-Andrés O, Suárez-Álvarez B, Sánchez-Ramos C, Monsalve M, Sánchez-Niño MD, Ruiz-Ortega M, Egido J, Ortiz A, Sanz AB. The inflammatory cytokine TWEAK decreases PGC-1 alpha expression and mitochondrial function in acute kidney injury. Kidney Int. 2016;89(2):399-410. Article. IF: 8.395; D1 • Sánchez-Niño MD, Sanz AB, Ortiz A. Chronicity following ischaemia-reperfusion injury depends on tubular-macrophage crosstalk involving two tubular cell-derived CSF-1R activators: CSF-1 and IL-34. Nephrol Dial Transpl. 2016;31(9):1409-16. Review. IF: 4.47; Q1 • Sanz AB, Ruiz-Andrés O, Sánchez-Niño MD, Ruiz-Ortega M, Ramos AM, Ortiz A. Out of the TWEAKlight: Elucidating the role of Fn14 and TWEAK in acute kidney injury. Semin Nephrol. 2016;36(3):189-98. Review. IF: 3.598; Q1 • Trimarchi H, Canzonieri R, Schiel A, Costales-Collaguazo C, Politei J, Stern A, Paulero M, Rengel T, Andrews J, Forrester M, Lombi M, Pomeranz V, Iriarte R, Muryan A, Zotta E, Sánchez-Niño MD, Ortiz A. Increased urinary CD80 excretion and podocyturia in Fabry disease. J Transl Med. 2016;14:289. Article. IF: 3.786; Q1 • Valino-Rivas L, González-Lafuente L, Sanz AB, Ruiz-Ortega M, Ortiz A, Sánchez-Niño MD. Non-canonical NF kappa B activation promotes chemokine expression in podocytes. Sci Rep-Uk. 2016;6:28857. Article. IF: 4.259; Q1 • Vos T, Allen C, Arora M, Barber RM, Bhutta ZA, Brown A, Carter A, Casey DC, Charlson FJ, Chen AZ, Coggeshall M, Cornaby L, Dandona L, Dicker DJ, Dilegge T, Erskine HE, Ferrari AJ, Fitzmaurice C, Fleming T, Forouzanfar MH, Fullman N, Gething PW, Goldberg EM, Graetz N, Haagsma JA, Johnson CO, Kassebaum NJ, Kawashima T, Kemmer L, Khalil IA, Kinfu Y, Kyu HH, Leung JN, Liang XF, Lim SS, López AD, Lozano R, Marczak L, Mensah GA, Mokdad AH, Naghavi M, Nguyen G, Nsoesie E, Olsen H, Pigott DM, Pinho C, Rankin Z, Reinig N, Salomon JA, Sandar L, Smith A, Stanaway J, Steiner C, Teeple S, Thomas BA, Troeger C, Wagner JA, Wang HD, Wanga V, Whiteford HA, Zoeckler L, Abajobir AA, Abate KH, Abbafati C, Abbas KM, Abd-Allah F, Abraham B, Abubakar I, Abu-Raddad LJ, Abu-Rmeileh NME, Ackerman IN, Adebiyi AO, Ademi Z, Adou AK, Afanvi KA, Agardh EE, Agarwal

Continue

193

3.4 Large System Pathology Area

3 INFORMATION GROUPS BY AREA

194

A, Kiadaliri AA, Ahmadieh H, Ajala ON, Akinyemi RO, Akseer N, Al-Aly Z, Alam K, Alam NKM, Aldhahri SF, Alegretti MA, Alemu ZA, Alexander LT, Alhabib S, Ali R, Alkerwi A, Alla F, Allebeck P, AlRaddadi R, Alsharif U, Altirkawi KA, Alvis-Guzman N, Amare AT, Amberbir A, Amini H, Ammar W, Amrock SM, Andersen HH, Anderson GM, Anderson B, Antonio CAT, Aregay AF, Arnlov J, Al Artaman, Asayesh H, Assadi R, Atique S, Avokpaho EFGA, Awasthi A, Quintanilla BPA, Azzopardi P, Bacha U, Badawi A, Balakrishnan K, Banerjee A, Barac A, Barker-Collo SL, Barnighausen T, Barregard L, Barrero LH, Basu A, Bazargan-Hejazi S, Bell B, Bell ML, Bennett DA, Bensenor IM, Benzian H, Berhane A, Bernabe E, Betsu BD, Beyene AS, Bhala N, Bhatt S, Biadgilign S, Bienhofff K, Bikbov B, Biryukov S, Bisanzio D, Bjertness E, Blore J, Borschmann R, Boufous S, Brainin M, Brazinova A, Breitborde NJK, Brown J, Buchbinder R, Buckle GC, Butt ZA, Calabria B, Campos-Nonato IR, Campuzano JC, Carabin H, Cardenas R, Carpenter DO, Carrero JJ, Castaneda-Orjuela CA, Rivas JC, Catala-López F, Chang JC, Chiang PPC, Chibueze CE, Chisumpa VH, Choi JYJ, Chowdhury R, Christensen H, Christopher DJ, Ciobanu LG, Cirillo M, Coates MM, Colquhoun SM, Cooper C, Cortinovis M, Crump JA, Damtew SA, Dandona R, Daoud F, Dargan PI, das Neves J, Davey G, Davis AC, De Leo D, Degenhardt L, Del Gobbo LC, Dellavalle RP, Deribe K, Deribew A, Derrett S, Des Jarlais DC, Dharmaratne SD, Dhillon PK, Díaz-Torne C, Ding EL, Driscoll TR, Duan LL, Dubey M, Duncan BB, Ebrahimi H, Ellenbogen RG, Elyazar I, Endres M, Endries AY, Ermakov SP, Eshrati B, Estep K, Farid TA, Farinha CSES, Faro A, Farvid MS, Farzadfar F, Feigin VL, Felson DT, Fereshtehnejad SM, Fernandes JG, Fernandes JC, Fischer F, Fitchett JRA, Foreman K, Fowkes GR, Fox J, Franklin RC, Friedman J, Frostad J, Furst T, Futran ND, Gabbe B, Ganguly P, Gankpe FG, Gebre T, Gebrehiwot TT, Gebremedhin AT, Geleijnse JM, Gessner BD, Gibney KB, Ginawi IAM, Giref AZ, Giroud M, Gishu MD, Glaser E, Godwin WW, Gómez-Dantes H, Gona P, Goodridge A, Gopalani SV, Gotay CC, Goto A, Gouda HN, Grainger R, Greaves F, Guillemin F, Guo YM, Gupta R, Gupta R, Gupta V, Gutierrez RA, Haile D, Hailu AD, Hailu GB, Halasa YA, Hamadeh RR, Hamidi S, Hammami M, Hancock J, Handal AJ, Hankey GJ, Hao YT, Harb HL, Harikrishnan S, Haro JM, Havmoeller R, Hay RJ, Heredia-Pi IB, Heydarpour P, Hoek HW, Horino M, Horita N, Hosgood HD, Hoy DG, Htet AS, Huang H, Huang JJ, Huynh C, Iannarone M, Iburg KM, Innos K, Inoue M, Iyer VJ, Jacobsen KH, Jahanmehr N, Jakovljevic MB, Javanbakht M, Jayatilleke AU, Jee SH, Jeemon P, Jensen PN, Jiang Y, Jibat T, Jiménez-Corona A, Jin Y, Jonas JB, Kabir Z, Kalkonde Y, Kamal R, Kan HD, Karch A, Karema CK, Karimkhani C, Kasaeian A, Kaul A, Kawakami N, Karimkhani C, Kasaeian A, Kaul A, Kawakami N, Keiyoro PN, Kemp AH, Keren A, Kesavachandran CN, Khader YS, Khaiff AR, Khaiff EA, Khang YH, Khera S, Khoja TAM, Khubchandani J, Kieling C, Kim P, Kim CI, Kim D, Kim YJ, Kissoon N, Knibbs LD, Knudsen AK, Kokubo Y, Kolte D, Kopec JA, Kosen S, Kotsakis GA, Koul PA, Koyanagi A, Kravchenko M, Defo BK, Bicer BK, Kudom AA, Kuipers EJ, Kumar GA, Kutz M, Kwan GF, Lal A, Lalloo R, Lallukka T, Lam H, Lam JO, Langan SM, Larsson A, Lavados PM, Leasher JL, Leigh J, Leung R, Levi M, Li YC, Li YM, Liang J, Liu SW, Liu Y, Lloyd BK, Lo WD, Logroscino G, Looker KJ, Lotufo PA, Lunevicius R, Lyons RA, Mackay MT, Abd El Razek MM, Mahdavi M, Majdan M, Majeed A, Malekzadeh R, Marcenes W, Margolis DJ, Martínez-Raga J, Masiye F, Massano J, McGarvey ST, McGrath JJ, McKee M, McMahon BJ, Meaney PA, Mehari A, Meija-Rodríguez F, Mekonnen AB, Melaku YA, Memiah P, Memish ZA, Mendoza W, Meretoja A, Meretoja TJ, Mhimbira FA, Miller TR, Mills EJ, Mirarefin M, Mitchell PB, Mock CN, Mohammadi A, Mohammed S, Monasta L, Hernández JCM, Montico M, Mooney MD, Moradi-Lakeh M, Morawska L, Mueller UO, Mullany E, Mumford JE, Murdoch ME, Nachega JB, Nagel G, Naheed A, Naldi L, Nangia V, Newton JN, Ng M, Ngalesoni FN, Le Nguyen Q, Nisar MI, Pete PMN, Nona JM, Norheim OF, Norman RE, Norrving B, Nunes BP, Ogbo FA, Oh IH, Ohkubo T, Olivares PR, Olusanya BO, Olusanya JO, Ortiz A, Osman M,

Ota E, Mahesh PA, Park EK, Parsaeian M, Passos VMD, Caicedo AJP, Patten SB, Patton GC, Pereira DM, Pérez-Padilla R, Perico N, Pesudovs K, Petzold M, Phillips MR, Piel FB, Pillay JD, Pishgar F, Plass D, Platts-Mills JA, Polinder S, Pond CD, Popova S, Poulton RG, Pourmalek F, Prabhakaran D, Prasad NM, Qorbani M, Rabiee RHS, Radfar A, Rafay A, Rahimi K, Rahimi-Movaghar V, Rahman M, Rahman MHU, Rahman SU, Rai RK, Rajsic S, Ram U, Rao P, Refaat AH, Reitsma MB, Remuzzi G, Resnikofff S, Reynolds A, Ribeiro AL, Blancas MJR, Rolm HS, Rojas-Rueda D, Ronfani L, Roshandel G, Roth GA, Rothenbacher D, Roy A, Sagar R, Sahathevan R, Sanabria JR, Sánchez-Niño MD, Santos IS, Santos JV, SarmientoSuárez R, Sartorius B, Satpathy M, Savic M, Sawhney M, Schaub MP, Schmidt MI, Schneider IJC, Schottker B, Schwebel DC, Scott JG, Seedat S, Sepanlou SG, Servan-Mori EE, Shackelford KA, Shaheen A, Shaikh MA, Sharma R, Sharma U, Shen JB, Shepard DS, Sheth KN, Shibuya K, Shin MJ, Shiri R, Shiue I, Shrime MG, Sigfusdottir ID, Silva DAS, Silveira DGA, Singh A, Singh JA, Singh OP, Singh PK, Sivonda A, Skirbekk V, Skogen JC, Sligar A, Silwa K, Soljak M, Soreide K, Soriano JB, Sposato LA, Sreeramareddy CT, Stathopoulou V, Steel N, Stein DJ, Steiner TJ, Steinke S, Stovner L, Stroumpoulis K, Sunguya BF, Sur P, Swaminathan S, Sykes BL, Szoeke CEI, Tabares-Seisdedos R, Takala JS, Landon N, Tanne D, Tavakkoli M, Taye B, Taylor HR, Te Ao BJ, Tedla BA, Terkawi AS, Thomson AJ, Thorne-Lyman AL, Thrift AG, Thurston GD, TobeGai R, Tonelli M, Topor-Madry R, Topouzis F, Tran BX, Dimbuene ZT, Tsilimbaris M, Tura AK, Tuzcu EM, Tyrovolas S, Ukwaja KN, Undurraga EA, Uneke CJ, Uthman OA, van Gool CH,Varakin YY, Vasankari T, Venketasubramanian N, Verma RK, Violante FS, Vladimirov SK, Vlassov VV, Vollset SE, Wagner GR, Waller SG, Wang LH, Watkins DA, Weichenthal S, Weiderpass E, Weintraub RG, Werdecker A, Westerman R, White RA, Williams HC, Wiysonge CS, Wolfe CDA, Won S, Woodbrook R, Wubshet M, Xavier D, Xu GL, Yadav AK, Yan LJL, Yano YCR, Yaseri M, Ye PP, Yebyo HG, Yip P, Yonemoto N, Yoon SJ, Younis MZ, Yu C, Zaidi Z, Zaki MES, Zeeb H, Zhou MG, Zodpey S, Zuhlke LJ, Murray CJL. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1545-602. Article. IF: 47.831; D1 • Wang HD, Bhutta ZA, Coates MM, Coggeshall M, Dandona L, Diallo K, Franca EB, Fraser M, Fullman N, Gething PW, Hay SI, Kinfu Y, Kita M, Kulikoff XR, Larson HJ, Liang J, Liang XF, Lind M, López AD, Lozano R, Mensah GA, Mikesell JB, Mokdad AH, Mooney MD, Nguyen G, Rakovac I, Salomon JA, Silpakit N, Sligar A, Sorensen RJD, Vos T, Zhu J, Abajobir AA, Abate KH, Abbas KM, Abd-Allah F, Abdulle AM, Abera SF, Aboyans V, Abraham B, Abubakar I, Abu-Raddad LJ, Abu-Rmeileh NME, Abyu GY, Achoki T, Adebiyi AO, Adedeji IA, Adelekan AL, Adou AK, Agarwal A, Ajala ON, Akinyemiju TF, Akseer N, Alam K, Alam NKM, Alasfoor D, Aldridge RW, Alegretti MA, Alemu ZA, Ali R, Alkerwi A, Alla F, Al-Raddadi R, Alsharif U, Altirkawi KA, Martin EA, Alvis-Guzmán N, Amare AT, Amberbir A, Amegah AK, Ameh EA, Ammar W, Amrock SM, Andersen HH, Anderson GM, Antonio CAT, Arnlov J, Al Artaman, Asayesh H, Asghar RJ, Assadi R, Atique S, Avokpaho EFGA, Awasthi A, Quintanilla BPA, Bacha U, Badawi A, Balakrishnan K, Banerjee A, Banigbe BF, Barac A, Barber RM, Barker-Collo SL, Barnighausen T, Barrero LH, Bayou TA, Bayou YT, BazarganHejazi S, Beardsley J, Bedi N, Bekele T, Bell ML, Bello AK, Bennett DA, Bensenor IM, Berhane A, Bernabe E, Betsu BD, Bhatt S, Biadgilign S, Bikbov B, Birlik SM, Bisanzio D, Bjertness E, Blore JD, Bourne RRA, Brainin M, Brazinova A, Breitborde NJK, Brown A, Buckle GC, Burch M, Butt ZA, Campos-Nonato IR, Campuzano JC, Cardenas R, Carpenter D, Carrero JJ, Carter A, Casey DC, Castaneda-Oquela CA, Rivas JC, Castro RE, Catala-López F, Cercy K, Chang HY, Chang JC, Chibueze CE, Chisumpa VH, Choi JYJ, Chowdhury R, Christopher DJ, Ciobanu LG, Colquhoun SM, Cooper C, Cornaby L, Damtew SA, Danawi H, Dandona R, das

Neves J, Davis AC, de Jager P, De Leo D, Degenhardt L, Deribe K, Deribew A, Jarlais DCD, deVeber GA, Dharmaratne SD, Dhillon PK, Ding EL, Doshi PP, Doyle KE, Duan LL, Dubey M, Ebrahimi H, Ellingsen CL, Elyazar I, Endries AY, Ermakov SP, Eshrati B, Esteghamati A, Faraon EJA, Farid TA, Farinha CSES, Faro A, Farvid MS, Farzadfar F, Fereshtehnejad SM, Fernandes JC, Fischer F, Fitchett JRA, Foigt N, Franklin RC, Friedman J, Furst T, Gambashidze K, Gamkrelidze A, Ganguly P, Gebre T, Gebrehiwot TT, Gebremedhin AT, Gebru AA, Gelefinse JM, Gessner BD, Ginawi IAM, Giref AZ, Gishu MD, Gómez-Dantes H, Gona P, Goodridge A, Gopalani SV, Goto A, Gouda HN, Gugnani HC, Guo YM, Gupta R, Gupta R, Gupta V, Gyawali B, Haagsma JA, Hafezi-Nejad N, Haile D, Hailu AD, Hailu GB, Hamadeh RR, Hancock J, Handal AJ, Hankey GJ, Harb HL, Harikrishnan S, Harun KM, Havmoeller R, Hay RJ, Heredia-Pi IB, Hoek HW, Horino M, Horita N, Hosgood HD, Hotez PJ, Hoy DG, Hsairi M, Hu GQ, Huang C, Huang JJ, Huang H, Huiart L, Iburg KM, Idrisov BT, Innos K, Jacobsen KH, Jahanmehr N, Javanbakht M, Jayatilleke AU, Jee SH, Jeemon P, Jha V, Jiang GH, Jiang Y, Jibat T, Jin Y, Jonas JB, Kabir Z, Kalkonde Y, Karnak R, Kan HD, Kang G, Karch A, Karema CK, Kasaeian A, Kaul A, Kawakami N, Kayibanda JF, Kazanjan K, Keiyoro PN, Kemp AH, Kengne AP, Keren A, Kereselidze M, Kesavachandran CN, Khader YS, Khalil IA, Khan AR, Khan EA, Khang YH, Khonelidze I, Khubchandani J, Kim CI, Kim D, Kim YJ, Kissoon N, Kivipelto M, Knibbs LD, Kokubo Y, Kosen S, Koul PA, Koyanagi A, Defo BK, Bicer BK, Kudom AA, Kumar GA, Kyu HH, Lal DK, Lalloo R, Lam H, Lam JO, Lansingh VC, Larsson A, Leigh J, Leung R, Li YC, Li YM, Lindsay MP, Liu PY, Liu SW, Lloyd BK, Lo WD, Logroscino G, Low N, Lunevicius R, Lyons RA, Ma S, Abd El Razek HM, Abd El Razek MM, Mandavi M, Majdan M, Majeed A, Malekzadeh R, Mapoma CC, Marcenes W, -Raga JM, Marzan MB, Masiye F, McGrath JJ, Meaney PA, Mehari A, Mehndiratta MM, Mekonnen AB, Melaku YA, Memiah P, Memish ZA, Mendoza W, Meretoja A, Meretoja TJ, Mhimbira FA, Miller TR, Mills EJ, Mirarefin M, Misganaw A, Mock CN, Mohammad KA, Mohammadi A, Mohammed S, Monasta L, Hernández JCM, Montico M, Moore AR, Moradi-Lakeh M, Morawska L, Mori R, Mueller UO, Murphy GAV, Murthy S, Nachega JB, Naheed A, Naidoo KS, Naldi L, Nand D, Nangia V, Neupane S, Newton CR, Newton JN, Ng M, Ngalesoni FN, Nguhiu P, Le Nguyen Q, Nisar MI, Pete PMN, Norheim OF, Norman RE, Ogbo FA, Oh IH, Ojelabi FA, Olivares PR, Olusanya BO, Olusanya JO, Oren E, Ota E, Mahesh PA, Park EK, Park HY, Parsaeian M, Caicedo AJP, Patten SB, Pedro JM, Pereira DM, Perico N, Pesudovs K, Petzold M, Phillips MR, Pillay JD, Pishgar F, Polinder S, Pope D, Popova S, Pourmalek F, Qorbani M, Rabiee RHS, Rafay A, RahimiMovaghar V, Rahman M, Ur Rahman MH, Ur Rahman S, Rai RK, Raju M, Ram U, Rana SM, Ranabhat CL, Rao P, Refaat AH, Remuzzi G, Resnikoff S, Reynolds A, Rojas-Rueda D, Ronfani L, Roshandel G, Roth GA, Roy A, Ruhago GM, Sagar R, Saleh MM, Sanabria JR, Sánchez-Niño MD, Santos IS, Santos JV, Sarmiento-Suárez R, Sartorius B, Satpathy M, Savic M, Sawhney M, Schneider IJC, Schottker B, Schwebel DC, Seedat S, Sepanlou SG, Servan-Mori EE, Se-

tegn T, Shahraz S, Shaikh MA, Shakh-Nazarova M, Sharma R, She J, Sheikhbahaei S, Shen JB, Sheth KN, Shibuya K, Shin HH, Shin MJ, Shiri R, Shuie I, Sigfusdottir ID, Silva DAS, Silverberg J, Simard EP, Sindi S, Singh A, Singh JA, Singh OP, Singh PK, Singh V, Soriano JB, Soshnikov S, Sposato LA, Sreeramareddy CT, Stathopoulou V, Steel N, Stroumpoulis K, Sturua L, Sunguya BF, Swaminathan S, Sykes BL, Szoeke CEI, Tabares-Seisdedos R, Tavakkoli M, Taye B, Tedla BA, Tefera WM, Tekle T, Shifa GT, Terkawi AS, Tesfay FH, Tessema GA, Thapa K, Thomson AJ, -Lyman ALT, Tobe-Gai R, Tonelli M, Topor-Madry R, Topouzis F, Tran BX, Troeger C, Truelsen T, Dimbuene ZT, Tura AK, Tyrovolas S, Ukwaja KN, Uneke CJ, Uthman OA, Vaezghasemi M, Vasankari T, Vasconcelos AMN, Venketasubramanian N, Verma RK, Violante FS, Vladimirov SK, Vlassov VV, Vollset SE, Wang LH, Wang YP, Weichenthal S, Weiderpass E, Weintraub RG, Weiss DJ, Werdecker A, Westerman R, Widdowson MA, Wijeratne T, Williams TN, Wiysonge CS, Wolfe CDA, Wolfe I, Won S, Wubshet M, Xiao QY, Xu GL, Yadav AK, Yakob B, Yano Y, Yaseri M, Ye PP, Yebyo HG, Yip P, Yonemoto N, Yoon SJ, Younis MZ, Yu CH, Zaidi Z, Zaki ME, Zeeb H, Zhang H, Zhao Y, Zheng YF, Zhou MG, Zodpey S, Murray CJL. Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1725-74. Article. IF: 47.831; D1 • Wang HD, Naghavi M, Allen C, Barber RM, Bhutta ZA, Carter A, Casey DC, Charlson FJ, Chen AZ, Coates MM, Coggeshall M, Dandona L, Dicker DJ, Erskine HE, Ferrari AJ, Fitzmaurice C, Foreman K, Forouzanfar MH, Fraser MS, Pullman N, Gething PW, Goldberg EM, Graetz N, Haagsma JA, Hay SI, Huynh C, Johnson C, Kassebaum NJ, Kinfu Y, Kulikoff XR, Kutz M, Kyu HH, Larson HJ, Leung J, Liang XF, Lim SS, Lind M, Lozano R, Marquez N, Mensah GA, Mikesell J, Mokdad AH, Mooney MD, Nguyen G, Nsoesie E, Pigott DM, Pinho C, Roth GA, Salomón JA, Sandar L, Silpakit N, Sligar A, Sorensen RJD, Stanaway J, Steiner C,Teeple S,Thomas BA, Troeger C, VanderZanden A, Vollset SE, Wanga V, Whiteford HA,Wolock T, Zoeckler L,Abate KH,Abbafati C,Abbas KM,AbdAllah F, Abera SF, Abreu DMX, Abu-Raddad LJ, Abyu GY, Achoki T, Adelekan AL, Ademi Z, Adou AK, Adsuar JC, Afanvi KA, Afshin A, Agardh EE, Agarwal A, Agrawal A, Kiadaliri AA, Ajala ON, Akanda AS, Akinyemi RO, Akinyemiju TF, Akseer N, Al Lami FH, Alabed S, Al-Aly Z, Alam K, Alam NKM, Alasfoor D, Aldhahri SF, Aldridge RW, Alegretti MA, Aleman AV, Alemu ZA, Alexander LT,Alhabib S,Ali R,Alkerwi A,Alla F,Allebeck P, Al-Raddadi R, Alsharif U, Altirkawi KA, Martin EA, Alvis-Guzman N, Amare AT, Amegah AK, Ameh EA, Amini H, Ammar W, Amrock SM, Andersen HH, Anderson B, Anderson GM, Antonio CAT, Aregay AF, Arnlov J, Arsenijevic VSA, Al Artaman, Asayesh H, Asghar RJ, Atique S, Avokpaho EFGA, Awasthi A, Azzopardi P, Bacha U, Badawi A, Bahit MC, Balakrishnan K, Banerjee A, Barac A, Barker-Collo SL, Barnighausen T, Barregard L, Barrero LH, Basu A, Basu S, Bayou YT, Bazargan-Hejazi S, Beardsley J, Bedi N, Beghi E, Belay HA, Bell B, Bell ML, Bello AK, Bennett DA, Bensenor IM, Berhane A, Bernabe E, Betsu BD, Beyene AS, Bhala N, Bhalla A, Biadgilign S, Bikbov B, Bin Abdulhak AA, Biroscak BJ, Biryukov S, Bjertness E, Blore JD, Blosser CD, Bohensky MA, Borschmann R, Bose D, Bourne RRA, Brainin M, Brayne CEG, Brazinova A, Breitborde NJK, Brenner H, Brewer JD, Brown A, Brown J, Brugha TS, Buckle GC, Butt ZA, Calabria B, Campos-Novato IR, Campuzano JC, Carapetis JR, Cardenas R, Carpenter D, Carrero JJ, Castañeda-Oquela CA, Rivas JC, Catalá-López F, Cavalleri F, Cercy K, Cerda J, Chen WQ, Chew A, Chiang PPC, Chibalabala M, Chibueze CE, Chimed-Ochir O, Chisumpa VH, Choi JYJ, Chowdhury R, Christensen H, Christopher DJ, Ciobanu LG, Cirillo M, Cohen AJ, Colistro V, Colomar M, Colqu-

Continue

195

3.4 Large System Pathology Area

3 INFORMATION GROUPS BY AREA

196

houn SM, Cooper C, Cooper LT, Cortinovis M, Cowie BC, Crump JA, Damsere-Derry J, Danawi H, Dandona R, Daoud F, Darby SC, Dargan PI, das Neves J, Davey G, Davis AC, Davitoiu DV, de Castro EF, de Jager P, de Leo D, Degenhardt L, Dellavalle RP, Deribe K, Deribew A, Dharmaratne SD, Dhillon PK, DíazTorne C, Ding EL, dos Santos KPB, Dossou E, Driscoll TR, Duan LL, Dubey M, Bartholow B, Ellenbogen RG, Lycke C, Elyazar I, Endries AY, Ermakov SP, Eshrati B, Esteghamati A, Estep K, Faghmous IDA, Fahimi S, Jose E, Farid TA, Farinha CSES, Faro A, Farvid MS, Farzadfar F, Feigin VL, Fereshtehnejad SM, Fernandes JG, Fernandes JC, Fischer F, Fitchett JRA, Flaxman A, Foigt N, Fowkes FGR, Franca EB, Franklin RC, Friedman J, Frostad J, Hirst T, Futran ND, Gall SL, Gambashidze K, Gamkrelidze A, Ganguly P, Gankpe FG, Gebre T, Gebrehiwot TT, Gebremedhin AT, Gebru AA, Geleijnse JM, Gessner BD, Ghoshal AG, Gibney KB, Gillum RF, Gilmour S, Giref AZ, Giroud M, Gishu MD, Giussani G, Glaser E, Godwin WW, Gómez-Dantes H, Gona P, Goodridge A, Gopalani SV, Gosselin RA, Gotay CC, Goto A, Gouda HN, Greaves F, Gugnani HC, Gupta R, Gupta R, Gupta V, Gutierrez RA, HafeziNejad N, Haile D, Hailu AD, Hailu GB, Halasa YA, Hamadeh RR, Hamidi S, Hancock J, Handal AJ, Hankey GJ, Hao YT, Harb HL, Harikrishnan S, Haro JM, Havmoeller R, Heckbert SR, Heredia-Pi IB, Heydarpour P, Hilderink HBM, Hoek HW, Hogg RS, Horino M, Horita N, Hosgood HD, Hotez PJ, Hoy DG, Hsairi M, Htet AS, Htike MMT, Hu GQ, Huang C, Huang H, Huiart L, Husseini A, Huybrechts I, Huynh G, Iburg KM, Innos K, Inoue M, Iyer VJ, Jacobs TA, Jacobsen KH, Jahanmehr N, Jakovljevic MB, James P, Javanbakht M, Jayaraman SP, Jayatilleke AU, Jeemon P, Jensen PN, Jha V, Jiang G, Jiang Y, Jibat T, Jiménez-Corona A, Jonas JB, Joshi TK, Kabir Z, Karnak R, Kan HD, Kant S, Karch A, Karema CK, Karimkhani C, Karletsos D, Karthikeyan G, Kasaeian A, Katibeh M, Kaul A, Kawakami N, Kayibanda JF, Keiyoro PN, Kemmer L, Kemp AH, Kengne AP, Keren A, Kereselidze M, Kesavachandran CN, Khader YS, Khalil IA, Khan AR, Khan EA, Khang YH, Khera S, Khoja TAM, Kieling C, Kim D, Kim YJ, Kissela BM, Kissoon N, Knibbs LD, Knudsen AK, Kokubo Y, Kolte D, Kopec JA, Kosen S, Koul PA, Koyanagi A, Krog NH, Defo BK, Bicer BK, Kudom AA, Kuipers EJ, Kulkarni VS, Kumar GA, Kwan GF, Lal A, Lal DK, Lalloo R, Lam H, Lam JO, Langan SM, Lansingh VC, Larsson A, Laryea DO, Latif AA, Lawrynowicz AEB, Leigh J, Levi M, Li Y, Lindsay MP, Lipshultz SE, Liu PY, Liu S, Liu Y, Lo LT, Logroscino G, Lotufo PA, Lucas RM, Lunevicius R, Lyons RA, Ma S, Machado VMP, Mackay MT, MacLachlan JH, El Razek HMA, El Razek MMA, Majdan M, Majeed A, Malekzadeh R, Manamo WAA, Mandisarisa J, Mangalam S, Mapoma CC, Marcenes W, Margolis DJ, Martin GR, Martínez-Raga J, Marzan MB, Masiye F, -Jones AJM, Massano J, Matzopoulos R, Mayosi BM, McGarvey ST, McGrath JJ, Mckee M, McMahon BJ, Meaney PA, Mehari A, Mehndiratta MM, Mena-Rodríguez F, Mekonnen AB, Melaku YA, Memiah P, Memish ZA, Mendoza W, Meretoja A, Meretoja TJ, Mhimbira FA, Micha R, Miller TR, Mirarefin M, Misganaw A, Mock CN, Mohammad KA, Mohammadi A, Mohammed S, Mohan V, Mola GLD, Monasta L, Hernández JCM, Montero P, Montico M, Montine TJ, Moradi-Lakeh M, Morawska L, Morgan K, Mori R, Mozaffarian D, Mueller U, Murthy GVS, Murthy S, Musa KI, Nachega JB, Nagel G, Naidoo KS, Naik N, Naldi L, Nangia V, Nash D, Nejjari C, Neupane S, Newton CR, Newton JN, Ng M, Ngalesoni FN, Ngirabega JD, Le Nguyen Q, Nisar MI, Pete PMN, Nomura M, Norheim OF, Norman PE, Norrving B, Nyakarahuka L, Ogbo FA, Ohkubo T, Ojelabi FA, Olivares PR, Olusanya BO, Olusanya JO, Opio JN, Oren E, Ortiz A, Osman M, Ota E, Ozdemir R, Pa M, Pandian JD, Pant PR, Papachristou C, Park EK, Park JH, Parry CD, Parsaeian M, Caicedo AJP, Patten SB, Patton GC, Paul VK, Pearce N, Pedro JM, Stokic LP, Pereira DM, Perico N, Pesudovs K, Petzold M, Phillips MR, Piel FB, Pillay JD, Plass D, Platts-Mills JA, Polinder S, Pope CA, Popova S, Poulton RG, Pourmalek F, Prabhakaran D, Qorbani M, QuameAmaglo J, Quistberg DA, Rafay A, Rahimi K, Rahimi-Movaghar V, Rahman M, Rahman MHU, Rahman SU, Rai RK, Rajavi Z, Rajsic S,

Raju M, Rakovac I, Rana SM, Ranabhat CL, Rangaswamy T, Rao P, Rao SR, Refaat AH, Rehm J, Reitsma MB, Remuzzi G, Resnikofff S, Ribeiro AL, Ricci S, Blancas MJR, Roberts B, Roca A, Rojas-Rueda D, Ronfani L, Roshandel G, Rothenbacher D, Roy A, Roy NK, Ruhago GM, Sagar R, Saha S, Sahathevan R, Saleh MM, Sanabria JR, Sánchez-Niño MD, Sánchez-Riera L, Santos IS, SarmientoSuárez R, Sartorius B, Satpathy M, Savic M, Sawhney M, Schaub MP, Schmidt MI, Schneider IJC, Schottker B, Schutte AE, Schwebel DC, Seedat S, Sepanlou SG, Servan-Mori EE, Shackelford KA, Shaddick G, Shaheen A, Shahraz S, Shaikh MA, Shakh-Nazarova M, Sharma R, She J, Sheikhbahaei S, Shen JB, Shen ZY, Shepard DS, Sheth KN, Shetty BP, Shi PL, Shibuya K, Shin MJ, Shiri R, Shiue I, Shrime MG, Sigfusdottir ID, Silberberg DH, Silva DAS, Silveira DGA, Silverberg JI, Simard EP, Singh A, Singh GM, Singh JA, Singh OP, Singh PK, Singh V, Soneji S, Soreide K, Soriano JB, Sposato LA, Sreeramareddy CT, Stathopoulou V, Stein DJ, Stein MB, Stranges S, Stroumpoulis K, Sunguya BF, Sur P, Swaminathan S, Sykes BL, Szoeke CEI,Tabares-Seisdedos R,Tabb KM,Takahashi K,Takala JS, Talongwa RT, Tandon N, Tavakkoli M, Taye B, Taylor HR, Ao BJT, Tedla BA,Tefera WM,Ten Have M,Terkawi AS,Tesfay FH,Tessema GA,Thomson AJ,Thorne-Lyman AL,Thrift AG,Thurston GD,Tillmann T, Tirschwell DL, Tonelli M, Topor-Madry R, Topouzis F, Nx JAT, Traebert J, Tran BX, Truelsen T, Trujillo U, Tura AK, Tuzcu EM, Uchendu US, Ukwaja KN, Undurraga EA, Uthman OA, Van Dingenen R, Van Donkelaar A, Vasankari T, Vasconcelos AMN, Venketasubramanian N, Vidavalur R, Vijayakumar L, Villalpando S, Violante FS,Vlassov VV,Wagner JA,Wagner GR,Wallin MT,Wang LH, Watkins DA, Weichenthal S, Weiderpass E, Weintraub RG, Werdecker A, Westerman R, White RA, Wijeratne T, Wilkinson JD, Williams HC, Wiysonge CS, Woldeyohannes SM, Wolfe CDA, Won SH, Wong JQ, Woolf AD, Xavier D, Xiao QY, Xu GL, Yakob B,Yalew AZ,Yan LL,Yano YC,Yaseri M,Ye P,Yebyo HG,Yip P,Yirsaw BD, Yonemoto N, Yonga G, Younis MZ, Yu SC, Zaidi Z, Zaki MES, Zannad F, Zavala DE, Zeeb H, Zeleke BM, Zhang H, Zodpey S, Zonies D, Zuhlke LJ, Vos T, López AD, Murray CJL. Global, regional, and national life expectancy, all-cause mortality, and causespecific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1459-544. Article. IF: 47.831; D1 • Zhou Q, Bajo MA, del Peso G, Yu XQ, Selgas R. Preventing peritoneal membrane fibrosis in peritoneal dialysis patients. Kidney Int. 2016;90(3):515-24. Review. IF: 8.395; D1

PUBLIC PROJECTS Selgas Gutiérrez R. Vasculopatía hialinizante en dialisis peritoneal. Relación con la transición endotelio-mesenquimal y la disfunción del endotelio y del músculo liso vascular (PI15/00120). ISCIII. 2016-2018. Management centre: FIBHULP

PRIVATE PROJECTS Jiménez Martín C. Grupos Emergentes. Wyeth Farma S.A. 2009-Ongoing. Management centre: FIBHULP Selgas Gutiérrez R. Cardiovascular disease and peritoneal membrane damage in peritoneal dialysis as concurrent consequences of a common mechanism dependent on the glucose effect in peritoneal adipocytes. Extramural. Baxter S.L. 2008-Ongoing. Management centre: FIBHULP

Nefrología: atención integral e interdisciplinar. Wyeth Farma S.A. 2007-Ongoing. Management centre: FIBHULP Selgas Gutiérrez R. Determinación de la nefrotoxicidad inducida por la ecografía con burbujas en un modelo animal como fase previa para su aplicación en transplante renal. Novartis Farmacéutica S.A. 2008-Ongoing. Management centre: FIBHULP Selgas Gutiérrez R. Atención domiciliaria continuada para pacientes en diálisis domiciliaria y biología celular del macrófago peritoneal y su relación con la fibrosis peritoneal. Baxter S.L. 2009-Ongoing. Management centre: FIBHULP Selgas Gutiérrez R. Historia natural de la microcirculación del injerto renal mediante ecografía resaltada por contraste. Análisis en el paciente trasplantado, tratado con/sin anti-calcineurínicos. Genzyme Europe Bv-Finance Department. 2009-Ongoing. Management centre: FIBHULP Selgas Gutiérrez R. Actualización y renovación de la actividad investigadora en Nefrología Clínica Hospitalaria. Abbvie Spain S.L.U. 2009-Ongoing. Management centre: FIBHULP Selgas Gutiérrez R. La donación de vivo en el trasplante renal: representaciones y prácticas sociales en la toma de decisión. Un estudio socio-antropológico. Varios Financiadores. 2013-Ongoing. Management centre: FIBHULP Selgas Gutiérrez R. Monitorización del rechazo humoral del receptor de trasplante renal. Novartis Farmacéutica S.A. 2015-Ongoing. Management centre: FIBHULP Selgas Gutiérrez R. IV Jornadas científicas sobre novedades socio-sanitarias en el trasplante renal de donante vivo. 2016-Ongoing. Management centre: FIBHULP

CLINICAL TRIALS Bajo Rubio MA. Estudio de la enfermedad de Fabry en pacientes en diálisis peritoneal. Sanofi Aventis S.A. HULP Code: PI-1920. Sponsored´s Protocol Code: GSSFBZ-2014-04. Signature Date: 11/1/2016 Bajo Rubio MA. Estudio de fase 3, aleatorizado, abierto y controlado con tratamiento activo para evaluar la eficacia y la seguridad de FG-4592 en el tratamiento de la enemia en pacientes con insuficiencia renal crónica no tratados con diálisis. Astellas Pharma Europe B.V. HULP Code: Anexo-I 4010. Sponsored´s Protocol Code: 1517-CL0610.

Signature Date: 25/03/2016 Bajo Rubio MA. Estudio de fase 3, aleatorizado, abierto y controlado con tratamiento activo para evaluar la eficacia y la seguridad de roxadustat en el tratamiento de mantenimiento de la anemia en sujetos en el estadio final de la insuficiencia renal que reciben diálisis estable. Astellas Pharma Europe B.V. HULP Code: Anexo-I 4276. Sponsored´s Protocol Code: 1517-CL0613. Signature Date: 18/04/2016 Peces Serrano R. Ensayo de fase IIIb, multicéntrico y abierto para evaluar la seguridad a largo plazo de tolvaptán de liberación inmediata (OPC-41061, de 30 mg a 120 mg/día, dosis dividida) en sujetos con poliquistosis renal autosómica dominante. Otsuka Pharmaceutical Development & Commercialización Inc. HULP Code: 4473. Sponsored´s Protocol Code: 156-13-211. Signature Date: 25/02/2016

PATENTS AND TRADEMARKS Selgas Gutiérrez R, Bellón Heredia T, Rodríguez Sanz AI, Álvarez Builla J, Vaquero López JJ, Sánchez Alonso P, Alajarín Fernández R, inventors; FIBHULP, Universidad de Alcalá, assignees. Use of compounds derived from salts of pyridazine[1’,6’:1,2]pyrido[3,4-b]indolinium as antiinflammatory agents. P201331143, PCT/ES2014/070603; 2013 July 25. Selgas Gutiérrez R, Bellón Heredia T, Rodríguez Sanz AI, Álvarez Builla J, Vaquero López JJ, Sánchez Alonso P, Alajarín Fernández R, inventors; FIBHULP, Universidad de Alcalá, assignees. Use of compounds derived from salts of piridazine[3,2-b]benzimidazolium as anti-inflammatory agents. P201430411, PCT/ES2014/070603; 2013 July 25. Sánchez Niño MD, Ortiz Arduán A, inventors; FIBHULP, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, assignees. Pharmaceutical composition and its use in the manufacture of a medicament for treating chronic kidney disease and method for selecting compounds. P201430081, PCT/ES2015/070039; 2014 January 27. Aguilera Peralta AI, López-Cabrera M, Selgas Gutiérrez R, Steppan S, Passlickdeetjen J, inventors; Fresenius Medical Care Deutschland GMBH, assignee. Pharmaceutical compositions containing steviosides. EP14191301.2, PCT/ EP2015/074955; 2014 October 31. López-Cabrera M, Aguilera Peralta AI, Selgas Gutiérrez R, Passlickdeetjen J. Buechel J, Steppan S, inventors; Fresenius Medical Care AG & Co. KGaA, assignee. Method and kit for diagnosing epitelial to mesenchymal transition of the peritoneum (EMT-Chip). DE102015115158.8; 2015.

Selgas Gutiérrez R. Evaluación e intervención en el bienestar emocional del personal y pacientes del Servicio de

Return to LARGE SYSTEM PATHOLOGIES AREA INDEX

197

3 INFORMATION GROUPS BY AREA

3.4 Large System Pathology Area

Research Activity PUBLICATIONS • Aakre I, Strand TA, Bjoro T, Norheim I, Barikmo I, Ares S, Alcorta MD, Henjum S. Thyroid function among breastfed children with chronically excessive iodine intakes. Nutrients. 2016;8(7):398. Article. IF: 3.55; Q2 • Alarcón A, Martínez-Biarge M, Cabañas F, Quero J, GarcíaAlix A. A Prognostic neonatal neuroimaging scale for symptomatic congenital cytomegalovirus infection. Neonatology. 2016;110(4):277-85. Article. IF: 2.598; Q1

NEONATOLOGY GROUP

• Alcaide MJ, Gómez-Rioja R, Louzao P, Fernández-Calle P, Oliver P, Iturzaeta JM, Fernández-Puntero B, Buño A. Vitamin K interference in the measurement of plasma ammonia. J Clin Pathol. 2016;69(5):458-9. Letter. IF: 2.687; Q2 • dal-Re R, Omeñaca F, Gracia D. When the information provided to participants of a comparative effectiveness trial ends up in the court: The opening of Pandora’s box? Med Clin-Barcelona. 2016;147(2):76-80. Article. IF: 1.125; Q3

18 61.438 11

• de la Calle M, Omeñaca F, Bartha JL. Varicella infection in pregnancy. Med Clin-Barcelona. 2016;146(1):40-1. Letter. IF: 1.125; Q3 • Estrin GL, Kyriakopoulou V, Makropoulos A, Ball G, Kuhendran L, Chew A, Hagberg B, Martínez-Biarge M, Allsop J, Fox M, Counsell SJ, Rutherford MA. Altered white matter and cortical structure in neonates with antenatally diagnosed isolated ventriculomegaly. Neuroimage Clin. 2016;11:139-48. Article. IF: 4.348; Q1 • García-Esquinas E, Guallar-Castillón P, Carnicero JA, Buño A, García-García FJ, Rodríguez-Mañas L, Rodríguez-Artalejo F. Serum uric acid concentrations and risk of frailty in older adults. Exp Gerontol. 2016;82:160-5. Article. IF: 3.34; Q1

Adelina Pellicer Martínez Jefe de Sección Sº Neonatología, HULP Prof Asociado pediatria, UAM Susana Ares Segura Facultativo Especialista de Área en Neonatología. HULP Juan Bernal Carrasco Jefe de Departamento de Fisiopatología Endocrina y Sistema Nervioso. IIB “Alberto Sols” Maria Carmen Bravo Laguna Facultativo Especialista de Área en Neonatología. HULP Antonio Buño Soto Jefe de Servicio de Laboratorio de Urgencias. HULP Fernando Cabañas González Facultativo Especialista de Área en Neonatología. HULP Profesor Asociado. Departamento de Pediatría y Neonatología. UAM María Jesús del Olmo Barros Profesora Contratada. Departamento Interfacultativo de Música. UAM María Dolores Elorza Fernández Jefe de Sección Sº Neonatología. HULP Miriam Martínez Biarge Facultativo Especialista de Área en Neonatología. Hospital Hammersmith, Londres María Teresa Montes Bueno Enfermera. HULP María Natividad Pastrana Pérez Enfermera. HULP María Luisa Prieto Postigo Auxiliar de Enfermería. HULP 198

Miguel Sáenz de Pipaón Marcos Facultativo Especialista de Área en Neonatología. HULP Profesor Asociado. UAM Belén Sáenz-Rico de Santiago Profesor Contratado Doctor “Didáctica y Organización Escolar”, UCM Laura Sánchez García Facultativo Especialista de Área en Neonatología. HULP Eva Valverde Núñez Facultativo Especialista de Área en Neonatología. HULP Profesora Asociada. UAM

Strategic Objective Prevent structural damage to organs and systems in the high risk newborn. Reduce the impact of the processes that occurred in the peri-neonatal stage in later life.

Research Lines • Developmental Neurobiology. • Neonatal pulmonary and cardiovascular pathology. • Thyroid in term and preterm neonates. • Nutrition. Breast feeding. Mycrobiota. • Perinatal and neonatal infectology. Inmunology and vaccines. • Neurodevelopmental. Follow–up.

• Kali GTJ, Martínez-Biarge M, Van Zyl J, Smith J, Rutherford M. Therapeutic hypothermia for neonatal hypoxic-ischaemic encephalopathy had favourable outcomes at a referral hospital in a middle-income country. Acta Paediatr. 2016;105(7):806-15. Article. IF: 2.043; Q2 • Martínez-Biarge M, Cheong JLY, Díez-Sebastián J, Mercuri E, Dubowitz LMS, Cowan FM. Risk factors for neonatal arterial ischemic stroke: The importance of the intrapartum period. J Pediatr-Us. 2016;173:62-8. Article. IF: 3.874; D1 • Martínez-Biarge M, Groenendaal F, Kersbergen KJ, Benders MJNL, Foti F, Cowan FM, de Vries LS. MRI based preterm white Matter injury classification: The importance of sequential imaging in determining severity of injury. Plos One. 2016;11(6):e0156245. Article. IF: 2.806; Q1 • Martínez-Cerón E, Buño A, García-Río F. Analytical performance requirements for biomarker-based studies evaluating continuous positive airway pressure effects in obstructive sleep apnea reply. Am J Resp Crit Care. 2016;194(4):523-4. Letter. IF: 13.204; D1 • Mazmanyan PA, Nikoghosyan KV, Kerobyan VV, Mellor KJ, DíezSebastián J, Martínez-Biarge M, Cowan FM. Preterm cranial ultrasound scanning is both feasible and effective in a middleincome country. Acta Paediatr. 2016;105(7):E291-9. Article. IF: 2.043; Q2 • Ng K, Stoll B, Chacko S, de Pipaón MS, Lauridsen C, Gray M, Squires EJ, Marini J, Zamora IJ, Olutoye OO, Burrin DG. Vitamin E in new-generation lipid emulsions protects against parenteral nutrition-associated liver disease in parenteral nutrition-fed preterm pigs. JPEN-Parenter Enter. 2016;40(5):656-71. Article. IF: 4.22; Q1 • Plomgaard AM, Hagmann C, Alderliesten T, Austin T, van Bel F, Claris O, Dempsey E, Franz A, Fumagalli M, Gluud C, Greisen G, Hyttel-Sorensen S, Lemmers P, Pellicer A, Pichler G, Benders M.

Brain injury in the international multicenter randomized SafeBoosC phase II feasibility trial: cranial ultrasound and magnetic resonance imaging assessments. Pediatr Res. 2016;79(3):466-72. Article. IF: 2.882; Q1 • Plomgaard AM, van Oeveren W, Petersen TH, Alderliesten T, Austin T, van Bel F, Benders M, Claris O, Dempsey E, Franz A, Fumagalli M, Gluud C, Hagmann C, Hyttel-Sorensen S, Lemmers P, Pellicer A, Pichler G, Winkel P, Greisen G. The SafeBoosC II randomized trial: treatment guided by near-infrared spectroscopy reduces cerebral hypoxia without changing early biomarkers of brain injury. Pediatr Res. 2016;79(4):528-35. Article. IF: 2.882; Q1 • Riera J, Cabañas F, Serrano JJ, Madero R, Pellicer A. New developments in cerebral blood flow autoregulation analysis in preterm infants: a mechanistic approach. Pediatr Res. 2016;79(3):460-5. Article. IF: 2.882; Q1 • Riera J, Hyttel-Sorensen S, Bravo MC, Cabañas F, López-Ortego P, Sánchez L,Ybarra M, Dempsey E, Greisen G, Austin T, Claris O, Fumagalli M, Gluud C, Lemmers P, Pichler G, Plomgaard AM, van Bel F, Wolf M, Pellicer A. The SafeBoosC phase II clinical trial: an analysis of the interventions related with the oximeter readings. Arch Dis Child-Fetal. 2016;101(4):F333-8. Article. IF: 3.786; D1 • Rosas R, Sanz MP, Fernández-Calle P, Alcaide MJ, Montes MT, Pastrana N, Segovia C, Omeñaca F, de Pipaón MS. Experimental study showed that adding fortifier and extra-hydrolysed proteins to preterm infant mothers’ milk increased osmolality. Acta Paediatr. 2016;105(12):E555-60. Article. IF: 2.043; Q2

PUBLIC PROJECTS Cabañas González F. Red de Salud Materno Infantil y del Desarrollo- SAMID (RD12/0026/0004). ISCIII. 2013-2014. Management centre: FIBHULP

PRIVATE PROJECTS Ares Segura S. Exceso de yodo: consecuencias en la fundación tiroidea y en el neurodesarrollo. Universidad de Akershus de Ciencias Aplicadas. 2013-Ongoing. Management centre: FIBHULP Bravo Laguna MC. Valoración cuantitativa de la repercusión hemodinámica del ductus arterioso persistente y su tratamiento en el recién nacido de bajo peso. Neonatcare S.L. 2008-Ongoing. Management centre: FIBHULP Bravo Laguna MC. Ensayo clínico multicéntrico sobre el tratamiento del ductus arterioso persistente ecocardiograficamente guiado en el recien nacido prematuro con ibuprofeno con perfusion continua intravenosa frente a bolos intravenosos: impacto en el pronóstico intestina. Fundacion Mutua Madrileña. 2016-Ongoing. Management centre: FIBHULP Buño Soto A. Actualización y renovación de la actividad investigadora en el Servicio de Análisis Clínicos del Hospital Universitario La Paz. Radiometer Iberica S.L. 2012-Ongong. Management centre: FIBHULP Buño Soto A. Method comparison evaluation between the radiometer procalitonin (PCT) assay on the AQT90 flex analyzer and the elecsys B.R.A.B.S. PCT on an automated roche immunoassay analyzer. Radiometer Medical A.P.S. 2015-Ongoing. Management centre: FIBHULP

Continue

199

3.4 Large System Pathology Area

3 INFORMATION GROUPS BY AREA Buño Soto A. Recogida de muestras en deportistas de alto rendimiento para la evaluacion de su variación biológica. FIBHULP. 2016-Ongoing. Management centre: FIBHULP Cabañas González F. Impacto de las técnicas de reproducción asistida en la salud del recién nacido. Varios. 2011-Ongoing. Management centre: FIBHULP del Olmo Barros MJ. Jornadas de investigación y atención directo en musicoterapia hospitalaria.Varios. 2015-Ongoing. Management centre: FIBHULP Omeñaca Terés F. Leche materna en niños prematuros: características nutricionales e infección por citomegalovirus. Infacare Pharmaceutical Corporation. 2010-Ongoing. Management centre: FIBHULP

INTERNATIONAL PROJECTS Pellicer Martínez A. Dobutamine for NEOnatal CIRCulatory failure defined by novel biomarkers GA - 282533 (NEO-CIRC). EU. 2011-2016. Management centre: FIBHULP

Omeñaca Terés F. Inmunogenicidad y seguridad de una dosis de recuerdo de Infanrix Hexa® (217744) de GSK biologicals en niños sanos nacidos de madres vacunadas con Boostrix® en el embarazo o en el posparto inmediato. Glaxosmithkline S.A. HULP Code: 4613. Sponsored´s Protocol Code: 201334 BOOSTRIX-049. Signature Date: 13/5/2016

AGING AND FRAGILITY IN THE ELDERLY GROUP

Omeñaca Terés F. Estudio en fase II, aleatorizado, enmascarado para el observador, controlado con placebo y con grupos secuenciales para determinar la inmunogenicidad y la seguridad de una vacuna. Novavax, Inc. HULP Code: 4663. Sponsored´s Protocol Code: RSV-M-301. Signature Date: 19/10/2016

17 47.113 3

PATENTS AND TRADEMARKS

CLINICAL TRIALS Omeñaca Terés F. Estudio en fase 3, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de un anticuerpo monoclonal humano, REGN2222, para la prevención de la infección por el VRS bajo atención médica en lactantes prematuros. Regeneron Pharmaceuticals Inc. HULP Code: 4458. Sponsored´s Protocol Code: R2222-RSV-1332. Signature Date: 21/07/2016

200

Omeñaca Terés F. Estudio de seguimiento para evaluar la seguridad y los resultados a largo plazo en lactantes nacidos de madres que participaron en los estudios de tratamiento con retosibán. Glaxosmithkline Research And Development Limited. HULP Code: Anexo-I 4322. Sponsored´s Protocol Code: 200722. Signature Date: 21/3/2016

Segovia Iñigo C, Montes Bueno MT, inventors; Segovia Iñigo C, assignee. Positioning device for neonates (Utility model). U201330102; 2013 January 31.

Return to LARGE SYSTEM PATHOLOGIES AREA INDEX

Juan Ignacio González Montalvo Jefe de Servicio de Geriatría. HULP Profesor Asociado.UAM Juan Carlos Abánades Herranz Médico. Centro de Salud Monóvar. Atención Primaria María Teresa Alarcón Alarcón Jefe de Sección de Geriatría. HULP Juan Cárdenas Valladolid Técnico de la Gerencia Adjunta de Planificación y Calidad de Atención Primaria. Atención Primaria María Victoria Castell Alcalá Facultativo Especialista de Área en Medicina Familiar y Comunitaria. Atención Primaria Carmen de Burgos Lunar Subdirectora General de Promoción, Prevención y Educación para la Salud. Dirección General de Salud Pública Macarena Díaz de Bustamante de Ussía Médico Interno Residente. HULP Araceli Garrido Barral Facultativo Especialista de Área en Medicina Familiar y Comunitaria. Atención Primaria Paloma Gómez Campelo Investigadora Postdoctoral. HULP Pilar Gotor Pérez Enfermera. Unidad de Valoración Geriátrica y Ortogeriatría. HULP Rosa Julián Viñals Facultativo Especialista de Área en Medicina Familiar y Comunitaria. Centro de Salud “Raúl de Castroviejo”. Atención Primaria Rocío Menéndez Colino Facultativo Especialista de Área en Geriatría. Hospital de Cantoblanco - HULP

Ángel Otero Puime Profesor Titular de Medicina Preventiva y Salud Pública. UAM Médico Adjunto Medicina Preventiva. HULP Rocío Queipo Matas Investigadora Predoctoral. UAM Raquel Ramírez Martín Médico Interno Residente. HULP Ana María Rosas Hernández Investigadora Predoctoral. UAM María del Pilar Sáez López Facultativo Especialista de Área en Geriatría. Complejo Asistencial de Ávila Miguel Ángel Salinero Fort Médico. Subdirección General de Investigación Sanitaria, Consejería de Sanidad de Madrid Mercedes Sánchez Martínez Profesor Asociado. UAMf

Strategic Objective • To promote and improve the quality of research in the field of Primary Health Care and Geriatrics in the area of influence of IdiPAZ. • To continue the follow-up of the Cohorts of the Group: elderly people with population-based (Peñagrande Study), patients with frailty syndrome (FONDA) and patients with Type 2 Diabetes Mellitus (MADiabetes). • Progress in the epidemiological study of frailty in the elderly. • To consolidate clinical studies related to hip fracture and chronic diseases in the elderly, specially the Diabetes Mellitus.

Continue

201

3 INFORMATION GROUPS BY AREA

3.4 Large System Pathology Area

Research Lines • Frailty syndrome in the elderly. To promote the detection of frailty syndrome in elderly people above 75 years that consults at the Primary Heatlh Care Center of the Hospital La Paz Setting and create a new cohort of those patients with functional impairment. Additionally, to develop and evaluate an intervention program with these patients, focused on the physical exercise, the geriatric evaluation, management of comorbidity, in the medication adjustment y in nutritional supplementation when necessary. • Hip fracture in the frail elderly. To evaluated the implementation and evaluation of the FONDA intervention with frail elderly patients hospitalized at the La Paz Hospital based on: physical exercise program (active and passive), early normalization of plasma levels of VitD, nutritional supplementation in patients with hypoproteinemia, low or vitamin D deficiency, and control of the pain and anemia. • Follow-up of patients with Type 2 Diabetes Mellitus (MADiabetes Cohort, more than 3.500 patients) and prediabetes patients (SPREDIA Cohort, n=600) of Madrid, to analyze clinical and psychosocial factors related to clinical outcomes (cardiovascular events, chronic kidney disease, retinopathy, and mortality), we are developing predictive models for main outcomes (chronic kidney disease, all-cause mortality and cardiovascular mortality).

Research Activity PUBLICATIONS • Alarcón T, González-Montalvo JI, Martín-Vega A, Gotor P. Improving persistence and adherence to osteoporosis treatment: a challenge to solve. Osteoporosis Int. 2016;27(3):1275-6. Letter. IF: 3.591; Q2 • de Hoyos-Alonso MC, Bonis J, Tapias-Merino E, Castell MV, Otero A. Estimated prevalence of dementia based on analysis of drug databases in the Region of Madrid (Spain). Neurología. 2016;31(1):1-8. Article. IF: 2.103; Q3 • de Hoyos-Alonso MD, Bonis J, Bryant V, Alcalá MVC, Puime AO. Quality of registration of dementia diagnosis in primary care: The situation in Spain in 2002-2011. Aten Prim. 2016;48(1):3341. Article. IF: 1.042; Q3 • Eiras A, Teixeira MA, González-Montalvo JI, Castell MV, Queipo R, Otero A. Consumption of drugs in over 65 in Porto (Portugal) and risk of potentially inappropriate medication prescribing. Aten Prim. 2016;48(2):110-20. Article. IF: 1.042; Q3 • González-Montalvo JI, Alarcón T, Gotor P, Queipo R, Velasco R, Hoyos R, Pardo A, Otero A. Prevalence of sarcopenia in acute hip fracture patients and its influence on short-term clinical outcome. Geriatr Gerontol Int. 2016;16(9):1021-7. Article. IF: 2.351; Q3 • Herbolsheimer F, Schaap LA, Edwards MH, Maggi S, Otero A, Timmermans EJ, Denkinger MD, van der Pas S, Dekker J, Cooper C, Dennison EM, van Schoor NM, Peter R. Physical activity patterns among older adults with and without knee osteoarthritis in six european countries. Arthrit Care Res. 2016;68(2):228-36. Article. IF: 3.319; Q2

202

• Jiménez-Trujillo I, González-Pascual M, Jiménez-García R, Hernández-Barrera V, Miguel-Yanes JMM, Méndez-Bailón M, de Miguel-Díez J, Salinero-Fort MA, Pérez-Farinos N, CarrascoGarrido P, López-de-Andrés A. Type 2 diabetes mellitus and thoracic aortic aneurysm and dissection an observational population-based study in Spain from 2001 to 2012. Medicine. 2016;95(18):e3618. Article. IF: 1.803; Q2

• van Schoor NM, Zambón S, Castell MV, Cooper C, Denkinger M, Dennison EM, Edwards MH, Herbolsheimer F, Maggi S, Sánchez-Martínez M, Pedersen NL, Peter R, Schaap LA, Rijnhart JJM, van der Pas S, Deeg DJH. Impact of clinical osteoarthritis of the hip, knee and hand on self-rated health in six European countries: the European Project on OSteoArthritis. Qual Life Res. 2016;25(6):1423-32. Article. IF: 2.344; Q2

• Lahoz C, Mostaza JM, Salinero-Fort MA, García-Iglesias F, González-Alegre T, Estirado E, Laguna F, de Burgos-Lunar C, Sánchez-Arroyo V, Sabín C, López S, Cornejo-del-Río V, Patrón P, Fernández-García P, Fernández-Puntero B, Vicent D, Montesano-Sánchez L. Peripheral atherosclerosis in patients with erectile dysfunction: A population-based study. J Sex Med. 2016;13(1):63-9. Article. IF: 2.978; Q2

• Zambón S, Siviero P, Denkinger M, Limongi F, Castell MV, van der Pas S, Otero A, Edwards MH, Peter R, Pedersen NL, SánchezMartínez M, Dennison EM, Gesmundo A, Schaap LA, Deeg DJH, van Schoor NM, Maggi S. Role of osteoarthritis, comorbidity, and pain in determining functional limitations in older populations: European Project on Osteoarthritis. Arthrit Care Res. 2016;68(6):801-10. Article. IF: 3.319; Q2

• López-de-Andrés A, Hernández-Barrera V, López R, MartínJunco P, Jiménez-Trujillo I, Álvaro-Meca A, Salinero-Fort MA, Jiménez-García R. Predictors of in-hospital mortality following major lower extremity amputations in type 2 diabetic patients using artificial neural networks. BMC Med Res Methodol. 2016;16:160. Article. IF: 3.295; Q1 • López-de-Andrés A, Jiménez-García R, Jiménez-Trujillo I, Hernández-Barrera V, de Miguel-Yanes JM, Méndez-Bailón M, Pérez-Farinós N, de Miguel-Díez J, Salinero-Fort MA, CarrascoGarrido P. Incidence, surgical procedures, and outcomes of hip fracture among elderly type 2 diabetic and non-diabetic patients in Spain (2004-2013). Osteoporosis Int. 2016;27(2):60516. Article. IF: 3.591; Q2

PUBLIC PROJECTS de Burgos Lunar C. Validación de los diagnósticos de fibrilación articular, infarto agudo de miocardio, ictus y exitus registrados en la Historia Clínica Informatizada de Atención Primaria (PI13/00632). ISCIII. 2014-2017. Management centre: FIBHULP Otero Puime A. Red de Investigación Cooperativa en Envejecimiento y Fragilidad (RETICEF) (RD12/0043/0019). ISCIII. 2013-2017. Management centre: FIBHULP

Salinero Fort MA. Análisis de Evolución temporal de las tasas y causas de mortalidad de una cohorte de diabetes mellitus tipo 2 y comparación con estadisticas oficiales (PI12/01806). ISCIII. 2013-2017. Management centre: FIBAP Salinero Fort MA. Estudio de cohortes sobre la morbilidad cardivascular y mortalidad de sujetos con diabetes tipo 2 conocida y no conocida, prediabetes y normoglucemia (PI15/00259). ISCIII. 2016-2018. Management centre: FIBAP

PRIVATE PROJECTS González Montalbo JI. Proyecto de actualización bibliográfica básica de temas de investigación, documentación, actualización y transmisión bibliográfica en sesiones conjuntas de servicio.EISAI FARMACEUTICA SA. 2008-Ongoing. Management centre: FIBHULP González Montalbo JI. Estudio de la evolución a medio y largo plazo tras el tratamiento integral de los pacientes con fractura de cadera. evaluación de los factores predictivos del pronóstico funcional y vital (Estudio FONDA). FIBHULP. 2012-Ongoing. Management centre: FIBHULP

• Salinero-Fort MA, Burgos-Lunar C, Lahoz C, Mostaza JM, Abanades-Herranz JC, Laguna-Cuesta F, Estirado-de Cabo E, García-Iglesias F, González-Alegre T, Fernández-Puntero B, Montesano-Sánchez L, Vicent-López D, Cornejo-del Río V, Fernández-García PJ, Sánchez-Arroyo V, Sabín-Rodríguez C, LópezLópez S, Patrón-Barandio P, Gómez-Campelo P. Performance of the finnish diabetes risk score and a simplified finnish diabetes risk score in a community-based, cross-sectional programme for screening of undiagnosed type 2 diabetes mellitus and dysglycaemia in Madrid, Spain: The SPREDIA-2 Study. Plos One. 2016;11(7):e0158489. Article. IF: 2.806; Q1 • Salinero-Fort MA, San Andrés-Rebollo FJ, de Burgos-Lunar C, Abanades-Herranz JC, Carrillo-de-Santa-Pau E, Chico-Moraleja RM, Jiménez-García R, López-de-Andrés A, Gómez-Campelo P. Cardiovascular and all-cause mortality in patients with type 2 diabetes mellitus in the MADIABETES cohort study: Association with chronic kidney disease. J Diabetes Complicat. 2016;30(2):227-36. Article. IF: 2.734; Q3 • Sánchez-Martínez M, Castell MV, González-Montalvo JI, de la Cruz JJ, Banegas JR, Otero A. Transitions in functional status of community dwelling older adults: Impact of physical performance, depression and cognition. Eur Geriatr Med. 2016;7(2):111-6. Article. IF: 1.336; Q4 • Siviero P, Zambón S, Limongi F, Castell MV, Cooper C, Deeg DJH, Denkinger MD, Dennison EM, Edwards MH, Gesmundo A, Otero A, Pedersen NL, Peter R, Queipo R, Timmermans EJ, van Schoor NM, Maggi S. How hand osteoarthritis, comorbidity, and pain interact to determine functional limitation in older people: Observations from the European Project on OSteoArthritis Study. Arthritis Rheumatol. 2016;68(11):2662-70. Article. IF: 6.918; D1 • van der Pas S, Schaap LA, Castell MV, Cooper C, Denkinger M, Edwards MH, Herbolsheimer F, Maggi S, Sánchez-Martínez M, Pedersen NL, Peter R, Zambón S, Wiegersma SB, Dekker J, Dennison EM, Deeg DJH. Availability and use of neighborhood resources by older people with osteoarthritis: Results from the European Project on OSteoArthritis. Health Place. 2016;37:1-7. Article. IF: 2.541; Q2

Return to LARGE SYSTEM PATHOLOGIES AREA INDEX

203

3 INFORMATION GROUPS BY AREA

3.4 Large System Pathology Area

Research Activity PUBLICATIONS

MOLECULAR HEPATOLOGY GROUP

7 22.662 5

Paloma Jara Vega Emérito Asistencial. HULP Sara Andueza Salazar Técnico de Investigación. HULP Carmen Camarena Grande Médico Adjunto de Hepatología Pediátrica. HULP Ángela de la Vega Bueno Médico Adjunto de Hepatología Pediátrica. HULP María Carmen Díaz Fernández Jefe de Servicio de Hepatología Pediátrica. HULP Esteban Frauca Remacha Médico Adjunto de Hepatología Pediátrica. HULP Loreto Hierro Llanillo Jefe de Sección Hepatología Pediátrica. HULP Gema Muñoz Bartolo Médico Adjunto de Hepatología Pediátrica. HULP María Ángeles Pajares Tarancón Investigador Científico. CSIC Luiz Stark Aroeira Investigador Senior. HULP David Vicent López Investigador Senior (Contrato Miguel Servet - I2). HULP

Strategic Objective Our research interest is focused on the study of the molecular mechanisms underlying the most severe paediatric liver disorders, namely cholestasis, which results from the impaired secretion of bile from the liver to the intestine. As such, it represents a clinical and biochemical syndrome that is produced by a wide variety of disease processes that affect the 204

liver. Individuals with cholestasis manifest jaundice, severe itching, malabsorption of fats and lipidsoluble vitamins and, in many cases, progressive liver damage. These clinical manifestations are due to the accumulation in blood and tissues of substances normally secreted in the bile, such as bilirubin, bile acids, and cholesterol and to the absence of bile from the intestine. When manifested in early infancy, cholestasis is often life threatening and usually requires liver transplantation. Extrahepatic biliary atresia (EHBA), Alagille syndrome and progressive familial intrahepatic cholestasis (PFIC) constitute the main paediatric cholestatic disorders. EHBA is an enigmatic disease of unknown aetiology, characterised by a precocious and accelerated obstruction of the biliary tree. Alagille syndrome is associated with mutations in the Jag1 gene and is characterised by a paucity or absence of intrahepatic bile ducts. PFIC encompasses a heterogeneous group of autosomal recessive diseases that exhibit similar clinical features. These diseases are caused by mutations in proteins located in the canalicular membrane of the hepatocyte and in proteins involved in bile secretion, such as the bile salt export pump (BSEP; ABCB11), the phospholipid transport protein MDR3 (ABCB4) and the aminophospholipid translocase FIC1 (ATP8B1). These cholestatic disorders constitute the most common indication for liver transplantation in childhood.

Research Lines • Molecular basis of paediatric liver diseases. • Liver Pathobiology.

• Bruguera M, Jara P, Berenguer M, Marino Z. Multidisciplinary units in tertiary referral hospitals to improve management of Wilson disease. Gastroent Hepat-Barc. 2016;39(9):571-3. Editorial Material. IF: 0.917; Q4 • Gordo-Gilart R, Andueza S, Hierro L, Jara P, Álvarez L. Functional rescue of trafficking-impaired ABCB4 mutants by chemical chaperones. Plos One. 2016;11(2):e0150098. Article. IF: 2.806; Q1 • Gordo-Gilart R, Hierro L, Andueza S, Muñoz-Bartolo G, López C, Díaz C, Jara P, Álvarez L. Heterozygous ABCB4 mutations in children with cholestatic liver disease. Liver Int. 2016;36(2):25867. Article. IF: 4.116; Q1 • Martínez-Vega R, Murillo-Cuesta S, Partearroyo T, Varela-Moreiras G, Varela-Nieto I, Pajares MA. Long-term dietary folate deficiency accelerates progressive hearing loss on CBA/Ca mice. Front Aging Neurosci. 2016;8:209. Article. IF: 4.504; Q1 • Pérez C, Pérez-Zuniga FJ, Garrido F, Reytor E, Portillo F, Pajares MA. The oncogene PDRG1 is an interaction target of methionine adenosyltransferases. Plos One. 2016;11(8):e0161672. Article. IF: 2.806; Q1 • Sánchez-Gómez FJ, Díez-Dacal B, García-Martín E, Agúndez JAG, Pajares MA, Pérez-Sala D. Detoxifying enzymes at the crossroads of inflammation, oxidative stress, and drug hypersensitivity: Role of glutathione transferase P1-1 and aldose reductase. Front Pharmacol. 2016;7:237. Article. IF: 4.4; Q1 • Torre-Cisneros J, Aguado JM, Gastón JJ, Almenar L, Alonso A, Cantisan S, Carratala J, Cervera C, Cordero E, Farinas MC, Fernández-Ruiz M, Fortún J, Frauca E, Gavalda J, Hernández D, Herrero I, Len O, López-Medrano F, Manito N, Marcos MA, MartínDávila P, Monforte V, Montejo M, Moreno A, Muñoz P, Navarro D, Pérez-Romero P, Rodríguez-Bernot A, Rumbao J, San Juan R, Vaquero JM, Vidal E. Management of cytomegalovirus infection in solid organ transplant recipients: SET/GESITRA-SEIMC/REIPI recommendations. Transplant Rev-Orlan. 2016;30(3):119-43. Article. IF: 3.113; Q2

PUBLIC PROJECTS Hierro Lanillo L. Identificación de causas genéticas y epigenéticas en enfermedades colestásicas infantiles idiopáticas (PI15/01127). ISCIII. 2016-2018. Management centre: FIBHULP Vicent López D. Miguel Servet Stabilisation Contracts (I2). ISCIII, CAM. 2008-Ongoing. Management centre: FIBHULP Vicente Capa C. Contrato de Técnico de Apoyo (PEJ15/ BIO/TL-0238). CAM. 2016-2018. Management centre: FIBHULP

PRIVATE PROJECTS

Díaz Fernández MC. Superando barreras... hacia una mejor calidad de vida: estado actual del trasplante pediátrico en el Hospital Infantil La Paz. Astellas Pharma S.A. 2014-Ongoing. Management centre: FIBHULP Hierro Llanillo L. Identificación de nuevos genes responsables de enfermedades hepáticas infantiles. Fundación ACS. 2015-Ongoing. Management centre: FIBHULP Hierro Llanillo L. Diagnóstico molecular de enfermeda-

des hepáticas infantiles de carácter hereditario. Asociación Española del Síndrome de Sotos. 2012-Ongoing. Management centre: FIBHULP Hierro Llanillo L. Desarrollo de métodos de diagnóstico molecular de enfermedades hepáticas infantiles de carácter hereditario. Fundación María Franscica de Roviralta. 2005-Ongoing. Management centre: FIBHULP Jara Vega P. Estudio epidemiológico, observacional sobre el riesgo de desarrollo de síndrome linfoproliferativo en pacientes pediátricos 3p-2007. Roche Pharma S.A. 2008-Ongoing. Management centre: FIBHULP Vicent López D. Caracterización clínica del nuevo factor de riesgo cardiovascular trimetilamina-n-oxido en pacientes diabéticos obesos. SENDIMAD. 2015-Ongoing. Managemet centre: FIBHULP

CLINICAL TRIALS Camarena Grande C. Estudio multicéntrico, aleatorizado, controlado por placebo de SBC-102 en pacientes con deficiencia de lipasa ácida lisosomal. Alexion Pharmaceutical Inc. HULP Code: Anexo-II 3955. Sponsored´s Protocol Code: LAL-CL02. Signature Date: 22/06/2016 Camarena Grande C. Estudio abierto y multicéntrico de sebelipasa alfa en pacientes con déficit de lipasa ácida lisosómica. Alexion Pharmaceutical Inc. HULP Code: Anexo-I 4130. Sponsored´s Protocol Code: LAL-CL06. Signature Date: 30/5/2016 Díaz Fernández MC. Estudio abierto y a largo plazo con un período de retirada farmacológico aleatorizado, controlado con placebo y doble ciego de LUM001, un inhibidor del trasportador apical de ácidos biliares depenciente de sodio (ASBTI), en pacientes con Síndrome de Alagille. Lumena Paharmaceuticals Inc. HULP Code: Anexo-II 4187. Sponsored´s Protocol Code: LUM001-304. Signature Date: 18/1/2016 Hierro Llanillo L. Estudio abierto, multicéntrico para evaluar la farmacocinética, la seguridad y la eficacia de ombitasvir (OBV), paritaprevir (PTV), ritonavir (RTV), con o sin dasabuvir (DSV) y con o sin ribavirina (RBV) en pacientes pediátricos con infección crónica por el virus de la hepatitis C (VHC) genotipo 1 o 4 (Zircon). Abbvie Deutschland GMBH. HULP Code: 4533. Sponsored´s Protocol Code: M14-748. Signature Date: 18/1/2016 Hierro Llanillo L. Estudio abierto, multicéntrico para evaluar la farmacocinética, la seguridad y la eficacia de ombitasvir (OBV), paritaprevir (PTV), ritonavir (RTV), con o sin dasabuvir (DSV) y con o sin ribavirina (RBV) en pacientes pediátricos con infección crónica por el virus de la hepatitis C (VHC) genotipo 1 o 4 (Zircon). Abbvie Deutschland GMBH. HULP Code: Anexo-1 4533. Sponsored´s Protocol Code: M14-748. Signature Date: 19/7/2016 Jara Vega P. Estudio abierto, no comparativo, a largo plazo, para evaluar la eficacia y la seguridad de un regimen de inmunosupresor basado en modigraf en pacientes pediátricos receptores de un aloinjerto de órgano sólido. Astellas Pharma Europe B.V. HULP Code: Anexo-III 3252. Sponsored´s Protocol Code: F506CL-0404. Signature Date: 10/2/2016

Return to LARGE SYSTEM PATHOLOGIES AREA INDEX

205

3 INFORMATION GROUPS BY AREA

3.4 Large System Pathology Area

Research Lines

DIAGNOSIS AND TREATMENT OF ALLERGIC DISEASES GROUP

38 130.932 8

• Food allergy (milk, egg, fruit, cereals): molecular diagnosis (by allergenic components) and treatment with oral desensitisation. Epidemiology, physiopathology, diagnosis and • treatment of angioedema and urticaria. • Studies on bronchial hyperresponsiveness to direct and indirect agents and airway inflammation. • Eosinophilic diseases of the respiratory tract (eosinophilic bronchitis) and digestive system (eosinophilic esophagitis). • Persistent and difficult to control asthma: Study on the influence of common and occupational allergens, comorbidities and new therapies. • Aspirin-exacerbated respiratory disease (AERD): inflammatory markers and desensitisation protocol. • Adverse immunologic reactions to drugs: study on the cellular and molecular mechanisms involved. • Molecular basis of allergy: characterization of allergens and modulating factors of allergenicity. Novel allergy biomarkers: microRNAs and mRNAs. Seeking the differences of specific IgE between allergic patients and asymptomatic individuals.

Research Activity Santiago Eugenio Quirce Gancedo Jefe de Servicio de Alergología. HULP María Pilar Encarnación Barranco Sanz Facultativo Especialista de Área en Alergología. HULP María Teresa Boyano Martínez Facultativo Especialista de Área en Alergología. HULP María Teresa Caballero Molina Facultativo Especialista de Área en Alergología. HULP María Luisa Caballero Soto Facultativo Especialista de Área en Inmunología. HULP Francisco Javier Contreras Porta Facultativo Especialista de Área en Alergología. HULP Francisco Javier Domínguez Ortega Facultativo Especialista de Área en Alergología. HULP Ana María del Carmen Fiandor Román Jefe de Sección de Alergología. HULP Carmen Gómez Traseira Facultativo Especialista de Área en Alergología. HULP Juan Alberto Luna Porta Facultativo Especialista de Área en Alergología. HULP María Magdalena Lluch Bernal Facultativo Especialista de Área en Alergología. HULP María Flora Martín Muñoz Facultativo Especialista de Área en Alergología. HULP Santiago Olalde Sánchez Facultativo Especialista de Área en Alergología. HULP María Pedrosa Delgado Facultativo Especialista de Área en Alergología. HULP María Rosa Rodríguez Pérez Investigadora Senior (Contrato Miguel Servet- Tipo 2). HULP Margarita Tomás Pérez Facultativo Especialista de Área en Alergología. HULP 206

Ana María Umpiérrez Rodríguez  Facultativo Especialista de Área en Alergología. HULP

Strategic Objective These group members are specialists in various areas of allergic diseases, which enable them to perform clinical studies and basic research on the main allergic diseases (food allergies, asthma and rhinitis, urticaria/ angio-oedema and drug allergies). The group’s strategic research objectives include: • The development of new techniques to improve the diagnosis of food allergies by determining the molecular sensitisation profile. • The treatment of food allergies with oral desensitisation protocols. • The study of hyperresponsiveness and airway inflammation in asthma, as well as the role of allergen exposure and comorbidities in this disease. • The study of the pathogenesis and treatment of eosinophilic diseases of the airways (eosinophilic bronchitis) and the gastrointestinal tract (eosinophilic oesophagitis). • The characterisation of various types of angiooedema caused by Bradykinin (hereditary and acquired) and improvements in their diagnosis and treatment. • Research on the epidemiology and pathomechanisms of severe adverse reactions caused by immune hypersensitivity reactions to drugs.

PUBLICATIONS • Aygoren-Pursun E, Bygum A, Beusterien K, Hautamaki E, Sisic Z, Boysen HB, Caballero T. Estimation of EuroQol 5-Dimensions health status utility values in hereditary angioedema. Patient Prefer Adher. 2016;10:1699-707. Article. IF: 1.798; Q2 • Belver MT, Michavila A, Bobolea I, Feito M, Bellón T, Quirce S. Severe delayed skin reactions related to drugs in the paediatric age group: A review of the subject by way of three cases (Stevens-Johnson syndrome, toxic epidermal necrolysis and DRESS). Allergol Immunopath. 2016;44(1):83-95. Review. IF: 1.439; Q4 • Caballero ML, Lluch-Bernal M, Vila-Nadal G, Lluncor M, Quirce S. IgE-mediated anaphylaxis induced by macrogol 6000. J Invest Allerg Clin. 2016;26(6):398-400. Article. IF: 3.094; Q2 • Caballero T, Maurer M, Longhurst HJ, Aberer W, Bouillet L, Fabien V. Triggers and prodromal symptoms of angioedema attacks in patients with hereditary angioedema. J Invest Allerg Clin. 2016;26(6):383-6. Article. IF: 3.094; Q2 • Canabal J, Caballero T, Caminoa M, Fiandor A, Quirce S, Cabanas R. Anaphylactic shock caused by a Hidden allergen in blood sausage. J Invest Allerg Clin. 2016;26(3):200-1. Editorial Material. IF: 3.094; Q2

• Domínguez-Ortega J, Entrala A, Pola-Bibian B, González-Muñoz M, Fiandor A, Quirce S. Delayed allergic reaction to acenocoumarol with a positive lymphocyte transformation test. J Invest Allerg Clin. 2016;26(4):273-4. Editorial Material. IF: 3.094; Q2 • Domínguez-Ortega J, Phillips-Angles E, González-Muñoz M, Heredia R, Fiandor A, Quirce S. Allergy to several local anesthetics from the amide group. J Allergy Clin Immunol Pract. 2016;4(4):771-2. Letter. IF: 5.317; Q1 • Espinosa E, Soriano V, Malvehy J, Berrocal A, de Prado PM, Quindos M, Soria A, Márquez-Rodas I, Palacio I, Cerezuela P, LópezVivanco G, Alonso L, Samaniego E, Ballesteros A, Puertolas T, Díaz-Beveridge R, de la Cruz-Merino L, Castro RL, López RL, Stevinson K, del Barrio P, Tornamira MV, Guillem V, Martín-Algarra S. Treatment patterns of adjuvant interferon-alpha 2b for high-risk melanoma: a retrospective study of the Grupo Español Multidisciplinar de Melanoma - Prima study. Melanoma Res. 2016;26(3):278-83. Article. IF: 2.615; Q2 • García-Boyano M, Pedrosa M, Quirce S, Boyano-Martínez T. Household almond and peanut consumption is related to the development of sensitization in young children. J Allergy Clin Immun. 2016;137(4):1248-51. Letter. IF: 13.081; D1 • García-Guereta L, García-Cerro E, Bret-Zurita M. Multidetector computed tomography for congenital anomalies of the aortic arch: vascular rings. Rev Esp Cardiol. 2016;69(7):681-93. Article. IF: 4.485; Q2 • González-Quevedo T, Larco JI, Marcos C, Guilarte M, Baeza ML, Cimbollek S, López-Serrano MC, Pinero-Saavedra M, Rubio M, Caballero T. Management of pregnancy and delivery in patients with hereditary angioedema due to C1 inhibitor deficiency. J Invest Allerg Clin. 2016;26(3):161-7. Article. IF: 3.094; Q2 • Laínez N, García-Donas J, Esteban E, Puente J, Saez MI, Gallardo E, Pinto-Marín A, Vázquez-Estévez S, León L, García-Carbonero I, Suárez-Rodríguez C, Molins C, Climent-Durán MA, LázaroQuintela M, del Alba AG, Méndez-Vidal MJ, Chirivella I, Afonso FJ, López-Brea M, Sala-González N, Domenech M, Basterretxea L, Santander-Lobera C, Gil-Arnaiz I, Fernández O, Caballero-Díaz C, Mellado B, Marrupe D, García-Sánchez J, Sánchez-Escribano R, Parra EF, Guzmán JCV, Martínez-Ortega E, González MB, Morán M, Suárez-Paniagua B, Lecumberri MJ, Castellano D. Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study. BMC Cancer. 2016;16:135. Article. IF: 3.288; Q2 • Longhurst HJ, Aberer W, Bouillet L, Caballero T, Maurer M, Fabien V, Zanichelli A. The icatibant outcome survey: treatment of laryngeal angioedema attacks. Eur J Emerg Med. 2016;23(3):2247. Article. IF: 2.025; Q2 • Martín-Muñoz MF, Pineda F, Parrado GG, Guillén D, Rivero D, Belver T, Quirce S. Food allergy in breastfeeding babies. Hidden allergens in human milk. Eur Ann Allergy Clin Immunol. 2016;48(4):123-8. Article. Not Indexed • Martín-Muñoz MF, Rivero D, Perales AD, Polanco I, Quirce S. Wheat allergy in celiac children. Pediat Allerg Imm-Uk. 2016;27(1):102-5. Letter. IF: 3.775; D1

• Carballeda-Sangiao N, Rodríguez-Mahillo AI, Careche M, Navas A, Caballero T, Domínguez-Ortega J, Jurado-Palomo J, GonzálezMuñoz M. Ani s 11-like protein is a pepsin- and heat-resistant major allergen of anisakis sppo and a valuable tool for anisakis allergy component-resolved diagnosis. Int Arch Allergy Imm. 2016;169(2):108-12. Article. IF: 2.72; Q3

• Moral VP, Rodríguez CA, Gómez-Outes A, Ruiz FG, Vina AL, Belinchón FJP, Zamora JP, Jiménez JAQ, Gancedo SQ, Ortega JS,Vilarrasa RS, Asens JRV. Obsolete anti-pneumococcal vaccination recommendations in the spanish guidelines for the management of asthma (GEMA 4.0): The authors reply. Arch Bronconeumol. 2016;52(8):449. Letter. IF: 2.979; Q2

• Contreras-Porta J, Ruiz-Baques A, Hortal EG,Torres FC, Pla MNA, Santisteban AZ, de la Maza ES. Evaluation of an educational programme with workshops for families of children with food allergies. Allergol Immunopath. 2016;44(2):113-9. Article. IF: 1.439; Q4

• Moscato G, Pala G, Folletti I, Siracusa A, Quirce S. Occupational rhinitis affects occupational asthma severity. J Occup Health. 2016;58(3):310-3. Article. IF: 1.848; Q2

• Domínguez-Ortega J, Barranco P, Rodríguez-Pérez R, Quirce S. Biomarkers in occupational asthma. Curr Allergy Asthm R. 2016;16(9):63. Review. IF: 3.735; Q2

• Palao-Ocharan P, Domínguez-Ortega J, Barranco P, Díaz-Almiron M, Quirce S. Does the profile of sensitization to grass pollen allergens have clinical relevance? J Invest Allerg Clin. 2016;26(3):188-9. Editorial Material. IF: 3.094; Q2

Continue

207

3.4 Large System Pathology Area

3 INFORMATION GROUPS BY AREA • Pedrosa M, Phillips-Angles E, López-Lera A, López-Trascasa M, Caballero T. Complement study versus CINH gene testing for the diagnosis of type I hereditary angioedema in children. J Clin Immunol. 2016;36(1):16-8. Letter. IF: 3.253; Q2 • Phillips-Angles E, González-Muñoz M, Domínguez-Ortega J, Cabañas R, Quirce S. Usefulness of basophil activation test in diagnosis of hypersensitivity to etoricoxib. J Allergy Clin Immunol Pract. 2016;4(2):350-1. Letter. IF: 5.317; Q1 • Plaza Moral V, Alonso Mostaza S, Álvarez Rodríguez C, GómezOutes A, Gómez Ruiz F, López Vina A, Molina París J, Pellegrini Belinchón FJ, Plaza Zamora J, Quintano Jiménez JA, Quirce Gancedo S, Sanz Ortega J, Soler Vilarrasa R, Villa Asensi JR. Spanish guideline on the management of asthma. J Invest Allerg Clin. 2016;26 Suppl 1(Suppl 1):1-92. Article. IF: 3.094; Q2 • Plaza V, del Río PR, Gómez F, Vina AL, Molina J, Quintano JA, Quirce S, Soler R, Villa JR, Nieto A. Identification of gaps in the clinical patient care of asthma in Spain. Results of the OPTIMAGEMA survey. An Sist Sanit Navar. 2016;39(2):181-201. Article. IF: 0.625; Q4 • Plaza V, Fernández-Rodríguez C, Melero C, Cosio BG, Entrenas LM, de Llano LP, Gutiérrez-Pereyra F, Tarragona E, Palomino R, López-Vina A, (Quirce Gancedo S). Validation of the ‘Test of the Adherence to Inhalers’ (TAI) for asthma and COPD Patients. J Aerosol Med Pulm D. 2016;29(2):142-52. Article. IF: 2.528; Q3 • Prieto-García A, Marcos C, Caballero T. Classification of angioedema without wheals. Ann Allerg Asthma Im. 2016; 116(2):177. Letter. IF: 3.728; Q2 • Prior N, Remor E, Pérez-Fernández E, Caminoa M, Gómez-Traseira C, Gaya F, Aabom A, Aberer W, Betschel S, Boccon-Gibod I, Bouillet L, Bygum A, Csuka D, Farkas H, Gomide M, Grumach A, Leibovich I, Malbran A, Moldovan D, Mihaly E, Obtulowicz K, Perpen C, Peveling-Oberhag A, Porebski G, Chavannes CR, Reshef A, Staubach P, Wiednig M, Caballero T. Psychometric field study of hereditary angioedema quality of life questionnaire for adults: HAE-QoL. J Allergy Clin Immunol Pract. 2016;4(3):464-73. Article. IF: 5.317; Q1 • Quirce S, Boyano-Martínez T, Díaz-Perales A. Clinical presentation, allergens, and management of wheat allergy. Expert Rev Clin Immu. 2016;12(5):563-72. Review. IF: 3.27; Q2 • Quirce S, Fiandor A. How should occupational anaphylaxis be investigated and managed? Curr Opin Allergy Cl. 2016;16(2):8692. Review. IF: 3.463; Q2 • Quirce S, Vandenplas O, Campo P, Cruz MJ, de Blay F, Koschel D, Moscato G, Pala G, Raulf M, Sastre J, Siracusa A, Tarlo SM, Walusiak-Skorupa J, Cormier Y. Occupational hypersensitivity pneumonitis: an EAACI position paper. Allergy. 2016;71(6):76579. Article. IF: 7.361; D1 • Raulf M, Buters JTM, Chapman M, Cecchi L, de Blay F, Doekes G, Eduard W, Heederik D, Jeebhay MF, Kespohl S, Krop E, Moscato G, Pala G, Quirce S, Sander I, Schlunssen V, Sigsgaard T, Walusiak-Skorupa J, Wiszniewska M, Wouters IM, Annesi-Maesano I. Monitoring of occupational and environmental aeroallergens - EAACI Position Paper. Allergologie. 2016;39(2):45-68. Article. IF: 0.311; Q4 • Sánchez R, Martínez J, Castro A, Pedrosa M, Quirce S, RodríguezPérez R, Gasset M.The amyloid fold of Gad m 1 epitopes governs IgE binding. Sci Rep-Uk. 2016;6:32801. Article. IF: 4.259; Q1 • Sanchez-García S, Olaguibel JM, Quirce S, Ibáñez MD. Measurement of lung function and bronchial inflammation in children is underused by Spanish allergists. J Invest Allerg Clin. 2016;26(2):126-8. Editorial Material. IF: 3.094; Q2 • Torrijos EG, Gimeno PM, Iglesias AM, Rodríguez RG, Bonilla PG, El Kaddioui S, Díaz YCM, Gancedo SQ. Non-asthmatic eosinophilic bronchitis and idiopathic eosinophilic esophagitis. J Invest Allerg Clin. 2016;26(3):190-1. Editorial Material. IF: 3.094; Q2

208

• Xepapadaki P, Fiocchi A, Grabenhenrich L, Roberts G, Grimshaw KEC, Fiandor A, Larco JI, Sigurdardottir S, Clausen M, Papadopoulos NG, Dahdah L, Mackie A, Sprikkelman AB, Schoemaker AA, Dubakiene R, Butiene I, Kowalski ML, Zeman K, Gavrili S, Keil T, Beyer K. Incidence and natural history of hen’s egg allergy in the first 2 years of lifethe EuroPrevall birth cohort study. Allergy. 2016;71(3):350-7. Article. IF: 7.361; D1 • Yucesoy B, Kashon ML, Johnson VJ, Lummus ZL, Fluharty K, Gautrin D, Cartier A, Boulet LP, Sastre J, Quirce S, Tarlo SM, Cruz MJ, Muñoz X, Luster MI, Bernstein DI. Genetic variants in TNF alpha, TGFB1, PTGS1 and PTGS2 genes are associated with diisocyanate-induced asthma. J Immunotoxicol. 2016;13(1):119-26. Article. IF: 2.021; Q3 • Zanichelli A, Longhurst HJ, Maurer M, Bouillet L, Aberer W, Fabien V, Andresen I, Caballero T. Misdiagnosis trends in patients with hereditary angioedema from the real-world clinical setting. Ann Allerg Asthma Im. 2016;117(4):394-8. Article. IF: 3.728; Q2

PUBLIC PROJECTS Caballero Molina MT. Estudio de carga de Enfermedad del Angioedema hereditario en España (PI13/01758). ISCIII. 2014-2016. Management centre: FIBHULP Caballero Soto ML. Estudio de tumorigenesis asociada a Anisakis simple (PI12/00888). ISCIII. 2013-2017. Management centre: FIBHULP Rodríguez Pérez MR. Identificación de genes y de microRNAs implicados en la función de los linfocitos T y B como nuevos biomarcadores para el diagnóstico in vitro de la alergia a Anisakis (PI12/00581). ISCIII. 2013-2016. Management centre: FIBHULP Rodríguez Pérez MR. Miguel Servet Contracts Type II (MSII13/000022). ISCIII.2014-Ongoing. Management centre: FIBHULP

PRIVATE PROJECTS Barranco Sanz MPE. Jornada de Investigación sobre asma de difícil control. Ediciones Mayo S. A. 2011-Ongoing. Management centre: FIBHULP Caballero Molina MT. Development and trans-cultural validation of an international specific questionnaire (IHAE-QOL) for assessment of health related quality of life in adult patients with hereditary angioedema due to c1 inhibitor deficiency (HAE) and quality of life. Hereditary Angio-Edema In. 2009-Ongoing. Management centre: FIBHULP Domínguez Ortega FJ. Asesoramiento para el diseño del estudio clínico “Ensayo clínico prospectivo multicéntrico aleatorizado de doble simulación controlado con placebo de búsqueda de la dosis más eficaz para el tratamiento de rinitis/rinoconjuntivitis por alergia frente al polen de gramínea”. Inmunotek. 2015-Ongoing. Management centre: FIBHULP Quirce Gancedo SE. Relación entre asma y obesidad en la población española mayor o igual a 18 años. Laboratorio Menarini S.A. 2009-Ongoing. Management centre: FIBHULP

Rodríguez Pérez MR. Desarrollo de un programa formativo de formación en investigación en centros de trabajo. Colegio Valle del Miro. 2016-Ongoing. Management centre: FIBHULP

INTERNATIONAL PROJECTS Quirce Gancedo SE. Integrated approaches for food allergen and allergy risk management (iFAAM). EU. 2013-2017. Management centre: FIBHULP.

CLINICAL TRIALS Barranco Sanz MPE. Carga del asma grave en España: estudio observacional multicéntrico. Glaxosmithkline S.A. HULP Code: PI-2300. Sponsored´s Protocol Code: 205738(HO-1516438). Signature Date: 9/6/2016 Caballero Molina MT. Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo, cruzado parcialmente, de dos períodos y tres secuencias para evaluar la eficacia y la seguridad de la administración subcutánea de 2000 u de un inhibidor de la esterasa c1 (humana) en líquido inyectable para la prevención de las crisis de angioedema en adolescentes y adultos con angioedema hereditario. Shire Viropharma, Inc. HULP Code: Anexo-I 4539. Sponsored´s Protocol Code: SHP-616300. Signature Date: 14/6/2016 Caballero Molina MT. Registro de pacientes de FIRAZYR-IOS (Icatibant Outcome Survey). Shire Pharmaceuticals Iberica S.L. HULP Code: Anexo-II 3080. Sponsored´s Protocol Code: IOS. Signature Date: 4/3/2016 Caballero Molina Mt. Estudio multicéntrico, abierto, no aleatorizado para evaluar la farmacocinética, tolerabilidad y seguridad de una única administración subcutánea de icatibant en niños y adolescentes con angioedema hereditario. Shire Human Genetic Therapies Inc. HULP Code: Anexo-II 3507. Sponsored´s Protocol Code: HGTFIR-086. Signature Date: 27/10/2016 Caballero Molina MT. Estudio (registro) postautorización de tipo observacional, multicéntrico, en varios países europeos de pacientes con angiodema hereditario (AEH) que reciben cinryze (inhibidor de la c1 [humano]) para el tratamiento o la prevención de las crisis de AEH. Viropharma SPRL. HULP Code: Anexo-I 3744. Sponsored´s Protocol Code: 0624-401. Signature Date: 14/03/2016 Caballero Molina MT. Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo, cruzado parcialmente, de dos períodos y tres secuencias para evaluar la eficacia y la seguridad de la administración subcutánea de 2000 u de un inhibidor de la esterasa c1 (humana) en líquido inyectable para la prevención de las crisis de angioedema en adolescentes y adultos con angioedema hereditario. Shire Viropharma Inc.

HULP Code: 4539. Sponsored´s Protocol Code: SHP-616-300. Signature Date: 16/2/2016 Caballero Molina MT. Estudio aleatorizado, doble ciego, controlado con placebo, de diferentes dosis y de grupos paralelos, para evaluar la eficacia, seguridad, tolerabilidad, propiedades farmacocinéticas y farmacodinámicas de BCX7353 como tratamiento preventivo para reducir la frecuencia de ataques en sujetos con angioedema hereditario. Biocryst Pharmaceuticals Inc. HULP Code: 4647. Sponsored´s Protocol Code: BCX7353-203. Signature Date: 5/9/2016 Domínguez Ortega FJ. Estudio fase IV, observacional, multinacional sobre el control de la enfermedad y los resultados notificados por los pacientes en tratamiento con inhaladores de combinación a dosis fija para asma persistente y EPOC en la práctica clínica habitual (SPRINT). Teva Pharmaceutical Industries Ltd. HULP Code: Anexo-I PI-2002. Sponsored´s Protocol Code: BFSAS-40087. Signature Date: 24/05/2016 Domínguez Ortega FJ. Estudio MARTE: estudio observacional sobre las características de los pacientes asmáticos en tratamiento de mantenimiento y rescate en España según práctica clínica habitual. Chiesi Farmaceutici S.P.A. HULP Code: PI-2281. Sponsored´s Protocol Code: CHIFOR-2015-01. Signature Date: 11/7/2016 Domínguez Ortega FJ. Estudio observacional para evaluar el uso de medicación de alivio en práctica clínica y su relación con el control del asma. Estudio MISTRAL. Astrazeneca Farmaceutica Spain, S.A. HULP Code: PI-2405. Sponsored´s Protocol Code: ASTASM-2016-01 y D589BR00035. Signature Date: 8/7/2016

PATENTS AND TRADEMARKS Valenta R, Constantin C, Quirce Gancedo SE, inventors; Phadia AB, assignee. Novel wheat allergens. PCT/SE2008/051377, EP2225266, US2010305049, AU2008330230, CA2707190, CN101932597, JP2011505134, RU2010126590; 2007 November 30. Caballero Molina MT, Prior Gómez N, Remor Bitencourt EA, authors, FIBHULP, assignee. Brand name: HAEQoL HEREDITARY ANGIOEDEMA QUALITY OF LIFE. CM 13.083.068; 2014 July 15.

Sánchez Herreros R, Martínez Fernández J, Castro Morera A, Gasset Vega M, Rodríguez Pérez RM, Pedrosa Delgado M, Quirce Gancedo S, inventors; CSIC, FIBHULP, assign. Food allergen extracts and methods of producing and using the same. 16382413.9; 2016 September 6.

Return to LARGE SYSTEM PATHOLOGIES AREA INDEX

209

3 INFORMATION GROUPS BY AREA

3.4 Large System Pathology Area

• Molecular disorders in preeclamsia, placenta and other obstetrical diseases.

Research Activity PUBLICATIONS

GYNECOLOGIC ONCOLOGY GROUP

• Brunel I, Iacoponi S, Hernández A, Diestro MD, de Santiago J, Zapardiel I. Intravascular leiomyomatosis: an exceptional entity. Clin Exp Obstet Gyn. 2016;43(3):443-5. Article. IF: 0.429; Q4

14 42.043 3

Ignacio Zapardiel Gutiérrez Subdirector Científico. IdiPAZ Facultativo Especialista de Área en Ginecología y Obstetricia. Unidad de Ginecología Oncológica. HULP Profesor Asociado Facultad de Medicina. UAM Diana Alecsandru Danceanu  Médico Especialista en Inmunología. IVI Madrid Covadonga Álvarez López Facultativo Especialista de Área en Ginecología y Obstetricia. HULP Ónica María Armijo Suárez Facultativo Especialista de Área en Ginecología y Obstetricia. Unidad de Reproducción Asistida. HULP María Cerrillo Martínez Ginecóloga Especialista en Reproducción Humana. IVI Madrid María Dolores Diestro Tejada Facultativo Especialista de Área en Ginecología y Obstetricia. Unidad de Ginecología Oncológica. HULP Juan Antonio García Velasco Profesor Titular. Universidad Rey Juan Carlos Cristina González Benítez Facultativo Especialista de Área en Ginecología y Obstetricia. HULP Alicia Hernández Gutiérrez Facultativo Especialista de Área en Ginecología y Obstetricia. Unidad de Ginecología Oncológica. HULP Profesor Asociado Facultad de Medicina. UAM María Herrera de la Muela Facultativo Especialista de Área en Ginecología y Obstetricia. Unidad de Patología Mamaria. HULP Ana López Carrasco Facultativo Especialista de Área en Ginecología y Obstetricia. HULP 210

• Arispe C, Pomares AI, de Santiago J, Zapardiel I. Evolution of radical hysterectomy for cervical cancer along the last two decades: single institution experience. Chinese J Cancer Res. 2016;28(2):215-20. Article. IF: 3; Q2

Israel Ortega Sánchez Coordinador del Departamento Internacional. IVI Madrid Margarita Sánchez-Pastor Ruiz Facultativo Especialista de Área en Ginecología y Obstetricia. HULP Profesor Asociado Facultad de Medicina. UAM María Serrano Velasco Facultativo Especialista de Área en Ginecología y Obstetricia. HULP María Elisa Varela Sanz Investigadora Postdoctoral. CNIO

Strategic Objective The main objective of our group is to study all aspects related to gynaecologic malignancies. It includes from diagnosis to treatment and follow-up. For the next years we will focus our research on the malignancies affecting female uterus, including cervical and endometrial cancer as well as uterine sarcomas. We will develop at least two stable and comprehensive specific research lines trying to pay attention to molecular aspects as well as clinical features of the Gynaecological cancers. But we will support the rest of aspects of the subspecialty.

Research Lines • Evaluation, treatment and surgery of oncologic diseases in gynecology. • Pelvic floor reconstructive surgery.

• Buda A, Papadia A, Zapardiel I, Vizza E, Ghezzi F, de Ponti E, Lissoni AA, Imboden S, Diestro MD, Verri D, Gasparri ML, Bussi B, Di Martino G, de la Noval BD, Mueller M, Crivellaro C. From conventional radiotracer Tc-99(m) with blue dye to indocyanine green fluorescence: A comparison of methods towards optimization of sentinel lymph node mapping in early stage cervical cancer for a laparoscopic approach. Ann Surg Oncol. 2016;23(9):2959-65. Article. IF: 4.041; D1

• Zapardiel I. Treatment of ovarian tumours of low malignant potential (borderline ovarian tumours). Int J Gynecol Cancer. 2016;26:14. Article. IF: 2.369; Q2

PUBLIC PROJECTS Antolín Alvarado E. Desarrollo de métodos predictivos basados en la integración de factores prenatales y postnatales para la detección de neurodesarrollo de cardiopatías congénitas (PI13/02364). ISCIII. 2014-2017. Management centre: FIBHULP

PRIVATE PROJECTS Herrera de la Muela MJ. Correlación de los hallazgos radiológicos y clínico-exploratorios con las características citológicas del fluido mamario obtenido mediante aspiración con el siste halo en una cohorte de mujeres snas portadoras de mutaciones delteteras en los genes BRCA. FIBHULP. 2015-Ongoing. Management centre: FIBHULP

• Enciso S, Díaz-Güemes I, Pérez-Medina T, Zapardiel I, de Santiago J, Uson J, Sánchez-Margallo FM. Validation of a structured intensive laparoscopic course for basic and advanced gynecologic skills training. Int J Gynecol Obstet. 2016;133(2):241-4. Article. IF: 2.174; Q2

Herrera de la Muela MJ. Calidad de vida y satisfacción con la cirugía en mujeres con cáncer de mama con reconstrucción postmastectomia: estudio BRECAR (Breast Cancer Reconstruction Study). FIBHULP. 2015-Ongoing. Management centre: FIBHULP

• Iacoponi S, Rubio P, García E, Oehler MK, Díez J, Díaz-de la Noval B, Mora P, Gardella B, Gómez I, Kotsopoulos IC, Zalewski K, Zapardiel I. Prognostic factors of recurrence and survival in vulvar melanoma: Subgroup analysis of the VULvar CANcer Study. Int J Gynecol Cancer. 2016;26(7):1307-12. Article. IF: 2.369; Q2

Zapardiel Gutiérrez I. Ultraestadificación molecular ganglio centinela en cáncer de cérvix: MRNA e6/e7 HPV. FIBHULP. 2013-Ongoing. Management centre: FIBHULP

• Iacoponi S, Zalewsld K, Fruscio R, Díaz-de la Noval B, de Iaco P, Ceccaroni M, Barazi D, Chen F, Zapardiel I. Prognostic factors for recurrence and survival among patients with invasive vulvar Paget disease included in the VULCAN study. Int J Gynecol Obstet. 2016;133(1):76-9. Article. IF: 2.174; Q2

Zapardiel Gutiérrez I. III Curso de investigación en laparoscópia avanzada en cadáveres. Karl Storz Endoscopia Ibética S.A. 2015-Ongoing. Management centre: FIBHULP

• López N, Grabowski JP, de Santiago J, Zapardiel I. Carcinoma of the recto-vaginal septum. Comprehensive literature review. J Obstet Gynaecol. 2016;36(4):450-4. Review. IF: 0.629; Q4 • Minig L, Otano L, Cruz P, Patrono MG, Botazzi C, Zapardiel I. Laparoscopic surgery for treating adnexal masses during the first trimester of pregnancy. J Minim Access Surg. 2016;12(1):22-5. Article. IF: 1.282; Q3 • Rodrigues MJ, Zapardiel I, Frelaut M, Brain E, Falandry C. A call for specific geriatric data on cervical cancers. Future Oncol. 2016;12(9):1101-4. Editorial Material. IF: 2.131; Q3

Zapardiel Gutiérrez I. Curso de investigación en laparoscopia ginecológica avanzada en cadáveres. Varios. 2013-Ongoing. Management centre: FIBHULP Zapardiel Gutiérrez I. Evaluación del antígeno epididimal humano -HE4 - en el diagnóstico diferencial y seguimiento de la endometriosis superficial y profunda.Abbott Laboratories S.A. 2015-Ongoing. Management centre: FIBHULP

• Rychlik A, Marín S, de Santiago J, Zapardiel I. Utility of laparoscopic indocyanine green-guided sentinel node biopsy in open cervical cancer surgery. Int J Gynecol Cancer. 2016;26(7):12889. Article. IF: 2.369; Q2

Zapardiel Gutiérrez I. Valor de la linfadectomía en el cáncer de endometrio de riesgo intermedio (LICERI). FIBHCSC. 2014-Ongoing. Management centre: FIBHCSC

• Zapardiel I, Cruz M, Diestro MD, Requena A, García-Velasco JA. Assisted reproductive techniques after fertility-sparing treatments in gynaecological cancers. Hum Reprod Update. 2016;22(3):281-305. Review. IF: 11.748; D1

CLINICAL TRIALS

• Zapardiel I, Gorostidi M, Ravaggi A, Allende MT, Silveira M, Abehsera D, Macuks R. Utility serum marker HE4 for the differential diagnosis between endometriosis and adnexal malignancy. Int J Gynecol Cancer. 2016;26(1):52-5. Article. IF: 2.369; Q2 • Zapardiel I, Moreno E, Pinera A, de Santiago J. Novel technique for the complete staging of endometrial cancer by single-port laparoscopy. Gynecol Oncol. 2016;140(2):369-71. Article. IF: 4.959; D1

Bartha Rasero JL. Ensayo clínico controlado, aleatorizado, doble ciego con prevastatina versus placebo para la prevención de preclampsia. STATIN. Fundación para la Formación e Investigación Sanitarias de la Región de Murcia. HULP Code: Contrato 4716. Sponsored´s Protocol Code: FFIS/2015/01/ST. Signature Date: 2/11/2016

Continue

211

3.4 Large System Pathology Area

3 INFORMATION GROUPS BY AREA de la Calle Fernández-Miranda M. Ensayo clínico uso precoz de progesterona para la prevención del parto pretérmino en la gestación gemelar. Estudio aleatorizado, doble ciego con placebo. Events. Fundación para la Formación e Investigación Sanitarias de la Región de Murcia. HULP Code: Contrato 4690. Sponsored´s Protocol Code: FFIS/2015/02/EV. Signature Date: 20/9/2016 de la Calle Fernández-Miranda M. Estudio de inmunogenicidad y seguridad de la vacuna DTPA de GSK biologicals, Boostrix® (263855), en mujeres embarazadas. Glaxosmithkline S.A. HULP Code: Anexo-I 4397. Sponsored´s Protocol Code: 116945. Signature Date: 4/10/2016 Usandizaga Elio R. Edstudio sobre las condiciones de uso

de Caribán® y de otros antieméticos en el tratamiento de las náuseas y vómitos en el embarazo: estudio prospectivo observacional longitudinal. Laboratorios Inibsa S.A. HULP Code: PI-2191. Sponsored´s Protocol Code: LINDOX-2015-01. Signature Date: 4/4/2016

PATENTS AND TRADEMARKS Zapardiel Gutiérrez I, de Santiago García J, inventors; FIBHULP, assignee. Laparoscopic surgical instrument. P201230950, PCT/ES2013/000139; 2012 June 18. Zapardiel Gutiérrez I, de Santiago García J, inventors; FIBHULP, assignee. Surgical device. P201330532, PCT/ ES2014/070277; 2013 April, 15.

PATIENT BLOOD MANAGEMENT GROUP

8 14.836 2 Manuel Quintana Díaz Facultativo Especialista de Área en Medicina Intensiva. Coordinador de Urgencias en Análisis Clínicos. HULP Profesor Asociado Facultad de Medicina. UAM María José Alcaide Martín Facultativo Especialista de Área en Análisis Clínicos. Tutora de residentes de Análisis Clínicos. HULP Rosa Capilla Pueyo Facultativo Especialista de Área en Medicina Familiar y Comunitaria. HULP Miriam Estebánez Muñoz Facultativo Especialista de Área en Medicina Interna. HULP Sara Fabra Cadenas Facultativo Especialista de Área en Medicina Familiar y Comunitaria. HULP Pilar Fernández Calle Facultativo Especialista de Área en Análisis Clínicos Coordinadora de Calidad de Análisis Clínicos. HULP Sonia Galindo Gómez Supervisora de Enfermería en Urgencias. HULP José Antonio García Erce Facultativo Especialista de Área en Hematología. Hospital San Jorge de Huesca Raquel Gómez Bravo Facultativo Especialista de Área en Medicina Familiar y Comunitaria. HULP Roswell Enrique González Rodiles Heredia Médico Interno Residente en Medicina Familiar y Comunitaria. HULP Manuel Jesús González Viñolis Facultativo Especialista de Área en Neumología. HULP Carmen Herrero Benito Enfermera. HULP Milagros Martí de Gracia Facultativo Especialista de Área en Radiodiagnóstico. Jefe de Sección de Radiología de Urgencias. HULP

212

Return to LARGE SYSTEM PATHOLOGIES AREA INDEX

Ana María Martínez Virto Facultativo Especialista de Área en Medicina Familiar y Comunitaria. Coordinadora Adjunta de Urgencias. HULP Marina Noguerol Gutiérrez Facultativo Especialista de Área en Medicina Familiar y Comunitaria. HULP Paloma Oliver Sáez Facultativo Especialista de Área en Análisis Clínicos. Tutora de residentes de Análisis Clínicos. HULP María Inmaculada Pinilla Fernández Facultativo Especialista de Área en Radiodiagnóstico. HULP María Angélica Rivera Núñez Facultativo Especialista de Área en Medicina Interna. HULP Marcelino Sánchez Casado Facultativo Especialista de Área en Medicina Intensiva. Hospital Virgen de la Salud María Torres de Sebastián Médico Interno Residente en Urgencias. HULP

Strategic Objective Stratifying risk in the critically ill patient: • Stratify pulmonary thromboembolis risk. • Try to diagnose the potentially ill politraumatized patient at the emergency room. • Early detection of sepsis at the emergecy room.  • Ehance the use of the critically ill room at the emergency department. Enhance the use of blood products: • Critically ill patient coagulopathy. • Early diagnose of anemia at the emergency room. • Intravenous ironusage

Continue

213

3 INFORMATION GROUPS BY AREA

3.4 Large System Pathology Area

Research Lines

tertiary hospital: Evaluation through a toxicovigilance program. Plos One. 2016;11(4):e0152876. Article. IF: 2.806; Q1

• Critical Bleeding.

• Nanwani K, Saravia A, Suárez N, Martínez-Virto A, Quintana-Díaz M. A 70-year-old male with respiratory arrest secondary to angioedema. Med Intensiva. 2016;40(6):385-7. Letter. IF: 1.231; Q4

Research Activity

• Quintana-Díaz M, Erce JAG. Need for multidisciplinary massive transfusion protocol for non-trauma patient. Med Intensiva. 2016;40(9):525-6. Editorial Material. IF: 1.231; Q4

DOCTORAL THESES Cancelliere Fernández N. Evaluación de los modelos educativos, teórico y práctico, en residentes de primer año de especialidades médico-quirúrgicas[dissertation]. Madrid: UAM: 2016(19/9/2016). Directors: Quintana Díaz M, Peña Sánchez JM. Mateos Pañero B. Valoración del Euroscore y SAPS III como predictor de mortalidad hospitalaria en el postoperatorio de cirugía cardiaca[dissertation]. Madrid: UAM: 2016(1/12/2016). Directors: Quintana Díaz M, Sánchez Casado M. Rodríguez Fernández R. Evaluación de la eficacia de la funduplicatura Nissen laparoscópica mediante el uso de un cuestionario de calidad de vida y estudio esofagogástrico baritado[dissertation]. Madrid: UAM: 2016(12/9/2016). Directors: Quintana Díaz M, Martínez Cortijo S.

BOOKS AND BOOK CHAPTERS García Erce JA, Quintana Díaz M. Interpretación de las alteraciones básicas de la coagulación: enfoque práctico. In: Manual de Formación Continuada 2015-2016: la efectividad en la Medicina del Laboratorio Clínico. Madrid: Asociación Española de Biopatología Médica (AEBM), 2016. p.48-71 Quintana Díaz M, Serrano Lázaro A. Uso de hemoderivados en el paciente crítico. In: Trauma en Medicina Intensiva. Madrid: Aula-Salud, 2016. p.1-12 Quintana-Díaz M, de Vega-Ríos E. Prevención secundaria con dabigatrán del ICTUS cardioembólico en la fibrilación auricular no valvular. In: López Soto A, García Alegría J, Manzano L, Quintana-Díaz M, Vega-Ríos E, Altimir Losada S. Casos clínicos de la práctica a la teoría. Consenso de uso de Dabigatrán. Proyecto ReThink. . Madrid: EdikaMed S.L., 2016. p.37-43 Serrano Lázaro A, Quintana Díaz M. Fluidos, transfusión y soporte vasoactivo en el paciente traumático grave. In:Trauma en Medicina Intensiva. Madrid: Aula-Salud, 2016. p.1-8.

PUBLICATIONS • Galán LAM, Egea-Guerrero JJ, Díaz MQ, Vilches-Arenas A. The effectiveness and safety of pharmacological prophylaxis against venous thromboembolism in patients with moderate to severe traumatic brain injury: A systematic review and meta-analysis. J Trauma. 2016;81(3):567-74. Review. IF: 3.403; Q1 • García-López S, Bocos JM, Gisbert JP, Bajador E, Chaparro M, Castano C, García-Erce JA, Gomollon F. High-dose intravenous treatment in iron deficiency anaemia in inflammatory bowel disease: early efficacy and impact on quality of life. Blood TransfusItaly. 2016;14(3):199-205. Article. IF: 1.607; Q4 • Muñoz R, Borobia AM, Quintana M, Martínez A, Ramírez E, Muñoz M, Frías J, Carcas AJ. Outcomes and costs of poisoned patients admitted to an adult emergency department of a spanish

214

• Quintana-Díaz M, Fabra-Cadenas S, Gómez-Ramírez S, Martínez-Virto A, García-Erce JA, Muñoz M. A fast-track anaemia clinic in the emergency department: feasibility and efficacy of intravenous iron administration for treating sub-acute iron deficiency anaemia. Blood Transfus-Italy. 2016;14(2):126-33. Article. IF: 1.607; Q4 • Revello R, Alcaide MJ, Dudzik D, Abehsera D, Bartha JL. Differential amniotic fluid cytokine profile in women with chorioamnionitis with and without funisitis. J Matern-Fetal Neo M. 2016;29(13):2161-5. Article. IF: 1.826; Q3

ENDOCRINE DISEASES GROUP

• Rodríguez-García J, Fernández-Santos R, García-Erce JA. Vaccination of patients with non-Hodgkin lymphoma under rituximab or other immunosuppressive drugs. Med Clin-Barcelona. 2016;146(1):43-4. Letter. IF: 1.125; Q3

PUBLIC PROJECTS Martí de Gracia M. Mejora de la adecuación de la solicitud de pruebas de imagen con radiacion ionizante (radiografia y TC) en los Servicios de Urgencias Hospitalarios. Proyectos MAPAC-imagen (PI13/01183). ISCIII. 2014-2016. Management centre: FIBHULP

11 40.961 4

Quianta Díaz M. Proyecto de innovación docente: taller de trabajo en equipo (PID2016/17). UAM. 2016-2017. Management centre: UAM

PRIVATE PROJECTS Oliver Sáez P. Estudio de gasometría en el lugar de asistencia. Beneficio para el paciente. Asociación Española de Farmacéuticos Analistas. 2012-Ongoing. Management centre: FIBHULP Oliver Sáez P. Estudio comparativo multicéntrico sobre contaminación por microorganismos de las tiras reactivas de glucemia de uso hospitalario. Abbott Laboratories S.A. 2012-Ongoing. Management centre: FIBHULP Quintaza Díaz M. Adecuación de las dosis de HBPM mediante la monitorización de los niveles de factor antixa en pacientes que reciben tromboprofilaxis ampliada desde Urgencias. Laboratorios Farmacéuticos Rovi S.A. 2013-Ongoing. Management centre: FIBHULP Quintaza Díaz M. Estudio de monitorización de heparinas de bajo peso molecular como profilaxis en un Servicio de Urgencias. Bayer Hispania S.L. 2011-Ongoing. Management centre: FIBHULP Quintaza Díaz M. Identificación de factores de gravedad en el paciente con traumatismo potencialmente grave. FIBHULP. 2013-Ongoing. Management centre: FIBHULP

Return to LARGE SYSTEM PATHOLOGIES AREA INDEX

Lucrecia Herranz de la Morena Jefe de Sección de Diabetes del Servicio de Endocrinología y Nutrición. HULP Cristina Álvarez Escola Facultativo Especialista de Área en Endocrinología y Nutrición. HULP Beatriz Barquiel Alcalá Facultativo Especialista de Área en Endocrinología y Nutrición. HULP Isabel Calvo Viñuela Enfermera de la Unidad de Obesidad, Endocrinología y Nutrición. HULP Ana Isabel de Cos Blanco Coordinadora de la Unidad Médico-Quirúrgica de Obesidad del Servicio de Endocrinología y Nutrición. HULP Sonia del Río Prados Facultativo Especialista de Área en Endocrinología y Nutrición. HULP Gumersindo Fernández Vázquez Facultativo Especialista de Área en Endocrinología y Nutrición. HULP Ruth Gaspar Lafuente Enfermera Educadora Endocrinología y Nutrición. Unidad de Diabetes. HULP

Noemí González Pérez de Villar Facultativo Especialista de Área en Endocrinología y Nutrición. HULP Natalia Hillman Gadea Facultativo Especialista de Área en Endocrinología y Nutrición. HULP Beatriz Lecumberri Santamaría Facultativo Especialista de Área en Endocrinología y Nutrición. HULP Luis Felipe Pallardo Sánchez Profesor Emérito. UYAM Paola Andrea Parra Ramírez Facultativo Especialista de Área en Endocrinología y Nutrición. HULP Lourdes Sáez de Ibarra y Vélez de Mendizábal Enfermera Educadora Unidad de Diabetes, Endocrinología y Nutrición. HULP

Strategic Objective The objective of this group is both basic and applied investigation, with its interest focused on translational investigation, comprising two specific areas within the speciality of Endocrinology and Nutrition. The first,

Continue

215

3.4 Large System Pathology Area

3 INFORMATION GROUPS BY AREA within metabolic pathology, includes diabetes and obesity. The second is focused on endocrine organspecific pathology (thyroid, pituitary gland, neuro-endocrinology and rare endocrine disorders).

Research Lines Metabolic pathology • Diabetes and pregnancy. • Diabetes related complications. • Advanced technologies in diabetes. • Epidemiological, clinical and comprehensive therapeutic approach to obesity. • Adipose brown tissue metabolism. Organ-specific pathology • Molecular biology applied to the diagnosis and treatment of neuroendocrine disorders.  • Prognosis and treatment of differentiated thyroid cancer. • Study of GnRH deficiency. • GH secretion alterations and cardiometabolic pathology. • Clinical-genetic characterizations of rare endocrine disorders and imprinting syndromes. 

• Martínez-Cerón E, Barquiel B, Bezos AM, Casitas R, Galera R, García-Benito C, Hernanz A, Alonso-Fernández A, GarcíaRío F. Effect of continuous positive airway pressure on glycemic control in patients with obstructive sleep apnea and type 2 diabetes A randomized clinical trial. Am J Resp Crit Care. 2016;194(4):476-85. Article. IF: 13.204; D1

PUBLICATIONS • Barquiel B, Herranz L, Hillman N, Burgos MA, Grande C, Tukia KM, Bartha JL, Pallardo LF. HbA1c and gestational weight gain are factors that influence neonatal outcome in mothers with gestational diabetes. J Womens Health. 2016;25(6):579-85. Article. IF: 2.322; Q2 • Bernabéu I, Pico A, Venegas E, Aller J, Álvarez-Escola C, GarcíaArnés JA, Marazuela M, Jonsson P, Mir N, Vargas MG. Safety of long-term treatment with Pegvisomant: analysis of Spanish patients included in global ACROSTUDY. Pituitary. 2016;19(2):12737. Article. IF: 2.481; Q3 • Chico A, Herranz L, Corcoy R, Ramírez O, Goya MM, Bellart J, González-Romero S, Codina M, Sánchez P, Cortázar A, Acosta D, Picón MJ, Rubio JA, Megia A, Sancho MA, Balsells M, Sola E, Gonzalez NL, López-López J. Glycemic control and maternal and fetal outcomes in pregnant women with type 1 diabetes according to the type of basal insulin. Eur J Obstet Gyn R B. 2016;206:84-91. Article. IF: 1.666; Q3 • Herranz L, Sáez-de-Ibarra L, Hillman N, Gaspar R, Pallardo LF. Glycemic changes during menstrual cycles in women with type 1 diabetes. Med Clin-Barcelona. 2016;146(7):287-91. Article. IF: 1.125; Q3 • Luque RM, Ibáñez-Costa A, Sánchez-Tejada L, Rivero-Cortes E, Robledo M, Madrazo-Atutxa A, Mora M, Álvarez CV, Lucas-Mo-

UROLOGY GROUP

• Mayor-Ibarguren A, Roldán-Puchalt MC, Gómez-Fernández C, Albizuri-Prado F, Álvarez-Escola C. Subacute cutaneous lupus erythematosus induced by mitotane. JAMA Dermatol. 2016;152(1):109-11. Letter. IF: 5.817; D1 • Mayor-Ibarguren A, Roldán-Puchalt MC, Sancho-Bueso T, PérezLópez C, Álvarez-Linera J, Frutos R, Álvarez-Escola C, RegojoZapata R, Beato-Merino MJ, Herranz-Pinto P, Lecumberri B. Kaposi sarcoma secondary to endogenous adrenocorticotropic hormone-dependent Cushing syndrome. Brit J Dermatol. 2016;174(6):1370-4. Article. IF: 4.706; D1

29 169.765 12

• Ramos-Levi AM, Bernabéu I, Álvarez-Escola C, Aller J, Lucas T, de Miguel P, Rodríguez-Canete L, Sampedro-Núñez MA, Halperin I, Puig-Domingo M, Marazuela M. Long-term treatment with pegvisomant for acromegaly: a 10-year experience. Clin Endocrinol. 2016;84(4):540-50. Article. IF: 3.327; Q2 • Ramos-Levi AM, Moreno JC, Álvarez-Escola C, Lacamara N, Montáñez MC. Coexistence of thyroid hormone resistance syndrome, pituitary adenoma and Graves’ disease. Endocrinol Nutr. 2016;63(3):139-41. Letter. IF: 1.106; Q4

Research Activity

216

rante T, Álvarez-Escola C, Fajardo C, Castaño L, Gaztambide S, Venegas-Moreno E, Soto-Moreno A, Gálvez MA, Salvador J,Valassi E,Webb SM, Pico A, Puig-Domingo M, Gilabert M, Bernabéu I, Marazuela M, Leal-Cerro A, Castano JP.The Molecular Registry of Pituitary Adenomas (REMAH): A bet of Spanish Endocrinology for the future of individualized medicine and translational research. Endocrinol Nutr. 2016;63(6):274-84. Article. IF: 1.106; Q4

• Thiele S, Mantovani G, Barlier A, Boldrin V, Bordogna P, de Sanctis L, Elli FM, Freson K, Garin I, Grybek V, Hanna P, Izzi B, Hiort O, Lecumberri B, Pereda A, Saraff V, Silve C, Turan S, Usardi A, Werner R, de Nanclares GP, Linglart A. From pseudohypoparathyroidism to inactivating PTH/PTHrP signalling disorder (IPPSD), a novel classification proposed by the EuroPHP network. Eur J Endocrinol. 2016;175(6):P1-17. Article. IF: 4.101; Q1

PRIVATE PROJECTS de Cos Blanco AI. Tratamiento interdisciplinar de diabetes gestacional y obesidad. Banco de Castilla- La Mancha S.A. 2011-Ongoing. Management centre: FIBHULP Herranz de la Morena L. Actualización y proyección de la unidad funcuional de la obesidad en la actividad clínica hospitalaria del Servicio de Endocrinología. Abbott Laboratories S.A. 2008-2017. Management centre: FIBHULP Herranz de la Morena L. Jornadas de formación en investigación sobre diabetes y obesidad. Astrazeneca Farmacéutica Spain S.A. 2013-Ongoing. Management centre: FIBHULP

Return to LARGE SYSTEM PATHOLOGIES AREA INDEX

Luis Martínez-Piñeiro Lorenzo Jefe de Servicio de Urología. HULP Alfredo Aguilera Bazán Facultativo Especialista de Área en Urología. HULP José María Alonso Dorrego Facultativo Especialista de Área en Urología. HULP Mario Álvarez Maestro Facultativo Especialista de Área en Urología. HULP Luisa María Botella Cubells Investigador Senior. Departamento de Medicina Celular y Molecular, Centro de Investigaciones Biológicas- CSIC José Ramón Cansino Alcaide Facultativo Especialista de Área en Urología. HULP Cristina de Castro Guerin Facultativo Especialista de Área en Urología. HULP Mercedes Ferrer Parra Departamento de Fisiología, UAM. Eugenia García Fernández Facultativo Especialista de Área en Anatomía Patológico. HULP Juan A. Gómez Rivas Facultativo Especialista de Área en Urología. HULP Estefanía Linares Espinós Facultativo Especialista de Área en Urología. HULP Pedro López Pereira Jefe de Servicio de Urología Pediátrica. HULP Nuria Malats Riera Investigador Senior. Centro Nacional de Investigaciones Oncológicas. CNIO José Antonio Moreno Valle Facultativo Especialista de Área en Urología. HULP María Justa García-Matres y Cortés Facultativo Especialista de Área en Urología. HULP

José Ramón Pérez-Carral García Facultativo Especialista de Área en Urología. HULP Francisco Real Investigador Senior. Centro Nacional de Investigaciones Oncológicas. CNIO Emilio Ríos González Médico Adjunto en Urología. Hosp. Univ. Infanta Sofía Fermín Rodríguez de Bethencourt y Codes Facultativo Especialista de Área en Urología. HULP Ángel Tabernero Gómez Facultativo Especialista de Área en Urología. HULP M. Mar Valés Gómez Investigador Senior. Centro Nacional de Biotecnología. CSIC

Strategic Objective We aim to consolidate a strong research group into: • Urologic Oncology • Reconstructive surgery • Endurologic and minimally invasive surgery • Lithiasis • Incontinence / Neuro-urology • Andrology / Reproduction Through basic and experimental research, clinical research, translational research and clinical trials. The results of this projects should be translated into doctoral theses, publications in high impact journals and visibility factor, as to finally achieve patents and trademarks.

Continue

217

3 INFORMATION GROUPS BY AREA

3.4 Large System Pathology Area

Research Lines

218

• Urological Oncology The group’s efforts will focus on the following fields of research: BLADDER CANCER - Immunological response in patients with bladder cancer treated with BCG. - Urinary markers in diagnosis and prediction of response in patients with bladder cancer. - New immunomodulatory treatments in bladder cancer. - New imaging methods for the diagnosis of bladder cancer. - Efficacy of combined chemo and immunotherapy hyperthermia in bladder cancer. PROSTATE CANCER - Castration-resistant prostate carcinoma, immune response, and evaluation of predictive markers of therapeutic response. - Medical treatment of locally advanced and metastatic prostate cancer. - Development of new surgical minimally invasive techniques for localized prostate cancer. KIDNEY CANCER - Development of new surgical minimally invasive techniques for localized kidney cancer. - Research of new therapeutic lines in hereditary renal cancer. - Medical treatment of locally advanced and metastatic renal carcinoma. • Reconstructive surgery - Development and improvement of new reconstructive surgery techniques for complex urethral strictures, genitourinary congenital malformations and genitourinary fistulas. - Development of a Regenerative Medicine Unit and Tissue Bioengineering applied to reconstructive urologic surgery. • Endurologic and minimally invasive surgery - Development of new endourological surgery techniques for minimally invasive treatment of benign prostatic hyperplasia and urinary lithiasis. - Development of a learning program in laparoscopy and other minimally invasive surgeries. • Lithiasis - Study of new inhibitors of crystallization of urine solutes as prevention of lithogenesis. - Metabolic study of renal lithiasis. • Incontinence and Neuro-urology - Study and treatment of chronic pelvic pain. - Development and improvement of new systems for the treatment of urinary incontinence. • Andrology / Reproduction - Study of new medical and surgical treatments for male infertility. - Development of new medical and surgical treatments for erectile dysfunction.

Research Activity DOCTORAL THESES Linares Espinós EE. Valor predictivo del volumen-centro de los resultados de la cirugía de cáncer renal con extensión venosa. Impacto en el modelo asistencial[dissertation]. Madrid: UAM, 2016(22/11/2016). Director: Carballido Rodríguez J

BOOKS AND BOOK CHAPTERS Cogorno L, Díez J, Sánchez J, Martínez-Piñeiro L. Urgencia miccional de novo tras cirugía de incontinencia urinaria de esfuerzo femenina. In: Archivos Clínicos de Urología. Monografía de vejiga hiperactiva. Coordinador: M. Unda. Editado por You & US, S.A., 2016, p. 37-43 Díez Rodríguez J, Sánchez Gómez J, Cogorno Wasylkowski L, Linares Quevedo A, Martínez-Piñeiro L. Tratamiento no farmacológico de las alteraciones urológicas en la enfermedad de Parkinson. Editores: Sociedad Española de Neurología y Federación Española de Parkinson, 2016. p. 30-41, 2016 Martínez-Piñeiro L, Rodríguez A, Medina R, GómezVeiga F. Manejo del paciente con recidiva bioquímica tras el tratamiento curativo. In: F. Gómez Veiga. Actualización en cáncer de próstata. Mensajes para la práctica clínica. Monografía y curso de formación médica continuada. Madrid: Ed. Mayo S.A., 2016, p. 27-34 Medina R, Martínez-Piñeiro L, Rodríguez A, GómezVeiga F. Criterios diagnósticos para la individualización en el tratamiento del cáncer de próstata. In: F. Gómez Veiga. Actualización en cáncer de próstata. Mensajes para la práctica clínica. Monografía y curso de formación médica continuada. Madrid: Ed. Mayo S.A., 2016, p. 16-26 Rodríguez A, Medina R, Martínez-Piñeiro L, Gómez-Veiga F. Biopsia, rebiopsia y evolución en el diagnóstico por imagen del cáncer de próstata. In: F. Gómez Veiga. Actualización en cáncer de próstata. Mensajes para la práctica clínica. Monografía y curso de formación médica continuada. Madrid: Ed. Mayo S.A., 2016, p. 11-15

assessed by innovative multimarker prognostic models. BMC Cancer. 2016;16:351. Article. IF: 3.288; Q2 • de Maturana EL, Pineda S, Brand A,Van Steen K, Malats N.Toward the integration of Omics data in epidemiological studies: still a “long and winding road”. Genet Epidemiol. 2016;40(7):558-69. Review. IF: 1.884; Q2 • Espinós EL, Sánchez-Salas R, Sivaraman A, Pérez-Reggeti JI, Barret E, Rozet F, Galiano M, Prapotnich D, Cathelineau X. Minimally invasive salvage prostatectomy after primary radiation or ablation treatment. Urology. 2016;94:111-6. Article. IF: 2.309; Q2 • Figueroa JD, Middlebrooks CD, Banday AR,Ye YQ, García-Closas M, Chatterjee N, Koutros S, Kiemeney LA, Rafnar T, Bishop T, Furberg H, Matullo G, Golka K, Gago-Domínguez M, Taylor JA, Fletcher T, Siddiq A, Cortessis VK, Kooperberg C, Cussenot O, Benhamou S, Prescott J, Porru S, Dinney CP, Malats N, Baris D, Purdue MP, Jacobs EJ, Albanes D, Wang ZM, Chung CC, Vermeulen SH, Aben KK, Galesloot TE, Thorleifsson G, Sulem P, Stefansson K, Kiltie AE, Harland M,Teo M, Offit K,Vijai J, Bajorin D, Kopp R, Fiorito G, Guarrera S, Sacerdote C, Selinski S, Hengstler JG, Gerullis H, Ovsiannikov D, Blaszkewicz M, Castelao JE, Calaza M, Martínez ME, Cordeiro P, Xu ZL, Panduri V, Kumar R, Gurzau E, Koppova K, Bueno-de-Mesquita HB, Ljungberg B, ClavelChapelón F, Weiderpass E, Krogh V, Dorronsoro M, Travis RC, Tjonneland A, Brennan P, Chang-Claude J, Riboli E, Conti D, Stern MC, Pike MC,Van den Berg D,Yuan JM, Hohensee C, Jeppson RP, Cancel-Tassin G, Roupret M, Comperat E, Turman C, de Vivo I, Giovannucci E, Hunter DJ, Kraft P, Lindstrom S, Carta A, Pavanello S, Arici C, Mastrangelo G, Kamat AM, Zhang LR, Gong Yl, Pu X, Hutchinson A, Burdett L, Wheeler WA, Karagas MR, Johnson A, Schned A, Hosain GMM, Schwenn M, Kogevinas M, Tardon A, Serra C, Carrato A, García-Closas R, Lloreta J, Andriole G, Grubb R, Black A, Diver WR, Gapstur SM, Weinstein S, Virtamo J, Haiman CA, Landi MT, Caporaso NE, Fraumeni JF, Vineis P, Wu XF, Chanock SJ, Silverman DT, Prokunina-Olsson L, Rothman N. Identification of a novel susceptibility locus at 13q34 and refinement of the 20p12.2 region as a multi-signal locus associated with bladder cancer risk in individuals of European ancestry. Hum Mol Genet. 2016;25(6):1203-14. Article. IF: 5.34; Q2 • Frantzi M, van Kessel KE, Zwarthoff EC, Márquez M, Rava M, Malats N, Merseburger AS, Katafigiotis I, Stravodimos K, Mullen W, Zoidakis J, Makridakis M, Pejchinovski M, Critselis E, Lichtinghagen R, Brand K, Dakna M, Roubelakis MG, Theodorescu D, Vlahou A, Mischak H, Anagnou NP. Development and validation of urine-based peptide biomarker panels for detecting bladder cancer in a multi-center study. Clin Cancer Res. 2016;22(16):4077-86. Article. IF: 9.619; D1

Rodríguez A, Medina R, Martínez-Piñeiro L, GómezVeiga F. Novedades en hormonoterapia y resistencia a castración. In: F. Gómez Veiga. Actualización en cáncer de próstata. Mensajes para la práctica clínica. Monografía y Curso de formación médica continuada. Madrid: Ed. Mayo S.A., 2016, p. 35-44

• Friesen MC, Wheeler DC, Vermeulen R, Locke SJ, Zaebst DD, Koutros S, Pronk A, Colt JS, Baris D, Karagas MR, Malats N, Schwenn M, Johnson A, Armenti KR, Rothman N, Stewart PA, Kogevinas M, Silverman DT. Combining decision rules from classification tree models and expert assessment to estimate occupational exposure to diesel exhaust for a case-control Study. Ann Occup Hyg. 2016;60(4):467-78. Article. IF: 1.71; Q3

PUBLICATIONS • Colombo JJ, Espinós EL, Tello JL, Cortés MDL, Merino JCA, Martínez-Pineiro L. Perirrenal presentation of extranodal RosaiDorfman disease. Arch Esp Urol. 2016;69(7):446-7. Editorial Material. IF: 0.323; Q4

• Gontero P, Sylvester R, Pisano F, Joniau S, Oderda M, Serretta V, Larre S, Di Stasi S, Van Rhijn B, Witjes AJ, Grotenhuis AJ, Colombo R, Briganti A, Babjuk M, Soukup V, Malmstrom PU, Irani J, Malats N, Baniel J, Mano R, Cai T, Cha EK, Ardelt P, Vakarakis J, Bartoletti R, Dalbagni G, Shariat SF, Xylinas E, Karnes RJ, Palou J. The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/Grade 3 bladder cancer treated with bacille Calmette-Guerin. BJU Int. 2016;118(1):44-52. Article. IF: 4.338; Q1

• de Maturana EL, Picornell A, Masson-Lecomte A, Kogevinas M, Márquez M, Carrato A, Tardón A, Lloreta J, García-Closas M, Silverman D, Rothman N, Chanock S, Real FX, Goddard ME, Malats N. Prediction of non-muscle invasive bladder cancer outcomes

• Hedegaard J, Lamy P, Nordentoft I, Algaba F, Hoyer S, Ulhoi BP, Vang S, Reinert T, Hermann GG, Mogensen K, Thomsen MBH, Nielsen MM, Márquez M, Segersten U, Aine M, Hoglund M, Birkenkamp-Demtroder K, Fristrup N, Borre M, Hartmann A, Stohr

• Aguilera A, Alonso-Dorrego JM, Bañuelos B, Cisneros J, González P, Díez J. Oncological results in high grade prostate cancer treated surgically. Arch Esp Urol. 2016;69(4):162-71. Article. IF: 0.323; Q4

R, Wach S, Keck B, Seitz AK, Nawroth R, Maurer T, Tulic C, Simic T, Junker K, Horstmann M, Harving N, Petersen AC, Calle ML, Steyerberg EW, Beukers W, van Kessel KEM, Jensen JB, Pedersen JS, Malmstrom PU, Malats N, Real FX, Zwarthoff EC, Orntoft TF, Dyrskjot L. Comprehensive transcriptional analysis of early-stage urothelial carcinoma. Cancer Cell. 2016;30(1):27-42. Article. IF: 27.407; D1 • Linares Espinós E, Barret E, Sivaraman A, Pérez-Reggeti J I, Sánchez-Salas R, Rozet F, Galiano M, Cathelineau X. Localized prostate cancer focal therapy: “A la carte” Model. Arch Esp Urol. 2016;69(6):345-52. Article. IF: 0.323; Q4 • Lope V, García-Esquinas E, Ruiz-Domínguez JM, LLorca J, JiménezMoleón JJ, Ruiz-Cerdá JL, Alguacil J, Tardón A, Dierssen-Sotos T, Tabernero A, Mengual L, Kogevinas M, Aragonés N, Castano-Vinyals G, Pollán M, Pérez-Gómez B. Perinatal and childhood factors and risk of prostate cancer in adulthood: MCC-Spain case-control study. Cancer Epidemiol. 2016;43:49-55. Article. IF: 2.343; Q2 • Machiela MJ, Zhou WY, Karlins E, Sampson JN, Freedman ND, Yang Q, Hicks B, Dagnall C, Hautman C, Jacobs KB, Abnet CC, Aldrich MC, Amos C, Amundadottir LT, Arslan AA, Beane-Freeman LE, Berndt SI, Black A, Blot WJ, Bock CH, Bracci PM, Brinton LA, Bueno-de-Mesquita HB, Burdett L, Buring JE, Butler MA, Canzian F, Carreon T, Chaffee KG, Chang IS, Chatterjee N, Chen C, Chen C, Chen KX, Chung CC, Cook LS, Bou MC, Cullen M, Davis FG, De Vivo I, Ding T, Doherty J, Duell EJ, Epstein CG, Fan JH, Figueroa JD, Fraumeni JF, Friedenreich CM, Fuchs CS, Gallinger S, Gao YT, Gapstur SM, García-Closas M, Gaudet MM, Gaziano JM, Giles GG, Gillanders EM, Giovannucci EL, Goldin L, Goldstein AM, Haiman CA, Hallmans G, Hankinson SE, Harris CC, Henriksson R, Holly EA, Hong YC, Hoover RN, Hsiung CA, Hu N, Hu W, Hunter DJ, Hutchinson A, Jenab M, Johansen C, Khaw KT, Kim HN, Kim YH, Kim YT, Klein AP, Klein R, Koh WP, Kolonel LN, Kooperberg C, Kraft P, Krogh V, Kurtz RC, LaCroix A, Lan Q, Landi MT, Le Marchand L, Li DH, Liang XL, Liao LM, Lin DX, Liu JJ, Lissowska J, Lu LG, Magliocco AM, Malats N, Matsuo K, McNeill LH, McWilliams RR, Melin BS, Mirabello L, Moore L, Olson SH, Orlow I, Park JY, Patino-García A, Peplonska B, Peters U, Petersen GM, Pooler L, Prescott J, Prokunina-Olsson L, Purdue MP, Qiao YL, Rajaraman P, Real FX, Riboli E, Risch HA, Rodríguez-Santiago B, Ruder AM, Savage SA, Schumacher F, Schwartz AG, Schwartz KL, Seow A, Setiawan VW, Severi G, Shen H, Sheng X, Shin MH, Shu XO, Silverman DT, Spitz MR, Stevens VL, Stolzenberg-Solomon R, Stram D, Tang ZZ, Taylor PR, Teras LR, Tobias GS,Van den Berg D, Visvanathan K, Wacholder S, Wang JC, Wang ZM, Wentzensen N, Wheeler W, White E, Wiencke JK, Wolpin BM, Wong MP, Wu C, Wu TC, Wu XF, Wu YL, Wunder JS, Xia L, Yang HP, Yang PC, Yu K, Zanetti KA, Zeleniuch-Jacquotte A, Zheng W, Zhou B, Ziegler RG, Pérez-Jurado LA, Caporaso NE, Rothman N, Tucker M, Dean MC, Yeager M, Chanock SJ. Female chromosome X mosaicism is age-related and preferentially affects the inactivated X chromosome. Nat Commun. 2016;7:118431. Article. IF: 12.124; D1 • Mager R, Daneshmand S, Evans CP, Palou J, Martínez-Salamanca JI, Máster VA, Mckiernan JM, Libertino JA, Haferkamp A, Haferkamp A, Capitanio U, Carballido JA, Chantada V, Chromecki T, Ciancio G, Daneshmand S, Evans CP, Gontero P, González J, Hohenfellner M, Huang WC, Koppie TM, Libertino JA, Espinos EL, Lorentz A, Martínez-Salamanca JI, Máster VA, Mckiernan JM, Montorsi F, Novara G, O’Malley P, Pahernik S, Palou J, Moreno JLP, Pruthi RS, Faba OR, Russo P, Scherr DS, Shariat SF, Spahn M, Terrone C, Tilki D, Vázquez-Martul D, Donoso CV, Vergho D, Wallen EM, Zigeuner R. Renal cell carcinoma with inferior vena cava involvement: prognostic effect of tumor thrombus consistency on cancer specific survival. J Surg Oncol. 2016;114(6):7648. Article. IF: 2.993; Q1 • Masson-Lecomte A, de Maturana EL, Goddard ME, Picornell A, Rava M, González-Neira A, Márquez M, Carrato A,Tardón A, Llo-

Continue

219

3.4 Large System Pathology Area

3 INFORMATION GROUPS BY AREA reta J, García-Closas M, Silverman D, Rothman N, Kogevinas M, Allory Y, Chanock SJ, Real FX, Malats N. Inflammatory-related genetic variants in non-muscle-invasive bladder cancer prognosis: A multimarker bayesian assessment. Cancer Epidem Biomar. 2016;25(7):1144-50. Article. IF: 4.142; Q1 • Middlebrooks CD, Banday AR, Matsuda K, Udquim KI, Onabajo OO, Paquin A, Figueroa JD, Zhu B, Koutros S, Kubo M, Shuin T, Freedman ND, Kogevinas M, Malats N, Chanock SJ, GarcíaClosas M, Silverman DT, Rothman N, Prokunina-Olsson L. Association of germline variants in the APOBEC3 region with cancer risk and enrichment with APOBEC-signature mutations in tumors. Nat Genet. 2016;48(11):1330-8. Article. IF: 27.959; D1 • Murcia-Pascual FJ, Gracia-Rodríguez R,Vázquez-Rueda F, Pereira PL, Esteban RMP.Testicular and paratesticular tumors in children. Arch Esp Urol. 2016;69(10):691-7. Article. IF: 0.323; Q4 • Pérez-Reggeti JI, Sánchez-Salas R, Sivaraman A, Espinós EL, de Gracia-Nieto AE, Barret E, Galiano M, Rozet F, Fregeville A, Renard-Penna R, Cathala N, Mombet A, Prapotnich D, Cathelineau X. High intensity focused ultrasound with Focal-One (R) device: Prostate-specific antigen impact and morbidity evaluation during the initial experience. Actas Urol Esp. 2016;40(10):608-14. Article. IF: 1.181; Q4 • Ríos E, Martínez-Pineiro L. Re: Primary endoscopic realignment of urethral disruption injuries-a double-edged sword? Eur Urol. 2016;69(3):536-7. Editorial Material. IF: 16.265; D1 • Rivas JG, Gregorio SAY, Álvarez-Maestro M. Prostate capsule sparing radical cystectomy - a safe procedure for few REPLY. Cent European J Urol. 2016;69(1):34. Editorial Material. Not Indexed • Rivas JG, Gregorio SAY, Gómez AT, Álvarez-Maestro M, Sebastián JD, Ledo JC. Laparoscopic radical cystectomy with prostate capsule sparing. Initial experience. Cent European J Urol. 2016;69(1):25-31. Article. Not Indexed • Rivas JG, Gregorio SAY, Ledo JC, Gómez AT, Sebastián JD, Barthel JJD. The role of perioperative blood transfusion on postoperative outcomes and overall survival in patients after laparoscopic radical cystectomy. J Cancer Res Ther. 2016;12(1):146-9. Article. IF: 0.75; Q4 • Rodríguez-Socarrás ME, Gómez-Rivas J, Álvarez-Maestro M, Tortolero L, Ribal MJ, Sanz MG, Roupret M. Spanish adaptation of the recommendations for the appropriate use of social networks in urology of the European Association of Urology. Actas Urol Esp. 2016;40(7):417-23. Review. IF: 1.181; Q4 • Sánchez-Salas R, Linares Espinos E. Monográfico terapia focal en cáncer de próstata. Arch Esp Urol. 2016;69(6):257-9. Article. IF: 0.323; Q4 • Shi JX, Park JH, Duan JB, Berndt ST, Moy W,Yu K, Song L,Wheeler W, Hua X, Silverman D, García-Closas M, Hsiung CA, Figueroa JD, Cortessis VK, Malats N, Karagas MR, Vineis P, Chang IS, Lin DX, Zhou BS, Seow A, Matsuo K, Hong YC, Caporaso NE, Wolpin B, Jacobs E, Petersen GM, Klein AP, Li DH, Risch H, Sanders AR, Hsu L, Schoen RE, Brenner H, Stolzenberg-Solomon R, Gejman P, Lan Q, Rothman N, Amundadottir LT, Landi MT, Levinson DF, Chanock SJ, Chatterjee N. Winner’s curse correction and variable thresholding improve performance of polygenic risk modeling based on genome-wide association study summarylevel data. Plos Genet. 2016;12(12):e1006493. Article. IF: 6.1; D1 • Wasylkowski LC, González ER, Lorenzo LMP. Diagnosis of urethral stenosis and follow-up after Urethroplasty. Arch Esp Urol. 2016;69(7):416-22. Article. IF: 0.323; Q4 • Witjes JA, Dalbagni G, Karnes RJ, Shariat S, Joniau S, Palou J, Serretta V, Larre S, di Stasi S, Colombo R, Babjuk M, Malmstrom PU, Malats N, Irani J, Baniel J, Cai T, Cha EGN, Ardelt P,Varkarakis J, Bartoletti R, Spahn M, Pisano F, Gontero P, Sylvester R. The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099

220

patients with T1G3 non muscle-invasive bladder cancer. Urol Oncol-Semin Ori. 2016;34(11):484.e19-e25. Article. IF: 3.767; Q1 • Zhang MF,Wang ZM, Obazee O, Jia JP, Childs EJ, Hoskins J, Figlioli G, Mocci E, Collins I, Chung CC, Hautman C, Arslan AA, BeaneFreeman L, Bracci PM, Buring J, Duell EJ, Gallinger S, Giles GG, Goodman GE, Goodman PJ, Kamineni A, Kolonel LN, Kulke MH, Malats N, Olson SH, Sesso HD,Visvanathan K,White E, Zheng W, Abnet CC, Albanes D, Andreotti G, Brais L, Bueno-de-Mesquita HB, Basso D, Berndt SI, Boutron-Ruault MC, Bijlsma MF, Brenner H, Burdette L, Campa D, Caporaso NE, Capurso G, Cavestro GM, Cotterchio M, Costello E, Elena J, Boggi U, Gaziano JM, Gazouli M, Giovannucci EL, Goggins M, Gross M, Haiman CA, Hassan M, Helzlsouer KJ, Hu N, Hunter DJ, Iskierka-Jazdzewska E, Jenab M, Kaaks R, Key TJ, Khaw KT, Klein EA, Kogevinas M, Krogh V, Kupcinskas J, Kurtz RC, Landi MT, Landi S, Le Marchand L, Mambrini A, Mannisto S, Milne RL, Neale RE, Oberg AL, Panico S, Patel AV, Peeters PHM, Peters U, Pezzilli R, Porta M, Purdue M, Quiros JR, Riboli E, Rothman N, Scarpa A, Scelo G, Shu XO, Silverman DT, Soucek P, Strobel O, Sund M, Malecka-Panas E, Taylor PR, Tavano F, Travis RC, Thornquist M, Tjonneland A, Tobias GS, Trichopoulos D,Vashist Y,Vodicka P, Wactawski-Wende J, Wentzensen N, Yu H, Yu K, Zeleniuch-Jacquotte A, Kooperberg C, Risch HA, Jacobs EJ, Li DH, Fuchs C, Hoover R, Hartge P, Chanock SJ, Petersen GM, Stolzenberg-Solomon RS, Wolpin BM, Kraft P, Klein AP, Canzian F, Amundadottir LT. Three new pancreatic cancer susceptibility signals identified on chromosomes 1q32.1, 5p15.33 and 8q24.21. Oncotarget. 2016;7(41):66328-43. Article. IF: 5.168; Q1 • Zhou WY, Machiela MJ, Freedman ND, Rothman N, Malats N, Dagnall C, Caporaso N, Teras LT, Gaudet MM, Gapstur SM, Stevens VL, Jacobs KB, Sampson J, Albanes D, Weinstein S, Virtamo J, Berndt S, Hoover RN, Black A, Silverman D, Figueroa J, GarcíaClosas M, Real FX, Earl J, Marenne G, Rodríguez-Santiago B, Karagas M, Johnson A, Schwenn M, Wu XF, Gu J, Ye YQ, Hutchinson A, Tucker M, Pérez-Jurado LA, Dean M,Yeager M, Chanock SJ. Mosaic loss of chromosome Y is associated with common variation near TCL1A. Nat Genet. 2016;48(5):563. Article. IF: 27.959; D1

PUBLIC PROJECTS García Fernández ME. Red de Biobancos (PT13/0010/0003). ISCIII-MICINN. 2014-2017. Management centre: FIBHULP

PRIVATE PROJECTS García Fernández ME. Facturación de Biobanco. CAM. 2014-2018. Management centre: FIBHULP López Pereira P. Curso CRM (Crisis Resource Management) en urología pediátrica.Varios Financiadores. 2016-2017. Management centre: FIBHULP López Pereira P. Utilización de constructos de mucosa urotelial autóloga obtenidos mediante ingeniería tisular para la realización uretroplastias reconstructivas en un modelo experimental de hipospadias proximal en conejos. Fundación para la Investigación en Urología. 2016-2018. Management centre: FIBHULP Martínez-Piñeiro Lorenzo L. Convenio de colaboración para el fomento de la formación. Covidien Spain S.L. (Tyco Healthcare Spain S.L). 2006-Ongoing. Management centre: FIBHULP

Return to LARGE SYSTEM PATHOLOGIES AREA INDEX

HEALTH CARE NURSES RESEARCH GROUP

3 5.784 1

Jesús Castro Toro Supervisor de Área Funcional. HULP Laura Alonso Recio Profesora Contratada. UNED Verónica Álvarez Gonzalo Fisioterapeuta. HULP Elena Calderari Fernández Enfermera en Centro de Especialidades José Marvá Alicia Cerón Serrano Enfermera asistencial. HULP María Nélida Conejo Pérez Enfermera en Servicio de Cuidados Intensivos Pediátricos. HULP Víctor Manuel Cornejo del Río Supervisor de Unidad Quirúrgica. Hospital Carlos III- HULP María Ricardina Delgado Sandoval Enfermera en Servicio de Consultas Externas. HULP María Luisa Díaz Martínez Profesora Contratada. UAM María Durán Agüí Enfermera en Servicio de Medicina Interna. HULP Matilde Fernández y Fernández-Arroyo Profesora en la Unidad Docente de Matronas. HULP Salomé Herrero Cereceda Enfermera Unidad Quirúrgica, Hospital Cantoblanco-HULP Patricia Luna Castaño Enfermera en Servicio de Cuidados Intensivos Pediátricos. HULP Jesús Morente López Enfermero en Unidad de Cuidados Críticos. HULP Profesor colaborador. Universidad Pontificia de Comillas Pedro Piqueras Rodríguez Supervisor de Enfermería en Unidad de Cuidados Intensivos Pediátricos. HULP

María del Carmen Sellán Soto Profesora Contratada.UAM Gema Tapia Serrano Enfermera de Cuidados Intensivos Pediátricos. HULP Adrián Torres Hidalgo Enfermero. Técnico de Salud en la Gerencia de Atención Especializada de la Comunidad de Madrid.

Strategic Objective Care is an indispensable activity for survival, since humanity exists. Care has been relevant as a primary function to promote and develop all those activities that make people live. This research group aims to collaborate on growing clinical evidence on health care. The real gap between what generates scientific knowledge and the decisions that are made in the day to day is ethically unacceptable. Between 30 and 40% of patients do not receive care consistent with the results of the research and around 20-25% of care may be unnecessary or potentially harmful. Evidence-Based Practice (PBE) or Evidence is based on the fact that greater knowledge and use of research results in clinical practice will contribute to improving the health of the population.Today, it is well known that the implementation of the best scientific evidence available in the clinical practice improves quality of care and clinical outcomes. In addition, decision-makers based on available evidence tend to be more satisfied with their role and focus on improving the quality of care given to patients. Finally, it should be noted that using evidence in daily

Continue

221

3.4 Large System Pathology Area

3 INFORMATION GROUPS BY AREA practice can achieve health goals at a minimum cost. Cost-effectiveness studies have been conducted in which evidence-based care is linked to a reduction in health costs compared to traditional care. At the same time, society is facing new economic, political, demographic, social and cultural challenges that require health services capable of meeting the growing health needs of the population. It is necessary to investigate in clinical practice the most advanced care in order to achieve the full development of care and ensure the achievement of the best results in terms of overall health and quality of life of patients, Effectiveness of interventions, greater cohesion of health care teams, and of course, all contribute to the sustainability of the health system and user satisfaction.

Research Lines • Vital Processes and complex care. • Technological innovation and its application in health care. • Management of care and results of professional practice.

Pedraza Anguera AM, Fernández y Fernández-Arroyo M, Gómez del Pulgar M, Reguera Carricondo A, de Castro Pedraza C, Adell Aguiló N, Tudela Valls C, de la Torre Luceño S. Valoración de la Autoestima en el programa de Salut i Escola. In: XX Encuentro Internacional de Investigación en Cuidados. Madrid: ISCIII, 2016. p.461-462 Piqueras-Rodríguez P, Arribas Estrada M, Carrión Navarro ME, Muños Pintor J. Seguridad del paciente como objetivo de la unidad. Implementación y valoración. In: 27 Jornadas Nacionales de Enfermeras Gestoras. Burgos: ANDE, 2016 Sellán MC, Díaz ML. Principios fundamentales de la bioética: dilemas éticos. In: Chillón Martínez R. Conceptos fundamentales para la práctica fisioterápica en atención primaria y atención especializada. Madrid: FUDEN, 2016 Tapia-Serrano G, Blázquez-García B, López-Sastre E, Piqueras-Rodríguez P. Cuestionario de satisfacción de padres de neonatos hospitalizados. In: XX Encuentro Internacional de Investigación en Cuidados. Madrid: ISCIII, 2016. p.149-152

PUBLICATIONS • Anguita-Palacios MC,Talayero-San-Miguel M, Herrero-Cereceda S, Martín-Cadenas M, Pardo-Cuevas P, Gil-Martínez A. Fear and preoperative anxiety behaviour and pain intensity perceived after knee arthroscopy. Enferm Clin. 2016;26(4):227-33. Article. Not Indexed

Research Activity BOOKS AND BOOK CHAPTERS Canencia Cid MP, Elola Vicente P, Najera Santos MC, Abad Martín D, Rebollo Deliz MJ, Gil Martínez A, Fernández Acevedo MR, Castro Toro J. Implementación de la estrategia para la higiene de manos en la unidad de extracciones de un hospital de tercer nivel. Hospital Universitario La Paz. In: 27 Jornadas Nacionales de Enfermeras Gestoras. Burgos: ANDE, 2016. Cornejo del Río V, Fernández y Fernández-Arroyo M, Gil Martínez A, Delgado Sandoval M, Calderari Fernández E, Cerón Serrano GA. Disfunción eréctil en pacientes diabéticos y prevención del Síndrome Cardiovascular. In: XX Encuentro Internacional de Investigación en Cuidados. Madrid: ISCIII, 2016. p.210-211 Fernández M. Actualización de conocimientos sobre Sexualidad Obstétrica/Ginecológica. In: León S. Actualización de conocimientos sobre sexualidad obstétrica/ginecológica. Una mirada especializada sobre el tema. Madrid: FUDEN, 2016. p.5-7 Fernández M. Una mirada especializada sobre el tema. In: Casado D, Sanz MJ . Embarazo y parto saludables. Conocimiento y recursos disponibles, y propuestas de mejora. Madrid: Polibea, 2016. p.1-40

MATERNAL AND FETAL MEDICINE GROUP*

• Lahoz C, Mostaza JM, Salinero-Fort MA, García-Iglesias F, González-Alegre T, Estirado E, Laguna F, de Burgos-Lunar C, Sánchez-Arroyo V, Sabín C, López S, Cornejo-del-Río V, Patrón P, Fernández-García P, Fernández-Puntero B,Vicent D, MontesanoSánchez L. Peripheral atherosclerosis in patients eith erectile dysfunction: A population-based study. J Sex Med. 2016;13(1):639. Article. IF: 2.978; Q2 • Salinero-Fort MA, Burgos-Lunar C, Lahoz C, Mostaza JM, Abanades-Herranz JC, Laguna-Cuesta F, Estirado-de Cabo E, García-Iglesias F, González-Alegre T, Fernández-Puntero B, Montesano-Sánchez L, Vicent-López D, Cornejo-del Río V, Fernández-García PJ, Sánchez-Arroyo V, Sabín-Rodríguez C, LópezLópez S, Patrón-Barandio P, Gómez-Campelo P. Performance of the finnish diabetes risk score and a simplified finnish diabetes risk score in a community-based, cross-sectional programme for screening of undiagnosed type 2 diabetes mellitus and dysglycaemia in Madrid, Spain: The SPREDIA-2 Study. Plos One. 2016;11(7):e0158489. Article. IF: 2.806; Q1

PRIVATE PROJECTS Castro Toro J. App para mejorara la adherencia al tratamiento en pacientes EPOC. Vivir con Epoc. Vodafone. 2016-Ongoing. Management centre: Reto Salud Andalucía

José Luis Bartha Rasero Jefe de Servicio de Obstetricia y Ginecología. HULP Catedrático de Obstetricia y Ginecología. UAM Eugenia Antolín Alvarado Jefe de Sección de Obstetricia y Ginecología. HULP Profesor asociado. UAM Marta Cortés León Médico Especialista en Ginecología y Obstetricia. HULP María Amparo Gimeno Sanmartín Médico Especialista en Ginecología y Obstetricia. HULP María del Mar González Arlazón Facultativo Especialista de Área en Ginecología y Obstetricia. HULP María de la Cruz González Álvarez Facultativo Especialista de Área en Ginecología y Obstetricia. HULP Beatriz Herrero Ruiz Médico Adjunto de la Sección de Ecografía y Medicina Fetal. HULP Sara López Magallón Facultativo Especialista de Área en Ginecología y Obstetricia. HULP Francisco López Sánchez Facultativo Especialista de Área en Ginecología y Obstetricia. HULP Fernando Magdaleno Dans Jefe de Sección de Obstetricia y Ginecología Profesor asociado. UAM María Elena Martín Boado Facultativo Especialista de Área en Ginecología y Obstetricia. HULP Nuría Martínez Sánchez Facultativo Especialista de Área en Ginecología y Obstetricia. HULP Inmaculada Orensanz Fernández Facultativo Especialista de Área en Ginecología y Obstetricia. HULP Roberto Rodríguez González Facultativo Especialista de Área en Ginecología y Obstetricia. HULP

Laura  Sotillo Mallo Facultativo Especialista de Área en Ginecología y Obstetricia. HULP Inmaculada Duyos Mateo Facultativo Especialista de Área en Ginecología y Obstetricia. HULP

Strategic Objective • To evaluate the involvement of placental energy metabolism in obstetric disorders • To find new biomarkers in gestational diabetes mellitus and macrosomia • To find new biomarkers of fetal and perinatal neurological damage establishing new prevention strategies • To improve our understanding of the pathophysiology fetal heart damage in Anti-Ro positivewomen and to find new lines of treatment in these cases

Research Lines • Diabetes mellitus, obesity and metabolic syndrome during pregnancy • Energy metabolism during pregnancy • Fetal neurodevelopment • Inflammation, autoimmunity and pregnancy

* Group recently created: february 2017

222

Return to LARGE SYSTEM PATHOLOGIES AREA INDEX

Return to LARGE SYSTEM PATHOLOGIES AREA INDEX

223

3.4 Large System Pathology Area

3 INFORMATION GROUPS BY AREA

EMERGENCY AND CRITICAL PATHOLOGY GROUP*

César Carballo Cardona Facultativo Especialista de Área en Urgencias. HULP Coordinador de Urgencias. HULP María Teresa Ayuso Aragoneses Médico Adjunto en Urgencias. HULP Gillermina Bejarano Redondo Médico Adjunto en Urgencias. HULP Labna Dani Ben Abdel Iah Facultativo Especialista de Área en Urgencias. HULP Guadalupe Buitrago Weiland Facultativo Especialista de Área en Urgencias. HULP María Elena Calvín García Facultativo Especialista de Área en Urgencias. HULP Julio Cobo Mora Jefe de la Unidad de Urgencias. HULP Isabel Gallego Mínguez Facultativo Especialista de Área en Urgencias. HULP María de los Ángeles García Martín Facultativo Especialista de Área especialista en Farmacia Hospitalaria. HULP Olga González Peña Facultativo Especialista de Área en Urgencias. HULP Manuel Jesús González Viñolis Facultativo Especialista de Área en Urgencias. HULP María Milagros Jaén Cañadas Facultativo Especialista de Área en Urgencias. HULP Macarena Lerín Baratas Facultativo Especialista de Área en Urgencias. HULP Crsitina López Paredes Facultativo Especialista de Área en Urgencias. HULP María Lorena López Corcuera Facultativo Especialista de Área en Medicina Interna. HULP

Alejandro Martín Quirós Unidad de Aislamiento de Alto Nivel. HULP Carlos Martínez Caballero Facultativo Especialista de Área en Urgencias. HULP Rosa Mayayo Alvira Médico Facultativo Especialista en Medicina Interna. HULP Mikel Rico Briñas Facultativo Especialista de Área en Urgencias. HULP Paloma Isabel Romero Gallego-Acho Facultativo Especialista de Área en Medicina Interna. HULP María José Simón Merlo Facultativo Especialista de Área en Radiología. HULP Yaletung Chen Facultativo Especialista de Área en Urgencias. HULP José Manuel Valero Recio Facultativo Especialista de Área en Urgencias. HULP

Strategic Objective Our group will investigate new strategies to address very different pathologies that are presented in our emergency department, national referent in different fields of diagnosis and treatment. This heterogeneous group of specialists, will approach 6 main lines of research, which aim to contribute to the better definition of clinical, diagnostic and treatment strategies. We collaborate with other research groups, to study clinical and prognostic usefulness tests in cardiology, to develop new strategies for the treatment and diagnosis of infectious diseases, and to investigate new antibiotics with the pneumology group.

We develop a new and pioneering line of imagingdiagnostic, with the line of emergency ultrasound, being national referents in research in this field, in which we have the active support of private enterprise. We will investigate the possibility of supporting us in new technologies that help the clinician in the decision making in the field of the treatment of the diabetes, impelling global initiatives both at the hospital and the population level. Finally, we will develop a line of toxicological research, focusing both on the early recognition of the intoxicated patient, as well as their adequate treatment, in collaboration with the clinical toxicology unit (CTU), with the aim of becoming a national reference center in the Management of the intoxicated patient, as well as in the development of protocols of attention to multiple victims of biological attack.

Research Lines • Integral management of the treatment and followup of the diabetic patient. • Emergency ultrasound. • Care of infectious diseases in the emergency room  • Optimization of the management of the acute intoxicated patient and use of chemical substances for terrorist purposes. • Attention to cardiovascular pathology of emergencies. • Attention to respiratory pathology.

* Group recently created: february 2017

224

Return to LARGE SYSTEM PATHOLOGIES AREA INDEX

225

3 INFORMATION GROUPS BY AREA

INGEMM- INSTITUTE OF MEDICAL AND MOLECULAR GENETICS GROUP

3.5

Cancer and Human Molecular Genetics Area Amparo Cano García

120 102 20

581.068 522.905 58

INGEMM- Institute of Medical and Molecular Genetics Group Translational Oncology Group Experimental Therapies and Biomarkers in Cancer Group Oto-Neurosurgery Research Group Cancer Molecular Pathology and Therapeutic Targets Group Mechanisms of Tumour Progression Group Animal and Cell Models for Detection and Characterization of Leukemic Stem Cells Group Research and Diagnosis of Inherited Metabolic Diseases Group Regulation of Ciliary Structure and Function by Phosphoinositides Group 226

Return to INFORMATION GROUPS BY AREA INDEX

23 67.289 7 Pablo Daniel Lapunzina Badía Coordinador INGEMM. HULP Cinthia Amiñoso Carbonero Técnico de Laboratorio. HULP Pedro Arias Lajara Técnico de Laboratorio. HULP Verónica Barca Tierno Investigadora Predoctoral. HULP Eva Barroso Ramos Investigadora Postdoctoral. HULP Alberta Belinchón Martínez Investigadora Postdoctoral. HULP Sara Benito Sanz Investigadora Postdoctoral. HULP Ángel Campos Barros Investigador Senior (Contrato Miguel Servet- I2). Jefe de Laboratorio. HULP Felipe de Frutos Pérez María Técnico de Laboratorio. HULP Ángela del Pozo Mate Técnico Informático. HULP Alicia Delicado Navarro Genetista. HULP María Ángeles Domínguez Díaz Técnico de Laboratorio. HULP Adela Escudero López Investigadora Predoctoral. HULP Begoña Ezquieta Zubicaray Bioquímico Adjunto. HULP Luis Fernández García-Moya Biólogo. HULP Blanca Nieves Fernández Martínez Técnico de Laboratorio. HULP

María Victoria Fernández Montaña Técnico de Laboratorio. HULP Amparo García Cardenal Técnico de Laboratorio. HULP Fe Amalia García Santiago Bióloga. HULP Sixto García-Miñaur Rica Genetista. HULP Isabel Gómez Nieto Técnico de Laboratorio. HULP Héctor González-Pecellín Técnico de Laboratorio. HULP Karen Elise Heath Investigadora Senior (Contrato Ramón y Cajal- I3). Jefe de Laboratorio. HULP Teresa López Jiménez Técnico de Laboratorio. HULP Alicia Llorente Alonso Técnico de Laboratorio. HULP María Elena Mansilla Aparicio Genetista. HULP María Soledad Martín Rodríguez Técnico de Laboratorio. HULP Pilar Martínez González Bióloga. HULP Víctor Manuel Martínez González Investigador Postdoctoral. HULP Isabel Martínez María Enfermera. HULP María Cruz Martínez Martínez Técnico de Laboratorio. HULP Paloma Martínez Montero Facultativo Especialista de Área en Análisis Bioquímicos. HULP

Continue

227

3.5 Cancer and Human Molecular Genetics Area

3 INFORMATION GROUPS BY AREA Jesús Molano Mateos Jefe de Sección. HULP María Ángeles Mori Álvarez Bioquímico Adjunto. HULP Julián Nevado Blanco Biólogo. HULP María Palomares Bralo Bióloga. HULP María Sol Pérez Coto Técnico de Laboratorio. HULP Teresa Ramos Álvarez Enfermera. HULP Sonia María Rodríguez Novoa Facultativo Especialista de Área. Responsable del Laboratorio de Genética de las Enfermedades Metabólicas. HULP Víctor Luis Ruiz Pérez Investigador Postdoctoral. IIB “Alberto Sols” Carmen Sánchez Gómez Técnico de Laboratorio. HULP Fernando Santos Simarro Médico Adjunto de Pediatría. HULP Juan Carlos Silla Castro Bioinformático de Sistemas. HULP Jesús Solera García Facultativo Especialista de Área en Análisis Bioquímicos. HULP Constanza Solís Villa Farmacéutica Adjunta. HULP María Luisa de Torres Perezhidalgo Bióloga Adjunto. HULP

Strategic Objective This is a clinical and basic research team that conducts several lines of research into early diagnosis, disease mechanisms and new therapeutic strategies for genetic diseases, developmental disorders and congenital defects. It is a heterogeneous group consisting of physicians, pharmacists, molecular biologists, bioinformaticians, technicians and administrative officers.

Research Lines • Subtelomeric rearrangements in patients with idiopathic mental retardation. • Genetic and functional analysis of the SHOX and SHOX2 genes in human growth. • Overgrowth syndrom. Clinical and molecular analysis. • Genetic aspects of harmonic short stature. • Genetic aspects of monogenic diabetes mellitus. • Genetics of the GHrelin axis in infantil onset obesity. • SNPs arrays in pharmacogenetics of HIV patients. • CGHarrays and genomic rearrangements in patients with congenital malformations, intelectual disability and tumours. • Molecular genetics of hypertrophic myocardiopathy. • Functional analysis of CLCN1 mutations in congenital myotonia. 228

• Molecular study of endothelial dysfunction in diabetes and ageing. • Molecular characterization of the 22q11.2 región by MLPA, microsatélites and FISH • Pharmacogenetics and pharcogenomics. • Autosomal recessive osteogénesis imperfect. • Genomic tools for diagnosis: BAC, oligos and SNP arrays. • Macrocephaly-capillary malformations and syndromes with macrocephaly. • Next generation sequencing as a new tool in the diagnosis of genetic diseases. • Dravet syndrome.

Research Activity PUBLICATIONS • Barraza-García J, Rivera-Pedroza CI, Belinchón A, FernándezCamblor C,Valenciano-Fuente B, Lapunzina P, Heath KE. A novel SMARCAL1 missense mutation that affects splicing in a severely affected Schimke immunoosseous dysplasia patient. Eur J Med Genet. 2016;59(8):363-6. Article. IF: 2.137; Q3 • Barraza-García J, Rivera-Pedroza CI, Salamanca L, Belinchón A, López-González V, Sentchordi-Montane L, del Pozo A, SantosSimarro F, Campos-Barros A, Lapunzina P, Guillén-Navarro E, González-Casado I, García-Miñaur S, Heath KE. Two Novel POC1A Mutations in the primordial Dwarfism, SOFT syndrome: clinical homogeneity but also unreported malformations. Am J Med Genet A. 2016;170(1):210-6. Article. IF: 2.259; Q3 • Eggermann K, Bliek J, Brioude F,Algar E, Buiting K, Russo S,Tumer Z, Monk D, Moore G, Antoniadi T, Macdonald F, Netchine I, Lombardi P, Soellner L, Begemann M, Prawitt D, Maher ER, Mannens M, Riccio A, Weksberg R, Lapunzina P, Gronskov K, Mackay DJG, Eggermann T. EMQN best practice guidelines for the molecular genetic testing and reporting of chromosome 11p15 imprinting disorders: Silver-Russell and Beckwith-Wiedemann syndrome. Eur J Hum Genet. 2016;24(10):1377-87. Article. IF: 4.287; Q1 • Eggermann T, Brioude F, Russo S, Lombardi MP, Bliek J, Maher ER, Larizza L, Prawitt D, Netchine I, Gonzales M, Gronskov K, Tumer Z, Monk D, Mannens M, Chrzanowska K, Walasek MK, Begemann M, Soellner L, Eggermann K,Tenorio J, Nevado J, Moore GE, Mackay DJG, Temple K, Gillessen-Kaesbach G, Ogata T, Weksberg R, Algar E, Lapunzina P. Prenatal molecular testing for Beckwith-Wiedemann and Silver-Russell syndromes: a challenge for molecular analysis and genetic counseling. Eur J Hum Genet. 2016;24(6):784-93. Review. IF: 4.287; Q1 • Fergelot P, Van Belzen M, Van Gils J, Afenjar A, Armour CM, Arveiler B, Beets L, Burglen L, Busa T, Collet M, Deforges J, de Vries BBA, Garrido ED, Dorison N, Dupont J, Francannet C, GarcíaMiñaur S, Vila EG, Gebre-Medhin S, Querol BG, Genevieve D, Gerard M, Gervasini CG, Goldenberg A, Josifova D, Lachlan K, Maas S, Maranda B, Moilanen JS, Nordgren A, Parent P, Rankin J, Reardon W, Rio M, Roume J, Shaw A, Smigiel R, Sojo A, Solomon B, Stembalska A, Stumpel C, Suarez F, Terhal P, Thomas S, Touraine R, Verloes A, Vincent-Delorme C, Wincent J, Peters DJM, Bartsch O, Larizza L, Lacombe D, Hennekam RC. Phenotype and genotype in 52 patients with rubinstein-taybi syndrome caused by EP300 mutations. Am J Med Genet A. 2016;170(12):3069-82. Article. IF: 2.259; Q3 • Grinspon RP, Nevado J, Álvarez MDM, del Rey G, Castera R, Venara M, Chiesa A, Podesta M, Lapunzina P, Rey RA. 46,XX ovo-

testicular DSD associated with a SOX3 gene duplication in a SRY-negative boy. Clin Endocrinol. 2016;85(4):673-5. Letter. IF: 3.327; Q2 • Haghighi A, Kavehmanesh Z, Haghighi A, Salehzadeh F, SantosSimarro F, Van Maldergem L, Cimbalistiene L, Collins F, Chopra M, Al-Sinani S, Dastmalchian S, de Silva DC, Bakhti H, Garg A, Hilbert P. Congenital generalized lipodystrophy: identification of novel variants and expansion of clinical spectrum. Clin Genet. 2016;89(4):434-41. Article. IF: 3.326; Q2 • Macatangga M, de la Calle M, Torres ML, Bartha JL. Monozygotic monochorionic twins discordant for trisomy 21: A reason to evaluate both fetuses a case report. J Reprod Med. 2016;61(42828):167-70. Article. IF: 0.848; Q4 • Martínez-Payo C, García M, Mansilla E, de Azua Ballesteros M Ruiz, Lapunzina P, Pérez Medina T. EP09.08: Sonographic findings in fetuses affected by microdeletion 17q21.31. Ultrasound Obstet Gynecol. 2016;48 Suppl 1:300. Article. IF: 4.71; D1 • Montane LS, Marín OR, Rivera-Pedroza CI, Vallespín E, del Pozo A, Heath KE. Early severe scoliosis in a patient with atypical progressive pseudorheumatoid dysplasia (PPD): identification of two WISP3 mutations, one previously unreported. Am J Med Genet A. 2016;170(6):1595-9. Article. IF: 2.259; Q3 • Navas P, Tenorio J, Quezada CA, Barrios E, Gordo G, Arias P, Meseguer ML, Santos-Lozano A, Doza JP, Lapunzina P, Subias PE. Molecular analysis of BMPR2, TBX4, and KCNK3 and genotypephenotype correlations in Spanish patients and families with idiopathic and hereditary pulmonary arterial hypertension. Rev Esp Cardiol. 2016;69(11):1011-9. Article. IF: 4.485; Q2 • Noguera-Morel L, Feito-Rodríguez M, Maldonado-Cid P, GarcíaMiñaur S, Kamsteeg EJ, González-Sarmiento R, de Lucas-Laguna R, Hernández-Martín A, Torrelo A. Two cases of autosomal recessive congenital ichthyosis due to CYP4F22 mutations: expanding the genotype of self-healing collodion baby. Pediatr Dermatol. 2016;33(2):E48-51. Article. IF: 0.99; Q4 • Pampols T, Ramos FJ, Lapunzina P, Gozalo-Salellas I, Pérez-Jurado LA, Pujol A. A view on clinical genetics and genomics in Spain: of challenges and opportunities. Mol Genet Genomic Med. 2016;4(4):376-91. Article. Not Indexed • Riancho-Zarrabeitia L, García-Unzueta M, Tenorio JA, GómezGerique JA, Pérez VLR, Heath KE, Lapunzina P, Riancho JA. Clinical, biochemical and genetic spectrum of low alkaline phosphatase levels in adults. Eur J Intern Med. 2016;29:40-5. Article. IF: 2.96; Q1 • Salas PC, Fernández L, Vela M, Bueno D, González B, Valentín J, Lapunzina P, Pérez-Martínez A. The role of CDKN2A/B deletions in pediatric acute lymphoblastic leukemia. Pediatr Hemat Oncol. 2016;33(42954):415-22. Article. IF: 1.12; Q3 • Sánchez-Delgado M, Riccio A, Eggermann T, Maher ER, Lapunzina P, MacKay D, Monk D. Causes and consequences of multi-locus imprinting disturbances in humans. Trends Genet. 2016;32(7):444-55. Review. IF: 10.844; D1 • Sánchez-Soler MJ, Tenorio J, García-Miñaur S, Santos-Simarro F, Lapunzina P. Overgrowth syndromes and development of embryonic tumours: A review of cases in the last 5 years. An Pediatr. 2016;85(2):104-5. Letter. IF: 1.14; Q3 • Scheps KG, Francipane L, Nevado J, Basack N, Attie M, Bergonzi MF, Cerrone GE, Lapunzina P, Varela V. Cover Image, Volume 170A, Number 4, April 2016. Am J Med Genet A. 2016;170(4):i. Article. IF: 2.259; Q3 • Scheps KG, Francipane L, Nevado J, Basack N, Attie M, Bergonzi MF, Cerrone GE, Lapunzina P, Varela V. Multiple copy number variants in a pediatric patient with Hb H disease and intellectual disability. Am J Med Genet A. 2016;170(4):986-91. Article. IF: 2.259; Q3

• Suter AA, Itin P, Heinimann K, Ahmed M, Ashraf T, Fryssira H, Kini U, Lapunzina P, Miny P, Sommerlund M, Suri M,Vaeth S,Vasudevan P, Gallati S. Rothmund-Thomson syndrome: novel pathogenic mutations and frequencies of variants in the RECQL4 and USB1 (C16orf57) gene. Mol Genet Genomic Med. 2016;4(3):359-66. Article. Not Indexed • Szafranski P, Gambin T, Dharmadhikari AV, Akdemir KC, Jhangiani SN, Schuette J, Godiwala N, Yatsenko SA, Sebastian J, Madan-Khetarpal S, Surti U, Abellar RG, Bateman DA, Wilson AL, Markham MH, Slamon J, Santos-Simarro F, Palomares M, Nevado J, Lapunzina P, Chung BHY, Wong WL, Chu YWY, Mok GTK, Kerem E, Reiter J, Ambalavanan N, Anderson SA, Kelly DR, Shieh J, Rosenthal TC, Scheible K, Steiner L, Iqbal MA, McKinnon ML, Hamilton SJ, Schlade-Bartusiak K, English D, Hendson G, Roeder ER, DeNapoli TS, Littlejohn RO, Wolff DJ, Wagner CL, Yeung A, Francis D, Fiorino EK, Edelman M, Fox J, Hayes DA, Janssens S, De Baere E, Menten B, Loccufier A,Vanwalleghem L, Moerman P, Sznajer Y, Lay AS, Kussmann JL, Chawla J, Payton DJ, Phillips GE, Brosens E, Tibboel D, de Klein A, Maystadt I, Fisher R, Sebire N, Male A, Chopra M, Pinner J, Malcolm G, Peters G, Arbuckle S, Lees M, Mead Z, Quarrell O, Sayers R, Owens M, Shaw-Smith C, Lioy J, Mckay E, de Leeuw N, Feenstra I, Spruijt L, Elmslie F, Thiruchelvam T, Bacino CA, Langston C, Lupski JR, Sen P, Popek E, Stankiewicz P. Pathogenetics of alveolar capillary dysplasia with misalignment of pulmonary veins. Hum Genet. 2016;135(5):56986. Article. IF: 4.637; Q1 • Tenorio J, Romanelli V, Martín-Trujillo A, Fernández GM, Segovia M, Perandones C, Jurado LAP, Esteller M, Fraga M, Arias P, Gordo G, Dapia I, Mena R, Palomares M, de Nanclares GP, Nevado J, García-Minaur S, Santos-Simarro F, Martínez-Glez V, Vallespín E, Monk D, Lapunzina P. Clinical and molecular analyses of Beckwith-Wiedemann syndrome: Comparison between spontaneous conception and assisted reproduction techniques. Am J Med Genet A. 2016;170(10):2740-9. Article. IF: 2.259; Q3 • Yaoita M, Niihori T, Mizuno S, Okamoto N, Hayashi S, Watanabe A, Yokozawa M, Suzumura H, Nakahara A, Nakano Y, Hokosaki T, Ohmori A, Sawada H, Migita O, Mima A, Lapunzina P, SantosSimarro F, García-Miñaur S, Ogata T, Kawame H, Kurosawa K, Ohashi H, Inoue SI, Matsubara Y, Kure S, Aoki Y. Spectrum of mutations and genotype-phenotype analysis in Noonan syndrome patients with RIT1 mutations. Hum Genet. 2016;135(2):209-22. Article. IF: 4.637; Q1

PUBLIC PROJECTS Barroso Ramos E. Identificación de nuevos genes responsables del Síndrome de Dravet y de espectros asociados de encefalopatías epilépticas febriles (PI14/01753). ISCIII. 2015-2017. Management centre: FIBHULP Campos Barros A. Aplicación de nuevas estrategias de análisis genómico a la identificacion de los determinantes genéticos de la deficiencia idiopática de GH y deficiencia primaria de IGF-I en hipocrecimiento (PI12/00649). ISCIII. 2013-2016. Management centre: FIBHULP Campos Barros A. Miguel Servet stabilisation contracts (I2). ISCIII/CAM. 2008-Ongoing. Management centre: FIBHULP Dapia García I. Contrato de garantía juvenil (PEJ15/BIO/ AI-0222). CAM. 2016-2018. Management centre: FIBHULP

Continue

229

3.5 Cancer and Human Molecular Genetics Area

3 INFORMATION GROUPS BY AREA Fernández Elvira M. Contrato de garantía juvenil (PEJ15/ BIO/TL-0158). CAM. 2016-2018. Management centre: FIBHULP García Santiago FA. Desarrollo de la detección de aneuploidias fetales en sangre materna mediante secuenciación masiva (PI13/01964). ISCIII. 2014-2017. Management centre: FIBHULP Heath KE. Ramón y Cajal stabilisation contracts (I3). CAM. 2009-Ongoing. Management centre: FIBHULP Heath KE. Identificación y caracterización funcional de nuevos genes y loci genómicos implicados en displasias esquelética (SAF2015-66831-R). MINECO. 2016-2017. Management centre: FIBHULP Lapunzina Badía PD. Búsqueda de nuevos genes y nuevas patologías mediante la aplicación de secuenciación masiva en una cohorte de pacientes con síndromes de sobrecrecimiento bien caracterizados clinicamente (PI15/01481). ISCIII. 2016-2018. Management centre: FIBHULP Lobato Vidal N. Contrato de garantía juvenil (PEJ15/BIO/ AI-0286). CAM. 2016-2018. Management centre: FIBHULP Palomares Bralo M. Secuenciación del exoma para el diagnóstico de niños con trastorno del desarrolllo neuológico o discapacidad intelectual severa-moderada (PI13/02010). ISCIII. 2014-2017. Management centre: FIBHULP Rodríguez Novoa S. Diagnóstico genético de hipercolesterolemia familiar mediante next generation sequencing: estudio funcional de nuevas variantes. Transcriptómica y miRNAS y su impacto en el fenotipo (PI15/00122). ISCIII. 2016-2018. Management centre: FIBHULP Santos Simarro F. Clinical characterization and molecular genetic analysis of the baf complex related syndromes (PI14/01922). ISCIII. 2015-2017. Management centre: FIBHULP Vallespín García E. Aplicación de un protocolo diagnóstico basado en secuenciación masiva (Cardiomassseq) para malformaciones cadiacas congénitas en la rutina clínica (PI13/01450). ISCIII. 2014-2016. Management centre: FIBHULP

PRIVATE PROJECTS Campos Barros A. Análisis genético de la deficiencia idiopática de GH y deficiencia primaria de IGF-1 en talla baja. Ipsen Pharma SPS. 2012-Ongoing. Management centre: FIBHULP Lapunzina Badía PD. Estudios citogenéticas y moleculares en población con enfermedades de base genética en el Hosptial La Paz. Agilent Technologies Spain S.L. 2007-Ongoing. Management centre: FIBHULP Lapunzina Badía PD. Análisis genómico global en el Síndrome de Sotos: evaluación de la dosis genómica mediante microarrays personalizados de SNPS y estudio de genes 230

candidatos mediante secuenciación masiva de nueva generación en pacientes negativos para NSD1 PI-1543. Asociación Española del Síndrome de Sotos. 2013-Ongoing. Management centre: FIBHULP

Lapunzina Badía PD. Determinación genómica de muestras del biomarcador del gen KRAS y NRAS. Amgen S.A. 2014-Ongoing. Management centre: FIBHULP

Lapunzina Badía PD. Análisis genético y genómico en pacientes afectados por la enfermedad de Gorham-Stout y por anomalías generales. Limphatic Malformation Institute. 2012-Ongoing. Management centre: FIBHULP

Solera García J. Estudio de microRNAs en pacientes con glucogenosis tipo II (enfermedad de Pompe) como marcadores de diagnóstico, progresión de la enfermedad y respuesta al tratamiento. Fundación Genzyme. 2013-Ongoing. Management centre: FIBHULP

Lapunzina Badía PD. Análisis genómico global en el Síndrome de Invdupdel(8p): evaluacion de la dosis genómica mediante microarrays personalizados de SNPS y estudio de genes candidatos del fenotipo. ASDID. 2015-Ongoing. Management centre: FIBHULP Lapunzina Badía PD. Análisis muticional del gen SCNA1 en pacientes con diganóstico clínico de Síndrome de Dravet. Abyntek Biopharma S.L. 2011. Management centre: FIBHULP Lapunzina Badía PD. Investigar y desarrollar un sistema diagnóstico rápido y eficaz de las patologías de origen genético. Construcción de un centro de excelencia de investigación en bioinformática que permita el desarrollo de la tecnología en proyectos de investigación que m. Dravet Syndrome Foundation (Delegación En España). 2012-Ongoing. Management centre: FIBHULP” Lapunzina Badía PD. Investigar y desarrollar un sistema diagnóstico rápido y eficaz de las patologías de origen genético. Construcción de un centro de excelencia de investigación en bioinformática que permita el desarrollo de la tecnología en proyectos de investigación que mediante la implantación de sistemas de secuenciación de nueva generación que permita proporcionar diagnóstico avanzado a las patologías genéticas. CAM. 2013-Ongoing. Management centre: FIBHULP Lapunzina Badía PD. Análisis global de la hipofosfatasia: evaluación de la dosis genómica mediante MLPA y estudio del gen ALPL en pacientes con sospecha clínica. Alexion Pharma Spain S.L. 2014-Ongoing. Management centre: FIBHULP Lapunzina Badía PD. Organización jornadas de investigación: XXVII Congreso nacional de la Asociación Española de Genética humana.Tilesa Kenes Spain S.L. 2013-Ongoing. Management centre: FIBHULP Lapunzina Badía PD. Estudio genético-molecular de genes candidatos en pacientes con hipertensión pulmonar idiopática.Actelion Pharmaceuticals España. 2011-Ongoing. Management centre: FIBHULP

Palomares M, Lapunzina P, Nevado J, Vallespin E, Vallcorba I, Melero J, authors; FIBHULP, Hospital Infanta Cristina (Badajoz) Fundesalud, assignees. Brand name: OncoHematoArray; ESM 2.958.703-4, USM 85.334.842, CM 10.009.181; 2010 December 02, 2011 June 01, 2011 May 31.

INGEMM, author; FIBHULP, assignee. Brand name: OncoArray; ESM 2.962.910, USM 85.363.107, CM 10.091.882; 2011 January 05, 2011 July 05, 2011 July 01.

PATENTS AND TRADEMARKS Friedman S, Li D, Narla G, Martignetti J, Heath K, inventors; Mount Sinai School of Medicine, assignee; Kruppel-like factor 6 (klf6), a tumor suppressor protein, and diagnostics, therapeutics, and screening based on this protein. PCT/US2001/025046, EP1332362, US2005181374, US2011059899, AU8479001, CA2419064; 2000 August 09. INGEMM, author; FIBHULP, assignee. Brand name: INGEMM Instituto de Genética Médica y Molecular del Hospital Universitario La Paz; ESM 2.884.849, USM 77.891.143, CM 8.746.869; 2009 July 16, 2009 December 11, 2009 December 10.

INGEMM, author; FIBHULP, assignee. Brand name: KaryoArray; USM 79.078.751, CM 8.512.907; 2010 January 07, 2009 August 27.

INGEMM, author; FIBHULP, assignee. Brand name: OverGrowthArray; ESM 2.958.709-3, USM 85.334.932, CM 10.009.256; 2010 December 02, 2011 June 01, 2011 May 31.

Lapunzina P, Nevado J, Solera J, Vallespin E, Martínez P, Martínez-González V, authors; FIBHULP, assignee. Brand name: ONCOSeq; USM 85.457.843, CM 9.969.064; 2011 October 27, 2011 May 16.

Moreno JC, Moya CM, Vallespin E, Lapunzina P, Nevado J, authors; FIBHULP, assignee. Brand name: ThyroArray; USM 85.686.688, CM 10.904.951; 2012 July 25, 2012 May 23.

Lapunzina Badía P, Borobia Pérez AM, Carcas Sansuán AJ, Tenorio Castaño JA, Arias Lajara P, Lubomirov Jristov R, authors; FIBHULP, UAM, assignees. Brand name: PharmArray; USM 86.004.412, CM 11.608.403; 2013 July 08, 2013 February 27.

INGEMM, author; FIBHULP, assignee. Brand name: MetabolArray; ESM 2.958.711-5, USM 85.334.903, CM 10.009.348; 2010 December 02, 2011 June 01, 2011 May 31.

Lapunzina Badía PD. Patrocinio Jornadas de DNA day. Varios. 2012-Ongoing. Management centre: FIBHULP Lapunzina Badía PD. Estudio clínico molecular en pacientes con Síndrome de Sobrecrecimiento (SSC). Estudio de los genes NSD1, NIZP1, HRAS, CDKN1C, GKP3, y de las regiones cromosómicas 5Q35, XQ26 y 11Q en pacientes con SSC. Effice Servicios para la InvestigaciÓn S.L. 2005-Ongoing. Management centre: FIBHULP

Return to LARGE SYSTEM PATHOLOGIES AREA INDEX

231

3.5 Cancer and Human Molecular Genetics Area

3 INFORMATION GROUPS BY AREA

232

The Translational Oncology group’s objective is to conduct highly scientific applied research in such a way that basic research can be rapidly translated to clinical practice. In other words, cancer patients at La Paz University Hospital benefit almost immediately from the results of research conducted by their own physicians. The main lines of study are based on tumours with the greatest incidence and impact on survival, such as lung, colorectal, breast and ovarian cancer, although other types of neoplasms have been incorporated such as gastric and renal cancer. A series of fundamental objectives have been established for these neoplasms that can be summarised as early diagnosis, molecular classification for therapeutic goals and the search for individualised treatments. The majority of TOU projects have as their primary objective the search for predictors of susceptibility or resistance to anticancer agents and the search for prognostic factors related to the evolution of the tumour.

TRANSLATIONAL ONCOLOGY GROUP

29 214.391 13

Jaime Feliú Batlle Jaime Feliú Batlle Jorge Barriuso Feijoó Facultativo Especialista de Área en Oncología. HULP Borja Belandía Gómez Científico Titular. IIB “Alberto Sols” Beatriz Castelo Fernández Facultativo Especialista de Área en Oncología. HULP Paloma Cejas Guerrero Investigadora Postdoctoral. HULP Roberto Crespo Martín Técnico Superior en Anatomía Patológica. HULP Ana Belén Custodio Carretero Facultativo Especialista de Área en Oncología. HULP Esther Díaz López Técnico de Laboratorio. HULP Enrique Espinosa Arranz Facultativo Especialista de Área en Oncología. HULP Profesor Asociado. UAM Juan Ángel Fresno Vara Investigador Senior (Contrato Miguel Servet - I2). Jefe de Laboratorio. HULP Ángelo Gámez Pozo Investigador Postdoctoral (Contrato Técnico de Apoyo). HULP Ismael Ghanem Cañete Médico Adjunto en Oncología Médica. HULP Juan Carlos Lacal Sanjuán Profesor de Investigación. IIB “Alberto Sols” Rocío López Vacas Técnico de Laboratorio (Contrato Técnico de Apoyo). HULP Virginia Martínez Marín Facultativo Especialista de Área en Oncología. HULP

Víctor Moreno García Facultativo Especialista de Área en Juan Moreno Rubio Investigador Postdoctoral. HULP Ignacio Palmero Rodríguez Científico Titular. IIB “Alberto Sols” Álvaro Pinto Marín Facultativo Especialista de Área en Andrés Redondo Sánchez Facultativo Especialista de Área en Profesor Asociado. UAM Nuria Rodríguez Salas Facultativo Especialista de Área en Pilar Zamora Auñón Facultativo Especialista de Área en Profesor Asociado. UAM

Research Lines • Identification of prognostic factors Clinical Genomic Proteomic. • Identification of mechanisms of resistance to drugs. • Efficacy and toxicity of antineoplastic therapies. • Palliative care and supportive treatments.

Oncología. HULP

Research Activity DOCTORAL THESES

Oncología. HULP

de Velasco Oria de Rueda  G. Análisis de un perfil de microARNs como factor pronóstico en cáncer de mama con afectación axilar [dissertation]. Madrid: UCM 2016(14/04/2016). Directors: Fresno Vara JA, Ciruelos Gil E, Paz-Ares L.

Oncología. HULP

BOOKS AND BOOK CHAPTERS

Oncología. HULP

Oncología. HULP

Strategic Objective The aim of cancer research is to improve understanding of all aspects of the disease, including deepening our understanding of the biology of the tumour, developing new treatments, analysing the efficacy of diagnostic tests and performing studies aimed at prevention and early diagnosis. Although important advances have been made in recent years in our understanding of the origin and evolution of cancer, their implementation in healthcare takes too much time. The Translational Oncology Unit (TOU) was established with the objective of facilitating the incorporation into clinical practice of new advances in molecular biology and the technology developed in this field.

Higueras O, Cruz P, Feliú J. Visión actual del cáncer. In: C. Gómez-Candela, S. Palma, S. Coral, P. Riobó, PJ. Robledo. Alimentación, Nutrición y Cáncer: prevención y tratamiento. Madrid: UNED , 2016.

PUBLICATIONS • Adrados I, Larrasa-Alonso J, Galarreta A, López-Antona I, Menéndez C, Abad M, Gil J, Moreno-Bueno G, Palmero I. The homeoprotein SIX1 controls cellular senescence through the regulation of p16INK4A and differentiation-related genes. Oncogene. 2016;35(27):3485-94. Article. IF: 7.519; D1 • Almagro E, González CS, Espinosa E. Prognostic factors of early breast cancer. Med Clin-Barcelona. 2016;146(4):167-71. Review. IF: 1.125; Q3 • Arance AM, Berrocal A, López-Martín JA, de la Cruz-Merino L, Soriano V, Algarra SM, Alonso L, Cerezuela P, la Orden B, Espinosa E. Safety of vemurafenib in patients with BRAF (V600) mutated metastatic melanoma: the Spanish experience. Clin Transl Oncol. 2016;18(11):1147-57. Article. IF: 2.353; Q3

• Bargiela-Iparraguirre J, Prado-Marchal L, Fernández-Fuente M, Gutiérrez-González A, Moreno-Rubio J, Muñoz-Fernández M, Sereno M, Sánchez-Prieto R, Perona R, Sánchez-Pérez I. CHK1 expression in gastric cancer is modulated by p53 and RB1/ E2F1: implications in chemo/radiotherapy response. Sci Rep-Uk. 2016;6:21519. Article. IF: 4.259; Q1 • Carmona-Bayonas A, Jiménez-Fonseca P, Lorenzo MLS, Ramchandani A, Martínez EA, Custodio A, Garrido M, Echavarría I, Cano JM, Barreto JEL, García TG, Mancenido FA, Lacalle A, Cardona MF, Mangas M, Visa L, Buxo E, Azkarate A, Díaz-Serrano A, Montes AF, Rivera F. On the effect of triplet or doublet chemotherapy in advanced gastric cancer: Results from a National Cancer Registry. J Natl Compr Canc Ne. 2016;14(11):1379-88. Article. IF: 4.675; Q2 • Cejas P, Li L, O’Neill NK, Duarte M, Rao P, Bowden M, Zhou CSW, Mendiola M, Burgos E, Feliú J, Moreno-Rubio J, Guadalajara H, Moreno V, García-Olmo D, Bellmunt J, Mullane S, Hirsch M, Sweeney CJ, Richardson A, Liu XS, Brown M, Shivdasani RA, Long HW. Chromatin immunoprecipitation from fixed clinical tissues reveals tumor-specific enhancer profiles. Nat Med. 2016;22(6):685-91. Article. IF: 29.886; D1 • Espinosa E, Soriano V, Malvehy J, Berrocal A, de Prado PM, Quindos M, Soria A, Márquez-Rodas I, Palacio I, Cerezuela P, LópezVivanco G, Alonso L, Samaniego E, Ballesteros A, Puertolas T, Díaz-Beveridge R, de la Cruz-Merino L, Castro RL, López RL, Stevinson K, del Barrio P, Tornamira MV, Guillem V, Martín-Algarra S. Treatment patterns of adjuvant interferon-alpha 2b for high-risk melanoma: a retrospective study of the Grupo Espanol Multidisciplinar de Melanoma - Prima study. Melanoma Res. 2016;26(3):278-83. Article. IF: 2.615; Q2 • Feliú J, de Corcuera ID, Manzano JL, Valladares-Ayerbes M, Alcaide J, García TG, Vera R, Sastre J. Effectiveness and safety of aflibercept for metastatic colorectal cancer: retrospective review within an early access program in Spain. Clin Transl Oncol. 2017;19(4):498-507. Review. IF: 2.353; Q3 • Forner A, Reig M, Varela M, Burrel M, Feliú J, Briceno J, Sastre J, Martí-Bonmati L, Llovet JM, Bilbao JI, Sangro B, Pardo F, Ayuso C, Bru C, Tabernero J, Bruix J. Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH. Med Clin-Barcelona. 2016;146(11):511.e1-511.e22. Article. IF: 1.125; Q3 • García-Alfonso P, Feliú J, García-Carbonero R, Grávalos C, Guillén-Ponce C, Sastre J, García-Foncillas J. Is regorafenib providing clinically meaningful benefits to pretreated patients with metastatic colorectal cancer? Clin Transl Oncol. 2016;18(11):1072-81. Review. IF: 2.353; Q3 • Gayarre J, Kamieniak MM, Cazorla-Jiménez A, Muñoz-Repeto I, Borrego S, García-Donas J, Hernando S, Robles-Díaz L, GarcíaBueno JM, Cajal TRY, Hernández-Agudo E, Soto VH, MárquezRodas I, Echarri MJ, Lacambra-Calvet C, Sáez R, Cusido M, Redondo A, Paz-Ares L, Hardisson D, Mendiola M, Palacios J, Benítez J, García MJ. The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients. J Gynecol Oncol. 2016;27(1):e7. Article. IF: 3.14; Q1 • González-Martín A, Alba E, Ciruelos E, Cortes J, Llombart A, Lluch A, Andrés R, Álvarez I, Aramenda JM, de la Peña FA, Barnadas A, Batista N, Calvo L, Galve E, García-Palomo A, GarcíaSáenz JA, de la Haba J, López R, López-Vivanco G, MartínezJanez N, de Dueñas EM, Plazaola A, Rodríguez-Lescure A, Ruiz M, Sánchez-Rovira P, Santaballa A, Segui MA, Tusquets I, Zamora P, Martín M. Nab-paclitaxel in metastatic breast cancer: Defining the best patient profile. Curr Cancer Drug Tar. 2016;16(5):41528. Article. IF: 2.992; Q3 • Higuera O, Ghanem I, Nasimi R, Prieto I, Koren L, Feliú J. Management of pancreatic cancer in the elderly. World J Gastroentero. 2016;22(2):764-75. Article. IF: 3.365; Q2

Continue

233

3.5 Cancer and Human Molecular Genetics Area

3 INFORMATION GROUPS BY AREA • Laimito KR, Gámez-Pozo A, Sepulveda J, Manso L, López-Vacas R, Pascual T, Vara JAF, Ciruelos E. Characterisation of the triple negative breast cancer phenotype associated with the development of central nervous system metastases. Ecancermedicalscience. 2016;10:632. Article. Not Indexed • Lamarca A, Mendiola M, Barriuso J. Hepatocellular carcinoma: Exploring the impact of ethnicity on molecular biology. Crit Rev Oncol Hemat. 2016;105:65-72. Review. IF: 4.971; Q1 • López-Gómez M, Casado E, Muñoz M, Alcalá S, Moreno-Rubio J, D’Errico G, Jiménez-Gordo AM, Salinas S, Sainz B. Current evidence for cancer stem cells in gastrointestinal tumors and future research perspectives. Crit Rev Oncol Hemat. 2016;107:5471. Review. IF: 4,971; Q1 • Martín-Algarra S, de la Cruz-Merino L, Soriano V, Manzano JL, Espinosa E. Clinical use of ipilimumab for metastatic melanoma in Spain: towards a more consistent approach. Clin Transl Oncol. 2016;18(10):1044-50. Article. IF: 2.353; Q3 • Martín-Broto J, Pousa AL, de las Penas R, del Muro XG, Gutiérrez A, Martínez-Trufero J, Cruz J, Álvarez R, Cubedo R, Redondo A, Maurel J, Carrasco JA, López-Martín JA, Sala A, Meana JA, Ramos R, Martínez-Serra J, López-Guerrero JA, Sevilla I, Balana C, Vaz A, de Juan A, Alemany R, Poveda A. Randomized phase II study of trabectedin and doxorubicin compared with doxorubicin alone as first-line treatment in patients with advanced soft tissue sarcomas: A Spanish group for research on sarcoma study. J Clin Oncol. 2016;34(19):2294-302. Article. IF: 24.008; D1 • Martínez-Iglesias OA, Alonso-Merino E, Gómez-Rey S, VelascoMartín JP, Orozco RM, Luengo E, Martín RG, Ibáñez de Cáceres I, Fernández AF, Fraga MF, González-Peramato P, Varona C, Palacios J, Regadera J, Aranda A. Autoregulatory loop of nuclear corepressor 1 expression controls invasion, tumor growth, and metastasis. P Natl Acad Sci Usa. 2016;113(3):E328-37. Article. IF: 9.661; D1 • Martínez-Jánez N, Chacón I, de Juan A, Cruz-Merino L, del Barco S, Fernández I, García-Teijido P, Gómez-Bernal A, Plazaola A, Ponce J, Servitja S, Zamora P. Anti-HER2 therapy beyond second-line for HER2-positive metastatic breast cancer: A short review and recommendations for several clinical scenarios from a Spanish expert panel. Breast Care. 2016;11(2):133-8.Article. IF: 1.553; Q3 • Martín-Richard M, Beveridge RD, Arrazubi V, Alsina M, Guzmán MG, Custodio AB, Gómez C, Muñoz FL, Pazo R, Rivera F. SEOM clinical guideline for the diagnosis and treatment of esophageal cancer (2016). Clin Transl Oncol. 2016;18(12):1179-86. Article. IF: 2.353; Q3 • Maurel J, López-Pousa A, Calabuig S, Bague S, del Muro XG, Sanjuan X, Rubio-Casadevall J, Cuatrecasas M, Martínez-Trufero J, Horndler C, Fra J, Valverde C, Redondo A, Poveda A, Sevilla I, Láinez N, Rubini M, García-Albéniz X, Martín-Broto J, de Alava E. Phosphorylated-insulin growth factor I receptor (p-IGF1R) and metalloproteinase-3 (MMP3) expression in advanced gastrointestinal stromal tumors (GIST). A GEIS 19 study. Clin Sarcoma Res. 2016;6:10. Article. Not Indexed • Mendiola M, Martínez-Marín V, Herranz J, Heredia V, Yébenes L, Zamora P, Castelo B, Pinto A, Miguel M, Díaz E, Gámez A, Fresno JA, de Molina AR, Hardisson D, Espinosa E, Redondo A. Predictive value of angiogenesis-related gene profiling in patients with HER2-negative metastatic breast cancer treated with bevacizumab and weekly paclitaxel. Oncotarget. 2016;7(17):24217-27. Article. IF: 5.168; Q1 • Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I, Ben-Baruch NE, Marth C, Madry R, Christensen RD, Berek JS, Dorum A, Tinker AV, du Bois A, González-Martín A, Follana P, Benigno B, Rosenberg P, Gilbert L, Rimel BJ, Buscema J, Balser JP, Agarwal S, Matulonis UA. Niraparib maintenance therapy in platinum-sensitive,

234

recurrent ovarian cancer. New Engl J Med. 2016;375(22):215464. Article. IF: 72.406; D1 • Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae DS, Oaknin A, Ray-Coquard I, Provencher DM, Karlan BY, Lhomme C, Richardson G, Rincon DG, Coleman RL, Marth C, Brize A, Fabbro M, Redondo A, Bamias A, Ma HJ, Vogl FD, Bach BA, Oza AM. Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2. Gynecol Oncol. 2016;143(1):27-34. Article. IF: 4.959; D1 • Pinto A, Segura PP. Primary prevention and early diagnosis of prostate cancer: recommendations from the prevention and early diagnosis working group of the Spanish Society of Medical Oncology (SEOM). Eur J Cancer Prev. 2016;25(2):137-41. Review. IF: 2.556; Q3 • Santaballa A, Barretina P, Casado A, García Y, González-Martín A, Guerra E, Láinez N, Martínez J, Redondo A, Romero I. SEOM clinical guideline in ovarian cancer (2016). Clin Transl Oncol. 2016;18(12):1206-12. Article. IF: 2.353; Q3 • Shi JJ, Zhang YF, Zheng W, Michailidou K, Ghoussaini M, Bolla MK, Wang Q, Dennis J, Lush M, Milne RL, Shu XO, Beesley J, Kar S, Andrulis IL, Anton-Culver H, Arndt V, Beckmann MW, Zhao ZG, Guo XY, Benitez J, Beeghly-Fadiel A, Blot W, Bogdanova NV, Bojesen SE, Brauch H, Brenner H, Brinton L, Broeks A, Bruening T, Burwinkel B, Cai H, Canisius S, Chang-Claude J, Choi JY, Couch FJ, Cox A, Cross SS, Czene K, Darabi H, Devilee P, Droit A, Dork T, Fasching PA, Fletcher O, Flyger H, Fostira F, Gaborieau V, García-Closas M, Giles GG, Grip M, Guenel P, Haiman CA, Hamann U, Hartman M, Miao H, Hollestelle A, Hopper JL, Hsiung CN, Investigators K, Ito H, Jakubowska A, Johnson N, Torres D, Kabisch M, Kang D, Khan S, Knight JA, Kosma VM, Lambrechts D, Li JM, Lindblom A, Lophatananon A, Lubinski J, Mannermaa A, Manoukian S, Le Marchand L, Margolin S, Marme F, Matsuo K, McLean C, Meindl A, Muir K, Neuhausen SL, Nevanlinna H, Nord S, Borresen-Dale AL, Olson JE, Orr N, van den Ouweland AMW, Peterlongo P, Putti TC, Rudolph A, Sangrajrang S, Sawyer EJ, Schmidt MK, Schmutzler RK, Shen CY, Hou MF, Shrubsole MJ, Southey MC, Swerdlow A, Teo SH, Thienpont B, Toland AE, Tollenaar RAEM,Tomlinson I,Truong T,Tseng CC,Wen WQ,Winqvist R, Wu AH, Yip CH, Zamora PM, Zheng Y, Floris G, Cheng CY, Hooning MJ, Martens JWM, Seynaeve C, Kristensen VN, Hall P, Pharoah PDP, Simard J, Chenevix-Trench G, Dunning AM, Antoniou AC, Easton DF, Cai QY, Long JR. Fine-scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer. Int J Cancer. 2016;139(6):1303-17. Article. IF: 6.513; Q1 • Vargas T, Moreno-Rubio J, Herranz J, Cejas P, Molina S, Mendiola M, Burgos E, Custodio AB, de Miguel M, Martín-Hernández R, Reglero G, Feliú J, de Molina AR. 3 ‘ UTR Polymorphism in ACSL1 gene correlates with expression levels and poor clinical outcome in colon cancer patients. Plos One. 2016;11():e0168423. Article. IF: 2.806; Q1 • Vera R, Dotor E, Feliú J, González E, Laquente B, Macarulla T, Martínez E, Maurel J, Salgado M, Manzano JL. SEOM clinical guideline for the treatment of pancreatic cancer (2016). Clin Transl Oncol. 2016;18(12):1172-8. Article. IF: 2.353; Q3

PUBLIC PROJECTS Álvarez Castelao B. Análisis mutacional en cáncer epidermoide de cabeza y cuello. Implicaciones pronósticas y predictivas de respuesta en el ensayo clínico fase III TTCC (PI14/00071). ISCIII. 2015-2017. Management centre: Fundación Instituto de Estudios de Ciencias

Cejas Guerrero P. Nuevos mecanismos de regulación epigenética de la expresión implicados en la respuesta a los esquemas de quimioterapia en cáncer colorrectal (PI13/01818). ISCIII. 2014-2017. Management centre: FIBHULP

Feliú Batlle J. Utilidad de la determinación del DNA circulante para monitorizar la respuesta al tratamiento neoadyuvante en los pacientes con cáncer de recto localmente avanzado. Fundación Salud 2000. 2014-Ongoing. Management centre: FIBHULP

Espinosa Arranz E. Alimentos funcionales y estrategias nutricionales eficaces para la prevención y tratamiento de enfermedades crónicas (S2013/ABI-2728-ALIBIRD). CAM. 2014-2018. Management centre: FIBHULP

Feliú Batlle J. Actualización en oncología y nuevos retos en investigación. Janssen-Cilag España S.A. 2014-Ongoing. Management centre: FIBHULP

Feliú Batlle J. Analisis de biomarcadores relacionados con la eficacia de las terapias dirigidas al cáncer colorectal (PI13/01659). ISCIII. 2014-2017. Management centre: FIBHULP Fresno Vara JA. Caracterización molecular del cáncer de mama triple negativo (PI12/00444). ISCIII. 2013-2017. Management centre: FIBHULP Fresno Vara JA. Evaluación del metaboloma sanguíneo como fuente de biomarcadores para el manejo del paciente de cáncer de mama (PI15/01310). ISCIII. 2016-2018. Management centre: FIBHULP Fresno Vara JA. Miguel Servet stabilisation contracts (I2). ISCIII, CAM. 2012-Ongoing. Management centre: FIBHULP

PRIVATE PROJECTS Barriuso Feijoó J. Estudio de biomarcadores predictores de resistencia a fármacos antiangiogénicos e inhibidores de MTOR en tumores neuroendocrinos gastro-enteropancreáticos. Fundación Eugenio Rodríguez Pascual. 2013-Ongoing. Management centre: FIBHULP Barriuso Feijoó J. Puesta a punto de la técnica de PCR cuantitativa y determinación de grupos de genes que permitirán el desarrollo del conocimiento de los tumores nueroendocrinos pancreáticos. Pfizer S.L.U. 2012-Ongoing. Management centre: FIBHULP Feliú Batlle J. Promover la actividad investigadora en el Servicio de Oncología. Amgen S.A. 2010-Ongoing. Management centre: FIBHULP Feliú Batlle J. 2ª Jornada de debates fármaco-económicos en Oncología e investigación. Astellas Pharma S.A. 2015-Ongoing. Management centre: FIBHULP Feliú Batlle J. Jornadas científicas sobre Investigación y actualización en Oncología. Astrazeneca Farmacéutica Spain S.A. 2016-Ongoing. Management centre: FIBHULP Feliú Batlle J. Implicaciones clínicas y terapeúticas de la expresión génica diferencial de las células madre tumorales procedentes de carcinomas de colón en estadíos operables. Cephalon Pharma S.L.U. 2008-Ongoing. Management centre: FIBHULP Feliú Batlle J. Estudio de factores predictivos de toxicidad grave (grado 3-4) en anciano. CAM. 2012-Ongoing. Management centre: FIBHULP

Feliú Batlle J. Sesiones de formación en oncología clínica e investigación. Lilly S.A. 2016-Ongoing. Management centre: FIBHULP Feliú Batlle J. Jornadas investigación traslacional en oncología. Pfizer S.L.U. 2016-Ongoing. Management centre: FIBHULP Feliú Batlle J. 3ª Jornada de debates fármaco-económicos en oncología. Roche Farma S.A. 2015-Ongoing. Management centre: FIBHULP Feliú Batlle J. MTA: procesamiento y tratamiento de muestras.Varios. 2016-Ongoing. Management centre: FIBHULP Feliú Batlle J. Proyecto desarrollo de consulta de Psicooncología en el Hospital Universitario La Paz. Varios. 2012-Ongoing. Management centre: FIBHULP Fresno Vara JA. Caracterización molecular del cáncer de mama mediante taqman low density arrays: aplicación al diagnósitico. FUAM. 2014-Ongoing. Management centre: FIBHULP Fresno Vara JA. Aplicación de ensayos funcionales con minigenes como estrategia para determinar la implicación de variantes de significado desconocido en el desarrollo de cáncer hereditario. FMMA. 2012-Ongoing. Management centre: FIBHULP Fresno Vara JA. Extracción y análisis de la expresión de miRNA en 160 biopsias de cáncer renal embebidas en parafina y su correlación con la evaluación clínica de los pacientes. Fundación para la Investigación Biomédica del Hospital Universitario 12 de Octubre. 2010-Ongoing. Management centre: FIBHULP Fresno Vara JA. Extracción y análisis de la expresión miRNA en biopsias de cáncer de mama embebidas en parafina y su correlación con la evolución clínica de los pacientes. Fundación para la Investigación Biomédica del Hospital Universitario 12 de Octubre. 2012-Ongoing. Management centre: FIBHULP Ghanem I. Alteraciones genómicas en carcinoma escamoso de ano. Secuenciación del exoma completo. Grupo Español Multidisciplinar de Cáncer de Aparato Digestivo. 2014-Ongoing. Management centre: Grupo Español Multidisciplinar de Cáncer de Aparato Digestivo Martínez Marín V. Estudio perfil mutacional e inmunohistoquímico en GIST: búsqueda de factores pronósticos y predictivos. Grupo Español de Investigacion en Sarcomas. 2013-Ongoing. Management centre: FIBHULP

Continue

235

3.5 Cancer and Human Molecular Genetics Area

3 INFORMATION GROUPS BY AREA Pinto Marín A. Evaluación del metaboloma sanguíneo como fuente de biomarcadores para el manejo del paciente con cáncer: el caso del cáncer de prostata metastásico. FIBHULP. 2015-Ongoing. Management centre: FIBHULP Redondo Sánchez A. Caracterización de la acción de trabectedina y análogos, lurbinectedina y análogos y PM60184 en modelos celulares en dos y tres dimensiones de carcinoma de ovario. Pharmamar S.A. 2016-Ongoing. Management centre: FIBHULP Redondo Sánchez A. Análisis de expresión de miRNAs relacionados con el proceso angiogénico en cáncer mama. Roche Farma S.A. 2014-Ongoing. Management centre: FIBHULP Redondo Sánchez A. Cáncer de mama y angiogénesis: estudio de perfiles de expresión génica en muestras parafinadas. Roche Farma S.A. 2009-Ongoing. Management centre: FIBHULP Zamora Auñón P. VI Curso de investigación en diagnóstico y tratamiento del cáncer de mama. Roche Farma S.A. 2014-Ongoing. Management centre: FIBHULP

CLINICAL TRIALS Castelo Fernández B. Riftos mki - pacientes asintomáticos con cáncer diferenciado de tiroides refractario al yodo radioactivo? Estudio observacional para evaluar la utilización de inhibidores de multiquinasa. Bayer Hispania S.L. HULP Code: 4413. Sponsored´s Protocol Code: BAY-SOR-2014-01. Signature Date: 22/06/2016 Castelo Fernández B. Ensayo clínico abierto, randomizado, multicéntrico fase 1b/3 de talimogene laherparepvec en combinación con pembrolizumab para el tratamiento de pacientes con carcinoma de células escamosas de cabeza y cuello metastásico o recurrente. Amgen S.A. HULP Code: 4538. Sponsored´s Protocol Code: 20130232. Signature Date: 11/04/2016 Castelo Fernández B. Ensayo clínico de fase 1b/3 multicentrico, aleatorizado, de talimogene laherparepvec en combinación con pembrolizumab para el tratamiento de pacientes con carcinoma de células escamosas de cabeza y cuello metastásico o recurrente. Amgen S.A. HULP Code: Anexo-I 4538. Sponsored´s Protocol Code: 20130232. Signature Date: 7/11/2016 Castelo Fernández B. Estudio de fase Ib-II, abierto y de un solo grupo de iph2201 preoperatorio en pacientes con carcinoma epidermoide de la cavidad bucal localmente avanzado y resecable. Medpace Germany Gmbh. HULP Code: 4548. Sponsored´s Protocol Code: IPH2201. Signature Date: 2/3/2016 Castelo Fernández B. Ensayo multicéntrico, aleatorizado, doble ciego de fase 2 de lenvatinib (e7080) en sujetos con cáncer tiroideo diferenciado resistente a 131i para determinar si una dosis oral inicial de 20 mg o 14 mg al día proporciona una eficacia comparable a la de una dosis inicial de 24 mg, pero con un mejor perfil de seguridad. EISAI Europe Limited.

236

HULP Code: 4588. Sponsored´s Protocol Code: E7080-G000-211. Signature Date: 14/4/2016 Castelo Fernández B. Ensayo multicéntrico, aleatorizado, doble ciego de fase 2 de lenvatinib (e7080) en sujetos con cáncer tiroideo diferenciado resistente a 131i para determinar si una dosis oral inicial de 20 mg o 14 mg al día proporciona una eficacia comparable a la de una dosis inicial de 24 mg, pero con un mejor perfil de seguridad. EISAI Europe Limited. HULP Code: Anexo-I 4588. Sponsored´s Protocol Code: E7080G000-211. Signature Date: 22/7/2016 Castelo Fernández B. Estudio de fase III, aleatorizado, abierto, global, multicéntrico de monoterapia con medi4736 y medi4736 en combinación con tremelimumab frente a terapia con tratamiento habitual en pacientes con carcinoma de células escamosas de cabeza y cuello recidivante o metastásico (CCECC). Astrazeneca Ab. HULP Code: 4653. Sponsored´s Protocol Code: D4193C00002. Signature Date: 15/6/2016 Custodio Carretero AB. Estudio fase II/III aleatorizado doble ciego de la combinación de sandostatin lar con axitinib vs sandostatin lar con placebo en pacientes con tumores neuroendocrinos avanzados g1-g2 (OMS 2010) de origen no pancreático. Grupo Español de Tumores Neuroendocrinos. HULP Code: Anexo-2 3398. Sponsored´s Protocol Code: AXIIIG-02. Signature Date: 15/2/2016 Custodio Carretero AB. Estudio fase II/III aleatorizado doble ciego de la combinación de sandostatin lar con axitinib vs sandostatin lar con placebo en pacientes con tumores neuroendocrinos avanzados g1-g2 (OMS 2010) de origen no pancreático. Grupo Español de Tumores Neuroendocrinos. HULP Code: Anexo-3 3398. Sponsored´s Protocol Code: AXIIIG-02. Signature Date: 20/7/2016 Custodio Carretero AB. Ensayo clínico de fase III, aleatorizado, controlado con tratamiento activo, con enmascaramiento parcial y con detección de biomarcadores, de pembrolizumab en monoterapia y en combinación con cisplatino + 5-fluorouracilo frente a placebo + cisplatino + 5-fluorouracilo como tratamiento de primera línea en sujetos con adenocarcinoma gástrico o de la unión gastroesofágica (UGE) avanzado. Merck Sharp & Dhome Corp. HULP Code: 4689. Sponsored´s Protocol Code: 3475-062. Signature Date: 22/9/2016 Custodio Carretero AB. Ensayo en fase III, abierto y multicéntrico del avelumab (msb0010718c) como tratamiento de tercera línea del adenocarcinoma de la unión gastroesofágica o gástrico, metastásico, recurrente o irresecable. Merck Kgaa. HULP Code: 4704. Sponsored´s Protocol Code: EMR100070-008. Signature Date: 27/9/2016 Custodio Carretero AB. Evaluación de la respuesta radiológica de los tumores neuroendocrinos pancreáticos: comparación de los criterios choi y recist. Grupo Español de Tumores Neuroendocrinos.

HULP Code: PI-2406. Sponsored´s Protocol Code: GETSUN-2015-01. Signature Date: 30/5/2016 Espinosa Arranz E. Ensayo clínico abierto, multicéntrico, no aleatorizado en fase II para evaluar la eficacia de nivolumab en combinación con ipilimumab en pacientes con melanoma uveal metastásico no tratados previamente. Grupo Español Multidisciplinar de Melanoma. HULP Code: 4655. Sponsored´s Protocol Code: GEM 1402. Signature Date: 23/2/2016 Espinosa Arranz E. Estudio de extension (transferencia) abierto de vemurafenib en pacientes con neoplasia maligna con la mutacion brafv600 incluidos previamente en un protocolo anterior de vemurafenib. F.Hoffmann-La Roche Ltd. HULP Code: Anexo-II 3871. Sponsored´s Protocol Code: GO28399. Signature Date: 01/3/2016 Espinosa Arranz E. Ensayo de fase 1b/3 multicéntrico de talimogene laherparepvec en combinación con pembrolizumab (mk-3475) para el tratamiento del melanoma en estadio IIIb a ivm1c no resecable (masterkey-265. Amgen, S.A.) HULP Code: 4636. Sponsored´s Protocol Code: 20110265. Signature Date: 12/5/2016 Feliú Batlle J. Estudio aleatorizado, multicéntrico, doble ciego, controlado con placebo, de fase 2/3 del inhibidor de la tirosina quinasa de bruton, ibrutinib, en combinación con nab-paclitaxel y gemcitabina frente a placebo en combinación con nab-paclitaxel y gemcitabina, en el tratamiento de primera línea de pacientes con adenocarcinoma de páncreas metastásico. Pharmacyclis Llc. HULP Code: 4502. Sponsored´s Protocol Code: PCYC-1137-CA. Signature Date: 20/1/2016 Feliú Batlle J. Estudio aleatorizado, multicéntrico, doble ciego, controlado con placebo, de fase 2/3 del inhibidor de la tirosina quinasa de bruton, ibrutinib, en combinación con nab-paclitaxel y gemcitabina frente a placebo en combinación con nab-paclitaxel y gemcitabina, en el tratamiento de primera línea de pacientes con adenocarcinoma de páncreas metastásico. Pharmacyclis Llc. HULP Code: Anexo-I 4502. Sponsored´s Protocol Code: PCYC1137-CA. Signature Date: 3/5/2016 Feliú Batlle J. Estudio de fase III aleatorizado y doble ciego para evaluar el uso de tas-102 más el mejor tratamiento sintomático frente a placebo más el mejor tratamiento sintomático en pacientes con cáncer gástrico metastásico resistente a los tratamientos de referencia. Taiho Oncology Usa Ine. HULP Code: 4549. Sponsored´s Protocol Code: TO-TAS-102-302. Signature Date: 7/4/2016 Feliú Batlle J. Elección de terapias personalizadas en pacientes con carcinoma de páncreas metastásico de acuerdo al análisis genético del tumor y al modelo avatar. Fundación Centro Nacional de Investigaciones Oncológicas Carlos III. HULP Code: 4607. Sponsored´s Protocol Code: ERCAVATAR2015. Signature Date: 12/5/2016 Feliú Batlle J. Estudio en fase 1b/2 del tratamiento combinado con ibrutinib en tumores gastrointestinales y ge-

nitourinarios avanzados seleccionados. Pharmacyclics Llc. HULP Code: 4630. Sponsored´s Protocol Code: PCYC-1128-CA. Signature Date: 2/6/2016 Feliú Batlle J. Ensayo de fase III, multicéntrico y no enmascarado sobre el tratamiento de mantenimiento con avelumab (msb0010718c) frente a la continuación de la quimioterapia de primera línea en sujetos con un adenocarcinoma gástrico, o de la zona de unión gastroesofágica, irresecable, localmente avanzado o metastásico. Merck Kgaa. HULP Code: 4643. Sponsored´s Protocol Code: EMR100070-007. Signature Date: 20/9/2016 Feliú Batlle J. Estudio en fase III, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y seguridad de gs-5745 en combinación con mfolfox6 como tratamiento de primera línea en pacientes con adenocarcinoma gástrico avanzado o de la unión gastroesofágica. Gilead Sciences Inc. HULP Code: 4569. Sponsored´s Protocol Code: GS-US-296-1080. Signature Date: 15/3/2016 Feliú Batlle J. Estudio en fase III, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y seguridad de GS-5745 en combinación con mfolfox6 como tratamiento de primera línea en pacientes con adenocarcinoma gástrico avanzado o de la unión gastroesofágica. Gilead Sciences Inc. HULP Code: Anexo-I 4569. Sponsored´s Protocol Code: GSUS-296-1080. Signature Date: 30/8/2016 Feliú Batlle J. Estudio en fase III, aleatorizado, doble ciego, sobre el inhibidor jak1/2, ruxolitinib o placebo combinado con capecitabina en sujetos con adenocarcinoma de pancreas avanzado o metastasico que no respondieron o no toleran la quimioterapia en primera linea (estudio janus 1). Incyte Corporation. HULP Code: Anexo-I 4186. Sponsored´s Protocol Code: INCB 18424-362. Signature Date: 27/7/2016 Martínez Marín V. Determinantes clínicos y moleculares de respuesta y progresión a la inhibición de kit en pacientes con tumores del estroma gastrointestinal (gist) con respuesta prolongada a imatinib. Grupo Español de Investigación en Sarcomas. HULP Code: PI-2367. Signature Date: 01/6/2016 Martínez Marín V. Estudio observacional, retrospectivo y multicéntrico para identificar el papel pronóstico y posibles implicaciones terapéuticas del receptor de la somatostatina (sstr) en el tumor de estroma gastrointestinal (gist) localizado (somagist. Grupo Español de Investigación en Sarcomas). HULP Code: PI-2453. Sponsored´s Protocol Code: GEIS 46. Signature Date: 15/7/2016 Pinto Marín A. Estudio de fase III, aleatorizado, controlado, multicéntrico y abierto, para comparar el tivozanib clorhidrato frente al sorafenib en sujetos con carcinoma de células renales avanzado resistente al tratamiento. Aveo Pharmaceuticals. HULP Code: 4570. Sponsored´s Protocol Code: AV-951-15-303. Signature Date: 2/6/2016

Continue

237

3.5 Cancer and Human Molecular Genetics Area

3 INFORMATION GROUPS BY AREA Pinto Marín A. Estudio de fase III, estudio multicéntrico, abierto, con un solo grupo de tratamiento para evaluar la seguridad de atezolizumab en pacientes con carcinoma urotelial o no urotelial del tracto urinario localmente avanzado o metastásico. F.Hoffmann-La Roche Ltd. HULP Code: 4699. Sponsored´s Protocol Code: MO299833. Signature Date: 5/10/2016 Pinto Marín A. Estudio de fase III, multicéntrico, multinacional, aleatorizado, abierto, con grupos paralelos sobre avelumab* (msb0010718c) más los mejores cuidados paliativos frente a los mejores cuidados paliativos solos como tratamiento de mantenimiento en pacientes con cáncer urotelial localmente avanzado o mestastásico sin progresión de la enfermedad tras completar la quimioterapia de primera línea basada en platino. Pfizer, S.L.U. HULP Code: 4659. Sponsored´s Protocol Code: B9991001. Signature Date: 4/7/2016 Pinto Marín A. Estudio exploratorio de fase II, abierto y con un solo grupo de tratamiento con afatinib oral en monoterapia tras el fracaso a platino en pacientes con carcinoma urotelial avanzado/metastásico con desregulación de los receptores erbb?. Boehringer Ingelheim España, S.A. HULP Code: 4632. Sponsored´s Protocol Code: 1200.261. Signature Date: 15/7/2016 Pinto Marín A. Validación del consorcio de la base de datos internacional de cáncer renal metastásico (imdc) como clasificación pronóstica para terapias dirigidas (inhibidores de la itc/mtor) en segunda línea después del tratamiento con pazopanib primera línea (spazo-2). Grupo Grupo Sogug. HULP Code: PI-2523. Sponsored´s Protocol Code: SOGUG2016-A-IEC. Signature Date: 26/10/2016 Redondo Sánchez A. Estudio de fase II aleatorizado de mln0128 (inhibidor doble de torc1/2), mln0128 + mln1117 (inhibidor de pi3k), paclitaxel semanal, o la combinación de paclitaxel semanal y mln0128 en mujeres con cáncer de endometrio avanzado, recurrente o persistente. Millennium Pharmaceuticals, Inc. HULP Code: 4614. Sponsored´s Protocol Code: C31004. Signature Date: 20/5/2016 Redondo Sánchez A. Estudio aleatorizado de fase III de lubinectedin (pm01183) frente a doxorrubicina liposomal pegilada o topotecán en pacientes con cáncer de ovario resistente a platino (ensayo corail. Pharmamar, S.A. HULP Code: Anexo-I 4400. Sponsored´s Protocol Code: PM1183C-004-14. Signature Date: 13/7/2016 Redondo Sánchez A. Estudio de fase 1b (abierto) / fase 2 (aleatorizado, doble ciego) en el que se evalúan gemcitabina y docetaxel, con o sin olaratumab, en el tratamiento del sarcoma de tejidos blandos en estadio avanzado. Lilly, S.A. HULP Code: 4543. Sponsored´s Protocol Code: I5B-MC-JGDL. Signature Date: 27/01/2016 Redondo Sánchez A. Estudio de fase 1b (abierto) / fase 2 (aleatorizado, doble ciego) en el que se evalúan gemcitabina y docetaxel, con o sin olaratumab, en el tratamiento del sarcoma de tejidos blandos en estadio avanzado. Lilly, S.A. 238

HULP Code: Anexo-I 4543. Sponsored´s Protocol Code: I5B-MCJGDL. Signature Date: 29/2/2016 Redondo Sánchez A. Estudio de fase 3, aleatorizado, en doble ciego, controlado con placebo y multicéntrico, del tratamiento de mantenimiento con niraparib en pacientes con cáncer de ovario avanzado portador de deficiencia de la recombinación homóloga (hrd) que han respondido a la quimioterapia de primera línea con platino. Tesaro Inc. HULP Code: 4642. Sponsored´s Protocol Code: PR-30-5017-C. Signature Date: 23/9/2016 Redondo Sánchez A. Estudio de fase III, abierto, multicentrico, randomizado para evaluar la eficacia y seguridad de trastuzumab emtansine versus trastuzumab como tratamiento adyuvante en pacientes con cancer de mama primario her2-positivo con presencia patologica de tumor residual en la mama o nodulo linfatico axilar tras tratamiento preoperatorio. F.Hoffmann-La Roche Ltd. HULP Code: Anexo-I 3783. Sponsored´s Protocol Code: BO27938. Signature Date: 12/1/2016 Redondo Sánchez A. Estudio de fase III, multicéntrico, aleatorizado, abierto de avelumab (msb0010718c) en monoterapia o en combinación con doxorubicina liposomal pegilada frente a doxorubicina liposomal pegilada en monoterapia en pacientes con cáncer de ovario refractario/ resistente a platino. Pfizer Inc. HULP Code: 4652. Sponsored´s Protocol Code: B9991009. Signature Date: 23/6/2016 Redondo Sánchez A. Estudio en fase III, multicéntrico, aleatorizado y controlado con placebo de atezolizumab (anticuerpo anti-pd-l1) combinado con nab-paclitaxel en comparación con placebo con nab-paclitaxel en pacientes con cáncer de mama triple negativo metastásico no tratado previamente. Roche Farma, S.A. HULP Code: 4581. Sponsored´s Protocol Code: WO29522. Signature Date: 20/4/2016 Redondo Sánchez A. Estudio fase II multicéntrico, abierto, de un solo brazo para evaluar la seguridad y eficacia de bevacizumab en combinación con carboplatino y paclitaxel en pacientes con cáncer de cérvix metastásico, recurrente o persistente. F.Hoffmann-La Roche Ltd. HULP Code: Anexo-I 4422. Sponsored´s Protocol Code: MO29594. Signature Date: 15/4/2016 Rodríguez Salas N. Ensayo clínico multicéntrico randomizado, de tratamiento de mantenimiento basado en biomarcadores para primera línea de cáncer colorrectal metastásico (modul). Roche Farma, S.A. HULP Code: 4532. Sponsored´s Protocol Code: MO29112. Signature Date: 4/1/2016 Rodríguez Salas N. Estudio abierto, aleatorizado, fase 2 que compara s95005 con bevacizumab frente a capecitabina con bevacizumab en pacientes con cáncer colorrectal metastásico no tratado previamente que no son candidatos a terapia intensiva. Laboratorios Servier, S.L. HULP Code: 4580. Sponsored´s Protocol Code: CL2-95005-002. Signature Date: 18/4/2016 Rodríguez Salas N. Estudio abierto, aleatorizado, fase 2 que compara s95005 con bevacizumab frente a capecita-

bina con bevacizumab en pacientes con cáncer colorrectal metastásico no tratado previamente que no son candidatos a terapia intensiva. Laboratorios Servier, S.L. HULP Code: Anexo-I 4580. Sponsored´s Protocol Code: CL295005-002. Signature Date: 23/9/2016

colorectal cancer. P200703230, PCT/ES2008/000757, EP2236625; 2007 December 04.

Rodríguez Salas N. Estudio fase II, prospectivo, multicéntrico, abierto, randomizado, controlado con fármaco activo, de 3 grupos paralelos, para comparar la eficacia y seguridad de masitinib en combinación con folfiri (irinotecán, 5-fluorouracil y ácido folínico) frente al masitinib solo, frente a mejores cuidados paliativos en pacientes con cáncer colorrectal metastásico en tercera o cuarta línea de tratamiento. Abscience. HULP Code: Anexo-I 4426. Sponsored´s Protocol Code: AB12010. Signature Date: 12/4/2016

Redondo Sánchez A, Hardisson Hernaéz D, Barriuso Feijoo J, Mendiola Sabio M, inventors; FIBHULP, assignee. Method to obtain useful data for the prediction of a patient’s clinical response to an anticancer treatment. P200930400; 2009 July 01.

Rodríguez Salas N. Tratamiento de inducción con folfox, con o sin aflibercept, seguido de quimio-radioterapia en carcinoma de recto localmente avanzado de alto riesgo. un ensayo abierto, fase II randomizado. Grupo Gemcad. HULP Code: Anexo-I 4230. Sponsored´s Protocol Code: GEMCAD-1402. Signature Date: 7/3/2016

Cejas Guerrero P, Belda Iniesta C, Feliú Batlle J, de Castro Carpeño J, Moreno García V, Burgos Lizalde E, Casado Sáenz E, Sánchez Hernández JJ, inventors; FIBHULP, UAM, Empresa Pública Hospital del Norte, assignees. Genomic fingerprint for predicting the clinical response to an antitumor therapy in colorectal cancer. P201130863, PCT/ES2012/070379; 2011 May 26.

Rubio Aparicio PM. Protocolo europeo de tratamiento para el neuroblastoma de riesgo bajo e intermedio”. Instituto Investigacion Sanitaria H La Fe. HULP Code: Anexo-I 3353. Sponsored´s Protocol Code: LINES. Signature Date: 31/5/2016

Moreno Rubio J, Cejas Guerrero P, Feliú Batlle J, Ramírez de Molina AI, Reglero Rada GJ, Vargas Alonso T, Molina Arranz S, González-Vallinas Garrachón M, inventors; FIBHULP, Fundación Imdea Alimentacion, assignees. Methods and kits for the prognosis of colorectal cancer. P201231918, PCT/ES2013/070864; 2012 December 10.

Zamora Auñón P. Estudio aleatorizado, doble ciego, controlado con placebo, de lee011 en combinacion con letrozol para el tratamiento de mujeres postmenopausicas con cancer de mama avanzado con receptor hormonal positivo, her2-negativo que no han recibido terapia previa para la enfermedad avanzada. Novartis Farmaceutica, S.A. HULP Code: Anexo-I 4070. Sponsored´s Protocol Code: CLEE011A2301. Signature Date: 4/3/2016 Zamora Auñón P. Estudio de fase II randomizado, multicéntrico, abierto para evaluar la eficacia y seguridad de palbociclib en combinación con fulvestrant o letrozol en pacientes con cáncer de mama metastasico her2 negativo, er+ (parsifal 1. Medica Scientia Innovation Research). HULP Code: Anexo-2 4390. Sponsored´s Protocol Code: MEDOPP067. Signature Date: 4/5/2016

Espinosa Arranz E, Fresno Vara JA, Gámez Pozo A, Sánchez Navarro I, inventors; FIBHULP, assignee. Method for tumor subclassification. P200803509, PCT/ ES2009/070533; 2008 December 11.

Redondo Sánchez A, Hardisson Hernaéz D, Barriuso Feijoo J, Mendiola Sabio M, inventors; FIBHULP, assignee. Method to obtain useful data for the prediction of a patient’s pathological response to an anticancer treatment. P200930438; 2009 July 10.

Espinosa Arranz E, Fresno Vara JA, Gámez Pozo A, López Vacas R, Berges Soria J, inventors; FIBHULP, assignee. Method for tumor subclassification. P201430887; 2014 June 09. Miranda Utrera N, Castellano D, Villacampa Aubá F, Fresno Vara JA, Gámez Pozo A, inventors; FIBH12O, FIBHULP, assignees. Prognostic method for determining the risk of relapse in renal cancer patients with a clear cell type of renal carcinoma, stages I and II, and kit for same. P201531360; 2015 September 23.

PATENTS AND TRADEMARKS Cejas Guerrero P, Belda Iniesta C, Feliú Batlle J, González Barón M, de Castro Carpeño J, Casado Sáenz E, Sánchez Hernández JJ, inventors; FIBHULP, UAM, assignees. Genomic fingerprint for the prognosis of the evolution of colorectal adenocarcinoma. P200703229, PCT/ ES2008/000756, EP2236626; 2007 December 04. Cejas Guerrero P, González Barón M, Casado Sáenz E, Sánchez Hernández JJ, Perona Abellón R, inventors; FIBHULP, UAM, CSIC, assignees. Use of trefoil factor family 3 (TFF3) in the prognosis of patients diagnosed with

Return to LARGE SYSTEM PATHOLOGIES AREA INDEX

239

3.5 Cancer and Human Molecular Genetics Area

3 INFORMATION GROUPS BY AREA

240

CLC biopsies predicts resistance to cisplatin with 80% specificity. miR-7 epigenetic regulation predicts early recurrence in ovarian cancer patients. We also discovered a combination therapy based in sequential treatment of gastric cancer cells with taxol followed by cisplatin, which induces mitotic catastrophe and increases cell death.Another target, MKP1, is a dualspecific phosphatase expressed at high levels in biopsies from early-stage NSCLC and is also associated with tumour progression of this disease.

EXPERIMENTAL THERAPIES AND BIOMARKERS IN CANCER GROUP

10 41.929 6

María Inmaculada Ibáñez de Cáceres Investigadora Senior (Contrato Miguel Servet - Tipo 2). Jefe de Laboratorio. HULP Javier de Castro Carpeño Jefe de Sección de Oncología. HULP Profesor Asociado. UAM Cristóbal Belda Iniesta Facultativo Especialista de Área en Oncología. HULP Jaime Carrillo García Investigador Postdoctoral. IIB “Alberto Sols” María Isabel Esteban Rodríguez Facultativo Especialista de Área en Anatomía Patológica. HULP María Galardi Castillo Investigadora Predoctoral. UAM Julia Jiménez Hernández Investigadora Predoctoral. IIB “Alberto Sols” Cristina Manguán García Técnico de Laboratorio. IIB “Alberto Sols” Olga Pernía Arias Técnico de Laboratorio (Contrato PTA). HULP Rosario Perona Abellón Profesora de Investigación. IIB “Alberto Sols” Verónica Pulido Sanz Investigadora Predoctoral. HULP Garcilaso Riesco Eizaguirre Facultativo Especialista de Área en Endocrinología y Nutrición. HULP Carlos Rodríguez Antolín Bioinformático Contratado. HULP Rocío Rosas Alonso Farmacéutica Interna Residente. HULP

Isabel Sánchez Pérez Profesora Contratada Doctor. UAM Leandro Sastre Garzón Investigador Científico. IIB “Alberto Sols” Javier Andrés Soto Investigador Predoctoral. UAM Olga Vera Puente Investigadora Predoctoral. HULP

Strategic Objective Our research is focused on two distinct areas: 1- Genetic and epigenetic mechanisms involved in the resistance to chemotherapeutic drugs. Drug resistance is a crucial problem in clinical practice. We have used various strategies to approach this problem, such as identifying new targets involved in drug responses and studying their alterations in human samples. In addition, we have identified epigenetic changes in tumour suppressor genes associated with drug resistance and new gene inducers of chromosome instability associated with drug responses. We have worked tow